fludarabine has been researched along with vidarabine in 3305 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (0.73) | 18.7374 |
| 1990's | 433 (13.10) | 18.2507 |
| 2000's | 1331 (40.27) | 29.6817 |
| 2010's | 1283 (38.82) | 24.3611 |
| 2020's | 234 (7.08) | 2.80 |
| Authors | Studies |
|---|---|
| Cristalli, G; Esker, JL; Jacobson, KA; Ji, XD; Melman, N; Olah, ME; Schneller, SW; Secrist, JA; Siddiqi, SM; Tiwari, KN | 1 |
| Cheson, BD | 10 |
| Anaissie, E; Elting, L; Kantarjian, H; Keating, M; Kontoyiannis, DP; Robertson, LE | 1 |
| Elmhorn-Rosenborg, A; Juliusson, G; Liliemark, J | 1 |
| Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Robertson, L | 1 |
| Robak, T | 3 |
| Butler, JJ; Hirsch-Ginsberg, C; Huh, YO; Kantarjian, H; Keating, MJ; Pugh, WC; Robertson, LE; Stass, S | 1 |
| Bosanquet, AG; Chapman, CS; Hutchinson, RM; Parker, AN | 1 |
| Phyliky, RL; Tefferi, A | 1 |
| Crowley, S; Dahut, WL; Frame, JN | 1 |
| Ali Ege, M; Amadori, S; Caruso, R; D'Adamo, F; Girelli, G; Maurillo, L; Mauro, FR; Picardi, A; Tosti, S | 1 |
| Gandhi, V; Plunkett, W | 6 |
| Adjei, AA; Dagnino, L; Paterson, AR; Wong, MM | 1 |
| Gandhi, V; Keating, M; Kemena, A; Plunkett, W; Shewach, DS | 1 |
| Huang, P; Plunkett, W | 4 |
| Lawrence, HJ; Perez, EA; Sanders, C | 1 |
| Marlton, P; McCarthy, C; Taylor, K | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 2 |
| Bastion, Y; Bryon, PA; Coiffier, B; Dumontet, C; Espinouse, D | 1 |
| Oken, MM | 1 |
| Crowley, J; Eyre, HJ; Hynes, HE; Jaeckle, C; Pollock, TW; Stephens, RL; Taylor, SA | 1 |
| Schilling, PJ | 1 |
| Gribbin, TE | 1 |
| Chubb, S; Huang, P; Plunkett, W | 1 |
| Grever, MR; Malspeis, L; Staubus, AE; Young, D | 1 |
| Catovsky, D; Davis, CL; Lister, TA; Mehta, AB; Ranson, M; Rohatiner, AZ; Rule, S; Smith, OP; Whelan, JS | 1 |
| Cassileth, PA; Green, MD; Hochster, HS; Kim, KM; Mann, RB; Neiman, RS; O'Connell, MJ; Oken, MM; Ritch, P; Stott, P | 1 |
| Gandhi, V; Keating, MJ; Kemena, A; Plunkett, W | 2 |
| Parks, NP; Santiago, NM; Trissel, LA | 1 |
| Sporn, JR | 1 |
| Kantarjian, HM; Keating, MJ; Schachner, J | 1 |
| Beran, M; Childs, C; Huh, Y; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Schachner, J | 1 |
| Finley, RS; Hood, MA | 1 |
| Bladé, J; Cervantes, F; Marín, P; Montserrat, E; Rozman, C; Rozman, M | 1 |
| Hutton, JJ; Von Hoff, DD | 1 |
| Huang, P; Plunkett, W; Siciliano, MJ | 1 |
| Barrueco, JR; Sirotnak, FM | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Danhauser, L; Gandhi, V; Plunkett, W | 1 |
| Barrueco, JR; Brockman, RW; Chang, CH; Jacobsen, DM; Sirotnak, FM | 1 |
| Bacon, PE; Brown, NC; Carter, GL; Cory, JG; Montgomery, JA; Sato, A | 1 |
| Kufe, D; Mitchell, T; Robbins, G; Spriggs, D | 1 |
| Clark, G; Hersh, M; Hutton, JJ; Kuhn, J; Phillips, J; Von Hoff, DD | 1 |
| Bell, DE; Dow, LW; Fridland, A; Poulakos, L | 1 |
| Brockman, RW; Cheng, YC; Montgomery, JA; Schabel, FM | 1 |
| Cory, JG; Montgomery, JA; Sato, A | 1 |
| Chello, PL; Dorick, DM; Montgomery, JA; Sirotnak, FM | 1 |
| Chello, PL; Dorick, DM; Montgomery, JA; Sirotnak, FM; Yang, CH | 1 |
| Avramis, VI; Plunkett, W | 2 |
| Alexander, L; Chubb, S; Montgomery, JA; Plunkett, W | 1 |
| Bennett, LL; Brockman, RW; Shaddix, SC; White, EL | 1 |
| Bennett, LL; Brockman, RW; Cheng, YC; Derse, D; Tseng, WC | 1 |
| Brockman, RW; El Dareer, SM; Hill, DL; Kirk, MC; Montgomery, JA; Shortnacy, AT; Struck, RF; Thorpe, MC | 1 |
| Ashique, A; Begleiter, A; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L | 1 |
| del Villar, V; López, L; Pascual, T | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Robertson, LE; Thall, P | 1 |
| Escudier, SM; Seymour, JF | 1 |
| Bourquard, P; Emberger, JM; Exbrayat, C; Fégueux, N; Lavabre-Bertrand, C; Lavabre-Bertrand, T; Navarro, M; Poncelet, P; Rousset, T; Taïb, J | 1 |
| Juliusson, G | 2 |
| Estey, E; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, W; Robertson, LE | 1 |
| Hiddemann, W; Pott-Hoeck, C | 2 |
| Dighiero, G | 2 |
| Carrara, P; Cenacchi, A; Clavio, M; Gamberi, B; Manfroi, S; Ottaviani, E; Testoni, N; Tosi, P; Visani, G; Zinzani, PL | 1 |
| Manfori, S; Ottaviani, E; Tosi, P; Tura, S; Visani, G; Zinzani, PL | 1 |
| Cabanillas, F; Dimopoulos, M; Gandhi, V; Gregoire, V; Kantarjian, H; Keating, MJ; Li, YY; McLaughlin, P; O'Brien, S; Robertson, LE | 1 |
| Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Bosanquet, AG; Catovsky, D; Crotty, GM; McCann, SR; Mills, MJ | 1 |
| Gollard, R; Lee, TC; Piro, LD; Saven, A | 1 |
| Estey, E; Gandhi, V; Plunkett, W | 1 |
| Cacciola, E; Di Raimondo, F; Giustolisi, R; Impera, S; Milone, G; Palumbo, GA; Romeo, MA | 1 |
| Paolini, R; Petracca, GE; Ramazzina, E; Rimondi, AP; Zamboni, S; Zennaro, R | 1 |
| Bromidge, TJ; Howe, DJ; Johnson, SA; Phillips, MJ | 1 |
| Bendandi, M; Tura, S; Zinzani, PL | 1 |
| Andreeff, M; Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE | 1 |
| Byrd, JC; Diehl, LF; Freiman, J; Hertler, AA; Kweder, SL; Weiss, RB | 1 |
| Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE | 1 |
| Andreeff, M; Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, LE | 1 |
| Brugiatelli, M; Callea, I; Callea, V; Iacopino, P; Messina, G; Morabito, F; Nobile, F; Rodinò, A | 1 |
| Leoni, P; Montillo, M; Tedeschi, A | 2 |
| Hakimian, D; Tallman, MS | 2 |
| Estey, EH; Jaiyesimi, IA; Kantarjian, HM | 1 |
| Faulds, D; McTavish, D; Ross, SR | 1 |
| Aitini, E; Bendandi, M; Gherlinzoni, F; Salvucci, M; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Gouldesbrough, DR; Macheta, MP; Parapia, LA | 1 |
| Keating, MJ; Li, L; Plunkett, W; Yang, LY | 2 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| O'Brien, RK; Sparling, TG | 1 |
| Byrd, JC; Diehl, LF; Hargis, JB; Hospenthal, DR; Kester, KE; Knutson, SW | 1 |
| Allegra, CJ; Chabner, BA; Chu, E; Grem, JL; Johnston, PG; Takimoto, CH; Van Groeningen, C | 1 |
| Björkholm, M; Osby, E | 1 |
| Briz, M; Cabrera, JR; Díez, JL; Fernández, MN; Forés, R; Herrero, M; Regidor, C; Sanjuán, I | 1 |
| del Giglio, A; Keating, M; O'Brien, S | 1 |
| Appleton, AL; Hamilton, PJ; Jackson, GH; Maung, ZT; Turner, GE; Wood, AC | 1 |
| Abboudi, Z; Agrawal, S; Catovsky, D; Matutes, E | 1 |
| Keating, MJ; O'Brien, S; Plunkett, W; Robertson, LE; Wright, SJ | 1 |
| Simon, R; Thall, PF | 1 |
| Cass, Y; Dann, EJ; Gillis, S; Polliack, A; Rochlemer, RR | 1 |
| Catovsky, D; Cunningham, D; Ellis, PA; Emmett, E; Hickish, T; Hill, M; Matutes, E; Mercieca, J; Milan, S; O'Brien, ME | 1 |
| Gandhi, V; Huang, P; Plunkett, W | 1 |
| Calvert, L; Deisseroth, AB; Feldman, E; Hester, J; Kantarjian, HM; Korbling, M; Liang, J; Rios, MB; Smith, TL; Talpaz, M | 1 |
| Benner, A; Bentz, M; Cabot, G; Coy, J; Diehl, D; Döhner, H; Fischer, K; Galle, PR; Hansen, K; Hunstein, W; Lichter, P; Poustka, A; Schlenk, R; Stilgenbauer, S; Volkmann, M | 1 |
| Alfarano, A; Bergui, L; Caligaris-Cappio, F; De Leo, AM; Gottardi, D; Stacchini, A | 1 |
| Piro, LD; Saven, A | 2 |
| Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Pierce, S; Robertson, B | 1 |
| Alexanian, R; Dimopoulos, MA; Estey, EE; Kantarjian, H; Keating, MJ; O'Brien, S | 1 |
| Saven, A | 3 |
| Juliusson, G; Liliemark, J | 3 |
| Piro, L; Saven, A | 1 |
| Lundberg, JH; Tefferi, A; Weitz, JJ; Witzig, TE | 1 |
| Brock, WA; Grégoire, V; Hittelman, WN; Hunter, N; Milas, L; Plunkett, W | 2 |
| Bastian, A; Cotelingam, JD; Fischmann, AB; Foss, FM; Ghosh, BC; Ihde, DC; Linnoila, IR; Schechter, GP; Steinberg, SM; Stocker, JL | 1 |
| Cheson, BD; Foss, FM; Sorensen, JM; Vena, DA | 1 |
| Hopkins, JA; Howe, D; Johnson, SA; Phillips, MJ; Richardson, DS | 1 |
| Domizio, P; Fearnley, J; Gawler, J; Goldin, J; Johnson, PW; Lister, TA; Nagendran, K; Rohatiner, AZ | 1 |
| Girmenia, C; Mauro, FR; Rahimi, S | 1 |
| Canellakis, ZN; Costin, D; Degar, B; Drygas, JC; Mani, M; Morse, L; Newcomb, EW; Potmesil, M; Rosenberg, CR; Silber, R | 1 |
| Brock, WA; Grégoire, V; Hittelman, WN; Milas, L; Plunkett, W; Stephens, LC; Van, NT | 1 |
| Bosly, A; Brousset, P; Delannoy, A; Pris, J; Riga-Huguet, F; Schlaifer, D | 1 |
| Aguilera, A; Liaño, F; Montalban, C | 1 |
| Bendandi, M; Buzzi, M; Farabegoli, P; Martinelli, G; Ottaviani, E; Salvucci, M; Tosi, P; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Dean, MG; Mulligan, SP | 1 |
| Buzzi, M; Farabegoli, P; Fortuna, A; Martinelli, G; Tosi, P; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Bruijn, JA; van Groningen, K; van Royen, EA; Wijermans, PW | 1 |
| Berman, E; Kempin, S; Spiess, T; Weiss, M | 1 |
| Doorduijn, JK; Michiels, JJ | 1 |
| Bendandi, M; Tabanelli, M; Tura, S; Zinzani, PL | 1 |
| Chubb, S; Ford, R; Hittelman, WN; Meyn, RE; Plunkett, W; Robertson, LE; Story, M | 1 |
| Delannoy, A; Ferrant, A; Hanique, G | 1 |
| Lemon, RH; Piro, LD; Saven, A | 1 |
| Larson, RA; Spielberger, RT; Stock, W | 1 |
| Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Robertson, LB | 1 |
| Leporrier, M; Reman, O; Troussard, X | 1 |
| Woodcock, BE | 1 |
| Clauvel, JP; Jaccard, A; Oksenhendler, E | 1 |
| Chamone, DF; Deisseroth, AB; Del Giglio, A; Ford, RJ; Johnston, D; Keating, M; Manning, J; O'Brien, S; Saya, H | 1 |
| Huh, Y; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, W; Robertson, L | 1 |
| Gandhi, V | 1 |
| Buckley, C; Hoffbrand, AV; Smith, OP | 1 |
| Collins, KA; Davda, RK; Kitchens, CS | 1 |
| Gandhi, V; Keating, MJ; Plunkett, W; Robertson, LE | 1 |
| Cabanillas, F; Gandhi, V; Gregoire, V; Keating, MJ; McLaughlin, P; O'Brien, S; Plunkett, W; Robertson, LE; Yang, L | 1 |
| Hałaburda, K; Hellmann, A | 1 |
| Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Kemena, A; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, L | 1 |
| Cacciola, E; Di Raimondo, F; Giustolisi, R; Kantarjian, H; Keating, MJ; O'Brien, S; Robertson, LB | 1 |
| Estey, E; Gandhi, V; Gregoire, V; Huang, P; Keating, MJ; Plunkett, W; Robertson, LE; Yang, LY | 1 |
| Amess, J; Ganjoo, RK; Johnson, PW; Lim, J; Lister, TA; Norton, AJ; Pigaditou, A; Rohatiner, AZ; Rossi, A; Whelan, JS | 1 |
| Engert, A; Freund, M; Gassmann, W; Hiddemann, W; Holtkamp, W; Pott, C; Sandford, D; Seufert, J; Unterhalt, M; Wörmann, B | 1 |
| Bapat, A; Goldberg, J; Goldman, N; Gordon, R; Gryn, J | 1 |
| Cleveland, KO; Gelfand, MS | 1 |
| Cannon, LM; Garfinkel, H; Pezzimenti, J; Rhodes, R; Spilove, L | 1 |
| Rai, KR | 3 |
| McCulloch, EA; Rayappa, C | 1 |
| Alexanian, R; Barlogie, B; Delasalle, K; Dimopoulos, MA; Kantarjian, H; Keating, MJ; O'Brien, S; Pierce, S | 1 |
| Bergmann, L; Fenchel, K; Hoelzer, D; Jahn, B; Mitrou, PS | 1 |
| Bendandi, M; Benfenati, D; Bocchia, M; Fanin, R; Gozzetti, A; Lauria, F; Raspadori, D; Rondelli, D; Zaja, F; Zinzani, PL | 1 |
| Benfenati, D; Bocchia, M; Cavo, M; Cirio, TM; Gozzetti, A; Lauria, F; Raspadori, D; Rondelli, D; Zaja, F; Zinzani, PL | 1 |
| Beran, M; Estey, E; Gandhi, V; Kantarjian, H; Keating, M; O'Brien, S; Plunkett, W; Rios, MB; Suki, S | 1 |
| Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB | 1 |
| Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Lerner, S; O'Brien, S; Robertson, LE; Smith, T | 1 |
| Abdallah, JM; Cohen, RB; Foss, F; Gray, JR | 1 |
| Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 2 |
| Hopkins, J; Howe, D; Johnson, SA; Phillips, MJ; Richardson, D | 1 |
| Cortes-Franco, J; Estey, E; Kornblau, SM | 1 |
| Ganjoo, R; Johnson, PW; Lister, TA; Rohatiner, AZ; Whelan, JS | 1 |
| Feldman, EJ; Keating, MJ | 1 |
| Binet, JL | 2 |
| Ang, KK; Brock, WA; Grégoire, V; Hittelman, WN; Plunkett, WK; Price, RE; Ruifrok, AC | 1 |
| Pawelski, S | 1 |
| Bergmann, L; Diehl, V; Engert, A; Fenchel, K; Hoelzer, D; Mitrou, PS; Pralle, H; Wijermans, P | 1 |
| Keating, MJ; Lerner, S; O'Brien, S; Robertson, LE; Seymour, JF | 1 |
| Archimbaud, E; Thomas, X | 1 |
| de Marie, S; Leenders, A; Sonneveld, P | 1 |
| Copplestone, JA; Craig, V; Curtis, D; Hamblin, TJ; Hamon, MD; Myint, H; Orchard, J; Oscier, DG; Prentice, AG | 1 |
| Algora, M; Briz, M; Cabrera, R; Díez, JL; Fernández, MN; Forés, R; Herrero, M; Regidor, C; Sanjuán, I | 1 |
| Calleja, E; Gabrilove, J; Menzel, T; Rahman, Z; White, K; Wieder, R; Wilson, EL | 1 |
| Björkholm, M; Celsing, F; Runarsson, G; Waldenström, J | 1 |
| Denny, AW; Huh, YO; Keating, MJ; Nelson, JA; Plunkett, W; Robertson, LE | 1 |
| Maclean, R; Meiklejohn, D; Soutar, R | 1 |
| Kelleher, DK; Thews, O; Vaupel, P | 1 |
| Anderlini, P; Estey, EH; Kantarjian, HM; Keating, MJ; Luna, M; O'Brien, S; Pierce, S | 1 |
| Estey, EH; Kantarjian, HM; Keating, MA | 1 |
| Hapke, DM; Mitchell, BS; Stegmann, AP | 1 |
| Bernabei, PA; D'Ippolito, G; Ermini, A; Rossi-Ferrini, P; Santini, V; Zoccolante, A | 1 |
| Falkson, CI | 1 |
| Brown, RD; Gibson, J; Joshua, DE; Luo, XF; Petersen, AJ; Pope, B; Schutz, L; Wiley, JS | 1 |
| Gandhi, V; Loughlin, S; Plunkett, W; Zwelling, LA | 1 |
| Catovsky, D; Murphy, RL | 1 |
| Alcorta, I; Briones, J; Pereira, A | 1 |
| Bachelez, H; Bazarbachi, A; Dehen, L; Delmer, A; Dubertret, L; Zittoun, R | 1 |
| Emmerich, B; Hiddemann, W; Johnson, S; Juliusson, G; Löffler, H; Osby, E; Smith, AG; Wyld, PJ | 1 |
| Geisen, F; Konwalinka, G; Michlmayr, G; Schirmer, M | 1 |
| Estey, EH; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Huang, P; Kamiya, K; Plunkett, W | 1 |
| Williamson, LM; Wimperis, JZ; Wood, ME; Woodcock, B | 1 |
| Falkson, CI; Falkson, G; Hocepied, AM | 1 |
| Gjedde, SB; Hansen, MM | 1 |
| Enzenauer, RJ; Judson, PH | 2 |
| Catovsky, D; Glynne, P; Hamblin, M; Matthey, F; Mehta, J; Middleton, G; Powles, R; Prendiville, J; Singhal, S; Treleaven, J; Zomas, A | 1 |
| Faure, P; Madelaine-Chambrin, I; Piquet-Sevrin, V | 1 |
| Keating, MJ; Wright, SJ | 1 |
| Estey, E; Kuschel, B | 1 |
| Bosch, F; Briones, J; Colomer, D; Esteve, J; Hadjieu, E; López-Guillermo, A; Montserrat, E; Rozman, C; Urbano-Ispizua, A | 1 |
| Lawrence, TS; McGinn, CJ; Shewach, DS | 1 |
| Chandra, J; Keating, M; McConkey, DJ; McDonnell, TJ; Plunkett, W; Reed, JC; Wright, S | 1 |
| Koeppen, H; Larson, RA; Olopade, OI; Ong, ST | 1 |
| Lärfars, G; Samuelsson, J; Udén-Blohmé, AM | 1 |
| Ueda, T | 1 |
| Crozat-Grosleron, S; Dubois, A; Reynaud, D; Rossi, JF; Yeche, S | 1 |
| Błasinka-Morawiec, M; Ceglarek, B; Dmoszynska, A; Durzynski, T; Dwilewicz-Trojaczek, J; Grieb, P; Hansz, J; Hellmann, A; Kasznicki, M; Komarnicki, M; Konopka, L; Kopec, I; Kotlarek-Haus, S; Krykowski, E; Lewandowski, K; Maj, S; Mazur, G; Potemski, P; Płuzanska, A; Robak, T; Sikorska, A; Skotnicki, AB; Urasinski, I; Zaucha, JM; Zdziarska, B | 1 |
| Bayle, C; Cartron, J; Lambert, T; Rudent, A; Tchernia, G; Tertian, G | 1 |
| Brock, WA; Grégoire, V; Hittelman, WN; Hunter, NR; Milas, L; Plunkett, W | 1 |
| Fraternale, A; Magnani, M; Rossi, L | 1 |
| Zaja, F | 1 |
| Johnson, SA | 3 |
| Lipton, JH; Pierratos, A; Tisler, A | 1 |
| Jacobs, A | 1 |
| Aristei, C; Aversa, F; Chionne, F; Latini, P; Martelli, MF; Perruccio, K; Raymondi, C; Terenzi, A | 1 |
| Adam, Z; Hejlová, N; Vorlícek, J | 1 |
| De Marco, C; Gornati, D; Orlandi, L; Silvestrini, R; Vaglini, M; Zaffaroni, N | 1 |
| Wiley, JS | 1 |
| Baldwin, SA; Beaumont, N; Boumah, CE; Cass, CE; Coe, I; Davies, A; Griffiths, M; Kwong, FY; Sundaram, M; Yao, SY; Young, JD | 1 |
| Al-Katib, A; Gabrilove, JL; König, A; Lynen, S; Menzel, T; Raveche, E; Rosén, A; Wrazel, L | 1 |
| Kantarjian, H; Keating, MJ; O'Brien, S | 1 |
| Byrnes, JJ; Frankfurt, OS; Villa, L | 1 |
| Bowen, AL; Catovsky, D; Dyer, MJ; Emmett, E; Matutes, E; Zomas, A | 1 |
| Bourantas, KL; Briasoulis, E; Christou, L; Konstantinidou, P; Panteli, A; Tsiara, S | 1 |
| Glassman, AB; Keating, MJ; Li, L; Liu, X; Plunkett, W; Stros, M; Yang, LY | 1 |
| Dimopoulos, M; Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Lerner, S; McLaughlin, P; O'Brien, S; Plunkett, W | 1 |
| Gati, WP; Kieller, DM; Rahn, JJ; Tyrrell, DL | 1 |
| Behrens, J; Killick, S; Mercieca, J; Nandi, A | 1 |
| Aziz, M; Levin, M; Opitz, L | 1 |
| Boscagli, A; Dujardin, P; Gary-Toussain, M; Peyrade, F; Roa, M; Taillan, B | 1 |
| Andersson, BS; Champlin, RE; Giralt, S; Keating, MJ; Khouri, IF; Körbling, M; Lerner, S; Mehra, RC; O'Brien, S; Palmer, JL; Przepiorka, D; van Besien, K; Vriesendorp, HM | 1 |
| Brisou, P; de Jaureguiberry, JP; Gisserot, O; Hequet, O; Jaubert, D; Muzellec, Y | 1 |
| Hayag, MV; Nouri, K; Taylor, JR; Tie, C | 1 |
| Alcala, A; Arias-Sampedro, J; Bosch, F; Fernandez, MN; Garcia-Conde, J; Guardia, R; Lopez-Lorenzo, JL; Manso, F; Martin, A; Montserrat, E; Odriozola, J; Oyarzabal, FJ; Prieto, E | 1 |
| Beran, M; Cortes, J; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Talpaz, M | 1 |
| Hiddemann, W; Pott, C | 1 |
| Bergmann, L | 1 |
| Hilgenfeld, E; Jäger, U; Knauf, WU; Mitterbauer, M; Wilfing, A | 1 |
| Arning, M; Schneider, W; Südhoff, T | 1 |
| Adkins, JC; Markham, A; Peters, DH | 1 |
| Petryshyn, RA; Slomiany, DJ; Woldehawariat, G | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Catovsky, D; Dyer, MJ; Emmett, E; Hale, G; Kelsey, SM; Mackay, HJ; Newland, AC; Thornton, P; Waldmann, H | 1 |
| Huang, P; Iwasaki, H; Keating, MJ; Plunkett, W | 1 |
| Or, R; Polliack, A; Teiman, S; Weiss, L | 1 |
| Bendandi, M; Gherlinzoni, F; Magagnoli, M; Merla, E; Tura, S; Zinzani, PL | 1 |
| Ballin, A; Davidovitz, Y; Meytes, D | 1 |
| Cohen, JD; Katz, TB; Marcel, PD; Strock, DJ; Teik, JE | 1 |
| Frewin, RJ; Provan, D; Smith, AG | 1 |
| Hájek, R; Krahulcová, E; Mayer, J; Penka, M; Vásová, I | 1 |
| Blanche, P; Colbert, N; Galezowski, N; Golstein, FW; Lasoudris, J; Mainardi, JL; Maulin, L; Nguyen, TB | 1 |
| Hoskin, PJ; Kanegaonkar, R; Mahadevan, A | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; North, L; Pate, O; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, AH; Younes, A | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Egle, A; Geley, S; Greil, R; Hartmann, BL; Kofler, R; Kos, M; Villunger, A | 1 |
| Ballal, K; Huang, P; Plunkett, W | 1 |
| Heitjan, DF | 1 |
| Cusack, JC; Keating, MJ; Lerner, S; Pollock, RE; Seymour, JF | 1 |
| Bendandi, M; Benni, M; Cavo, M; de Vivo, A; Magagnoli, M; Rondelli, D; Tura, S; Zamagni, E; Zinzani, PL | 1 |
| Emilia, G; Ferrara, L; Gandini, G; Longo, G; Torelli, U | 1 |
| Magagnoli, M; Ottaviani, E; Pellacani, A; Tosi, P; Tura, S; Zinzani, PL | 1 |
| Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Talpaz, M | 1 |
| Alfarano, A; Aragno, M; Bergui, L; Caligaris-Cappio, F; Circosta, P; De Leo, AM; Gottardi, D; Gregoretti, MG; Stacchini, A | 1 |
| Bolam, S; Orchard, J; Oscier, D | 1 |
| Cummins, M; Deane, M; Emery, V; Gor, D; Griffith, PD; Macmahon, ME; Prentice, HG | 1 |
| Soda, R; Tada, A; Takahashi, K; Takeuchi, M | 1 |
| Antich Rojas, J; Balaguer, H; Cladera, A | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Abbondanzo, SL; Aguilera, NI; Byrd, JC; Diehl, LF; Lichy, JH; Shields, DJ | 1 |
| Begleiter, A; Daeninck, P; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L; Williams, G | 1 |
| Berrebi, A; Klepfish, A; Shtarlid, M; Shvidel, L; Sigler, E | 1 |
| Baccarani, M; Marin, L; Rogato, A; Russo, D; Silvestri, F; Zaja, F | 1 |
| Cullis, JO; Czepulkowski, B; Gover, PA; Grace, R; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE; Rassam, SM; Samaratunga, IR | 1 |
| Andreeff, M; Armitage, RJ; Clodi, K; Consoli, U; Palmer, JL; Snell, V; Thomas, EK; Younes, A; Zhao, S | 1 |
| Kapelushnik, J; Nagler, A; Or, R; Slavin, S | 1 |
| Beal, CL; Byrd, JC; Chaffin, DJ; Vick, DJ | 1 |
| Avramis, VI; Kowck, R; Krailo, MD; Liu-Mares, W; Ramilo-Torno, LV; Reaman, GH; Sato, JK; Sharpe, A; Wiersma, S | 1 |
| Bolam, S; Orchard, JA; Oscier, DG | 1 |
| Chapman, R; Grigg, A; Szer, J | 1 |
| Losonczy, H | 1 |
| Bertone, A; Candoni, A; Grattoni, R; Russo, D; Zaja, F | 1 |
| Nagler, A; Slavin, S | 1 |
| Byrd, JC; Diehl, LF; Freiman, J; Kweder, SL; Weiss, RB | 1 |
| Duley, JA; Fabianowska-Majewska, K; Ruckemann, K; Simmonds, HA | 1 |
| Fabianowska-Majewska, K; Wyczechowska, D | 2 |
| Amoroso, V; Baccarani, M; Beltrami, CA; Damiani, D; Di Loreto, C; Fanin, R; Infanti, L; Mariuzzi, L; Russo, D; Salmaso, F; Silvestri, F; Zaja, F | 1 |
| Arizpe-Bravo, D; Garcés-Eisele, J; Ponce-de-León, S; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ; Sánchez-Sosa, S | 1 |
| Aitini, E; Costa, P; Forghieri, ME; Lazzarini, L; Luzzati, R; Nicolato, A; Perboni, G; Scalzini, A; Zinzani, PL | 1 |
| Ferrara, F; Latagliata, R; Magrin, S; Mele, G; Mirto, S; Montillo, M; Petti, MC; Pinto, A; Tedeschi, A; Zagonel, V | 1 |
| Ben-Othman, T; Caspard, H; Clauvel, JP; Deconinck, E; Delgado, MA; Delmer, A; Duboisset, P; Entezam, S; Fort, N; Guibon, O; Harousseau, JL; Hermine, O; Leblond, V; Maloisel, F; Mariette, X; Merlet, M; Morel, P; Taksin, AL; Yakoub-Agha, I | 1 |
| Baudet, S; Binet, JL; Blanc, C; Issaly, F; Mentz, F; Merle-Beral, H | 1 |
| Beauduin, M; Bruniaux, M; De Coster, B; Grégoire, V; Octave Prignot, M; Scalliet, P | 1 |
| Cheson, BD; Frame, JN; Quashu, N; Sorensen, JM; Vena, D | 1 |
| Clauvel, JP; Eftekhari, P; Lassoued, K; Oksenhendler, E; Scieux, C | 1 |
| Alfinito, F; Bonelli, P; Chiurazzi, F; Costantini, S; Defrance, T; Lamberti, A; Romano, MF; Tassone, P; Tuccillo, F; Turco, MC; Venuta, S | 1 |
| Leach, M; Parsons, RM; Reilly, JT; Winfield, DA | 2 |
| O'Brien, S | 1 |
| Keating, MJ | 1 |
| Bellucci, R; Cordone, I; de Fabritiis, P; De Propris, MS; Foà, R; Lisci, A; Mauro, FR; Sala, R | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE | 1 |
| Brugiatelli, M; Callea, I; Callea, V; Console, G; Dattola, A; di Raimondo, F; Iacopino, P; Morabito, F; Pucci, G; Stelitano, C | 1 |
| Catovsky, D; Killick, S; Matutes, E; Sternberg, AJ; Wotherspoon, AC | 1 |
| Bromidge, TJ; Howe, DJ; Johnson, SA; Rule, SA; Turner, DL | 1 |
| Azar, N; Binet, JL; Dighiero, G; Gabarre, J; Gonzalez, H; Leblond, V; Sutton, L; Vernant, JP | 1 |
| Anderlini, P; Andersson, B; Champlin, R; Claxton, D; Donato, M; Gajewski, J; Gee, A; Giralt, S; Ippoliti, C; Keating, M; Khouri, IF; Körbling, M; O'Brien, S; Przepiorka, D; Ueno, N; von Wolff, B | 1 |
| Miller, M | 1 |
| Bai, L; Bräutigam, M; Kon, K; Tatsumi, M; Yamaguchi, M | 1 |
| Bode, U; Fleischhack, G; Graf, N; Hasan, C; Mann, G | 1 |
| Christopherson, RI; Mulligan, SP; Szabados, E; Wilson, PK | 1 |
| Boumpas, DT; Davis, JC; Fessler, BJ; Fleisher, TA; Klippel, JH; McInnes, IB; Pillemer, S; Tassiulas, IO; Wilder, R; Yarboro, CH | 1 |
| Bolam, S; Hamblin, TJ; Myint, H; Orchard, J; Oscier, DG | 1 |
| Kim, HS; Niihara, Y; Yospur, L | 1 |
| Hamblin, TJ; Myint, H; Orchard, JA; Oscier, DG | 1 |
| Ballerini, F; Beltrami, G; Bruni, R; Canepa, L; Cavaliere, M; Celesti, L; Clavio, M; Congiu, M; Damasio, E; Gobbi, M; Miglino, M; Nati, S; Pierri, I; Pietrasanta, D; Rossi, E; Santini, G; Spriano, M; Vallebella, E; Vimercati, R | 1 |
| Anaissie, EJ; Kantarjian, H; Keating, MJ; Kontoyiannis, DP; Lerner, S; O'Brien, S; Robertson, L | 1 |
| Flandrin, G; Maloisel, F; Troussard, X | 1 |
| Callea, I; Console, G; Filangeri, M; Messina, G; Morabito, F; Sculli, G | 1 |
| Byrd, JC; Diehl, LF; Flinn, IW; Fuchs, EJ; Grever, MR; Lehman, TA; Nguyen, PL; Sausville, E; Shinn, C; Waselenko, JK | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Nowak, B; Plunkett, W | 1 |
| Huang, P; Plunkett, W; Robertson, LE; Wright, S | 1 |
| Consoli, U; Plunkett, W; Sandoval, A | 1 |
| Gandhi, V; Huang, P; Plunkett, W; Seymour, JF | 1 |
| Cawley, M; Kaplan, B; Narasihman, P; Taha, HM; Venkatesh, L | 1 |
| Azgui, Z; Baudet, S; Brefort, K; Chretien, MC; Dujarric, C; Maloum, K; Mentz, F; Merle-Béral, H; Sevin, O; Vinsobre, MF | 1 |
| Crollo, R; D'Oronzio, L; Dambra, P; Dell'Osso, A; Grande, M; Lasaracina, E; Loria, MP; Lucivero, G | 1 |
| Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ | 1 |
| Filangeri, M; Morabito, F; Oliva, B; Sculli, G | 1 |
| Andrieu, V; Carbon, C; Couvelard, A; Encaoua, R; Grange, MJ | 1 |
| Adams, EM; Bartlett, ML; Fleisher, T; Hicks, JE; McGarvey, C; Plotz, PH; Pucino, F; Sonies, BC; Thornton, B; Villalba, ML; Yarboro, C | 1 |
| Machaczka, M; Rucińska, M; Skotnicki, AB; Załuska, A | 1 |
| Estey, EH | 2 |
| Bosanquet, AG | 1 |
| Berrebi, A; Klepfish, A; Shimoni, A; Shtalrid, M; Shvidel, L; Sigler, E | 1 |
| Koski, T; Vilpo, J; Vilpo, L | 2 |
| Asfoura, J; Butty, H; Cortese, F; Doyle, M; Rutecki, G | 1 |
| Astori, C; Bernasconi, C; Brusamolino, E; Corso, A; Lazzarino, M; Montillo, M; Morra, E; Orlandi, E; Pagnucco, G; Simoncini, L; Tedeschi, A | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Davies, S; Frewin, R; Johnson, S; Rule, S; Tighe, M; Turner, D | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Karadogan, I; Timuragaoglu, A; Undar, L | 1 |
| Bamborschke, S; Diehl, V; Fätkenheuer, G; Lehrke, R; Re, D; Reiser, M; Salzberger, B; Schröder, R; Tesch, H | 1 |
| Bergmann, L; Hoelzer, D; Jäger, E; Käfer, G; Mitrou, PS; Pfreundschuh, M; Reinhardt, U; Rummel, MJ | 1 |
| Brugiatelli, M; Callea, V; Iuliano, F; Kropp, MG; Levato, D; Molica, S; Morabito, F; Nobile, F; Oriana, V; Stelitano, C | 1 |
| Elliott, MA; Hammack, JE; Hoyer, JD; Letendre, L; Li, CY | 1 |
| Albertini, P; Magagnoli, M; Ottaviani, E; Pellacani, A; Tosi, P; Tura, S; Zinzani, PL | 1 |
| Lossos, IS; Paltiel, O; Polliack, A | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, EH; Freireich, E; Kantarjian, H; Keating, MJ; Pierce, S; Thall, PF | 1 |
| Bardy, P; Byron, K; Grigg, A; Seymour, JF; Szer, J | 1 |
| Al-Katib, AM; Beck, FW; Dutcher, BS; Hamdy, N; Limvarapuss, C; Mohammad, RM; Wall, NR | 1 |
| Frank, DA; Mahajan, S; Ritz, J | 1 |
| Camerone, G; Epis, R; Marruchella, A; Tondini, M | 1 |
| Hughes, RA; Lunn, MP; Schey, S; Wilson, HC | 1 |
| Zingman, BS | 1 |
| Bravery, CA; Hoffbrand, AV; Lewin, J; Mehta, AB; Mengubas, K; Owens, DL; Riordan, FA; Wickremasinghe, RG | 1 |
| Alvegård, TA; Békássy, AN; Chan, KW; Ha, CS; Nunez, C; Sallerfors, B | 1 |
| Byrd, JC; Diehl, LF; Dow, NA; Hospenthal, DR; Howard, RS; McGrail, LH | 1 |
| Emmanouilides, C; Kunkel, L; Rasti, S; Rosen, P; Territo, M | 1 |
| Friedenberg, WR; Hogan, TF; Marx, JJ; Mazza, JJ; Musser, C; Rodvold, KA; Rushing, DA; Spencer, SK; Tewksbury, DA | 1 |
| Dizdari, A; Lemoli, RM; Leopardi, G; Martinelli, G; Motta, MR; Pastano, R; Piccaluga, PP; Ricci, P; Rizzi, S; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Bouabdallah, R; Cohen-Valensi, R; Coso, D; Costello, R; Gastaut, JA; Nezri, M; Sainty, D | 1 |
| Aleskog, A; Höglund, M; Kristensen, J; Larsson, R; Sundström, C | 1 |
| Kalaycio, M; Sen, K | 1 |
| Chen, JH; Grant, S; Kramer, LB; Rao, AS; Tang, L; Vrana, JA; Wang, Z | 1 |
| Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Ketterer, N; Moullet, I; Salles, G; Sonet, A; Thieblemont, C | 1 |
| Dreger, P; Emmerich, B; Hallek, M; Montserrat, E; Schmitt, B; Wendtner, CM; Wilhelm, M | 1 |
| del Potro Gómez, E; Morales Sanz, D | 1 |
| Hieke, K; Howard, P; Kerrigan, M; McIntyre, AM; Smartt, PF; Sweetenham, J; Townshend, S | 1 |
| Bosanquet, AG; Johnson, SA; Richards, SM | 1 |
| Callet Bauchu, E; Dumontet, C; Fabianowska-Majewska, K; Fang, X; Gandhi, V; Gazzo, S; Lepoivre, M; MacKey, J; Mantincic, D; Peters, GJ; Rolland, MO; Tigaud, I; Vanier-Viornery, A; Voorn, DA; Wyczechowska, D | 1 |
| Blanche, P; Bouscary, D; Dreyfus, F; Gombert, B; Sicard, D; Stieltjes, N | 1 |
| Fiser, J; Jindra, P; Koza, V; Svojgrová, M; Vozobulová, V | 1 |
| Ahmed, N; Baumforth, KR; Hassan, HT; Laverick, L; Sammons, J | 1 |
| Algeri, R; Bigazzi, C; Bocchia, M; Forconi, F; Lauria, F; Marconcini, S; Marotta, G | 1 |
| Demeter, J; Lehoczky, D; Varga, F | 1 |
| Costello, C; Shah, S; Stern, SC | 1 |
| Magagnoli, M; Pellacani, A; Tosi, P; Tura, S; Visani, G; Zinzani, PL | 1 |
| Austin, HA; Balow, JE; Boumpas, DT; Fleisher, TA; Kim, Y; Piscitelli, S; Pucino, F; Tassiulas, IO; Vaughan, E | 1 |
| Hast, R; Hjalmar, V; Jacobsson, B; Petrescu, A | 1 |
| Akça, S; Karadoğan, I; Undar, L | 1 |
| Allen, PD; Kelsey, SM; Newland, AC; Richardson, DS | 2 |
| Bellosillo, B; Colomer, D; Gil, J; Montserrat, E; Pons, G; Villamor, N | 1 |
| Cawley, JC; Pettitt, AR; Sherrington, PD | 2 |
| Baccarani, M; Marin, L; Ramello, M; Russo, D; Silvestri, F; Zaja, F | 1 |
| Bolgert, F; Camporo, P; Gonzalez, H; Leblond, V | 1 |
| Beinert, T; Hallek, M; Langelotz, C; Mergenthaler, HG; Possinger, K; Schmid, P; Schweigert, M; Sezer, O | 1 |
| Aitini, E; Battista, R; Bendandi, M; Bocchia, M; Cellini, C; De Renzo, A; Fattori, PP; Gentilini, P; Gherlinzoni, F; Guardigni, L; Magagnoli, M; Moretti, L; Ronconi, F; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Cawley, JC; Clarke, AR; Griffiths, SD; Pettitt, AR | 1 |
| Ahsan, G; Jones, R; Schey, S | 1 |
| Catovsky, D; Ribeiro, I; Tsatalas, C | 1 |
| Peterson, BA | 1 |
| Barrett, J; Childs, RW; Clave, E; Hensel, N; Plante, M; Tisdale, J | 1 |
| Barrett, J; Cheson, BD; Freidlin, B; Vena, DA | 1 |
| Li, MJ; Yang, LY | 1 |
| Ciolli, S; Ferrara, F; Leoni, F; Magrin, S; Mele, G; Mirto, S; Montillo, M; Morra, E; Pinto, A; Zagonel, V | 1 |
| Bentley, P; Davies, S; Hidalgo de Quintana, J; Hoy, T; Pepper, C; Thomas, A | 1 |
| Blaschke, V; Braess, J; Brinck, U; Dames, K; Letschert, M; Neumann, C; Reich, K; Rünger, TM; Wörmann, B | 1 |
| Bahceci, E; Barrett, J; Childs, R; Clave, E; Epperson, D | 1 |
| Grau, E; Pastor, E; Real, E; Sandra, S | 1 |
| Belanger, C; Bouabdallah, R; Brice, P; Brousse, N; Coiffier, B; Haioun, C; Janvier, M; Neidhardt-Bérard, EM; Péaud, PY; Pico, JL; Solal-Celigny, P; Tilly, H | 1 |
| Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB | 1 |
| Faure, I; Leng, B; Mercié, P; Pellegrin, JL; Viallard, JF | 1 |
| Albertioni, F; Eriksson, S; Månsson, E; Sällström, J; Spasokoukotskaja, T | 1 |
| Arcaini, L; Astori, C; Baldanti, F; Bernasconi, C; Furione, M; Gerna, G; Lazzarino, M; Orlandi, E; Pagnucco, G; Paulli, M; Viglio, A | 1 |
| Gandhi, V; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Plunkett, W; Robertson, LE; Santini, V; Seymour, JF | 1 |
| Albertioni, F; Larsson, BS; Liliemark, J; Lindemalm, S | 1 |
| Calvo Villas, J; Ramírez Sánchez, M; Sicilia Guillén, F | 1 |
| Honma, Y; Niitsu, N; Umeda, M | 1 |
| Bauer, O; Golfier, S; Klein, A; Miera, O; Schriever, F | 1 |
| Campos, F; Dufour, P; Giron, C; Maloisel, F | 1 |
| Arnaud, MC; Otto, J; Pivot, X; Schneider, M; Tchiknavorian, X; Thyss, A | 1 |
| Battista, R; Bendandi, M; Cellini, C; Ciccone, F; De Renzo, A; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Magagnoli, M; Marra, R; Mazza, P; Moretti, L; Ricciuti, F; Ronconi, F; Stefoni, V; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Cantú, OE; Gómez-Almaguer, D; González-Llano, O; Hernández, NE; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ | 1 |
| Lamberti, A; Romano, MF; Turco, MC; Venuta, S | 1 |
| Amurri, B; Mazza, P; Palazzo, G; Pricolo, G; Prudenzano, A; Stani, L | 1 |
| Bowyer, JD; Gregson, RM; Horn, EH; Johnson, EM | 1 |
| Bennett, JM; Cassileth, PA; Gordon, LI; Hochster, HS; Oken, MM; Raphael, BG; Winter, JN | 1 |
| Carella, AM; Giralt, S; Slavin, S | 1 |
| Calabrò, ML; Coppolino, S; Ficarra, P; Ficarra, R; Melardi, S; Semreen, M; Tommasini, S; Villari, A | 1 |
| Blum, HE; Geissler, M; Krohne, TU; Mohr, L; Roberts, B; Shankara, S; Wands, JR; Yoon, SK | 1 |
| Horning, SJ | 1 |
| Ahmad, I; Al-Katib, AM; Beck, FW; Liu, KZ; Mantsch, HH; Mohammad, RM; Wall, NR | 1 |
| Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S | 1 |
| Freireich, EJ; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S; Robertson, LE; Smith, TL | 1 |
| Bigazzi, C; Bocchia, M; Bucalossi, A; Galieni, P; Laszlo, D; Lauria, F; Marotta, G; Raspadori, D; Scalia, G; Tozzi, M | 1 |
| Chastang, C; Chevret, S; Leporrier, M | 1 |
| Casabianca, A; Celeste, AG; Chiarantini, L; Fraternale, A; Magnani, M; Schiavano, GF; Tonelli, A | 1 |
| Chatterjee, R; Goldstone, A; Haines, GA; Morris, ID; Perera, DM | 1 |
| Andreeff, M; Clodi, K; Consoli, U; Jiang, S; Kliche, KO; Schenk, T; Snell, V; Weidner, D; Zhao, S | 1 |
| Apperley, JF; Belhabri, A; Björkstrand, B; Dreger, P; Hamon, M; Kimby, E; Michallet, M; Milpied, N; Remes, K; Santini, G; Tanguy, ML; Thiébaut, A | 1 |
| Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P | 1 |
| Bernard, N; Beylot, J; Delevaux, I; Lacoste, D; Morlat, P; Nouts, C | 1 |
| Belanger, C; François, S; Hermine, O; Lebas de La Cour, JC; Lefrère, F; Tilly, H; Troussard, X; Valensi, F; Varet, B | 1 |
| Bosanquet, AG; Bosanquet, MI | 1 |
| Barth, S; Diehl, V; Engert, A; Oberhäuser, F; Pfitzner, T; Schinköthe, T; Schulz, H; Wittor, H | 1 |
| Cerretti, R; Coluzzi, S; Foa, R; Giannarelli, D; Girelli, G; Mandelli, F; Mauro, FR | 1 |
| Eberhardt, W; Heim, MM; Müller, MR; Seeber, S | 1 |
| Champlin, R; Giralt, S; Khouri, I | 1 |
| Bendandi, M; Cellini, C; Gherlinzoni, F; Magagnoli, M; Orcioni, GF; Pileri, SA; Stefoni, V; Tura, S; Zinzani, PL | 1 |
| Achanta, G; Feng, L; Huang, P; Pelicano, H; Plunkett, W; Zhang, W | 1 |
| Eckhaus, MA; Fowler, DH; Gress, RE; Petrus, MJ; Williams, JF | 1 |
| Nagler, A; Naparstek, E; Or, R; Samuel, S; Slavin, S; Varadi, G | 1 |
| Braess, J; Hiddemann, W; Jahns-Streubel, G; Kern, W; Keye, S; Schleyer, E; Unterhalt, M; Wegendt, C | 1 |
| Haznedar, R; Sucak, GT; Yağci, M | 2 |
| Chim, CS; Liang, R; Wong, SS; Yuen, KY | 1 |
| Grigg, A; Roberts, A; Seymour, JF; Szer, J | 1 |
| Januszewicz, EH; Juneja, S; Prince, HM; Seymour, C; Strickland, AH; Wolf, M | 1 |
| Catovsky, D; Dearden, CE; Matutes, E | 1 |
| Beer, M; Byrd, JC; Grever, MR; Lucas, MA; Waselenko, JK | 1 |
| Kipps, TJ | 1 |
| Foss, FM | 1 |
| Ambinder, RF; Byrd, JC; Diehl, LF; Flinn, IW; Grever, MR; Jamison, J; Morrison, C; Murphy, T; Piantadosi, S; Seifter, E; Vogelsang, G | 1 |
| Auxenfants, E; Bourgeois, E; Dubest, C; Jouffrey, C; Mahieu, M; Rose, C | 1 |
| Molinari, A; Poletti, G; Poletti, V; Salvucci, M; Zaccaria, A; Zanchini, R; Zuffa, E | 1 |
| Nagler, A; Or, R; Slavin, S; Varadi, G | 1 |
| Campbell, S; Ghosh, S; Parker, A; Thomas, R | 1 |
| Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Kroschinsky, F; Naumann, R; Neubauer, A; Platzbecker, U; Plettig, R; Röllig, C; Schuler, U; Thiede, C | 1 |
| Vastag, B | 1 |
| Cawley, JC; Pettitt, AR | 1 |
| Galloway, MJ; Hamilton, PJ; Tiplady, CW | 1 |
| Huang, P; Keating, MJ; Plunkett, W; Sandoval, A; Van Den Neste, E | 1 |
| Byrd, JC; Rai, KR | 1 |
| Au, WY; Choy, C; Kwong, YL; Ng, WM | 1 |
| Cervantes, F; Cervera, A; Cid, J; Ferrer, I; Montserrat, E; Muñoz, E; Revilla, M | 1 |
| Akhter, S; Ambrus, JL; Donahue, T; Islam, A; Sands, AM; Vladutiu, AO | 1 |
| Amaranto, P; Capria, S; Cimino, G; Cordone, I; de Fabritiis, P; Foa, R; Mandelli, F; Mauro, F; Meloni, G; Proia, A; Rapanotti, C; Reato, G; Vignetti, M | 1 |
| Baccarani, M; Capello, D; Fanin, R; Gaidano, G; Patriarca, F; Zaja, F | 1 |
| Bartholomew, A; Chen, YH; Devine, S; Hoffman, R; Koshy, M; Peace, D; Sher, D; Sosman, J; Stock, W; van Besien, K | 1 |
| Glenn, M; Golde, DW; Maslak, P; Noy, A; Rahman, Z; Scheinberg, DA; Weiss, MA; Zelenetz, A | 1 |
| Casado, FJ; Inzillo, SM; Larrayoz, IM; Lostao, MP; Mata, JF; Pastor-Anglada, M | 1 |
| Crawley, CR; Foran, JM; Gupta, RK; Johnson, PW; Johnson, SA; Lister, TA; Matthews, J; Micallef, IN; Radford, JA; Rohatiner, AZ; Summers, K; Sweetenham, JW | 1 |
| Chakrabarti, S; Chakraverty, RK; Chopra, R; de Elvira, MC; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD | 1 |
| Gabeeva, NG; Kaplanskaia, IB; Kremenetskaia, AM; Moiseeva, TN; Pivnik, AV; Samoĭlova, RS; Varlamova, EIu; Zybunova, EE | 1 |
| Astori, C; Bernasconi, C; Bernasconi, P; Boni, M; Calatroni, S; Caresana, M; Cavigliano, P; Giglio, S; Lazzarino, M; Orlandi, E; Pagnucco, G | 1 |
| Boguszewski, CL; Collaço, LM; Graf, H; Neto, JZ; Nomura, LM; Pereira, FO | 1 |
| Acholonu, S; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, RE; Cohen, A; Giralt, S; Hagemeister, F; Khouri, I; Körbling, MJ; Manning, J; Mclaughlin, P; Romaguera, J; Sarris, A; Ueno, NT | 1 |
| Du, M; Gandhi, V; Keating, MJ; Nowak, B; Paff, MT; Plunkett, W; Ramakrishna, P; Rodriguez, CO | 1 |
| Chee, YL; Culligan, DJ; Kurtz, JB; Molyneaux, P; Olson, JA; Watson, HG | 1 |
| Albertini, P; Bendandi, M; Magagnoli, M; Rondelli, D; Stefoni, V; Tani, M; Tura, S; Zinzani, PL | 1 |
| Abdel-Raheem, MM; Gross, GG; Jamil, MG; Potti, A | 1 |
| Adachi, S; Carrera, CJ; Carson, DA; Chao, Q; Cottam, HB; Genini, D; Leoni, LM; Rose, DW | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Chott, A; Geissler, K; Gisslinger, H; Jäger, U; Knöbl, P; Lechner, K; Schwarzinger, I; Thalhammer-Scherrer, R | 1 |
| Plunkett, W; Sampath, D | 1 |
| Harousseau, JL; Mahé, B; Milpied, N; Morin, O; Rapp, MJ; Vigouroux, S | 1 |
| Bishop, MR; McCarthy, NJ | 1 |
| Bigazzi, C; Bocchia, M; Lauria, F; Lenoci, M; Marotta, G; Tozzi, M | 1 |
| Appelbaum, FR; Cheson, BD; Elias, L; Hines, J; Kolitz, J; Larson, RA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L; Threatte, GA | 1 |
| Binet, JL; Dighiero, G | 1 |
| Acquaah-Mensah, GK; Biswal, SS; Datta, K; Kehrer, JP | 1 |
| Higashi, Y; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Oddis, CV | 1 |
| Johnson, SA; Thomas, W | 1 |
| Back, DJ; Hoggard, PG; Johnson, MA; Kewn, S; Sales, SD | 1 |
| Aul, C; Gattermann, N; Germing, U; Misgeld, E | 1 |
| del Mar Castellanos, M; Gardella, S; Mata, MI; Ortiz, MR | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Ciolli, S; Fanci, R; Leoni, F; Nozzoli, C; Rossi Ferrini , P; Santini, V | 1 |
| Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A | 1 |
| Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X | 1 |
| Auerbach, AD; Boulad, F; Collins, N; George, D; Gillio, A; Kernan, NA; O'Reilly, RJ; Prasad, V; Regan, AD; Small, TN; Torok-Castanza, J | 1 |
| Baccarani, M; Fanin, R; Patriarca, F; Silvestri, F; Sperotto, A; Zaja, F | 1 |
| Almeida, A; Daly, P; Dokal, I; McCloy, M; Roberts, IA; Vulliamy, T | 1 |
| Ahn, J; Chi, H; Kim, W; Lee, J; Lee, K; Park, C | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Claviez, A; Dreger, P; Glass, B; Humpe, A; Schmitz, N; Schoch, R; Seyfarth, B; Suttorp, M; von Neuhoff, N | 1 |
| Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Beran, M; Cortes, J; Giles, FJ; Kantarjian, HM; Keating, M; Koller, CA; Lerner, S; O'Brien, SM | 1 |
| Bruzzone, BM; Cataldi, A; Franceschini, R; Icardi, G; Tenconi, GL | 1 |
| Dai, Y; Decker, R; Dent, P; Grant, S; Harvey, S; Kramer, L; Schaefer, G; Tang, L | 1 |
| Ahlmann, M; Baumann, M; Boos, J; Freund, A; Lanvers, C; Lümkemann, K; Rössig, C | 1 |
| Chisesi, T; Congiu, AM; Gallamini, A; Gobbi, M; Marino, G; Mattei, D; Nati, S; Pierluigi, D; Rossi, E; Rubagotti, A; Santini, G; Sertoli, MR; Spriano, M; Truini, M; Vimercati, R | 1 |
| Bone, N; Han, L; Kay, NE; Williams, G | 1 |
| Filippa, D; Glenn, M; Keenan, JR; Maslak, P; Noy, A; Rahman, ZU; Verma, R; Weiss, M; Zelenetz, AD | 1 |
| Brandi, G; Casabianca, A; Chiarantini, L; Fraternale, A; Magnani, M; Tonelli, A | 1 |
| Andolina, M; Jankovic, G; Lepore, L; Maximova, N; Parco, S; Rabusin, M; Tuveri, G | 1 |
| Aker, M; Brautbar, C; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G | 1 |
| Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ | 1 |
| Greene, V; Kanold, J; Schneider, P; Vannier, JP | 1 |
| Chan, KW; Chik, KW; Jeha, S; Li, CK; Shing, MK; Worth, LL; Yuen, PM | 1 |
| Weiss, MA | 1 |
| Barosi, G; Liberato, LN; Marchetti, M | 1 |
| Copur, MS; Ledakis, P; Muhvic, J | 1 |
| Celik, I; Erman, M; Tekuzman, G | 1 |
| Mounter, P; Proctor, SJ; Summerfield, GP | 1 |
| Ayres, M; Du, M; Gandhi, V; Hodge, JP; Keating, MJ; O'Brien, S; Plunkett, W; Ramakrishna, P; Rodriguez, CO; Rosner, GL; Weller, S | 1 |
| Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Mohr, B; Platzbecker, U; Röllig, C; Schaich, M; Schäkel, U; Thiede, C | 1 |
| Nagler, A; Or, R; Panigrahi, S; Shapira, MY; Slavin, S; Wolf, DG | 1 |
| Hendrick, A | 1 |
| Balázs, M; Kappelmayer, J; Karászi, E; Kiss, A; Mezei, G; Rák, K; Rejtó, L; Telek, B; Udvardy, M; Ujj, G | 1 |
| Joshi, SS; Pavletic, ZS; Vu, UE; Wang, X | 1 |
| Imrie, KR; Tinmouth, A; Zanke, B | 1 |
| Chatterjee, R; Goldstone, AH; Kottaridis, PD; McGarrigle, H | 1 |
| Boumpas, DT; Burstein, AH; Illei, GG; Kuo, GM; Pucino, F; Yarboro, C | 1 |
| Antin, JH; Duffy, KM; Kathakali, A; Laport, G; Leonard, DG; Luger, SM; McDaid, K; Orloff, G; Porter, DL; Schuster, SJ; Stadtmauer, EA; Tsai, D | 1 |
| Child, FJ; Clift, A; Russell-Jones, R; Sabroe, R; Scarisbrick, JJ; Spittle, M; Whittaker, SJ | 1 |
| Akiyama, H; Hiruma, K; Kaku, H; Karasawa, K; Kono, N; Maeda, Y; Mizuchi, D; Mori, S; Ohashi, K; Okamoto, R; Okoshi, Y; Okuyama, Y; Sakamaki, H; Sasaki, E; Sasaki, T | 1 |
| Carbone, GM; Catapano, CV; Fernandes, DJ | 1 |
| Byrd, JC; Flinn, IW; Grever, MR; Lehman, T; Lucas, D; Sausville, E; Shinn, C; Willis, CR | 1 |
| Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD | 1 |
| Ogura, M | 1 |
| Bourikas, G; Kaloutsi, V; Kotsianidis, I; Margaritis, D; Martinis, G; Tsatalas, C | 1 |
| Dumontet, C; Galmarini, CM; Mackey, JR | 1 |
| Barlogie, B; Crowley, JJ; Dhodapkar, MV; Gertz, MA; Jacobson, JL; Kyle, RA; Rivkin, SE; Roodman, GD; Shurafa, M; Tuscano, JM | 1 |
| Allen, J; Amagai, M; Carmichael, AJ; Dean, D; Frith, P; Gooptu, C; Hashimoto, T; Littlewood, TJ; Lyon, CC; MacWhannell, A; Oliwiecki, S; Wojnarowska, F | 1 |
| Delannoy, A; Feremans, W; Ferrant, A; Michaux, L; Van Den Neste, E | 1 |
| Ariola, C; Cordone, I; Fazi, F; Fenu, S; Mandelli, F; Montefusco, E; Nanni, M; Petti, MC; Spadea, A; Spiriti, MA | 1 |
| Carella, AM; Carotenuto, M; Cascavilla, N; D'Arena, G; Greco, MM; Ladogana, S; Melillo, L; Perla, G; Sajeva, MR | 1 |
| Balleari, E; Beltrami, G; Canepa, L; Carrara, P; Cerri, R; Clavio, M; Damasio, E; Gatto, S; Ghio, R; Gobbi, M; Masoudi, B; Miglino, M; Pierri, I; Sessarego, M | 1 |
| Ghalie, R; Gregory, SA; Kraemer, K; Menduni, T; Modiano, M; Rifkin, R; Rubin, A; Vose, J | 1 |
| Baccarani, M; Bertone, A; Bucalossi, A; De Vivo, A; Gobbi, M; Lauria, F; Marin, L; Mazza, P; Michelutti, A; Michieli, M; Pierri, I; Pricolo, G; Raspadori, D; Russo, D; Zaccaria, A; Zuffa, E | 1 |
| Cacciola, E; Di Raimondo, F; Giustolisi, R; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S | 1 |
| Cazin, B; Chevret, S; Delabarre, F; Leporrier, M; Levy, V; Porcher, R | 1 |
| Boehrer, S; Chow, KU; Engels, K; Hansmann, ML; Harder, L; Hinz, T; Hoelzer, D; Janssen, O; Kabelitz, D; Kriener, S; Mitrou, PS; Rummel, MJ; Siebert, R; Weidmann, E | 1 |
| Emmerich, B; Hallek, M; Schmitt, B; Stein, H | 1 |
| Brandt, L; Glimelius, B; Kimby, E; Nygren, P | 1 |
| Blume, KG; Chauncey, T; Feinstein, L; Flowers, C; Georges, G; Kiem, HP; Little, MT; Maloney, D; Maris, M; McSweeney, PA; Nash, RA; Niederwieser, D; Radich, J; Sandmaier, B; Shizuru, J; Storb, R; Woolfrey, A; Zaucha, JM | 1 |
| Hallek, M; Schmitt, B | 1 |
| Bentley, P; Fegan, C; Hoy, T; Pepper, C; Thomas, A | 1 |
| Braess, J; Büchner, T; Hiddemann, W; Kern, W; Ohnesorge, J; Schleyer, E; Unterhalt, M; Wittmer, E; Wörmann, B | 1 |
| Bryon, RJ; Chakrabarti, S; Griffiths, MJ; Handa, SK; Milligan, DW | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Jenke, A; Lutterbeck, K; Oelschlagel, U; Platzbecker, U; Plettig, R; Röllig, C; Thiede, C | 1 |
| Classen, CF; Debatin, KM; Fairbanks, L; Friedrich, W; Hoffmann, GF; Schulz, AS; Sigl-Kraetzig, M; Simmonds, HA | 1 |
| Grigg, AP; Ritchie, DS; Roberts, AW; Seymour, JF; Szer, J | 1 |
| de Medeiros, CR; Pasquini, R; Silva, LM | 1 |
| Blume, KG; Chauncey, T; Forman, S; Maloney, DG; Maris, M; McSweeney, PA; Niederwieser, D; Sandmaier, BM; Shizuru, J; Storb, R; Woolfrey, A | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Martell, RE; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Czuczman, MS | 2 |
| Derigs, HG; Fischer, T; Huber, C; Kolbe, K; Kreiter, S; Schneider, PM; Schuler, M; Ullmann, AJ; Winkelmann, N | 1 |
| Cazin, B; Chevret, S; Fermand, JP; Guibon, O; Harousseau, JL; Leblond, V; Lévy, V; Maloisel, F; Porcher, R; Remenieras, L | 1 |
| Brittinger, G; Busch, R; Döhner, H; Emmerich, B; Fostitsch, HP; Franke, A; Freund, M; Hallek, M; Herold, M; Hiddemann, W; Knauf, W; Kröber, A; Kuse, R; Nerl, C; Schmitt, B; Schriever, F; Sezer, O; Thiel, E; Wendtner, CM; Wilhelm, M | 1 |
| Fujioka, T; Hirabayashi, N; Ikegame, K; Kawakami, M; Murakami, M; Ogawa, H; Soma, T; Sugiyama, H; Takahashi, R; Takimoto, T; Tamaki, H | 1 |
| Chi, HS; Kim, WK; Lee, JH; Lee, JS; Lee, KH | 1 |
| Akerstein, A; Engelhard, D; Gelfand, Y; Morecki, S; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G | 1 |
| Churn, M; Clough, V | 1 |
| de Andrés, I; Gallardo, E; Illa, I | 1 |
| Bassan, R; Di Gaetano, N; Erba, E; Golay, J; Introna, M; Rambaldi, A; Xiao, Y | 1 |
| Ehninger, G; Fiedler, F; Friedrichsen, K; Hänel, A; Hänel, M; Herbst, R; Morgner, A; Neser, S; Nicklisch, M; Teich, M | 1 |
| Owen, RG | 1 |
| Eigler, A; Emmerich, B; Endres, S; Loher, F; Meinhardt, G; Siegmund, B; Welsch, J | 1 |
| Beran, M; Cortes, J; Despa, S; Estey, EH; Faderl, S; Giles, FJ; Kantarjian, H; Koller, CA; O'Brien, S; Shen, Y; Thomas, DA | 1 |
| Cortes, J; Giles, F; Kantarjian, H; Keating, M; Koller, C; Loscertales, J; O'Brien, S; Thomas, D | 1 |
| Chizuka, A; Iijima, K; Iizuka, A; Kamijo, K; Kanai, S; Kanda, Y; Kawano, Y; Makimoto, A; Mineishi, S; Nakai, K; Niiya, H; Ohnishi, M; Ohnishi, T; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Ueda, K; Wakasugi, H; Yakushijin, K | 1 |
| Amin, K; Chen, YH; Devine, H; Devine, SM; Huml, M; Jessop, E; Maningo, M; Peace, D; Sanborn, R; Stock, W; Thomason, D; van Besien, K; Wickrema, A; Yassine, M | 1 |
| Rouger, P; Wautier, JL | 1 |
| Kashyap, A; Snowden, J | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Pagnucco, G; Varettoni, M | 1 |
| Lim, LC; Ng, HJ | 1 |
| Cazin, B; Deconinck, E; Desablens, B; Fermand, JP; Gardembas, M; Guibon, O; Guilhot, F; Harousseau, JL; Leblond, V; Lévy, V; Maloisel, F; Marit, G; Philippe, G; Porcher, R; Remenieras, L; Stamatoullas, A | 1 |
| Sallah, S; Wan, JY | 1 |
| Beltrami, G; Carella, AM; Carella, M; Corsetti, MT; Greco, M; Scalzulli, RP | 1 |
| Battista, C; Broccia, G; Capalbo, S; Castoldi, G; Cuneo, A; Leoni, P; Liso, V; Molica, S; Montillo, M; Pogliani, E; Specchia, G | 1 |
| Abreu-Díaz, G; Bravo, G; Gómez-Almaguer, D; Jaime-Pérez, JC; López-Martínez, B; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ | 1 |
| Egerer, G; Ho, AD; Sauerland, K | 1 |
| Gabrilove, JL | 1 |
| Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Keating, MJ; Nowak, BJ; Plunkett, W; Yamauchi, T | 1 |
| Engstrom, LW; Fuchs, EJ; Iannone, R; Jalla, S; Luznik, L | 1 |
| Bornhäuser, M; Ehninger, G; Hertenstein, B; Kiehl, M; Kröger, N; Martin, H; Runde, V; Sayer, HG; Schetelig, J; Schwerdtfeger, R; Siegert, W; Theuser, C | 1 |
| Bargay, J; Caballero, MD; Canals, C; Conde, JG; Léon, A; Martino, R; Odriozola, J; Rayón, C; San Miguel, J; Sarrá, J; Sierra, J; Simón, JA; Solano, C; Urbano-Ispízua, A | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Bensinger, WI; Gooley, T; Maloney, DG; Sandmaier, BM; Storb, R; Weissinger, F | 1 |
| Anderlini, P; Cabanillas, FF; Champlin, RE; Donato, ML; Gajewski, JL; Giralt, SA; Hagemeister, FB; Ippoliti, C; Khouri, IF; Korbling, M; Lee, MS; McLaughlin, P; Okoroji, GJ; Saliba, RM; Younes, A | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Levesque, MC; Moore, J; Silber, R; Smith, KL; Weinberg, JB | 1 |
| Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 2 |
| Barrett, AJ; Carter, C; Childs, R; de Witte, M; Kang, EM; Leitman, SF; Little, R; Malech, H; Morgan, RA; Phang, S; Tisdale, JF | 1 |
| Brune, M; Ekman, T; Johansson, JE | 1 |
| Bacigalupo, A; Endo, T; Fujimoto, K; Koike, T; Nakao, S; Nishio, M; Sakai, T; Sawada, K; Takashima, H | 1 |
| Chevret, S; Mahé, C | 1 |
| Czyz, M; Fabianowska-Majewska, K; Wyczechowska, D | 1 |
| Branson, K; Chakrabarti, S; Chakraverty, R; Chopra, R; Craddock, C; Geary, J; Goldstone, AH; Hale, G; Hunter, A; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Milligan, DW; Parker, A; Peggs, K; Thuraisundaram, D; Verfuerth, S; Waldmann, H; Williams, CD; Yong, K | 1 |
| Imamura, N | 1 |
| Kolb, HJ; Ledderose, G; Schlemmer, M; Schleuning, M; Stoetzer, O; Waterhouse, C | 1 |
| Cuello, MT; Fundia, AF; González-Cid, M; Larripa, I | 1 |
| Champain, K; Csermak, K; Ganeshaguru, K; Gordon, M; Hart, SM; Hoffbrand, AV; Jones, DT; Man, A; Mehta, AB; Prentice, HG; Virchis, AE; Wickremasinghe, RG | 1 |
| Appelbaum, FR | 1 |
| Cavenagh, J; Edgar, JD; Haque, T; Helbert, MR; Longhurst, HJ; Syndercombe-Court, D; Taussig, D | 1 |
| Benyunes, M; Bernstein, SH; Bernstein, ZP; Brown, K; Czuczman, MS; Fallon, A; Grillo-López, AJ; Klippenstein, D; Loud, P; McCarthy, P; Miller, K; Mohr, A; Rock, MK; Skipper, M; Stewart, C; Wentling, D | 1 |
| Cabanillas, F; Ford, RJ; Jiang, Y; McLaughlin, P; Medeiros, LJ; Rassidakis, GZ; Sarris, AH; Thomaides, A; Tsimberidou, AM | 1 |
| Albitar, M; Keating, MJ; O'Brien, S | 1 |
| Fezoui, H; Genet, P; Lionnet, F; Louvel, D; Pulik, M; Touahri, T | 1 |
| Aschan, J; Barkholt, L; Brune, M; Hentschke, P; Mattsson, J; Ringdén, O; Stierner, U; Uzunel, M | 1 |
| Bertz, H; Finke, J; Illerhaus, G; Veelken, H | 1 |
| Casanova, B; de la Fuente, MT; Garcia-Gila, M; Garcia-Marco, J; Garcia-Pardo, A; Moyano, JV; Sanz, L; Silva, A | 1 |
| Carter, C; Hillmen, P; Kennedy, B; Lucas, G; Rawstron, A; Ryan, M; Speed, K | 1 |
| Bradlow, BA; Chen, YH; Devine, SM; Hoffman, R; Huml, M; Jessop, E; Maynard, V; Peace, D; Shah, R; Stock, W; Thomason, D; van Besien, K; Verma, A | 1 |
| de Frutos, MA | 1 |
| Mounter, PJ; Proctor, SJ; Summerfield, GP; Taylor, PR | 1 |
| Beltrami, G; Carella, AM; Cavaliere, M; Corsetti, MT; Lerma, E | 1 |
| Bashey, A | 1 |
| Anagnostopoulos, A; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kiamouris, C; Mantzios, G; Nicolaides, C; Papageorgiou, E | 1 |
| Hulkkonen, J; Hurme, M; Kivekäs, I; Vilpo, J; Vilpo, L | 1 |
| Apostolidis, J; Bradburn, M; Cavenagh, JD; Crawley, CR; Foran, JM; Gupta, RK; Leonhardt, M; Lister, TA; Matthews, J; Micallef, IN; Okukenu, E; Rohatiner, AZ; Salam, A; Wiggins, C | 1 |
| Byrd, JC; Flynn, JM; Howard, RS; Perkins, JG | 1 |
| Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC | 1 |
| Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R | 1 |
| Jain, VK; Ogden, JL; Wilder, DD | 1 |
| Abruzzo, LV; Jones, D; Keating, MJ; Luthra, R; Manning, JT; Medeiros, LJ; Rosales, CM; Vega, F | 1 |
| Goldschmidt, H; Görner, M; Ho, AD; Kordelas, L; Luft, T; Moos, M; Pfeiffer, S; Punzel, M; Thalheimer, M; Ustaoglu, F; Weber-Nordt, R | 1 |
| Albitar, M; Binet, JL; Brettman, L; Byrd, J; Flinn, I; Hillmen, P; Jain, V; Keating, MJ; Rai, KR; Santabarbara, P; Wacker, B | 1 |
| Clausen, NT; Hansen, PB; Larsen, CR | 1 |
| Isaksson, HJ; Mosher, DF; Onundarson, PT; Salamat, MS; Vidarsson, B | 1 |
| Halaburda, K; Hellmann, A; Lewandowski, K | 1 |
| Castells, G; Escoda, L; Marés, R; Richart, C; Saumoy, M; Ugarriza, A | 1 |
| Dwyer, KM; Firkin, F; Hill, PA; Lee, P; Murphy, BF | 1 |
| Da Prada, GA; Della Cuna, GR; Giorgiani, G; Giraldi, E; Landonio, G; Locatelli, F; Pedrazzoli, P; Schiavo, R; Siena, S; Zambelli, A | 1 |
| Barton, P; Bryan, S; Davenport, C; Fry-Smith, A; Hyde, C; Song, F; Wake, B | 1 |
| Barth, S; Borchmann, P; Diehl, V; Engert, A; Oberhäuser, F; Pfitzner, T; Reiser, M; Schinköthe, T; Schulz, H; Tur, M; Wessels, J | 1 |
| Voutsadakis, IA | 1 |
| Cerretti, R; De Propriis, MS; Foa, R; Gentile, M; Giannarelli, D; Guarini, A; Mancini, F; Mauro, FR | 1 |
| Kawai, Y; Ueda, T; Yamauchi, T | 1 |
| Amir, G; Berrebi, A; Cohen, Y; Da'as, N; Libster, D; Polliack, A | 1 |
| Kasznicki, M; Robak, T | 1 |
| Bosanquet, AG; Bosanquet, MI; Daniel, PT; Dörken, B; Essmann, F; Head, DJ; Sturm, I; Wieder, T | 1 |
| Hallek, M | 3 |
| Barlogie, B; Desikan, KR; Dhodapkar, MV | 1 |
| Amir, G; Cohen, Y; Polliack, A | 1 |
| Ang, KK; Beauduin, M; Garden, AS; Grégoire, V; Hamoir, M; Hittelman, WN; Humblet, Y; Khuri, FR; Milas, L; Mitine, C; Rosier, JF; Scalliet, P | 1 |
| Andreesen, R; Bauer, S; Eissner, G; Gerbitz, A; Haffner, S; Holler, E; Kirchner, S; Multhoff, G; Sondermann, D | 1 |
| Diehl, V; Voliotis, D | 1 |
| Bissières, P; Devillers, C; Dusanter-Fourt, I; Fagard, R; Feuillard, J; Lenoir, G; Martin, A; Mouas, H; Raphaël, M; VanTan, H | 1 |
| Brando, B; Cafro, AM; Cairoli, R; Montillo, M; Morra, E; Oreste, P; Pungolino, E; Rossi, V; Tedeschi, A; Veronese, S | 1 |
| Batlle, M; Feliu, E; Mate, JL; Millá, F; Ribera, JM; Rodríguez, L; Xicoy, B | 1 |
| Itälä, M; Remes, K | 1 |
| Brugger, S; Gisslinger, H; Greinix, HT; Kalhs, P; Keil, F; Lechner, K; Mannhalter, C; Mitterbauer, G; Mitterbauer, M; Moser, K; Prinz, E | 1 |
| Cohen, HJ; Elias, L; Hines, J; Hurwitz, HI; Larson, RA; Martell, RE; Morrison, VA; Peterson, BL; Petros, WP; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Bard, V; Foon, KA; LaRocca, RV; Rohatgi, N; Sethuraman, G | 1 |
| Basmaji, N; Garg, MS; Garg, S | 1 |
| Herrera, GA; Isaac, J | 1 |
| Guo, K; Song, Z; Wu, B; Xiao, L; Yan, D; Yang, Y | 1 |
| Batár, P; Kiss, A; Rák, K; Rejtó, L; Reményi, G; Telek, B; Udvardy, M | 1 |
| Bergmann, M; Busch, R; Emmerich, B; Franke, A; Hallek, M; Hiddemann, W; Hopfinger, G; Pasold, R; Schlag, R; Schmitt, B; Wendtner, CM | 1 |
| Arcache, J; Arnaud, P; Berger, F; Callet-Bauchu, E; Coiffier, B; Dumontet, C; Felman, P; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Andreeff, M; Cortes, JE; Faderl, S; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Tsimberidou, AM | 1 |
| Bos, GM; Huugen, D; Jansen, M; Jansen, R; Lalisang, R; Schouten, HC; Wagstaff, J | 1 |
| Aivado, M; Burger, J; Finke, J; Haas, R; Henze, L; Schulte, K | 1 |
| Chakrabarti, S; Chakraverty, RK; Chopra, R; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; MacKinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Ruiz de Elvira, MC; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD | 1 |
| Bellosillo, B; Bosch, F; Campo, E; Colomer, D; López-Guillermo, A; Marcé, S; Montserrat, E; Villamor, N | 1 |
| Montserrat, E | 2 |
| Plunkett, W; Sampath, D; Shi, Z | 1 |
| Champlin, RE; Keating, MJ; Khouri, IF; Saliba, RM | 1 |
| Bargay, J; Brunet, S; Caballero, MD; Canals, C; Léon, A; Martino, R; Moraleda, JM; Pérez-Simón, JA; San Miguel, J; Sanz, GF; Sarrá, J; Sierra, J; Simón, JA; Solano, C; Urbano-Ispízua, A | 1 |
| Cheson, BD; Hegde, UP; White, T; Wilson, WH | 1 |
| Belch, AR; Cass, CE; Coupland, R; Graham, KA; Mackey, JR; Reiman, T; Wong, J; Young, J | 1 |
| Appel, GB; Radhakrishnan, J; Rosenstock, JL; Sherman, WH; Stern, L | 1 |
| Chao, NJ; Clay, TM; Hobeika, AC; Lyerly, HK; Morse, MA; Mosca, PJ; Rizzieri, D; Stenzel, TT; Vredenburgh, JJ | 1 |
| Balzarotti, M; Bertuzzi, A; Castagna, L; Farè, M; Grimoldi, MG; Magagnoli, M; Nozza, A; Santoro, A; Sarina, B; Sinnone, M; Siracusano, L; Timofeeva, I | 1 |
| de Fabritiis, P; De Propris, MS; Foa, R; Gentile, M; Giammartini, E; Giannarelli, D; Mandelli, F; Mauro, FR; Meloni, G; Rapanotti, MC | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Ales, NC; Byrd, JC; Helman, DL; Shorr, AF | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Brettman, L; Cooper, MR; Freter, CE; Mercier, RJ; Mitchell, BS; Rai, KR; Santábarbara, P; Stadtmauer, EA; Wacker, B | 1 |
| Darbyshire, PJ; Kinning, E; Ortín, M; Raj, R; Williams, M | 1 |
| Aleman, A; Alexanian, R; Anagnostopoulos, A; Anderlini, P; Champlin, R; Donato, M; Gajewski, J; Giralt, S; Khouri, I; Korbling, M; Molldrem, J; Ueno, NT; Weber, D | 1 |
| Field, K; Seymour, JF; Slavin, MA | 1 |
| Andreeff, M; Bennett, F; Charboneau, L; Kim, Y; Kipps, TJ; Kitada, S; Liotta, LD; Pedersen, IM; Rassenti, L; Reed, JC; Schimmer, A; Sporn, MB; Zapata, JM | 1 |
| Bolaños-Meade, J; Khanwani, SL; Sarkodee-Adoo, C | 1 |
| Fukiya, E; Kimura, S; Kobayashi, Y; Kuroda, J; Murotani, Y; Ozawa, M; Terao, K; Yoshikawa, T | 1 |
| Afanasyev, BV; Anagnostopoulos, A; Andreeff, M; Champlin, RE; Mikhailova, N; O'Brien, S; Pankratova, OS; Rondón, G; Semenova, EV; Ueno, NT; Zaritskey, AY; Zoubarovskaya, LS | 1 |
| Azuma, T; Fujita, S; Ishimura, M; Takada, K; Yamauchi, H; Yasukawa, M | 1 |
| Licht, A; Meier, R; Taverna, C; Trojan, A | 1 |
| Andersson, BS; Brown, C; Chaudhry, A; Duggan, P; Glick, S; Gyonyor, E; Morris, D; Quinlan, D; Ruether, JD; Russell, JA; Stewart, D; Tran, HT | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Aulitzky, WE; Diehl, V; Engert, A; Hallek, M; Hensel, M; Herold, M; Hinke, A; Huhn, D; Klein, SK; Knauf, WU; Rehwald, U; Reiser, M; Schulz, H | 1 |
| Caballero, D; Chopra, R; Craddock, C; García-Conde, J; Goldstone, AH; Hunter, A; Kottaridis, PD; Leon, A; Linch, DC; Mackinnon, S; Martino, R; Milligan, DW; Parker, A; Pérez-Simón, JA; San Miguel, JF; Schey, S; Sierra, J; Sureda, A; Urbano-Ispizua, A; Yong, K | 1 |
| Byrd, JC; Hoke, E; Jacobson, R; Larson, RA; Morrison, VA; Park, K; Peterson, BL; Rai, K; Schiffer, CA; Vardiman, JW | 1 |
| Ayuk, F; Fehse, B; Kiehl, M; Kröger, N; Nagler, A; Renges, H; Sayer, HG; Schmitz, N; Schwerdtfeger, R; Wittkowsky, G; Zabelina, T; Zander, AR | 1 |
| Anasetti, C; Blume, KG; Chauncey, T; Deininger, M; Hegenbart, U; Lange, T; Little, MT; Maloney, DG; Maris, M; McSweeney, PA; Niederwieser, D; Petersdorf, E; Pönisch, W; Sandmaier, BM; Shizuru, JA; Storb, RF; Storer, B; Woolfrey, A | 1 |
| Belohradsky, BH; Blanche, S; Bordigoni, P; Cant, A; Di Bartolomeo, P; Fischer, A; Flood, T; Gungor, T; Landais, P; Müller, S; Nagler, A; Ozsahin, H; Passwell, JH; Porta, F; Seger, RA; Slavin, S; Wulffraat, N; Zintl, F | 1 |
| Ackerstein, A; Aker, M; Amar, A; Nagler, A; Naparstek, E; Or, R; Resnick, I; Samuel, S; Shapira, MY; Slavin, S | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Eucker, J; Huhn, D; Jakob, C; Kingreen, D; Mergenthaler, HG; Possinger, K; Schetelig, J; Schille, C; Schmid, P; Sezer, O | 1 |
| Böck, HP; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Gertz, MA | 2 |
| Antoun, S; Carpiuc, I; Delabarthe, A; Driss, B; Fenaux, R; Griscelli, F; Ribrag, V; Vantelon, JM | 1 |
| Canazzio, A; De Stefano, P; Giorgiani, G; Locatelli, F; Nobili, B; Perrotta, S; Rossi, G; Zecca, M | 1 |
| Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M | 1 |
| Hansz, J | 1 |
| Garzia, M; Laurenti, L; Leone, G; Piccioni, P; Sabatelli, M; Sora', F | 1 |
| Basara, N; Fauser, AA; Guenzelmann, S; Kiehl, MG; Kraut, L; Roemer, E; Schmetzer, B | 1 |
| Aversa, F; Carotti, A; Falcinelli, F; Felicini, R; Martelli, MF; Tabilio, A; Terenzi, A; Velardi, A | 1 |
| Agura, E; Blume, KG; Bruno, B; Chauncey, TR; Feinstein, L; Forman, S; Georges, GE; Hegenbart, U; Little, MT; Malone, DG; Maris, M; McSweeney, PA; Niederweiser, D; Pulsipher, MA; Radich, JP; Sahebi, F; Sandmaier, BM; Shizuru, JA; Storb, R; Woolfrey, AE | 1 |
| Ayuk, FA; Erttmann, R; Hansen, A; Hessling, J; Kordes, U; Kröger, N; Panse, J; Renges, H; Werner, M; Zabelina, T; Zander, AR | 1 |
| Basok, A; Mostoslavsky, M; Rogachev, B; Shnaider, A; Tovbin, D | 1 |
| Brandi, G; Casabianca, A; Chiarantini, L; Fraternale, A; Magnani, M; Orlandi, C; Silvestri, G | 1 |
| Chamorey, AL; Milano, G; Thyss, A | 1 |
| Anxionnat, R; Grignon, Y; Hulin, C; Léonard, S; Taillandier, L; Vespignani, H | 1 |
| Altés, A; Bellosillo, B; Besalduch, J; Bosch, F; Cobo, F; Colomer, D; Esteve, J; Ferrer, A; Giné, E; López-Guillermo, A; Montserrat, E; Perales, M; Ribera, JM; Villamor, N | 1 |
| Giralt, S; Goldman, JM; Hale, G; Mackinnon, S; Slavin, S; Waldmann, H | 1 |
| Abonour, R; Logan, TF; Nelson, RP | 1 |
| Gajewski, JL; Hicks, K; Peng, D | 1 |
| Baldwin, SA; Cass, CE; Clarke, ML; Mackey, JR; Young, JD | 1 |
| Grenier, JF; Guévin, R; Klasa, RJ; Laplante, S; Maksymiuk, A; Meyer, RM; Rubinger, M; Samosh, M; Sawka, CA; Shustik, C; Smith, A | 1 |
| Albertioni, F; Elford, H; Eriksson, S; Flordal, E; Lagercrantz, S; Liliemark, J; Månsson, E; Spasokoukotskaja, T | 1 |
| Horie, T; Horikoshi, A; Hosokawa, Y; Sawada, S; Takei, K | 1 |
| Cavalli-Björkman, N; Gruber, A; Kalin, M; Lundin, J; Osby, E; Osterborg, A | 1 |
| Cragg, L; Feldman, EJ; Grant, S; Roberts, JD; Smith, MR | 1 |
| Appelbaum, FR; Bruno, B; Chauncey, TR; Feinstein, LC; Gooley, TA; Hegenbart, U; Maloney, DG; Maris, MB; McSweeney, PA; Niederwieser, DW; Sandmaier, BM; Storb, RF | 1 |
| Baron, F; Beguin, Y; Fillet, G; Frère, P; Herens, C | 1 |
| Caenazzo, L; Calore, E; Cesaro, S; De Silvestro, G; Destro, R; Gazzola, MV; Marson, P; Messina, C; Pillon, M; Varotto, S; Zanesco, L | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Pralle, H; Schmidt-Wolf, I; Strehl, J; Ziske, C | 1 |
| Adams, DJ; Chao, NJ; DeCastro, CM; Foster, T; Gasparetto, C; Gockerman, JP; Ibom, VK; Long, GD; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL; Thompson, M; Vredenburgh, JJ | 1 |
| Chakrabarti, S | 1 |
| Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK | 1 |
| Eagleton, H; Hatton, C; Leyden, K; Littlewood, T; Pearson, D; Pillai, N; Sternberg, A; Turner, S | 1 |
| Chakrabarti, S; Mackinnon, S | 1 |
| Byrd, JC; Larson, RA; Peterson, B; Piro, L; Saven, A; Schiffer, C; Vardiman, JW | 1 |
| Jeleń, M; Kuliczkowski, K; Kuliszkiewicz-Janus, M; Małecki, R | 1 |
| Balleari, E; Capaia, M; Clavio, M; de Totero, D; Foa, R; Gobbi, M; Montera, MP; Tazzari, PL | 1 |
| Fernandez, MJ; Grau, E; Llopis, I; Pastor, E; Real, E | 1 |
| Clouse, LH; Hussain, K; Mazza, JJ | 1 |
| Beyer, J; Bornhäuser, M; Ehninger, G; Fauser, AA; Hensel, M; Ho, AD; Kiehl, M; Kienast, J; Kröger, N; Neubauer, A; Scheffold, C; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zander, AR | 1 |
| Beyan, C; Cetin, T; Kaptan, K; Nevruz, O; Satar, B | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Albiin, N; Barkholt, L; Hentschke, P; Martola, J; Mattsson, J; Pisa, P; Remberger, M; Ringdén, O; Söderberg, M; Thörne, A; Uzunel, M; Wernerson, A; Wersäll, P | 1 |
| Abdul-Hai, A; Amir, G; Or, R; Polliack, A; Weiss, L | 1 |
| Bourikas, G; Kaloutsi, V; Margaritis, D; Pantelidou, D; Spanudakis, E; Tsatalas, C | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Bacigalupo, A; Balleari, E; Ballerini, F; Beltrami, G; Canepa, L; Carella, AM; Carrara, P; Cerri, R; Clavio, M; Galbusera, V; Gatto, S; Ghio, R; Gobbi, M; Miglino, M; Pierri, I; Quintino, S; Risso, M; Sessarego, M; Varaldo, R; Venturino, C | 1 |
| Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P | 1 |
| Bocchia, M; Forconi, F; Gentili, S; Lauria, F; le Noci, M; Tozzi, M | 1 |
| Dreyling, M; Hiddemann, W; Unterhalt, M | 1 |
| Ayash, L; Braun, T; Ferrara, JL; Hutchinson, R; Levine, JE; Ratanatharathorn, V; Reynolds, C; Silver, SM; Uberti, JP; Yanik, G | 1 |
| Albitar, M; Alvarado, Y; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Thomas, DA; Tsimberidou, AM; Verstovsek, S; Wierda, W | 1 |
| Flowers, ME; Leisenring, W; Maloney, DG; Maris, MB; Martin, PJ; Mielcarek, M; Sandmaier, BM; Storb, R | 1 |
| Aliff, TB; Frankel, SR; Horgan, D; Jurcic, JG; Kossman, SE; Lamanna, N; Maslak, PG; Scheinberg, DA; Weiss, MA | 1 |
| Abbasi, MR; Sarta, C; Sparano, JA; Wiernik, PH | 1 |
| Comoli, P; De Stefano, P; Giorgiani, G; Locatelli, F; Maccario, R; Nobili, B; Rossi, G; Salvaneschi, L | 1 |
| Abebe, L; Adiga, GU; Wiernik, PH | 1 |
| Anasetti, C; Appelbaum, FR; Bornhauser, M; Deeg, HJ; Ehninger, G; Hansen, J; Jenke, A; Martin, PJ; McDonald, GB; Nichols, WG; Radich, J; Schleyer, E; Slattery, JT; Storer, B; Thiede, C; Woolfrey, A | 1 |
| Baron, F; Baudoux, E; Beguin, Y; Fillet, G; Frère, P; Sautois, B | 1 |
| Canelhas, A; Coelho, H; Guerra, M; Lima, M; Pinto Ribeiro, AC; Teixeira, Mdos A | 1 |
| Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Kontoyiannis, D; Lerner, S; O'Brien, S; Plunkett, W | 1 |
| Joshi, SS; Pavletic, ZS; Wang, P | 1 |
| Bar, M; Cohen, NS; del Prete, S; Flamm, M; Garrett, TJ; Heitjan, D; Hesdorffer, CS; Lonberg, M; March, R; Mears, JG; Nichols, G; Oster, MW; Savage, DG; Talbot, S; Taub, RN | 1 |
| Lucas, T; Samorapoompichit, P; Schedled, A; Sperr, WR; Steiner, M; Valent, P; Wachtler, F | 1 |
| De Braekeleer, M; Herry, A; Le Bris, MJ; Morel, F; Morice, P | 1 |
| Aquino, VM; Berryman, B; Collins, RH; Douek, DC; Jain, VK; Johnson, M | 1 |
| Korycka, A; Robak, T | 2 |
| Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Bertz, H; Finke, J; Potthoff, K | 1 |
| Gazelka, H; Go, RS; Hogan, JD; Wester, SM | 1 |
| Kovacs, MJ; Wells, T | 1 |
| Bosanquet, AG; Daniel, PT; Dörken, B; Güner, D; Hermann, S; Sturm, I | 1 |
| Barlogie, B; Crowley, JJ; Dhodapkar, MV; Gertz, MA; Jacobson, JL | 1 |
| Choquet, S; Leblond, V | 1 |
| Agura, EA; Blume, KG; Chauncey, TR; Feinstein, LC; Forman, SJ; Gooley, TA; Hegenbart, U; Maloney, DG; Maris, MB; McSweeney, PA; Niederwieser, DW; Pulsipher, MA; Sandmaier, BM; Storb, RF; Stuart, MJ | 1 |
| Beyer, J; Biersack, H; Bornhäuser, M; Ehninger, G; Kiehl, M; Kröger, N; Sayer, HG; Schäfer-Eckardt, K; Schwerdtfeger, R; Wandt, H; Zander, AR | 1 |
| Barker, JN; Blazar, BR; DeFor, TE; Miller, JS; Wagner, JE; Weisdorf, DJ | 1 |
| Balcerzak, SP; Chapman, RA; Dakhil, SR; Fisher, RI; Grogan, TM; Lanier, KS; Lew, D; Miller, TP; Spiridonidis, CH; Velasquez, WS | 1 |
| Bravo-Hernández, G; Estrada, E; Gómez-Rangel, D; López-Martínez, B; Manuel Hernández, J; Marín-López, A; Ruiz-Argüelles, GJ | 1 |
| Hiruma, K; Maeda, Y; Matsumoto, G; Omuro, Y; Sakamaki, H; Sasaki, T; Takahashi, T; Tanaka, Y; Tsuruta, K | 1 |
| Boudová, L; Cerná, K; Jindra, P; Karas, M; Koza, V; Lysák, D; Svojgrová, M; Vozobulová, V | 1 |
| Brand, R; Corradini, P; Deliliers, GL; Dreger, P; Finke, J; Hansz, J; Martino, R; Michallet, M; Milligan, D; Niederwieser, D; Russell, N; Van Biezen, A | 1 |
| Davis, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Shen, Y; Thomas, MB; Yang, Y | 1 |
| Amir, G; Cohen, Y; Da'as, N; Libster, D; Polliack, A | 1 |
| Björkstrand, B; Gruber, A; Johnsen, HE; Pelliniemi, TT; Rasmussen, T; Remes, K | 1 |
| Ajchenbaum-Cymbalista, F; DeCaprio, JA; Delmer, A; Sanhes, L; Tang, R | 1 |
| Arase, Y; Hamaki, T; Hayashi, M; Igarashi, M; Ishibashi, T; Kami, M; Kusumi, E; Miyakoshi, S; Morinaga, S; Mutou, Y; Shimamura, K; Takaue, Y | 1 |
| Paschal, BR | 1 |
| Bearman, SI; Cagnoni, PJ; Jones, RB; Kolhouse, JF; McSweeney, PA; Medeiros, BC; Nieto, Y; Rabinovitch, R; Ryder, J; Shpall, EJ | 1 |
| Pettitt, AR | 1 |
| Baker, RJ; Foroni, L; Ganeshaguru, K; Jones, DT; Mehta, AB; Mitchell, WA; Prentice, HG; Wickremasinghe, RG | 1 |
| Cortes, JE; Giles, FJ; Kantarjian, HM; Keating, AR; Keating, MJ; O'Brien, SM; Shi, GG; Thomas, D | 1 |
| Agura, E; Anasetti, C; Blume, K; Chauncey, T; Hegenbart, U; Heimfeld, S; Maloney, D; Maris, MB; McSweeney, P; Niederwieser, D; Petersdorf, E; Pulsipher, M; Sandmaier, BM; Slattery, J; Storb, R; Storer, B; Stuart, M; Woolfrey, A | 1 |
| Annunziata, M; Copia, C; D'Amico, MR; De Simone, M; Ferrara, F; Palmieri, S; Pocali, B; Schiavone, EM; Vecchio, LD | 1 |
| Amin, K; Chen, YH; Cheung, T; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sosman, J; Stock, W; van Besien, K; Vijayakumar, S; Wickrema, A; Yassine, M | 1 |
| Alliot, C | 1 |
| Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Matsouka, C; Mitsibounas, D; Papadimitriou, C; Siapkaras, I | 1 |
| Carta, F; Dore, F; Dore, S; Pinna, A; Salis, A | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Beyer, J; Bornhauser, M; Ehninger, G; Fauser, AA; Held, TK; Hensel, M; Ho, AD; Hoffken, K; Kiehl, M; Kienast, J; Kroger, N; Neubauer, A; Sayer, HG; Scheffold, C; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zander, AR | 1 |
| Okamoto, S | 1 |
| Durrant, S; Grigg, AP; Morton, J; Ritchie, DS; Roberts, AW; Shuttleworth, P; Szer, J | 1 |
| Fruchtman, S; Grosskreutz, C; Isola, L; Ross, V; Scigliano, E | 1 |
| Anderlini, P; Booser, DJ; Champlin, RE; Cheng, YC; Couriel, DR; de Lima, MJ; Gajewski, JL; Giralt, SA; Hortobagyi, GN; Hosing, C; Jonasch, E; Khouri, IF; Pagliaro, LC; Rondón, G; Tannir, NM; Ueno, NT | 1 |
| Chi, HS; Choi, SJ; Kim, S; Kim, WK; Lee, JH; Lee, JL; Lee, JS; Lee, KH; Lee, YS; Park, CJ; Seol, M | 1 |
| Cotter, M; Enright, H | 1 |
| Bunjes, D; Döhner, H; Zenz, T | 1 |
| Burrows, A; Edenfield, WJ; Ekstrand, J; Lucas, M; Myhand, RC; Nelson, DA; Waselenko, JK | 1 |
| Plunkett, W; Rao, VA | 1 |
| Disel, U; Paydas, S; Sahin, B; Yavuz, S | 1 |
| Amylon, M; Casella, JF; Chen, AR; Fuchs, EJ; Iannone, R; Jones, RJ; Storb, RF; Sullivan, KM; Walters, MC; Woolfrey, A | 1 |
| Callea, V; Cutrona, G; Ferrarini, M; Ferraris, AM; Mangiola, M; Morabito, F; Oliva, BM; Rapezzi, D; Rossi, E; Spriano, M; Stelitano, C; Zupo, S | 1 |
| Amin, K; Chen, YH; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sossman, J; Stock, W; Van Besien, K; Wickrema, A; Yassine, M | 1 |
| Bardou, VJ; Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Braud, AC; Cahn, JY; Chabannon, C; Choufi, B; Faucher, C; Fleury, J; François, S; Gratecos, N; Gravis, G; Maraninchi, D; Michallet, M; Mohty, M; Sotto, JJ; Viens, P; Viret, F | 1 |
| Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D | 1 |
| Ackerstein, A; Bitan, M; Elad, S; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Zilberman, I | 2 |
| Castagna, L; Santoro, A; Sarina, B | 1 |
| Aquaro, S; Balestra, E; Casabianca, A; Cervasi, B; Fraternale, A; Garaci, E; Magnani, M; Paiardini, M; Perno, CF | 1 |
| Caracciolo, F; Fazzi, R; Galimberti, S; Petrini, M | 1 |
| Azar, N; Bastit, D; Belhadj, K; Cazin, B; Delmer, A; Diviné, M; Feugier, P; Grosbois, B; Leprètre, S; Maloisel, F; Maloum, K; Manhès, G; Michallet, M; Tournilhac, O; Travade, P; Villard, F; Villemagne, B | 1 |
| de la Fuente, J; Dokal, I; McCloy, M; Rahemtulla, A; Reiss, S; Roberts, IA; Vulliamy, T | 1 |
| Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, S; Thomas, DA; Tsimberidou, AM; Verstovsek, S | 1 |
| Black, JH; Fleming, DR; Frankel, AE; Gartenhaus, R; Hall, PD; Leftwich, C; Powell, BL | 1 |
| Bentley, P; Fegan, C; Hooper, L; Hoy, T; Milligan, D; Pepper, C; Pratt, G; Starczynski, J; Thomas, A | 1 |
| Astrow, AB | 1 |
| Fujioka, T; Ikegame, K; Kawakami, M; Kawase, I; Ogawa, H; Oji, Y; Oka, Y; Sugiyama, H; Tamaki, H; Tsuboi, A | 1 |
| Hino, M; Yamane, T | 1 |
| Ogawa, H | 1 |
| Miyakoshi, S | 1 |
| Kusumi, E; Taniguchi, S | 1 |
| Nakao, S | 1 |
| Omuro, Y; Sasaki, T | 1 |
| Koshida, K; Nakao, S; Namiki, M; Takami, A | 1 |
| Figgitt, DP; Plosker, GL | 1 |
| Huhn, D | 1 |
| Oscier, D | 1 |
| Chan, KW; Gomez Almaguer, D; Gordon, N; Mullen, CA; Tran, H; Worth, L | 1 |
| Fil'chenkov, AA; Nesina, IP; Smirnova, IA; Zavelevich, MP | 1 |
| Aymerich, M; Carreras, E; Fernández-Avilés, F; Jiménez, M; Martínez, C; Montserrat, E; Rovira, M; Talarn, C; Urbano-Ispizua, A | 1 |
| Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Xu, D; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Barrett, AJ; Childs, RW; Greene, A; Sloand, E; Solomon, S; Young, NS | 1 |
| Boyer, MW; Giver, CR; Jaye, DL; Li, JM; Lonial, S; Mittelstaedt, S; Montes, RO; Waller, EK | 1 |
| Brito, C; Cayota, A; Dighiero, G; Gabús, R; Landoni, AI; Oppezzo, P; Pritsch, O; Robello, C; Tiscornia, AC; Vuillier, F | 1 |
| Addison, E; Folarin, NI; Ganeshaguru, K; Hoffbrand, AV; Jones, DT; Lowdell, MW; Mehta, AB; North, JM; Wickremasinghe, RG | 1 |
| Boumpas, DT; Danning, CL; Davis, JC; Fleisher, TA; Illei, GG; Kuroiwa, T; Schlimgen, R; Takada, K; Tassiulas, IO; Yarboro, CH | 1 |
| Brando, B; Cafro, AM; Cairoli, R; D'Avanzo, G; Farioli, R; Intropido, L; Montillo, M; Morra, E; Pungolino, E; Rossi, V; Scarpati, B; Tedeschi, A; Veronese, S | 1 |
| Bergmann, M; Emmerich, B; Fingerle-Rowson, G; Goede, V; Hallek, M; Schmitt, B; Schweighofer, C; Wendtner, CM | 1 |
| Ciancia, R; De Divitiis, B; De Renzo, A; Del Giudice, A; Pane, F; Persico, M; Picardi, M; Quintarelli, C; Rotoli, B; Salvatore, F | 1 |
| Dumontet, C; Fernández-Calotti, P; Galmarini, CM; Gamberale, R; Geffner, J; Giordano, M; Jordheim, L; Sánchez-Avalos, J | 1 |
| Begleiter, A; Gibson, SB; Hu, X; Johnston, JB; Kabore, AF; Kropp, DM; Kuschak, B; Paul, JT; Strutinsky, J | 1 |
| Boeckh, M; Carter, RA; Corey, L; Junghanss, C; Maloney, DG; Maris, MB; McSweeney, PA; Sandmaier, BM; Storb, R | 1 |
| Ambulkar, I; Parikh, PM; Saikia, T | 1 |
| Cantero, E; Casanova, B; de la Fuente, MT; Garcia-Marco, J; Garcia-Pardo, A; Hernández del Cerro, M; Silva, A | 1 |
| Beyer, J; Claviez, A; Dörffel, W; Dreger, P; Ehninger, G; Klingebiel, T; Nürnberger, W; Schmitz, N; Suttorp, M | 1 |
| Fujisawa, S; Hatsumi, N; Kishi, K; Miyakoshi, S; Miyawaki, S; Mori, S; Nakajima, H; Oki, M; Sakamaki, H; Sakura, T; Tanaka, Y; Ueyama, J; Yokota, A | 1 |
| Balow, JE; Bolan, CD; Boumpas, DT; Illei, GG; Klippel, JH; Leitman, SF; Popovsky, MA; Tisdale, JF | 1 |
| Fu, ZZ; Li, CX; Lin, BJ; Liu, YJ; Ma, X; Miao, M; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xia, XM | 1 |
| Ai, HS; Guo, M; Qiao, JH; Shi, BF; Sun, QY; Sun, WJ; Wang, DH; Yao, B; Yu, CL; Zhang, S | 1 |
| Stiefelhagen, P | 1 |
| Battle, TE; Dong, DA; Fisher, DC; Frank, DA; Freedman, AS; Friedberg, JW; Gribben, JG; Jurgens, R; Kim, H; Li, S; Neuberg, D; Noonan, K; Stephans, K; Takvorian, T | 1 |
| Ueda, T; Yamauchi, T | 1 |
| Hirayama, Y; Kawano, Y; Kogawa, K; Kuribayashi, K; Matsunaga, T; Murase, K; Niitsu, Y; Okamoto, T; Sato, T; Takayama, T; Watanabe, H | 1 |
| Lokhorst, HL; Petersen, EJ; Verdonck, LF | 1 |
| Hoffbrand, AV; Koh, M; Mehta, A; Potter, M; Prentice, HG; Rankin, P; Virchis, A | 1 |
| Ferry-Dumazet, H; Mamani-Matsuda, M; Marit, G; Molimard, M; Mossalayi, MD; Moynet, D; Reiffers, J | 1 |
| Baccarani, M; Fanin, R; Gentile, M; Mandelli, F; Marin, L; Mauro, FR; Stefoni, V; Tura, S; Vegna, ML; Zaja, F; Zinzani, P | 1 |
| Fricová, M; Guman, T; Kafková, A; Stecová, N; Tóthová, E | 1 |
| Kiewe, P; Knauf, W; Körper, S; Rieger, K; Seyfert, S; Thiel, E | 1 |
| Braester, A; Elmalah, Y; Quitt, M | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Erba, HP | 1 |
| Adil, SN; Khurshid, M; Sajid, R; Usman, M | 1 |
| Dlubek, D; Dybko, J; Klimczak, A; Lange, A | 1 |
| Fan, H; Sun, YF; Yao, SQ; Zhu, HL | 1 |
| Beelen, D; Bornhäuser, M; Ehninger, G; Fauser, AA; Held, TK; Kiehl, M; Kröger, N; Runde, V; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zabelina, T; Zander, A | 1 |
| Byrd, JC; Flinn, IW; Grever, MR; Hackbarth, ML; Harbison, J; Heerema, NA; Lin, T; Lozanski, G; Lucas, D; Lucas, M; Moran, M; Proffitt, JH; Smith, L; Webb, J | 1 |
| Abecasis, M; da Costa, FL; Miranda, N; Nave, M; Nunes, R; Passos-Coelho, JL | 1 |
| Bairey, O; Berrebi, A; Lugassy, G; Polliack, A; Rahimi-Levene, N; Shpilberg, O; Shtalrid, M; Shvidel, L | 1 |
| Amadori, S; Ballatore, G; Caravita, T; Catalano, G; Cristina Cox, M; Cudillo, L; Cupelli, L; Dentamaro, T; Fabritiis Pd, Pd; Picardi, A; Venditti, A | 1 |
| Paydas, S | 1 |
| Champlin, RE; Donato, ML; Gershenson, DM; Levenback, C; McMeekin, S | 1 |
| Chizuka, A; Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Tajima, K; Takaue, Y; Taniguchi, S; Usubuchi, N | 1 |
| Hamaki, T; Heike, Y; Hori, A; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Tanosaki, R; Ueyama, J; Yuji, K | 1 |
| Barry, T; Ben Alon, D; Ben Dor, D; Blumental, R; Ducach, A; Lugassy, G; Nemets, A | 1 |
| Champlin, RE; Khouri, IF | 1 |
| Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y | 1 |
| Enosawa, S; Haga, S; Ohnuma, N; Ozaki, M; Terui, K | 1 |
| Grigg, A; Januszewicz, EH; Matthews, JP; Morgan, SJ; Prince, HM; Seymour, JF; Wolf, MM | 1 |
| Imagawa, J; Imamura, N; Katayama, Y; Kimura, A; Nimi, H; Simomura, T | 1 |
| Hillmen, P | 3 |
| Bongarzoni, V; Buffolino, S; Cimino, G; Montanaro, M; Niscola, P; Scaramucci, L | 1 |
| Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K | 1 |
| Devereux, S; Ho, AY; Kenyon, M; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE | 1 |
| Bordonaro, R; Cordio, S; Giannitto-Giorgio, C; Giuffrida, D; Manusia, M; Marletta, F; Novello, G; Petralia, G; Restuccia, N; Salice, P; Serraino, D; Todaro, AM; Ursino, M | 1 |
| Bucher, C; Buser, AS; Gratwohl, A; Heim, D; Passweg, JR; Tichelli, A | 1 |
| Al-Kadhimi, Z; Angelopoulou, M; Cohen, S; Falk, PM; Forman, SJ; Fung, HC; Kogut, N; Krishnan, AY; Nademanee, A; O'Donnell, MR; Parker, P; Popplewell, L; Rodriguez, R; Sahebi, F; Schriber, J; Senitzer, D; Slovak, M; Smith, D; Snyder, DS; Somlo, G; Spielberger, R; Stein, A | 1 |
| Gartenhaus, RB; Nabhan, C; Tallman, MS | 1 |
| Chen, JB; Kaushal, GP; Kurten, RC; Lacy, HM; Schichman, SA; Zent, CS | 1 |
| Biesma, DH; Daenen, SM; Delforge, M; Graveland, WJ; Löwenberg, B; Muus, P; Noordhuis, P; Ossenkoppele, GJ; Peters, GJ; Schaafsma, MR; Selleslag, D; Sonneveld, P; van der Holt, B; Verdonck, LF; Verhoef, GE; Westveer, PH | 1 |
| Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, R; Korbling, M; Madden, T; Pierre, B; Russell, JA; Shahjahan, M; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Gadea, I; Llamas, P; Prieto, E; Román, A; Santos, AB; Subirá, D; Tomás, JF | 1 |
| Leporrier, M | 1 |
| Eichhorst, BF; Hallek, M | 1 |
| Boogaerts, MA | 1 |
| Zinzani, PL | 2 |
| Jackson, GH | 1 |
| Carella, AM | 1 |
| Guan, ZZ; Huang, HQ; Jiang, WQ; Li, XB; Li, YH; Lin, TY; Peng, YL; Sun, XF; Xia, ZJ | 1 |
| Albert, S; Bhogal, B; Black, MM; Oyama, N; Powell, AM; Sakuma-Oyama, Y | 1 |
| Coyle, L; Hsiao, E; Huynh, T; Mansberg, R; Roach, P | 1 |
| Nicolle, A; Proctor, SJ; Summerfield, GP | 1 |
| Bolognesi, A; Farini, V; Lubelli, C; Polito, L; Ricci, F; Stirpe, F; Tazzari, PL; Zinzani, PL | 1 |
| Grdisa, M | 1 |
| Fujioka, T; Ishida, Y; Numaoka, H; Omori, S; Ono, Y | 1 |
| Boniver, J; de Leval, L; De Prijck, B; Du, MQ; Harris, NL; Isaacson, P; Vivario, M; Zhou, Y | 1 |
| Beran, M; Cortes, JE; Estey, E; Giles, FJ; Kantarjian, HM; O'Brien, SM | 1 |
| Ferrajoli, A; O'Brien, SM | 1 |
| Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Coso, D; Damaj, G; Faucher, C; Gastaut, JA; Maraninchi, D; Michallet, AS; Michallet, M; Mohty, M; Perreau, V; Stoppa, AM; Tabrizi, R | 1 |
| Alizadeh, AA; Arthur, DC; Chuang, EY; Davis, RE; Fowler, DH; Marti, GE; Mitchell, JB; Rosenwald, A; Staudt, LM; Wiestner, A; Wilson, WH | 1 |
| Appelbaum, FR; Byrd, JC; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, K; Schiffer, CA; Shepherd, L | 1 |
| Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 2 |
| Alinari, L; Baccarani, M; Gabriele, A; Marchi, E; Musuraca, G; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Galieni, P; Laszlo, D; Lauria, F; Martinelli, G; Raspadori, D; Tozzi, M | 1 |
| Anastasi, J; Larson, R; Odenike, T; Smith, S; Stock, W; Thirman, M; Van Besien, K | 1 |
| Christopherson, RI; Mulligan, SP; Wilson, PK | 1 |
| Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E | 1 |
| Disel, U; Ergin, M; Paydas, S; Yavuz, S | 1 |
| Fujiwara, T; Harigae, H; Ishizawa, K; Kameoka, J; Minegishi, M; Miyamura, K; Sasaki, T; Tomiya, Y; Tsuchiya, S; Yamada, M | 1 |
| Hamaki, T; Hayashi, T; Kami, M; Kanemaru, M; Kim, SW; Kishi, Y; Kobayashi, K; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Ueyama, J; Yuji, K | 1 |
| Giver, CR; Hossain, MS; Li, JM; Lonial, S; Waller, EK | 1 |
| Improta, S; Mastrullo, L; Nitrato Izzo, G; Polistina, MT; Quirino, AA; Rocco, S; Russolillo, S; Sagristani, M | 1 |
| Balashov, DN; Dyshlevaja, ZM; Maschan, AA; Rumiantsev, AG; Samochatova, EV; Shipicina, IP; Skorobogatova, EV; Skvortsova, YV; Trakhtman, PE | 1 |
| Andreeff, M; Beran, M; Ferrajoli, A; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Tsimberidou, AM; Wierda, WG | 1 |
| Blume, KG; Edelstein, CL; Maloney, DG; Maris, MB; McSweeney, P; Nieto, Y; Parikh, CR; Sahebi, F; Sandmaier, BM; Schrier, RW; Storb, RF | 1 |
| Cao, Z; Chen, YC; Fang, J; Jiang, BH; Reed, E | 1 |
| Baran-Marszak, F; Béchet, JM; Bornkamm, GW; Dusanter-Fourt, I; Fagard, R; Feuillard, J; Le Clorennec, C; Najjar, I; Raphaël, M | 1 |
| Alinari, L; Baccarani, M; Bonifazi, F; Gentilini, P; Guardigni, L; Martelli, M; Molinari, AL; Perrotti, A; Pileri, S; Pulsoni, A; Stefoni, V; Tani, M; Tura, S; Villivà, N; Visani, G; Zinzani, PL | 1 |
| Assmann, M; Bartsch, R; Eschenburg, H; Franke, A; Herold, M; Jentsch-Ullrich, K; Kahl, C; Knauf, W; Koenigsmann, M; Lakner, V; Mohren, M; Müller, G; Pasold, R | 1 |
| Baker, JE; Baron, F; Blume, KG; Chauncey, TR; Gooley, TA; Grumet, FC; Heimfeld, S; Little, MT; Maloney, DG; Maris, MB; Oparin, D; Radich, JP; Sandmaier, BM; Storb, R; Zellmer, E | 1 |
| Avivi, I; Chakrabarti, S; Dogan, A; Goldstone, AH; Kottaridis, P; Kyriaku, C; Linch, D; Mackinnon, S; Milligan, DW | 1 |
| Al-Ali, H; Brand, R; Deininger, M; Gentilini, C; Hegenbart, U; Krahl, R; Lange, T; Leiblein, S; Niederwieser, D; Petersdorf, E; Poenisch, W; Storb, RF; Uharek, L | 1 |
| Barnardo, M; Campbell, AJ; Collins, GP; Eagleton, H; Jones, J; Keen-Mcguire, A; Littlewood, TJ; Malladi, RK; Miller, E; Morgenstern, G; Norton, AE; Peniket, AJ; Samol, J | 1 |
| Acharya, MR; Figg, WD | 1 |
| Holyoake, TL; McQuaker, IG; Osborne, WL; Parker, AN | 1 |
| Böck, HP; Dreyling, M; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rohrberg, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Asch, J; Ford, CD; Petersen, FB; Pulsipher, M | 1 |
| Bowen, A; Catovsky, D; Hendry, L; Matutes, E; Swansbury, J | 1 |
| Agura, E; Chauncey, T; Langston, AA; Maloney, DG; Maris, MB; Maziarz, RT; Pulsipher, M; Sandmaier, BM; Storb, R; Storer, BE; Stuart, MJ | 1 |
| Au, WY; Ho, SL; Kwong, YL; Leung, SY; Mak, W | 1 |
| Buser, A; Gratwohl, A; Heim, D; Kostova, G; Passweg, J; Tichelli, A | 1 |
| Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C | 1 |
| Dreyling, M; Hiddemann, W; Lenz, G | 1 |
| Barr, WG; Brush, M; Burt, RK; Oyama, Y; Quigley, K; Statkute, L; Traynor, A; Verda, L; Yaung, K | 1 |
| Baumbach, T; Benner, A; Ho, AD; Kerowgan, M; Kraemer, A; Leo, A; Leo, E; Mey, U; Parwaresch, R; Scheuer, L; Schmidt-Wolf, IG; Schmitt, C | 1 |
| D'Arena, G; Di Renzo, N; Iodice, G; Pizza, V; Tartarone, A; Vigliotti, ML; Volpe, G | 1 |
| Aversa, S; Candela, M; Chisesi, T; Congiu, AM; Marino, G; Nati, S; Patti, C; Polacco, A; Porcellini, A; Ravetti, JL; Rizzoli, V; Rubagotti, A; Santini, G; Spriano, M; Vimercati, R; Zoli, V; Zupo, S | 1 |
| Dmoszyńska, A; Hellmann, A; Komarnicki, M; Kowal, M; Kuliczkowski, K; Kłoczko, J; Lewandowski, K; Piszcz, J; Roznowski, K; Skotnicki, AB; Wegrzyn, J; Wołowiec, D | 1 |
| Byun, JH; Hong, YS; Kim, CC; Lee, JW; Lee, MA; Min, WS; Park, JN; Roh, SY; Shim, BY; Song, CW | 1 |
| Cheang, M; Gibson, SB; Haney, N; Hu, X; Johnston, JB; Kropp, DM; Neufeld, NJ; Paul, JT | 1 |
| Argyrakos, T; Galani, V; Grigoriou, E; Harhalakis, N; Kanavaros, P; Kapsimali, V; Karmiris, T; Naum, C; Nikiforakis, E; Pantelidaki, C; Rontogianni, D; Tsantekidou, M | 1 |
| Grigg, AP; Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Delavault, P; Fegan, CD; Hambly, RM; Pepper, CJ; Thurston, DE | 1 |
| Delarue, R; François, S; Hermine, O; Ifrah, N; Lefrère, F; Lévy, V; Tilly, H; Troussard, X; Valensi, F; Varet, B | 1 |
| Bone, ND; Geyer, SM; Kaufmann, SH; Kay, NE; Lee, YK; Narayanan, VL; Sausville, EA; Shanafelt, TD; Strege, AK | 1 |
| Alegre, A; Ayuk, F; Beyer, J; Brand, R; Fauser, A; Kiehl, M; Klingemann, H; Kröger, N; Leon, A; Martino, R; Myint, H; Nagler, A; Perez-Simon, JA; San Miguel, JF; Sayer, HG; Schwerdtfeger, R; Shimoni, A; Tomas, JF; Zabelina, T; Zander, AR | 1 |
| Arnold, R; Dörken, B; Heine, F; Le Coutre, P; Massenkeil, G; Nagy, M; Rosen, O | 1 |
| Kawai, Y; Takagi, K; Ueda, T; Yamauchi, T | 1 |
| Binet, JL; Cass, CE; Dabbagh, L; Delmer, A; Dumontet, C; Galmarini, CM; Glubrecht, D; Graham, KA; Hanson, J; Jewell, LD; Joy, AA; Lai, R; Lang, T; Mackey, JR; Merle-Béral, H; Young, JD | 1 |
| Lamanna, N; Weiss, M | 1 |
| Bitan, M; Mador, N; Or, R; Resnick, IB; Saleh, N; Samuel, S; Schechter, E; Shapira, MY; Slavin, S; Weinberger, KM; Wolf, DG | 1 |
| Bellosillo, B; Bosch, F; Campo, E; Colomer, D; Espinet, B; Ferrer, A; López-Guillermo, A; Marcé, S; Montserrat, E; Solé, F; Villamor, N | 1 |
| Carew, JS; Dunner, K; Huang, P; Keating, MJ; McConkey, DJ; Nawrocki, ST; Wierda, WG; Xu, RH | 1 |
| Ahn, HS; Choi, HS; Kang, HJ; Shin, HY | 1 |
| Kolb, HJ; Ledderose, G; Rolf, B; Schleuning, M; Schnittger, S; Schoch, C; Schwerdtfeger, R; Weisser, M | 1 |
| Bengtzen, S; Lehmann, S; Merup, M; Mollgard, L; Nahi, H; Paul, C; Selivanova, G; Wiman, KG | 1 |
| Batár, P; Kiss, A; Méhes, L; Rejto, L; Telek, B; Udvardy, M | 1 |
| Ai, HS; Hou, CM; Li, JJ; Mao, N; Wu, Y; Zhang, MW; Zhang, Y | 1 |
| Celsing, F; Jondal, M; Morales, AA; Olsson, A; Osorio, LM; Osterborg, A | 1 |
| Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ | 1 |
| Brecher, BA; Butrin, L; Goldberg, SL; Hsu, JS; Kobbe, K; McKiernan, P; Pecora, AL; Preti, R; Rowley, SD | 1 |
| Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Huber-Ruano, I; Marcé, S; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M; Villamor, N | 1 |
| Chan, ES; Linn, YC; Samuel, M; Tan, DC; Zhu, Q | 1 |
| Briones, J; Forné, I; Juarez, C; Martinez-Gallo, M; Martinez-Lostao, L; Rodriguez-Sanchez, JL; Sierra, J | 1 |
| Alessandrino, EP; Bernasconi, P; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Montanari, F; Troletti, D; Vanelli, L; Varettoni, M | 1 |
| Belka, C; Daniel, PT; Dörken, B; Hasenjäger, A; Klöpfer, A; Schulze-Osthoff, K | 1 |
| Aleskog, A; Höglund, M; Larsson, R; Laurell, A; Lindhagen, E; Nilsson, K; Nygren, P; Roos, G; Rosenquist, R; Sundström, C; Thunberg, U; Tobin, G | 1 |
| Korycka, A; Robak, T; Smolewski, P | 1 |
| Blumberg, N; Fenton, P; Horan, JT; Liesveld, JL; Walters, MC | 1 |
| Broekhuizen, R; Cloos, J; Creutzig, U; Fleischhack, G; Haarman, EG; Hubeek, I; Huismans, DR; Kaspers, GJ; Litvinova, E; Peters, GJ; Zwaan, CM | 1 |
| Fabbri, A; Forconi, F; Gozzetti, A; Lauria, F; Lenoci, M; Marotta, G; Raspadori, D | 1 |
| Majumdar, G; Ramachandran, A | 1 |
| Broekhuizen, AJ; Hubeek, I; Kaspers, GJ; Peters, GJ | 1 |
| Cao, TM; Grumet, FC; Johnston, LJ; Laport, GG; Lowsky, R; Negrin, RS; Sheehan, K; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ; Wong, RM | 1 |
| Beilken, A; Das, A; Gal, A; Grigull, L; Luecke, T; Lukacs, Z; Rehe, K; Sander, A; Sauer, M; Schmid, H; Schrappe, M; Stanulla, M; Sykora, KW; Welte, K | 1 |
| Childs, RW; Leppert, MF; Otterud, BE; Riddell, SR; Sandmaier, BM; Storb, R; Thompson, JA; Tykodi, SS; Warren, EH | 1 |
| Amadori, S; Bruno, A; Buccisano, F; Cox, MC; Degan, M; Del Poeta, G; Del Principe, MI; Gattei, V; Marini, R; Maurillo, L; Panetta, P; Suppo, G; Venditti, A | 1 |
| Boyd, RL; Clyde, J; Halbherr, T; Millenson, MM; Morris, GJ; Padavic-Shaller, K; Rogatko, A; Schilder, RJ; Smith, MR; Wang, H; Yeslow, G | 1 |
| Beltrami, G; Carella, AM; Corsetti, MT; Musto, P; Scalzulli, P | 1 |
| Asaka, M; Ehira, N; Fukushima, A; Imamura, M; Kanamori, H; Masauzi, N; Minami, H; Musashi, M; Obara, S; Ogura, N; Tanaka, J; Tsutsumi, Y; Yamato, H | 1 |
| Canpinar, H; Demirpençe, E; Doğan, A; Doğan, AL; Duzgunçinar, O | 1 |
| Kato, Y; Kohno, A; Morishita, Y; Narimatsu, H; Ozeki, K; Saito, S; Shimada, K | 1 |
| Chang, V; Donepudi, S; Kotenko, S; Lee, J; Mansour, A; McCarthy, B; Raveche, E; Schwander, SK | 1 |
| Gibson, SB; Haney, N; Hu, X; Johnston, JB; Kabore, AF; Kropp, D | 1 |
| Abdall, N; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gatto, S; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R; Venturino, C | 1 |
| Briones, J; Ferrer, B; Forné, I; Juarez, C; Martinez-Gallo, M; Martinez-Lostao, L; Rodriguez-Sanchez, JL; Sierra, J | 1 |
| Alexander, PJ; Feliz, A; Gok, F; Good, RA; Jones, JM; Jones, OY; Lacson, A; Madivi, C; Marikar, Y | 1 |
| Lennard, AL; Osborne, WL | 1 |
| Creamer, D; Devereux, S; Mufti, G; Perera, GK; Salisbury, J | 1 |
| Ball, SE; Freires, M; Gordon-Smith, EC; Gupta, V; Marsh, JC; Ortin, M; Sage, D | 1 |
| Benesch, M; Lackner, H; Schwinger, W; Sykora, KW; Urban, C | 1 |
| Hamasaki, Y; Hara, T; Ihara, K; Imayoshi, M; Ishii, E; Miyazaki, S; Muraoka, K | 1 |
| Borelli, S; Herr, D; Kempf, W; Trojan, A | 1 |
| Alam, A; Benyunes, M; Bernstein, SH; Bernstein, ZP; Blumenson, L; Brown, K; Chanan-Khan, A; Czuczman, MS; Donohue, K; Grillo-Lopez, A; Hernandez-Ilizaliturri, F; Klippenstein, D; Koryzna, A; Loud, P; McCarthy, P; Mohr, A; Rock, MK; Skipper, M; Stewart, C | 1 |
| Berthou, C; Casassus, P; Colombat, P; Deconinck, E; Delwail, V; Desablens, B; Foussard, C; Ghandour, C; Gressin, R; Lamy, T; Mahé, B; Maisonneuve, H; Pignon, B; Rachieru, P; Rousselet, MC | 1 |
| Cabanillas, F; Coleman, M; Gregory, SA; Hagemeister, F; Zinzani, PL | 1 |
| Catovsky, D; Del Giudice, I; Matutes, E; Osuji, N; Parry-Jones, N; Swansbury, J | 1 |
| Chevret, S; Leblond, V; Lévy, V; Morel, P; Porcher, R; Wattel, E | 1 |
| Ayyildiz, O; Bolaman, Z; Isikdogan, A; Muftuoglu, E | 1 |
| Dziecioł, J; Kłoczko, J; Lemancewicz, D; Piszcz, J | 1 |
| Gershanovich, ML; Tikhonova, VV | 1 |
| Abe, Y; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Tachikawa, Y | 1 |
| Ayuk, F; Fehse, B; Fehse, N; Kröger, N; Kvasnicka, HM; Panse, J; Schieder, H; Stute, N; Thiele, J; Waschke, O; Zabelina, T; Zander, A | 1 |
| Bellas, C; Catovsky, D; Matutes, E; Pocock, C; Santon, A; Shah, G; Thornton, PD; Wotherspoon, AC | 1 |
| Nichols, GL; Skerrett, DL | 1 |
| Hartwig, UF; Herr, W; Huber, C; Kolbe, K; Kreiter, S; Meyer, RG; Schneider, PM; Ullmann, AJ; Wehler, T; Winkelmann, N | 1 |
| Ahlberg, L; Apperley, JF; Björkstrand, B; Boiron, JM; Carella, A; Cavenagh, J; Chopra, R; Crawley, C; Einsele, H; Gahrton, G; Garban, F; Gilleece, M; Gratwohl, A; Juliusson, G; Lalancette, M; Mackinnon, S; Nagler, A; Niederwieser, D; Peggs, K; Shimoni, A; Sureda, A; Szydlo, R; Zander, A | 1 |
| Choi, SJ; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, YS; Ryu, SG; Seol, M | 1 |
| Badagnani, I; Brett, CM; Burchard, EG; Carlson, EJ; Castro, RA; Chan, W; Ferrin, TE; Giacomini, KM; Huang, CC; Johns, SJ; Kawamoto, M; Stryke, D | 1 |
| Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M | 1 |
| Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F | 1 |
| Diaconescu, R; Maloney, DG; Maris, MB; McSweeney, P; Parikh, CR; Sandmaier, BM; Schrier, RW; Sorror, ML; Storb, R; Storer, B | 1 |
| Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Jenke, A; Johne, C; Knoth, H; Schleyer, E | 1 |
| Mikhailenko, VM; Philchenkov, AA; Zavelevich, MP | 1 |
| Emerson, SG; Goldstein, SC; Green, J; Loren, AW; Luger, SM; Nasta, SD; Oliver, JC; Orloff, G; Perl, A; Porter, DL; Schuster, S; Stadtmauer, EA; Tsai, DE | 1 |
| Byrd, JC; Grever, MR; Lin, TS | 1 |
| Albitar, M; Beran, M; Cortes, J; Do, KA; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; Lerner, S; O'Brien, S; Thomas, D; Wen, S; Wierda, W | 1 |
| Albitar, M; Andreeff, M; Cortes, J; Detry, MA; Faderl, S; Giles, F; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; Lynn, A; O'Brien, S; Plunkett, W; Thomas, D; Wierda, W | 1 |
| Jindra, P; Koza, V; Lysak, D; Schutzova, M; Steinerova, K; Vozobulova, V | 1 |
| Baron, F; Chauncey, TR; Diaconescu, R; Flowers, ME; Maloney, DG; Maris, MB; Mielcarek, M; Sandmaier, BM; Sorror, M; Storb, R; Storer, BE; Woolfrey, AE | 1 |
| Barulli, S; D'Adamo, F; Guiducci, B; Isidori, A; Leopardi, G; Malagola, M; Malerba, L; Mele, A; Nicolini, G; Piccaluga, P; Politi, P; Sparaventi, G; Stramigioli, S; Talevi, N; Visani, G | 1 |
| Andreesen, R; Blüml, S; Burger, V; Eissner, G; Haffner, S; Holler, E; Iacobelli, M | 1 |
| Jindra, P; Koza, V; Lysák, D; Steinerová, K; Vozobulová, V | 1 |
| Naito, K; Ohnishi, K | 1 |
| Jaeger, U; Johnson, SA; Leblond, V; Levy, V; Oscier, DG; Owen, RG; Seymour, JF | 1 |
| Abati, A; Berman, DM; Dudley, ME; Filie, AC; Gea-Banacloche, J; Gracia, GJ; Jones, SA; Kammula, U; Mangiameli, DP; Mavroukakis, SA; Pelletier, MM; Restifo, NP; Robinson, MR; Rogers, LJ; Rosenberg, SA; Royal, RE; Sherry, RM; Topalian, SL; White, DE; Wunderlich, JR; Yang, JC | 1 |
| Agura, E; Al-Ali, HK; Blume, KG; Bruno, B; Chauncey, TR; Epner, EM; Gooley, T; Hegenbart, U; Kerbauy, FR; Maloney, DG; Niederwieser, D; Radich, JP; Sandmaier, BM; Shizuru, J; Storb, R | 1 |
| Agirre, X; Calasanz, MJ; Giraldo, P; Larráyoz, MJ; Odero, MD; Rubio-Felix, D; Rubio-Martinez, A; Valgañón, M | 1 |
| Arbiser, J; Battle, TE; Frank, DA | 1 |
| Agura, E; Al-Ali, H; Blume, KG; Bredeson, C; Bruno, B; Chauncey, TR; Hegenbart, U; Langston, A; Leis, J; Loken, MR; Maloney, DG; Maris, MB; McSweeney, P; Pulsipher, M; Radich, JP; Sandmaier, BM; Sorror, ML; Storb, R; Storer, BE; Stuart, MJ | 1 |
| Fong, D; Gastl, G; Kaiser, A; Spizzo, G; Tzankov, A | 1 |
| Dumontet, C; Galmarini, CM; Jordheim, LP | 1 |
| Coiffier, B; Michallet, AS; Michallet, M; Salles, G | 1 |
| Brenner, MK; Carrum, G; Heslop, HE; Krance, RA; Lamba, R; May, R; Popat, U | 1 |
| Benesch, M; Dornbusch, HJ; Lackner, H; Schwinger, W; Sovinz, P; Urban, C | 1 |
| Li, WX; Mao, X; Yu, C | 1 |
| Langiewicz, P; Rzepecki, P; Sarosiek, T; Szczylik, C; Zolnierek, J | 1 |
| Czock, D; Hertenstein, B; Keller, F; Kielstein, JT; Radermacher, J; Stadler, M | 1 |
| Richards, S | 1 |
| Kalhorn, TF; McCune, JS; Ren, AG; Slattery, JT; Wang, J | 1 |
| Burger, JA; Burger, M; Fujii, N; Hartmann, T; Kipps, TJ; Krome, M; Rawluk, J; Tamamura, H | 1 |
| Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M | 1 |
| Dührsen, U; Frey, UH; Nückel, H; Röth, A; Siffert, W | 1 |
| Beyer, M; Darabi, K; Debey, S; Endl, E; Hallek, M; Jensen, M; Knolle, PA; Kochanek, M; Popov, A; Schultze, JL; Thomas, RK; von Bergwelt-Baildon, M | 1 |
| Ayuk, F; Beyer, J; Binder, T; Bornhäuser, M; Eiermann, T; Iacobelli, S; Kiehl, M; Kröger, N; Madrigal, A; Marks, DI; Nagler, A; Peggs, K; Sayer, HG; Schwerdtfeger, R; Shaw, B; Shimoni, A; Zabelina, T; Zander, AR | 1 |
| Molica, S; Ribatti, D; Tucc, L; Vacca, A | 1 |
| Bond, R; Brown, M; Campbell, P; Grigg, AP; Ritchie, D; Scarlett, J; Seymour, JF; Tam, C; Underhill, C | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH | 1 |
| Briones, J; Brunet, S; Caballero, D; Cañizo, C; Clopés, A; Martino, R; Mateos, M; Moreno, E; Pérez-Simón, JA; Queraltó, JM; San Miguel, JF; Sierra, J; Sureda, A; Vazquez, L | 1 |
| Attarbaschi, A; Gadner, H; Grois, N; Holter, W; Matthes-Martin, S; Minkov, M; Ouachee, M; Steiner, M; Unger, E; Vormoor, J; Wawer, A; Woessmann, W | 1 |
| Amin, CJ; Rabinowitz, I | 1 |
| Boudreaux, CW; Michael, CW; Richardson, PH | 1 |
| Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A | 1 |
| Califano, C; D'Arco, AM; Danise, P; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B | 1 |
| Goor, KM; Huijgens, PC; Schaafsma, MR; van Agthoven, M | 1 |
| Hara, S; Hayashi, S; Kamimura, T; Ogata, K; Suzumiya, J; Takamatsu, Y; Tamura, K; Yamauchi, K | 1 |
| Chim, CS; Leung, WH; Tsang, SF | 1 |
| Barrett, AJ; Childs, R; Donohue, T; Espinoza-Delgado, I; Geller, N; Gorak, E; Srinivasan, R; Suffredini, A | 1 |
| Adler, SS; Enschede, SH; Gregory, SA; Porter, C; Rao, R; Shammo, JM; Venugopal, P | 1 |
| Artz, A; Bennett, D; Cao, D; Casey, B; Daugherty, C; Del Cerro, P; Godley, L; Jones, D; Larson, RA; Odenike, O; Rich, S; Smith, S; Stock, W; Thirman, M; van Besien, K; Wickrema, A; Zimmerman, T | 1 |
| Hillmen, P; Johnson, SA; Owen, RG; Rule, SA; Seymour, JF; Thomas, DW; Wolf, MM | 1 |
| Hirschman, R; Mastan, A; Ng, R; Rashid, K; Sager, D | 1 |
| Baba, Y; Fujimaki, K; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Takabayashi, M; Takasaki, H; Yamaji, S | 1 |
| Berdel, WE; Berning, B; Beyer, J; Bornhauser, M; Buchner, T; Ehninger, G; Fauser, AA; Heinecke, A; Kienast, J; Kroger, M; Neubauer, A; Sauerland, MC; Scheffold, C; Silling, G; Stelljes, M | 1 |
| Claxton, DF; Ehmann, C; Rybka, W | 1 |
| Kwong, YL; Lam, CC; Ma, ES | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Carluccio, P; Ciuffreda, L; Liso, A; Liso, V; Mestice, A; Pastore, D; Pietrantuono, G; Rizzi, R; Specchia, G | 1 |
| Berger, C; Bernstein, ZP; Chanan-Khan, A; Czuczman, MS; Donohue, K; Klippenstein, D; Koryzna, A; Miller, KC; Mohr, A; Takeshita, K; Wallace, P; Zeldis, JB | 1 |
| Auerbach, AD; Defor, TE; Macmillan, ML; Slungaard, A; Tan, PL; Wagner, JE | 1 |
| Bao, L; Huang, XJ; Jiang, B; Lu, DP; Lu, J; Lu, XJ; Qiu, JY; Shi, HX; Wang, DB; Wang, FR | 1 |
| Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T | 1 |
| Mielcarek, M; Storb, R | 1 |
| Kolb, HJ; Ledderose, G; Schleuning, M; Schmid, C; Tischer, J | 1 |
| Cesarman, E; Chadburn, A; Coleman, M; Fiore, J; Furman, RR; Goldsmith, SJ; Kostakoglu, L; Kroll, S; Leonard, JP; Muss, D; Niesvizky, R; Schuster, MW; Tidmarsh, G; Vallabhajosula, S | 1 |
| Jacobs, MI; Mantha, S; Savage, DG | 1 |
| Hamblin, TJ | 1 |
| Au, WY; Chim, CS; Kwong, YL; Lam, CC; Pang, AW | 1 |
| Bornkessel, A; Hahnfeld, S; Weyers, W; Ziemer, M | 1 |
| Barrett, AJ; Childs, R; Kurlander, R; Leitman, SF; Montero, A; Read, EJ; Savani, BN; Solomon, SR | 1 |
| Chaleteix, C; Choquet, S; Christian, B; Delmer, A; Dreyfus, F; Fermand, JP; Grange, MJ; Leblond, V; Lévy, V; Morel, P; Stalniewicz, L; Tamburini, J | 1 |
| Bontemps, F; Cardoen, S; Offner, F; Van den Neste, E | 1 |
| Carew, JS; Dunner, K; Huang, P; Keating, MJ; Krupnik, YV; McConkey, DJ; Nawrocki, ST | 1 |
| Aulitzky, W; Borchmann, P; Elter, T; Engert, A; Gramatzki, M; Hallek, M; Hasan, I; Jensen, M; Josting, A; Rech, J; Reiser, M; Schinköthe, T; Schnell, R; Schulz, H; Staib, P; Stützer, H; Trelle, S | 1 |
| Bakkun, A; Medved, I; Sergienko, T; Slobozhanina, E; Svirnovski, A; Tamashevski, A; Taras, I | 1 |
| Hori, H; Kawai, Y; Ueda, T; Yoshio, N | 1 |
| Abbott, BL | 1 |
| Cho, HS; Chun, SH; Hyun, MS; Kim, KO; Kim, MK; Lee, KH; Shin, SJ | 1 |
| Baumgart, J; Casper, J; Freund, M; Grobe, N; Hähling, D; Hartung, G; Hilgendorf, I; Junghanss, C; Kahl, C; Lück, A; Pichlmeier, U; Steiner, B; Wilhelm, S; Wolff, D | 1 |
| Austin, H; Balow, JE; Barrett, J; Childs, R; Geller, N; Igarashi, T; Lundqvist, A; Sabnis, S; Srinivasan, R; Takahashi, Y; Tisdale, J | 1 |
| Albertioni, F; Löfgren, C; Paul, C | 1 |
| Chun, K; Daly, A; Gupta, V; Hasegawa, W; Kamel-Reid, S; Kiss, T; Lipton, JH; Messner, H; Minden, M; Tsang, R; Yi, QL | 1 |
| Benner, A; Gerull, S; Goerner, M; Goldschmidt, H; Hegenbart, U; Ho, AD; Klein, U; Schaefer, H | 1 |
| Batár, P; Telek, B; Uvardy, M | 1 |
| Appelbaum, FR; Boldt, DH; Budd, GT; Dakhil, SR; Dobin, SM; Elias, L; Foon, KA; Gundacker, H; Head, DR; Hussein, MA | 1 |
| Avanzini, P; Baccarani, M; Bocchia, M; Bonini, A; Candoni, A; Castelli, M; Damiani, D; de Vivo, A; Fanin, R; Fiacchini, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michielutti, A; Ottaviani, E; Piccaluga, PP; Pricolo, G; Raspadori, D; Rondoni, M; Russo, D; Testoni, N; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Bhatia, M; Bradley, B; Cairo, MS; Cooney, E; Del Toro, G; Foley, S; Garvin, J; George, D; Harrison, L; Hawks, R; Militano, O; Roman, E; Satwani, P; Unal, E; van de Ven, C; Wolownik, K | 1 |
| Bacigalupo, A; Cesaro, S; Lanino, E; Locasciulli, A; Locatelli, F; Marsh, J; Maury, S; Passweg, J; Prete, A; Socié, G | 1 |
| De La Cruz, M; Ferrin, TE; Giacomini, KM; Huang, CC; Johns, SJ; Kawamoto, M; Lagpacan, LL; Owen, RP; Stryke, D; Taylor, TR | 1 |
| Bergmann, M; Brittinger, G; Busch, R; Döhner, H; Eichhorst, BF; Emmerich, B; Hallek, M; Hensel, M; Hopfinger, G; Jäger, U; Pasold, R; Schweighofer, C; Siehl, S; Steinbrecher, C; Stilgenbauer, S; Wendtner, CM | 1 |
| Cass, CE; Damaraju, VL; King, KM; Lang, T; Mowles, DA; Ng, AM; Tackaberry, TE; Vickers, MF; Yao, SY; Young, JD | 1 |
| Ernemann, U; Hebart, H; Herrlinger, U; Kanz, L; Knop, S | 1 |
| Alinari, L; Baccarani, M; Fina, M; Gabriele, A; Marchi, E; Musuraca, G; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Barbarotto, E; Corallini, F; di Iasio, MG; Melloni, E; Secchiero, P; Tiribelli, M; Zauli, G | 1 |
| Amadori, S; Bruno, A; Buccisano, F; Cantonetti, M; Capelli, G; Consalvo, MA; Del Poeta, G; Del Principe, MI; Gattei, V; Gianní, L; Lo Coco, F; Maurillo, L; Mazzone, C; Venditti, A | 1 |
| Beijnen, JH; Hillebrand, MJ; Rosing, H; Silvertand, LH; van Maanen, MJ; Vazvaei, F; Weigl, P | 1 |
| Ball, ED; Bashey, A; Carrier, E; Castro, JE; Corringham, S; Hassidim, K; Holman, P; Ihasz, A; Keese, K; Lane, TA; Liu, L; Medina, B | 1 |
| Adam, K; Bergmann, J; Buchheidt, D; Hehlmann, R; Hummel, M; Reiter, S | 1 |
| Abdul Hai, A; Ben-Harush, M; Bitan, M; Hershkovitz, E; Kapelushnik, J; Or, R; Resnick, IB; Schwartz, A; Shapira, MY; Slavin, S | 1 |
| Begum, G; Chopra, R; Cook, G; Cook, M; Craddock, C; Goldstone, A; Hale, G; Hunter, A; Jackson, G; Khwaja, A; Littlewood, T; Mackinnon, S; Mahendra, P; Marsh, J; Milligan, D; Parker, A; Peggs, K; Peniket, A; Russell, N; Tauro, S | 1 |
| Asaka, M; Ikarashi, Y; Kuwatani, M; Mineishi, S; Wakasugi, H | 1 |
| Blau, IW; Fietz, T; Gentilini, C; Glass, B; Marinets, O; Muessig, A; Munz, DL; Rieger, K; Sandrock, D; Thiel, E; Uharek, L | 1 |
| Byrd, JC; Diehl, LF; Flinn, IW; Garrett-Mayer, E; Goodman, SN; Grever, MR; Kasamon, YL; Lucas, MS | 1 |
| Baxter-Lowe, LA; Cowan, M; Desantes, K; Englert, L; Horn, B; McMillan, A; Quinn, M | 1 |
| Chen, L; Ng, AP; Prince, HM; Seymour, JF; Slavin, M; Thursky, K; Worth, L | 1 |
| Carney, DA; Estrov, Z; Garcia-Prieto, C; Harris, DM; Huang, P; Jin, Z; Kang, Y; Keating, MJ; Kondo, S; Liu, J; Lou, C; Pelicano, H; Xu, RH; Yu, W; Zhou, Y | 1 |
| Andreani, M; Gaziev, J; Lucarelli, G; Polchi, P; Sodani, P | 1 |
| Bornhäuser, M; Ehninger, G; Fruehauf, S; Kiehl, MG; Kienast, J; Kröger, N; Mundhenk, P; Sayer, HG; Schafer-Eckart, K; Scheid, C; Schwerdtfeger, R; Stelljes, M; Theuser, C; Wandt, H; Zander, AR | 1 |
| Byrd, JC; Caligiuri, MA; Grever, MR; Gribben, JG; Heerema, NA; Lampson, B; Larson, RA; Lozanski, G; Lucas, DM; Peterson, BL | 1 |
| Hong, WD; Li, J; Luo, SK; Tong, XZ; Zhao, Y | 1 |
| Cortes, J; Do, KA; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Lerner, S; O'brien, S; Ravandi-Kashani, F; Thomas, D; Wang, X; Wierda, W | 1 |
| Avery, RK; Mawhorter, SD; Prayson, RA; Procop, GW; Sierk, A; Sobecks, R; Staugaitis, SM; Yen-Lieberman, B | 1 |
| Bukin, M; Jabłońska, E; Kiersnowska-Rogowska, B; Parfieńczyk, A; Puzewska, W; Rogowski, F | 1 |
| Ito, M; Johnson-Pais, TL; Kajiya, H; Key, LL; Reddy, SV; Srinivasan, S | 1 |
| Cassoni, A; Cooper, N; Delgado, J; Duarte, R; Jarmulowicz, M; Kottaridis, P; Mackinnon, S; Peggs, K; Thomson, K | 1 |
| Bernardi, M; Bregni, M; Corradini, P; Deola, S; Fleischhauer, K; Guggiari, E; Lunghi, F; Mazzi, B; Monari, M; Peccatori, J; Pescarollo, A; Re, F; Scaramuzza, S; Servida, P; Setola, E | 1 |
| Abramenko, I; Bazyka, D; Bebeshko, V; Bilous, N; Chumak, A; Kryachok, I | 1 |
| Cho, HS; Kim, CC; Kim, SY; Kim, Y; Lee, JW; Lee, S; Lee, SM; Min, CK; Min, WS; Woo, HY | 1 |
| Atanackovic, D; Ayuk, F; Dahlke, J; Kröger, N; Nagler, A; Panse, J; Renges, H; Schieder, H; Shimoni, A; Wolschke, C; Zabelina, T; Zander, A | 1 |
| Rzepecki, P; Sarosiek, T; Szczylik, C | 1 |
| Gale, R; Gray, A; Hancock, B; Hutchinson, J; Lloyd, A | 1 |
| Fay, M; Murphy, PT; Nolan, A; O'Donnell, R; Quinn, J; Swords, R | 1 |
| Champlin, RC; Chan, KW; Choroszy, M; Ha, CS; Madden, R; Mahajan, A; Mullen, CA; Petropoulos, D; Worth, LL | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Plunkett, W; Shan, J | 1 |
| Barón, A; Bearman, SI; Hawkins, T; Jones, RB; McSweeney, PA; Nieto, Y; Patton, N; Rabinovitch, R; Shpall, EJ; Spearing, R; Zeng, C | 1 |
| Fujimori, Y; Hara, H; Itoi, H; Itsukuma, T; Kai, S; Misawa, M; Nakajima, T; Nishioka, K; Nomura, K; Ogawa, H; Okada, M; Takatsuka, H; Toda, A; Wakae, T | 1 |
| Kneba, M; Moosig, F; Schoch, R | 1 |
| Khurshid, M; Syed, NN | 1 |
| Inamoto, Y; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Oba, T; Tokunaga, M; Tsujimura, A | 1 |
| Bernardi, P; Cabrelle, A; Cesura, AM; Colonna, R; Costantini, P; Gambalunga, A; Milanesi, E; Petronilli, V; Pinard, E; Semenzato, G | 1 |
| Sikorski, AF; Stebelska, K; Wyrozumska, P | 1 |
| Benson, GM; Clarke, J; Kettle, PJ; Murtagh, E; Wilson, L | 1 |
| Birchall, J; Johnson, SA; Luckie, C; Oscier, DG; Owen, RG | 1 |
| Kami, M; Kusumi, E; Masuoka, K; Miura, Y; Murashige, N; Tachibana, S; Taniguchi, S; Yoshimura, M | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-Rangel, JD; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Rivas-Vera, S; Ruiz-Argüelles, GJ; Sobrevilla-Calvo, P; Vela-Ojeda, J | 1 |
| Faria, JR; Faria, RM; Kerbauy, J; Oliveira, JS; Yamamoto, M | 1 |
| Castro, ED; Coelho, AM; Linden, R; Maia, RC; Silva, KL; Vasconcellos, DV | 1 |
| Abe, Y; Choi, I; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Shibata, K; Tachikawa, Y | 1 |
| Choudhry, VP; Chowdhary, DR; Kumar, R; Mahapatra, M; Mehra, NK; Mishra, P; Narendra, AM; Pillai, L; Prem, S; Saxena, R; Seth, T | 1 |
| Higashihara, M; Horie, R; Motoji, T; Okamura, T; Shoda, M; Taira, M; Umezawa, K; Utsunomiya, A; Watanabe, M; Watanabe, T | 1 |
| Alberto, MF; Fernández-Calotti, P; Gamberale, R; Geffner, J; Giordano, M; Sánchez-Avalos, J | 1 |
| Aguado, JM; Díaz-Pedroche, C; Folgueira, D; Giménez-Mesa, E; Lizasoain, M | 1 |
| Robak, E; Sysa-Jedrzejowska, A; Wozniacka, A | 1 |
| Ikeda, Y; Murase, T; Nishida, H; Park, JW; Ueno, H; Yano, T | 1 |
| Andreeff, M; Kojima, K; Konopleva, M; McQueen, T; O'Brien, S; Plunkett, W | 1 |
| Agura, E; Blume, KG; Bruno, B; Chauncey, TR; Kliem, C; Langston, AA; Maloney, DG; Maris, MB; Maziarz, RT; McSweeney, PA; Pulsipher, M; Sandmaier, BM; Shizuru, JA; Storb, R; Storer, BE; Wade, J | 1 |
| Costas, M; Fernández-Calotti, P; Gamberale, R; Geffner, J; Giordano, M; Sánchez Avalos, J | 1 |
| Culligan, DJ; Johnston, PW; Milner, BJ; Mittal, S | 1 |
| Kay, NE | 1 |
| Imamura, T; Kadota, J; Kikuchi, H; Kohno, K; Ogata, M; Ohtsuka, E; Tomo, T | 1 |
| Seymour, JF; Tam, CS | 1 |
| Asano, S; Iseki, T; Konuma, T; Nakaoka, T; Ooi, J; Takahashi, S; Takasugi, K; Tojo, A; Tomonari, A; Tsukada, N; Uchiyama, M | 1 |
| Cai, Z; Wu, WJ | 1 |
| Cairoli, R; Colosimo, A; Intropido, L; Miqueleiz, S; Montagna, M; Montillo, M; Morra, E; Nichelatti, M; Regazzi, M; Ricci, F; Scarpati, B; Tedeschi, A; Veronese, S | 1 |
| Benetatos, L; Bourantas, KL; Hatzimichael, E; Vassou, A | 1 |
| Bretonnet, AS; Cros, E; Dumontet, C; Gagnieu, MC; Galmarini, CM; Jordheim, LP; Krimm, I; Lancelin, JM | 1 |
| Liu, H; Sheng, ZY; Yao, YM; Yu, Y | 1 |
| Barrett, AJ; Childs, RW; Dorrance, C; Espinoza-Delgado, I; Geller, N; Igarashi, T; Lundqvist, A; McCoy, JP; Srinivasan, R; Takahashi, Y; Young, NS | 1 |
| Carney, D; Januszewicz, EH; Lin, KI; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M | 1 |
| Byrd, JC; Croce, CM; De Lay, MD; Edwards, RB; Grever, MR; Johnson, AJ; Lucas, DM; Muthusamy, N; Smith, LL | 1 |
| Au, WY; Chan, LC; Kwong, YL; Liang, R | 1 |
| Mitra, S; Murphy, PT; O'Donghaile, D | 1 |
| Califano, C; Celentano, M; D'Amico, MR; D'Arco, AM; Ferrara, F; Mele, G; Palmieri, S; Pollio, F | 1 |
| Abdul-Hai, A; Ackerstein, A; Aker, M; Bitan, M; Gesundheit, B; Lvovich, A; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Tsirigotis, PD; Yoffe, L; Zilberman, I | 1 |
| Hanamura, A; Hayakawa, M; Naito, K | 1 |
| Ohnishi, K | 1 |
| Smolej, L | 2 |
| Inamoto, Y; Kasai, M; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Murata, M; Naoe, T; Oba, T; Terakura, S; Tokunaga, M; Tsujimura, A | 1 |
| Goh, YT; Hwang, WY; Koh, BC; Koh, LP; Linn, YC; Loh, SM; Ratnagopal, P; Tan, HC | 1 |
| Aly, F; Diehl, V; Rehwald, U; Schmitz, S; Steinmetz, T | 1 |
| Abinun, M; Ferreira, RA; Foster, HE; Kuis, W; Modesto, C; Olivé, T; Vastert, SJ; Wulffraat, NM | 1 |
| Ackerstein, A; Aker, M; Bitan, M; Elad, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S | 1 |
| Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M | 1 |
| Alexopoulou, A; Archimandritis, AJ; Dourakis, SP; Karayiannis, P; Pandelidaki, H | 1 |
| de la Fuente Bobillo, MA; Mendo González, M; Peñarrubia Ponce, MJ; Rodríguez Toves, A; Torres Nieto, A; Vara Castrodeza, A | 1 |
| Bohlius, J; Greil, R; Pall, G; Richards, S; Schwarzer, G; Steurer, M | 2 |
| Giver, CR; Li, JM; Waller, EK | 1 |
| Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Laurenti, L; Leone, G; Piccioni, P; Piccirillo, N; Sica, S; Tarnani, M | 1 |
| Cutting, R; Edbrooke, D; El-Ghariani, K; Ezaydi, Y; Snowden, JA; Stamps, R | 1 |
| Byrd, JC; Esseltine, DL; Faderl, S; Flinn, IW; Gribben, J; Keating, MJ; O'Brien, S; Rai, K; Sheng, S | 1 |
| Adachi, S; Hamanoue, S; Inoue, H; Ishiguro, H; Kato, S; Koike, H; Koike, K; Koike, T; Kojima, S; Matsumoto, M; Mori, T; Morimoto, A; Sako, M; Suzuki, K; Tsuchida, M; Tsuji, K; Yabe, H; Yabe, M | 1 |
| Bowcock, SJ; Lim, Z; Mufti, GJ; Rassam, SM; Ryali, MM; Ward, SM | 1 |
| Januszewicz, EH; Milner, A; Polizzotto, MN; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Alexaki, P; Christakis, GB; Megalakaki, A; Perlorentzou, S; Zarkadis, IK | 1 |
| Cantu-Rodríguez, O; Gomez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, H; Herrera-Garza, J; Jaime-Pérez, J; Mancias-Guerra, C | 1 |
| Coleman, M; Feldman, EJ; Harpel, J; Leonard, JP; Roboz, GJ; Schuster, MW; Shore, T; Silver, RT | 1 |
| Chuah, CT; Goh, YT; Hwang, WY; Koh, LP; Koh, MB; Linn, YC; Loh, YS; Ng, HJ; Ng, HY; Tan, DC; Tan, KW; Tan, PH | 1 |
| Elter, T; Engert, A; Hallek, M | 1 |
| Audouin, J; Compérat, E; Delmer, A; Diebold, J; Le Tourneau, A; Molina, TJ | 1 |
| Brugiatelli, M; Callea, V; Console, G; Iacopino, P; Irrera, G; Martino, M; Morabito, F; Musolino, C; Piro, E; Praticò, G; Quartarone, E; Stelitano, C | 1 |
| Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Khouri, IF; Korbling, M; Lekakis, L; Martin, T; Shpall, EJ | 1 |
| Bauta, WE; Cantrell, WR; Schulmeier, BE | 1 |
| Taniguchi, S | 1 |
| Fujii, H; Goto, H; Ikuta, K; Isaki, S; Kajiwara, R; Kuroki, F; Takahashi, H; Yanagimachi, M; Yokota, S | 1 |
| Choudhury, A; Kiaii, S; Lundin, J; Mellstedt, H; Mozaffari, F; Osterborg, A; Rezvany, R | 1 |
| Czepulkowski, B; Devereux, S; Duarte, RF; Ho, AY; Ingram, W; Kenyon, M; Lim, ZY; Mufti, GJ; Pagliuca, A; Pearce, L | 1 |
| Bulanov, AIu; Chernova, NG; Gretsov, EM; Kalinin, NN; Kravchenko, SK; Kremenetskaia, AM; Mar'in, DS; Petrova, VI; Semenova, EA; Valiev, TT; Vinogradova, IuE; Volkova, IaK; Vorob'ev, AI | 1 |
| Böck, HP; Dreyling, M; Einsele, H; Forstpointner, R; Hänel, A; Hartmann, F; Hiddemann, W; Lehmann, T; Metzner, B; Pott, C; Repp, R; Seymour, JF; Unterhalt, M; Wandt, H | 1 |
| Everett, PC; Lerner, A; Makkinje, A; Meyers, JA; Rabbi, M | 1 |
| Keating, MJ; Moufarij, MA; Plunkett, W; Sampath, D | 1 |
| Cabanillas, F; Liboy, I; Pavia, O; Rivera, E | 1 |
| Andreasson, B; Birgegård, G; Brune, M; Kutti, J; Lazarevic, V; LeBlanc, K; Malm, C; Merup, M; Nahi, H; Nilsson, L | 1 |
| Dmoszyńska, A; Giannopoulos, K; Roliński, J | 1 |
| Beri, R; Chen, HY; Chunduri, S; Dobogai, LC; Hoffman, R; Jessop, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y | 1 |
| Brychtova, Y; Dolezal, T; Doubek, M; Dvorakova, D; Horky, O; Koristek, Z; Krejci, M; Lengerova, M; Mayer, J; Pospisil, Z; Racil, Z; Vorlicek, J | 1 |
| Dalal, J; Davies, SM; Filipovich, A; Kamani, N; Lee, SM; Rao, A; Shenoy, S | 1 |
| Nelson, JA; Pan, BF | 1 |
| Denning, MF; Nickoloff, BJ; Qin, JZ; Sitailo, LA; Xin, H | 1 |
| Benedetti, F; Boccadoro, M; Chisesi, T; De Blasio, A; Drandi, D; Gallamini, A; Ladetto, M; Locasciulli, A; Majolino, I; Tarella, C | 1 |
| Montillo, M; Ricci, F; Tedeschi, A | 1 |
| Carter, WH; Cragg, L; Feldman, EJ; Grant, S; Honeycutt, C; Millenson, MM; Murgo, AJ; Padavic-Shaller, K; Ramakrishnan, V; Roberts, JD; Roboz, GJ; Smith, MR; Thune, R | 1 |
| Ijichi, O; Ikarimoto, N; Ishikawa, S; Kawano, Y; Kodama, Y; Manago, K; Nishikawa, T; Okamoto, Y; Shinkoda, Y; Tanabe, T | 1 |
| Hori, A; Kami, M; Kobayashi, K; Komatsu, T; Kurita, N; Kusakabe, M; Matsumura, T; Murashige, N; Narimatsu, H; Tanaka, Y; Yoshimi, A; Yuji, K | 1 |
| Barkholt, L; Hassan, Z; Mattsson, J; Omazic, B; Remberger, M; Ringdén, O; Sairafi, D; Uzunel, M | 1 |
| Cervasi, B; Engram, J; Fraternale, A; Lawson, B; Magnani, M; Menotta, M; Paiardini, M; Perno, CF; Piedimonte, G; Serafini, S; Silvestri, G; Staprans, SI | 1 |
| Campo, E; Gaya, A; Martinez, A; Mercadal, S; Nomdedeu, B; Rozman, M; Salamero, O | 1 |
| Aribi, A; Faderl, S; Ferrajoli, A; Huh, Y; Kantarjian, H; Keating, M; O'brien, S; Ravandi, F; Wierda, W | 1 |
| Chang, VT; Harrison, J; Mansour, A; Raveche, E; Srinivas, S | 1 |
| Aghaiipour, M; Bernard, D; David, G; Hadjati, E; Iravani, M; Shaiegan, M | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Tiongson, LP; Younes, A | 1 |
| Bianchi, M; Castiglioni, MG; Mechelli, S; Pandolfo, C; Scatena, P | 1 |
| Fabianowska-Majewska, K; Krawczyk, B | 1 |
| Alyea, EP; Antin, JH; Cutler, C; DeAngelo, DJ; Ho, V; Kim, HT; Ritz, J; Soiffer, RJ; Stone, R | 1 |
| Dhar, S; Fryknäs, M; Göransson, H; Gustafsson, M; Isaksson, A; Larsson, R; Nygren, P; Oberg, F; Pettersson, U; Rickardson, L; Rydåker, M | 1 |
| Januszewicz, EH; Kenealy, M; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M | 1 |
| Busch, R; Eichhorst, BF; Emmerich, B; Hallek, M; Schweighofer, C; Wendtner, CM | 1 |
| Alyea, EP; Antin, JH; Brown, JR; Cutler, C; Fisher, DC; Gribben, JG; Ho, V; Kim, HT; Lee, SJ; Li, S; Milford, EL; Ritz, J; Soiffer, RJ; Stephans, K | 1 |
| Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S | 1 |
| Anhalt, GJ; Cummins, DL; Meyerle, JH; Mimouni, D; Owens, N; Tzu, J | 1 |
| Flinn, IW; Kasamon, YL | 1 |
| Croce, C | 1 |
| Lazarevic, V; Wahlin, A | 1 |
| Kay, NE; O'Brien, S; Rai, KR | 1 |
| Eurelings, M; Fijnheer, R; Franssen, H; Lokhorst, H; Niermeijer, JM; Notermans, NC; Wokke, JH | 1 |
| Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K | 1 |
| Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J | 1 |
| Cebula, B; Linke, A; Robak, P; Robak, T; Smolewski, P | 1 |
| Brunstein, C; DeFor, T; Ebeling, B; Green, K; Jacobson, P; McGlave, P; Rogosheske, J; Weisdorf, D | 1 |
| Hartmann, JT; Kanz, L; Klingel, K; Kröber, SM; Meisinger, I; Weisel, K | 1 |
| Bergeman, T; Bonin, M; Bornhauser, M; Ehninger, G; Illmer, T; Leopold, T; Pursche, S; Schleyer, E | 1 |
| Hanke, A; Lohse, P; Meissner, B; Rehe, K; Sauer, M; Sykora, KW; Welte, K; Zeidler, C | 1 |
| Emmons, RV; Jillella, AP; Klumpp, TR; Mangan, KF; Shafer, D | 1 |
| Celsing, F; Hansson, L; Karlsson, C; Lundin, J | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ | 1 |
| Baccarani, M; Bergonzi, C; Bocchia, M; Bonini, A; Candoni, A; Cesana, B; Damiani, D; Fanin, R; Filí, C; Geromin, A; Gobbi, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michelutti, A; Ottaviani, E; Piccaluga, PP; Pierri, I; Priccolo, G; Roccaro, AM; Russo, D; Skert, C; Testoni, N; Tiribelli, M; Visani, G; Vivo, AD; Zaccaria, A; Zuffa, E | 1 |
| Alyea, E; Antin, JH; Attar, E; Ballen, KK; Cutler, C; Dey, BR; Haspel, R; Ho, V; Kao, G; Lee, S; Liney, D; McAfee, S; Soiffer, R; Spitzer, TR; Yeap, BY | 1 |
| Bakke, AC; Braziel, RM; Fan, G; Gatter, KM; Huang, JZ; Leis, JF; Maziarz, RT; Zhong, Y | 1 |
| Avcu, F; Cetin, T; Kubar, A; Nevruz, O; Safali, M; Tastan, HB; Ural, AU | 1 |
| King, I; Li, Z; Liu, L; Song, BL; Zheng, LM | 1 |
| Bertz, H; Bley, TA; Feuerhake, F; Finke, J; Mielke, S; Potthoff, K; Windfuhr, M | 1 |
| Abrahamsson, J; Clausen, N; Forestier, E; Gustafsson, G; Hasle, H; Heldrup, J; Hovi, L; Jonmundsson, G; Zeller, B | 1 |
| Appelbaum, FR; Bennett, JM; Dewald, GW; Flinn, IW; Grever, MR; Hussein, MA; Larson, RA; Moore, DF; Neuberg, DS; Paietta, EM; Tallman, MS | 1 |
| Cavaliere, AL; Coppola, C; Curcio, A; De Serio, D; Ellison, GM; Galuppo, V; Gasparri, C; Indolfi, C; Leone, A; Surace, FC; Torella, D | 1 |
| Bociek, RG; Boyd, TE; Chanan-Khan, AA; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Pavletic, S; Rai, KR; Seymour, JF; Skotnicki, A | 1 |
| Andreesen, R; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Fauser, AA; Fietz, T; Freund, M; Hopfenmüller, W; Kanz, L; Keilholz, U; Knauf, W; Marinets, O; Ruutu, T; Schmidt-Hieber, M; Stuhler, G; Thiel, E; Trenschel, R; Uharek, L; Volin, L | 1 |
| Aschan, J; Barkholt, L; Dahllöf, G; Gustafsson, B; Hassan, Z; Ljungman, P; Mattsson, J; Omazic, B; Remberger, M; Ringdén, O; Svahn, BM; Svenberg, P; Uzunel, M; Winiarski, J | 1 |
| Abidi, MH; Alangaden, G; Chandrasekar, PH; Heilbrun, LK; Klein, JL; Mellon-Reppen, S; Narreddy, S; Peres, E; Smith, D | 1 |
| Gadre, SA; Ge, Y; Lockhart, LH; Northup, JK; Velagaleti, GV | 1 |
| Chuhjo, T; Kondo, Y; Kotani, T; Nakao, S; Ohtake, S; Okumura, H; Ozaki, J; Sugimori, C; Sugimori, N; Takami, A; Ueda, M; Yamaguchi, M; Yamazaki, H | 1 |
| Brown, C; Chaudhry, A; Larratt, L; Morris, D; Quinlan, D; Russell, JA; Stewart, D; Turner, AR | 1 |
| Calixto, R; Domingues, MC; Florêncio, R; Ostronoff, F; Ostronoff, M; Souto Maior, AP; Sucupira, A; Tagliari, C | 1 |
| Austin, HA; Balow, JE; Boumpas, DT; Chitkara, P; Fleisher, T; Illei, GG; Klippel, JH; Kuroiwa, T; Schlimgen, R; Tisdale, JF; Yarboro, CH | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Iwasaki, H; Kawai, Y; Kishi, S; Takemura, H; Ueda, T; Urasaki, Y; Yamamoto, S; Yamauchi, T; Yoshida, A | 1 |
| Algüneş, C; Demir, M; Ongören, S; Pala, FS; Pamuk, GE; Soysal, T; Tabakcioğlu, K; Turgut, B; Vural, O | 1 |
| Bauters, F; Berthon, C; Boulanger, F; Cracco, P; Darré, S; Jouet, JP; Micol, JB; Terriou, L; Tricot, S; Yakoub-Agha, I | 1 |
| Bertetto, O; Busca, A; de Fabritiis, P; Falda, M; Locatelli, F; Novarino, A; Picardi, A; Zeuli, M | 1 |
| Ashida, T; Higashishiba, M; Kanamaru, A; Kawanishi, K; Mayama, T; Miyatake, J; Tatsumi, Y | 1 |
| Bruno, C; Cappelli, B; Castagnola, E; Cuzzubbo, D; Dallorso, S; Dini, G; Faraci, M; Lanino, E; Micalizzi, C; Morreale, G; Rossi, A; Schiaffino, MC | 1 |
| Bay, JO; Bertuzzi, A; Carrabba, MG; Castagna, L; Corradini, P; Demirer, T; Grosso, F; Niederwieser, D; Pedrazzoli, P; Secondino, S; Siena, S; Spina, F | 1 |
| O' Brien, S | 1 |
| Borthakur, G; Cortes, JE; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Thomas, DA; Wierda, WG | 1 |
| Ikezoe, T; Koeffler, HP; Nishioka, C; Taguchi, H; Yang, J | 1 |
| Bonnefoy-Bérard, N; Brien, G; Trescol-Biemont, MC | 1 |
| Algarotti, A; Bernasconi, P; Boni, M; Brusamolino, E; De Amici, M; Giardini, I; Lazzarino, M; Orlandi, E; Paulli, M; Perfetti, V; Tenore, AM; Vanelli, L; Zibellini, S | 1 |
| Antolak, J; Chan, KW; Ha, CS; Kornguth, DG; Mahajan, A; Woo, S | 1 |
| Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; de Meis, E; Donato, M; Ghosh, S; Giralt, S; Hosing, C; Kebriaei, P; Khouri, I; Oran, B; Popat, U; Qazilbash, M; Saliba, R | 1 |
| Busch, R; Eichhorst, BF; Hallek, M; Herschbach, P; Kuhn-Hallek, I; Obwandner, T | 1 |
| Bocchia, M; Bucalossi, A; Defina, M; Forconi, F; Gozzetti, A; Lauria, F; Pirrotta, MT | 1 |
| Robak, P; Robak, T | 1 |
| Attarbaschi, A; Fritsch, G; Gadner, H; Lawitschka, A; Lion, T; Matthes-Martin, S; Minkov, M; Mittheisz, E; Steiner, M; Zoubek, A | 1 |
| Bunker, CB; Chapman, A; Dearden, CE; Dungarwalla, M; Field-Smith, A; Jameson, C; Matutes, E; Riley, U | 1 |
| Buzyn, A; Candon, S; Casadevall, N; Hummel, A; Ittah, M; Lavie, F; Louache, F; Mariette, X; Soumelis, V; Terrier, B; Tourneur, L | 1 |
| Chao, NJ; Chute, JP; Dressman, HK; Ginsburg, GS; Marshall, D; Meadows, S; Muramoto, GG; Nevins, JR | 1 |
| Hashimoto, T; Hull, CM; Ishii, N; Leiferman, KM; Taintor, AR; Zone, JJ | 1 |
| Mikkelsen, NE; Piskur, J; Sandrini, MP; Söderbom, F | 1 |
| Bardy, PG; Bradstock, KF; Gibson, J; Grigg, AP; Kennedy, G; Koelmeyer, RL; Reynolds, J; Roberts, AW; Shuttleworth, P; Szer, J; To, LB | 1 |
| Amadori, S; de Fabritiis, P; Del Poeta, G; Fratoni, S; Maurillo, L; Niscola, P; Palombi, M; Piccioni, D; Principe, MI | 1 |
| Choi, Y; Keam, B; Kim, BK; Kim, I; Koo, NH; Lee, KH; Park, S; Yoo, KY; Yoon, SS | 1 |
| Kiyoi, H; Mizutani, E; Murata, M; Naoe, T; Narimatsu, H; Tomita, A | 1 |
| Chandy, M; George, B; Kavitha, ML; Mathews, V; Srivastava, A; Viswabandya, A | 2 |
| Chen, J; Li, JP; Zhang, T; Zhong, J; Zhu, KE | 1 |
| Arkenau, HT; Chau, I; Cunningham, D; Gordon, C; Norman, A; Wotherspoon, A | 1 |
| Arbelaez, JE; Bacigalupo, A; Bregni, M; Carnevalli, E; Corradini, P; Davoli, M; De Fabritiis, P; Di Bartolomeo, P; Locasciulli, A; Majolino, I; Musso, M; Narni, F; Olivieri, A; Pogliani, L; Ruscio, C; Scimè, R; Selleri, C | 1 |
| Admirand, J; Bueso-Ramos, C; Champlin, RE; Giralt, S; Keating, MJ; Khouri, IF; Korbling, M; Lee, MS; Lima, de M; O'Brien, S; Saliba, RM; Samuels, BI | 1 |
| Allwinn, R; Beske, F; Klingebiel, T; Kriener, S; Lehrnbecher, T; Modrow, S; Schmidt, H; Schwabe, D; Sörensen, J | 1 |
| Alimoghaddam, K; Ashouri, A; Chahardovali, B; Evazi, MR; Ghaffari, SH; Ghavamzadeh, A; Iravani, M; Mousavi, SA; Samiee, S; Shamshiri, AR; Tavakoli, M | 1 |
| Blau, IW; Blau, O; Göldner, H; Hopfenmüller, W; Knauf, W; Leschinger, N; Schmidt-Hieber, M; Thiel, E | 1 |
| Akahane, D; Fukuda, T; Heike, Y; Kim, SW; Kusumoto, S; Mori, S; Morita-Hoshi, Y; Onishi, Y; Sugimoto, K; Takaue, Y; Tanosaki, R; Tobinai, K | 1 |
| Arakawa, S; Hamanoue, S; Inoue, H; Ishiguro, H; Katob, S; Koike, T; Masukawa, A; Matsumoto, M; Miyachi, H; Morimoto, T; Ohshima, T; Yabe, H; Yabe, M; Yamashita, T | 1 |
| Aprahamian, M; Deharvengt, S; Hajri, A; Rejiba, S; Wack, S | 1 |
| Bilgrami, S; Mahipal, A | 1 |
| Blaise, D; Faucher, C; Mohty, M; Vey, N | 1 |
| Balère-Appert, ML; Boiron, JM; Bordigoni, P; Chir, Z; Galambrun, C; Kanold, J; Maillard, N; Marie-Cardine, A; Maury, S; Milpied, N; Socié, G; Yakouben, K | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Appelbaum, FR; Bedalov, A; Bryant, EM; Chang, C; Clurman, BE; Deeg, HJ; Flowers, ME; Hansen, JA; Nash, RA; Sanders, JE; Sandmaier, BM; Scott, BL; Shulman, HM; Storb, R; Storer, BE; Witherspoon, RP | 1 |
| Brugiatelli, M; Federico, M; Liberati, M; Marcheselli, R; Merli, F; Orsucci, L; Pozzi, S; Sacchi, S; Tucci, A; Vallisa, D | 1 |
| León-Mateos, A; Sánchez-Aguilar, D; Toribio, J | 1 |
| Au, WY; Chan, JC; Kwong, YL; Lam, CC; Leung, AY; Pang, A; Tse, E | 1 |
| Alinari, L; Andritsos, L; Baiocchi, RA; Byrd, JC; Lapalombella, R; Lin, TS | 1 |
| Byrd, JC; Grever, M; Jacob, ST; Kutay, H; Lucas, DM; Majumder, S; Motiwala, T; Neuberg, DS; Smith, DS | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, CH; Jaime-Pérez, JC; Martinez-González, O; Morales-Toquero, A; Ruiz-Argüelles, GJ; Salazar-Riojas, R; Tarín-Arzaga, LC | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, SY; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Barker, JN; Blazar, BR; Brunstein, CG; DeFor, TE; McGlave, PB; Miller, JS; Wagner, JE; Weisdorf, DJ | 1 |
| Chiang, KY; Doering, CB; Gangadharan, B; Ide, LM; Spencer, HT | 1 |
| Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T | 1 |
| Cascavilla, N; D'Arena, G | 1 |
| Delavault, P; Fegan, C; Hartley, JA; Lowe, H; Pepper, C; Thurieau, C; Thurston, DE | 1 |
| Chen, CS; Goh, YT; Hwang, WY; Koh, LP; Koh, MB; Lee, YM; Lim, S; Linn, YC; Liu, TC; Loh, YS; Mow, BM; Ng, HJ; Ng, HY; Tai, BC; Tan, B; Tan, DC; Tan, KW; Tan, LK; Tan, PH | 1 |
| Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR | 1 |
| Gojkovic, Z; Hasholt, L; Joergensen, T; Knecht, W; Le Breton, C; Munch-Petersen, B; Piskur, J; Rozpedowska, E; Sandrini, MP; Willer, M | 1 |
| Alexander, S; Ballen, KK; Dey, BR; Dombkowski, D; McAfee, S; Means, TK; Preffer, FI; Sachs, DH; Saidman, S; Shaffer, J; Spitzer, TR; Sykes, M; Villard, J | 1 |
| Albarello, A; Bacigalupo, A; Balleari, E; Balocco, M; Carella, AM; Catania, G; Clavio, M; Gobbi, M; Manna, A; Michelis, G; Miglino, M; Pierri, I; Sessarego, M; Van Lint, MT; Varaldo, R; Vignolo, L | 1 |
| Anderlini, P; Champlin, RE; Couriel, DR; Giralt, SA; Jabbour, E; Khouri, IF; Rondon, G | 1 |
| Barge, RM; Beaumont, F; Falkenburg, JH; Hoogendoorn, M; Jedema, I; Marijt, EW; van Luxemburg-Heijs, SA; Willemze, R | 1 |
| Allione, B; Bacigalupo, A; Baldi, I; Bruno, B; Busca, A; Falda, M; Locatelli, F; Mordini, N; Morello, E; Narni, F; Rambaldi, A; Santarone, S | 1 |
| Balashov, D; Filimonov, A; Maschan, A; Maschan, M; Novichkova, G; Shelikhova, L; Shipicina, I; Skorobogatova, E; Skvortsova, Y; Trakhtman, P | 1 |
| Goto, H; Ito, S; Kajiwara, R; Kuroki, F; Yanagimachi, M; Yokosuka, T; Yokota, S | 1 |
| Chae, YS; Cho, GJ; Cho, YY; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Moon, JH; Shin, HJ; Sohn, SK; Yang, DH | 1 |
| Giles, FJ; Gojo, I; Greer, J; Johnson, B; Karp, JE; Low, J; Morris, L; Sznol, M; Thein, M | 1 |
| Alousi, A; Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; Detry, MA; Giralt, S; Hosing, C; Kebriaei, P; Khouri, IF | 1 |
| Kay, NE; Shanafelt, TD | 1 |
| Bezares, RF; Bosanquet, AG; Brito-Babapulle, V; Catovsky, D; Child, JA; Davis, Z; Dearden, CE; Dyer, M; Else, M; Hamblin, T; Hamilton, MS; Hillmen, P; Matutes, E; Milligan, DW; Oscier, D; Pettitt, AR; Richards, S; Smith, AG; Wade, R | 1 |
| Anderson, VR; Perry, CM | 1 |
| Gesundheit, B; Resnick, IB | 1 |
| Antonov, M; Buyukunal, E; Demirkesen, C; Kursunoglu, SG; Ozguroglu, M; Serdaroglu, S; Turna, H; Yanmaz, MT; Yildiz, O | 1 |
| Hardan, I; Herscovici, C; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
| Bierings, M; Bittencourt, M; Bonfim, C; Champagne, MA; Darbyshire, P; Fernandez, MN; Gluckman, E; Harris, RE; Ionescu, I; Kurtzberg, J; Locatelli, F; Pasquini, R; Rocha, V; Wagner, J | 1 |
| Cassells, R; Cheow, HK; Giles, A; Lim, Z; Mir, N | 1 |
| Keating, MJ; Tam, CS | 2 |
| Hillmen, P; Rawstron, AC; Sayala, HA | 1 |
| Bureo, E; Diaz de Heredia, C; Gonzalez-Vicent, M; Maldonado, MS; Martinez, A; Muñoz, A; Olivé, T; Sastre, A | 1 |
| Cordonnier, M | 1 |
| Cervasi, B; Fraternale, A; Magnani, M; Paiardini, M; Serafini, S; Silvestri, G | 1 |
| Byrd, JC; Lee, RJ; Muthusamy, N; Wu, J; Zhao, X | 1 |
| Amarasinghe, K; Dalley, C; Dokal, I; Gupta, V; Laurie, A; Marsh, J | 1 |
| Bhatia, R; Chang, K; Forman, SJ; Kirschbaum, M; Kogut, N; Naing, A; Nakamura, R; O'Donnell, MR; Palmer, J; Pullarkat, V; Rodriguez, R; Slovak, ML; Spielberger, R; Stein, A; Tsai, N | 1 |
| Anevlavis, E; Christopoulos, C; Fortis, A; Tassidou, A | 1 |
| Celsing, F; Choudhury, A; Derkow, K; Jondal, M; Norberg, M; Okvist, A; Olsson, A; Osorio, LM; Osterborg, A; Rosenquist, R; Tobin, G | 1 |
| Christopherson, RI; Henrich, S | 1 |
| Baou, M; Naresh, K; Wagner, SD; Willimott, S | 1 |
| Mirabelli, R; Molica, S; Montillo, M; Morra, E; Ribatti, D; Ricci, F; Tedeschi, A; Vacca, A; Veronese, S | 1 |
| Decker, T; Fend, F; Götze, KS; Hoffmann, D; Peschel, C; Schätzl, HM | 1 |
| Bacchu, S; Fegan, C; Neal, J | 1 |
| Demidova, IA; Kut'ina, RM; Misiurin, AV; Ol'shanskaia, IuV; Parovichnikova, EN; Poreshina, LP; Savchenko, VG; Shpakova, AP | 1 |
| Biderman, BV; Kolosheĭnova, TI; Kolosova, LIu; Kovaleva, LG; Lorie, IuIu; Nikitin, EA; Risinskaia, NA; Salogub, GN; Stadnik, EA; Sudarikov, AB; Tsyba, NN; Zaritskiĭ, IuA | 1 |
| Artz, AS; Daugherty, C; Godley, L; Huo, D; Larson, R; Odenike, OM; Pollyea, DA; Rich, E; Smith, SM; Stock, W; van Besien, K; Zhang, Y; Zimmerman, T | 1 |
| Abdul-Hai, A; Ackerstein, A; Aker, M; Amar, A; Bitan, M; Gesundheit, B; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Tsirigotis, P | 1 |
| Alvarez, I; Arranz, R; Caballero, D; Canales, M; Cavet, J; Garcia-Conde, J; Goldstone, AH; Hunter, A; Linch, DC; Mackinnon, S; Mahendra, P; Milligan, D; Parker, A; Peggs, KS; Qian, W; Ribera, JM; Sanz, G; Sierra, J; Sureda, A; Thomson, K; Urbano-Ispizua, A | 1 |
| Chitarrelli, I; Fabbri, A; Gobbi, M; Gozzetti, A; Lauria, F; Lenoci, M; Olcese, F; Raspadori, D | 1 |
| Bifulco, C; Parnes, A; Vanasse, GJ | 1 |
| Baer, MR; Barcos, M; Claydon, MA; Conroy, JM; Nowak, NJ; Sait, SN | 1 |
| Bamberg, M; Belka, C; Bethge, W; Faul, C; Handgretinger, R; Heinzelmann, F; Lang, PJ; Ottinger, H | 1 |
| Canales, MA; de Paz, R; Hernandez-Navarro, F; Martin-Salces, M | 1 |
| Grosskreutz, C; Isola, L; Osman, K; Scigliano, E | 1 |
| Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C | 1 |
| Bowen, DA; Call, TG; Habermann, TM; Hoyer, JD; Jelinek, DF; Kay, NE; Maddocks-Christianson, K; Reinalda, M; Schwager, S; Shanafelt, TD; Slager, SL; Zent, CS | 1 |
| Mulligan, SP | 1 |
| Browning, M; Faderl, S; Ferrajoli, A; Kantarjian, H; Khouri, I; Lerner, S; O'Brien, S; Tam, CS; Tsimberidou, AM; Wierda, WG | 1 |
| Barr, P; Cooper, B; Creger, R; Fu, P; Hartman, P; Kane, D; Laughlin, M; Lazarus, H; Meyerson, H; Reyes, R; Stear, K; Tse, W | 1 |
| Boulad, F; Castro-Malaspina, H; Chewning, JH; Collins, NH; Heller, G; Hsu, KC; Jakubowski, A; Kernan, NA; O'Reilly, RJ; Papadopoulos, EB; Perales, MA; Prockop, SE; Small, TN; van den Brink, MR; Young, JW | 1 |
| Huisman, CA; Laros-van Gorkom, BA; Schipperus, MR; Wijermans, PW | 1 |
| Li, SX; Liu, Y; Lu, XC; Zhu, HL | 1 |
| An, XM; Cao, S; Qi, J; Ren, XB; Xin, N; Yu, JP | 1 |
| Dyer, MJ; Gesk, S; Kennedy, DB; Majid, A; Siebert, R; Tsoulakis, O; Walewska, R | 1 |
| Bi, X; Fang, J; Meng, D; Wu, G; Xue, J | 1 |
| Austen, B; Baker, C; Dyer, M; Gardiner, A; Majid, A; Moss, PA; Oscier, D; Powell, JE; Siebert, R; Skowronska, A; Stankovic, T; Taylor, AM | 1 |
| Heiskanen, J; Itälä, M; Jantunen, E; Juvonen, E; Koistinen, P; Koivunen, E; Kuittinen, T; Nousiainen, T; Remes, K; Siitonen, T; Silvennoinen, R; Volin, L | 1 |
| Ding, W; Meng, H; Ni, W; Qian, W; Yang, C; Yang, X | 1 |
| Bethge, W; Bornhäuser, M; de Witte, T; Kobbe, G; Kröger, N; Kvasnicka, HM; Schubert, J; Schwerdtfeger, R; Thiele, J; Zander, A | 1 |
| Garratty, G; Petz, LD | 1 |
| Byrd, JC; Flynn, JM | 1 |
| Chen, MH; Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Hsu, HC; Lin, PC; Liu, JH | 1 |
| Anderlini, P; Andersson, BS; Caldera, Z; Champlin, RE; Chan, KW; Cook, JD; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Jabbour, E; Kebriaei, P; Khouri, I; Martin, TG; McCormick, G; Patah, PA; Qazilbash, M; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Baran-Marszak, F; Bornkamm, GW; Fagard, R; Feuillard, J; Gachard, N; Le Clorennec, C; May, E; Najjar, I; Reminieras, L; Youlyouz-Marfak, I | 1 |
| Ikezoe, T; Nishioka, C; Togitani, K; Yokoyama, A | 1 |
| Alonzo, TA; Arceci, RJ; Arndt, C; Barnard, DR; Dinndorf, P; Dusenbery, K; Feig, S; Feusner, J; Gerbing, RB; Heerema, NA; Lange, BJ; Luna-Fineman, S; Seibel, N; Shannon, K; Smith, FO; Weiman, M | 1 |
| Akdemir, Y; Arpaci, F; Balci, YI; Cetin, M; Gumruk, F; Uckan, D | 1 |
| Dabrowska, M; Dzieciol, J; Kloczko, J; Lemancewicz, D; Piszcz, JA; Rusak, M | 1 |
| Heimfeld, S; McCune, JS; Ren, AG; Wang, J; Woodahl, EL | 1 |
| Cattaneo, R; Frenzke, ME; Johnston, PB; Lampe, J; Parker, WB; Sorscher, EJ; Springfeld, C; Ungerechts, G | 1 |
| Chao, N; Chute, J; Essell, J; Gasparetto, C; Horwitz, ME; Long, G; Morris, A; Rizzieri, D; Spasojevic, I; Sullivan, K; Telen, M | 1 |
| Bernardo, ME; Di Bartolomeo, P; Fagioli, F; Locatelli, F; Longoni, D; Messina, C; Morreale, G; Nobili, B; Pession, A; Porta, F; Zecca, M | 1 |
| Barnes, Y; Bleesing, J; Davies, SM; Filipovich, AH; Hansen, MD; Hayashi, R; Jodele, S; Mehta, P; Shenoy, S | 1 |
| Byrd, J; Cheney, C; Chu, P; Hariharan, K; Molina, A; Pathan, NI | 1 |
| Bettembourg, O; Cochard, C; Cochener, B; Roussel, B | 1 |
| Díaz, MA; González-Vicent, M; Madero, L; Pérez, A; Ramirez, M; Sevilla, J | 1 |
| Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N | 1 |
| Catovsky, D; Dearden, C; Else, M; Hamblin, T; Milligan, D; Richards, S; Wade, R | 1 |
| Fabianowska-Majewska, K; Krawczyk, B; Rudnicka, K | 1 |
| Hardan, I; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
| Grosicki, S; Hołowiecki, J; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Seferynska, I; Skotnicki, AB; Warzocha, K; Zdziarska, B | 1 |
| Avalos, JS; Cañones, C; Chianelli, M; Fernández Calotti, P; Galmarini, CM; Gamberale, R; Giordano, M; Rosenstein, R; Saénz, D | 1 |
| Debey, S; Hallek, M; Kofler, D; Königs, S; Pallasch, CP; Schultze, JL; Schulz, A; Schwamb, J; Ultsch, A; Wendtner, CM | 1 |
| Bernal, MT; Besalduch, J; Brunet, MS; Caballero, D; Carrera, D; Ferra, C; Martin, J; Martino, R; Moraleda, JM; Nieto, JB; Perez-Simón, JA; Piñana, JL; Ribera, JM; Sampol, A; Sierra, J; Valcárcel, D; Vazquez, L | 1 |
| Barbarotto, E; Celeghini, C; Corallini, F; Fadda, R; Grill, V; Mischiati, C; Rimondi, E; Vaccarezza, M | 1 |
| Besser, M; Cargill, JS; Craig, JI; Crawley, C; Enoch, DA; Follows, G; Gudgin, E; Ludlam, HA; Marcus, RE; Min, SY; Sartori, P; Todd, T | 1 |
| Cho, HS; Hyun, MS; Kim, HD; Kim, MK; Lee, KH; Shin, KC | 1 |
| Abella, E; Altés, A; Asensi, A; Aymerich, M; Bertazzoni, P; Bosch, F; Briones, J; Escoda, L; Ferrer, A; Font, L; Gardella, S; Giné, E; González, M; González-Barca, E; Montserrat, E; Muntañola, A; Pérez-Ceballos, E; Rozman, M; Sayas, MJ; Villamor, N | 1 |
| Alexandrescu, DT; Wiernik, PH | 1 |
| Browning, ML; Faderl, S; Ferrajoli, A; Keating, MJ; LaPushin, R; O'Brien, SM; Wierda, WG | 1 |
| Byrd, JC; Caligiuri, MA; Carson, WE; Cheney, C; Gowda, A; Hussain, SR; Jarjoura, D; Joshi, T; Kindsvogel, W; Lehman, A; Muthusamy, N; Ramanunni, A; Roda, J; Schmidt, S; Tridandapani, S; Zhang, X | 1 |
| Brown, JR; Estrov, Z; Ferrajoli, A; Fiorentino, A; Garcia-Manero, G; Kantarjian, HM; Keating, MJ; Kipps, TJ; Kurzrock, R; Lerner, S; O'Brien, S; Plunkett, W; Ravandi-Kashani, F; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Baccarani, M; Derenzini, E; Fanti, S; Fina, M; Musuraca, G; Perrotti, A; Stefoni, V; Tani, M; Vitolo, U; Zinzani, PL | 1 |
| Bearden, JD; Greco, FA; Hainsworth, JD; Raefsky, E; Saez, RA; Spigel, DR; Vazquez, ER | 1 |
| Fujiwara, M; Hashimoto, S; Koike, T; Satoh, N; Takenouchi, S | 1 |
| Azuma, T; Kami, M; Komatsu, T; Kusumi, E; Matsumura, T; Miura, Y | 1 |
| An, J; Ando, Y; Cui, W; Cui, Y; Feng, W; Guo, K; Ikehara, S; Inaba, M; Li, M; Li, Q; Omae, M; Sakaguchi, Y; Song, C; Tsuda, M; Wang, J; Wang, X | 1 |
| Fukuda, T; Heike, Y; Kato, R; Kim, S; Koido, K; Maruyama, D; Mori, S; Takaue, Y; Tanosaki, R; Teshima, T; Tobinai, K; Usui, E; Yamasaki, S | 1 |
| Kohno, A; Kuwatsuka, Y; Miyamura, K; Morishita, Y; Murata, M; Narimatsu, H; Sugimoto, K; Uchida, T; Watanabe, M | 1 |
| Anagnostopoulos, A; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Papageorgiou, S; Psyrri, A; Tsatalas, C; Xiros, N | 1 |
| Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A | 1 |
| Huisman, C; Lokhorst, HM; Meijer, E; Petersen, EJ; Verdonck, LF | 1 |
| Andersson, BS; Bahlis, NJ; Brown, C; Chaudhry, MA; Geddes, M; Kangarloo, SB; Naveed, F; Quinlan, D; Russell, JA; Savoie, ML; Stewart, D; Storek, J | 1 |
| Agura, ED; Bethge, WA; Blume, KG; Bruno, B; Chauncey, TR; Curtin, PT; Epner, E; Forman, SJ; Lange, T; Laport, GG; Maloney, DG; Maris, MB; Petersen, FB; Sandmaier, BM; Scott, BL; Storb, RF; Storer, BE; Stuart, MJ; Wade, JC; Wong, RM | 1 |
| Acholonu, S; Anderlini, P; Andersson, B; Champlin, RE; Couriel, D; de Lima, M; Fayad, L; Giralt, SA; Hagemeister, F; Hosing, C; Khouri, IF; Munsell, MF; Pro, B; Qazilbash, MH; Romaguera, J; Saliba, R; Ueno, NT; Younes, A | 1 |
| Baron, F; Beguin, Y; Castermans, E; Cheynier, R; Geenen, V; Gothot, A; Herens, C; Meuris, N; Schaaf-Lafontaine, N; Seidel, L; Vanbellighen, JF; Willems, E | 1 |
| Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; de Sevilla, AF; Domingo-Doménech, E; Escoda, L; Estany, C; Galán, P; Gardella, S; López-Guillermo, A; Montoto, S; Montserrat, E; Moreno, C; Oriol, A; Pedro, C; Ribera, JM; Vivancos, P | 1 |
| Fukushima, M; Hasegawa, D; Hosokawa, Y; Kawasaki, K; Kosaka, Y; Mizukami, T; Morio, T; Nunoi, H; Ochiai, H; Takeda, H | 1 |
| Dickmeiss, E; Heilmann, C; Jakobsen, B; Kornblit, B; Madsen, HO; Masmas, T; Olesen, G; Petersen, SL; Ryder, LP; Sengeløv, H; Svejgaard, A; Vindeløv, L | 1 |
| Esser, R; Kalaäoui, RE; Klingebiel, T; Kloess, S; Koehl, U; Kreuter, J; Lehrnbecher, T; Munkelt, D; Schubert, R; Schwabe, D; Wehner, S; Zimmermann, SY | 1 |
| Chen, L; Lü, SQ; Ni, X; Song, XM; Wang, JM; Xu, XQ; Yang, JM; Zhang, WP | 1 |
| Beri, R; Chen, YH; Chunduri, S; Dobogai, LC; Hurter, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y | 1 |
| Bari, A; Brugiatelli, M; Buda, G; Gobbi, PG; Lazzaro, A; Lombardo, M; Luminari, S; Marcheselli, L; Marcheselli, R; Morabito, F; Pozzi, S; Quarta, G; Sacchi, S; Stelitano, C | 1 |
| Andrýs, C; Belada, DZ; Krejsek, J; Malý, J; Siroký, O; Smolej, L; Zák, P | 1 |
| Asslaber, D; Greil, R; Hamacher, F; Heyder, C; Holler, C; Merkel, O; Papak, C; Prokesch, A; Scheideler, M; Stöcher, M; Tinhofer, I; Trajanoski, Z | 1 |
| Auerbach, AD; Boulad, F; Chaudhury, S; Heller, G; Kernan, NA; O'Reilly, RJ; Prockop, SE; Scaradavou, A; Small, TN; Wolden, S | 1 |
| Gandhi, V; Jewell, RC; Keating, MJ; Lerner, S; O'Brien, S; Plunkett, W; Rodriguez, CO; Tam, C | 1 |
| Friedberg, JW | 1 |
| Catovsky, D; Dearden, CE; Dungarwalla, M; Evans, SO; Matutes, E; Riley, U | 1 |
| Bierings, MB; Heitink-Pollé, KM; Lilien, MR | 1 |
| Bernardeschi, P; Del Conte, A; Dentico, P; Fiorentini, G; Giannessi, PG; Giustarini, G; Montenora, I; Rossi, S; Turrisi, G | 1 |
| Bengtzen, S; Concha, H; Lehmann, S; Merup, M; Möllgård, L; Nahi, H; Paul, C; Selivanova, G; Svensson, A; Wiman, KG | 1 |
| Baccarani, M; Cabras, MG; De Luca, S; De Renzo, A; Derenzini, E; Fabbri, A; Fanti, S; Fattori, P; Fina, M; Gobbi, M; Guardigni, L; Marchi, E; Musuraca, G; Pellegrini, C; Perotti, A; Piccaluga, PP; Pileri, S; Pulsoni, A; Rigacci, L; Ronconi, S; Stefoni, V; Tani, M; Voso, MT; Zaccaria, A; Zinzani, PL | 1 |
| Murata, M; Naoe, T; Narimatsu, H; Sugimoto, K; Terakura, S | 1 |
| Attal, M; Blaise, D; Boiron, JM; Bordigoni, P; Bourhis, JH; Chir, Z; Deconinck, E; Esperou, H; Le, QH; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Nicolini, F; Prébet, T; Renaud, M; Rio, B; Yakoub-Agha, I | 1 |
| Anderson, KC; Ciccarelli, B; Dammacco, F; Ghobrial, IM; Hatjiharissi, E; Jia, X; Leleu, X; Moreau, AS; Ngo, HT; Patterson, CJ; Roccaro, AM; Russo, D; Sacco, A; Treon, SP; Vacca, A; Xu, L | 1 |
| Bonavita, S; Conforti, R; Della Corte, M; Gallo, A; Monsurrò, MR; Russo, A; Sacco, R; Tedeschi, G; Tessitore, A | 1 |
| Christian, BA; Lin, TS | 1 |
| Koike, N; Mulé, JJ; Pilon-Thomas, S | 1 |
| Hamdi, S; Huguet, F; Laporte, F; Oksman, F | 1 |
| Banerji, V; Gibson, SB; Hu, X; Johnston, JB; Mendoza, FJ; Sun, J | 1 |
| Adachi, S; Kobayashi, C; Kojima, S; Kurosawa, H; Manabe, A; Nakahata, T; Nakazawa, Y; Nara, T; Ogawa, C; Ohtsuka, Y; Osugi, Y; Sako, M; Tokuyama, M; Yabe, H; Yabe, M; Yanagimachi, M | 1 |
| Blough, DK; Heimfeld, S; McCune, JS; O'Donnell, PV; Phillips, B; Risler, L; Sandmaier, BM; Wang, J; Woodahl, EL | 1 |
| Cutler, FJ; Murphy, JA; Niciu, C; Soutar, RL | 1 |
| Chao, N; Chute, J; Gasparetto, C; Horwitz, ME; Long, G; McPherson, J; Morris, A; Rizzieri, D; Sullivan, K | 1 |
| Cortes, J; Do, KA; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S; Tam, CS; Thomas, DA; Wen, S; Wierda, W | 1 |
| Alousi, A; Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Fayad, L; Giralt, S; Hagemeister, F; Hosing, C; Khouri, IF; Korbling, M; Kwak, LW; Lee, MS; McLaughlin, P; Medeiros, LJ; Neelapu, SS; Saliba, RM; Samaniego, F; Samuels, BI; Ueno, NT | 1 |
| Coiffier, B; Rioufol, C | 1 |
| Calvo-Villas, JM; Sicilia, F; Umpierrez, AM; Urcuyo, BM | 1 |
| Atanackovic, D; Ayuk, F; Bacher, U; Bethge, W; Bokemeyer, C; Bornhäuser, M; Dierlamm, J; Gutierrez, NC; Hansen, T; Kröger, N; Liebisch, P; Miguel, JS; Nagler, A; Otterstetter, S; Penas, EM; Pérez-Simón, JA; San Miguel, J; Schilling, G; Schwerdtfeger, R; Shimoni, A; Simon-Perez, JA; Zabelina, T; Zander, A | 1 |
| Auberger, J; Clausen, J; Erdel, M; Gastl, G; Gunsilius, E; Nachbaur, D; Petzer, A; Willenbacher, W | 1 |
| Barge, RM; Falkenburg, JH; Marijt, EW; Starrenburg, CW; von dem Borne, PA; Willemze, R | 1 |
| He, GS; Jin, ZM; Miao, M; Sun, AN; Wang, XL; Wu, DP; Zhang, X | 1 |
| Anolik, J; Conners, C; Fisher, RI; Friedberg, JW; Kleiner, A; Rich, L; Walker, AR | 1 |
| Bertz, H; Finke, JM; Hahn, J; Holler, E; Ihorst, G; Marks, R; Potthoff, K; Spyridonidis, A | 1 |
| Forsberg, K; Lazarevic, VLj; Liljeholm, M; Söderberg, S; Wahlin, A | 1 |
| Atra, AA; Baothman, A; Elimam, NA; Kassar, A; Khattab, TM; Zayed, A | 1 |
| Hamaki, T; Hori, A; Kami, M; Kanda, Y; Katayama, Y; Kishi, Y; Kobayashi, K; Mori, S; Murashige, N; Onishi, Y; Tajima, K; Takaue, Y; Tanosaki, R | 1 |
| Gill, S; Grigg, A; Ritchie, D; Szer, J | 1 |
| Curbo, S; Karlsson, A | 1 |
| Shen, JP; Ye, BD; Zhou, YH | 1 |
| Ambinder, RF; Bolaños-Meade, J; Borrello, I; Brodsky, RA; Chen, AR; Flowers, M; Fuchs, EJ; Gooley, TA; Harrington, E; Huff, CA; Jones, RJ; Kaup, M; Leffell, MS; Luznik, L; Matsui, W; O'Donnell, PV; Piantadosi, S; Powell, JD; Sandmaier, BM; Storb, RF; Symons, HJ; Warnock, S; Zahurak, M | 1 |
| Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D | 1 |
| Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, RB; Korbling, M; Pierre, B; Roberson, S; Russell, JA; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Casper, J; Freund, M; Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Wojnar, J | 1 |
| Bhatla, D; Bleesing, J; Crockett, M; Davies, SM; Filipovich, AH; Hansen, M; Harris, RE; Jodele, S; Jordan, M; Mehta, PA; Shenoy, S; Shoultz, L; Smolarek, T | 1 |
| Baldwin, SA; Cass, CE; Damaraju, VL; Elwi, AN; Kuzma, ML; Sawyer, MB; Young, JD | 1 |
| Brandi, G; Dominici, S; Magnani, M; Schiavano, GF | 1 |
| Thieblemont, C | 1 |
| Hagist, S; Hallek, M; Krause, G; Pallasch, CP; Patz, M; Veldurthy, A; Wendtner, CM | 1 |
| Chakraborty, NG; Chattopadhyay, S; Chhabra, A; Das, R; Hegde, U; Ray, S | 1 |
| Azlin, I; Fadilah, SA; Muhaya, M | 1 |
| Gorman, C; Hudson, E; Lester, JF; Maughan, TS; Poynton, CH; Westmoreland, D | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Chen, Z; Du, M; Feng, L; Huang, P; Keating, MJ; Pelicano, H; Plunkett, W; Trachootham, D; Wierda, WG; Zhang, H; Zhang, W; Zhou, Y | 1 |
| Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Innocenti, I; Laurenti, L; Leone, G; Piccirillo, N; Sica, S; Sorà, F; Tarnani, M; Zini, G | 1 |
| van der Griend, R; van der Spek, E | 1 |
| Nabhan, C | 1 |
| Berger, J; Berger, MG; Jeanpierre, S; Maguer-Satta, V; Michallet, M; Nicolini, FE; Richard, C; Satta, VM; Tournilhac, O | 1 |
| Austen, B; Brennan, P; Fegan, C; Hewamana, S; Hiller, L; Hills, R; Hooper, L; Lin, TT; Pepper, C; Pratt, G; Stankovic, T; Starczynski, J; Ward, R | 1 |
| Christopherson, RI; Crossett, B; Gez, S; Henrich, S; Mulligan, SP | 1 |
| Cass, CE; Dabbagh, L; Ghosh, S; King, K; Lai, R; Mackey, JR; Santos, C; Tsang, RY; Young, J | 1 |
| Candoni, A; Chiarvesio, A; Damiani, D; Fanin, R; Malagola, M; Martinelli, G; Michelutti, A; Piccaluga, PP; Russo, D; Simeone, E; Tiribelli, M; Toffoletti, E | 1 |
| Angelucci, E; Baronciani, D; Depau, C; Di Bartolomeo, P; Iori, AP; Mico, C; Pettinau, M; Pilo, F; Rambaldi, A; Santarone, S | 1 |
| Baccarani, M; Bergonzi, C; Bocchia, M; Bonini, A; Candoni, A; Damiani, D; De Rosa, F; Fanin, R; Filì, C; Gobbi, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Paolini, S; Peli, A; Piccaluga, PP; Pierri, I; Priccolo, G; Roccaro, AM; Russo, D; Skert, C; Tiribelli, M; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duan, Q; Duggan, P; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N | 1 |
| Fujimori, Y; Hara, H; Ikegame, K; Itoi, H; Itsukuma, T; Kai, S; Misawa, M; Nakajima, T; Nishioka, K; Ogawa, H; Okada, M; Okikawa, Y; Satake, A; Takatsuka, H; Tamaki, H | 1 |
| Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ | 1 |
| Andersen, MK; Christiansen, CB; Geisler, C; Hastrup, N; Jurlander, J; Madsen, HO; Pedersen, LB; Rath, J | 1 |
| Fabbri, A; Forconi, F; Gozzetti, A; Lauria, F; Lenoci, M; Raspadori, D; Sozzi, E; Tassi, M | 1 |
| Berthou, C; Dalbies, F; De Braekeleer, M; Feuerbach, J; Ianotto, JC; Le Bris, MJ; Marion, V; Tempescul, A | 1 |
| Alessandro, A; Allegra, A; Alonci, A; Bellomo, G; Caterina, M; D'Angelo, A; Granata, A; Quartarone, E; Rizzotti, P | 1 |
| Bednarek, JD; Blonski, JZ; Goralski, P; Hanausek, M; Kilianska, ZM; Piekarski, H; Robak, T; Rogalinska, M; Walaszek, Z; Wozniak, K | 1 |
| Cwynarski, K; Duke, VM; Hart, SM; Hoffbrand, AV; Howard-Reeves, JD; Kottaridis, PD; Nacheva, EP; Prentice, AG; Steele, AJ; Vassilev, LT; Wickremasinghe, RG; Yogashangary, BC | 1 |
| Becker, ST; Klapper, W; Repp, R; Sinis, N; Warnke, PH; Wiltfang, J | 1 |
| Cupelli, L; de Fabritiis, P; Dentamaro, T; Giovannini, M; Niscola, P; Palumbo, R; Perrotti, AP; Piccioni, D; Scaramucci, L; Tendas, A | 1 |
| Mattsson, J; Remberger, M; Ringdén, O; Svahn, BM | 1 |
| Bhandari, S; Cranfield, T; Simon, G; Walker, M | 1 |
| Lamanna, N; Weiss, MA | 1 |
| Camera, A; Cantore, N; Ferrara, F; Grimaldi, F; Guerriero, A; Luciano, L; Mastrullo, L; Mele, G; Mettivier, V; Miraglia, E; Palmieri, S; Rinaldi, CR; Rotoli, B | 1 |
| Andresen, S; Bolwell, BJ; Chan, J; Cherni, K; Copelan, E; Dean, R; Ferraro, C; Kalaycio, M; Macklis, R; Pohlman, B; Rybicki, LA; Sobecks, RM; Sweetenham, J; Theil, KS | 1 |
| Chen, LJ; Gu, WJ; Hong, M; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Wu, YJ; Xu, W | 1 |
| Blau, IW; Busse, A; Knauf, W; Reufi, B; Schmidt-Hieber, M; Thiel, E | 1 |
| Lamanna, N; Sauter, C; Weiss, MA | 1 |
| Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ | 1 |
| Bole, J; Castro, JE; Kipps, TJ; Rassenti, L; Sandoval-Sus, JD | 1 |
| Adams, DJ; Decastro, CM; Gockerman, JP; Moore, JO; Peterson, BL; Petros, WP; Rao, AV; Rizzieri, DA; Sand, GJ; Spasojevic, I; Younis, IR | 1 |
| Cheon, HG; Jung, WH; Rhee, SD; Sung, YY | 1 |
| Baldanti, F; Citro, A; Gatti, M; Lazzarino, M; Orlandi, EM; Pochintesta, L | 1 |
| Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J | 1 |
| Hara, J; Hashii, Y; Kusuki, S; Ohta, H; Ozono, K; Sakai, N; Takizawa, S; Taniike, M; Tokimasa, S | 1 |
| Baron, F; Baudoux, E; Beguin, Y; Bonnet, C; Fillet, G; Frère, P; Gothot, A; Hafraoui, K; Herens, C; Seidel, L; Vanbellinghen, JF; Vanstraelen, G; Wanten, N; Willems, E | 1 |
| Citrin, DE; Downey, SG; Dudley, ME; Huang, J; Hughes, MS; Kammula, U; Klapper, J; Laurencot, C; Leitman, SF; Morton, K; Restifo, NP; Robbins, PF; Rosenberg, SA; Royal, R; Sherry, R; Smith, FO; Thomasian, A; White, DE; Wunderlich, J; Yang, JC | 1 |
| de Campos-Nebel, M; González-Cid, M; Larripa, I | 1 |
| Karasawa, M | 1 |
| Balakrishnan, K; Burger, JA; Gandhi, V; Wierda, WG | 1 |
| Benninghoff, U; Debatin, KM; Friedrich, W; Gatz, S; Hoenig, M; Schuetz, C; Schulz, A; Speth, F | 1 |
| Almenara, JA; Atadja, P; Coe, S; Dent, P; Grant, S; Maggio, SC; Rosato, RR | 1 |
| Atkinson, K; Burns, AM; Hart, DN; Kambouris, ME; Lange, J; Lourie, R; Munster, DJ; Rice, AM; Sinfield, L; Turner, BE | 1 |
| Ahmed, N; Bollard, CM; Brenner, MK; Carrum, G; Gottschalk, S; Heslop, HE; Krance, RA; Leung, KS; Myers, GD; Rosenblatt, H | 1 |
| Kersting, S; Verdonck, LF | 1 |
| Campo, E; Casado, FJ; Colomer, D; López-Guerra, M; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M; Trigueros-Motos, L; Villamor, N | 1 |
| Chim, CS; Kwong, YL; Loong, F; Ng, WK | 1 |
| Dmoszynska, A; Halicka, HD; Klimek, P; Kowal, M; Podhorecka, M | 1 |
| Führer, M | 1 |
| Ambinder, RF; Bolaños-Meade, J; Brodsky, RA; Fuchs, EJ; Huff, CA; Jones, RJ; Kasamon, YL; Levy, MY; Luznik, L; Matsui, WH; Muth, M; Powell, JD; Smith, BD; Swinnen, LJ | 1 |
| Blum, KA; Brooker-McEldowney, M; Byrd, JC; Dalton, JT; Farley, KL; Fischer, B; Grever, MR; Heerema, NA; Hurh, E; Jarjoura, D; Johnson, AJ; Lin, TS; Mitchell, SM; Moran, ME; Phelps, MA; Rozewski, DM; Schaaf, LJ; Wu, D | 1 |
| Bernardo, ME; Caocci, G; Comoli, P; Cugno, C; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Merli, P; Piras, E; Vacca, A; Zecca, M | 1 |
| Carney, DA; di Iulio, J; Herbert, KE; Morgan, S; Prince, HM; Seymour, JF; Westerman, DA; Wolf, MM; Yuen, K | 1 |
| Asano, S; Iseki, T; Kasahara, S; Kato, S; Konuma, T; Monma, F; Ooi, J; Sato, A; Takahashi, S; Tojo, A; Tomonari, A; Tsukada, N; Uchimaru, K | 1 |
| Borchmann, P; Elter, T; Engert, A; Hallek, M; Kilp, J; Schulz, H | 1 |
| Bauduer, F | 1 |
| Berchem, G; Bouzar, AB; Boxus, M; Bron, D; Burny, A; Chatelain, B; Chatelain, C; Defoiche, J; Lagneaux, L; Macallan, D; Pettengell, R; Willems, L; Willis, F | 1 |
| Dumoulin, FL; Fischer, HP; Sauerbruch, T; Wasmuth, JC | 1 |
| Champlin, RE; Couriel, D; de Lima, M; de Souza, J; Giralt, S; Komanduri, KV; Oran, B; Patah, P; Rondon, G; Saliba, RM | 1 |
| Branagan, AR; Emmanouilides, C; Frankel, SR; Gregory, SA; Ioakimidis, L; Kimby, E; Lister, A; Matous, J; Morel, P; Patterson, CJ; Soumerai, JD; Treon, SP; Turnbull, B; Wasi, P | 1 |
| Abenhardt, W; Busch, R; Eichhorst, BF; Hallek, M; Kneba, M; Ritgen, M; Schweighofer, CD; Wendtner, CM | 1 |
| Borsky, M; Brychtova, Y; Cejkova, S; Chumchalova, J; Doubek, M; Klabusay, M; Mayer, J; Novakova, V; Pospisilova, S; Potesil, D; Rocnova, L; Smardova, J; Trbusek, M; Zezulkova, D | 1 |
| Abruzzo, LV; Barron, LL; Coombes, KR; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Kipps, TJ; Lerner, S; Lin, KI; O'Brien, S; Rassenti, L; Schlette, E; Tam, CS; Wierda, WG | 1 |
| Aloyz, R; Amrein, L; Ferrario, C; Gibson, SB; Hernandez, TA; Johnston, J; Panasci, L | 1 |
| Bloor, A; Chakraverty, R; Clark, F; Cook, G; Linch, DC; Mackinnon, S; Milligan, D; Morris, EC; Parker, A; Peggs, KS; Thomson, KJ; Yung, L | 1 |
| Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
| Bierman, P; Bociek, RG; Dickinson, JD; Emanuel, K; Hegde, GV; Joshi, AD; Joshi, SS; Kollessery, GJ; Mittal, AK; Peterson, KJ; Vose, JM; Weisenburger, DD | 1 |
| Ahmadi, T; Schuster, SJ | 1 |
| Boyiadzis, M; Butchko, A; Foon, KA; Laman, A; Land, SR; Lenzer, D; Marks, S; Meisner, D; Pietragallo, L; Raptis, A; Schaefer, P; Sulecki, M; Tarhini, A | 1 |
| Brentjens, RJ; Gencarelli, AN; Golde, DW; Heaney, ML; Jurcic, JG; Lamanna, N; Maslak, P; Noy, A; Panageas, KS; Scheinberg, DA; Weiss, MA; Zelenetz, AD | 1 |
| Ativitavas, T; Jootar, S; Niparuck, P; Ungkanont, A | 1 |
| du Toit, C; McDonald, A; Novitzky, N; Thomas, V | 1 |
| Chen, ZC; Li, QB; Li, WM; Xia, LH; You, Y; Zhou, H; Zou, P | 1 |
| Brennan, P; Burnett, AK; Fegan, C; Hewamana, S; Jenkins, C; Jordan, CT; Lin, TT; Pepper, C; Rowntree, C | 1 |
| Amato, R; Butler, EB; Furge, K; Gao, Y; Hui, Z; Li, Y; Mai, W; Qian, CN; Teh, BS; Teh, BT; Tretiakova, M; Wang, X; Zhang, Z; Zhu, JX | 1 |
| Akhter, S; Chaudhuri, A; Kanmogne, GD; Yang, B | 1 |
| Benvegnú, DM; Bonfanti, G; Frediani, AV; Gonçalves, TL; Pereira, DV; Rocha, JB | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Barba, P; Briones, J; Brunet, S; Delgado, J; Martino, R; Moreno, E; Piñana, JL; Sierra, J; Sureda, A; Valcárcel, D; Vega, M | 1 |
| Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Ryu, SG; Seol, M; Shin, HJ | 1 |
| Flomenberg, N; Greipp, PR; Huff, CA; Lazarus, HM; Vesole, DH; Zhang, L | 1 |
| Briones, J; Brunet, S; Delgado, J; Marco, A; Martino, R; Moreno, E; Piñana, J; Sierra, J; Sureda, A; Valcarcel, D | 1 |
| Baker, JM; Crooks, BN; Doyle, JJ; Dror, Y; Duval, M; Fernandez, CV; Freedman, MH; Lewis, VA; Yuille, K | 1 |
| Tan, J; Wu, T; Yang, K | 1 |
| Blazar, BR; Brunstein, CG; Burns, LJ; Cantero, S; Cao, Q; Majhail, N; McClune, B; McGlave, PB; Miller, JS; Tomblyn, M; Wagner, JE; Weisdorf, DJ | 1 |
| Cafro, AM; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Nosari, AM; Ricci, F; Tedeschi, A | 1 |
| Bae, SH; Joo, YD; Kim, H; Lee, JH; Lee, KH; Lee, WS; Mo Ryoo, H; Park, JH | 1 |
| Higuchi, T; Kako, S; Kanda, Y; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sato, M; Tanaka, Y; Tanihara, A; Terasako, K; Yamazaki, R | 1 |
| Eve, HE; Linch, D; Qian, W; Ross, M; Rule, SA; Seymour, JF; Smith, P; Stevens, L | 1 |
| Eve, HE; Rule, SA; Seymour, JF | 1 |
| Kamijo, T; Koike, K; Nakazawa, Y; Sakashita, K; Shikama, N; Shiohara, M; Tanaka, M; Yanagisawa, R | 1 |
| Byrd, JC; Caligiuri, MA; Cheney, C; Heerema, N; Lin, TS; Lucas, DM; Lucas, MS; Moran, ME; Wei, L; Woyach, JA | 1 |
| Angrilli, F; Baldini, L; Bari, A; Ilariucci, F; Lazzaro, A; Luminari, S; Marcheselli, L; Pozzi, S; Sacchi, S; Stelitano, C | 1 |
| Ben-Bassat, I; Bonstein, L; Gafter-Gvili, A; Raanani, P; Ram, R; Shpilberg, O | 1 |
| Aksoy, S; Dizdar, O; Harputluoğlu, H; Hayran, M | 1 |
| Cao, J; Reilly, JZ; Rodmyre, RM; Thompson, JA; Wallen, H; Yee, C | 1 |
| Boyer, SH; Erion, MD; Linemeyer, DL; MacKenna, DA; Montag, A | 1 |
| Butters, TD; Ganeshaguru, K; Gerrard, G; Mehta, AB | 1 |
| Carney, DA; Mulligan, SP | 1 |
| Boelens, J; Bracke, M; Derycke, L; Janssens, A; Lust, S; Offner, F; Philippé, J; Van Bockstaele, F; Van Gele, M; Vanhoecke, B | 1 |
| Antic, D; Gotic, M; Jakovic, L; Jankovic, S; Mihaljevic, B; Perunicic-Jovanovic, M; Sretenovic, A | 1 |
| Cazin, B; Chapiro, E; Davi, F; Delmer, A; Dreyfus, B; Leporrier, M; Leprêtre, S; Lesty, C; Mahe, B; Maloum, K; Merle-Béral, H; Nguyen-Khac, F; Settegrana, C; Tournilhac, O | 1 |
| Apter, S; Besser, MJ; Catane, R; Hardan, I; Itzhaki, O; Kubi, A; Kuchuk, I; Markel, G; Nagler, A; Nun, AB; Schachter, J; Schallmach, E; Segal, E; Shalmon, B; Shapira-Frommer, R; Shimoni, A; Treves, AJ; Zippel, D | 1 |
| Brown, JR; Dal Cin, P; Feng, Y; Fisher, DC; Fisher, RI; Freedman, AS; Friedberg, JW; Joyce, R; Liesveld, J; Marquis, D; Neuberg, D; Phillips, K; Scofield, S; Takvorian, RW | 1 |
| Ferrajoli, A | 1 |
| Karas, M; Koza, V; Steinerova, K; Vokurka, S | 1 |
| Ashcroft, AJ; Moreton, P; Owen, RG; Rawstron, AC; Varghese, AM | 1 |
| Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kastritis, E; Migkou, M; Roussou, M; Tassidou, A; Terpos, E | 1 |
| Alamos, SM; Greco, A; Morra, E; Ricci, F; Tedeschi, A | 1 |
| Castejón, R; Citores, MJ; García-Marco, JA; Vargas, JA; Villarreal, M; Yebra, M | 1 |
| Hong, M; Li, JY; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R | 1 |
| Brass, D; Cunningham, J; Gelly, K; Groves, M; MacCallum, S; Sales, M; Tauro, S | 1 |
| Keating, MJ; Tsimberidou, AM | 2 |
| Elliott, P; Haines, I; Stanley, R | 1 |
| Bruns, I; Czibere, A; Fenk, R; Gräf, T; Haas, R; Kobbe, G; Schroeder, T; Zohren, F | 1 |
| Bojarska-Junak, A; Bullinger, L; Dmoszynska, A; Döhner, H; Giannopoulos, K; Kowal, M; Rolinski, J; Stilgenbauer, S; Wasik-Szczepanek, E | 1 |
| Cho, BS; Cho, SG; Chung, NG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Asaka, M; Endo, T; Hashino, S; Imamura, M; Kahata, K; Koike, T; Kondo, T; Nishio, M; Okada, K; Onozawa, M; Ota, S; Sato, N; Shigematsu, A; Sugita, J; Takahata, M; Tanaka, J; Yamamoto, S; Yasumoto, A | 1 |
| Abidi, MH; Braun, TM; Ibrahim, RB; Khaled, YA; Krijanovski, OI; Levine, JE; Mineishi, S; Peres, E | 1 |
| Dishaw, LJ; Dorsey, MJ; Morrow, MR; Petrovic, A; Sleasman, JW | 1 |
| Bordigoni, P; Cachin, F; Curtillet, C; David, A; Demeocq, F; Dore, E; Halle, P; Isfan, F; Kanold, J; Merlin, E; Michel, G; Paillard, C; Rochette, E; Rousseau, R; Salmon, A | 1 |
| Brown, PV; Conneally, E; Delaney, E; Hayat, A; Lawler, M; Liptrot, S; McCann, SR; McGuckin, S; O'Brien, D; O'Rourke, P; Quinn, F; Vandenberghe, E | 1 |
| Eyzaguirre-Zapata, R; Gómez-Almaguer, D; González-Carrillo, ML; Gutiérrez-Aguirre, CH; Gutiérrez-Riveroll, KI; Priesca-Marin, M; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ | 1 |
| Ferrajoli, A; Motta, M; Wierda, WG | 1 |
| Alonso, R; Bantia, S; Bontemps, F; Campo, E; Colomer, D; López-Guerra, M; Manz, C; Mehrling, T; Montserrat, E; Smal, C; Upshaw, R; Villamor, N | 1 |
| Amdur, RJ; Buzzeo, MP; Cable, C; Jamieson, K; Khan, S; Leather, H; Moreb, J; Reddy, V; Schold, JD; Scornik, J; Wingard, JR | 1 |
| Beri, R; Chen, YH; Chunduri, S; Dobogai, LC; Mactal-Haaf, C; Mahmud, N; Peace, DJ; Quigley, JG; Rondelli, D; Shord, S; Sweiss, K | 1 |
| Ahn, JS; Chae, YS; Cho, YY; Choi, YJ; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Lee, SR; Shin, HJ; Sohn, SK; Yang, DH | 1 |
| Chen, YM; Dou, HJ; Hu, JP; Tang, Y; Yao, YY; Zhu, Q; Zou, LF | 1 |
| Bartholomé, K; Buchner, M; Burger, M; Chevalier, N; Dierks, C; Fuchs, S; Gribben, JG; Jumaa, H; Pfeifer, D; Prinz, G; Timmer, J; Vallat, L; Veelken, H; Zirlik, K | 1 |
| Burgaleta, C; Cabrera, C; Canales, M; De la Serna, J; Fernández de Sevilla, A; Gonzalez, M; Martínez, R; Martínez-López, J; Montalbán, C; Monteagudo, MD; Paz-Carreira, J; Peñalver, FJ; Peñarrubia, MJ; Prieto, E; Queizán, JA; Rapado, I; Rivero, A; Salar, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Andersson, BS; Champlin, RE; de Lima, M; Madden, T; Russell, JA; Thall, PF | 1 |
| Hazar, V; Karasu, GT; Kupesiz, A; Uygun, V; Yesilipek, MA | 1 |
| Brent, S; Dyker, A; Erhorn, S; Ferrie, L; Horsley, W; Macfarlane, K; Palmer, S; Thomas, S; Walker, S; White, S | 1 |
| Bleakley, M; Hudecek, M; Kostic, A; Maloney, D; Nishida, T; Riddell, SR; Storb, R; Warren, EH | 1 |
| Sosnowski, M; Trusz-Gluza, M; Wita, K; Wróbel, W | 1 |
| Imataki, O; Ishida, T; Kitanaka, A; Kubota, Y; Ohbayashi, Y; Ohnishi, H; Tanaka, T | 1 |
| Ando, K; Hayashi, M; Hotta, T; Ishizawa, K; Itoh, K; Matsusako, M; Morishima, Y; Nakata, M; Nawano, S; Ogura, M; Taniwaki, M; Terauchi, T; Tobinai, K; Uchida, T; Watanabe, T; Yamamoto, J | 1 |
| Bühler, A; Busch, R; Döhner, H; Dreger, P; Dührsen, U; Finke, J; Groner, S; Hallek, M; Hensel, M; Hohloch, K; Jäger, U; Kneba, M; Lengfelder, E; Schlag, R; Schlenk, RF; Söling, U; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Al-Mojalli, H; Ashour, M; Ayas, M; Turkistani, W | 1 |
| Bergmann, MA; Brittinger, G; Burkhard, O; Busch, R; Döhner, H; Eichhorst, BF; Emmerich, B; Fink, AM; Fischer, K; Goede, V; Hallek, M; Kranzhöfer, N; Ritgen, M; Rohrberg, R; Schweighofer, CD; Söling, U; Stauch, M; Stilgenbauer, S; Wendtner, CM; Westermann, A | 1 |
| Kay, NE; Lamanna, N | 1 |
| Lin, TS; Maddocks, KJ | 1 |
| Carney, D; Gill, S; Januszewicz, H; Prince, HM; Ritchie, D; Seymour, JF; Westerman, D; Wolf, M | 1 |
| Bos, GM; Fleskens, AJ; Jansen, RL; Lalisang, RI; Schouten, HC; van Gelder, M | 1 |
| Carney, D; Januszewicz, EH; Peinert, S; Prince, HM; Seymour, JF | 1 |
| Chew, E; Fairlie, WD; Grigg, AP; Huang, DC; Khaw, SL; Lee, EF; Mason, KD; Rayeroux, KC; Roberts, AW; Seymour, JF; Szer, J | 1 |
| Bühler, A; Busch, R; Denzel, T; Döhner, H; Groner, S; Häbe, S; Hallek, M; Mertens, D; Mohr, J; Sarno, A; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Faderl, S; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Wierda, W | 1 |
| Beijnen, JH; Rosing, H; Schellens, JH; Vainchtein, LD | 1 |
| Janikova, A; Koristek, Z; Kral, Z; Mayer, J; Navratil, M; Pavlik, T; Sticha, M; Vasova, I; Vinklarkova, J | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Champlin, RE; de Lima, M; de Padua Silva, L; de Souza, JA; Efebera, Y; Hosing, C; Patah, P; Popat, U; Qazilbash, MH; Ribeiro, R; Rondon, G; Saliba, RM | 1 |
| Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL | 1 |
| Canales, MA; Domingo-Domenech, E; Estany, C; Fraile, G; Gallardo, F; Montalbán, C; Salar, A; Servitje, O | 1 |
| Eurelings, M; Franssen, H; Lokhorst, HL; Niermeijer, JM; Notermans, NC; van der Pol, WL; Wokke, JH | 1 |
| Abe, Y; Arita, Y; Baba, E; Choi, I; Harada, M; Ito, T; Kawabe, K; Miyamoto, T; Nagafuji, K; Nakano, S; Teshima, T | 1 |
| Stilgenbauer, S; Zenz, T | 1 |
| Assanasen, T; Polprasert, C; Prayongratana, K; Wongchitrat, C | 1 |
| Błoński, JZ; Kiliańska, ZM; Robak, T; Wesierska-Gadek, J; Zolnierczyk, JD | 1 |
| Adams, S; Amrolia, PJ; Berrie, E; Bird, P; Brenner, MK; Brown, L; Davies, EG; Eyrich, M; Gaspar, HB; Gennery, AR; Goulden, N; Hale, G; Landais, P; Rao, K; Schlegel, PG; Straathof, KC; Veys, PA | 1 |
| Candoni, A; Fanin, R; Malagola, M; Russo, D; Simeone, E; Tiribelli, M | 1 |
| Aljurf, M; Anderlini, P; Bacigalupo, A; Marsh, J; Maury, S; Oneto, R; Passweg, JR; Socié, G | 1 |
| Jeong, KH; Lew, BL; Sim, WY | 1 |
| Boyd, TE; Chanan-Khan, AA; Gribben, J; Itri, LM; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Rai, KR; Seymour, JF; Skotnicki, AB | 1 |
| Cao, TM; Franke, GN; Gyurkocza, B; Hoppe, R; Lange, T; Leisenring, W; Maloney, DG; Negrin, RS; Sandmaier, BM; Shizuru, JA; Sorror, M; Storb, RF | 1 |
| Tam, CS | 2 |
| Eve, HE; Gambell, J; Qian, W; Rule, SA; Smith, P | 1 |
| Brum, S; Carvalho, D; Carvalho, F; Ferreira, AC; Pataca, I; Santos, JR; Santos, MC | 1 |
| Beert, E; Bontemps, F; Connerotte, T; de Viron, E; Hermans, C; Knoops, L; Michaux, L; Saussoy, P; Smal, C; Van Den Neste, E; Vannuffel, P; Vekemans, MC | 1 |
| Brion, JP; Epaulard, O; Garin-Bastuji, B; Gressin, R; Maurin, M; Meneses, A; Pavese, P; Stahl, JP | 1 |
| Appelbaum, FR; Deeg, HJ; Fisher, DR; Gooley, TA; Gopal, AK; Martin, PJ; Matthews, DC; Pagel, JM; Press, OW; Rajendran, J; Sandmaier, BM; Storb, RF; Wilson, WA | 1 |
| Abboud, CN; Augustin, KM; Cashen, AF; Dipersio, JF; Goyal, S; Hladnik, L; Martin, MG; Monahan, RS; Reichley, RM; Stockerl-Goldstein, K; Tiwari, D; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Baurmann, H; Bethge, W; Bornhäuser, M; Brand, R; Burchert, A; Corradini, P; de Witte, TM; Dreger, P; Einsele, H; Holler, E; Kaufmann, M; Kobbe, G; Kröger, N; Kvasnicka, HM; Nagler, A; Niederwieser, D; Schubert, J; Schwerdtfeger, R; Stelljes, M; Thiele, J; Uharek, L; Wandt, H; Wulf, GG; Zabelina, T; Zander, AR | 1 |
| Desjardins, P; Duncan, AM; Fernandez, L; Kipps, T; Larratt, L; Li, D; Rassenti, L; Rizi, D; Rubin, S; Sadura, A; Shepherd, L; Shustik, C; Turner, AR | 1 |
| Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC | 1 |
| Andritsos, L; Bechtel, T; Benson, DM; Blum, W; Byrd, JC; Devine, SM; Elder, P; Garzon, R; Hamadani, M; Hofmeister, C; Klisovic, R; Krugh, D; Lin, T; Marcucci, G; O'Donnell, L; Penza, S; Phillips, G | 1 |
| Browne, PV; Butini, S; Campiani, G; Catherwood, MA; Greene, LM; Hayat, A; Lawler, M; Maginn, EN; McElligott, AM; McGuckin, S; Vandenberghe, E; Williams, DC; Zisterer, DM | 1 |
| Horiike, S; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M | 1 |
| Buti, M; Esteban, R; Homs, M; Palacios, A; Rodriguez-Frias, F; Sanchez, MJ | 1 |
| Hong, M; Li, JY; Li, Q; Lu, H; Qian, SX; Qiu, HX; Sheng, WY; Wu, HX; Xu, W; Zhang, R | 1 |
| Chen, X; Tian, LP; Wang, JS; Wang, Z; Wu, L | 1 |
| Byrd, JC; Castro, J; Flinn, IW; Harris, S; Heerema, N; Hughes, S; Kipps, TJ; Leigh, B; Lin, TS; Molina, A; O'Brien, S; Tangri, S; Wierda, W; Woodworth, J; Wynne, D | 1 |
| Brejcha, M; Brychtova, Y; Cejkova, S; Doubek, M; Klabusay, M; Kuglik, P; Malcikova, J; Mayer, J; Pospisilova, S; Rocnova, L; Skuhrova Francova, H; Smardova, J; Svitakova, M; Tichy, B; Trbusek, M; Vranova, V | 1 |
| Brown, M; Gibson, SB; Hernandez, TA; Hu, X; Johnston, JB; Kumar, SA; Kuschak, B | 1 |
| Greenblatt, DJ; Karyagina, EV; Lister-James, J; Lundberg, AS; Yin, W | 1 |
| Byrd, JC; Gockerman, J; Hohl, R; Hurd, D; Larson, RA; Nattam, S; Perry, MC; Peterson, BL; Rai, KR | 1 |
| Abruzzo, L; Admirand, J; Keating, MJ; Lerner, S; Lin, KI; O'Brien, S; Schlette, EJ; Tam, C; Wierda, W | 1 |
| Harnalikar, M; Kharkar, V; Khopkar, U; Pande, S | 1 |
| Alatrash, G; Albitar, M; Burger, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Keating, MJ; Lerner, S; Manshouri, T; O'Brien, S; Wang, X; Wierda, WG | 1 |
| Kosseifi, SG; Krishnaswamy, G; Smith, S; Vyas, B; Vyas, H | 1 |
| Bruno, B; Chauncey, TR; Maloney, DG; Maris, MB; Nakamae, H; Panse, J; Petersdorf, E; Petersen, FB; Pulsipher, MA; Sandmaier, BM; Storb, R; Storek, J; Storer, BE; Wade, JC; Woolfrey, A | 1 |
| Błoński, JZ; Góralski, P; Kiliańska, ZM; Komina, O; Piekarski, H; Robak, T; Rogalińska, M; Wesierska-Gadek, J; Zołnierczyk, JD | 1 |
| Bornhäuser, M; Brand, R; de Witte, T; Gahrton, G; Heinzelmann, M; Kröger, N; Morris, C; Nagler, A; Niederwieser, D; Schilling, G; Schwerdtfeger, R; Shimoni, A; Zander, AR | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Hirayama, Y; Ishitani, K; Iyama, S; Kato, J; Kobune, M; Kohda, K; Koike, K; Kuroda, H; Neda, H; Sato, T; Takimoto, R; Terui, T | 1 |
| Bradstock, K; George, B; Gilroy, N; Gottlieb, D; Hertzberg, M; Huang, G; Kerridge, I | 1 |
| Buda, G; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Irish, W; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N | 1 |
| Chen, HR; DU, ZL; He, XP; Hu, B; Si, YJ; Yang, K; Zhang, CC; Zhang, XM | 1 |
| Eldering, E; Kater, AP; Tonino, SH; van Gelder, M; van Oers, MH | 1 |
| Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
| Celadin, M; Furlan, A; Pietrogrande, F; Sanzari, M; Vianello, F; Villanova, F | 1 |
| Bazargan, A; Tam, CS | 1 |
| Hoffman, PC | 1 |
| Baiocchi, RA; Blum, KA; Byrd, JC; Fischer, DB; Grever, MR; Johnson, AJ; Kraut, EH; Lin, TS; Mitchell, SM; Moran, ME; Porcu, P; Ruppert, AS; Schaaf, LJ | 1 |
| HANDA, H; KARASAWA, M; MATSUSHIMA, T; MAWATARI, M; MURAKAMI, H; NOJIMA, Y; OSAKI, Y; SAITOH, T; SEKIGAMI, T; TAHARA, K; TOYAMA, K; TSUKAMOTO, N; UCHIUMI, H; YOKOHAMA, A | 1 |
| Castejon, R; Citores, MJ; Garcia-Marco, JA; Rosado, S; Vargas, JA; Villarreal, M | 1 |
| Desmond, R; Farrell, M; Gleeson, M; Lynch, K; Murphy, P | 1 |
| Hong, M; Li, JY; Lu, H; Qian, SX; Wu, HX; Xu, W | 1 |
| Kiss, E; Szodoray, P | 1 |
| Aleksandrowicz, P; Dolińska-Krajewska, B; Draga, A; Dubielecka, PM; Grzybek, M; Jaźwiec, B; Kolondra, A; Kołodziejczyk, M; Kuliczkowski, K; Serwotka, A; Sikorski, AF; Warchoł, J | 1 |
| Abonour, R; Baute, JA; Cornetta, K; Cox, EA; Cripe, LD; Dlouhy, SR; Farag, SS; Fausel, CA; Haut, PR; Hromas, R; Nelson, RP; Robertson, KA; Robertson, MJ; Schwartz, JE; Srivastava, S; Vance, GH; Wood, LL; Yu, M | 1 |
| Chiba, K; Horiuchi, K; Ikegami, H; Kimura, T; Kosaki, N; Matsumoto, M; Nakamura, T; Okada, Y; Ota, N; Tajima, K; Takaishi, H; Takito, J; Tohmonda, T; Toyama, Y; Yoda, M | 1 |
| Biagi, E; Brenner, MK; Carrum, G; Dotti, G; Foster, AE; Goodell, MA; Heslop, HE; Lu, A; Okur, FV; Savoldo, B; Yvon, E | 1 |
| Aldridge, J; Alyea, EP; Antin, JH; Armand, P; Cutler, C; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ | 1 |
| Bell, T; Inaba, H; Leung, W; Pounds, S; Pui, CH; Ribeiro, RC; Rooney, B; Rubnitz, JE | 1 |
| Cavallin, M; Damante, G; Damiani, D; Fabbro, D; Fanin, R; Geromin, A; Malagola, M; Michelutti, A; Pianta, A; Russo, D; Tiribelli, M | 1 |
| Akiba, T; Hyodo, H; Ishiguro, H; Kato, S; Koike, T; Morimoto, T; Shimizu, T; Yabe, H; Yabe, M | 1 |
| Fan, L; Li, JY; Liu, P; Miao, KR; Qiao, C; Wu, YJ; Xu, W; Yao, L; Zhu, DX; Zhu, HY | 1 |
| Chow, KU; Dreyling, M; Hess, G; Jäger, E; Kim, SZ; Krause, SW; Kruse, J; Mitrou, PS; Napieralski, S; Rech, J; Soekler, M; Subklewe, M; Weidmann, E; Weisel, KC | 1 |
| Aractingi, S; Auffret, N; Bodemer, C; Brousse, N; Duong, T; Fraitag, S; Grange, F; Hermine, O | 1 |
| Asaka, M; Endo, T; Hashino, S; Imamura, M; Ito, YM; Kahata, K; Koike, T; Kondo, T; Nishio, M; Okada, K; Onozawa, M; Shigematsu, A; Sugita, J; Takahata, M; Tanaka, J; Yamamoto, S | 1 |
| Elliott, B; Grosskreutz, C; Isola, L; Malone, A; Mandeli, J; Osman, K; Scigliano, E | 1 |
| Fernández-Calotti, P; Pastor-Anglada, M | 1 |
| Brace, JR; Lee, MS; McKinney, AM; Santacruz, K | 1 |
| Afanasiev, BV; Catalano, J; Dartigeas, C; Dmoszynska, A; Ganly, PS; Geisler, CH; Larratt, L; Loscertales, J; Maurer, J; Mendila, M; Moiseev, SI; Montillo, M; Robak, T; Rosta, A; Saville, MW; Solal-Céligny, P; Valente, N; Warzocha, K; Wenger, MK; Zyuzgin, I | 1 |
| Chan, G; Davis, R; Dyer, MJ; Furman, RR; Hellmann, A; Hillmen, P; Kipps, TJ; Kozak, T; Losic, N; Mayer, J; Osterborg, A; Padmanabhan, S; Piotrowska, M; Robak, T; Russell, CA; Stilgenbauer, S; Trneny, M; Wierda, WG; Williams, CD; Wilms, J | 1 |
| Andreadis, C; Kanetsky, PA; Nasta, SD; Olin, RL; Schuster, SJ; Ten Have, TR | 1 |
| Ansell, SM; Elliott, MA; Gastineau, DA; Hogan, WJ; Holtan, SG; Inwards, DJ; Johnston, PB; Lacy, MQ; Litzow, MR; Micallef, IN; Porrata, LF | 1 |
| Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszyñska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Hellmann, A; Jamroziak, K; Konopka, L; Kostyra, A; Lewandowski, K; Piotrowska, M; Piszcz, J; Potoczek, S; Robak, T; Seferynska, I; Stella-Holowiecka, B; Warzocha, K; Zawilska, K; Zdunczyk, A | 1 |
| Abad, L; Diaz, MA; Gonzalez-Vicent, M; Perez, A; Ramirez, M; Sevilla, J | 1 |
| Bojarska-Junak, A; Chocholska, S; Dmoszynska, A; Klimek, P; Kowal, M; Podhorecka, M | 1 |
| Bishop, RJ; Caruso, R; Chan, CC; Cunningham, D; Ding, X; Heller, CK; Illei, G; Pavletic, S | 1 |
| Andresen, S; Bolwell, B; Copelan, EA; Dean, R; Kalaycio, M; Mickelson, DM; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J | 1 |
| Ali, MA; Balbaa, OA; Farahat, NM; Hussein, Ael-S; Shamaa, LA | 1 |
| Baran, Y; Bassoy, EY; Oztekin, C | 1 |
| Bot, FJ; Chaker, L; Maartense, E; Segeren, CM | 1 |
| Acholonu, S; Champlin, R; Dabaja, B; Donato, M; Duvic, M; Hosing, C; Khouri, I; Richmond, H; Singh, L; Wei, W | 1 |
| Buus, S; Garred, P; Kornblit, B; Larsen, ME; Larsen, MV; Lund, O; Masmas, TN; Nielsen, M; Stryhn, A; Thiim, M; Vindelov, L | 1 |
| Disel, U; Karakoc, E; Paydas, S; Yavuz, S | 1 |
| Auewarakul, CU; Karoopongse, E; Khuhapinant, A | 1 |
| Golubeva, ME; Isaeva, NV; Kudriavtseva, AV; Malykh, OV; Tkachenko, SB; Zagoskina, TP | 1 |
| Albert, MH; Belohradsky, BH; Ehl, S; Freudenberg, F; Güngör, T; Koletzko, S; Prell, C; Roesen-Wolff, A; Roesler, J; Roos, D; Seger, R; Strahm, B; Tommasini, A; Ventura, A; Wintergerst, U | 1 |
| Chakraverty, R; Denovan, S; Fielding, AK; Hough, R; Kottaridis, PD; Linch, DC; Mackinnon, S; Mead, AJ; Mohamedbhai, S; Morris, EC; Orti, G; Peggs, KS; Thomson, KJ | 1 |
| de Rezende, LC; Guimarães, MC; Rangel, LB; Silva, IV | 1 |
| Brunstein, CG; Cao, Q; Green, KG; Jacobson, PA; Long-Boyle, JR; McGlave, PB; Miller, JS; Rogosheske, J; Wagner, JE; Weisdorf, DJ | 1 |
| Alter, BP; Baker, KS; Dietz, AC; Giller, RH; Orchard, PJ; Savage, SA; Tolar, J | 1 |
| Garratty, G | 1 |
| Beitinjaneh, A; Cao, Q; McKinney, AM; Weisdorf, DJ | 1 |
| Lamanna, N | 1 |
| Khouri, I; Tam, CS | 1 |
| Balakrishnan, K; Bantia, S; Bickel, S; Chen, Y; Gandhi, V; Kantarjian, H; Keating, MJ; Kilpatrick, JM; O'Brien, S; Ravandi, F; Tyler, BF; Verma, D | 1 |
| Asano-Mori, Y; Ishiwata, K; Masuoka, K; Matsuno, N; Miyakoshi, S; Ohashi, K; Ota, Y; Takagi, S; Takahashi, K; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, H | 1 |
| Bednarek, A; Fabianowska-Majewska, K; Rudnicka, K; Stefanska, B | 1 |
| Brewer, SC; Cleveland, KO; Gelfand, MS | 1 |
| Blanc, A; Corre, J; Fournié, JJ; Gross, E; Kühlein, E; Laurent, G; Quillet-Mary, A; Ysebaert, L | 1 |
| Aoyama, M; Hashimoto, S; Itagaki, N; Iwanaga, T; Kawamura, M; Kazuta, T; Matsuda, M; Rai, S; Yamairi, N | 1 |
| Aouali, N; Berchem, G; Bernardin, F; Cornillet-Lefebvre, P; Delmer, A; Duhem, C; El Khoury, V; Leners, B; Moussay, E; Muller, A; Palissot, V; Poirel, HA; Ries, F; Vallar, L; van Dyck, E; Van Moer, K; Wenner, T | 1 |
| Bacigalupo, A; Brune, M; Cesaro, S; Lanino, E; Locasciulli, A; Locatelli, F; Marsh, J; Oneto, R; Passweg, J; Prete, A; Shimoni, A; Socie', G; Van Lint, MT | 1 |
| Aschan, J; Baumgart, J; Blau, IW; Casper, J; Freund, M; Giebel, S; Hilgendorf, I; Holowiecki, J; Knauf, W; Kröger, N; Mylius, HA; Pichlmeier, U; Ruutu, T; Schäfer-Eckart, K; Volin, L; Wandt, H; Wolff, D; Zander, AR | 1 |
| Chocholska, S; Dmoszynska, A; Halicka, D; Klimek, P; Kowal, M; Podhorecka, M | 2 |
| Cavazzini, F; Ciccone, M; Cuneo, A; De Angeli, C; Ferracin, M; Grilli, A; Lupini, L; Negrini, M; Rizzotto, L; Saccenti, E; Veronese, A; Zagatti, B | 1 |
| Balasubramanian, A; Bambach, BJ; Bennett, RR; Darras, BT; Estrella, E; Gussoni, E; Kang, PB; Kunkel, LM; Kurtzberg, J; Lidov, HG; Mitchell, M; Shapiro, FD; White, AJ | 1 |
| Brice, P; Copin, MC; Fermé, C; Feugier, P; Lamy, T; Morschhauser, F; Mounier, N; Sebban, C; Solal-Celigny, P; Tilly, H | 1 |
| Aarden, L; Baars, JW; Beijnen, JH; Huitema, AD; Tran, L | 1 |
| Li, JY; Xu, W; Yao, L | 1 |
| Andersson, BS; Valdez, BC | 2 |
| Flowers, ME; Frangoul, H; Kiem, HP; Kletzel, M; Kurre, P; Leisenring, W; Pulsipher, MA; Sandmaier, BM; Storb, R; Thakar, MS; Woolfrey, A | 1 |
| Appelbaum, FR; Douglas, JG; Mayadev, JS; Storb, R; Storer, BE | 1 |
| Berman, DM; Buchwald, P; Han, D; Kenyon, NM; Kenyon, NS; Rothen, D; Willman, M | 1 |
| Bloor, A; Chakraverty, R; Clark, A; Clark, R; Collin, M; Crawley, C; Fielding, A; Hale, G; Johnson, P; Kottaridis, P; Mackinnon, S; Milligan, D; Morris, E; Orti, G; Parker, A; Peggs, K; Pettengell, R; Pettitt, A; Roughton, M; Shen, J; Snowden, J; Thomson, K | 1 |
| Almog, S; Gopher, A; Halkin, H; Hassoun, E; Kurnik, D; Loebstein, R; Nagler, A; Shimoni, A | 1 |
| Chiang, R; Earp, J; Gootenberg, JE; Keegan, P; Lemery, SJ; McDougal, A; Pazdur, R; Pilaro, A; Rothmann, MD; Yang, J; Zhang, J; Zhao, H | 1 |
| Bond, KM; Cianciolo, GJ; Diehl, LF; Friedman, DR; Gockerman, JP; Kennedy, MN; Lanasa, MC; Moore, JO; Mowery, YM; Pizzo, SV; Weinberg, JB | 1 |
| Chiusolo, P; D'Arena, G; De Padua, L; Efremov, DG; Falcucci, P; Innocenti, I; Laurenti, L; Leone, G; Marietti, S; Piccirillo, N; Sica, S; Sora', F; Tarnani, M; Zini, G | 1 |
| Cao, X; Dong, HJ; Fang, C; Hong, M; Li, JY; Miao, KR; Wang, DM; Xu, W; Zhu, DX | 1 |
| Beiske, K; Berentsen, S; Dalgaard, J; Hjorth-Hansen, H; Jacobsen, EM; Randen, U; Thoresen, AS; Tjønnfjord, GE; Vågan, AM; Vik, A | 1 |
| Dong, HJ; Fang, C; Li, JY; Miao, KR; Qiao, C; Wang, DM; Wu, YJ; Xu, W; Zhu, DX; Zhu, HY | 1 |
| Gocke, CD; Hristov, AC; Nava, VE; Saladino, A | 1 |
| Allain, JP; Candotti, D; El Chaar, M; Power, JP; Spillane, D; Temple, J; Thomas, M | 1 |
| Burroughs, LM; Carpenter, PA; Englund, J; Ochs, HD; Rawlings, DJ; Sanders, J; Scharenberg, AM; Skoda-Smith, S; Storb, R; Torgerson, TR; Woolfrey, AE | 1 |
| Mupo, A; Russo, GL; Russo, M; Spagnuolo, C; Tedesco, I; Volpe, S | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Batár, P; Rejto, L; Telek, B; Udvardy, M | 1 |
| Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Zohren, F | 1 |
| Bishop, MR; Bryant, K; Dean, RM; Fowler, DH; Hakim, F; Jamshed, S; Neelapu, SS; Odom, J; Steinberg, SM | 1 |
| Appay, V; Canellini, G; Laurent, J; Leyvraz, S; Papaioannou, A; Rimoldi, D; Romero, P; Rufer, N; Speiser, DE; Touvrey, C; Vicari, M; Voelter, V | 1 |
| Aytac, S; Balci, YI; Cetin, M; Gumruk, F; Gurgey, A; Kuskonmaz, B; Tavil, B; Tuncer, M; Uckan, D; Unal, S; Yetgin, S | 1 |
| Tsimberidou, AM | 1 |
| Ahn, HS; Cho, B; Chung, NG; Im, HJ; Kang, HJ; Kim, HK; Kim, SY; Koo, HH; Lee, YH; Lim, YT; Park, JE; Park, SK; Seo, JJ; Shin, HY; Sung, KW; Yoo, KH | 1 |
| Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE | 1 |
| Cattaneo, R; Frenzke, ME; Johnston, PB; Miest, T; Ungerechts, G; Yaiw, KC | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW | 1 |
| Atkins, JN; Bengtson, EM; Byrd, JC; Donohue, KA; Hoke, EE; Larson, RA; Lin, TS; Link, BK; Lucas, MS; Rai, KR | 1 |
| Bergmann, M; Bühler, A; Busch, R; Denzel, T; Döhner, H; Edelmann, J; Eichhorst, B; Häbe, S; Hallek, M; Hensel, M; Hopfinger, G; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Alyea, E; Antin, JH; Armand, P; Attar, E; Ballen, K; Boussiotis, VA; Brown, J; Cutler, C; Dey, BR; Herrera, M; Ho, V; Kao, G; Kim, HT; Koreth, J; Liney, D; McDonough, S; Reynolds, C; Ritz, J; Soiffer, R; Spitzer, T; Stevenson, K | 1 |
| Arber, C; Bucher, C; Buser, A; Gerull, S; Gratwohl, A; Halter, J; Heim, D; Stern, M; Tichelli, A | 1 |
| Afanasiev, BV; Bence-Bruckler, I; Catalano, J; Dmoszynska, A; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Geisler, CH; Larratt, L; Loscertales, J; Moiseev, SI; Montillo, M; Robak, T; Rossiev, VA; Solal-Celigny, P; Spleiss, O; Warzocha, K; Weisser, M; Wenger, MK; Yeh, RF; Zhi, J | 1 |
| Brychtová, Y; Doubek, M; Mayer, J; Panovská, A | 1 |
| Anasetti, C; Ayala, E; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kim, J; Perez, L; Perkins, J; Pidala, J | 1 |
| Au, MA; Boeckh, MJ; Chien, JW; Deeg, HJ; Milano, F | 1 |
| Ahmed, S; Al-Anazi, K; Al-Mohareb, F; Al-Sharif, F; Al-Zahrani, H; Aljurf, M; Bakr, M; Chaudhri, N; Elhassan, T; Elkum, N; Hussain, F; Ibrahim, K; Mohamed, S; Nassar, A; Nurgat, Z; Patel, M; Rasheed, W; Saleh, AJ | 1 |
| Bär, C; Brantner, P; Buchner, M; Burger, M; Dierks, C; Gribben, JG; Mertelsmann, R; Ott, A; Pfeifer, D; Prinz, G; Stickel, N; Veelken, H; Zirlik, K | 1 |
| Anderson, KC; Ghobrial, IM; Rourke, M | 1 |
| Dan, K; Yamaguchi, H | 1 |
| Bulgar, AD; Donze, JR; Gerson, SL; Kirkland, EB; Li, L; Liu, L; Snell, M; Xu, Y; Yang, S | 1 |
| Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Garvin, JH; George, D; Harrison, L; Milone, MC; Morris, E; Satwani, P; Schwartz, J; Shaw, LM; Styczynski, J; Tallamy, B; van de Ven, C; Waxman, I | 1 |
| Giné, E; Gutiérrez-García, G; López-Guillermo, A | 1 |
| Brassac, M; Fournié, JJ; Gross, E; Kheirallah, S; L'Faqihi-Olive, FE; Laurent, G; Quillet-Mary, A; Struski, S; Ysebaert, L | 1 |
| Abramson, J; Brown, JR; Dalton, V; Freedman, AS; Hochberg, E; Kuang, Y; McDonough, SM; Mikler, E; Neuberg, D; Reynolds, H; Ritz, J; Thompson, C; Werner, L | 1 |
| Angchaisuksiri, P; Apilugsanachit, A; Atichartakarn, V; Boonsakan, P; Chuncharunee, S; Jootar, S; Kanoksil, W; Karntisaviwat, K; Niparuck, P; Nitiyanant, P; Rerkamnuatchoke, B; Ungkanont, A | 1 |
| Baldini, L; Federico, M; Ferrario, A; Goldaniga, MC; Luminari, S; Mannina, D; Marcheselli, L; Mazza, P; Merli, F; Russo, M; Stelitano, C | 1 |
| Eto, T; Fukuda, T; Hagihara, M; Hatanaka, K; Iida, H; Kanda, Y; Kasai, M; Kawano, F; Maeda, Y; Masuoka, K; Mori, T; Murata, M; Nagafuji, K; Nakagawa, H; Nakamae, M; Nishiwaki, K; Shirafuji, N; Takahashi, S; Takaue, Y; Taniguchi, S; Taniwaki, M; Togami, K; Uchida, T; Ueda, Y; Utsunomiya, A; Wake, A; Waki, F; Yakushiji, K; Yakushijin, K; Yamashita, T | 1 |
| Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; El Cheikh, J; Esterni, B; Farnault, L; Faucher, C; Fürst, S; Ladaique, P; Lemarie, C; Marchetti, N; Mohty, M; Prebet, T; Stoppa, AM; Vey, N | 1 |
| De Brasi, C; Narbaitz, M; Noriega, MF; Rodríguez, A; Slavutsky, I | 1 |
| Egle, A; Gassner, FJ; Geisberger, R; Greil, R; Hartmann, TN; Hofbauer, JP; Tinhofer, I; Weiss, L | 1 |
| Carney, DA; Seymour, JF | 1 |
| Chao, NJ; Chute, JP; Gasparetto, C; Hogge, DE; Horwitz, ME; Kanda, J; Long, GD; Morris, A; Niedzwiecki, D; Nitta, J; Rizzieri, DA; Smith, CA; Song, K; Sullivan, KM | 1 |
| Burchette, J; Foo, WC; Huang, Q; Hutchinson, CB; Sebastian, S; Wang, E | 1 |
| Dagis, A; Forman, S; Hitt, D; Naeem, H; Qian, D; Rosenthal, J; Stein, A; Thomas, SH; Wong, J | 1 |
| Bergmann, M; Berrebi, A; Böttcher, S; Bühler, A; Busch, R; Caligaris-Cappio, F; Catalano, J; Cazin, B; Döhner, H; Eichhorst, BF; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, M; Hensel, M; Hess, G; Hopfinger, G; Jäger, U; Kneba, M; Mayer, J; Mendila, M; Ritgen, M; Seymour, JF; Staib, P; Stilgenbauer, S; Trneny, M; von Grünhagen, U; Wendtner, CM; Westermann, A; Winkler, D; Zenz, T; Zinzani, PL | 1 |
| Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Komrokji, RS; Nishihori, T; Perkins, J; Pidala, J; Roman-Diaz, J | 1 |
| Artz, AS; Del Cerro, P; Godley, LA; Hart, J; Horowitz, S; Innocenti, F; Larson, RA; O'Donnell, PH; Odenike, OM; Pai, RK; Stock, W; Undevia, SD; Van Besien, K | 1 |
| Peinert, S; Seymour, JF | 1 |
| Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Perez, L; Perkins, J; Pidala, J | 1 |
| Bouscary, D; Dreyfus, F; Park, S; Pilorge, S; Tamburini, J | 1 |
| Chao, NJ; Chino, JP; Craciunescu, O; Folz, RJ; Horwitz, ME; Kelsey, CR; Marks, LB; Rizzieri, DA; Steffey, B | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Valdez, BC | 1 |
| Baron, F; Beguin, Y; Castermans, E; Cheynier, R; Dutrieux, J; Geenen, V; Gothot, A; Hannon, M; Humblet-Baron, S; Sandmaier, BM; Seidel, L; Storb, R; Vanbellinghen, JF; Willems, E | 1 |
| Eldering, E; Kater, AP; Tonino, SH; van Laar, J; van Oers, MH; Wang, JY | 1 |
| Januszewicz, EH; Peinert, S; Prince, HM; Scarlett, J; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Acholonu, SA; Anderlini, P; Bassett, RE; Champlin, RE; Giralt, SA; Okoroji, GJ; Popat, UR; Qazilbash, MH; Shpall, EJ; Worth, LL | 1 |
| Lech-Maranda, E; Robak, P; Robak, T | 1 |
| Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL | 1 |
| Holmes, NE; Kelman, A; Korman, TM; Opat, S | 1 |
| Came, N; Carney, DA; Januszewicz, EH; Kenealy, M; Milner, A; Prince, HM; Ritchie, D; Seymour, JF; Tam, CS; Westerman, DA; Wolf, M | 1 |
| Béliveau, C; Cohen, S; Kent, D; Kiss, T; Labbé, AC; Lachance, S; Laverdière, M; Logvinenko, T; Martel-Laferrière, V; Roy, J; Snydman, DR; Su, SH | 1 |
| Canales, M; de la Serna, J; de Oña, R; de Sevilla, AF; Martínez, R; Martínez-López, J; Montalbán, C; Paz-Carreira, J; Rapado, I; Rivero, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Arnold, R; Dokal, I; Dörken, B; Hemmati, PG; le Coutre, P; Neuburger, S; Terwey, TH; Vulliamy, T; Vuong, LG | 1 |
| Main, C; Moxham, T; Pitt, M; Stein, K | 1 |
| Aurora, M; Bachanova, V; Blazar, BR; Brunstein, C; Burns, L; Cao, Q; Cooley, S; Defor, T; Dusenbery, K; Kaufman, D; Macmillan, M; Majhail, NS; McClune, B; McGlave, P; Miller, J; Oran, B; Slungaard, A; Tomblyn, M; Vercellotti, G; Verneris, M; Wagner, J; Warlick, ED; Weisdorf, DJ | 1 |
| Jordheim, LP | 1 |
| Bahlis, NJ; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; El Kourashy, S; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Williamson, T; Yang, M; Zacarias, N | 1 |
| Dan, K; Mizuki, T; Nakamura, H; Nakayama, K; Tajika, K; Yamaguchi, H | 1 |
| An, X; Cao, S; Chen, Y; Hao, X; Li, H; Ren, X; Sun, H; Yan, F; Yu, J; Zhang, N | 1 |
| Bredeson, C; Ewell, M; Goodman, SA; Horowitz, MM; Kahl, BS; Laport, GG; Negrin, RS; Tomblyn, MR; Vose, JM | 1 |
| Anderlini, P; Andersson, BS; Bashir, Q; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Fernandez-Vina, M; Giralt, S; Popat, U; Rodrigues, M; Sharma, M; Shpall, EJ; Wei, W | 1 |
| Best, G; Buggins, AG; Devereux, S; Dyer, MJ; Fegan, C; Fishlock, K; Hewamana, S; Hills, R; Kennedy, BJ; Lin, TT; Majid, A; Miall, F; Oscier, DG; Pepper, C; Pratt, G; Wagner, S; Yallop, D | 1 |
| Choi, MK; Chung, CW; Hong, JY; Jang, JH; Kim, DH; Kim, HO; Kim, K; Kim, SJ; Kim, WS; Min, YH | 1 |
| Ascaso, FJ; Fuertes, MA; Jimenez, B; Keane, PA; Sadda, S | 1 |
| Ali, D; Bengtzén, S; Deneberg, S; Jönsson-Videsäter, K; Lehmann, S; Nahi, H; Paul, C | 1 |
| Aloyz, R; Amrein, L; Assouline, S; Caplan, S; Desjardins, P; Egorin, MJ; Hebb, J; Panasci, L; Rousseau, C | 1 |
| Amarnath, S; Buxhoeveden, N; Felizardo, TC; Foley, J; Fowler, DH; Mariotti, J; Massey, PR; Mossoba, ME; Ryan, K; Taylor, J | 1 |
| Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R | 1 |
| Anasetti, C; Ayala, E; Fancher, K; Fernandez, H; Field, T; Gardiner, JA; Kharfan-Dabaja, MA; Kim, J; Miller, S; Milone, MC; Perez, L; Perkins, J; Shaw, LM; Tate, C | 1 |
| Gao, W; Nimmagadda, S; Patel, P; Rondelli, D; Sweiss, K | 1 |
| Nagler, A; Shimoni, A | 1 |
| Doorduijn, JK; Lam, KH; van de Langerijt, B; van den Bent, MJ | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Palmieri, S; Riccardi, C | 1 |
| Abadie, E; Ersbøll, J; Gravanis, I; Marty, M; Pignatti, F; Skovlund, E | 1 |
| Amsailale, R; Arts, A; Bastin-Coyette, L; Bontemps, F; Cardoen, S; de Viron, E; Smal, C; Van Den Neste, E | 1 |
| Che, Y; Christopherson, RI; Henrich, S; Kohnke, PL; Mactier, S | 1 |
| Angulo-Pachón, CA; Carda, M; Díaz-Oltra, S; Falomir, E; Marco, JA; Murga, J | 1 |
| Chen, R; Delioukina, M; Forman, S; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Rosenthal, J; Shen, J; Smith, E | 1 |
| Casak, SJ; Davis, G; Jarral, V; Keegan, P; Khandelwal, A; Lemery, SJ; Pazdur, R; Rothmann, MD; Shen, YL; Zhao, H | 1 |
| Bae, KS; Choi, Y; Han, SB; Hur, EH; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lim, HS; Lim, SN; Noh, GJ; Yun, SC | 1 |
| Huisman, C; Paquay, MM; Tilanus, MG; van der Straaten, HM; van Geloven, N; Verdonck, LF | 1 |
| Balashov, D; Brooks, R; Maschan, A; Or, R; Resnick, IB; Revel-Vilk, S; Rheingold, L; Shapira, MY; Skorobogatova, E; Stein, J; Stepensky, P; Trakhtman, P; Weintraub, M | 1 |
| Booth, GA; Brown, J; Cocks, K; Cohen, DR; Dearden, C; Ezekwisili, R; Fegan, C; Hillmen, P; Kennedy, DB; Mercieca, J; Milligan, DW; Pettitt, A; Pocock, C; Radford, J; Rawstron, AC; Sayala, HA; Smith, AF; Varghese, AM | 1 |
| Brunstein, CG; DeFor, TE; Oran, B; Wagner, JE; Weisdorf, DJ | 1 |
| Evangelista, M; Lucotti, S; Patella, F; Rainaldi, G; Rizzo, M | 1 |
| Badoux, XC; Burger, J; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, SM; Wang, X; Wierda, WG | 2 |
| Anasetti, C; Ayala, E; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Perkins, J; Pidala, J; Roman-Diaz, J; Tate, C; Tomblyn, M | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Ariga, T; Cho, Y; Ichikawa, M; Iguchi, A; Inamoto, J; Kaneda, M; Kawamura, N; Kobayashi, I; Kobayashi, R; Ohkura, Y; Ohshima, J; Sato, T; Takezaki, SI; Yamada, M | 1 |
| Bakun, AV; Fedosenko, VV; Khlebko, PV; Kustanovich, AM; Serhiyenka, TF; Svirnovski, AI; Taras, IB | 1 |
| Bossuyt, X; Mariën, G; Uyttebroeck, A | 1 |
| Bajo, R; Burgaleta, C; Caballero, MD; Canales, M; De La Serna, J; De Oña, R; De Sevilla, AF; Díaz, N; Martínez, R; Martínez-López, J; Montalbán, C; Peñalver, J; Prieto, E; Queizán, JA; Salar, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Delioukina, ML; Forman, SJ; Krishnan, A; Palmer, JM; Stiller, T; Thomas, SH | 1 |
| de Lima, M; de Souza Santos, FP; Hamerschlak, N; Kerbauy, FR; Kutner, JM; Ribeiro, AA; Rodrigues, M; Sobrinho, JN; Torres, MA | 1 |
| Bansal, D; Gautam, V; Marwaha, N; Marwaha, RK; Oberoi, S; Sharma, RR | 1 |
| Atsuta, Y; Imahashi, N; Ito, T; Kato, T; Miyamura, K; Morishita, Y; Murata, M; Naoe, T; Nishiwaki, S; Ohashi, H; Sawa, M; Suzuki, R; Terakura, S; Yasuda, T | 1 |
| Colledan, M; Conter, V; Cornelli, P; Fiocchi, R; Giraldi, E; Provenzi, M; Rambaldi, A; Torre, G | 1 |
| Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J | 1 |
| Assisi, D; D'Andrea, M; Dessanti, L; Maini, CL; Petti, MC; Pisani, F; Sciuto, R | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ | 1 |
| Schnaiter, A; Stilgenbauer, S | 1 |
| Byrd, JC; Gribben, JG; Heerema, NA; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Ruppert, AS; Woyach, JA | 1 |
| Abrisqueta, P; Bosch, F; Crespo, M | 1 |
| Freedman, AS; Sweetenham, JW | 1 |
| Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W | 1 |
| Castillo, JJ; Reagan, JL | 1 |
| Baumann, M; Bluyssen, HA; Chmielewski, S; Heemann, U; Przybyl, L; Sikorski, K; Wesoly, J | 1 |
| Cervigón, I; Palomo, A; Solano, F; Torres-Iglesias, LM; Zapata, AM | 1 |
| Delioukina, M; Forman, S; Palmer, JM; Thomas, S; Tsai, N; Zain, J | 1 |
| Baurmann, H; Braess, J; Buechner, T; Haferlach, C; Hahn, J; Haude, KH; Hiddemann, W; Holler, E; Kolb, HJ; Oruzio, D; Schleuning, M; Schlimok, G; Schmid, C; Schwerdtfeger, R; Spiekermann, K; Tischer, J | 1 |
| Abraham, J; Andritsos, L; Benson, DM; Blum, W; Bunner, P; Craig, M; Cumpston, A; Devine, SM; Efebera, Y; Elder, P; Garzon, R; Gibson, L; Hamadani, M; Hofmeister, C; Leadmon, S; Penza, S; Phillips, GS; Remick, SC; Tse, W | 1 |
| Cai, YX; Lu, QY; Niu, XQ; Wang, Z; Zaho, JN | 1 |
| Hattori, H; Karasuno, T; Kotake, T; Kuwayama, M | 1 |
| Bautista, G; Cabrera, JR; Gonzalo-Daganzo, R; Regidor, C | 1 |
| Berentsen, S | 1 |
| Alsina, M; Anasetti, C; Ayala, E; Di Nicola, M; Fernandez, H; Field, T; Janssen, W; Kharfan-Dabaja, MA; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Santarone, S | 1 |
| Hivert, B; Leblond, V; Morel, P; Tamburini, J; Tournilhac, O; Vekhoff, A | 1 |
| Aimoto, M; Aimoto, R; Hayashi, Y; Hino, M; Inoue, A; Inoue, E; Koh, H; Koh, KR; Nakamae, H; Nakamae, M; Nakane, T; Nishimoto, M; Terada, Y; Yamane, T; Yoshimura, T | 1 |
| Alousi, AM; Anderlini, P; Andersson, BS; Champlin, RE; de Lima, MJ; Giralt, SA; Hosing, C; Kebriaei, P; Khouri, IF; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Saliba, RM | 1 |
| Fan, L; Fang, C; Hong, M; Li, JY; Liu, P; Miao, KR; Qiao, C; Wu, YJ; Xu, M; Xu, W; Zhu, DX; Zhu, HY; Zhuang, Y | 1 |
| Tadmor, T | 1 |
| Ba, LA; Doering, M; Hallek, M; Herling, M; Jacob, C; Lilienthal, N; Peer-Zada, AA; Prinz, C | 1 |
| Allen, JC; Chowbay, B; Diong, CP; Goh, YT; Hwang, WY; Linn, YC; Loh, SM; Wong, AM | 1 |
| Fujioka, T; Ikegame, K; Inoue, T; Kaida, K; Kato, R; Kim, EH; Nakata, J; Ogawa, H; Okada, M; Soma, T; Tamaki, H; Taniguchi, K; Yoshihara, S | 1 |
| Catovsky, D; Dearden, CE; Gonzalez, D; Hockley, S; Martinez, P; Matutes, E; Morgan, GJ; Oscier, D; Richards, SM; Wade, R | 1 |
| Ansaldi, F; Balleari, E; Bedognetti, D; Boccardo, F; Bruzzone, A; Caltabiano, G; De Maria, A; Durando, P; Ferrarini, M; Icardi, G; Marincola, FM; Massucco, C; Messina, M; Racchi, O; Sertoli, MR; Zanardi, E; Zoppoli, G; Zupo, S | 1 |
| Chan, G; Chang, CN; Dürig, J; Gorczyca, M; Griniute, R; Griskevicius, L; Gupta, I; Hernandez-Ilizaliturri, FJ; Hess, G; Kipps, TJ; Mayer, J; Nielsen, TG; Padmanabhan, S; Russell, CA; Smolej, L; Stilgenbauer, S; Wierda, WG | 1 |
| Costello, R; Csako, G; Langan, RC; Prieto, PA; Rosenberg, SA; Sherry, RM; White, DE; Wunderlich, J; Yang, JC; Zlott, D | 1 |
| Gopal, AK; Guthrie, KA; Maloney, DG; Matesan, MC; Oliveira, G; Pagel, JM; Press, OW; Rajendran, J; Storb, RF | 1 |
| Cassuto, JP; Cluzeau, T; De Matteis, M; Gratecos, N; Mannone, L; Mounier, N; Raynaud, S; Sirvent, A; Thyss, A; Ticchioni, M | 1 |
| Chen, S; Du, X; Li, Y; Liu, Q; Wu, J; Wu, X; Yang, L; Zhu, K | 1 |
| Gupta, V; Hayden, J; Ho, AY; Ireland, RM; Islam, MS; Koh, MB; Lim, Z; Marks, DI; Marsh, JC; Mufti, GJ; Pagliuca, A; Potter, V; Russell, N | 1 |
| Cencini, E; Fabbri, A; Forconi, F; Lauria, F; Raspadori, D; Sicuranza, A; Sozzi, E | 1 |
| Cavallin, M; Damante, G; Damiani, D; Fabbro, D; Fanin, R; Geromin, A; Michelutti, A; Pianta, A; Russo, D; Tiribelli, M | 1 |
| Bae, SH; Choi, SJ; Hyun, MS; Jeon, M; Joo, YD; Kang, MJ; Kang, YA; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Lee, YS; Park, JH; Ryoo, HM; Seol, M; Yun, SC | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Cavalieri, E; De Renzo, A; Derenzini, E; Fanti, S; Fina, M; Gandolfi, L; Montini, GC; Pellegrini, C; Pileri, S; Pulsoni, A; Quirini, F; Rossi, M; Scopinaro, F; Stefoni, V; Tani, M; Torelli, F; Zinzani, PL | 1 |
| Ai, WZ; Czerwinski, DD; Hsu, FJ; Hwang, J; Kohrt, HE; Levy, R; Taidi, B; Timmerman, J | 1 |
| Calixto, R; Chandrasekaran, V; Domingues, MC; Florêncio, R; Maior, AP; Ostronoff, F; Ostronoff, M; Sucupira, A | 1 |
| Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J | 1 |
| Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Yamazaki, R | 1 |
| Ayari, S; Blin, N; Brissot, E; Cahu, X; Chevallier, P; Clavert, A; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Harousseau, JL; Le Gouill, S; Mahe, B; Malard, F; Miplied, N; Mohty, M; Moreau, P | 1 |
| Crathorne, L; Garside, R; Hoyle, M; Hyde, C | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M | 1 |
| Haller, NA; Lee, B; Novak, R; Robertson, S; Smith, RS; Tanphaichitr, N | 1 |
| Einberger, C; Fleiss, K; Fonatsch, C; Gaiger, A; Gruber, M; Hauswirth, AW; Heintel, D; Jäger, U; Porpaczy, E; Shehata, M; Skrabs, C; Thalhammer, R; Vanura, K | 1 |
| Chen, R; Ewald, B; Plunkett, W; Sampath, D; Wierda, W; Zecevic, A | 1 |
| Barbour, SJ; Beaulieu, MC; Magil, AB; Zalunardo, NY | 1 |
| Khouri, IF | 1 |
| Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR | 1 |
| Cohen, GI; Fayad, LE; Kuepfer, C; Liebmann, JE; Modiano, MR; Pro, B; Romaguera, JE; Singer, JW; Srokowski, TP | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Hadjibabaie, M; Hayatshahi, A; Iravani, M; Javadi, MR; Khoee, SH; Mansouri, A; Shamshiri, AR | 1 |
| Bayer, R; Fung, HC; Gregory, SA; Karmali, R; Kassar, M; O'Brien, T; Shammo, JM; Venugopal, P | 1 |
| Bossow, S; Cattaneo, R; Grossardt, C; Leber, MF; Rieber, EP; Sawall, S; Temme, A; Ungerechts, G; von Kalle, C | 1 |
| Burchert, A; Neubauer, A; Wilhelm, C | 1 |
| Abdullah, A; Ho, AY; Kenyon, M; Krishnamurthy, P; Lea, N; Lim, ZY; Marsh, J; Mufti, GJ; Nagi, W; Pagliuca, A; Potter, V; Reiff-Zall, L; Tindell, V | 1 |
| Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC | 1 |
| Argentieri, D; Bartomioli, M; Bezares, RF; Diaz, A; Garay, G; Milone, G; Ryser, R; Stemelin, G; Zubiaur, EL | 1 |
| James, DF; Kipps, TJ | 1 |
| Arampatzis, S; Eleftheriadis, T; Giannakoulas, N; Karasavvidou, F; Kourti, P; Liakopoulos, V; Matsouka, P; Stefanidis, I | 1 |
| Beksac, M; Björkstrand, B; Bosi, A; Corradini, P; de Witte, T; Gahrton, G; Goldschmidt, H; Greinix, H; Gruber, A; Hegenbart, U; Iacobelli, S; Milone, G; Morris, C; Musto, P; Narni, F; Niederwieser, D; Volin, L | 1 |
| Battista, ML; Benevolo, G; Lazzarino, M; Meneghini, V; Morra, E; Nichelatti, M; Pioltelli, P; Ricci, F; Sacchi, S; Tedeschi, A; Varettoni, M; Visco, C; Vitolo, U; Zaja, F; Zinzani, PL | 1 |
| Blough, DK; Deeg, HJ; McCune, JS; McDonald, GB; O'Donnell, PV; Pawlikowski, MA; Rezvani, A; Yeh, RF | 1 |
| Brychtova, Y; Doubek, M; Dvorakova, D; Horky, O; Krejci, M; Lengerova, M; Mayer, J; Navratil, M; Pospisilova, S; Racil, Z; Tomiska, M | 1 |
| Andersohn, F; Bronder, E; Garbe, E; Grüneisen, A; Hildebrandt, M; Klimpel, A; Kurtal, H; Mayer, B; Salama, A; Schrezenmeier, H; Späth-Schwalbe, E; Thomae, M | 1 |
| Bergmann, L; Chow, KU; Cordes, HJ; Kim, SZ; Schlegelberger, B; Stilgenbauer, S; von Neuhoff, N; Wunderle, L | 1 |
| Badoux, X; Burger, J; Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Parikh, SA; Wang, X; Wierda, WG | 1 |
| Solis, EC | 1 |
| Boiron, JM; Bouabdallah, K; Coiffard, J; Dilhuydy, MS; Lafarge, X; Leguay, T; Marit, G; Melot, C; Milpied, N; Pigneux, A; Schmitt, A; Tabrizi, R; Vigouroux, S | 1 |
| Connors, JM; Gerrie, AS; Li, CH; Ramadan, KM; Sutherland, J; Toze, CL; Yee, A | 1 |
| Attolico, I; Crugnola, M; De Blasio, A; Ilariucci, F; Montillo, M; Morra, E; Petrizzi, VB; Ricci, F; Spedini, P; Spriano, M; Tedeschi, A; Uziel, L; Vismara, E; Zaccaria, A | 1 |
| Colović, M; Colović, N; Fekete, MD; Janković, G; Palibrk, V; Suvajdžić, N; Tomin, D | 1 |
| Jungova, A; Karas, M; Koza, V; Svoboda, T; Vokurka, S | 1 |
| Cao, JN; Fan, Y; Gu, KS; Guo, Y; Hong, XN; Li, XQ; Liu, XJ; Wang, CF; Wu, XH; Zhang, J | 1 |
| Baccarani, M; Bandini, G; Bontadini, A; Curti, A; D'Addio, A; Dan, E; Fruet, F; Giudice, V; Isidori, A; Lemoli, RM; Martinelli, G; Motta, MR; Paolini, S; Parisi, S; Ruggeri, L; Trabanelli, S; Urbani, E; Velardi, A | 1 |
| Chang, T; Dang, E; Feng, Z; Jin, L; Liu, Y; Shi, X; Wang, G | 1 |
| Appelbaum, FR; Bennett, JM; Byrd, JC; Dewald, G; Flinn, IW; Grever, MR; Hussein, MA; Larson, RA; Lazarus, HM; Litzow, MR; Neuberg, D; Paietta, EM; Rowe, JM; Smith, MR; Tallman, MS | 1 |
| Chao, NJ; Chute, JP; Gasparetto, C; Hennig, T; Horwitz, ME; Kanda, J; Li, Z; Long, GD; Morris, A; Rizzieri, DA; Sullivan, KM | 1 |
| Bergmann, M; Buske, C; Dreyling, M; Egensperger, R; Franke, D; Herold, T; Mumm, FF; Schinwald, N; Seiler, T; Trumm, C | 1 |
| Friedmann, M; Gutierrez, H; Han, L; Hornberger, J; Keating, MJ; Lerner, S; Reyes, C; Satram-Hoang, S; Shewade, A | 1 |
| Huynh, M; Neubauer, A | 1 |
| Cook, H; Datto, M; Daugherty, FJ; Davis, PH; DeCastro, CM; Diehl, LF; Friedman, DR; Gockerman, JP; Lanasa, MC; Li, Z; Matta, KM; Moore, JO; Rehder, C; Rizzieri, D; Weinberg, JB | 1 |
| Bahlis, NJ; Carlson, L; Duan, Q; Duggan, P; Hasegawa, W; Russell, JA; Stewart, DA; Voralia, M | 1 |
| Horino, S; Matsuhashi, T; Minegishi, M; Niizuma, H; Onuma, M; Rikiishi, T; Sakamoto, O; Sasahara, Y; Tsuchiya, S; Uchiyama, T; Uematsu, M | 1 |
| Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D | 1 |
| Aleman, BM; Boot, H; de Boer, JP; de Jong, D; Raderer, M; van Tinteren, H | 1 |
| Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Della-Latta, P; Freedman, J; Garvin, JH; George, D; Geyer, MB; Harrison, L; Jacobson, JS; Moore, V; Morris, E; Satwani, P; Schwartz, J; van de Ven, C | 1 |
| Aurran-Schleinitz, T; Dartigeas, C; Feugier, P; Leprêtre, S; Letestu, R; Van Den Neste, E; Ysebaert, L | 1 |
| Chan, GW; Gupta, IV; Lisby, S; Osterborg, A; Padmanabhan, S; Wierda, WG | 1 |
| Acholonu, S; Alousi, AM; Anderlini, P; Champlin, RE; Chancoco, C; Ciurea, S; Fanale, MA; Hosing, CM; Khouri, IF; Ledesma, C; Nieto, Y; Popat, UR; Saliba, RM; Shpall, EJ; Valverde, R; Younes, A | 1 |
| Abraham, A; Kasow, KA; Morales-Tirado, VM; Persons, DA; Riberdy, JM; Shurtleff, SA; Wichlan, D | 1 |
| Al-Ahmari, A; Al-Jefri, A; Al-Seraihi, A; Aldali, A; Ayas, M; El-Solh, H; Khairy, A; Markiz, S; Siddiqui, K | 1 |
| Boudova, L; Jindra, P; Karas, M; Kazakov, D; Koza, V; Svoboda, T; Vokurka, S | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
| Fan, L; Li, JY; Liu, P; Miao, KR; Xu, M; Xu, W | 1 |
| Bezares, RF; Bitsmans, A; Borge, M; Galmarini, CM; Gamberale, R; Giordano, M; González, M; Jancic, C; Morande, PE; Nannini, P; Rodríguez, AL; Zanetti, SR | 1 |
| Bhattacharyya, J; Kimura, A; Mihara, K; Takihara, Y | 1 |
| Sinsabaugh, C | 1 |
| Acar, H; Aydemir, E; Bayrak, OF; Gulluoglu, S; Ozen, M; Sahin, F; Sevli, S; Yalvac, ME | 1 |
| Capoluongo, N; Coppola, N; Fiore, M; Guastafierro, S; Iodice, V; Messina, V; Pasquale, G; Pisaturo, M; Sagnelli, C; Sagnelli, E; Stanzione, M; Tonziello, G | 1 |
| Baldini, L; Cortelezzi, A; Gritti, G; Maura, F; Molica, S; Neri, A; Piciocchi, A; Reda, G | 1 |
| Asmar, L; Boehm, KA; Di Bella, N; Hyman, W; Lyons, RM; Reynolds, C; Richards, DA; Robbins, GJ; Vellek, M; Zhan, F | 1 |
| Molica, S | 2 |
| Iwasaki, H; Kawai, Y; Takagi, K; Ueda, T; Yamauchi, T | 1 |
| Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F | 1 |
| Arnoulet, C; Béné, MC; Brumpt, C; Capiod, JC; de Carvalho Bittencourt, M; Degenne, M; Durrieu, F; Eghbali, H; Feugier, P; Feuillard, J; Garand, R; Geneviève, F; Kara-Terki, A; Kulhein, E; Maynadié, M; Ochoa-Noguera, ME; Plesa, A; Roussel, M; Truchan-Graczyk, M | 1 |
| Eshkar-Sebban, L; Gellman, YN; Lytton, SD; Nagler, A; Naor, D; Or, R; Refaeli, E; Rosenblum, N; Shimoni, A; Shimony, O; Stanevsky, A; Yerushalmi, R | 1 |
| Alimoghaddam, K; Bahar, B; Behfar, M; Ghavamzadeh, A; Hamidieh, AA; Iravani, M; Jahani, M; Jalali, A; Jalili, M; Mousavi, SA | 1 |
| Kalk, E; Karanth, M; Khan, N; McLarnon, A; Moss, PA; Murray, J; Piper, KP; Pratt, G | 1 |
| Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Neumann, T; Wilfert, H | 1 |
| Bassett, R; Champlin, RE; Chan, KW; Ciurea, SO; Couriel, DR; de Lima, M; Fernandez-Vina, M; Hamerschlak, N; Hosing, CM; Jones, RB; Karduss Aurueta, AJ; Kebriaei, P; McMannis, J; Nieto, Y; Petropoulos, D; Qazilbash, M; Rondon, G; Saliba, RM; Sharma, M; Shpall, EJ; Worth, LL | 1 |
| Jäger, U; Janssens, A; Leblond, V; Lepretre, S; Nikitin, E; Robak, T; Wendtner, CM | 1 |
| Elter, T; Engert, A; Gercheva-Kyuchukova, L; Hallek, M; Jaksic, B; Kyrcz-Krzemień, S; Pylylpenko, H; Rekhtman, G; Robak, T; Sirard, C; Vatutin, M; Wu, J | 1 |
| Amadori, S; Biagi, A; Bomben, R; Bruno, A; Buccisano, F; Bulian, P; Coletta, AM; Dal Bo, M; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Gattei, V; Luciano, F; Maurillo, L; Neri, B; Rossi, FM; Simotti, C; Venditti, A; Zucchetto, A | 1 |
| Aguilar, J; Al-Katib, A; del Busto, R; Johnson, LB; Obeid, KM; Sharma, M; Szpunar, S | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Cornblath, DR; Huff, CA; Hughes, RA; Merkies, IS | 1 |
| Beaumont, M; Garidi, R; Ghomari, K; Gruson, B; Just, A; Marolleau, JP; Merle, P; Merlusca, L; Royer, B | 1 |
| Baro, J; Bermúdez, A; Colorado, M; Conde, E; Díez-Gallarreta, Z; Gutiérrez, ML; Insunza, A; Iriondo, A; López-Duarte, M; Olalla, I; Pérez-Vázquez, G; Richard, C; Sanroma, P; Yañez, L | 1 |
| Cesano, A; Evensen, E; Fantl, WJ; Huang, YW; Nolan, GP; Palazzo, AL | 1 |
| Fournié, JJ; Laurent, G; Liffraud, C; Quillet-Mary, A; Ysebaert, L | 1 |
| Hollweg, A; Rai, KR | 1 |
| Bertoni, F; Bruscaggin, A; Cerri, M; Chiaretti, S; Cresta, S; Dalla-Favera, R; Deaglio, S; Deambrogi, C; Del Giudice, I; Fangazio, M; Foà, R; Forconi, F; Gaidano, G; Gargiulo, E; Gattei, V; Guarini, A; Khiabanian, H; Messina, M; Monti, S; Pasqualucci, L; Rabadan, R; Rasi, S; Rossi, D; Spina, V; Vaisitti, T | 1 |
| Bergier, G; Glass, F; McCardle, T; Moscinski, L; Naghashpour, M; Setoodeh, R; Sokol, L | 1 |
| Agura, E; Bethge, W; Blume, KG; Bruno, B; Chauncey, TR; Franke, GN; Georges, GE; Hari, P; Hübel, K; Langston, A; Laport, GG; Maloney, DG; Maris, MB; Maziarz, RT; McSweeney, PA; Mielcarek, M; Niederwieser, D; Petersen, FB; Pulsipher, MA; Sahebi, F; Sandmaier, BM; Sorror, ML; Storb, R; Storer, BE; Vindeløv, L; Yeager, A | 1 |
| Mineishi, S | 1 |
| Choi, ES; Im, HJ; Jang, S; Kim, BE; Koh, KN; Kwon, SW; Park, CJ; Seo, JJ | 1 |
| Spaner, DE | 1 |
| Dietrich, S; Dreger, P; Giese, T; Hahn, E; Hess, M; Ho, AD; Hüllein, J; Krämer, OH; Luft, T; Rieger, M; Schäfer, C; Tretter, T; Zenz, T | 1 |
| Dai, Y; Dent, P; Grant, S; Hock, S; Rosato, R | 1 |
| Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H | 1 |
| Schuh, A | 1 |
| Keating, MJ; McDonnell, TJ; Medeiros, LJ; Tang, G; Wang, SA; Wierda, WG; Zhou, Y | 1 |
| Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Komina, O; Robak, P; Smolewski, P; Węsierska-Gądek, J; Żołnierczyk, JD | 1 |
| Anne, N; Eeva, J; Heli, U; Liisa, V; Tapani, R | 1 |
| Beaumont, T; Breij, EC; Eldering, E; Elias, JA; Geest, CR; Kater, AP; Luijks, DM; Tromp, JM; van Laar, J; van Oers, MH | 1 |
| Best, G; Christopherson, RI; Crossett, B; Henrich, S; Mactier, S; Mulligan, SP | 1 |
| Apperley, J; Foroni, L; Ibrahim, A; Marin, D; Milojkovic, D; Reid, A | 1 |
| Byrd, JC; Woyach, JA | 1 |
| Best, OG; Che, Y; Christopherson, RI; Forsyth, C; Mulligan, SP; Singh, N | 1 |
| Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ | 1 |
| Anasetti, C; Cooley, S; Curtsinger, J; Defor, T; Devine, S; DiPersio, J; Drobyski, W; Farag, S; Fehniger, TA; Haagenson, M; Miller, J; Porter, D; Waller, EK; Weisdorf, D | 1 |
| Chatterjee, A; Mahata, SK; Mir, SA; Mitra, A; Pathak, K; Sarkar, S | 1 |
| Baumgart, J; Beelen, DW; Blau, I; Bornhaeuser, M; Casper, J; Einsele, H; Freund, M; Giebel, S; Holowiecki, J; Kruzel, T; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Ruutu, T; Schaefer-Eckart, K; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Wandt, H; Zander, AR | 1 |
| Brown, JR | 2 |
| Catovsky, D; Cocks, K; Crofts, S; Else, M; Richards, SM; Smith, AG; Wade, R | 1 |
| Baldini, L; Ferrario, A; Gamba, E; Goldaniga, M; Mannina, D; Merli, F; Musto, P; Olivero, B; Pulsoni, A; Rigacci, L; Rossi, F; Rossi, G; Stelitano, C; Tedeschi, A; Vitolo, U | 1 |
| Colomer, D; Fernández-Calotti, PX; Lopez-Guerra, M; Pastor-Anglada, M | 1 |
| Anasetti, C; Ayala, E; Fernandez, HF; Field, TL; Kharfan-Dabaja, MA; Kim, J; Perez, LE; Perkins, JB; Pidala, JA; Sullivan, DM; Tomblyn, MR | 1 |
| Bonacorsi, G; Bulgarelli, J; Castelli, I; Coluccio, V; Deaglio, S; Debbia, G; Fiorcari, S; Fontana, M; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Narni, F; Torelli, G; Zucchini, P | 1 |
| Breikša, B; Chapenko, S; Feldmane, L; Garcia-Cabeza, M; Gomez-Roman, J; Jaunmuktane, Z; Lejniece, S; Lejnieks, A; Murovska, M; Ziediņa, I | 1 |
| Connors, JM; Gerrie, AS; Zypchen, LN | 1 |
| Borthakur, G; Cortes, J; Eghtedar, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
| Dmoszynska, A; Joshi, A; Li, J; Mangat, R; Robak, T; Valente, N; Visich, J; Wenger, M; Zhi, J | 1 |
| Ichikawa, M; Iwata, A; Koya, J; Kurokawa, M; Nagashima, Y; Nakamura, F; Tsuji, S | 1 |
| Ding, KY; Geng, LQ; Liu, HL; Sun, ZM; Tang, BI; Tong, J; Wang, XB; Wang, ZY | 1 |
| Bacigalupo, A; Bazarbachi, A; Geara, F; Kharfan-Dabaja, MA; Mahfouz, RA; Otrock, ZK | 1 |
| Jacobson, PA; Jensen, K; Johnson, LA; Kachler, S; Kirstein, MN; Klotz, KN; Lamba, J | 1 |
| Fan, H; Guo, B; Li, SX; Lin, J; Lu, XC; Ran, HH; Yang, Y; Zhai, B; Zhu, HL | 1 |
| Chen, CH; Kuo, CY; Ma, MC; Pei, SN; Rau, KM; Su, CY; Wang, MC | 1 |
| Artz, AS; Hart, J; O'Donnell, PH; Pai, RK; van Besien, K | 1 |
| Feliu, J; García-Muñoz, R; Olavarría, E; Zabalza, A | 1 |
| Argnani, L; Cabras, MG; Casadei, B; De Renzo, A; Derenzini, E; Fabbri, A; Gandolfi, L; Gobbi, M; Pellegrini, C; Perotti, A; Pulsoni, A; Rigacci, L; Voso, MT; Zaccaria, A; Zinzani, PL | 1 |
| Elashoff, D; Giannoni, F; Kahl, CA; Kohn, DB; Lee, CC; Louie, SG; Martinez, M; Sumiyoshi, T; Tarantal, AF; Wherley, J | 1 |
| Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El Cheikh, J; Esterni, B; Etienne, A; Faucher, C; Fürst, S; Prebet, T; Vey, N | 1 |
| Bertoni, F; Bruscaggin, A; Chiaretti, S; Cresta, S; Dalla-Favera, R; Daniele, G; Deaglio, S; Deambrogi, C; Del Giudice, I; Fabbri, G; Famà, R; Fangazio, M; Foà, R; Forconi, F; Gaidano, G; Gattei, V; Greco, M; Guarini, A; Marinelli, M; Monti, S; Pasqualucci, L; Rasi, S; Rossi, D; Spina, V; Vaisitti, T | 1 |
| Bishop, MR; Bryant, K; Dean, RM; Dunleavy, K; Fowler, DH; Fry, TJ; Gress, RE; Hakim, F; Hughes, TE; Odom, J; Pavletic, SZ; Salit, RB; Steinberg, SM; Wilson, WH | 1 |
| Barrenetxea, C; Boluda, JC; de Heredia, CD; Ferrá, C; González, M; Martín, C; Martinez, AM; Sanz, GF; Sanz, J; Sanz, MA; Serrano, D; Solano, C | 1 |
| Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R | 1 |
| Berentsen, S; Tjønnfjord, GE | 1 |
| Böttcher, S; Bühler, A; Busch, RM; Döhner, H; Eichhorst, BF; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, MJ; Kneba, M; Mendila, M; Ritgen, M; Stilgenbauer, S; Wendtner, CM; Wenger, MK; Zenz, T | 1 |
| Chen, DB; Shen, DH | 1 |
| Faber, E; Hubacek, J; Indrak, K; Jarosova, M; Katrincsakova, B; Kurfurst, P; Pikalova, Z; Raida, L; Rusinakova, Z; Skoumalova, I; Tucek, P; Vondrakova, J | 1 |
| Bauer, K; Elter, T; Engert, A; Hallek, M; Monsef, I; Roloff, V; Skoetz, N | 1 |
| Aurran, T; Béné, MC; Casasnovas, O; Cazin, B; Chevret, S; Corront, B; Cymbalista, F; Delépine, R; Delmer, A; Feugier, P; Leblond, V; Lepretre, S; Letestu, R; Mahé, B; Maisonneuve, H; Royer, B; Tournilhac, O; Van Den Neste, E; Vaudaux, S | 1 |
| Li, QS; Mao, P; Zhuang, XY | 1 |
| Burger, JA; Chen, G; Croce, CM; Garcia-Prieto, C; Huang, P; Keating, MJ; Liu, J; Lu, W; Pelicano, H; Plunkett, W; Trachootham, D; Zhang, W | 1 |
| Farrow, S; Lea, S; Metryka, A; Plumb, J; Singh, D; Southworth, T | 1 |
| Beum, PV; Beurskens, FJ; Engelberts, P; Farooqui, M; Lindorfer, MA; Mackus, WJ; Parren, PW; Taylor, RP; Wiestner, A | 1 |
| Byrd, JC; Gordon, A; Gribben, JG; Heerema, NA; Larson, RA; Lozanski, A; Lozanski, G; Lucas, DM; Marcucci, G; Morrison, VA; Rai, KM; Ruppert, AS | 1 |
| Gan, SL; Ma, P; Sun, H; Wang, WM; Xie, XS | 1 |
| Döhner, H; Gribben, JG; Hallek, M; Keating, MJ; Stilgenbauer, S; Zenz, T | 1 |
| Barisone, E; Berger, M; Fagioli, F; Galletto, C; Manicone, R; Masetti, R; Pession, A; Quarello, P; Rivetti, E | 1 |
| Elonen, E; Honkanen, T; Jantunen, E; Jyrkkiö, S; Karjalainen-Lindsberg, ML; Kuittinen, O; Lehto, M; Mikkola, M; Poikonen, E; Räsänen, A; Räty, R; Rauhala, A; Rimpiläinen, J; Siitonen, S; Suominen, M; Vapaatalo, M | 1 |
| Christiansen, H; Griesinger, F; Lederer, K; Nitsche, M; Pradier, O; Schmidberger, H | 1 |
| Chae, YS; Choi, JY; Kang, BW; Kim, JG; Kim, YK; Lee, SJ; Lee, YJ; Moon, JH; Seo, JW; Shin, HC; Sohn, SK; Suh, JS | 1 |
| Asami, K; Kato, S; Koike, T; Morimoto, T; Muroi, K; Oshima, K; Shimizu, T; Takakura, H; Takata, M; Tsukamoto, H; Yabe, H; Yabe, M; Yamashita, T | 1 |
| Blough, DK; Cheng, MM; Devine, EB; Goulart, B; Veenstra, DL | 1 |
| Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R | 1 |
| Ba, Y; Hou, Y; Wang, HQ | 1 |
| Agrawal, S; Auer, RL; Cavenagh, JD; Davies, JK; Gribben, JG; Lister, TA; MacDougall, F; Oakervee, HE; Syndercombe-Court, D; Taussig, D | 1 |
| Boyiadzis, M; Foon, KA; Kropf, P; Lentzsch, S; Lenzner, D; Marks, S; Mehta, D; Pietragallo, L; Sulecki, M; Tarhini, A | 1 |
| Cambot, M; Cosset, FL; Costa, C; Dubart-Kupperschmitt, A; Joubert, C; Le Grand, R; Leboulch, P; Legrand, F; Nègre, D; Prost, S; Relouzat, F; Verhoeyen, E | 1 |
| Bono, M; Bruno, S; Casciaro, S; Decensi, A; Fais, F; Ghiotto, F; Luzzi, P; Mazzarello, AN; Morabito, F; Recchia, A; Tenca, C | 1 |
| Adachi, S; Fujita, N; Ishii, E; Kanai, R; Nishi, M; Nishimura, R; Ohga, S; Okamura, T; Sato, E; Sawada, A; Suzuki, N; Yano, J; Yasumi, T; Yasutomo, K | 1 |
| Amsailale, R; Arts, A; Bontemps, F; Smal, C; Starczewska, E; Van Den Neste, E | 1 |
| Han, W; Wei, Z; Yanxia, Y; Ying, X; Yuhua, J | 1 |
| Aisa, Y; Kato, J; Mori, T; Nakamura, Y; Nakazato, T; Okamoto, S; Shigematsu, N | 1 |
| Baurmann, H; Bethge, WA; Bornhauser, M; Bunjes, D; Dittmann, H; Faul, C; Federmann, B; Kanz, L; Stelljes, M; Trenschel, R; Vogel, W; von Harsdorf, S | 1 |
| Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M | 1 |
| Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D | 1 |
| Bae, SH; Hyun, MS; Joo, YD; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Park, JH; Ryoo, HM | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Adams, RH; Anderlini, P; Antin, JH; Arai, S; Carter, SL; Confer, DL; Deeg, HJ; Difronzo, NL; Eapen, M; Ewell, M; Gersten, ID; Horowitz, MM; Horwitz, M; Leifer, ES; McCarty, JM; Nakamura, R; Pulsipher, MA; Tolar, J | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E | 1 |
| Fathi, AT; Hasserjian, R; Sadrzadeh, H | 1 |
| Abbenante, MC; Astolfi, A; Baccarani, M; Candoni, A; Cattina, F; Damiani, D; Fanin, R; Ferrari, A; Formica, S; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Lonetti, A; Malagola, M; Martinelli, G; Michelutti, A; Ottaviani, E; Papayannidis, C; Parisi, S; Russo, D; Sazzini, M; Simeone, E | 1 |
| Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Döhner, H; Elter, T; Engert, A; Fink, AM; Fischer, K; Gassmann, W; Hallek, M; Hasan, I; James, R; Kahl, C; Ritgen, M; Staib, P; Stauch, M; Stilgenbauer, S; Wendtner, CM; Winkler, D | 1 |
| Baxter-Lowe, LA; Cowan, MJ; Dvorak, CC; Horn, B; Law, J; Long-Boyle, JR; Musick, L | 1 |
| Ramos, CA | 1 |
| Fan, L; Fang, C; Hong, M; Li, JY; Liu, P; Miao, KR; Wang, YH; Xu, W; Zhu, DX; Zhu, W; Zou, ZJ | 1 |
| Ehlert, K; Fruehwald, MC; Groll, AH; Juergens, H; Rossig, C | 1 |
| Burnett, AK; Fegan, C; Pearce, L; Pepper, C; Walsby, E | 1 |
| Almazi, JG; Best, OG; Christopherson, RI; Crossett, B; Mactier, S; Mulligan, SP | 1 |
| Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M | 1 |
| Best, OG; Mulligan, SP | 1 |
| Borowiec, M; Błoński, JZ; Franiak-Pietryga, I; Korycka-Wołowiec, A; Maciejewski, H; Mirowski, M; Robak, T; Sałagacka, A | 1 |
| Kato, J; Kikuchi, T; Kohashi, S; Mori, T; Okamoto, S; Ono, Y; Shimizu, T; Yamane, A | 1 |
| Adamson, J; Carter, A; Catovsky, D; Dearden, C; Gonzalez, D; Johnson, GG; Lin, K; Matutes, E; Oates, M; Oscier, DG; Pettitt, AR; Richards, S; Wade, R | 1 |
| Alvarnas, J; Bhatia, R; Cai, JL; Chang, K; Chao, J; Forman, SJ; Maegawa, R; Nakamura, R; O'Donnell, MR; Palmer, JM; Parker, PM; Pullarkat, V; Senitzer, D; Snyder, DS; Stein, AS; Stiller, T; Thomas, SH; Wang, S | 1 |
| Arima, N; Niino, D; Ohshima, K; Tsuda, H; Tsuji, T; Yamasaki, H | 1 |
| Andritsos, L; Blum, KA; Byrd, JC; Flynn, JM; Grever, MR; Gupta, SV; Gurcan, M; Herman, SE; Johnson, AJ; Jones, JA; Kong, H; Lehman, A; Lucas, DM; Mahoney, E; Smith, LL; Wagner, AJ; Yeh, YY; Zhang, X | 1 |
| Denk, U; Egle, A; Greil, R; Hamacher, F; Hofbauer, JP; Kenner, L; Kocher, T; Melchardt, T; Merkel, O; Scheideler, M; Schlederer, M; Sifft, E; Steurer, M; Wacht, N | 1 |
| Ave, E; Brunati, AM; Cabrelle, A; Carraro, S; Facco, M; Frezzato, F; Gattazzo, C; Martini, V; Semenzato, G; Teramo, A; Tibaldi, E; Trentin, L; Trimarco, V; Zambello, R | 1 |
| Mitra, S; Pyatt, N | 1 |
| Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Kantarjian, HM; Pierce, S; Shan, J; Storer, B | 1 |
| Ariga, T; Hershfield, MS; Imai, K; Kanegane, H; Miyawaki, T; Nomura, K; Santisteban, I; Taneichi, H; Wada, T; Yachie, A | 1 |
| Bosanquet, AG; Catovsky, D; Else, M; Matutes, E; Richards, SM; Wade, R | 1 |
| Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A | 1 |
| Canaani, J; Dezorella, N; Eshel, R; Gepstein, L; Herishanu, Y; Naparstek, E; Perry, C; Polliack, A; Rothman, R; Sarid, N; Shpringer, M; Solar, I | 1 |
| Bonfim, C; Deeg, HJ; Flowers, ME; Gooley, T; Kiem, HP; O'Donnell, P; Pasquini, R; Ribeiro, L; Sandmaier, BM; Storb, R; Thakar, MS; Woolfrey, AE | 1 |
| Almazi, JG; Christopherson, RI; Crossett, B; Kohnke, PL; Mactier, S | 1 |
| Bahlis, N; Brown, C; Chaudhry, A; Daly, A; Duggan, P; Geddes, M; Russell, J; Savoie, ML; Shafey, M; Stewart, D; Storek, J; Turner, AR | 1 |
| Ambinder, R; Aoki, J; Bolaños-Meade, J; Borowitz, M; Fuchs, E; Jones, R; Kasamon, Y; Luznik, L; Swinnen, L; Symons, H; Zeidan, A | 1 |
| André, M; Bouabdallah, R; Coiffier, B; Di Raimondo, F; Doorduijn, JK; Dreyling, MH; Feugier, P; Forstpointner, R; Geisler, CH; Hallek, M; Hermine, O; Hiddemann, W; Hoster, E; Kanz, L; Klapper, W; Kluin-Nelemans, HC; Kremers, S; Lepeu, G; Lugtenburg, PJ; Macro, M; Pfreundschuh, M; Procházka, V; Ribrag, V; Sanhes, L; Stilgenbauer, S; Szymczyk, M; Thieblemont, C; Tilly, H; Trneny, M; Unterhalt, M; Uppenkamp, M; Vehling-Kaiser, U; Walewski, J; Zijlstra, JM | 1 |
| Peterson, A; Shah, BK; Uprety, D | 1 |
| Bo, L; Chen, F; Fang, Y; Fu, J; Li, Y; Liang, A; Lu, H; Zhang, H; Zhu, D | 1 |
| Arima, H; Imai, Y; Inoue, D; Kiuchi, M; Maruoka, H; Matsushita, A; Mori, M; Nagano, S; Oita, T; Tabata, S; Takahashi, T; Takiuchi, Y; Yamashiro, A | 1 |
| Aldred, VL; Bellesso, M; Chamone, DA; Costa, RO; Hallack Neto, AE; Pereira, J; Ruiz, MA | 1 |
| Rossi, D | 1 |
| Appelbaum, FR; Belch, A; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Solh, M; Tallman, MS | 1 |
| Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M | 1 |
| Bosanquet, AG; Lin, K; Melarangi, T; Oates, M; Pettitt, AR; Rockliffe, N; Slupsky, JR; Zhuang, J | 1 |
| Fabiano, AJ; Fenstermaker, RA; Qiu, J; Rigual, D | 1 |
| Chevrier, S; Houot, R; Lamy, T; Marchand, T; Poullot, E; Revest, M; Tattevin, P | 1 |
| Fan, L; Fang, C; Li, JY; Liu, L; Xu, W; Yang, S; Zhang, LN; Zou, ZJ | 1 |
| Bruyere, H; Chan, MJ; Dalal, CB; Gerrie, AS; Gillan, TL; Huang, SJ; Ramadan, KM; Toze, CL | 1 |
| Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R | 1 |
| Ahmed, O; Davies, M; Kottaridis, PD; Narvekar, N; Papageorgiou, SG | 1 |
| Cacoub, P; Choquet, S; Decaux, O; Hermine, O; Jego, P; Karras, A; Pineton de Chambrun, M; Saadoun, D | 1 |
| Aker, M; Dray, L; Grisariu, S; Kedmi, M; Or, R; Resnick, IB; Shapira, MY; Stepensky, P | 1 |
| Ellwanger, S; Gibney, G; Janssen, W; Kudchadkar, R; Kuhn, L; Marzban, S; Mulé, JJ; Pilon-Thomas, S; Royster, E; Sarnaik, AA; Sondak, VK; Weber, J; Zager, J | 1 |
| Brychtova, Y; Chovancova, J; Doubek, M; Francova, HS; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Stehlikova, O; Tichy, B; Tomiska, M | 1 |
| Bozsó, T; Iványi, JL; Plander, M; Skrapits, J; Szendrei, T | 1 |
| Fan, L; Li, JY; Liu, L; Wang, DM; Xu, W; Yang, S; Zhang, LN; Zou, ZJ | 1 |
| Dallas, MH; Hartford, C; Laver, J; Leung, W; Pillai, A; Shook, DR; Srinivasan, A; Triplett, BM | 1 |
| Andrieux, J; Baranger, L; Barin, C; Bilhou-Nabera, C; Blons, H; Callet-Bauchu, E; Chapiro, E; Chevret, S; Chiesa, J; Daudignon, A; Eclache, V; Gachard, N; Grelier, A; Henry, C; Lambert, J; Leblondon, V; Lejeune, J; Luquet, I; Merle-Beral, H; Mossafa, H; Mould, S; Mozziconacci, MJ; Mugneret, F; Nguyen-Khac, F; Owen, R; Penther, D; Struski, S; Terre, C; Veronese, L | 1 |
| Borel, C; Bouvet, E; Cazin, B; Compaci, G; Laurent, G; Michallet, AS; Obéric, L; Ysebaert, L | 1 |
| Cheong, JW; Hong, DS; Joo, YD; Kim, BK; Kim, CS; Kim, DY; Kim, H; Kim, I; Kim, MK; Kim, SH; Koh, Y; Lee, HK; Lee, JH; Lee, KH; Lee, SM; Min, YH; Park, E; Park, MR; Park, S; Park, SK; Sohn, SK; Won, JH; Yoon, SS | 1 |
| Alchalby, H; Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Fehse, B; Hansen, T; Heinzelmann, M; Klyuchnikov, E; Kröger, N; Schilling, G; Schwarz, S; Stübig, T; Wolschke, C; Zabelina, T; Zander, AR; Zeschke, S | 1 |
| Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B | 1 |
| Ahmad, A; Becker, MW; Coppage, M; Iqbal, A | 1 |
| Helton, KJ; Patay, Z; Triplett, BM | 1 |
| Catovsky, D; Collins, A; Cross, NC; Else, M; Forster, J; Gardiner, A; Gomez, B; Gonzalez de Castro, D; Oscier, DG; Parker, A; Parker, H; Rose-Zerilli, MJ; Strefford, JC; Winkelmann, N | 1 |
| Bay, JO; Blaise, D; Bordigoni, P; El-Cheikh, J; Labussière-Wallet, H; Michallet, M; Milpied, N; Mohty, M; Morisset, S; Sobh, M; Socié, G; Tabrizi, R | 1 |
| Ahmed, G; Davis, Z; Dyer, M; Gonzalez, D; Matutes, E; Moss, P; Oldreive, C; Oscier, D; Parker, A; Richards, S; Skowronska, A; Stankovic, T; Taylor, AM; Thomas, P | 1 |
| Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Esterni, B; Fürst, S; Granata, A; Oudin, C; Vey, N | 1 |
| Bhadelia, N; Freedberg, DE; Oster, MW; Poneros, JM | 1 |
| DeCook, LJ; Hogan, WJ; Holtan, SG; Huneke, T; Johnson, ND; Litzow, MR; Patnaik, MM; Porrata, LF; Thoma, M; Wiegand, RA | 1 |
| Duszeńko, E; Haus, O; Kałwak, K; Musiał, J; Ussowicz, M | 1 |
| Autore, F; Chiusolo, P; Innocenti, I; Laurenti, L; Leone, G; Sica, S; Sorà, F; Vannata, B | 1 |
| Bae, SH; Hyun, MS; Joo, YD; Kim, DY; Kim, H; Kim, MK; Kim, SD; Lee, GW; Lee, JH; Lee, KH; Lee, WS; Min, YJ; Park, JH; Ryoo, HM | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Forman, SJ; Htut, M; Karanes, C; Krishnan, AY; Murata-Collins, J; Palmer, J; Rincon, A; Sahebi, F; Shen, Y; Somlo, G; Thomas, SH | 1 |
| Bauer, K; Elter, T; Engert, A; Hallek, M; Rancea, M; Roloff, V; Skoetz, N | 1 |
| Galaup, A; Paci, A | 1 |
| Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK | 1 |
| Bai, LY; Byrd, JC; Chan, KK; Cheney, C; Herman, SE; Jarjoura, D; Jin, Y; Lee, LJ; Lee, RJ; Mao, Y; Marcucci, G; Mo, X; Muthusamy, N; Ramanunni, A; Wang, X; Yu, B | 1 |
| Bolognia, JL; Cooper, DL; Parker, TL; Seropian, SE | 1 |
| Brannagan, TH; Leitch, MM; Sherman, WH | 2 |
| Bellemare, J; Bilban, M; Fleiss, K; Gaiger, A; Gleiss, A; Gruber, M; Guillemette, C; Hoermann, G; Jaeger, U; Le, T; Lévesque, É; Mannhalter, C; Porpaczy, E; Shehata, M; Skrabs, C; Vanura, K; Zehetmayer, S | 1 |
| Giannakakis, C; Guido, G; Mosillo, G; Rocca, AR; Salviani, C; Serriello, I | 1 |
| Alhede, M; Bjarnsholt, T; Braendstrup, P; Clasen-Linde, E; Eickhardt, S; Høiby, N; Jensen, KE; Moser, C; Vindeløv, L | 1 |
| McCormack, C; McCurdy, O; Prince, HM; Ritchie, D | 1 |
| Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Casadei, B; Celli, M; Derenzini, E; Fanti, S; Gandolfi, L; Pellegrini, C; Pileri, S; Poletti, V; Quirini, F; Stefoni, V; Zinzani, PL | 1 |
| Anderlini, P; Bassett, R; Champlin, R; de Lima, M; Ganesan, P; Giralt, S; Kebriaei, P; Khouri, I; Parmar, S; Rondon, G; Thall, P | 1 |
| Baker, D; Betz, A; Burke, R; Coffey, G; DeGuzman, F; Druker, BJ; Fletcher, LB; Hollenbach, SJ; Loriaux, MM; Pak, Y; Pandey, A; Sinha, U; Spurgeon, SE; Tyner, JW | 1 |
| Aljurf, M; Maury, S | 1 |
| Apollonio, B; Caligaris-Cappio, F; Fazi, C; Fonte, E; Ghia, P; Muzio, M; Ranghetti, P; Scarfò, L | 1 |
| Blaise, D; Castagna, L | 1 |
| Blaise, D; Siddiqi, T | 1 |
| Appelbaum, FR; Belch, AR; Byrd, JC; Geyer, S; Kolitz, J; Larson, RA; Lin, TS; Morrison, VA; Rai, K; Ruppert, AS; Tallman, MS; Woyach, JA | 1 |
| Chevret, S; Choquet, S; Copplestone, A; Dartigeas, C; Dilhuydy, MS; Ewings, M; Johnson, S; Leblond, V; Lejeune, J; Malphettes, M; Morel, P; Nguyen-Khac, F; Owen, RG; Patmore, RD; Pratt, G; Royer, B; Rule, S; Seymour, JF; Tournilhac, O; Willoughby, S; Wright, D | 1 |
| Diker-Cohen, T; Lahav, M; Natur, A; Shapira, H; Szyper-Kravitz, M; Uziel, O | 1 |
| Ichikawa, M; Kurokawa, M; Nakagawa, M; Nakamura, F; Nannya, Y; Yamazaki, S | 1 |
| du Toit, C; Novitzky, N; Thomas, V | 1 |
| Chen, LY; Collins, D; Coupland, R; Fung, AT; Gerrie, AS; Maberley, D; Moloney, G; Rossman, D; White, V; Wong, PC | 1 |
| Fan, ZP; Huang, F; Jiang, QL; Liu, H; Liu, QF; Sun, J; Wu, MQ; Yu, GP; Zhang, X; Zhou, HS | 1 |
| Ayari, S; Blin, N; Chevallier, P; Clavert, A; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lestang, E; Mahe, B; Mohty, M; Moreau, P; Planche, L; Roland, V; Tessoulin, B | 1 |
| Barba, P; Carreras, E; Fernández-Avilés, F; Garcia-Cadenas, I; López Corral, L; López-Anglada, L; Martino, R; Novelli, S; Pérez-Simón, JA; Piñana, JL; Rovira, M; Sierra, J; Valcárcel, D | 1 |
| Cook, G; Craddock, CF; Fielding, AK; Kirkland, KE; Littlewood, TJ; Marks, DI; Medd, PG; Milligan, DW; Pearce, R; Peniket, AJ; Perry, J; Potter, MN; Shaw, BE | 1 |
| Balleisen, L; Eimermacher, H; Freier, W; Heit, W; Hinke, A; Ibach, S; Knauf, W; Megdenberg, D; Niederle, N; Weiß, J | 1 |
| Castillo, JJ; Olszewski, AJ | 1 |
| Boelens, JJ; Raphael, MF; Rottier, BL | 1 |
| Ajana, F; Ettahar, N; Legout, L; Massongo, M; Patoz, P; Rose, C; Senneville, E | 1 |
| Bertz, H; Christopoulos, P; Finke, J; Marks, R; Schmoor, C; Wäsch, R; Waterhouse, M | 1 |
| Fan, Z; Guo, X; Huang, F; Li, Y; Liu, H; Liu, Q; Nie, D; Song, Z; Sun, J; Tu, S; Xiao, Y; Yu, G; Zhai, X; Zhang, Y; Zhou, H | 1 |
| Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Geyer, MB; Harrison, L; Jin, Z; Morris, E; Radhakrishnan, K | 1 |
| Azoulay, E; Darmon, M; Epelboin, L; Levy, V; Malphettes, M; Schnell, D; Vincent, F; Xhaard, A | 1 |
| Abdel-Rahman, F; Abu-Jazar, H; Al-Zaben, A; Frangoul, H; Ghatasheh, L; Hammada, T; Hussein, AA; Najjar, R; Natsheh, A; Sharma, S | 1 |
| Chiba, S; Fukuda, T; Kako, S; Kanda, Y; Kondo, Y; Kurokawa, M; Miyamoto, T; Miyamura, K; Nagafuji, K; Nakao, S; Ohashi, Y; Okoshi, Y; Oshima, K; Takaue, Y; Taniguchi, S; Uchida, N | 1 |
| Schmutz, JL; Trechot, P | 1 |
| Andersson, BS; Bayraktar, UD; Boulad, F; Castro-Malaspina, HR; Champlin, RE; Chen, J; Chiattone, A; de Lima, M; Giralt, S; Jakubowski, AA; Kernan, NA; Maloy, M; O'Reilly, RJ; Papadopoulos, EB; Rondon, G; Saliba, RM | 1 |
| Alloush, H; Anderson, E; Conway, M; Lamont, J; Martin, A; Mehta, P; Ruddock, M; Salisbury, V; Smith, JG; Smith, MA | 1 |
| Bogusz, J; Cebula-Obrzut, B; Majchrzak, A; Mędra, A; Robak, T; Smolewski, P | 1 |
| Baldini, L; Barate', C; Benevolo, G; Frustaci, AM; Gini, G; Goldaniga, MC; Luraschi, A; Morra, E; Motta, M; Nichelatti, M; Pioltelli, P; Ricci, F; Tedeschi, A; Varettoni, M; Vismara, E; Vitolo, U | 1 |
| Fahrmann, JF; Hardman, WE | 1 |
| Brychtová, Y; Doubek, M; Lindtnerová, M; Lysák, D; Malčíková, J; Mayer, J; Motyčková, M; Panovská, A; Pospíšilová, Š; Šimkovič, M; Smolej, L; Trbušek, M; Vodárek, P | 1 |
| Albrecht, M; Bökkerink, J; Claviez, A; Dörffel, W; Holte, H; Karlen, J; Lüders, H; Mann, G; Marciniak, H; Niggli, F; Pötter, R; Rühl, U; Schellong, G; Schmiegelow, K; Schwarze, EW; Wickmann, L | 1 |
| Busch, R; Cramer, P; Döhner, H; Eichhorst, B; Fingerle-Rowson, G; Fink, AM; Hallek, M; Herling, M; Hopfinger, G; Kandler, G; Pflug, N; Reinart, N; Stilgenbauer, S; Weit, N; Westermann, A; Winkler, D | 1 |
| Fan, L; Fang, C; Li, JY; Liu, L; Xu, W; Zhang, LN; Zhu, HJ; Zou, ZJ | 1 |
| Bene, MC; Blin, N; Chevallier, P; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lode, L; Loirat, M; Mahe, B; Malard, F; Mohr, C; Mohty, M; Moreau, P; Peterlin, P; Planche, L | 1 |
| Angrilli, F; Arcaini, L; Brugiatelli, M; Carella, AM; Dell'olio, M; Di Raimondo, F; Dondi, A; Federico, M; Franco, V; Gaidano, G; Galimberti, S; Luminari, S; Marcheselli, L; Merli, F; Pulsoni, A; Rigacci, L; Sacchi, S; Stelitano, C; Tucci, A; Vitolo, U | 1 |
| Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D | 1 |
| Qin, Q; Xie, Z; Zhu, Y | 1 |
| Cho, B; Chung, NG; Jang, PS; Jeong, DC; Kim, HK; Lee, JW | 1 |
| Alyea, EP; Antin, JH; Armand, P; Attar, EC; Ballen, KK; Chen, YB; Coughlin, E; Cutler, C; Dey, BR; Ho, VT; Kennedy, KF; Koreth, J; McAfee, SL; Soiffer, RJ; Spitzer, TR | 1 |
| Cherne, MK; Jorstad, NL; Keene, CD; Khademi, SB; Montine, KS; Montine, TJ; Shiao, C; Yang, Y | 1 |
| Dubielecka, PM; Grzybek, M; Korycka, J; Meissner, J; Michalczyk, I; Seweryn, E; Sikorski, AF; Toporkiewicz, M | 1 |
| Ghavamzadeh, A; Hamdi, A; Hamidieh, AA; Nabavi, M; Pourpak, Z | 1 |
| Frangoul, H; Hussein, AA | 1 |
| Bertoni, F; Cavalli, F; Lobetti-Bodoni, C; Stussi, G; Zucca, E | 1 |
| Banov, L; Calvillo, M; Dufour, C; Fioredda, F; Fischer, A; Gallicola, F; Miano, M; Micalizzi, C; Molinari, AC; Montobbio, G; Parasole, R; Petruzziello, F; Poggi, V; Svahn, J | 1 |
| Baba, T; Hamanishi, J; Kang, HS; Kharma, B; Konishi, I; Mandai, M; Matsumura, N; Murphy, SK; Yamaguchi, K; Yamanoi, K; Yoshioka, Y | 1 |
| Bahlo, J; Böttcher, S; Busch, R; Cramer, P; Döhner, H; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Goede, V; Hallek, M; Kneba, M; Langerbeins, P; Mayer, J; Pflug, N; Schubert, F; Stilgenbauer, S; Wendtner, CM | 1 |
| Boyer, J; Frey, NV; Goldstein, SC; Hexner, EO; June, CH; Kumar, AJ; Levine, BL; Loren, AW; Luger, SM; Porter, DL; Reshef, R; Smith, J; Stadtmauer, EA | 1 |
| Jiang, H; Liu, L; Ma, Y; Pan, H; Pan, S; Sun, X; Wang, D; Wang, J; Wu, Y; Xu, D; Xu, Z; Zhao, B | 1 |
| Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Issaragrisil, S; Jetsrisuparb, A; Pakakasama, S; Rujkijyanont, P; Sirachainan, N; Sirireung, S; Songdej, D; Srisala, S; Sruamsiri, R; Ungkanont, A | 1 |
| Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U | 1 |
| Broward, MA; Godwin, AK; Pessetto, ZY; Sethi, G; Weir, SJ | 1 |
| Adams, RH; Betcher, JA; Dueck, AC; Fauble, VD; Khera, N; Klein, JL; Leis, JF; Noel, P; Reeder, CB; Slack, JL; Sproat, LO | 1 |
| Haeusler, GM; Lingaratnam, S; Seymour, JF; Slavin, MA; Tam, CS; Teh, BW; Thursky, KA; Worth, LJ | 1 |
| Hashiguchi, M; Imamura, R; Kawaguchi, K; Koteda, S; Makimura, K; Mouri, F; Nagafuji, K; Nakamura, T; Nomura, K; Okamura, T; Oku, E; Osaki, K; Seki, R | 1 |
| Almasan, A; Hill, BT; Kalaycio, M; Mazumder, S; Sharma, A; Singh, K | 1 |
| Aquino, S; Avenoso, D; Ballerini, F; Bergamaschi, M; Clavio, M; Colombo, N; Cruciani, F; De Astis, E; Ghiggi, C; Gobbi, M; Grasso, R; Guolo, F; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G | 1 |
| Li, F; Li, ZJ; Qi, JY; Qiu, LG; Xing, LJ; Xu, Y; Yi, SH; Yu, Z; Zhao, YZ | 1 |
| De Revel, T; Doghmi, K; Jennane, S; Konopacki, J; Mahtat, el M; Malfuson, JV; Mikdame, M | 1 |
| Behfar, M; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hashemi, S; Moin, M; Pourpak, Z; Yari, K | 1 |
| Beum, PV; Lee, E; Lindorfer, MA; Marti, G; Mo, CC; Njuguna, N; Taylor, RP; Vire, B; Wiestner, A; Wilson, WH | 1 |
| Brychtova, Y; Doubek, M; Dusek, J; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Racil, Z; Tomiska, M | 1 |
| Evangelista, M; Lucotti, S; Rainaldi, G; Rizzo, M | 1 |
| Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Kotkowska, A; Robak, T; Rogalińska, M; Smolewski, P; Wawrzyniak, E; Żołnierczyk, JD | 1 |
| Berquist, L; Bonavida, B; Chu, P; Clanton, D; Hariharan, K; Ho, SN; Molina, A; Murphy, T; Vega, MI | 1 |
| Bethge, WA; Bouvier, ME; Bruno, B; Chauncey, TR; Fukuda, T; Hari, P; Hübel, K; Kornblit, B; Maloney, DG; Maziarz, RT; Petersen, FB; Pulsipher, MA; Sandmaier, BM; Storb, R; Storek, J; Storer, BE; Vucinic, V | 1 |
| Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
| Azik, F; Emir, S; Erdem, AY; Isik, P; Metin, A; Tavil, B; Tunc, B; Uckan, D | 1 |
| Daly, A; Kangarloo, SB; Ng, ES | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Compain, L | 1 |
| Abe, M; Fukuda, S; Kanai, R; Katsube, Y; Mishima, S; Ogushi, H; Tadokoro, M; Taketani, T; Yamaguchi, S; Yuba, S | 1 |
| Kalaycio, M; Lukenbill, J | 1 |
| Böttcher, S; Bühler, A; Busch, R; Döhner, H; Eichhorst, B; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, M; Hensel, M; Hopfinger, G; Kneba, M; Mayer, J; Pflug, N; Ritgen, M; Staib, P; Stilgenbauer, S; Wendtner, CM; Wenger, M; Winkler, D; Zenz, T | 1 |
| Jaskova, Z; Navrkalova, V; Sebejova, L; Trbusek, M; Zemanova, J | 1 |
| Faderl, S; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Strati, P; Wierda, W | 1 |
| Badoux, X; Jones, JA; Kantarjian, H; Keating, MJ; Kipps, TJ; O'Brien, S; Plunkett, W; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Barrett, J; Childs, RW; Cook, L; Donohue, T; Geller, N; Khuu, H; Kurlander, R; Leitman, S; Pantin, J; Ramos, C; Shah, AA; Stroncek, D; Tian, X; Young, NS | 1 |
| Bühler, A; Busch, R; Cazzola, M; Döhner, H; Döhner, K; Edelmann, J; Hallek, M; Kless, S; Mack, S; Mertens, D; Paschka, P; Rossi, M; Schnaiter, A; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Lemarie, C; Oudin, C; Saillard, C; Signori, A | 1 |
| Chen, K; Darcy, PK; Dickinson, M; Gambell, P; Haurat, J; Hönemann, D; Kershaw, MH; Khot, A; Kravets, L; Neeson, PJ; Peinert, S; Prince, HM; Ritchie, DS; Scott, AM; Shin, M; Smyth, MJ; Tai, T; Tainton, K; Trapani, JA; Wall, DM; Westerman, DA; Westwood, JA | 1 |
| Barré, L; Delamare, J; Deloye, JB; Gourand, F; Guillouet, S; Leporrier, M; Patin, D; Tirel, O | 1 |
| Atsuta, Y; Goto, H; Inagaki, J; Inoue, M; Ishii, E; Kato, K; Kawa, K; Koike, K; Ohga, S; Okada, K; Sawada, A; Suzuki, N; Suzuki, R; Yabe, H; Yasutomo, K | 1 |
| Argnani, L; Broccoli, A; Casadei, B; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Cartron, G; Davies, A; Lei, G; Marcus, R; Morschhauser, F; Radford, J; Salles, G; Vitolo, U; Wassner-Fritsch, E; Wenger, M | 1 |
| Abbas, A; Barré, L; Dhilly, M; Dumontet, C; Fillesoye, F; Galateau, F; Gourand, F; Guillouet, S; Leporrier, M; MacKenzie, ET; Patin, D; Tirel, O | 1 |
| Bahlis, NJ; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Kangarloo, SB; Larratt, L; Russell, JA; Savoie, ML; Shafey, M; Stewart, DA; Storek, J; Turner, AR; Williamson, T; Yang, M; Yue, P; Zacarias, N | 1 |
| Bashir, Q; Champlin, R; Ciurea, S; De Lima, M; Dinh, YT; Giralt, S; Hosing, CM; Jones, R; Kebriaei, P; Khan, H; Liu, P; Nieto, Y; Oran, B; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Rondon, G; Shah, JJ; Shah, N; Shpall, E; Thall, PF | 1 |
| Bartalucci, G; Bocchia, M; Bosi, A; Cencini, E; Dottori, R; Fabbri, A; Gozzetti, A; Puccini, B; Rigacci, L | 1 |
| Mapara, MY | 1 |
| Burke, RT; Druker, BJ; Loriaux, MM; Prins, RC; Spurgeon, SE; Tyner, JW | 1 |
| Aloyz, R; Assouline, SE; Autexier, C; Chu, TW; Gryaznov, SM; Johnston, JB; Lees-Miller, SP; Martinez-Marignac, V; Shawi, M; Yu, Y | 1 |
| Burger, J; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Strati, P; Tam, C; Wierda, W | 1 |
| Goi, K; Hara, T; Kamachi, Y; Kojima, S; Kumaki, S; Morio, T; Muramatsu, H; Sasahara, Y; Sugita, K; Takada, H; Tsuchiya, S; Urabe, T | 1 |
| Colturato, VA; de Castro, FA; Lanchote, VL; Simões, BP; Voltarelli, JC | 1 |
| Alvarez De Celis, I; Baldini, L; Bari, A; Boccomini, C; Botto, B; Castellino, C; Chiappella, A; Chiarenza, A; Ciccone, G; De Angelis, F; De Renzo, A; Evangelista, A; Gamba, E; Ladetto, M; Lobetti-Bodoni, C; Parvis, G; Pinto, A; Rossi, G; Tucci, A; Vitolo, U; Zaja, F | 1 |
| Abel, G; Barthelmes, J; Dueregger, A; Guggenberger, F; Haunschild, J; Intelmann, D; Klocker, H; Ramoner, R; Sampson, N; Schuh, M; Stecher, G | 1 |
| Agrwal, N; Blair, JE; Carey, EJ; De Petris, G; Kusne, S; Ronan, BA; Seville, MT; Vikram, HR | 1 |
| Anasetti, C; Ayala, E; Betts, B; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kunter, G; Locke, F; Nieder, M; Nishihori, T; Ochoa-Bayona, JL; Perez, L; Perkins, JB; Pidala, J; Tomblyn, M | 1 |
| Byrtek, M; Cerhan, JR; Dawson, K; Flowers, CR; Friedberg, JW; Link, BK; Martin, P; Ziemiecki, R | 1 |
| Aweeka, F; Huang, L; Lizak, P; Long-Boyle, J | 1 |
| Arion, C; Coliţă, A; Coliţă, AD; Tanase, A; Varady, Z | 1 |
| Arakawa, T; Hino, M; Koh, H; Nakamae, H; Nakane, T; Nishimoto, M; Ohsawa, M; Watanabe, K | 1 |
| Chen, BA; Ding, BH; Ding, JH; Li, YF; Qian, J; Yu, ZP | 1 |
| Catovsky, D; Dearden, CE; Else, M; Hillmen, P; Richards, S | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Eto, T; Fukuda, T; Ikegame, K; Imai, K; Kako, S; Kanamori, H; Kato, H; Minagawa, K; Mizuta, S; Morishima, Y; Nagamura-Inoue, T; Nakamae, H; Nishiwaki, S; Sakamaki, H; Shigematsu, A; Suzuki, R; Tanaka, J; Tanaka, M; Yujiri, T | 1 |
| Berkahn, L; Bryant, A; Cannell, P; Doocey, R; Fay, K; George, B; Hertzberg, M; Kalff, A; Kennedy, G; Moore, J; Nivison-Smith, I; Patil, S; Pillai, ES; Ritchie, D; Spearing, R; Spencer, A | 1 |
| Gibson, SB; Graham, BA; Ishdorj, G; Johnston, JB; Yoon, JY | 1 |
| Bouvet, E; Cazin, B; Coiffier, B; Laurent, G; Michallet, AS; Mosser, L; Oberic, L; Salles, G; Schlaifer, D; Ysebaert, L | 1 |
| Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Coso, D; Crocchiolo, R; D'Incan, E; Devillier, R; El-Cheikh, J; Etienne, A; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Picard, C; Schiano, JM; Stoppa, AM; Vey, N | 1 |
| Bajwa, RP; Rose, MJ; Woods, G | 1 |
| Abella, E; Abrisqueta, P; Bobillo, S; Bosch, F; Calvo, X; Carbonell, F; Constants, M; Delgado, J; Escoda, L; Ferrà, C; Ferrer, S; García-Marco, JA; González, M; González, Y; González-Barca, E; Jarque, I; Montoro, JB; Montserrat, E; Monzó, E; Muntañola, A; Terol, MJ; Villamor, N | 1 |
| Carr, DF; Catovsky, D; Cox, TF; Eccles, R; Else, M; Gardiner, LJ; Gonzalez de Castro, D; Johnson, GG; Lin, K; Lloyd, B; Oates, M; Oscier, DG; Pettitt, AR; Pirmohamed, M; Sibson, DR; Strefford, JC | 1 |
| Caimi, P; Habecker, B; Hill, BT; Kalaycio, M; Kindwall-Keller, T | 1 |
| Andersson, BS; Champlin, RE; Corn, P; Dominguez, JR; Li, Y; Song, G; Valdez, BC | 1 |
| Beelen, D; Berdel, WE; Braess, J; Büchner, T; Fiegl, M; Grüneisen, A; Heinecke, A; Hentrich, M; Hiddemann, W; Kern, W; Reichle, A; Rieger, C; Sauerland, C; Schiel, X; Schöndube, D; Serve, H; Spiekermann, K; Staib, P; Unterhalt, M; Wörmann, B | 1 |
| Ahmad, I; Albert, MH; Belohradsky, BH; Bredius, R; Fasth, A; Fernandes, JF; Fischer, A; Gaspar, HB; Gennery, A; Gruhn, B; Güngör, T; Haddad, E; Hassan, M; Hough, R; Kentouche, K; Lachance, S; Moshous, D; Rentsch, K; Resnick, IB; Schanz, U; Schlegel, PG; Seger, R; Shaw, PJ; Slatter, M; Stepensky, P; Stussi, G; Teira, P; Telles da Cunha, JM; Vermont, C; Veys, P | 1 |
| Abrams, S; Chen, GL; Hahn, T; Liu, H; McCarthy, PL; Ross, M; Zhang, Y | 1 |
| Jindra, P; Lysák, D | 1 |
| Wang, YF; Wang, ZX; Wu, XX; Xu, XX; Yan, B; Yang, HL; Yu, Y; Zhang, YZ; Zhao, DD | 1 |
| Bluyssen, HA; Czerwoniec, A; Sikorski, K; Szatkowska, K; Szelag, M; Wesoly, J | 1 |
| Bojarska-Junak, A; Chocholska, S; Dmoszyńska, A; Hus, I; Roliński, J; Tomczak, W; Woś, J | 1 |
| Eketorp Sylvan, S; Hansson, L; Karlsson, C; Lundin, J; Norin, S; Osterborg, A | 1 |
| Beckers, MM; Daenen, S; Doorduijn, JK; Doreen Te Raa, G; Eldering, E; Kater, AP; Lankheet, NA; Liu, RD; Luijks, DM; Slinger, E; Spiering, M; Tonino, SH; van Oers, MH | 1 |
| Huang, XJ; Ji, Y; Liu, DH; Liu, KY; Sun, YQ; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH; Zhang, XH; Zhang, YY | 1 |
| Bayhan, T; Ceylaner, S; Demir, HA; Emir, S; Karakuş, E; Kurtulan, O; Özyörük, D; Üner, A | 1 |
| Amital, H; Davidson, T; Kneller, A; Schiby, G; Twig, G; Yaniv, G; Zavdy, O | 1 |
| Barth, MJ; Czuczman, MS | 1 |
| Medeiros, BC | 2 |
| Aldoss, I; Haider, M; Ji, L; Pullarkat, V | 1 |
| Autore, F; D'arena, G; De Padua, L; Efremov, DG; Falcucci, P; Innocenti, I; Laurenti, L; Marietti, S; Piccirillo, N; Sica, S; Vannata, B; Za, T | 1 |
| Albano, F; Angrilli, F; Brugiatelli, M; Carella, AM; Chiarenza, A; Chiaretti, S; Cortelezzi, A; Cuneo, A; De Propris, MS; Del Giudice, I; Della Starza, I; Fazi, P; Foà, R; Gentile, G; Guarini, A; Laurenti, L; Marasca, R; Marinelli, M; Mauro, FR; Molica, S; Musolino, C; Nanni, M; Nobile, F; Piciocchi, A; Vignetti, M; Zaja, F | 1 |
| Bartelink, IH; Bierings, MB; Boelens, JJ; de Wildt, A; Gerhardt, CE; Lindemans, CA; van Maarseveen, EM; van Reij, EM; Versluys, B | 1 |
| Barker, JN; Castro-Malaspina, H; Ceberio, I; Devlin, SM; Giralt, S; Goldberg, JD; Jakubowski, AA; Koehne, G; Lechner, L; Moskowitz, CH; Papadopoulos, EB; Perales, MA; Sauter, CS; Zelenetz, AD; Zheng, J | 1 |
| Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Crocchiolo, R; Devillier, R; El-Cheikh, J; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Mohty, B; Oudin, C; Rey, J; Stoppa, AM; Vey, N | 1 |
| Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP | 1 |
| Ahn, KW; Aljurf, MD; Alyea, EP; Arora, M; Brown, JR; Cortes, J; de Lima, M; Gale, RP; Holland, HK; Hsu, JW; Inamoto, Y; Kalaycio, ME; Kamble, RT; Laughlin, MJ; Lewis, ID; Maziarz, RT; Saber, W; Sabloff, M; Seftel, M; Sobecks, RM; Wirk, BM; Zhu, X | 1 |
| Behfar, M; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hashemi, S; Moin, M; Movahedi, M; Pourpak, Z; Yari, K | 1 |
| Cao, F; Feng, B; Gangeswaran, R; Gao, D; Lemoine, NR; Spurrell, E; Tollefson, A; Wang, P; Wang, Y; Wold, W | 1 |
| Geisler, CH | 1 |
| Craig, M; Cumpston, A; Evans, K; Goff, L; Hamadani, M; Kanate, AS; Leadmon, S; Rauenzahn, S; Truong, Q; Wen, S; Zhang, J | 1 |
| Blackford, AL; Carraway, HE; Gojo, I; Gore, SD; Greer, JM; Ivy, SP; Karp, JE; Levis, MJ; McDevitt, MA; Pratz, KW; Smith, BD; Zeidner, JF | 1 |
| Streu, E | 2 |
| Agarwal, R; Ball, JB; Hutchinson, SK; Kharbanda, S; Lamb, LS; McKenna, DH; Smith, AR; Wagner, JE; Weinberg, KI | 1 |
| Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N | 1 |
| Bo, J; Cai, B; Gao, C; Han, X; Huang, W; Jing, Y; Li, H; Luo, L; Wang, Q; Yu, L; Zhang, L; Zhao, Y; Zhu, H | 1 |
| Dijkstra, FS; Janssen, JJ; Ossenkoppele, GJ; Visser, OJ; Witte, BI; Wondergem, MJ; Zweegman, S | 1 |
| Ball, LM; Bredius, RG; Hissink Muller, P; Jol-van der Zijde, EC; Lankester, AC; Vermont, CL; Vossen, AC | 1 |
| Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B | 1 |
| Ambrosetti, A; Attolico, I; Barzan, A; Benedetti, F; Bergui, L; Billio, A; Carlo-Stella, C; Chiarenza, A; Devizzi, L; Di Nicola, M; Di Raimondo, F; Gianni, AM; Gueli, A; Guidetti, A; Intermesoli, T; Magni, M; Matteucci, P; Montanari, M; Mulè, A; Olivieri, A; Parvis, G; Patti, C; Rambaldi, A; Scimè, R; Tarella, C; Trentin, L; Valagussa, P; Viero, P; Viviani, S | 1 |
| Bertaina, A; Brescia, L; Comoli, P; Corbella, F; Giorgiani, G; Locatelli, F; Pagliara, D; Perotti, C; Strocchio, L; Zecca, M | 1 |
| Chennupati, S; Golla, M; Nalla, S; Rangasamy, M; Thappali, S; Vakkalanka, S; Veeraraghavan, S; Viswanadha, S | 1 |
| Booker, R; Brown, C; Chaudhry, MA; Cox-Kennett, N; Daly, A; Duggan, P; Griffiths, CD; Kangarloo, SB; Ng, ES; Russell, JA; Savoie, L; Storek, J; Williamson, TS; Yue, P | 1 |
| Advani, P; Akhtar, D; Chanan-Khan, A; Chitta, K; Colon-Otero, G; Foran, J; Khan, AN; Masood, A; Miller, KC; Paulus, A; Rivera, C; Roy, V | 1 |
| Hafner, J; Kumar, K; Mulligan, S; Ng, K | 1 |
| Citrin, DE; Rosenberg, SA; Tseng, J; Waldman, M; White, DE; Yang, JC | 1 |
| Akahoshi, Y; Ashizawa, M; Ishihara, Y; Kako, S; Kanda, J; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, S; Nakano, H; Nakasone, H; Nishida, J; Sakamoto, K; Sato, M; Tanihara, A; Terasako, K; Ugai, T; Wada, H; Yamasaki, R; Yamazaki, R | 1 |
| Abbas, AY; Bradshaw, TD; Brennan, P; Fegan, C; Fischer, PM; Pepper, C; Pratt, G; Shao, H; Walsby, E; Wang, S | 1 |
| Chen, H; Fu, HX; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Tang, FF; Wang, FR; Wang, Y; Xu, LP | 1 |
| Brandberg, Y; Gill, D; Hammerström, J; Hertzberg, M; Johansson, H; Juliusson, G; Jønsson, V; Karlsson, K; Liliemark, J; McLennan, R; Mulligan, SP; Norman, J; Strömberg, M; Sundström, G; Uggla, B; Wallvik, J | 1 |
| Choi, I; Jang, YJ; Jeon, M; Jung, SJ; Kang, M; Kang, YA; Kim, DY; Kim, H; Kim, HJ; Lee, JH; Lee, JL; Lee, KH; Lee, YS; Park, SY; Seol, M; Yeom, YI; Yoon, SR; Yun, SC | 1 |
| Appelbaum, FR; Cassaday, RD; Fisher, DR; Gooley, TA; Gopal, AK; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Shields, A | 1 |
| Chambellan, A; Chevallier, P; Delasalle, B; Delaunay, J; Dirou, S; Germaud, P; Guillaume, T; Lemarchand, P; Malard, F; Mohty, M; Moreau, P | 1 |
| González-Ramírez, MP; Hernández-Reyes, J; Martagón-Herrera, NA; Rosales-Durón, AD; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Velázquez-Sánchez-de-Cima, S; Zamora-Ortiz, G | 1 |
| Dave, SS; Kulbacki, E; McKinney, MS; Papalas, JA; Wang, E | 1 |
| Chae, YK; Estrov, Z; Jain, P; Keating, MJ; Rozovski, U; Trinh, L; Wang, X; Wierda, WG | 1 |
| Bilmon, I; Bryant, A; Greenwood, M; Hertzberg, M; Kennedy, G; Moore, J; Nivison-Smith, I; Ritchie, D; Spencer, A | 1 |
| Kawakami, T; Kitano, K; Mimura, Y; Nakazawa, H; Nakazawa, K; Nishina, S; Sakai, K; Senoo, Y | 1 |
| Aoki, S | 1 |
| Imamura, Y | 1 |
| Abrisqueta, P; Bosch, F; Calpe, E; Carabia, J; Carpio, C; Castellví, J; Crespo, M; Palacio, C; Purroy, N | 1 |
| Blijlevens, NM; de Haan, AF; Donnelly, JP; Herbers, AH; van der Velden, WJ | 1 |
| Carey, P; Hurst, E; Jayakody Arachchillage, D; Keenan, F; Menne, T; Moses, S; O'Brien, SG; Wallis, JP | 1 |
| Bekele, N; Borthakur, G; Estey, E; Jabbour, EJ; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, WK; Ravandi-Kashani, F; Tsimberidou, AM | 1 |
| Hoang, KQ; Momin, F; Reyes, C; Satram-Hoang, S; Skettino, S | 1 |
| Dahllöf, G; Heimdahl, A; Legert, KG; Remberger, M; Ringdén, O | 1 |
| Chantepie, SP; Gac, AC; Reman, O | 1 |
| Araoka, H; Asano-Mori, Y; Hayashi, M; Ishiwata, K; Ito, T; Izutsu, K; Kaji, D; Makino, S; Masuoka, K; Matsuno, N; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Uchida, Y; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A | 1 |
| Chen, T; Fang, J; Huang, Y; Lin, X; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B | 1 |
| Burger, J; Challagundla, P; Estrov, Z; Faderl, SH; Ferrajoli, A; Jain, N; Jorgensen, J; Keating, MJ; O'Brien, SM; Strati, P; Tambaro, FP; Wierda, WG | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Bachanova, V; Blazar, BR; Cooley, S; Curtsinger, J; Defor, TE; Hippen, K; Lewis, D; McGlave, P; McKenna, DH; Miller, JS; Panoskaltsis-Mortari, A; Verneris, MR; Weisdorf, DJ; Zhang, B | 1 |
| Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY | 1 |
| Abenhardt, W; Dörfel, S; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Meyer, D; Münz, M | 1 |
| Abrahamse-Testroote, MC; Doorduijn, J; Geisler, CH; Ghidey Alemayehu, W; Itälä Remes, M; Jurlander, J; Kimby, E; Kozak, T; Polliack, A; Tjønnfjord, G; van Oers, MH; van T' Veer, MB; Walewski, J; Wittebol, S; Wu, KL | 1 |
| Morgensztern, D; Peddi, PF; Peddi, S; Santos, ES | 1 |
| Ayres, ML; Baladandayuthapani, V; El-Mabhouh, AA; Gandhi, V; Keating, MJ; Shpall, EJ; Wierda, WG | 1 |
| Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
| Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; López-Otín, C; Matas-Céspedes, A; Montraveta, A; Pérez-Galán, P; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S | 1 |
| Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Garvin, J; George, D; Geyer, MB; Hawks, R; Jin, Z; Lee, MT; Licursi, M; Morris, E; Radhakrishnan, K; Satwani, P; Schwartz, J; Smilow, E; Zuckerman, W | 1 |
| Aweeka, F; Dvorak, CC; Huang, L; Lizak, P; Long-Boyle, J | 1 |
| Jiang, C; Liu, Y; Rong, Y; Xu, K; Xu, Q; Yang, C | 1 |
| Bae, SH; Choi, JH; Joo, YD; Jung, CW; Kim, BS; Kim, H; Kim, HJ; Kim, I; Kim, MK; Kim, SH; Kwak, JY; Lee, KH; Lee, WS; Oh, S; Park, JH; Shin, HJ; Sohn, SK; Won, JH | 1 |
| Barrett, J; Childs, RW; Cho, E; Cook, L; Donohue, T; Geller, N; Khuu, H; Pantin, J; Ramos, C; Scheinberg, P; Stroncek, D; Tian, X; Vasu, S; Young, NS | 1 |
| Campos, JG; Carrillo-Cruz, E; Cuadrado, IM; De la Cruz Vicente, F; Galiana, ML; Gonzalez, JF; Marín Niebla, A; Perez-Simón, JA; Rios-Herranz, E; Rodriguez, MS; Tocino, IE | 1 |
| Brown, JR; O'Brien, SM; Porter, DL | 1 |
| Assanelli, A; Battaglia, M; Bernardi, M; Bondanza, A; Bonini, C; Bordignon, C; Carbone, MR; Carrabba, M; Ciceri, F; Clerici, D; Corti, C; Crocchiolo, R; Crotta, A; Crucitti, L; Ferraro, A; Fleischhauer, K; Forcina, A; Giglio, F; Guggiari, E; Locatelli, F; Lorusso, A; Lunghi, F; Marcatti, M; Marktel, S; Mastaglio, S; Messina, C; Noviello, M; Olek, S; Oliveira, G; Patriarca, F; Peccatori, J; Roncarolo, MG; Rossini, S; Stanghellini, MT; Tassara, M; Vago, L; Zecca, M | 1 |
| Duvignaud, JB; Gauchat, D; Godin-Ethier, J; Grandvaux, N; Hanafi, LA; Lapointe, R; Leclerc, D; Possamaï, D | 1 |
| Bence-Bruckler, I; Benner, A; Bloehdorn, J; Busch, R; Catalano, J; Dmoszynska, A; Döhner, H; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Fink, AM; Fischer, K; Geisler, CH; Hallek, M; Larratt, L; Loscertales, J; Montillo, M; Nguyen, TQ; Palermo, G; Robak, T; Rossiev, VA; Salogub, GN; Shi, X; Solal-Celigny, P; Stilgenbauer, S; Stinson, SY; Valente, N; Warzocha, K; Weisser, M; Wenger, MK; Yeh, RF; Yu, N | 1 |
| Amadori, S; Bo, MD; Bomben, R; Buccisano, F; Bulian, P; Capelli, G; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Gaidano, G; Gattei, V; Maurillo, L; Niscola, P; Pozzo, F; Ragusa, D; Rossi, D; Rossi, FM; Zucchetto, A | 1 |
| Bleesing, JJ; Chandrakasan, S; Davies, SM; Filipovich, AH; Jordan, MB; Marsh, RA | 1 |
| Giannopoulos, K; Jamroziak, K; Robak, T; Szemraj, J; Tukiendorf, A | 1 |
| Ando, T; Kamachi, K; Kimura, S; Kojima, K; Nishijima, A; Takeshita, M | 1 |
| Bartalucci, G; Bocchia, M; Candi, V; Cencini, E; Crupi, R; Defina, M; Fabbri, A; Frasconi, A; Gozzetti, A; Lauria, F; Papini, G; Raspadori, D; Schiattone, L | 1 |
| Almazi, JG; Best, OG; Christopherson, RI; Kohnke, PL; Mactier, S; Mulligan, SP | 1 |
| Bierne, H; Boulant, S; Cossart, P; Dixit, E; Durbin, AF; Franz, KM; Gehrke, L; Kagan, JC; Odendall, C; Stavru, F | 1 |
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Ugarte-Berzal, E | 1 |
| Ali, S; Olszewski, AJ; Shafqat, H | 1 |
| Al-Ahmari, A; Al-Jefri, A; Al-Musa, A; Al-Seraihy, A; Ayas, M; El-Solh, H; Khairy, A; Markiz, S; Shahin, H; Siddiqui, K | 1 |
| Andreasson, B; Bacigalupo, A; Barosi, G; Boyer, M; Goldberg, JD; Gupta, V; Hoffman, R; Isola, L; Klisovic, RB; Marchioli, R; Mascarenhas, J; Miller, C; Najfeld, V; Orazi, A; Prchal, JT; Price, LS; Prosperini, G; Rambaldi, A; Rondelli, D; Scarano, M; Shore, TB; Silverman, LR; Vannucchi, AM; Weinberg, RS; Wetzler, M | 1 |
| Hernandez, F; Jaksa, R; Klanova, M; Klener, P; Kulvait, V; Lateckova, L; Lorkova, L; Maswabi, B; Mavis, C; Molinsky, J; Petrak, J; Pospisilova, J; Trneny, M; Vejmelkova, D; Vit, O; Vockova, P; Vokurka, M | 1 |
| Bittencourt, H; Ceppi, F; Duval, M; Mallette, B; Ovetchkine, P; Teira, P; Therrien, R | 1 |
| Alam, N; Atenafu, EG; Gupta, V; Kim, DH; Kuruvilla, J; Lipton, JH; Messner, HA; Seftel, M; Shanavas, M; Uhm, J | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL | 1 |
| Awan, FT; Clemmons, AB; DeRemer, DL; Evans, S | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Cruciani, F; De Astis, E; Di Grazia, C; Galaverna, F; Ghiggi, C; Ghiso, A; Gobbi, M; Guolo, F; Lemoli, RM; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G; Raiola, AM; Varaldo, R | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Estey, EE; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, TM; Kantarjian, H; Koller, C; Luthra, R; O'Brien, S; Patel, K; Ravandi, F; Wang, X | 1 |
| Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Elmore, L; Khawaja, MR; Mumaw, CL; Nelson, RP; Orschell, C; Paczesny, S; Perkins, SM | 1 |
| Afrough, A; Hamdi, A; Hosing, CM; Lu, G; Muzzafar, T; Popat, UR; Qazilbash, MH | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Ding, K; Geng, L; Liu, H; Liu, X; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zheng, C; Zhu, X | 1 |
| Alati, C; Console, G; Cuzzola, M; Dattola, A; Fedele, R; Gallo, GA; Irrera, G; Martinello, T; Martino, M; Messina, G; Molica, S; Moscato, T; Pontari, A; Princi, D; Ronco, F | 1 |
| Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lee, HJ; O'Brien, S; Qiao, W; Wierda, W | 1 |
| Abedin, S; Choi, S; Couriel, DR; Levine, JE; Peres, E; Yanik, G | 1 |
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Almasan, A; Erzurum, SC; Hill, BT; Janocha, AJ; Sharma, A; Smith, MR | 1 |
| Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Issaragrisil, S; Jetsrisuparb, A; Meekaewkunchorn, A; Mekjaruskul, P; Pakakasama, S; Pongtanakul, B; Rujkijyanont, P; Sanpakit, K; Sirachainan, N; Songdej, D; Sruamsiri, R; Ungkanont, A | 1 |
| Avni, B; Grisariu, S; Or, R; Resnick, IB; Shapira, MY; Stepensky, P; Tsirigotis, PD | 1 |
| Chang, TY; Chen, SH; Hsueh, C; Hung, IJ; Jaing, TH; Yang, CP | 1 |
| Russo, GL; Russo, M; Spagnuolo, C | 1 |
| Gupta, V; Hamad, N; Kim, DD; Kuruvilla, J; Lipton, JH; Messner, HA; Michelis, FV; Seftel, M; Shanavas, M; Uhm, J | 1 |
| Calvo, K; Cole, K; Cuellar-Rodriguez, J; Freeman, A; Gea-Banacloche, J; Grossman, J; Hakim, F; Hickstein, DD; Holland, SM; Hughes, T; Parta, M; Zerbe, C | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC | 1 |
| Castellano, G; Dominguez, N; Fernandez, I; Manzano, ML; Martin, A; Muñoz, R | 1 |
| Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C | 1 |
| Guzailinuer, W; Li, Y; Liu, H; Maimaitili, Y; Wang, X; Xiao, M | 1 |
| Fan, L; Li, JY; Min, K; Wang, L; Wu, JZ; Xu, J; Xu, W | 1 |
| Awan, FT; Byrd, JC; Flinn, IW; Hellmann, A; Hillmen, P; Hughes, SG; Robak, T; Shannon, M; Trone, D | 1 |
| Fu, Y; Fuchs, EJ; Lin, Q; Maeda, H; Montgomery, RA; Shen, ZY; Sun, Z; Wang, Y; Warren, DS; Williams, GM | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Bassett, RL; Ciurea, S; Gulbis, A; Jabbour, E; Khouri, IF; Korbling, M; Oran, B; Popat, UR; Rondon, G; Turturro, F; Wei, W | 1 |
| Chen, T; Du, Q; Huang, Y; Lin, X; Lu, Z; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B | 1 |
| Carpenter, RO; Chen, CC; Dudley, ME; Feldman, S; Feldman, T; Goy, A; Hughes, MS; Kassim, SH; Kochenderfer, JN; Kranick, SM; Li, YF; Lu, L; Morton, KE; Nath, A; Nathan, DA; Ngo, LT; Phan, GQ; Raffeld, M; Rosenberg, SA; Sherry, RM; Somerville, RP; Spaner, DE; Stetler-Stevenson, M; Toomey, MA; Wang, ML; Yang, JC | 1 |
| Bunin, N; Heimall, J; Morsheimer, M; Oshrine, B | 1 |
| Blin, N; Brissot, E; Chevallier, P; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lodé, L; Mahé, B; Mohty, M; Moreau, P; Peterlin, P | 1 |
| Anghel, AG; Badea, M; Bleotu, C; Bordei, E; Crantea, G; Gavrilă, RI; Grecu, A; Grumezescu, AM; Holban, AM; Jercan, DA; Nicolae, BC; Tchinda, K; Vochiţoaia, GC; Voicu, G | 1 |
| Hiroshima, Y; Ichikawa, N; Kirihara, T; Kobayashi, H; Kurihara, T; Mori, Y; Sato, K; Shibazaki, M; Sumi, M; Takeda, W; Ueki, T; Ueno, M | 1 |
| Anheier, N; Bergmann, M; Busch, R; Cramer, P; Döhner, H; Dürig, J; Eichhorst, B; Fink, AM; Fischer, K; Goebeler, ME; Hallek, M; Hurtz, HJ; Langerbeins, P; Stauch, MB; Stilgenbauer, S; Wendtner, CM | 1 |
| Baker, KS; Burroughs, LM; Deeg, HJ; Delaney, C; Domm, J; Englund, JA; Flowers, ME; Giller, RH; Nemecek, ER; Rawlings, DJ; Shimamura, A; Skoda-Smith, S; Storb, R; Storer, BE; Talano, JA; Thakar, MS; Torgerson, TR; Woolfrey, AE | 1 |
| Rule, S; Seymour, JF; Shah, N; Tam, C | 1 |
| Coiteux, V; de Berranger, E; Duhamel, A; Duléry, R; Gauthier, J; Gomez, E; Langlois, C; Magro, L; Terriou, L; Yakoub-Agha, I | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Ahn, HS; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Kim, S; Lee, JW; Lee, SH; Park, JD; Park, KD; Shin, HY; Song, SH; Yu, KS | 1 |
| Andersson, BS; Champlin, RE; de Lima, MJ; Furlong, T; Jones, RJ; Kanakry, CG; Luznik, L; Medeot, M; Mielcarek, M; O'Donnell, PV; Thall, PF; Wei, W | 1 |
| Cortes, J; Do, KA; Ferrajoli, A; Kantarjian, H; Keating, MJ; Khouri, I; Lerner, S; O'Brien, S; Plunkett, W; Tam, CS; Wang, X; Wierda, W | 1 |
| Blaise, D; Chevallier, P; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Le Gouill, S; Malard, F; Milpied, N; Mohty, M; Moreau, P; Tabrizi, R; Vigouroux, S | 1 |
| Dinur-Schejter, Y; Erlich, O; Gorelik, N; Krauss, AC; Porat, I; Stein, J; Stepensky, P; Weintraub, M; Yahel, A; Zaidman, I | 1 |
| Chen, XC; Huang, XO; Li, JJ; Liu, T; Liu, ZG; Lu, ZP; Tang, Y | 1 |
| Nishikawa, H | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Divoka, M; Faber, E; Indrak, K; Langova, K; Pikalova, Z; Raida, L; Rohon, P; Rusinakova, Z; Skoumalova, I; Szotkowska, R | 1 |
| Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lerner, S; O'Brien, S; Qiao, W; Strom, SS; Trinh, L; Wang, X; Wierda, W | 1 |
| Chen, HR; Guo, Z; He, XP; Liu, XD; Lou, JX; Zhang, Y | 1 |
| Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y | 2 |
| Cox, EA; Cripe, LD; Farag, SS; Khawaja, MR; Kiel, PJ; Nelson, RP; Perkins, SM; Robertson, MJ; Sayar, H; Schwartz, JE; Vance, GH | 1 |
| Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S | 1 |
| Derks, IA; Eldering, E; Geisler, CH; Hüllein, J; Jethwa, A; Kater, AP; Lodén, M; Malcikova, J; Moerland, PD; Monsuur, H; Navrkalova, V; Oldreive, C; Pospisilova, S; Skowronska, A; Stankovic, T; Te Raa, GD; Trbusek, M; van Laar, J; van Oers, MH; Zenz, T | 1 |
| Hirabayashi, K; Koike, K; Kurata, T; Nakazawa, Y; Saito, S; Sakashita, K; Tanaka, M; Yanagisawa, R; Yoshikawa, K | 1 |
| Accornero, E; Algeri, M; Baio, A; Comoli, P; Corbella, F; Cugno, C; Del Fante, C; Giorgiani, G; Gurrado, A; Perotti, C; Pession, A; Strocchio, L; Zecca, M | 1 |
| Becker, HJ; Beckmann, L; Brinkmann, K; Fandrey, J; Frenzel, LP; Hallek, M; Huelsemann, MF; Kashkar, H; Otto, T; Pallasch, CP; Patz, M; Reinhardt, HC; Theurich, S; von Bergwelt-Baildon, M; Wendtner, CM; Zahedi, RP | 1 |
| Afanasyev, B; Baron, F; Deconinck, E; Jindra, P; Labopin, M; Mohty, M; Nagler, A; Peniket, A; Sanz, MA | 1 |
| Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Guthrie, KA; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Rezvani, AR; Sandmaier, BM; Sorror, ML; Storb, RF; Storer, BE | 1 |
| Avraham, GP; Brammer, JE; Curtin, P; Frires, R; Gajewski, J; Hayes-Lattin, B; Kovacsovics, T; Leis, JF; Maziarz, RT; Meyers, G; Nemecek, E; Palmbach, G; Slater, S; Stentz, A; Subbiah, N | 1 |
| Donaldson, SL; McGonagle, DG; Owen, RG | 1 |
| Alberti, N; Crombe, A; De Roquefeuil, E; Dousset, V; Gilles, M; Guy, A; Tourdias, T | 1 |
| Choi, YS; Jeon, YW; Kim, DY; Kim, HJ; Kim, JH; Kim, YJ; Lee, JH; Lee, JW; Lee, KH; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Bay, JO; Bilger, K; Bulabois, CE; Buzyn, A; Ceballos, P; Chevallier, P; Chevret, S; Clement, L; Cornillon, J; Dauriac, C; Françoise, S; Fürst, S; Gluckman, E; Huynh, A; Legrand, F; Maillard, N; Margueritte, G; Maury, S; Michallet, M; Michel, G; Milpied, N; Nguyen, S; Rio, B; Rocha, V; Ruggeri, A; Simon, T; Sirvent, A; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I | 1 |
| Bleesing, JJ; Davies, SM; Filipovich, AH; Haines, HL; Hornung, L; Jordan, MB; Marsh, RA | 1 |
| Assanelli, A; Bernardi, M; Carrabba, M; Ciceri, F; Claudiani, S; Corti, C; De Freitas, T; Giglio, F; Guggiari, E; Lunghi, F; Lupo-Stanghellini, MT; Marcatti, M; Marktel, S; Peccatori, J; Piemontese, S | 1 |
| Guilcher, GM; Lewis, VA; Moorjani, R; Truong, TH | 1 |
| Byrd, JC; Gordon, A; Guinn, D; Hertlein, E; Jaglowski, S; Johnson, AJ; Larson, R; Lin, TS; Maddocks, K; Marcucci, G; Ruppert, AS; Woyach, J | 1 |
| Aldrin, A; Andersson, PO; Björkstrand, B; Häggström, J; Hansson, L; Norin, S; Rommel, F; Timberg, L | 1 |
| Chen, C; Chen, Y; Ding, Y; Fu, J; Liang, A; Lu, H; Wang, W; Wu, H; Zhang, W; Zou, S | 1 |
| Hasegawa, K; Hirayama, Y; Ishihara, T; Kanagawa, M; Koyama, J; Suzuki, T; Terui, T | 1 |
| Inagaki, J; Kakuda, H; Kudo, K; Kurosawa, H; Manabe, A; Ohtsuka, Y; Sakashita, K; Watanabe, K; Yabe, H; Yabe, M; Yoshida, N | 1 |
| Foltynski, P; Ladyzynski, P; Molik, M | 1 |
| Champlin, RE; Eapen, M; Horowitz, MM; Lee, SJ; Logan, BR; Perales, MA; Rocha, V; Soiffer, RJ; Zhong, X | 1 |
| Adachi, S; Atsuta, Y; Goto, H; Hasegawa, D; Inagaki, J; Inoue, M; Ishida, H; Kato, K; Kawa, K; Koh, K; Kudo, K; Okamoto, Y; Yabe, H | 1 |
| Azzi, N; De Ville, A; Dedeken, L; Devalck, C; Ferster, A; Huybrechts, S; Massin, M; Rooze, S; Roufosse, F; Sanoussi, I; Sauvage, D | 1 |
| Błoński, JZ; Góralski, P; Hartman, M; Kiliańska, ZM; Koceva-Chyła, A; Piekarski, H; Robak, P; Robak, T; Rogalińska, M; Rogalska, A; Wawrzyniak, E | 1 |
| Chan, TS; Cheung, CY; Gill, H; Hwang, YY; Kwong, YL; Wong, IY; Yeung, IY | 1 |
| Chen, F; Chen, S; Fu, Z; Han, Y; Jin, S; Jin, Z; Liu, L; Ma, X; Miao, M; Qiu, H; Sun, A; Tang, X; Wang, X; Wu, D; Zhang, X | 1 |
| Benajiba, L; Dalle, JH; Galambrun, C; Jubert, C; Peffault de Latour, R; Salvado, C; Socié, G; Soulier, J | 1 |
| Chen, H; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH; Zhang, XH; Zhang, YY | 1 |
| Abraham, A; Benton, M; Brown, C; Chiang, KY; Dioguardi, JL; Grizzle, A; Haight, A; Hale, G; Horan, JT; Kanter, J; Kasow, KA; Nieder, M; Shelman, C | 1 |
| Araoka, H; Asano-Mori, Y; Ikebe, T; Ishiwata, K; Izutsu, K; Kon, A; Makino, S; Masuoka, K; Matsuno, N; Nakano, N; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A | 1 |
| Aljurf, MD; Arat, M; Bader, P; Boelens, JJ; Duarte, R; Faraci, M; Lawitschka, A; Peters, C; Socie, G; Tichelli, A; Veys, P; Wachowiak, J; Yaniv, I | 1 |
| Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C | 1 |
| Bollard, C; Cuellar-Rodriguez, J; Freeman, AF; Gea-Banacloche, J; Grossman, J; Hickstein, DD; Holland, SM; Kong, HH; Moutsopoulos, N; Murdock, H; Parta, M; Shah, N; Stone, K; Su, H | 1 |
| Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L | 1 |
| Baron, F; Beguin, Y; De Becker, A; Emonds, MP; Graux, C; Kerre, T; Lewalle, P; Maertens, J; Ory, A; Seidel, L; Theunissen, K; Van Gelder, M; Willems, E; Zachée, P | 1 |
| Allegrini, S; Camici, M; Chaloin, L; Cividini, F; Cros-Perrial, E; Dumontet, C; Jordheim, LP; Pesi, R; Tozzi, MG | 1 |
| Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B | 1 |
| Ariel, A; Bairey, O; Braester, A; Fineman, R; Goldschmidt, N; Herishanu, Y; Joffe, E; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shapiro, M; Shvidel, L; Tadmor, T | 1 |
| Ahmed, S; Al Atrash, G; Alousi, AM; Andersson, B; Brammer, JE; Champlin, RE; Chen, J; Ciurea, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Nieto, Y; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saliba, RM; Shah, N; Shpall, EJ | 1 |
| Iida, H; Imahashi, N; Kasai, M; Kato, C; Kato, T; Kiyoi, H; Kohno, A; Kurahashi, S; Miyamura, K; Miyao, K; Murata, M; Naoe, T; Nishida, T; Ohashi, H; Ozawa, Y; Sakemura, R; Sawa, M; Terakura, S; Watamoto, K; Yokohata, E | 1 |
| Arthur, C; Fay, K; Gifford, G; Greenwood, M; Kerridge, I; Stevenson, W; Wong, K | 1 |
| Li, BL; Li, J; Li, SX; Liu, Y; Wang, HT; Wang, TM; Zhai, B; Zhu, HL | 1 |
| Azzollini, K; Bejot, C; Bhattacharyya, PK; Chow, KF; Feldman, T; Foon, KA; Gadaleta, G; Goy, A; Howlett, C; Kdiry, S; Mato, AR; Mrkulic, M; Pascual, LN; Porter, D; Schuster, SJ; Strelec, L; Svoboda, J; Valentinetti, M; Yannotti, K; Zenreich, J | 1 |
| Brunet, S; Clapés, V; Guardia, R; Oriol, A; Piernas, S; Ribera, JM; Sierra, J; Subirà, M; Vives, S | 1 |
| Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Murray, D; Popat, U; Valdez, BC | 1 |
| Alonzo, TA; Arceci, RJ; Balis, FM; Bunin, NJ; Castleberry, RP; Cheng, JW; Cooper, TM; Emanuel, PD; Gerbing, RB; Jayaprakash, N; Liu, YL; Loh, ML; Stieglitz, E; Ward, AF; Widemann, BC | 1 |
| Aldenhoven, M; Bierings, MB; Boelens, JJ; Bonney, D; Borrill, RE; Coussons, M; Jones, SA; Mercer, J; van der Ploeg, AT; van Hasselt, PM; Versluys, B; Wijburg, FA; Wynn, RF | 1 |
| Bosman, WM; Langenberg, JC; Ritchie, ED; van den Bremer, J | 1 |
| Butler, AC; Chan, G; Fang, L; Jewell, RC; Kipps, TJ; Laubscher, KH; Lewis, E; Lindeman, R; Patton, WN; Sedoti, D; Witman, P; Zhou, YY | 1 |
| Appelbaum, FR; Bennett, JM; Byrd, JC; Claus, R; Dewald, GW; Flinn, IW; Grever, MR; Gribben, JG; Hussein, MA; Jelinek, DF; Larson, RA; Lozanski, A; Lozanski, G; Lucas, DM; Moore, DF; Neuberg, DS; Paietta, EM; Plass, C; Ruppert, AS; Tallman, MS | 1 |
| Fujieda, A; Imai, H; Katayama, N; Masuya, M; Miyazami, K; Nagaharu, K; Sugimoto, Y; Tamura, A; Umino, A; Yamaguchi, M | 1 |
| Dyer, MJ; Furman, RR; Goldstein, N; Gupta, IV; Hellmann, A; Hillmen, P; Jewell, RC; Kipps, TJ; Kozak, T; Lisby, S; Losic, N; Mayer, J; Österborg, A; Padmanabhan-Iyer, S; Phillips, JL; Piotrowska, M; Robak, T; Stilgenbauer, S; Struemper, H; Trnêný, M; Wierda, WG; Williams, CD | 1 |
| Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; Lymp, J; O'Brien, S; Pagel, JM | 1 |
| Baron, F; Beguin, Y; Daulne, C; de Bock, M; Ehx, G; Fillet, M; Gothot, A; Graux, C; Hannon, M; Humblet-Baron, S; Kerre, T; Maertens, J; Ory, A; Seidel, L; Servais, S; Willems, E | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Yoon, JH | 1 |
| Bixby, D; Braun, T; Choi, S; Churay, T; Couriel, DR; Frame, D; Goldstein, SC; Harris, A; Kitko, C; Levine, J; Li, Y; Magenau, JM; Mineishi, S; Parkin, B; Pawarode, A; Reddy, P; Riwes, MM; Yanik, G | 1 |
| Champagne, C; Farrant, P; Taylor, M | 1 |
| da Silva, AS; de Mello, LM; Koury, Cde N; Nunes, AA; Souza, KM | 1 |
| Bashey, A; Brown, SL; Connor, K; Hilton, S; Holland, HK; Morris, LE; Sanacore, M; Solomon, SR; Zhang, X | 1 |
| Andritsos, L; Brown, JR; Bühler, A; Byrd, JC; Caligaris-Cappio, F; Devin, J; Gabrilove, J; Ghia, P; Grever, MR; Hallek, M; Heerema, NA; Janssens, A; Johnson, AJ; Kipps, TJ; Lanasa, MC; Larson, RA; Leblond, V; Milligan, DW; Stilgenbauer, S | 1 |
| Best, OG; Crassini, K; Mulligan, SP; Stevenson, WS | 1 |
| Alvarez, I; Anastasia, A; Arcari, A; Bari, A; Botto, B; Carella, AM; Chiarenza, A; Dondi, A; Federico, M; Marcheselli, L; Puccini, B; Salvi, F | 1 |
| Huang, P; Li, S; Liu, Q; Wang, J; Xu, N; Zhang, F; Zhao, X | 1 |
| Blazar, BR; DeFor, TE; Dusenbery, KE; MacMillan, ML; Slungaard, A; Wagner, JE; Weisdorf, DJ; Young, JA; Zierhut, H | 1 |
| Beck, C; Dreyfus, B; Dyer, MJ; Gupta, IV; Hellman, A; Hess, G; Hillmen, P; Jewell, RC; Kozlowski, P; Lisby, S; Mayer, J; Nebot, N; Österborg, A; Pfreundschuh, M; Phillips, JL; Rizzi, R; Schetelig, J; Schuh, A; Smolej, L; Spacek, M; Wierda, WG; Williams, V | 1 |
| Bergmann, M; Wendtner, CM | 1 |
| Tsukasaki, K | 1 |
| Davis, J; Haut, P; Hayashi, R; Kothari, A; Loechelt, BJ; Murray, L; Ngwube, A; Shenoy, S | 1 |
| Iliakis, G; Magin, S; Papaioannou, M; Saha, J; Staudt, C | 1 |
| Abdel-Azim, H; Kapoor, N; Mahadeo, K; Mehta, B | 1 |
| Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ | 1 |
| Chen, P; Chen, Y; Hu, W; Li, N; Li, X; Yang, W | 1 |
| Allegrini, S; Camici, M; Cividini, F; Filoni, DN; Pesi, R; Tozzi, MG | 1 |
| Bellman, D; Bleesing, JJ; Chandra, S; Dandoy, C; Davies, SM; El-Bietar, J; Filipovich, AH; Gefen, A; Grimley, M; Jodele, S; Jordan, MB; Khandelwal, P; Kumar, AR; Leemhuis, T; Marsh, RA; Mehta, PA; Myers, KC; Rao, MB; Zhang, K | 1 |
| Alousi, A; Anderlini, P; Andreeff, M; Benton, CB; Champlin, R; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Kebriaei, P; Konopleva, M; Lu, H; McMullin, B; Nieto, Y; Parmar, S; Popat, U; Qiao, W; Rondon, G; Schober, W; Shpall, E; Thall, PF; Wang, RY; Woodworth, G; Zeng, Z | 1 |
| Amigo-Jiménez, I; García-Marco, JA; García-Pardo, A; Lozano-Santos, C; Nova-Gurumeta, S; Pérez-Sanz, N | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 2 |
| Bae, SH; Choi, Y; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Ryoo, HM | 1 |
| Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A | 1 |
| Allan, PW; Carroll, WR; Chung, TK; Clemons, L; Conry, RM; Hong, J; Hunt, FR; Lowman, D; Mannion, K; Nabell, L; Parker, WB; Richman, J; Rosenthal, EL; Sorscher, EJ | 1 |
| Assouline, S; Badoux, X; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Hourcade-Potelleret, F; McIntyre, C; Sayyed, P | 1 |
| Boyraz, MS; Çağdaş, D; Güçer, Ş; Tezcan, İ; Uçkan Çetinkaya, D; Ünal, Ş | 1 |
| Brennig, S; Czarnecki, K; Dilloo, D; Heinz, N; Heise, M; Heuser, M; Kaever, V; Kempf, H; Lachmann, N; Moritz, T; Phaltane, R; Schambach, A | 1 |
| Daimon, T; Ikegame, K; Ishii, S; Kaida, K; Kanda, Y; Kaya, H; Kodera, Y; Kurokawa, T; Maeda, Y; Ogawa, H; Okada, M; Okumura, H; Shimizu, H; Tamaki, H; Taniguchi, K; Taniguchi, S; Ueda, Y; Yoshida, T; Yoshihara, S | 1 |
| Aulitzky, W; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Lange, T; Maschmeyer, G; Morgner, A; Neugebauer, S; Niederwieser, D; Peter, N; Pönisch, W; Schäfer-Eckart, K; Schetelig, J; Schulze, A; Thiel, A; Wilhelm, M | 1 |
| Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
| Brenner, MK; Dotti, G; Heslop, HE; Huye, L; Narala, N; Ninomiya, S; Ramos, CA; Rooney, CM; Savoldo, B; Yagyu, S | 1 |
| Groeneveld, ON; Kersten, MJ; Kraan, W; Linn, C; Minnema, MC; Pals, ST; Vos, JM | 1 |
| Baranovsky, A; Bogushevich, S; Golubeva, M; Kalinichenko, E; Kulak, T; Kuzmitsky, B; Tsybulskaya, I | 1 |
| Deng, L; Guo, KY; He, YZ; Huang, YX; Lin, X; Long, H; Lu, ZG; Song, CY; Tu, SF; Wu, BY; Xu, JH | 1 |
| Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L | 1 |
| Bemer, MJ; Heimfeld, S; Mager, DE; McCune, JS; Sandmaier, BM; Storer, BE | 1 |
| Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G | 1 |
| Treon, SP | 1 |
| Bazarbachi, A; Beelen, D; Bermudez, A; Blaise, D; Fegueux, N; Hamladji, RM; Kharfan-Dabaja, MA; Kroeger, N; Labopin, M; Lioure, B; Mohty, M; Nagler, A; Or, R; Socie, G; Veelken, H | 1 |
| Abramson, J; Antin, JH; Armand, P; Barnes, J; Brown, J; Chen, YB; Cutler, C; Del Rio, C; Driscoll, J; El-Jawahri, A; Fisher, DC; Ho, VT; Hochberg, E; Jacobsen, E; Li, S; McAfee, S; Soiffer, R; Spitzer, TR; Takvorian, R | 1 |
| Asma, S; Boga, C; Kasar, M; Kozanoglu, I; Maytalman, E; Ozdogu, H; Yeral, M | 1 |
| Baba, J; Ichikawa, K; Igarashi, N; Ishikawa, D; Kagamu, H; Kondo, R; Koshio, J; Koya, T; Miura, S; Nakata, K; Narita, I; Nozaki, K; Okajima, M; Saida, Y; Sato, K; Shoji, S; Tanaka, J; Tanaka, T; Watanabe, S; Yoshizawa, H | 1 |
| Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Chammas, MJ; Cutler, CS; Glotzbecker, B; Ho, VT; Kim, HT; Koreth, J; Lange, PB; Nikiforow, S; Reynolds, CG; Ritz, J; Soiffer, RJ | 1 |
| Boga, C; Kasar, M; Kozanoglu, I; Ozdogu, H; Sariturk, C; Yeral, M | 1 |
| Mamorska-Dyga, A; Seiter, K | 1 |
| Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J | 1 |
| Bodzenta-Lukaszyk, A; Bolkun, L; Dabrowska, M; Eljaszewicz, A; Jasiewicz, M; Kaminski, K; Kloczko, J; Lapuc, I; Luksza, E; Miklasz, P; Moniuszko, M; Piszcz, J; Ptaszynska-Kopczynska, K; Rusak, M; Singh, P | 1 |
| Chocholska, S; Dmoszynska, A; Hus, M; Klimek, P; Kowal, M; Macheta, A; Podhorecka, M; Szymczyk, A | 1 |
| Baxter-Lowe, L; Bruckner, A; Cairo, MS; Chen, M; Christiano, AM; Fabricatore, S; Geyer, MB; Giller, R; Harel, S; Kandel, J; Kiuru, M; LeBoeuf, N; McGrath, J; Morel, KD; Radhakrishnan, K; Uitto, J; Umegaki, N; Woodley, D | 1 |
| Blaise, D; Ceballos, P; Chevallier, P; Cornelissen, J; Einsele, H; Gluckman, E; Holler, E; Kenzey, C; Linkesch, W; Maillard, N; Pagliuca, A; Pascal, L; Petersen, E; Rocha, V; Ruggeri, A; Sengeloev, H; Tabrizi, R; Tucunduva, L; Yakoub-Agha, I | 1 |
| Hu, W; Huang, Q; Liu, J; Qiu, L; Wang, Z; Zhou, Y | 1 |
| Anacak, Y; Aydinok, Y; Balkan, C; Delcastello, BE; Kamer, SA; Karadaş, N; Karapinar, DY; Kavakli, K | 1 |
| Alatrash, G; Andersson, BS; Champlin, R; Charafeddine, Y; Chen, J; Ciurea, S; Kebriaei, P; Lee, HC; Medeiros, LJ; Oran, B; Popat, U; Rondon, G; Saliba, RM; Shpall, E | 1 |
| Iida, S; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Masaki, A; Masuda, A; Narita, T; Ri, M; Totani, H; Yoshida, T | 1 |
| Cassin, R; Cortelezzi, A; Gaidano, G; Giannarelli, D; Orofino, N; Reda, G; Rossi, D; Sciumè, M; Vincenti, D | 1 |
| Armistead, P; Chung, Y; Coghill, J; Comeau, T; Gabriel, D; Ivanova, A; Rao, K; Sarantopoulos, S; Serody, J; Shea, TC; Sheets, J; Walko, C; Wood, W | 1 |
| Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Short, NJ; Smith, SC; Wierda, WG | 1 |
| Broers, AE; Janssen, JJ; Raymakers, R; Slot, S; Smits, K; Te Boekhorst, PA; van de Donk, NW; Witte, BI; Zweegman, S | 1 |
| Avigdor, A; Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
| Du, Q; Jiang, X; Li, Q; Meng, F; Mo, W; Wei, Y; Yu, B; Zhou, M | 1 |
| Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q | 1 |
| Derks, IA; Eldering, E; Hoogendoorn, M; Kater, AP; Laddach, N; Leeksma, AC; Loden-van Straaten, M; Luijks, DM; Moerland, PD; Navrkalova, V; Skowronska, A; Stankovic, T; te Raa, GD; Trbusek, M; van Oers, MH; Yigittop, H; Zenz, T | 1 |
| Hirano, T; Tsuji, T; Tuda, H; Yamasaki, H | 1 |
| Chan, TY; Soon, AK | 1 |
| Bulian, P; Cerri, M; Chiarenza, A; Cortelezzi, A; Coscia, M; Cuneo, A; De Paoli, L; Del Giudice, I; Del Poeta, G; Foà, R; Forconi, F; Gaidano, G; Gattei, V; Gentile, M; Ghilardi, G; Laurenti, L; Marasca, R; Massaia, M; Mauro, FR; Montillo, M; Morabito, F; Moreno, C; Motta, M; Neri, A; Perbellini, O; Rigolin, GM; Rossi, D; Tedeschi, A; Terzi-di-Bergamo, L; Vincelli, I; Visco, C; Zaja, F; Zinzani, PL | 1 |
| Alam, M; Arrey, TN; Doktorova, E; Klanova, M; Klener, P; Lorkova, L; Maswabi, B; Petrak, J; Pospisilova, J; Scigelova, M; Vit, O; Vockova, P | 1 |
| Bahlo, J; Busch, R; Chataline, V; Goede, V; Hallek, M; Kremers, S; Müller, L; Reschke, D; Schlag, R; Schmidt, B; Stilgenbauer, S; Vehling-Kaiser, U; Wedding, U | 1 |
| Bucur, S; Cohen, JB; Colbert, A; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; King, N; Langston, AA; Lechowicz, MJ; Lonial, S; Sinha, R; Waller, EK; Winton, EF | 1 |
| Ai, HS; Dong, Z; Guo, M; Hu, KX; Huang, XM; Huang, YJ; Liu, ZQ; Qiao, JH; Sun, QY; Wang, SF; Wang, Y; Yu, CL; Zuo, HL | 1 |
| Buño, I; Martinez-Laperche, C; Muñoz-Calleja, C; Perez-Chacon, G; Rebolleda, N; Somovilla-Crespo, B; Zapata, JM | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Langerbeins, P | 1 |
| Conlon, KC; Jaffe, ES; Kreitman, RJ; Pastan, I; Steinberg, SM; Stetler-Stevenson, M; Waldmann, TA; Wilson, W | 1 |
| Brown, JR; Cohen, JB; Flowers, CR; Jaye, DL; Katzen, HI; Lakhanpal, S; Leis, JF; Rosenthal, H; Sinha, R; Stock, W; Waller, EK | 1 |
| Jallad, B; Mawri, S; Nabi, S; Won, J | 1 |
| Ali, M; Chellapandian, D; Gassas, A; Krueger, J; Naqvi, A; Schechter, T; Weitzman, S | 1 |
| Boztug, H; Cant, A; Glogova, E; Lankester, A; Peters, C; Pötschger, U; Skinner, R; Slatter, M; Sykora, KW; Veys, P; Wachowiak, J; Zecca, M | 1 |
| Bruce, AJ; Chaudhry, HM; Hashmi, SK; Hogan, WJ; Kremers, WK; Litzow, MR; Patnaik, MS; Phillips, GL; Wolf, RC | 1 |
| Bethge, WA; Buechele, C; Faul, C; Federmann, B; Helwig, A; Kanz, L; Schmohl, J; Schneidawind, D; Vogel, W | 1 |
| Byrne, WL; Cummins, J; Lehouritis, P; McCarthy, FO; Murphy, CT; Reid, G; Stanton, M; Tangney, M; Urbaniak, C | 1 |
| Dai, B; Qiu, M; Su, W; Zhang, H; Zhu, M | 1 |
| Al-Ali, HK; Behre, G; Franke, GN; Hochhaus, A; Jentzsch, M; Klink, A; Niederwieser, D; Pfrepper, C; Sayer, HG; Schenk, T; Schwind, S | 1 |
| Jeon, M; Kang, YA; Kim, DY; Lee, JH; Lee, KH; Lee, YS; Seol, M | 1 |
| Alessandrino, EP; Arcese, W; Bacigalupo, A; Boschini, C; Bosi, A; Bruno, B; Busca, A; Carella, AM; Cavattoni, I; Chiusolo, P; Corradini, P; Grassi, A; Guidi, S; Marfisi, RM; Marotta, G; Masciulli, A; Micò, MC; Milone, G; Montanari, M; Mordini, N; Nagler, A; Oldani, E; Pastore, D; Patriarca, F; Pini, M; Raimondi, R; Rambaldi, A; Risitano, AM; Russo, D; Santarone, S; Saporiti, G; Scimè, R; Terruzzi, E; Torelli, GF | 1 |
| Barrett, M; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Maisel, D; Nguyen, T; Palermo, G; Robak, T; Smith, H; Weisser, M; Yeh, RF | 1 |
| Byrne, JA; Earl, JW; Fraser, CJ; Koyyalamudi, SR; Kuzhiumparambil, U; Nath, CE; O'Brien, TA; Shaw, PJ | 1 |
| Iida, H; Kato, T; Kawashima, N; Kohno, A; Kusumoto, S; Kuwatsuka, Y; Miyamura, K; Miyao, K; Mizuta, S; Morishita, Y; Murata, M; Naito, K; Nakase, K; Nishida, T; Ozawa, Y; Sao, H; Sawa, M; Taji, H; Tsurumi, H | 1 |
| Avivi, I; Ben-Barouch, S; Cohen, O; Ram, R; Vidal, L | 1 |
| Catovsky, D; Else, M; Oscier, D; Wade, R | 1 |
| Bazargan, A; Carney, DA; Cheah, CY; Filshie, R; Januszewicz, EH; Lew, TE; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M | 1 |
| Bagarolo, ML; Cacciapuoti, G; Marabotti, A; Martino, E; Porcelli, M; Scafuri, B | 1 |
| Drozdinsky, G; Erlich, O; Gorelik, N; Lamdan, R; Natsheh, J; Or, R; Simanovsky, N; Stepensky, P; Weintraub, M | 1 |
| Bahlo, J; Böttcher, S; Cramer, P; Döhner, H; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Ghia, P; Goede, V; Hallek, M; Herling, CD; Herling, M; Kneba, M; Kovacs, G; Kreuzer, KA; Langerbeins, P; Marlton, P; Maurer, C; Seymour, JF; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Delgado, D; Hege, K; Quigg, T | 1 |
| Freireich, EJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Plunkett, W; Smith, SC; Stingo, F; Tam, CS; Thompson, PA; Wierda, WG | 1 |
| Zhang, L; Zou, W | 1 |
| Ave, E; Castelli, M; Chiodin, G; Facco, M; Frezzato, F; Gattazzo, C; Giorgi, CA; Lessi, F; Martini, V; Piazza, F; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A; Zambello, R | 1 |
| Fujisawa, S; Ishibashi, D; Ishigatsubo, Y; Kawasaki, R; Koharazawa, H; Matsumoto, K; Nakajima, Y; Tachibana, T; Tanaka, M; Yamamoto, E | 1 |
| Gergis, U; Mayer, S; Parmar, S; Patel, K; Shah, S; Shore, T; van Besien, K | 1 |
| Alyea, EP; Blum, W; Carter, S; Champlin, RE; Chen, YB; Devine, SM; Giralt, S; Hars, V; Horowitz, MM; Hsu, JW; Larson, RA; Linker, C; Mulkey, F; Owzar, K; Shea, TC; Sibley, AB; Slack, J; Soiffer, RJ; Stone, RM; Vij, R | 1 |
| Annechini, G; Capria, S; D'Elia, GM; De Angelis, F; Foà, R; Pulsoni, A; Russo, E; Stefanizzi, C; Tosti, ME | 1 |
| Fuji, S; Fukuda, T; Hagiwara, S; Hatanaka, K; Hidaka, M; Ito, T; Kim, SW; Kurosawa, S; Nakamae, H; Ohashi, K; Takami, A; Yamaguchi, T; Yamashita, T; Yano, S | 1 |
| Alomari, M; Best, OG; Christopherson, RI; Haynes, PA; Jenkins, Y; Kaufman, KL; Mactier, S; Mirzaei, M; Mulligan, SP; Pascovici, D | 1 |
| Amadori, S; Bittolo, T; Bomben, R; Buccisano, F; Cefalo, M; Dal Bo, M; de Fabritiis, P; De Santis, G; Del Poeta, G; Del Principe, MI; Gaidano, G; Gattei, V; Maurillo, L; Rossi, D; Rossi, FM; Venditti, A; Zucchetto, A | 1 |
| Bahlo, J; Borsi, L; Civello, D; Eichhorst, B; Fingerle-Rowson, G; Fischer, K; Hallek, M; Kaiser, P; Kellermann, L; Mensch, A; Müller, D; Reiser, M; Stock, S; Walshe, R | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L | 1 |
| Behfar, M; Faghihi-Kashani, S; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hosseini, AS; Moin, M; Movahedi, M; Mozafari, M; Pourpak, Z | 1 |
| Bolam, S; Follows, G; Gambell, J; Hillmen, P; Jack, A; Johnson, PW; Johnson, S; Kirkwood, AA; Kruger, A; Linch, D; Pocock, C; Rule, S; Seymour, JF; Smith, P; Toncheva, M; Walewski, J | 1 |
| Bhargava, S; Chakrabarti, A; Chakrabarti, S; Chatterjee, S; Jaiswal, SR; O'Donnell, P; Ray, K | 1 |
| Berrebi, A; Shvidel, L | 1 |
| Davies, SM; Filipovich, AH; Jodele, S; Lane, A; Marsh, RA; Mehta, PA; Neumeier, L | 1 |
| Balser, C; Barth, J; Blau, W; Boeck, HP; Brugger, W; Hahn, L; Hinke, A; Kaiser, U; Kauff, F; Losem, C; Mueller, L; Niederle, N; Rummel, M; Sandherr, M; Stauch, M; Vereshchagina, J; von Gruenhagen, U; Weidmann, E; Welslau, M | 1 |
| Agathangelidis, A; Baliakas, P; Belessi, C; Blakemore, SJ; Chiorazzi, N; Clifford, R; Cortese, D; Davi, F; Gaidano, G; Ghia, P; Höglund, M; Juliusson, G; Kotaskova, J; Langerak, AW; Ljungström, V; Mansouri, L; Ntoufa, S; Oscier, D; Panagiotidis, P; Pandzic, T; Plevova, K; Pospisilova, S; Pott, C; Rosenquist, R; Rossi, D; Schuh, A; Sjöblom, T; Smedby, KE; Stamatopoulos, K; Stavroyianni, N; Strefford, JC; Sutton, LA; Trentin, L; Young, E | 1 |
| Biemond, BJ; Cornelissen, JJ; Graux, C; Hazenberg, CL; Kuball, J; Löwenberg, B; Maertens, J; Ossenkoppele, G; Pabst, T; Passweg, JR; Schouten, HC; Theobald, M; van Putten, WL; Vellenga, E; Versluis, J | 1 |
| Andronescu, E; Geanaliu-Nicolae, RE; Iordache, F; Pîrvan, AA; Voicu, G | 1 |
| Aytaç Eyüboğlu, S; Bayhan, T; Çetin, M; Gümrük, F; Kuşkonmaz, B; Tavil, B; Uçkan Çetinkaya, D; Ünal, Ş | 1 |
| Barkholt, L; Ericzon, BG; Mattsson, J; Omazic, B; Potácová, Z; Remberger, M; Ringdén, O; Söderdahl, G; Wersäll, P | 1 |
| Ahmadzadeh, A; Khodadadi, A; Saki, G; Teimoori, A; Valizadeh, A | 1 |
| Du, H; Jing, Y; Lu, W; Luan, Z; Tang, X; Wu, N; Xu, S; Zhang, B | 1 |
| Chen, J; Ding, L; Li, B; Li, Q; Luo, C; Wang, J | 1 |
| Breuer, A; Dürig, J; Gigel, C; Herling, M; Mayer, P; Möllmann, M; Stiefelhagen, M; Vasyutina, E | 1 |
| Chang, W; Chen, F; Fu, C; Jin, Z; Ma, X; Miao, M; Qiu, H; Ruan, C; Sun, A; Tang, X; Wu, D; Xue, S | 1 |
| Appelbaum, FR; Carpenter, PA; Flowers, ME; Furlong, T; Martin, PJ; McCune, JS; Mielcarek, M; O'Donnell, PV; Storb, R; Storer, BE | 1 |
| Andersson, PO; Chang, CN; Daly, S; Gorczyca, M; Grosicki, S; Gupta, I; Kaplan, P; Kryachok, I; Kulyaba, Y; Lisby, S; Mazur, G; Middeke, JM; Montillo, M; Österborg, A; Rekhtman, G; Schuh, A; Steurer, M; Udvardy, M; Zaritskey, A | 1 |
| Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Cooney-Qualter, E; Fabricatore, S; Harrison, L; Kletzel, M; Luisi, P; Militano, O; Morris, E; Ricci, A; Roy, S; van de Ven, C; Wolownik, K; Zahler, S | 1 |
| Adachi, K; Hirabayashi, K; Koike, K; Nakazawa, Y; Nanba, E; Saito, S; Sakai, N; Sakashita, K; Shibazaki, T; Shigemura, T; Shiohara, M; Takagi, M | 1 |
| Aoki, J; Fujii, E; Ishigatsubo, Y; Kanamori, H; Matsumoto, K; Tanaka, M; Yamamoto, E; Yamamoto, W | 1 |
| Brown, M; Myers, D; Radhi, M; Rahmetullah, R; Shreve, N | 1 |
| Li, H; Li, Z; Liu, H; Liu, W; Lü, R; Qiu, L; Xiong, W; Yi, S; Zou, D | 1 |
| Chen, J; Hu, J; Huang, H; Huang, X; Jin, J; Li, J; Li, Y; Liang, Y; Ma, J; Sun, Y; Wang, C; Wang, J; Wang, L; Wu, D; Xiao, Y; Yu, K | 1 |
| Abramovici, O; Carlos Molano, L; Cuvelier, A; Darmon, A; Duval-Modeste, AB; Louvel, JP; Muir, JF; Piton, N | 1 |
| Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R | 1 |
| Hoshino, A; Ikegame, K; Imai, K; Inoue, T; Kaida, K; Kanegane, H; Morio, T; Ogawa, H; Okada, M; Soma, T; Tamaki, H; Yamashita, M | 1 |
| Ishiyama, K; Kawabata, H; Kitano, T; Kondo, T; Sugimoto, N; Takaori-Kondo, A; Takeda, J | 1 |
| Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Harbi, S; Lemarie, C; Vey, N; Wanquet, A; Weiller, PJ | 1 |
| Goto, H; Goto, S; Yokosuka, T | 1 |
| Ichinohe, T; Iida, H; Kako, S; Kanamori, H; Kanda, Y; Kato, C; Koh, H; Maeda, T; Mori, T; Nakao, S; Onishi, Y; Onizuka, M; Ozawa, Y; Suzuki, R; Yamazaki, H | 1 |
| Han, HJ; Lu, YW; Xia, RX | 1 |
| Calvieri, S; Cantisani, C; Giustini, S; Iacovino, C; Miraglia, E | 1 |
| Ding, K; Geng, L; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zhang, L; Zhang, X; Zheng, C; Zhu, X | 1 |
| Assouline, S; Badoux, X; Berthillon, N; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Li, S; McIntyre, C; Sayyed, P; Trneny, M | 1 |
| Bermúdez, A; Caballero, MD; Cabrero, M; Conde, E; De La Serna, J; Gómez, V; Lahuerta, JJ; Moraleda, JM; Perez, SG; Sanz, G; Sanz, J; Serrano, D; Vallejo, C | 1 |
| Akhtar-Ali, M; Ban, K; Baumann, T; Blakemore, SJ; Campo, E; Clifford, R; He, L; Hellström, AR; Hellström, M; Kundu, S; Larsson, J; Ljungström, V; Lopez-Guillermo, A; Mansouri, L; Pandzic, T; Rosenquist, R; Schuh, A; Sjöblom, T; Strefford, JC | 1 |
| Alchalby, H; Ayuk, F; Cassinat, B; Christopeit, M; Kröger, N; Peffault de Latour, R; Porcher, R; Robin, M; Sicre de Fontbrune, F; Socié, G; Wolschke, C; Zabelina, T | 1 |
| Becker, U; Hautala, A; Kyttälä, M; Martikainen, J; Poikonen, E; Soini, E | 1 |
| Alexandrova, IY; Grishina, GV; Kozlov, VA; Makarov, SV; Minaev, YL; Mishchenko, OV; Rossiev, VA; Semagina, OV | 1 |
| Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Kowalczyk, P; Maciejewski, H; Misiewicz, M; Ostrowska, K; Voit, B | 1 |
| Annechini, G; Argnani, L; Broccoli, A; Casadei, B; De Renzo, A; Gandolfi, L; Morigi, A; Pellegrini, C; Pulsoni, A; Quirini, F; Stefoni, V; Tonialini, L; Zinzani, PL | 1 |
| Chadwick, H; Counsell, N; Evans, K; Johnson, RJ; Pottinger, BT; Rudin, CE; Smith, P; Townsend, W; Wickham, C | 1 |
| Hong, DS; Ji, YS; Kim, CK; Kim, HJ; Kim, KH; Kim, SH; Lee, KT; Lee, MS; Min, CW; Park, SK; Won, JH; Yun, J | 1 |
| Böhme, A; Dreyling, M; Fries, S; Höhler, T; Kellermann, L; Kiewe, P; Zoellner, AK | 1 |
| Alousi, AM; Anderlini, P; Champlin, RE; Fanale, MA; Hagemeister, FB; Hosing, CM; Khouri, IF; Ledesma, C; Neelapu, S; Nieto, Y; Oki, Y; Plair, T; Popat, UR; Romaguera, JE; Saliba, RM; Shpall, EJ; Younes, A | 1 |
| Barré, L; Dhilly, M; Guillouet, S; Hovhannisyan, N; Leporrier, M | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Miglino, M; Minetto, P; Pastori, G; Rebesco, B; Sessarego, M | 1 |
| Ahn, HS; Cho, B; Chung, NG; Hong, KT; Im, HJ; Jung, HJ; Kang, HJ; Kim, H; Kim, HK; Kim, SY; Koh, KN; Koo, HH; Lee, JH; Lee, JW; Lee, SH; Lee, YH; Lim, YJ; Lim, YT; Park, JA; Park, JE; Park, KD; Park, SK; Ryu, KH; Seo, JJ; Shin, HY; Sung, KW; Yoo, ES; Yoo, KH | 1 |
| Brundage, R; Brunstein, CG; Cao, Q; Jacobson, PA; Jensen, K; Kirstein, MN; Kurtzweil, A; Long-Boyle, J; Rogosheske, J; Sanghavi, K; Wagner, J; Warlick, ED; Weisdorf, DJ; Wiseman, A | 1 |
| Castejon, R; Losada-Fernandez, I; Martinez, A; Morado, M; Perez-Aciego, P; Perez-Chacon, G; Rebolleda, N; Rosado, S; Vallejo-Cremades, MT; Vargas-Nuñez, JA | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Kim, DY; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M | 1 |
| Campion, L; Chevallier, P; Delaunay, J; Duquesne, A; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Mohty, M; Moreau, P; Peterlin, P | 1 |
| Bachanova, V; Devine, SM; Fenske, T; Gersten, I; Horowitz, M; Hosing, C; Laport, GG; Lazarus, HM; Logan, B; Longo, W; Nademanee, A; Riches, ML; Wu, J | 1 |
| Bahlo, J; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kovacs, G; Langerbeins, P; Maurer, C; Müller, L; Pflug, N; Ritgen, M; Seiler, T; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Boubaya, M; Choquet, S; Delmer, A; Dupuis, J; Le Gouill, S; Leblond, V; Levy, V; Ouzegdouh, M; Pégourié-Bandelier, B; Souchet, L; Tamburini, J; Tournilhac, O; Vargaftig, J | 1 |
| Deng, L; Huang, QX; Huang, R; Huang, YX; Li, YH; Song, CY; Tu, SF; Wu, BY | 1 |
| Gao, ZY; Li, WD; Lu, DP; Lu, DY; Yu, XJ | 1 |
| Artz, A; Bredeson, C; Burkart, J; DiPersio, J; Fernandez, HF; Kamishohara, M; Le-Rademacher, J; Mehta, J; Mineishi, S; Nakamura, Y; Pasquini, MC; Ratanatharathorn, V; Sobecks, R; Zhu, X | 1 |
| Aye, Y; Blessing, WA; Fletcher, EA; Li, M; Long, MJ; Weiss, RS; Wisitpitthaya, S; Zhao, Y | 1 |
| Choi, ES; Im, HJ; Jang, S; Koh, KN; Kwon, SW; Lee, SW; Park, CJ; Seo, JJ; Suh, JK | 1 |
| Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC | 1 |
| Chan, KW; Chaudhury, S; Douglas, D; Gilman, AL; Hale, GA; Haut, P; Hayashi, RJ; Kasow, KA; Madden, LM; Murray, LM; Pulsipher, MA; Shenoy, S | 1 |
| Bahlo, J; Böttcher, S; Busch, R; Döhner, H; Eichhorst, B; Fink, AM; Fischer, K; Gregor, M; Hallek, M; Kiehl, M; Klapper, W; Kneba, M; Köchling, G; Köppler, H; Kovacs, G; Kreuzer, KA; Lange, E; Maurer, C; Plesner, T; Plöger, C; Schlag, R; Sökler, M; Stilgenbauer, S; Trneny, M; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Arana Echarri, A; Beyaert, M; Bol, V; Bontemps, F; Michaux, L; Saussoy, P; Smal, C; Starczewska, E; Van Den Neste, E; Vekemans, MC | 1 |
| Bendell, J; Brown, JR; Derks, IA; Eichhorst, B; Eldering, E; Fernandes, SM; Filvaroff, EH; Garrick, B; Hallek, M; Hege, K; Kater, AP; Kersten, MJ; Michot, JM; Reinhardt, HC; Rodríguez, MS; Ter Burg, J; Thijssen, R; Trowe, T; van Bochove, GG; van Kampen, RJ | 1 |
| Adams, S; Allwood, Z; Amrolia, P; Chiesa, R; Lucchini, G; Qasim, W; Rao, K; Silva, J; Veys, P; Worth, A | 1 |
| Akiyama, K; Aoki, T; Arakawa, Y; Hanada, R; Ikeda, Y; Koh, K; Mori, M; Sekinaka, Y | 1 |
| Brown, JR; Hallek, MJ; Pagel, JM | 1 |
| Aleric, I; Bakovic, M; Bilic, E; Ceovic, R; Curtis, LM; Delimar, V; Desnica, L; Milos, O; Nemet, D; Pavletic, SZ; Pulanic, D; Pulanic, TK; Seiwerth, RS; Stipetic, MM; Vrhovac, R | 1 |
| Kay, BK; Koduvayur, SP; Lavie, A; Su, Y | 1 |
| Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Li, Y; Liu, Y; Murray, D; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Baxter-Lowe, LA; Cairo, MS; Dalal, R; Dozor, AJ; Fabricatore, S; Harrison, L; Jin, Z; Majzner, R; Morris, E; Sandoval, C; van de Ven, C; Wolownik, K | 1 |
| Becker, U; Briggs, AH; Moreno, SG; Ngo, P; Ray, JA; Samanta, K | 1 |
| Asano-Mori, Y; Ishiwata, K; Izutsu, K; Kageyama, K; Kaji, D; Makino, S; Masuoka, K; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A; Yuasa, M | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Cebula-Obrzut, B; Franiak-Pietryga, I; Kaczmarek, A; Klajnert-Maculewicz, B; Maciejewski, H; Robak, T; Smolewski, P; Voit, B; Ziemba, B; Ziółkowska, E | 1 |
| Ayala, E; Kharfan-Dabaja, MA; LaFave, D; Nishihori, T | 1 |
| Bahlo, J; Busch, R; Eichhorst, B; Fischer, K; Hallek, M; Hensel, M; Hess, G; Hopfinger, G; Kutsch, N; Maria Fink, A; Mayer, J; von Grünhagen, U; Wendtner, CM | 1 |
| Altenhofer, P; Andel, J; Burcoveanu, C; Burgstaller, S; Doubek, M; Egle, A; Flochová, E; Fridrik, M; Gercheva, L; Girschikofsky, M; Greil, R; Hrubiško, M; Jäger, U; Klingler, A; Kozák, T; Králiková, E; Ladická, M; Mayer, J; Melchardt, T; Mihaylov, G; Mikušková, E; Nösslinger, T; Obrtlíková, P; Oexle, H; Palášthy, S; Papajík, T; Pecherstorfer, M; Petzer, A; Pleyer, L; Raynov, J; Smolej, L; Spasov, E; Stehlíková, O; Steurer, M; Zabernigg, A | 1 |
| Andou, T; Fujisawa, S; Hagihara, M; Ishii, Y; Itabashi, M; Koyama, S; Matsumoto, K; Motohashi, K; Numata, A; Yamamoto, W | 1 |
| Chinratanalab, W; Engelhardt, BG; Goodman, SA; Greer, JP; Jagasia, M; Kassim, AA; Kennedy, VE; Savani, BN; Sengsayadeth, S | 1 |
| Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL | 1 |
| Vargas Núñez, JA | 1 |
| Hogan, JJ; Weiss, BM | 1 |
| Hawkes, N | 2 |
| Katsanis, E; Kopp, LM; Pelayo-Katsanis, L; Sapp, LN; Whitney, K; Zeng, Y | 1 |
| Antin, JH; Armand, P; Caballero, D; Cabrero, M; Esquirol, A; Kekre, N; Lopez-Corral, L; Marquez-Malaver, FJ; Martino, R; Pérez-Simon, JA; Piñana, J; Soiffer, RJ; Solano, C; Terol, MJ | 1 |
| Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY | 1 |
| Hey, SP; Kesselheim, AS | 1 |
| Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J | 1 |
| Borsky, M; Brychtova, Y; Bryja, V; Collakova, J; Dzimkova, M; Hylse, O; Janovska, P; Jaskova, Z; Kasparkova, M; Kohoutek, J; Oltova, A; Paruch, K; Trbusek, M; Verner, J; Vesely, P; Zaprazna, K; Zemanova, J | 1 |
| Cao, H; Chen, G; Ding, J; Li, J; Pang, N; Qu, J; Wang, L; Yuan, H; Zhang, R; Zhang, Z; Zhao, F | 1 |
| Ahmed, S; Alatrash, G; Anderlini, P; Bassett, RL; Burger, JA; Ciurea, SO; Ferrajoli, A; Gulbis, AM; Jabbour, EJ; Jorgensen, JL; Kadia, TM; Khouri, IF; Ledesma, C; Marin, D; Medeiros, LJ; Olson, A; Oran, B; Patel, KK; Popat, UR; Samuels, BI; Sui, D; Turturro, F | 1 |
| Berger, C; Chaney, C; Chen, X; Cherian, S; Hanafi, LA; Hawkins, R; Heimfeld, S; Hudecek, M; Li, D; Maloney, DG; Pender, B; Riddell, SR; Robinson, E; Soma, L; Turtle, CJ; Wood, B | 1 |
| Allsup, D; Bloor, A; Collett, L; Hillmen, P; Hockaday, A; Howard, DR; Munir, T; Oughton, JB; Phillips, D; Rawstron, AC | 1 |
| Ayres, ML; Balakrishnan, K; Burger, JA; Cortes, JE; Ferrajoli, A; Gandhi, V; Jain, N; Kadia, TM; Keating, MJ; O'Brien, SM; Tambaro, FP; Wierda, WG | 1 |
| Cheng, H; Hu, X; Li, R; Lv, S; Song, X; Wang, J; Wang, L; Yang, J; Zhang, W | 1 |
| Chen, YY; Fan, L; Hong, M; Li, JY; Miao, KR; Miao, YQ; Qian, SX; Wang, L; Wu, W; Xia, Y; Xie, Y; Xu, W; Yu, H; Zhao, HH; Zhu, H; Zhu, HY; Zhu, Y | 1 |
| Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kastritis, E; Kyrtsonis, MC; Migkou, M; Mpakiri, M; Roussou, M; Tasidou, A; Terpos, E; Vassilakopoulos, TP | 1 |
| Abdulkadyrov, K; Błoński, JZ; Carey, JL; Chang, CN; Gorczyca, MM; Govind Babu, K; Grosicki, S; Gupta, IV; Homenda, W; Kryachok, I; Kuliczkowski, K; Kulyaba, Y; Kłoczko, J; Lisby, S; Loscertales, J; McKeown, A; Rekhtman, G; Robak, T; Warzocha, K | 1 |
| Bay, JO; Beckerich, F; Blaise, D; Bourhis, JH; Bulabois, CE; Chevallier, P; Contentin, N; Daguindau, E; de La Tour, RP; Delage, J; Detrait, M; François, S; Guillaume, T; Guillerm, G; Huynh, A; Labopin, M; Legrand, F; Lioure, B; Maillard, N; Mohty, M; Turlure, P; Vigouroux, S; Yakoub-Agha, I | 1 |
| Choe, HK; Gergis, U; Mayer, SA; Nagar, H; Phillips, AA; Shore, TB; Smith, MJ; van Besien, K | 1 |
| Babu, V; Biersack, B; Bloehdorn, J; Chessa, L; Crispatzu, G; Efremov, DG; Hallek, M; Herling, CD; Herling, M; Knittel, G; Lohmann, G; Mayer, P; Muenzner, JK; Prinz, C; Reinart, N; Reinhardt, HC; Schneider, JI; Schobert, R; Schumacher, B; Stilgenbauer, S; Vasyutina, E | 1 |
| Bonfigli, S; Careddu, MG; Coppola, L; Dessì, L; Dore, F; Dore, S; Fozza, C; Giannico, DB; Longinotti, M; Longu, F; Nieddu, RM; Pardini, S; Podda, L; Sotgiu, G | 1 |
| Bittenbring, J; Ganser, A; Hallek, M; Huynh, A; Kröger, N; Labopin, M; Malard, F; Michallet, M; Mohty, M; Nagler, A; Savani, BN; Schmid, C; Stuhler, G; Tischer, J | 1 |
| Abdulkadyrov, K; Bal, V; Błoński, JZ; Chang, CN; Govind Babu, K; Grosicki, S; Gupta, IV; Homenda, W; Kryachok, I; Kuliczkowski, K; Kulyaba, Y; Kłoczko, J; Lisby, S; Loscertales, J; McKeown, A; Rekhtman, G; Robak, T; Warzocha, K | 1 |
| Beyer, M; Dietrich, S; Göder, A; Heinzel, T; Kiweler, N; Krämer, OH; Linnebacher, M; Mahboobi, S; Mahendrarajah, N; Nikolova, T; Rauch, A; Reich, TR; Schäfer, C; Schneider, G; Sellmer, A; Sonnemann, J; Stojanovic, N; Tomicic, MT; Wieczorek, M | 1 |
| Aurran-Schleinitz, T; Birsen, R; Bonnet, C; Boubaya, M; Choquet, S; Cymbalista, F; Delarue, R; Dietrich, PY; Dupuis, J; Fahri, J; Lamy, T; Leblond, V; Lemal, R; Lepretre, S; Levy, V; Michallet, AS; Re, D; Troussard, X; Wanquet, A; Ysebaert, L | 1 |
| Belsito, V; Carella, AM; Cortellezzi, A; Cuneo, A; De Propris, MS; Ferretti, A; Foà, R; Guarini, AR; Liberati, AM; Marinelli, M; Mauro, FR; Molica, S; Nanni, M; Orlando, SM; Paoloni, F; Rizzi, R; Spriano, M; Tosi, P; Vignetti, M; Zaja, F | 1 |
| Crazzolara, R; Haas, OA; Kager, L; Kropshofer, G; Matthes-Martin, S | 1 |
| Appelhans, D; Bednarek, M; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Maciejewski, H; Misiewicz, M; Ostrowska, K; Ziemba, B | 1 |
| Ikegame, K; Inoue, T; Ishii, S; Kaida, K; Kojima, H; Kusunoki, Y; Ogawa, H; Okada, M; Saji, H; Soma, T; Tamaki, H; Yoshihara, K; Yoshihara, S | 1 |
| Celeghin, A; De Rossi, A; Dolcetti, R; Freguja, R; Giunco, S; Nalio, S; Zangrossi, M | 1 |
| Coelho, R; Flagg, A; Gonzalez, BE; Hanna, R; Harrington, S; Kusick, K; Ondrejka, S; Procop, GW; Stempak, LM; Zembillas, A | 1 |
| Bruzzese, D; Busiello, T; Cesaro, E; Chiurazzi, F; Ciano, M; Costanzo, P; Fiammetta Romano, M; Garofalo, O; Romano, S; Simeone, L; Sodaro, G | 1 |
| Damiani, D; Geromin, A; Tiribelli, M | 1 |
| Chandra, S; Emoto, C; Fukuda, T; Khandelwal, P; Marsh, RA; Mehta, PA; Neumeier, L; Teusink-Cross, A; Vinks, AA | 1 |
| Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; Domingo-Domenech, E; Escoda, L; Estany, C; Fernández de Sevilla, A; Gardella, S; González-Barca, E; López-Guillermo, A; Magnano, L; Montoto, S; Moreno, C; Muntañola, A; Oriol, A; Pedro, C; Ribera, JM; Salar, A; Sancho, JM; Vivancos, P | 1 |
| Abounader, DM; Andresen, S; Bolwell, BJ; Dean, R; Ferraro, C; Gerds, AT; Hamilton, BK; Hanna, R; Hill, BT; Kalaycio, M; Liu, H; Majhail, NS; Mustafa Ali, M; Pohlman, B; Rybicki, LA; Sobecks, RM; Starn, J; Winslow, V; Yurch, MA | 1 |
| Blaise, D; D'Aveni-Piney, M; Daguindeau, E; Diez-Martin, JL; Hamladji, RM; Irrera, G; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Richard, C; Rubio, MT; Santarone, S; Sanz, MA; Savani, BN; Yakoub-Agha, I; Yeshurun, M | 1 |
| Clavio, M; Gobbi, M; Guolo, F; Lemoli, RM; Miglino, M; Minetto, P | 1 |
| Baker, KS; Boulad, F; Davies, SM; Guinan, E; Kernan, NA; Lane, A; Leemhuis, T; Lehmann, L; Margolis, D; Mehta, PA; Myers, K; O'Reilly, RJ; Prockop, SE; Scaradavou, A; Williams, DA | 1 |
| Daly, A; Geddes, M; Lam, W; Li, H; Storek, J | 1 |
| Bigley, V; Collin, M; Craddock, C; Dickinson, AM; Green, K; Jackson, G; Jardine, L; Mackinnon, S; Nagra, S; Nicolson, PLR; Pearce, K; Peggs, KS; Sellar, RS; Thomson, K | 1 |
| Bloor, A; Blundell, J; Fegan, C; Gribben, JG; Hamblin, M; Hillmen, P; Hockaday, A; Howard, DR; McParland, L; Munir, T; Pettitt, A; Phillips, D; Pocock, C; Rawstron, AC; Varghese, A | 1 |
| Cairoli, R; Greco, R; Grillo, G; Mancini, V; Marbello, L; Molteni, A; Ravano, E; Riva, M; Zucchetti, E | 1 |
| Ali, M; Courtney, S; Krueger, J; Lowry, J; Ramzan, M; Schechter Finkelstein, T | 1 |
| Ball, LM; Bresters, D; Fiocco, M; Louwerens, M; van Doorn, R; Wanders, DCM | 1 |
| Bendall, L; Bradstock, KF; Hart, D; Hsu, WH; Mattar, Z; Shahin, K; Silveira, P | 1 |
| Ayala, A; Cabanillas, F; Fanale, MA; Fayad, L; Feng, L; Fowler, NH; Goy, AH; Hagemeister, FB; McLaughlin, P; Nastoupil, LJ; Neal, E; Neelapu, SS; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, M; Westin, JR | 1 |
| Becker, U; Miguel, LS; Paquete, AT; Pereira, C; Pinto, CG | 1 |
| Go, RS; Kay, NE; Winters, JL | 1 |
| Arechaga, I; Bravo-Navas, S; Cabezas, M; Cabezón, E; Pipaón, C; Sánchez-Carrera, D; Yáñez, L | 1 |
| Jin, JG | 1 |
| Alyea, EP; Bashey, A; Deeg, HJ; Devine, SM; Fernandez, HF; Geller, NL; Giralt, S; Hamadani, M; Horowitz, MM; Horwitz, ME; Le-Rademacher, J; Leifer, E; Logan, BR; Maziarz, RT; Mendizabal, AM; Pasquini, MC; Porter, DL; Scott, BL; Warlick, ED; Wu, J | 1 |
| Ashida, A; Ashida, T; Enomoto, A; Hamada, S; Matsunaga, K; Miki, H; Mukai, T; Torihata, S; Uchihashi, T; Yasumoto, M; Yasutake, N | 1 |
| Abedi-Valugerdi, M; Benkessou, F; Hassan, M; Zhao, Y; Zheng, W | 1 |
| Cros-Perrial, E; Dumontet, C; Jordheim, LP; Lefebvre-Tournier, I; Peyrottes, S; Puy, JY | 1 |
| Boelens, JJ; Egas, AC; Langenhorst, JB; Punt, AM; van Kesteren, C; van Maarseveen, EM | 1 |
| Afanasyev, B; Bethge, W; Brand, R; de Witte, T; Deliliers, GL; Dreger, P; Franke, GN; Guidi, S; Günther, A; Heim, D; Hübel, K; Iacobelli, S; Kobbe, G; Kröger, N; Onida, F; Pini, M; Platzbecker, U; Poiré, X; Robin, M; Scheid, C; Stelljes, M; Uddin, R; van Os, M; Volin, L; Weber, T | 1 |
| Ansell, SM; Burnette, BL; Colgan, JP; Epperla, N; Habermann, TM; Inwards, DJ; Johnston, PB; Macon, WR; Markovic, SN; Micallef, IN; Nowakowski, GS; Pham, AQ; Porrata, LF; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
| Barré, L; Dhilly, M; Fidalgo, M; Fillesoye, F; Guillouet, S; Hovhannisyan, N; Sola, B | 1 |
| Chaudhry, HM; Mauermann, ML; Rajkumar, SV | 1 |
| Abraham, A; Balasubramanian, P; Edison, ES; Fouzia, NA; George, B; Korula, A; Lakshmi, KM; Mathews, V; Mohanan, E; Panetta, JC; Srivastava, A; Viswabandya, A | 1 |
| Borthakur, G; Cortes, J; Daver, N; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, HM; Ohanian, M; Oran, B; Pemmaraju, N; Ragon, BK; Ravandi, F | 1 |
| Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 2 |
| Alousi, A; Burke, E; Cao, K; Champlin, R; Chen, J; de Lima, M; Hosing, C; Kaur, I; Kebriaei, P; Marin, D; Mehta, RS; Olson, A; Oran, B; Parmar, S; Popat, U; Rezvani, K; Saliba, RM; Shah, N; Shpall, EJ; Skerrett, D | 1 |
| Chaiwangyen, W; Daher, S; Markert, UR; Morales-Prieto, DM; Ospina-Prieto, S; Pereira de Sousa, FL; Photini, SM; Sass, N; Schleussner, E; Weber, M | 1 |
| Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC | 1 |
| Baculea, S; Cote, S; Diels, J; Van Sanden, S | 1 |
| Abraham, A; Cluster, A; Delgado, D; Hulbert, ML; Jacobsohn, D; Kukadiya, D; Murray, L; Shenoy, S | 1 |
| Chauffaille, MLLF; Fonseca, ARBMD; Goncalves, MV; Guedes, NR; Lacerda, MP; Pereira, AD; Rodrigues, CA; Yamakawa, PE; Yamamoto, M | 1 |
| Cheng, L; Feng, Z; Li, H; Ni, W; Pan, X; Tang, Q; Zheng, W | 1 |
| Curry, JL; Khan, M; Naqvi, K; Siddiqi, R | 1 |
| Apel, A; Bernardi, M; Bonini, C; Ciceri, F; Danylesko, I; Greco, R; Lo Russo, A; Lupo Stanghellini, MT; Nagler, A; Peccatori, J; Shem-Tov, N; Shimoni, A; Vago, L; Yerushalmi, R | 1 |
| Brierley, CK; Eyre, TA | 1 |
| Austin, E; Burt, DJ; Byatte, AJ; Chester, KA; Gilham, DE; Guest, RD; Halford, SER; Hawkins, RE; Kirillova, N; Nabarro, S; Pillai, M; Rothwell, DG; Sharma, SK; Thistlethwaite, FC; Valle, JW; Wan, S; Westwood, NB | 1 |
| Aweeka, F; Chan, D; Cowan, MJ; Dvorak, CC; Huang, L; Ivaturi, V; Jennissen, C; Liu, T; Long-Boyle, J; Orchard, PJ; Pai, SY; Stricherz, M; Tolar, J; Wahlstrom, J | 1 |
| Chan, KW; De Oliveira, S; Eapen, M; Fei, M; Hattersely, G; Horowitz, MM; Kurtzberg, J; Mendizabal, A; Schultz, KR; Wagner, JE; Wall, D; Zhang, MJ | 1 |
| Buxhofer-Ausch, V; Geissler, K; Girschikofsky, M; Gleixner, K; Herndlhofer, S; Hoermann, G; Jaeger, U; Knoebl, P; Kundi, M; Machherndl-Spandl, S; Poehnl, R; Sliwa, T; Sperr, WR; Strecker, K; Valent, P; Weltermann, A | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L | 2 |
| Barker, JN; Boulad, F; Castro-Malaspina, H; Fuller, K; Hilden, PD; Hsu, KC; Jakubowski, AA; Kernan, NA; Koehne, G; O'Reilly, RJ; Papadopoulos, EB; Perales, MA; Prockop, SE; Scaradavou, A; Spitzer, B; van den Brink, MR; Young, JW | 1 |
| Billingham, L; Brock, K; Copland, M; Siddique, S; Sirovica, M; Yap, C | 1 |
| Anand, S; Chao, NJ; Corbet, K; Gasparetto, C; Horwitz, ME; Long, GD; Lopez, R; Morris, AK; Rizzieri, DA; Sarantopoulos, S; Sullivan, KM; Sung, AD; Thomas, S | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Jander, M; Maciejewski, H; Robak, T; Treliński, J; Voit, B; Ziemba, B | 1 |
| Delaney, C; Gammill, H; Kanaan, SB; Milano, F; Nelson, JL; Oliver, DC | 1 |
| Connolly, EC; Dhere, V; Edelman, S; Esiashvili, N; Graiser, M; Khan, MK; Langston, A; Switchenko, JM; Waller, EK | 1 |
| Chen, X; Guo, N; Liu, Y; Lou, B; Tian, Y; Wu, Y; You, H; Yuan, Z; Zhang, Y; Zhao, Q; Zhou, D; Zhou, J | 1 |
| Bot, A; Feldman, SA; Kochenderfer, JN; Lam, N; Lu, T; McIntyre, L; Rosenberg, SA; Rossi, J; Sherry, RM; Somerville, RPT; Yang, JC | 1 |
| Abenhardt, W; Bahlo, J; Bentz, M; Blau, I; Bühler, A; Busch, R; Döhner, H; Eckart, MJ; Eichhorst, B; Emmerich, B; Fischer, K; Freier, W; Fuss, H; Goebeler, M; Hallek, M; Hartmann, F; Hoechstetter, MA; Hopfinger, G; Hurtz, HJ; Jäger, U; Müller, L; Schimke, H; Stilgenbauer, S; Vehling-Kaiser, U; Wendtner, CM; Winkler, D | 1 |
| Chen, B; Gao, C; Ge, Z; Liu, R; Zhang, X | 1 |
| Björklund, A; Garming-Legert, K; Hassan, M; Ljungman, P; Mattsson, J; Remberger, M; Serafi, IE; Sundin, M; Törlen, J | 1 |
| Aoki, J; Atsuta, Y; Eto, T; Fukuda, T; Ichinohe, T; Ishiyama, K; Iwato, K; Kahata, K; Kako, S; Kanamori, H; Kanda, Y; Kawamura, K; Kondo, T; Mizuta, S; Ozawa, Y; Sawa, M; Uchida, N; Yano, S | 1 |
| Chen, ZB; Li, ZY; Liang, YB; Ma, ZF; Tang, H; Wu, JG; Yang, W; Zeng, LJ | 1 |
| Bay, JO; Blaise, D; Bulabois, CE; Ceballos, P; Chantepie, S; Charbonnier, A; Chevallier, P; Contentin, N; Cornillon, J; Daguindau, E; Deconinck, E; Labopin, M; Le Bourgeois, A; Maillard, N; Marçais, A; Marchand, T; Mercier, M; Mohty, M; N'Guyen, S; Peffault de Latour, R; Rorhlich, PS; Turlure, P; Vigouroux, S; Yakoub-Agha, I | 1 |
| Appleby, N; Cahill, MR; Crotty, G; Enright, H; Hayat, A; Hennessy, B; Hodgson, A; Kelly, J; Leahy, M; O'Brien, D; O'Dwyer, M; O'Leary, H; Parker, I; Quinn, FM; Scott, K; Smyth, L; Vandenberghe, EA | 1 |
| Bell, AD; Cheng, JC; Gutierrez, L; Karras, NA; Pawlowska, AB; Rosenthal, J; Sun, W; Wang, LD | 1 |
| Hosokawa, I; Hosokawa, Y; Matsuo, T; Ozaki, K | 1 |
| Brown, JR; Chai-Adisaksopha, C | 1 |
| Damlaj, M; Patnaik, MM | 1 |
| Ahmed, S; Ahn, KW; Armand, P; Epperla, N; Fenske, TS; Hamadani, M; Jagasia, M; Jaglowski, S; Kenkre, VP; Savani, B; Shah, NN; Smith, SM; Sureda, A | 1 |
| Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M | 1 |
| Aurran-Schleinitz, T; Benchikh, R; Cymbalista, F; Defoi, Y; Feugier, P; Godmer, P; Guillermin, Y; Herbaux, C; Jardel, H; Laribi, K; Leblond, V; Leprêtre, S; Letestu, R; Lévy, V; Michallet, AS; Orsini, F; Pegourié, B; Salles, G; Subtil, F; Vallais, F; Vaudaux, S | 1 |
| Abu-Arja, R; Guilcher, GMT; Pai, V; Rangarajan, HG; Soni, S | 1 |
| Ahn, JS; Choi, Y; Lee, HS; Lee, JH; Lee, JO; Lee, WS; Moon, JH; Park, S; Shin, DY; Shin, HJ; Song, IC; Yoon, SS | 1 |
| Angelucci, E; Angrilli, F; Arcaini, L; Bertoldero, G; Cascavilla, N; Chiarenza, A; Dondi, A; Federico, M; Ferrari, A; Ferreri, AJM; Gaidano, G; Kovalchuk, S; Luminari, S; Manni, M; Marcheselli, L; Merli, F; Pulsoni, A; Rusconi, C; Salvi, F; Stelitano, C; Tarantino, V; Tucci, A; Vallisa, D; Vitolo, U | 1 |
| Brown, JR; Kay, NE | 1 |
| Hawkes, EA; Opat, S | 1 |
| Bentz, M; Binnenhei, M; Bohl, SR; Bullinger, L; Bunjes, D; Döhner, H; Döhner, K; Drognitz, K; Kuchenbauer, F; Kündgen, L; Moulin, JC; Nguyen, TM; Ringhoffer, M; Schlenk, RF; Teleanu, V; von Harsdorf, S; Wais, V | 1 |
| Coyne, CP; Narayanan, L | 1 |
| Abd Hamid, IJ; Abinun, M; Amrolia, P; Cant, AJ; Chiesa, R; Elfeky, R; Flood, T; Gaspar, HB; Gennery, AR; Hambleton, S; Nademi, Z; Pearce, MS; Qasim, W; Rao, K; Slatter, MA; Veys, P; Worth, A | 1 |
| Burger, J; Cortes, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, H; Keating, MJ; Luthra, R; Nogueras González, GM; O'Brien, S; Quesada, A; Rozovski, U; Sanchez-Petitto, G; Sarwari, N; Tam, C; Thompson, PA; Wierda, WG | 1 |
| Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I | 1 |
| Abraham, RS; Chadha, R; Kohli, S; Nivargi, S; Prakash Yadav, S; Rastogi, N; Thakkar, D | 1 |
| Cao, Q; Dusenbery, KE; Gao, RW; Smith, AR; Yuan, J | 1 |
| Gladstone, DE; Gocke, CD | 1 |
| Baculea, S; Côté, S; Diels, J; Dorman, E; Fahrbach, K; Sanden, SV; Xu, Y | 1 |
| Baer, MR; Ding, J; Hess, JR; Zimrin, AB | 1 |
| Schmidt, C | 1 |
| Ahmadi, AR; Akpinarli, B; Brandacher, G; Budihardjo, J; Etra, JW; Fidder, SAJ; Furtmüller, GJ; Lee, WPA; Lopez, J; Lough, DM; Miller, DT; Montgomery, RA; Nägele, F; Quan, A; Raimondi, G; Sun, Z; Vasilic, D; Wang, HD | 1 |
| Albano, F; Chiurazzi, F; Cimmino, C; Fiume, G; Frieri, C; Golino, G; Iaccino, E; Mallardo, M; Mimmi, S; Pastore, A; Pisano, A; Quinto, I; Scala, G; Vecchio, E | 1 |
| Han, TT; Huang, XJ; Mo, XD; Sun, YQ; Tang, FF; Wang, JZ; Wang, WJ; Xu, LP; Zhang, XH | 1 |
| Altiparmak, D; Cetin-Atalay, R; Guven, EB; Kucukdumlu, A; Tuncbilek, M | 1 |
| Li, H; Li, ZJ; Liu, HM; Lü, R; Qiu, LG; Wang, TY; Xiong, WJ; Yi, SH; Yu, Z | 1 |
| Bruce, K; Domm, J; Evans, M; Frangoul, H; Isbell, J | 1 |
| Ballerini, F; Cagnetta, A; Carminati, E; Cea, M; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Matarese, S; Miglino, M; Minetto, P; Raiola, AM | 1 |
| Cherry, MA; Crew, RM; Kim, YM; Li, S; Liu, G; Liu, Y; Lu, X; Wang, X; Wen, Z | 1 |
| Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
| Baccarani, M; Candoni, A; Fanin, R; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Martinelli, G; Papayannidis, C; Simeone, E; Visani, G | 1 |
| Algeri, M; Aricò, M; Basso, G; Caniglia, M; Cesaro, S; Di Bartolomeo, P; Fagioli, F; Favre, C; Giardino, S; Locatelli, F; Marzollo, A; Merli, P; Messina, C; Pillon, M; Porta, F; Prete, A; Rabusin, M; Ripaldi, M; Rovelli, A; Saglio, F; Sieni, E; Zecca, M; Ziino, O | 1 |
| Boulad, F; Curran, K; Kernan, NA; O'Reilly, RJ; Prockop, SE; Ruggiero, J; Scaradavou, A; Takpradit, C; Zakak, N | 1 |
| Bund, C; De Seze, J; Kremer, S; Lhermitte, B; Namer, IJ | 1 |
| Avni, B; Grisariu, S; Hussein, F; Lokshin, E; NaserEddin, A; Oron, HC; Shadur, B; Stepensky, P; Zaidman, I | 1 |
| Asma, S; Aytan, P; Boga, C; Gereklioglu, C; Kozanoglu, I; Maytalman, E; Ozdogu, H; Sariturk, C; Yeral, M | 1 |
| Aurran, T; Banos, A; Cartron, G; Dartigeas, C; de Guibert, S; Delmer, A; Dupuis, J; Ferrant, E; Feugier, P; Gagez, AL; Guiu, B; Leblond, V; Leprêtre, S; Letestu, R; Letuan, P; Mahé, B; Orsini-Piocelle, F; Rouillé, V; Ternant, D; Tournilhac, O; Tout, M; Villemagne, B | 1 |
| Abuelgasim, KA; Al Atwi, N; Al Balwi, M; Almughairi, A; Alshieban, S; Alsubaie, M; Rehan, H | 1 |
| Cairo, MS; Cooper, T; Dang, H; Dvorak, CC; Gao, Y; Grupp, SA; Hirsch, B; Kahwash, S; Loh, ML; Mazor, T; Mehta, PA; Olshen, AB; Parker, JS; Patel, N; Pei, Q; Raimondi, S; Satwani, P; Skeens, M; Stieglitz, E; Wall, D | 1 |
| Choo, S; Cole, T; Mechinaud, F; Richards, S | 1 |
| Claxton, D; Miki, K; Mineishi, S; Naik, S; Rakszawski, K; Shike, H; Wagner, H | 1 |
| Aurran, T; Béné, MC; Casasnovas, O; Cazin, B; Chevret, S; Corront, B; Cymbalista, F; Delépine, R; Delmer, A; Feugier, P; Leblond, V; Leprêtre, S; Letestu, R; Mahé, B; Maisonneuve, H; Nguyen-Khac, F; Ross-Weil, D; Royer, B; Tournilhac, O; Van Den Neste, E; Vaudaux, S | 1 |
| Alyea, EP; Antin, JH; Armand, P; Cutler, CS; Glotzbecker, BE; Gooptu, M; Ho, VT; Kim, HT; Koreth, J; Nageshwar, P; Nikiforow, S; Ritz, J; Soiffer, RJ | 1 |
| Alani, M; Baugier de Materre, A; Besançon, A; Denizon, N; Farhi, J; Ghnaya, H; Laribi, K | 1 |
| Bancaud, A; Bradbury, A; Cazaux, C; Filleron, T; Fournié, JJ; Gilhodes, J; Grgurevic, S; Hoffmann, JS; Laurent, G; Montilla-Perez, P; Pelofy, S; Queille, S; Quillet-Mary, A; Récher, C; Ysebaert, L | 1 |
| Antoniou, MN; Biswas, A; Buckley, SMK; Chan, JKY; Choolani, M; Dighe, NM; Johana, N; Mattar, CNZ; Sandikin, D; Shaw, SSW; Tan, KW; Tan, LG; Tan, YW; Waddington, SN | 1 |
| Feng, S; Li, J; Liu, R; Shi, X; Song, Z; Yue, Y | 1 |
| Becktell, K; Burke, MJ; Houser, K | 1 |
| Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J | 1 |
| Calip, G; Oh, A; Patel, P; Rondelli, D; Sweiss, K | 1 |
| Chen, L; Chen, M; Chen, W; Zhang, B; Zhang, L; Zhang, Y | 1 |
| Chen, H; Chen, Y; Huang, XJ; Liu, KY; Qin, J; Wang, FR; Xu, LP; Yang, YL; Zhang, XH | 1 |
| Ding, W; Feng, X; He, Y; Li, C; Lin, G; Liu, H; Pei, F; Peng, Z; Wu, X; Yang, M; Yi, W; Zhang, C | 1 |
| Borthakur, G; Burger, JA; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Jabbour, E; Jain, N; Jorgensen, J; Kadia, TM; Keating, MJ; O'Brien, SM; Peterson, CB; Strati, P; Thompson, PA; Wierda, WG | 1 |
| Amado, R; Binder, G; Jakobsen, BK; Lowe, KL; Mackall, CL; Norry, E | 1 |
| Fang, X; Jiang, Y; Li, Y; Liu, X; Sui, X; Wang, X; Xu, H; Zhang, L | 1 |
| Bredius, RGM; Bresters, D; Jacobse, J; Kollen, WJW; Mensink, H; van der Stoep-Yap, MYEC | 1 |
| Fauble, V; Hogan, WJ; Jain, T; Khera, N; Kunze, KL; Leis, JF; Mesa, RA; Noel, P; Palmer, J; Partain, DK; Patnaik, MS; Roy, V; Slack, JL; Sproat, LZ; Temkit, M | 1 |
| Abraham, A; Ahn, KW; Artz, A; Boelens, JJ; Dvorak, C; Fei, M; Frangoul, H; Freytes, C; Gale, RP; Harris, AC; Hong, S; Lazarus, HM; Levine, JE; Loren, A; Mineishi, S; Nishihori, T; O'Brien, T; Pasquini, MC; Williams, K | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Girschikofsky, M; Greil, R; Hartmann, TN; Lang, A; Melchardt, T; Petzer, A; Pleyer, L; Steurer, M; Thaler, J; Voskova, D; Weiss, L; Zaborsky, N | 1 |
| Biondi, A; Corsi, A; Dazzi, F; Granata, V; Michelozzi, IM; Pievani, A; Rambaldi, B; Serafini, M | 1 |
| Hamilton, BK | 1 |
| Chung, H; Hong, KT; Kang, HJ; Kim, S; Lee, JW; Rhee, SJ; Yoon, SH; Yu, KS | 1 |
| Tam, CS; Thompson, PA | 1 |
| Deotare, U; Khalil, MMI; Kim, DD; Lipton, JH; Messner, HA; Michelis, FV; Thyagu, S; Viswabandya, A | 1 |
| Arad, A; Aviv, A; Bairey, O; Braester, A; Fineman, R; Goldschmidt, N; Greenbaum, U; Herishanu, Y; Joffe, E; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T | 1 |
| Chen, X; Huang, Y; Huang, Z; Lan, H; Ma, X; Meng, F; Sun, Q; Wu, B; Wu, S; Xu, J; Yao, Q; Zhu, Z | 1 |
| Aktan, M; Bosch, F; Dartigeas, C; Ferra Coll, CM; Foà, R; Gresko, E; Kisro, J; Leblond, V; Merot, JL; Montillo, M; Raposo, J; Robson, S; Stilgenbauer, S | 1 |
| Allen, CE; Andolina, JR; Baker, KS; Bollard, CM; Bryant, C; Burroughs, L; Connelly, J; Dawson, P; Eapen, M; Hanna, R; Kean, L; Marsh, R; Pai, SY; Pulsipher, MA; Ramirez, A; Roehrs, P; Schultz, KR; Shenoy, S; Stenger, EO; Talano, JA | 1 |
| Blaise, D; Brecht, A; Cahn, JY; Heinicke, T; Hicheri, Y; Huynh, A; Labopin, M; Ledoux, MP; Milpied, N; Mohty, M; Mufti, GJ; Nagler, A; Polge, E; Savani, BN; Scheid, C; Schmid, C; Socié, G | 1 |
| Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I | 1 |
| Aljurf, M; Arcese, W; Beohou, E; Bonifazi, F; Bruno, B; Labopin, M; Lanza, F; Mohty, M; Nagler, A; Passweg, J; Pioltelli, P; Santarone, S; Saraceni, F; Savani, BN; Sociè, G; Stepensky, P; Yakoub-Agha, I | 1 |
| Al-Agil, A; Al-Ahmari, A; Al-Seraihi, A; Ayas, M; Ayas, MF; Ghemlas, I | 1 |
| Ashkenazi, M; Avni, B; Grisariu, S; Or, R; Shapira, MY; Sheth, V; Stepensky, P | 1 |
| Blaise, D; Decroocq, J; Devillier, R; Fan, X; Fürst, S; Hu, J; Tian, L; Vey, N; Wan, M; Wang, L; Wang, LN | 1 |
| Bittenbring, J; Brecht, A; Canaani, J; Ganser, A; Labopin, M; Labussière-Wallet, H; Mayer, J; Mohty, M; Nagler, A; Savani, B; Sheth, V; Shouval, R; Volin, L | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Arigoni, M; Benes, V; Brychtova, Y; Calogero, RA; Cerna, K; Chochola, V; Doubek, M; Mayer, J; Mraz, M; Musilova, K; Oppelt, J; Pavlasova, G; Pospisilova, S; Radova, L; Seda, V; Trbusek, M | 1 |
| Baker, L; Holder, K; Kanellopoulos, A; Kaparou, M; Kishore, B; Lovell, R; Nikolousis, E; Paneesha, S; Ryan, L; Suhr, J; Xenou, E | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Park, SS; Yoon, JH | 1 |
| Anderson, E; Bone, H; Heywood, J; Mayer, L; Mehta, P; Rees, B; Reynolds, D; Robinson, G; Salisbury, V | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Jander, M; Maciejewski, H; Ostrowska, K; Treliński, J; Voit, B; Ziemba, B | 1 |
| Ross Reichard, R; Vaubel, RA | 1 |
| Abou Mourad, Y; Abuhaleeqa, M; Daly, A; Nitta, J; Paulson, K; Seftel, MD; Speziali, C | 1 |
| Angelucci, E; Arcese, W; Baron, F; Benedetto, B; Blaise, D; Carella, MA; Giannotti, F; Labopin, M; Mohty, M; Nagler, A; Rambaldi, A; Rocha, V; Ruggeri, A; Saccardi, R; Santarone, S; Santasusana, JR; Sanz, J; Shouval, R; Sierra, J | 1 |
| Barré, L; Fillesoye, F; Gourand, F; Guillouet, S; Hovhannisyan, N; Ibazizene, M; Plancoulaine, B; Toutain, J; Valable, S | 1 |
| Bahlo, J; Cramer, P; Dürig, J; Eichhorst, B; Fink, AM; Hallek, M; Herling, M; Hopfinger, G; Kreuzer, KA; Mayer, P; Oberbeck, S; Pflug, N; Robrecht, S; Schrader, A; Seiler, T; Stilgenbauer, S; Westermann, A; Zenz, T | 1 |
| Boelens, JJ; Dorlo, TPC; Huitema, ADR; Kuball, J; Langenhorst, JB; Nierkens, S; van Kesteren, C; van Maarseveen, EM | 1 |
| Byun, JE; Choi, I; Huy, H; Jung, H; Kim, DO; Kim, MJ; Kim, TD; Kim, WS; Lee, J; Lee, KH; Noh, JY; Park, YJ; Yoon, SR | 1 |
| Chen, J; Chen, L; Cheng, H; Gao, L; Hu, XX; Li, HM; Luo, YR; Ni, X; Song, XM; Tang, GS; Wang, JM; Wang, ZW; Xia, XX; Yang, D; Yang, JM; Zhang, WP; Zhou, H | 1 |
| Luo, W; Ni, X; Wei, J; Yu, H; Zou, X | 1 |
| Levin-Epstein, R; Oliai, C; Schiller, G | 1 |
| Kanda, Y | 1 |
| Ahmed, S; Al-Atrash, G; Alousi, AM; Anderlini, P; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, SO; Hosing, CM; Im, JS; Jones, R; Kawedia, J; Kebriaei, P; Khouri, I; Marin, D; Mehta, RS; Nieto, Y; Olson, A; Oran, B; Parmar, S; Popat, UR; Qazilbash, MH; Rezvani, K; Shah, N; Shpall, EJ; Srour, SA; Valdez, BC | 1 |
| Tian, C; Yu, Y; Zhang, Y | 1 |
| Arroyo, DS; Bussi, C; Heller, V; Iribarren, P; Rodriguez, CM; Sastre, D; Slavutsky, I; Stanganelli, C | 1 |
| Blumenthal, GM; Bouchkouj, N; Bryan, W; de Claro, RA; George, B; Kasamon, YL; Lee, S; Lin, X; McKee, AE; Pazdur, R | 1 |
| Crispino, JD; Fu, C; Gong, Y; Marinaccio, C; Shi, H; Shi, X; Sun, Z; Wan, Y; Wang, Z; Xu, K | 1 |
| Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Maloney, DG; Press, OW; Puronen, CE; Sandmaier, BM; Stevenson, PA; Storb, RF | 1 |
| Bakala, J; Declercq, H; Delette, C; Drumez, E; Duhamel, A; Guidez, S; Hivert, B; Labreuche, J; Marolleau, JP; Morel, P; Protin, C; Verlay, M; Ysebaert, L | 1 |
| Andersson, PO; Asklid, A; Bjellvi, J; Hansson, L; Johansson, H; Karlsson, C; Karlsson, K; Kimby, E; Klintman, J; Lauri, B; Mattsson, M; Norin, S; Österborg, A; Sandstedt, AB; Strandberg, M; Sylvan, SE; Tolvgård, S | 1 |
| Alahdab, F; Almader-Douglas, D; Firwana, B; Jain, T; Palmer, J; Sonbol, MB | 1 |
| Jain, N | 1 |
| Chen, K; Feng, Z; Li, X; Lin, J; Pan, X; Qi, W; Yan, Y | 1 |
| Adachi, S; Atsuta, Y; Hashii, Y; Imai, K; Inoue, M; Kato, K; Kobayashi, M; Koga, Y; Morio, T; Okada, K; Sasahara, Y; Sato, M; Takahashi, Y; Umeda, K; Yabe, H; Yoshida, N | 1 |
| Alatrash, G; Andersson, BS; Champlin, RE; Chen, J; Crain, AK; Di Stasi, A; Jones, RB; Kidwell, KM; Popat, U; Shpall, EJ; Thall, PF; Zope, M | 1 |
| Alessandrino, EP; Bacigalupo, A; Bonifazi, F; Bosi, A; Bregante, S; Bruno, B; Carella, AM; Fanin, R; Finazzi, MC; Mammoliti, S; Masciulli, A; Messina, G; Milone, G; Narni, F; Patriarca, F; Pavoni, C; Rambaldi, A; Russo, D | 1 |
| Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; McIver, T; Morariu-Zamfir, R; O'Brien, S; Pagel, JM | 1 |
| Basu, O; Döring, M; Ebinger, M; Gruhn, B; Handgretinger, R; Heinzelmann, F; Holzer, U; Lang, P; Paulsen, F; Teltschik, HM; Wegener, D; Weidner, N; Wittig, A; Zips, D | 1 |
| Calip, GS; Oh, AL; Patel, PR; Rondelli, D; Sweiss, K | 1 |
| Stanford, M; Virgo, J; Williams, G | 1 |
| Baird, DM; Fegan, CD; Hillmen, P; Hills, R; Norris, K; Pepper, C; Rawstron, A | 1 |
| Appelhans, D; Danani, A; Deriu, MA; Gorzkiewicz, M; Grasso, G; Janaszewska, A; Klajnert-Maculewicz, B; Pułaski, Ł; Studzian, M | 1 |
| Li, Y; Wang, X; Xu, Y; Zhang, Y; Zhou, X | 1 |
| Arai, Y; Hatsumi, N; Honda, S; Ishida, F; Kano, Y; Komatsu, N; Machida, S; Miyawaki, S; Morii, T; Naoe, T; Nishii, K; Ogura, M; Ohnishi, K; Takeshita, A; Usui, N; Yamauchi, T | 1 |
| Hatsumi, N; Hoshino, T; Sakura, T; Takada, S | 1 |
| Aviv, A; Bairey, O; Braester, A; Fineman, R; Herishanu, Y; Levi, I; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T; Yuklea, M | 1 |
| Araujo, C; Banos, A; Compaci, G; Despas, F; Larcher, M; Laurent, G; Oberic, L; Sahnes, L; Sommet, A; Ysebaert, L | 1 |
| Antic, D; Dencic-Fekete, M; Djurasinovic, V; Karan-Djurasevic, T; Kostic, T; Marjanovic, I; Mihaljevic, B; Pavlovic, S; Tosic, N; Vukovic, V | 1 |
| Acharya, UH; Cassaday, RD; Chapuis, AG; Chen, X; Cherian, S; Dhawale, TM; Gauthier, J; Gooley, T; Hawkins, RM; Hay, KA; Hendrie, PC; Hirayama, AV; Kiem, HP; Li, D; Lynch, RC; Maloney, DG; Pender, BS; Ramos, J; Riddell, SR; Shadman, M; Steinmetz, RN; Till, BG; Turtle, CJ; Vakil, A; Voutsinas, JM; Wu, Q | 1 |
| Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A | 1 |
| Ariznavarreta, GD; Carbonell, F; Champ, D; Costa, MAA; De La Serna Torroba, J; De Marcos, NS; De Oteyza, JP; De Paz Arias, R; Díaz, MG; Fernández, IP; Ferrer, S; García-Marco, JA; García-Vela, JA; González-Barca, E; Guinaldo, MAR; Jarque, I; Jiménez, JL; Llanos, EB; Malo, MDG; Martin, EMD; Martinez, RM; Parraga, FJP; Persona, EP; Ramírez, MJ; Recasens, V; Suarez, JG; Tatay, AC; Valle, MDCF; Yañez, L; Zarzoso, MF | 1 |
| Li, LJ; Yu, K; Zhang, JY | 1 |
| Ahmed, S; Al-Atrash, G; Alousi, AM; Anderlini, P; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, SO; Hosing, CM; Im, JS; Kebriaei, P; Khouri, I; Marin, D; Mehta, RS; Molldrem, JJ; Nieto, Y; Olson, A; Oran, B; Popat, UR; Qazilbash, MH; Rezvani, K; Shpall, EJ; Srour, SA | 1 |
| Chen, Y; Feng, J; Lin, F; Lu, N; Ma, Y; Shi, Y; Sun, L; Tang, L; Wang, N; Xing, C; Yu, K | 1 |
| Bačíková, A; Kozubek, S; Lukášová, E; Řezáčová, M; Šebejová, L; Vávrová, J | 1 |
| Beelen, D; Bochtler, T; Brecht, A; Bunjes, D; Eder, M; Einsele, H; Kröger, N; Labopin, M; Labussière-Wallet, H; Mohty, M; Nagler, A; Niederwieser, D; Saraceni, F; Savani, BN; Tischer, J | 1 |
| Chung, Y; Han, B; Kim, HY; Kim, M; Lee, J; Lee, YK; Park, JY | 1 |
| Brychtova, Y; Brzobohata, A; Doubek, M; Mayer, J; Mraz, M; Panovska, A; Pavlova, S; Pospisilova, S; Skuhrova Francova, H; Spunarova, M; Tom, N; Trbusek, M | 1 |
| Baggerly, KA; Benton, CB; Champlin, R; Chen, J; Konoplev, S; Konopleva, M; Liu, W; Lu, H; Shpall, E; Wang, RY; Zeng, Z | 1 |
| Blaise, D; Bramanti, S; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Devillier, R; Faucher, C; Fürst, S; Granata, A; Harbi, S; Hospital, MA; Legrand, F; Lemarie, C; Lining, W; Maisano, V; Mokart, D; Pagliardini, T; Porta, MD; Rey, J; Saillard, C; Vey, N; Weiller, PJ | 1 |
| Aiyer, HM; Bansal, S; Bhakuni, P; Bhargava, S; Chakrabarti, S; Jaiswal, SR | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Candoni, A; Cerrano, M; Crisà, E; D'Ardia, S; Dubbini, MV; Ferrero, D; Zannier, ME | 1 |
| Wierda, WG | 1 |
| Imanaga, H; Ohno, Y; Ohta, T; Oku, S; Sugio, Y | 1 |
| Wendtner, CM | 1 |
| Artz, A; Bishop, MR; Champlin, RE; Chen, J; Ciurea, SO; Gergis, U; Guarneri, D; Liu, H; Mayer, SA; Rondon, G; Shore, T; Srour, SA; Stock, W; van Besien, K | 1 |
| Chen, B; Fang, Q; He, Z; Li, P; Ma, D; Ren, M; Wang, J; Zhe, N; Zhong, Q; Zhou, Z | 1 |
| Burgess, M; Cheung, C; Gill, D; McMillan, NA; Mollee, P; Saunders, NA; Tate, C | 1 |
| Bashey, A; Holland, HK; Morris, LE; Solh, M; Solomon, SR; Zhang, X | 1 |
| Chua, KYL; Holmes, NE; Meher-Homji, Z; Phillips, EJ; Seymour, JF; Siderov, J; Slavin, MA; Tam, CS; Trubiano, JA | 1 |
| Al-Ahmari, A; Al-Jefri, A; Al-Saedi, H; Al-Seraihi, A; Alanazi, A; Ayas, M; Ayas, MF; Ghemlas, I; Jafri, R; Siddiqui, K | 1 |
| Cao, J; Chen, W; Cheng, H; Jing, G; Li, H; Qi, K; Qiao, J; Shi, M; Wang, G; Wu, Q; Xu, K; Zeng, L; Zhao, J; Zheng, J | 1 |
| Alonso Caballero, C; Barrenetxea Lekue, C; D'Amore, F; Grasso Cicala, S; Herráez Rodríguez, S; Jørgensen, JM; Leal Martínez, I; Leppä, S; Stauffer Larsen, T; Toldbod, H | 1 |
| Barr, PM; Barrientos, J; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Jelinek, DF; Kay, NE; Leis, JF; Little, RF; Litzow, M; Mato, AR; Mullane, MP; O'Brien, S; Shanafelt, TD; Singh, AK; Stone, RM; Tallman, M; Wang, XV; Zhang, CC | 1 |
| Facco, M; Frezzato, F; Gurrieri, C; Imbergamo, S; Martini, V; Pagnin, E; Piazza, F; Pravato, S; Raggi, F; Scomazzon, E; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A | 1 |
| Chen, J; Cheng, H; Gao, L; Hu, X; Luo, Y; Tang, G; Wang, J; Yang, D; Yang, J; Zhang, W | 1 |
| Stirrups, R | 1 |
| Bijou, F; Durrieu, F; Filleron, T; Gauthier, M; Martin, E; Obéric, L; Peres, M; Quillet Mary, A; Vergez, F; Ysebaert, L | 1 |
| Bosch, F; Böttcher, S; Cantin, G; Cortelezzi, A; Foà, R; Gresko, E; Knauf, W; Leblond, V; Merot, JL; Robson, S; Stilgenbauer, S; Tausch, E; Tiab, M; Trunzer, K; Turgut, M; Zaritskey, A | 1 |
| Czyż, A; Danylesko, I; Fein, JA; Nagler, A; Shem Tov, N; Shimoni, A; Shouval, R; Sobas, M; Vega, Y; Yerushalmi, R | 1 |
| Holzer, S; Jenkyn-Bedford, M; Kilkenny, ML; Pellegrini, L; Rzechorzek, NJ; Short, IR | 1 |
| Behre, G; Döhring, C; Franke, GN; Grimm, J; Hille, A; Jentzsch, M; Linke, R; Niederwieser, D; Pönisch, W; Schwind, S; Vucinic, V | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Hether, T; Jain, N; Jorgensen, JL; Keating, MJ; O'Brien, SM; Peterson, C; Srivastava, J; Strati, P; Thompson, PA; Wierda, WG | 1 |
| Abrams, ZB; Abruzzo, LV; Bahlo, J; Barron, LL; Benner, A; Bloehdorn, J; Bondaruk, JE; Coombes, KR; Czerniak, BA; Ferrajoli, A; Fischer, K; Hallek, M; Herling, CD; Keating, MJ; Majewski, T; Oakes, CC; Stilgenbauer, S | 1 |
| Arthur, C; Fay, K; Greenwood, M; Kerridge, I; Lindsay, J; Lwin, Y; Reid, C; Stevenson, W; Wong, K | 1 |
| Al-Atrash, G; Alousi, A; Bashir, Q; Betul, O; Bittencourt, MCB; Champlin, RE; Ciurea, SO; Daver, N; Hosing, C; Jabbour, E; Kantarjian, H; Kebriaei, P; Khouri, I; Kongtim, P; Konopleva, M; Masarova, L; Mehta, R; Olson, A; Perez, JMR; Popat, U; Ravandi, F; Saliba, RM; Short, N; Srour, SA | 1 |
| Bednarski, JJ; Bhatt, ST; Hente, M; Murray, L; Schulz, G; Shenoy, S; Slater, A | 1 |
| Shimoni, A | 1 |
| Shen, YF; Sun, HL; Zhou, X; Zou, ZJ | 1 |
| Fujita, N; Fukano, R; Fukuda, T; Hashii, Y; Inagaki, J; Inoue, M; Kato, K; Kobayashi, R; Maseki, N; Mitsui, T; Mori, T; Okada, K; Sato, A; Shimoyama, T; Shindo, M; Suzuki, R; Suzumiya, J; Tabuchi, K | 1 |
| Bolwell, B; Gerds, AT; Hamilton, BK; Hanna, R; Kalaycio, M; Majhail, NS; Patel, SS; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Blaise, D; Choi, G; Cornelissen, J; Heinicke, T; Kuball, J; Labopin, M; Mohty, M; Nagler, A; Niederwieser, D; Paul, F; Platzbecker, U; Polge, E; Potter, V; Savani, BN; Schaap, N; Sengelov, H; van Gorkom, G | 1 |
| Battiwalla, M; Brazauskas, R; Buchbinder, D; Cahoon, EK; Curtis, RE; Engels, EA; Flowers, ME; Herr, MM; Morton, LM; Shaw, BE; Tecca, HR; Tucker, MA | 1 |
| Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J | 1 |
| Beutel, G; Dammann, E; Eder, M; Eggers, H; Ehrlich, S; Gabdoulline, R; Ganser, A; Göhring, G; Hambach, L; Heuser, M; Klement, P; Koenecke, C; Markel, D; Neziri, B; Rehberg, A; Reuter, M; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Wichmann, M | 1 |
| Jayakumar, I; Patel, S; Raj, R; Ramakrishnan, B; Ramanan, KM; Ravichandran, N; Swaminathan, VV; Uppuluri, R | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Danilewicz, M; Franiak-Pietryga, I; Jander, M; Kuncman, W; Sikorska, H; Ziemba, B | 1 |
| Gennery, AR; Hoenig, M; Lum, SH; Slatter, MA | 1 |
| Brinda, BJ; Foxworthy Scott, S; Karr, AH; Kiel, PJ; Nelson, RP; Podichetty, JT; Prasad, NK; Quinney, S | 1 |
| Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R | 1 |
| Anagnostopoulos, A; Bhoi, S; Duran-Ferrer, M; Ghia, P; Kollia, P; Ljungström, V; Malousi, A; Mansouri, L; Martin-Subero, JI; Moysiadis, T; Oscier, D; Papakonstantinou, N; Plevova, K; Pospisilova, S; Pott, C; Queirós, AC; Ritgen, M; Rosenquist, R; Stamatopoulos, K; Stavroyianni, N; Trentin, L; Tsagiopoulou, M | 1 |
| Agar, S; Altay, F; Gölcü, A; Sayin, VO; Şenel, P; Yurtsever, M | 1 |
| Aotsuka, N; Hangaishi, A; Hoshino, T; Kako, S; Kanda, Y; Kato, J; Kobayashi, T; Matsumoto, K; Mori, T; Najima, Y; Okamoto, S; Onizuka, M; Shimizu, H; Shono, K; Tachibana, T; Tanaka, M; Tsukamoto, S; Usuki, K; Watanabe, R; Yamazaki, E; Yano, S | 1 |
| Doorduijn, JK; Dreyling, MH; Feugier, P; Geisler, CH; Hermine, O; Hoster, E; Kaiser, F; Kanz, L; Klapper, W; Kluin-Nelemans, HC; Pott, C; Ribrag, V; Salles, G; Schmidt, C; Stilgenbauer, S; Szymczyk, M; Thieblemont, C; Tilly, H; Trneny, M; Unterhalt, M; Walewski, J; Zijlstra, JM | 1 |
| Alousi, A; Bashir, Q; Champlin, RE; Chen, J; Ciurea, SO; Daver, N; Hosing, C; Kongtim, P; Konopleva, M; Mehta, R; Olson, A; Oran, B; Popat, U; Rondon, G; Srour, S; Varma, A | 1 |
| Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I | 1 |
| Briones, J; Brunet, S; Caballero, A; Esquirol, A; Garcia-Cadenas, I; Garrido, A; Granell, M; Martino, R; Moreno, C; Novelli, S; Querol, S; Saavedra, S; Sierra, J | 1 |
| Angelucci, E; Bacigalupo, A; Bregante, S; Bruno, B; Chiusolo, P; Grazia, CD; Grisariu, S; Iori, AP; Mordini, N; Olivieri, A; Patriarca, F; Raiola, AM; Rambaldi, A; Sica, S; Sora, F; Terruzzi, E | 1 |
| Cai, Y; Jiang, J; Wan, L; Wang, C; Yang, J | 1 |
| Achyut, BR; Allan, PW; Behbahani, T; Ealick, SE; Gilbert-Ross, M; Hong, J; Joshi, D; Parker, WB; Rab, R; Sorscher, EJ; Waud, WR | 1 |
| Boelens, JJ; de Witte, MA; Dorlo, TPC; Huitema, ADR; Langenhorst, JB; Nierkens, S; van Kesteren, C; van Maarseveen, EM | 1 |
| Melarcode Ramanan, K; Patel, S; Raj, R; Ravichandran, N; Uppuluri, R; Vellaichamy Swaminathan, V | 1 |
| Chhabra, S; D'Souza, A; Dhakal, B; Drobyski, WR; Fenske, TS; George, G; Hamadani, M; Hari, PN; Jerkins, JH; Michaelis, LC; Narra, RK; Pasquini, MC; Rizzo, RD; Saber, W; Shah, NN; Shaw, BE; Szabo, A; Wu, R | 1 |
| Govindaraju, S; Grosicki, S; Kryachok, I; Lewerin, C; Mazur, G; Middeke, JM; Miklos, U; Montillo, M; Österborg, A; Rekhtman, G; Stefanelli, T; Steurer, M; Strugov, V; Vincent, G | 1 |
| Higashi, T; Hirosawa, M; Kominato, Y; Morimoto, H; Tanaka, A; Tsukada, J; Yamaguchi, T | 1 |
| Antoniou, P; Blakemore, SJ; Bryant, D; Carr, L; Catovsky, D; Chan, J; Clifford, R; Colins, A; Cragg, MS; Davis, Z; Else, M; Forster, J; Kadalyayil, L; Larrayoz, M; McCarthy, H; Morilla, R; Oscier, DG; Parker, H; Robbe, P; Rose-Zerilli, MJJ; Schuh, A; Speight, G; Stankovic, T; Stec-Dziedzic, E; Steele, AJ; Strefford, JC; Vavoulis, D; Walewska, RJ | 1 |
| Bąbol-Pokora, K; Dąbrowska-Leonik, N; Frączkiewicz, J; Gul, K; Janeczko-Czarnecka, M; Kałwak, K; Martuszewski, A; Mielcarek-Siedziuk, M; Młynarski, W; Nowak, M; Paluszkiewicz, P; Salamonowicz-Bodzioch, M; Sierżęga-Staykov, K; Ussowicz, M; Wawrzyniak-Dzierżek, E; Wolska-Kuśnierz, B | 1 |
| Dreger, P; Hegenbart, U; Herfarth, K; Luft, T; Müller-Tidow, C; Radujkovic, A | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Busch, R; Cazin, B; Cymbalista, F; Döhner, H; Dreyfus, B; Eichhorst, B; Fink, AM; Fischer, K; Groß-Ophoff-Müller, C; Hallek, M; Herling, CD; Hoechstetter, MA; Ibach, S; Kaiser, F; Kneba, M; Langerbeins, P; Leblond, V; Leprêtre, S; Letestu, R; Levy, V; Porcher, R; Robrecht, S; Stilgenbauer, S; Wentner, CM | 1 |
| Beckerleg, W; Milman, N; van der Jagt, R | 1 |
| Al-Chami, F; Angelucci, E; Bazarbachi, A; Bonifazi, F; Bruno, B; Carella, AM; Castagna, L; El-Cheikh, J; Iori, AP; La Nasa, G; Labopin, M; Mohty, M; Nagler, A; Santarone, S; Savani, B | 1 |
| Andersen, NS; Friis, LS; Grønbæk, K; Hansen, JW; Kornblit, B; Petersen, SL; Schjødt, I; Sengeløv, H; Wedge, E | 1 |
| Fujita, N; Fukano, R; Hashimoto, H; Kada, A; Kamei, M; Kobayashi, R; Koga, Y; Mitsui, T; Mori, T; Ohki, K; Osumi, T; Saito, AM; Sekimizu, M; Tanaka, F; Ueyama, J | 1 |
| Banerjee, H; Blonski, J; Govind Babu, K; Grosicki, S; Homenda, W; Kriachok, I; Kłoczko, J; Lech-Maranda, E; Litvinskaya, E; Loscertales, J; Rekhtman, G; Robak, T; Rybka, J; Stefanelli, T; Vincent, G | 1 |
| Al Tourah, AJ; Bruyere, H; Dueck, G; Galbraith, P; Gerrie, AS; Hardy, E; Hrynchak, M; Huang, SJ; Noble, MC; Ramadan, KM; Sehn, L; Toze, CL; Tsang, P; Tucker, T; Young, S | 1 |
| Deguchi, T; Kato, M; Kiyotani, C; Matsumoto, K; Mizuno, T; Nakadate, H; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yoshimura, S | 1 |
| Chen, K; Han, X; Hao, H; Huang, T; Lei, J; Li, Q; Liu, C; Liu, Y; Yu, F | 1 |
| Bishton, MJ; Clifton-Hadley, L; Haynes, A; Lush, R; McMillan, A; Patmore, R; Rule, S; Turner, D; Wilson, W | 1 |
| Ahn, KW; Awan, FT; Chow, VA; Eghtedar, A; Fenske, TS; Hamadani, M; Karmali, R; Khanal, M; Kharfan-Dabaja, MA; Litovich, C; Sauter, C; Winter, A | 1 |
| Chevassut, T; Milne, K; Sturrock, B | 1 |
| Akasaka, T; Atsuta, Y; Eto, T; Fukuda, T; Hidaka, M; Kanda, J; Kondo, T; Miyakoshi, S; Ota, S; Shiratori, S; Takami, A; Uchida, N; Yamashita, T; Yano, S | 1 |
| Chen, X; Chen, Y; Li, J; Li, Z; Liu, F; Liu, L; Pui, CH; Ruan, M; Wang, J; Wang, S; Wang, Y; Yang, JJ; Zhong, M; Zhu, X | 1 |
| Gordiienko, I; Ivanivska, T; Shcherbina, V; Shlapatska, L; Sidorenko, S | 1 |
| Beitinjaneh, A; Flinn, IW; Fung, H; Goy, A; Hill, BT; Holmes, H; Houot, R; Jacobson, CA; Jaglowski, S; Jain, RK; Kersten, MJ; Locke, FL; McSweeney, PA; Miklos, DB; Milpied, N; Munoz, J; Pagel, JM; Peng, W; Rao, AV; Reagan, PM; Rossi, JM; Timmerman, JM; Topp, MS; Wang, M; Zheng, L | 1 |
| Asher, N; Ben-Betzalel, G; Ben-Nun, A; Besser, MJ; Brezinger, K; Itzhaki, O; Kubi, A; Levi, M; Markel, G; Nagler, A; Nissani, A; Schachter, J; Shapira-Frommer, R; Shimoni, A; Zeltzer, LA; Zikich, D; Zippel, DB | 1 |
| Suzumiya, J; Takizawa, J | 1 |
| Agrawal, N; Agrawal, P; Ahmed, R; Bhurani, D; Kapoor, J; Khushoo, V; Mirgh, SP; Naim, F; Pramanik, SK | 1 |
| Ahluwalia, MS; Alban, TJ; Bayik, D; Cheng, F; Grabowski, MM; Hong, C; Horbinski, C; Hwang, TH; Khalil, AM; Kristensen, BW; Lathia, JD; Lauko, A; Lo, A; McGraw, M; Otvos, B; Park, C; Roversi, G; Silver, DJ; Sorensen, M; Vail, D; Vogelbaum, MA; Watson, DC; Zhou, Y | 1 |
| Byrd, JC; Lee, DA; Mani, R; Mo, X; Muthusamy, N; Nunes, J; Rajgolikar, G; Vasu, S; Wasmuth, R; Zapolnik, K | 1 |
| Bertrand, Y; Girard, S; Marceau-Renaut, A; Penel-Page, M; Plesa, A; Renard, C | 1 |
| Bloehdorn, J; Döhner, H; Lichter, P; Mertens, D; Stilgenbauer, S; Yosifov, DY | 1 |
| Barcellini, W; Berentsen, S; Brudevold, R; D'Sa, S; Dahm, AEA; Dalgaard, J; Fattizzo, B; Frøen, H; Hallstensen, RF; Haukås, E; Hjorth-Hansen, H; Jæger, PH; Kell, M; Małecka, A; Oksman, M; Randen, U; Rolke, J; Sekhar, M; Sørbø, JH; Tjønnfjord, E; Tjønnfjord, GE; Tsykunova, G; Tvedt, THA | 1 |
| Bernardi, R; Bongiovanni, L; Coltella, N; Ghia, P; Magliulo, D; Ponzoni, M; Scarfò, L; Valsecchi, R | 1 |
| Al Malki, MM; Aldoss, I; Ali, H; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; Pullarkat, V; Salhotra, A; Sandhu, K; Smith, E; Snyder, D; Stein, A; Tsai, NC | 1 |
| Allain, EP; Bat, V; Caron, P; Demirtas, D; Droit, A; Guillemette, C; Hubmann, R; Jäger, U; Joly-Beauparlant, C; Labriet, A; Le, T; Lévesque, E; Rouleau, M; Schnabl, S; Shehata, M; Staber, PB; Tremblay, S; Turcotte, V; Vaillancourt, J; Vanura, K; Villeneuve, L | 1 |
| Atsuta, Y; Fujita, N; Goto, H; Inoue, M; Kato, K; Kawaguchi, H; Kobayashi, R; Koh, K; Kojima, S; Kudo, K; Miyamura, T; Okada, K; Okamoto, Y; Suzuki, R; Takahashi, Y; Watanabe, K; Yabe, H; Yabe, M; Yoshida, N | 1 |
| Cheah, R; Dendle, C; Gregory, G; Mohan, B; Tey, A | 1 |
| Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L | 1 |
| Choi, Y; Do, YR; Jung, SH; Kim, DS; Koh, Y; Lee, JH; Lee, S; Lee, SS; Lee, WS; Moon, JH; Mun, YC; Park, HS; Park, Y; Yang, DH; Yhim, HY; Yi, JH | 1 |
| Baron, F; Hsu, J; Van Besien, K | 1 |
| Ahmed, S; Ahn, KW; Aljurf, M; Bacher, VU; Bredeson, C; Epperla, N; Farhadfar, N; Freytes, CO; Ganguly, S; Ghosh, N; Hamadani, M; Haverkos, B; Inwards, D; Kamble, RT; Khanal, M; Kharfan-Dabaja, MA; Lazarus, HM; Lekakis, L; Litovich, C; Murthy, HS; Nishihori, T; Ramakrishnan, P; Rizzieri, DA; Sureda, A; Yared, JA | 1 |
| Ussowicz, M | 1 |
| Andrés, AM; Arreola, NM; González-Navarro, P; Hernández-Oliveros, F; Machuca, M; Mestre, C; Navarro-Zapata, A; Papa-Gobbi, R; Pascual-Miguel, B; Pérez-Martínez, A; Pires-Lobo, SC; Stringa, P; Vela, M | 1 |
| Daly, A; Dharmani-Khan, P; Duggan, PR; Jamani, K; Jimenez-Zepeda, V; Kalra, A; Khan, FM; Ousia, S; Prokopishyn, N; Russell, JA; Storek, J; Williamson, TS | 1 |
| Bertz, H; Duque-Afonso, J; Finke, J; Ihorst, G; Köhler, T; Marks, R; Müller-Quernheim, J; Wäsch, R; Waterhouse, M; Yücel, M; Zeiser, R | 1 |
| Kolb, HJ; Schmid, C | 1 |
| Cao, J; Cheng, H; Gao, X; Jiao, J; Li, D; Li, W; Li, Z; Liu, H; Ma, Y; Qin, Y; Sang, T; Sang, W; Shi, M; Song, X; Sun, C; Sun, H; Sun, K; Wang, Y; Wu, M; Xu, K; Xu, L; Yan, D; Yan, Z; Yang, J; Yao, M; Zeng, L; Zhang, B; Zheng, J; Zhu, F | 1 |
| Anagnostopoulos, A; Chatzidimitriou, A; Galigalidou, C; Gemenetzi, K; Ghia, P; Ioannou, N; Iskas, M; Koravou, E; Kotouza, M; Kotta, K; Kouvatsi, A; Papazoglou, D; Pasentsis, K; Psomopoulos, F; Ramsay, AG; Scarfó, L; Stamatopoulos, K; Stavroyianni, N; Vardi, A; Vlachonikola, E | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yoon, JH | 1 |
| de Castro, DG; Dietrich, S; Dreger, P; Dreyling, M; Grabe, N; Hermine, O; Hoster, E; Hüttl, K; Klapper, W; Kluin-Nelemans, HC; Müller-Tidow, C; Ott, G; Pott, C; Roider, T; Rosenwald, A; Stewart, JP; Wang, X | 1 |
| Bruce, AAK; Desai, S; Guilcher, GMT; Le, D; Leaker, MT; Lewis, V; Shah, RM; Steele, M; Truong, TH; Wright, NAM | 1 |
| Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G | 1 |
| Akashi, K; Eto, T; Fujishima, N; Harada, M; Hidaka, M; Kishimoto, J; Maeda, Y; Matsumoto, K; Miyamoto, T; Mori, SI; Morita, K; Murayama, T; Sakura, T; Taniguchi, S; Teshima, T; Uchida, N; Yamashita, T; Yoshimoto, G | 1 |
| Slater, H | 1 |
| Callander, N; D'Angelo, CR; Hall, A; Hematti, P; Juckett, M; Kenkre, VP; Kim, K; Longo, W; Mattison, R; Woo, KM | 1 |
| Appelhans, D; Borowiec, M; Bryszewska, M; Danilewicz, M; Franiak-Pietryga, I; Jander, M; Kuncman, W; Lewkowicz, P; Ostrowska, K; Sikorska, H; Ziemba, B | 1 |
| Beaven, AW; Brenner, MK; Buchanan, FB; Cheng, CJ; Dittus, C; Dotti, G; Eldridge, PW; Gee, AP; Grilley, BJ; Grover, NS; Heslop, HE; Ivanova, A; Lulla, PD; McKay, KL; Mehta, B; Morrison, K; Park, SI; Ramos, CA; Rooney, CM; Savoldo, B; Serody, JS; Shea, TC; Wang, T; Wu, MF | 1 |
| Ahmed, P; Anwer, F; Chaudhry, QUN; Farhan, M; Ghafoor, T; Humayun, S; Iftikhar, R; Khan, MA; Khattak, TA; Mahmood, SK; Rehman, J; Risalat, A; Satti, HS; Satti, TM; Shahbaz, N; Shamshad, GU; Wahab, A | 1 |
| Ahn, IE; Fleisher, T; Gaglione, E; Lotter, J; Maric, I; Mu, R; Pittaluga, S; Pleyer, C; Rampertaap, S; Rosenzweig, S; Soto, S; Stetler-Stevenson, M; Sun, C; Superata, J; Tian, X; Wiestner, A; Yuan, CM | 1 |
| Armand, P; Arnason, J; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hanna, J; Lee, B; McDonough, M; Montegaard, J; Odejide, O; Tyekucheva, S | 1 |
| Ali, T; Behfar, M; Farajifard, H; Hamidieh, AA; Hkima Abou Fakher, F; Kheder, M | 1 |
| Hino, Y; Kato, J; Kikuchi, T; Koda, Y; Matsumoto, K; Mishina, T; Mori, T; Morita, K; Nagao, Y; Ohwada, C; Okamoto, S; Onizuka, M; Onoda, M; Sakaida, E; Shimizu, H; Shono, K; Takeda, Y; Yokota, A; Yokoyama, H | 1 |
| Brochstein, J; Sahdev, I; Stiles, J; Werther, N | 1 |
| Beelen, DW; Blaise, D; Bornhäuser, M; Byrne, JL; Fegueux, N; Giebel, S; Karadogan, I; Labopin, M; Mohty, M; Nagler, A; Rovira, M; Savani, BN; Sobczyk-Kruszelnicka, M; Spyridonidis, A; Stelljes, M | 1 |
| An, Y; Gao, X; Jingquan, G; Xiao, K; Xie, W; Yang, L | 1 |
| Aanei, C; Baseggio, L; Béné, MC; Boubaya, M; Campos, L; Cartron, G; Chatelain, B; Cymbalista, F; Dahmani, A; Dartigeas, C; Debliquis, A; Delepine, R; Drénou, B; Feugier, P; Jacob, MC; Katsahian, S; Le Garff-Tavernier, M; Leblond, V; Legac, E; Leprêtre, S; Letestu, R; Lévy, V; Lhoumeau, AC; Quiney, C; Robillard, N; Rouillé, V; Ticchioni, M; Van Den Neste, E; Vaudaux, S | 1 |
| Cao, R; Chen, M; Dong, Z; Su, Q; Wang, F | 1 |
| Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR | 1 |
| Bar, M; Bezerra, ED; Cassaday, RD; Chapuis, AG; Chou, CK; Cowan, AJ; Fiorenza, S; Gauthier, J; Green, DJ; Hawkins, RM; Hirayama, AV; Jamieson, AW; Kiem, HP; Kimble, EL; Maloney, DG; Milano, F; Pender, BS; Phi, TD; Riddell, SR; Shadman, M; Sheih, A; Steinmetz, RN; Till, BG; Turtle, CJ; Vakil, A | 1 |
| Ata, O; Inci, TG; Kocer, S; Mutlu, O; Sariyer, E; Turgut-Balik, D; Ugurel, E; Ugurel, OM | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Iwamoto, S; Kakuda, H; Koh, K; Miyamura, T; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D; Yuza, Y | 1 |
| Cao, L; Du, XY; Fan, L; Li, JY; Wang, F; Wang, L; Xu, W; Zhu, HY | 1 |
| Chu, X; Fang, X; Geng, L; Liu, H; Qiang, P; Song, K; Sun, G; Sun, Z; Tang, B; Tong, J; Wan, X; Yao, W; Zhang, X; Zhu, X | 1 |
| Banet, A; Battipaglia, G; Belhocine, R; Bianchessi, A; Bonnin, A; Boussaroque, A; Brissot, E; Duléry, R; Favale, F; Hirsch, P; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Memoli, M; Mohty, M; Paviglianiti, A; Sestili, S; Van de Wyngaert, Z; Vekhoff, A | 1 |
| Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I | 1 |
| Arabi, A; Bazarbachi, A; Bekadja, MA; Bouhass, R; Brahimi, M; Osmani, S; Serradj, F; Yafour, N | 1 |
| Bejar, J; Garty-Ofir, M; Kreiniz, N; Polliack, A; Tadmor, T | 1 |
| Chauvin-Fleurence, CN; Courtney, AN; Dakhova, O; Di Pierro, EJ; Dotti, G; Ghatwai, N; Heczey, A; Li, M; Liu, B; Liu, K; Metelitsa, LS; Montalbano, A; Ngai, H; Raveh-Sadka, T; Robinson, S; Savoldo, B; Xu, X | 1 |
| Angelucci, E; Beauvais, D; Beelen, D; Bornhäuser, M; Castagna, L; Chevallier, P; Czerw, T; de Wreede, L; Finke, J; Hayden, P; Helbig, G; Hernández-Boluda, JC; Karakasis, D; Kröger, N; Maertens, J; Mauff, K; McLornan, D; Mear, JB; Mohty, M; Passweg, J; Polverelli, N; Reményi, P; Rifòn, J; Robin, M; Rubio, MT; Russo, D; Sirait, T; Vrhovac, R; Yakoub-Agha, I | 1 |
| Bansal, M; Bhargava, R; Chakraborty, S; Dua, V; Hamal, S; Sachdev, M | 1 |
| Cui, Q; Hu, Y; Huang, H; Liang, Z; Shao, M; Wu, Z; Xiao, L; Zhang, H | 1 |
| Albano, F; Angelucci, E; Battistini, R; Coscia, M; Cuneo, A; De Propris, MS; Del Giudice, I; Del Poeta, G; Della Starza, I; Foà, R; Gozzetti, A; Guarini, AR; Ilariucci, F; Liberati, AM; Mauro, FR; Molica, S; Musolino, C; Nanni, M; Neri, A; Piciocchi, A; Pietrasanta, D; Raponi, S; Re, F; Reda, G; Soddu, S; Tedeschi, A; Vignetti, M; Zaja, F | 1 |
| Ahmed, P; Ansar, I; Anwer, F; Ashraf, R; Chaudhry, QUN; Farhan, M; Ghafoor, T; Iftikhar, R; Khan, M; Khan, MA; Khattak, TA; Mahmood, SK; Marsh, J; Neupane, K; Rafae, A; Rehman, J; Satti, TM; Shahbaz, N; Shamshad, GU | 1 |
| Brammer, JE; Choe, H; Dickerson, T; Elder, P; Jaglowski, S; Larkin, K; Mims, A; Penza, S; Puto, M; Rasor, B; Roddy, JVF; Saad, A; Vasu, S; Wall, SA; William, B; Zhao, Q | 1 |
| Kapoor, R; Rastogi, N; Yadav, SP | 1 |
| Fukuhara, S; Izutsu, K; Kinoshita, T; Ohashi, Y; Suzumiya, J; Takizawa, J; Tobinai, K; Yamamoto, G | 1 |
| Moreno, C | 1 |
| Barbarino, M; Bottaro, M; Cipollini, M; Corrado, A; Dell'Anno, I; Gemignani, F; Giordano, A; Landi, S; Luzzi, L; Martin, SA; Melaiu, O; Melani, A; Paolicchi, E; Silvestri, R | 1 |
| Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A | 1 |
| Clement, NF; Dietrich, J; Hochberg, EP; Martinez-Lage, M; Winter, SF | 1 |
| Mathews, W; Muldoon, D; Tolar, J; Vanden Oever, M | 1 |
| El-Sharkawi, D; Stewart, A; Williams, R | 1 |
| Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K | 1 |
| Chan, W; Ding, H; Hao, L; Li, J; Liu, J; Ren, J; Wang, J; Wang, M; Wei, W; Yang, Q; Yue, Y | 1 |
| Angelucci, E; Arcese, W; Battipaglia, G; Blaise, D; Chalandon, Y; Chiusolo, P; Contentin, N; Czerw, T; de Wreede, LC; Fanin, R; Fox, ML; Hayden, P; Hernandez-Boluda, JC; Iori, AP; Kroger, N; Marotta, G; Mauff, K; McLornan, D; Mohty, M; Pioltelli, P; Rubio, MT; Santarone, S; Sever, M; Solano, C; Wendel, L; Yakoub-Agha, I | 1 |
| Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M | 1 |
| Chen, A; Hayes-Lattin, B; Maziarz, RT; Murphree, C; Nagle, SJ; Nemecek, E; Raess, PW; Schachter, L | 1 |
| Atalay, RC; Guven, EB; Kucukdumlu, A; Tuncbilek, M | 1 |
| Andersen, MA; da Cunha-Bang, C; Frederiksen, H; Grønbaek, K; Hjalgrim, H; Niemann, CU; Rostgaard, K; Rotbain, EC | 1 |
| Ayash, L; Deol, A; Kim, S; Modi, D; Ratanatharathorn, V; Singh, V; Uberti, JP | 1 |
| Edahiro, T; Fujii, T; Fujino, K; Fukushima, N; Hirata, Y; Ichinohe, T; Kawase, T; Mino, T; Miyama, T; Morioka, T; Nagoshi, H; Nishizawa, M; Noma, M; Toishigawa, K; Yoshida, T | 1 |
| Chamo, M; Gazit, R; Goldstein, O; Ilic, S; Keinan, N; Scharff, Y | 1 |
| Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Campbell, TB; Jagannath, S; Madduri, D; Neumann, F; Parekh, S; Petrocca, F | 1 |
| Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S | 1 |
| Algarra, L; Amador Barciela, ML; Barragán, E; Bergua Burgues, J; Colorado, M; Falantes, JF; Fernández, MÁ; Foncillas, MÁ; García, O; Gascón, A; Gil, C; Herrera, P; Labrador, J; Lavilla, E; López-Lorenzo, JL; Martínez-Cuadrón, D; Martínez-López, J; Martínez-Sánchez, MP; Montesinos, P; Olave, MT; Paiva, B; Pérez-Encinas, MM; Ramos, F; Rodríguez-Veiga, R; Salamero, O; Sanz, MÁ; Sayas, MJ; Serrano, A; Serrano, J; Simiele, A; Tormo, M; Vidriales, B; Vives, S | 1 |
| Ashida, T; Atsuta, Y; Fukuda, T; Hara, M; Ichinohe, T; Ikeda, T; Ishikawa, T; Kawakita, T; Maruyama, Y; Morishige, S; Shimomura, Y; Takada, S; Takanashi, M; Uchida, N; Wake, A; Yamamoto, H | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Demsky, C; Gorfinkel, L; Kupfer, G; Pashankar, F; Shah, NC | 1 |
| Cuesta, M; Esquirol, A; Ferrà, C; Garcia-Cadenas, I; Herruzo, B; Martino, R; Pascual, MJ; Pérez, A; Sierra, J; Torio, A; Torrent, A | 1 |
| Ding, H; Gao, C; Gao, S; Li, Z; Lin, S; Wen, C; Xing, Z; Yu, Y; Zou, P | 1 |
| Abraham, A; Abubacker, FN; Devasia, AJ; George, B; Korula, A; Kulkarni, U; Lakshmi, KM; Lionel, S; Mathews, V; Selvarajan, S; Sindhuvi, E | 1 |
| Asher, N; Ben-Betzalel, G; Besser, MJ; Itzhaki, O; Jacoby, E; Lev-Ari, S; Markel, G; Meirson, T; Nissani, A; Schachter, J; Shapira-Frommer, R | 1 |
| Cho, HW; Hyun, JK; Ju, HY; Koo, HH; Lee, JW; Lim, DH; Sung, KW; Yoo, KH | 1 |
| Cheng, Z; Feng, L; He, F; Wei, R; Wu, Y; Xiao, M; Zhao, G | 1 |
| Ayala, A; Borthakur, G; Bose, P; Burger, J; Estrov, Z; Ferrajoli, A; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Lopez, W; O'Brien, S; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Takahashi, K; Thompson, P; Wang, S; Wang, W; Wang, X; Wierda, WG | 1 |
| Chaudhury, S; Duerst, RE; Jacobsohn, D; Kletzel, M; Kwon, S; Rossoff, J; Schneiderman, J; Tse, WT | 1 |
| Isobe, M; Konuma, T; Monna-Oiwa, M; Okabe, M; Takahashi, S; Tojo, A | 1 |
| Allsup, D; Bloor, A; Emmerson, J; Hillmen, P; Hockaday, A; Howard, D; Munir, T; Nathwani, A; Oughton, JB; Paneesha, S; Phillips, D; Rawstron, A; Turner, D | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M | 1 |
| Hajifathali, A; Mabani, M; Mehdizadeh, M; Parkhideh, S; Rezvani, H; Salari, S | 1 |
| Bai, S; Cai, Z; Gong, J; Huang, H; Huang, T; Peng, Y; Xiong, G; Xiu, H; Zhang, G; Zhang, S | 1 |
| Amagai, M; Fujita, T; Fukuda, K; Funakoshi, T; Handa, M; Hirai, I; Iwata, T; Kamijuku, H; Kato, J; Kawakami, Y; Koda, Y; Mori, M; Mori, T; Noji, S; Ohta, S; Okamoto, S; Sakurai, M; Tanosaki, R; Watanabe, N; Yaguchi, T | 1 |
| Ahmed, SO; Alahmari, A; Alfraih, F; Alhakim, A; Alhayli, S; Aljurf, M; Almohareb, F; Alsadi, H; Alshaibani, A; Alsharif, F; Alshomar, A; Alzahrani, H; Assiri, A; Babiker, F; Balbaid, A; Chaudhri, N; El Fakih, R; Elhassan, T; Ghabashi, E; Hanbali, A; Kotb, A; Rasheed, W; Samarkandi, H; Shaheen, M | 1 |
| Arai, Y; Atsuta, Y; Eto, T; Fukuda, T; Hirabayashi, S; Ichinohe, T; Ikegame, K; Kanda, J; Kawata, T; Kimura, T; Kondo, T; Marumo, A; Tabuchi, K; Tanaka, M; Uchida, N; Uozumi, R; Wake, A; Yanada, M; Yano, S | 1 |
| Allsup, D; Baird, DM; Bomben, R; Bulian, P; Catovsky, D; Fegan, CD; Gattei, V; Hillmen, P; Hockaday, A; Norris, K; Ow, PL; Pepper, AGS; Pepper, C; Polesel, J; Rawstron, A; Soe, Z; Tissino, E; Zucchetto, A | 1 |
| Atsuta, Y; Eto, T; Fukuda, T; Hara, M; Hirabayashi, S; Ichinohe, T; Kanda, Y; Kawakita, T; Kimura, T; Kondo, T; Maruyama, Y; Mizuno, S; Mukae, J; Nakano, N; Ota, S; Ozawa, Y; Shimomura, Y; Tanaka, M; Uchida, N; Yanada, M | 1 |
| Araqi Houssaini, L; Chiheb, S; Hali, F; Marnissi, F; Quessar, A | 1 |
| Illés, Á; Szász, R; Telek, B | 1 |
| Barhoom, D; Behfar, M; Hamidieh, AA; Mohseni, R | 2 |
| Amini, R; Ashofteh, N; Baazm, M; Karami, H; Molaee, N | 1 |
| Cai, QQ; Cao, JN; Feng, JF; Gao, Y; Huang, HQ; Jiang, WQ; Jin, J; Li, ZM; Wang, HQ; Wang, XX; Zhang, HL | 1 |
| Agrawal, V; Ahn, KW; Aljurf, M; Bacher, U; Bashey, A; Beitinjaneh, A; Bredeson, C; Cerny, J; Chhabra, S; Copelan, E; Diaz, MA; Farhadfar, N; Farhan, S; Fretham, C; Gale, RP; Ganguly, S; Grunwald, MR; Hale, GA; Hashmi, S; Hildebrandt, GC; Jain, T; Kalaycio, M; Kharfan-Dabaja, MA; Lazarus, HM; Liesveld, JL; Litzow, M; Majhail, NS; Marks, DI; Murthy, HS; Nakamura, R; Nathan, S; Nishihori, T; Olsson, RF; Oran, B; Pawarode, A; Popat, U; Reshef, R; Rizzieri, D; Saber, W; Sabloff, M; Savani, BN; Scott, BL; Seo, S; Szer, J; van der Poel, M; Verdonck, LF; Weisdorf, D; Wirk, B; Yared, JA; Yves-Cahn, J | 1 |
| Barr, PM; Barrientos, JC; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Kay, NE; Leis, JF; Lesnick, CE; Litzow, MR; Mato, AR; Mullane, MP; O'Brien, S; Paietta, EM; Shanafelt, TD; Singh, AK; Stone, R; Tallman, MS; Tschumper, RC; Wang, XV; Zhang, CC | 1 |
| Al-Ammari, M; Albtoosh, BM; Alfayez, M; AlGhamdi, MS; Alnoamani, MS; AlShehry, NF; Altaf, SY; Aoun, SMA; Iqbal, S; Marei, MA; Motabi, IH; Tailor, IK; Zaidi, SZ | 1 |
| Ansari, M; Ben Hassine, K; Bittencourt, H; Bredius, RGM; Daali, Y; Kassir, N; Krajinovic, M; Lewis, V; Nath, CE; Nava, T; Shaw, PJ; Théoret, Y; Uppugunduri, CRS | 1 |
| Adams, JM; Anderson, MA; Blombery, P; Carney, DA; Chen, X; Dengler, MA; Handunnetti, SM; Huang, DCS; Lew, TE; Lin, VS; Nguyen, T; Panigrahi, A; Roberts, AW; Seymour, JF; Tam, CS; Thompson, ER; Wei, AH; Westerman, DA | 1 |
| Aoki, J; Atsuta, Y; Fukuda, T; Imada, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y | 1 |
| Dong, J; Meng, G; Wei, J; Wu, J; Zhang, H; Zhang, Y; Zuo, S | 1 |
| Atanackovic, D; Bukhari, A; Dahiya, S; Gahres, N; Gottlieb, D; Hardy, NM; Holtzman, NG; Kansagra, AJ; Kim, DW; Kocoglu, MH; Law, JY; Lee, ST; Lutfi, F; Matsumoto, LR; Mohindra, P; Molitoris, J; Mustafa Ali, M; Rapoport, AP; Ruehle, K; Samanta, S; Yan, J; Yared, JA | 1 |
| Alcoceba, M; Andreu, MÁ; Anguita, E; Collado, R; Córdoba, R; de la Serna, J; de Oteyza, JP; Deben, G; Fernández, MC; Fernández-Cuevas, B; Fernández-Zarzoso, M; García-Malo, MD; García-Marco, JA; Garcia-Vela, JA; Gómez, S; González, M; González-Barca, E; González-Rincón, J; López-Jiménez, J; Navarro-Matilla, B; Nova-Gurumeta, S; Paz-Arias, R; Peñalver, FJ; Pérez-Persona, E; Pérez-Sanz, N; Recasens, V; Ruíz-Guinaldo, MÁ; Sánchez-Beato, M; Yáñez, L | 1 |
| Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I | 1 |
| Bağrıaçık, EÜ; Gökçen, S; Kayhan, H; Yağcı, M | 1 |
| Avivi, I; Bot, A; Bouabdallah, K; Dong, J; Dührsen, U; Houot, R; Kerber, A; Kersten, MJ; Kim, JJ; Kuruvilla, J; Lugtenburg, PJ; Minnema, MC; Plaks, V; Rossi, JM; Sherman, M; Song, KW; Thieblemont, C; Topp, MS; van Meerten, T; Vardhanabhuti, S; Wermke, M; Zheng, Y | 1 |
| Akiyama, M; Goto, H; Hasegawa, D; Honda, T; Kumamoto, T; Ogawa, S; Takagi, M; Terao, YM; Yamaoka, M; Yoshida, K | 1 |
| Antin, JH; Brock, J; Cutler, CS; DeAngelo, DJ; Fell, G; Garcia, JS; Gooptu, M; Ho, VT; Karp, HQ; Kim, AS; Kim, HT; Koreth, J; Letai, A; Lindsley, RC; Loschi, F; Lucas, F; Mashaka, T; Murdock, HM; Nikiforow, S; Potter, D; Romee, R; Ryan, J; Shapiro, R; Soiffer, RJ; Stone, RM | 1 |
| DiNardo, C; Gibson, A; Khazal, S; Mahadeo, KM; Petropoulos, D; Ragoonanan, D; Rodriguez, N; Tewari, P | 1 |
| Adachi, H; Atsuta, Y; Doki, N; Igarashi, A; Ikegawa, S; Inamoto, K; Kaito, S; Kishida, Y; Kobayashi, T; Konishi, T; Konuma, R; Marumo, A; Mukae, J; Nagata, A; Nagata, R; Najima, Y; Noguchi, Y; Ohashi, K; Sakamaki, H; Toya, T; Wada, A; Yamada, Y | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Appelbaum, FR; Cooper, JP; Deeg, HJ; Doney, K; Flowers, MED; Gooley, T; Martin, PJ; McCune, JS; McFarland, C; O'Donnell, PV; Schoch, G; Sorror, ML; Storer, BE; Yeh, AC | 1 |
| Armand, P; Arnason, J; Brown, JR; Davids, MS; Fernandes, SM; Fisher, DC; Gadi, D; Griffith, A; Lederer, JA; Lee, B; Lehmberg, TZ; Machado, JH; Martindale, SP; Odejide, O; Rai, V; Thrash, E; Tyekucheva, S; Vartanov, A; Wang, Z | 1 |
| Geng, L; Li, G; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wan, X; Yao, W; Zhang, L; Zhang, S; Zhang, X; Zhu, X | 1 |
| Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB | 1 |
| Baggott, C; Boelens, JJ; Brown, PA; Chinnabhandar, V; Curran, KJ; Egeler, E; Fabrizio, VA; Goksenin, AY; Hermiston, M; Karras, NA; Keating, AK; Krupski, C; Kunicki, M; Laetsch, TW; Mackall, CL; Margossian, SP; Mauguen, A; Mavroukakis, S; Moskop, A; Myers, GD; Pacenta, H; Phillips, CL; Prabhu, S; Qayed, M; Rabik, CA; Rossoff, J; Satwani, P; Schultz, LM; Stefanski, HE; Talano, JA; Verneris, MR; Wilcox, R | 1 |
| Abboud, R; Andolina, JR; DiPersio, JF; Eastburg, L; Fountaine, T; Huselton, E; Russler-Germain, DA | 1 |
| Almazi, JG; Alomari, M; Belov, L; Best, OG; Christopherson, RI; Graham, ME; Mulligan, SP; Shen, Y | 1 |
| Alimoghaddam, K; Badalzadeh, M; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Mahdaviani, SA; Pourpak, Z; Setarehdan, SA; Souri, M; Tajik, S; Vaezi, M | 1 |
| Algeri, M; Alseraihy, A; Angelucci, E; Corbacioglu, S; Cseh, A; de la Fuente, J; Fisgin, T; Galimard, JE; Isgrò, A; Kleinschmidt, K; La La Nasa, G; Lankester, A; Locatelli, F; Lüftinger, R; Peters, C; Salzer, E; Smiers, FJ; Unal, E; Yesilipek, A; Zecca, M; Zubarovskaya, N | 1 |
| Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A | 1 |
| Cen, S; Dong, D; Guo, F; Guo, S; Li, Q; Li, X; Liu, Q; Liu, Z; Ma, L; Wei, T; Yi, D; Zhang, Y; Zhao, J | 1 |
| Allsup, DJ; Bloor, A; Cairns, D; Clifford, R; Craig, Z; Gattei, V; Hillmen, P; Hockaday, A; Howard, D; Munir, T; Pepper, C; Rawstron, A; Robbe, P; Schuh, A; Soe, Z; Zucchetto, A | 1 |
| Admiraal, R; Bierings, M; Blok, H; Calkoen, FG; De Koning, C; Dekker, L; Hoogerbrugge, P; Huitema, ADR; Jiang, Y; Lindemans, CA; Nierkens, S; Nijstad, AL; Pieters, R; Spoon, M; Van Der Elst, KCM; Van Der Vlugt, M; Van Tinteren, H; Veldkamp, SR; Visscher, H; Vormoor, B; Vormoor, HJ | 1 |
| Andersson, BS; Murray, D; Nieto, Y; Popat, U; Valdez, BC; Yuan, B | 1 |
| Asquith, KL; Barr, I; Chen, L; Foster, PS; Hsu, AC; Laurie, K; Li, X; Liu, C; Liu, X; Yang, M | 1 |
| Atsuta, Y; Fukuda, T; Imada, K; Ishiyama, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kimura, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y | 1 |
| Bowornruangrit, P; Kumkate, S; Leardkamolkarn, V; Sirigulpanit, W | 1 |
| Bassermann, F; Braitsch, K; Götze, KS; Herhaus, P; Hubbuch, M; Keller, U; Koch, K; Menzel, H; Schwarz, A; Verbeek, M | 1 |
| Bazarbachi, A; Bethge, W; Blau, IW; Bondarenko, S; Brecht, A; Brissot, E; Bulabois, CE; Eder, M; Einsele, H; Forcade, E; Giebel, S; Huynh, A; Labopin, M; Mohty, M; Nagler, A; Rodríguez-Arbolí, E; Savani, B; Schmid, C; Spyridonidis, A; Stölzel, F; Tischer, J; Verbeek, M | 1 |
| Baj, G; Bortolussi, G; de Alencastro, G; Jang, H; Kay, MA; Muro, AF; Pekrun, K; Stephens, CJ; Tsuji, S; Zhang, F | 1 |
| Arpinati, M; Baronciani, D; Bernasconi, P; Bonifazi, F; Brunello, L; Bruno, B; Busca, A; Carella, AM; Carluccio, P; Casini, M; Chiusolo, P; Ciceri, F; Cilloni, D; Cupri, A; Di Grazia, C; Gheorghiu, A; Giglio, F; Girmenia, C; Grassi, A; Grillo, G; Iori, AP; Luppi, M; Martino, M; Masciulli, A; Musso, M; Nozzoli, C; Oldani, E; Onida, F; Palazzo, G; Parma, M; Patriarca, F; Pavoni, C; Peccatori, J; Picardi, A; Proia, A; Rambaldi, A; Sacchi, N; Santarone, S; Sorasio, R; Tringali, S; Vacca, A; Vallisa, D | 1 |
| Ali, N; Bal, SK; Boughan, KM; Caimi, PF; Cooper, BW; de Lima, M; de Rezende, ACP; Gallogly, M; Hamerschlak, N; Kerbauy, L; Kerbauy, MN; Latif, BM; Malek, E; Mansur, D; Metheny, L; Otegbeye, F; Pereira, G; Ribeiro, AF; Sakuraba, R; Sanchez, G; Sekaly, RP; Sharma, AA; Tomlinson, BK; Weltman, E | 1 |
| Azarnoush, S; Dhunputh, C; Ducassou, S; Leverger, G; Merched, M; Pasquet, M; Petit, A; Strullu, M | 1 |
| Derlon, JM; Gourand, F; Guillouet, S; Kalaeva, D; Khokholova, E; Kobyakov, G; Maryashev, S; Pitskhelauri, D; Postnov, A; Potapov, A; Pronin, I; Pyzhik, E; Rizhova, M; Toutain, J; Usachev, D; Valable, S; Vikhrova, N | 1 |
| Afanasyev, B; Beynarovich, A; Borzenkova, E; Kondakova, E; Kozlov, A; Kulagin, A; Lepik, K; Mikhailova, N; Moiseev, I; Pirogova, O; Stelmakh, L; Volkov, N; Zalyalov, Y; Zubarovskaya, L | 1 |
| Alkhateeb, HB; Barreto, EF; Bartoo, GT; Hogan, WJ; Kutzke, JL; Leung, N; Litzow, MR; Mangaonkar, AA; Mara, KC; Merten, JA; Pawlenty, AG; Shah, MV | 1 |
| Crodel, CC; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Linke, P; Miethke, J; Schnetzke, U; Scholl, S | 1 |
| Abraham, A; Balasubramanian, P; Devasia, AJ; Fouzia, NA; George, B; Kavitha, ML; Korula, A; Kulkarni, UP; Lionel, S; Mathews, V; Pai, AA; Selvarajan, S; Sindhuvi, E; Srivastava, A | 1 |
| Ahmed, S; Alousi, A; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Hosing, C; Kawedia, J; Kebriaei, P; Kornblau, S; Ma, J; Myers, A; Nieto, Y; Oran, B; Parmar, S; Popat, UR; Rezvani, K; Shah, N; Shpall, E; Thall, PF; Valdez, BC | 1 |
| Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| AlRiyami, L; Grunebaum, E; Hook, R; Rao, H; Schechter, T; Wall, DA; Xu, M | 1 |
| Babushok, DV; Frey, NV; Freyer, CW; Gill, SI; Hexner, EO; Loren, AW; Luger, SM; Maity, A; Martin, ME; Plastaras, JP; Porter, DL | 1 |
| Arora, S; Di Stasi, A; Jamy, O; Meredith, R; Minagawa, K; Mineishi, S; Saad, A; Salzman, D | 1 |
| Diaz, A; Maziarz, RT; Miklos, DB; Shah, NN | 1 |
| Bertz, H; Bornhäuser, M; Burchert, A; Dreger, P; Finke, J; Glass, B; Grishina, O; Hegenbart, U; Kobbe, G; Reicherts, C; Schmoor, C; Schub, N; Sohlbach, K; Stelljes, M; Wagner-Drouet, EM | 1 |
| Brissot, E; Clement, L; Dalle, JH; Gandemer, V; Grain, A; Jubert, C; Labopin, M; Michel, G; Mohty, M; Paillard, C; Plantaz, D; Pochon, C; Rialland, F; Rohrlich, PS; Sirvent, A | 1 |
| Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X | 1 |
| Cioccio, J; Claxton, DF; Ehmann, WC; Minagawa, K; Mineishi, S; Naik, S; Nickolich, M; Pizzola, CJ; Rakszawski, KL; Rybka, WB; Shike, H; Silar, B; Wirk, B; Zheng, H; Zhou, S | 1 |
| Dimitrova, D; Kanakry, JA | 1 |
| Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z | 1 |
| Ling, Y; Qi, Y; Xu, W; Xu, X; Yang, S; Ye, H; Zhao, Y | 1 |
| Chen, J; Hu, S; Huang, X; Jiang, E; Jiang, H; Lan, M; Li, C; Li, F; Lin, F; Liu, S; Lu, P; Lu, Y; Luo, C; Sun, S; Sun, Y; Tang, Y; Wan, D; Wang, S; Wu, X; Xu, L; Xu, Y | 1 |
| Aviv, A; Bairey, O; Bomben, R; Braester, A; Bronstein, Y; Chiarenza, A; Coscia, M; Cuneo, A; Del Poeta, G; Del Principe, MI; Fineman, R; Foà, R; Gaidano, G; Gattei, V; Gentile, M; Goldschmidt, N; Gutwein, O; Herishanu, Y; Laurenti, L; Levi, S; Loseto, G; Mauro, FR; Morabito, F; Murru, R; Neri, A; Olivieri, J; Perry, C; Pietrasanta, D; Reda, G; Rossi, D; Ruchlemer, R; Shvidel, L; Sportoletti, P; Tadmor, T; Trentin, L; Varettoni, M; Visentin, A; Ziv-Baran, T; Zucchetto, A | 1 |
| Gale, RP; Halahleh, KA; Ma'koseh, M; Muradi, I; Rimawi, DH; Sultan, I | 1 |
| Do Nascimento, J; Domingo-Domenech, E; Encuentra, M; Ferrá, C; Gallardo, D; González-Barca, E; López, P; Oliveira, AC; Ribera, JM; Rodriguez-Luaces, M; Roncero, JM; Sarrá, J; Sureda, A | 1 |
| Arat, M; Berceanu, A; Giebel, S; Hamladji, RM; Kröger, N; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Potter, V; Rambaldi, A; Sanz, J; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R; Yakoub-Agha, I | 1 |
| Abuasab, T; Alvarado, Y; Borthakur, G; Brandt, MA; Daver, N; DiNardo, C; Haddad, FG; Kadia, T; Kantarjian, H; Pemmaraju, N; Ravandi, F; Senapati, J | 1 |
| Ara, T; Ashida, T; Atsuta, Y; Fukuda, T; Kamijo, K; Kanaya, M; Kim, SW; Kondo, E; Kuriyama, T; Kusumoto, S; Maseki, N; Matsuoka, KI; Mizuno, I; Mizuno, S; Nakazawa, H; Onizuka, M; Shimomura, Y; Shinohara, A; Usui, Y; Yamaguchi, M | 1 |
| Chan, WYK; Cheuk, DKL; Cheung, C; Ha, SY; Kan, EYL; Lee, PPW; Leung, W; Shelia, WSN; Tso, WWY; Yeung, WL | 1 |
| Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M | 1 |
| Hanke, C; Shah, M; Wald, J | 1 |
| Fan, Z; Guo, Z; Huang, F; Jin, H; Liang, X; Lin, R; Ling, Y; Liu, C; Liu, H; Liu, Q; Liu, X; Ou, R; Qu, H; Sun, J; Wu, M; Xu, N; Xu, X; Xuan, L; Yu, S; Zhai, X; Zhang, H; Zhang, Y; Zhao, Y | 1 |
| Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F | 1 |
| Dai, L; Ding, C; Fan, L; Jiang, R; Li, J; Miao, Y; Qin, S; Qiu, J; Qiu, T; Sha, Y; Shen, H; Wu, W; Wu, Y; Xia, Y; Xu, W; Yang, Y; Zhu, H | 1 |
| Bazinet, A; Keating, MJ; O'Brien, SM; Peterson, CB; Plunkett, W; Saha, S; Tam, CS; Thompson, PA; Wierda, WG | 1 |
| Boubaya, M; Bravetti, C; Chapiro, E; Davi, F; Dehgane, L; Doualle, C; Garnier, D; Grange, B; Jondreville, L; Lerner, LK; Nguyen-Khac, F; Roos-Weil, D; Smagghe, L; Susin, SA; Tournilhac, O | 1 |
| Carlow, DC; Schofield, RC; Scordo, M; Shah, G | 1 |
317 review(s) available for fludarabine and vidarabine
| Article | Year |
|---|---|
New antimetabolites in the treatment of human malignancies.
Topics: Animals; Antimetabolites, Antineoplastic; Cladribine; Clinical Trials as Topic; Drugs, Investigational; Forecasting; Humans; Immunosuppression Therapy; Leukemia; Lymphoma; Pentostatin; Purines; Vidarabine | 1992 |
[New analogs of deoxyadenosine for treatment of lymphoid malignancies].
Topics: Antineoplastic Agents; Cladribine; Deoxyadenosines; Formycins; Humans; Leukemia; Lymphoma; Vidarabine | 1992 |
A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities.
Topics: 2-Chloroadenosine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Chlorambucil; Deoxyadenosines; Dose-Response Relationship, Drug; Histocompatibility Testing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prednisone; Prognosis; Survival Rate; Vidarabine | 1992 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma.
Topics: Antineoplastic Agents; Humans; Interferon-alpha; Lymphoma, Non-Hodgkin; Multiple Myeloma; Vidarabine | 1992 |
New purine analogues for the treatment of chronic B-cell malignancies.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1991 |
Fludarabine: a review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Neoplasms; Remission Induction; Vidarabine | 1991 |
[Treatment with cyclosporin A of the anemia associated with chronic lymphatic leukemia].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclosporins; Erythropoiesis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Red-Cell Aplasia, Pure; T-Lymphocytes, Regulatory; Thrombocytopenia; Vidarabine | 1990 |
Membrane transport and the antineoplastic action of nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Membrane; Humans; Nucleosides; Vidarabine | 1987 |
Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Cladribine; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1994 |
Evolution of the arabinosides and the pharmacology of fludarabine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cytarabine; Humans; Leukemia; Vidarabine | 1994 |
Clinical experience with fludarabine in leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 1994 |
Fludarabine in the management of malignant lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Incidence; Lymphoma; Lymphoma, Non-Hodgkin; Mycoses; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Potential immunological action of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cladribine; Humans; Immunosuppressive Agents; Leukemia; Pentostatin; Purine Nucleosides; Vidarabine | 1994 |
The expanding role of fludarabine in hematologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
The optimal management of hairy cell leukaemia.
Topics: Antineoplastic Agents; Cladribine; Combined Modality Therapy; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Leukemia, Hairy Cell; Pentostatin; Splenectomy; Vidarabine | 1995 |
Modulation of arabinosylcytosine metabolism during leukemia therapy.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Biotransformation; Cytarabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia; Vidarabine | 1994 |
Infectious and immunosuppressive complications of purine analog therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Humans; Immune Tolerance; Infections; Pentostatin; Purines; Vidarabine | 1995 |
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 1995 |
Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance; Humans; Lymphoproliferative Disorders; Pentostatin; Purine Nucleosides; Vidarabine | 1995 |
Advances in therapy for hairy cell leukemia. A review.
Topics: 2-Chloroadenosine; Deoxyadenosines; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Leukemia, Hairy Cell; Male; Pentostatin; Splenectomy; Vidarabine | 1993 |
Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Neoplasms, Experimental; Vidarabine | 1993 |
Antimetabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Cytarabine; Drug Resistance; Fluorouracil; Humans; Mercaptopurine; Methotrexate; Vidarabine | 1994 |
Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Chlorambucil; Chromosome Aberrations; Cladribine; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Vidarabine | 1995 |
The role of fludarabine in hematological malignancies.
Topics: Adult; Aged; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias.
Topics: Acute Disease; Animals; Antineoplastic Agents; DNA Replication; Humans; Leukemia; Leukemia, Experimental; Mice; Vidarabine | 1994 |
The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma; Pentostatin; Vidarabine | 1993 |
Purine analogs in lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Multiple Myeloma; Pentostatin; Vidarabine | 1993 |
Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia; Lymphoma; Molecular Structure; Pentostatin; Purine Nucleosides; Vidarabine | 1993 |
Neurotoxicity of purine analogs: a review.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Male; Middle Aged; Nervous System; Nervous System Diseases; Pentostatin; Purine Nucleosides; Vidarabine | 1994 |
Nucleoside analogs in treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Survival Rate; Vidarabine | 1993 |
Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL).
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Cell Division; DNA Repair; Drug Resistance; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Prognosis; Proliferating Cell Nuclear Antigen; Vidarabine | 1993 |
Fludarabine for treatment of adult acute myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Molecular Structure; Multicenter Studies as Topic; Radiation-Sensitizing Agents; Remission Induction; Tumor Cells, Cultured; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Neoplasms; Vidarabine | 1993 |
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
Fludarabine in the treatment of lymphoproliferative malignancies.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoproliferative Disorders; Vidarabine | 1993 |
[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Remission Induction; Vidarabine | 1995 |
[Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Hematopoietic Cell Growth Factors; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Remission Induction; Salvage Therapy; Vidarabine | 1995 |
New chemotherapeutic agents in acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotoxins; Leukemia, Myeloid; Oligonucleotides, Antisense; Retinoids; Vidarabine | 1996 |
Key issues in the treatment of chronic lymphocytic leukaemia (CLL)
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; Hematopoietic Cell Growth Factors; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Risk Factors; Vidarabine | 1995 |
Intracellular pharmacodynamics in leukemia therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Mitoxantrone; Vidarabine | 1996 |
Current results and prospective trials of cladribine in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prospective Studies; Vidarabine | 1996 |
The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia.
Topics: Alkylation; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1996 |
[Current therapeutic methods in onco-hematology].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cladribine; Docetaxel; Humans; Keratolytic Agents; Leukemia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tretinoin; Vidarabine | 1996 |
Radiosensitizing nucleosides.
Topics: Animals; Deoxycytidine; Gemcitabine; Humans; Hydroxyurea; Nucleosides; Pyrimidines; Radiation-Sensitizing Agents; Thymidine; Vidarabine | 1996 |
[Antileukemic agents--new drugs and attempts of rational administration].
Topics: Antineoplastic Agents; Drug Administration Schedule; Humans; Idarubicin; Leukemia; Vidarabine | 1996 |
Purine analogues in the management of lymphoproliferative diseases.
Topics: Antineoplastic Agents; Cladribine; Humans; Lymphoproliferative Disorders; Pentostatin; Vidarabine | 1996 |
[Treatment of chronic lymphatic leukemia].
Topics: Antineoplastic Agents; Cladribine; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Vidarabine | 1996 |
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Purine Nucleosides; Vidarabine; Waldenstrom Macroglobulinemia | 1996 |
2-Chlorodeoxyadenosine treatment of lymphoma.
Topics: Adenosine Deaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell, Cutaneous; Pentostatin; Vidarabine; Waldenstrom Macroglobulinemia | 1996 |
Pharmacology of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Cladribine; Hematologic Neoplasms; Humans; Pentostatin; Purine Nucleosides; Vidarabine | 1996 |
Adverse and beneficial immunological effects of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Cladribine; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Purine Nucleosides; Vidarabine | 1996 |
Clinical experience with fludarabine in hemato-oncology.
Topics: Antineoplastic Agents; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Vidarabine | 1996 |
Perspectives on purine analogues.
Topics: Antineoplastic Agents; Cladribine; Forecasting; Humans; Leukemia; Pentostatin; Purines; Vidarabine | 1996 |
Purine analogs in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1997 |
Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Recurrence; Remission Induction; Vidarabine | 1997 |
Is there a place for 2-CDA in the treatment of B-CLL?
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thrombocytopenia; Vidarabine | 1997 |
Prophylactic strategies to meet infectious complications in fludarabine-treated CLL.
Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Granulocyte Colony-Stimulating Factor; Humans; Immunoglobulins, Intravenous; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Opportunistic Infections; Salvage Therapy; Vidarabine | 1997 |
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Synergism; Drug Tolerance; Hematologic Neoplasms; Humans; Vidarabine | 1997 |
[A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
Topics: Antineoplastic Agents; Hematologic Neoplasms; Humans; Vidarabine | 1997 |
Complications in the treatment of CLL with purine analogues.
Topics: Anemia, Hemolytic, Autoimmune; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Purine Nucleosides; Vidarabine | 1997 |
[Current principles of diagnosis and treatment of chronic lymphocytic B-cell leukemia].
Topics: Alkylating Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1998 |
Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Combined Modality Therapy; Cytokines; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunotherapy, Adoptive; Interleukin-2; Lymphoma; Neoplasm Recurrence, Local; Neoplasm, Residual; Recombinant Proteins; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 1998 |
Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Vidarabine | 1998 |
Clinical challenges in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Splenectomy; Vidarabine | 1998 |
Chronic lymphocytic leukemia in the next decade: where do we go from here?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1998 |
Hairy cell leukemia. What is new forty years after the first description?
Topics: 2-Chloroadenosine; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; B-Lymphocytes; Bone Marrow; Clinical Trials as Topic; Deoxyadenosines; Humans; Immunologic Factors; Interferon Type I; Leukemia, Hairy Cell; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Recombinant Proteins; Splenectomy; Vidarabine | 1998 |
[Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Neoplasm, Residual; Pentostatin; Remission Induction; Splenectomy; Vidarabine | 1998 |
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Humans; Idarubicin; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Topotecan; Vidarabine | 1998 |
Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk-adapted therapy.
Topics: Bacterial Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 1999 |
[Multiple myeloma and other plasma cell dyscrasias].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Diagnosis, Differential; Heavy Chain Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Prognosis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 1999 |
Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Eosinophilia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1999 |
Current treatment of follicular low-grade lymphomas.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Lymphoma, Follicular; Vidarabine | 1999 |
CD40 and B chronic lymphocytic leukemia cell response to fludarabine: the influence of NF-kappaB/Rel transcription factors on chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; CD40 Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Oncogene Proteins v-rel; Tumor Cells, Cultured; Vidarabine | 2000 |
Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.
Topics: Antineoplastic Agents; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2000 |
Follicular lymphoma: have we made any progress?
Topics: Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Lymphoma, Follicular; Male; Prognosis; Recurrence; Survival Rate; Vidarabine | 2000 |
Non myeloablative "mini transplants".
Topics: Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Vidarabine | 1999 |
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Remission Induction; Vidarabine | 2000 |
Chronic lymphocytic leukemia.
Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; CD79 Antigens; Chromosome Aberrations; Chromosomes, Human; Cladribine; Combined Modality Therapy; Cytokines; Female; Genes, Immunoglobulin; Genes, p53; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Stem Cells; Prognosis; Risk Factors; Vidarabine | 2000 |
Combination therapy with purine nucleoside analogs.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxyadenosines; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Interferons; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Pentostatin; Purine Nucleosides; Treatment Outcome; Vidarabine | 2000 |
Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Vidarabine | 1999 |
Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations.
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2000 |
Clinical trials review: idiopathic inflammatory myopathy.
Topics: Azathioprine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Methotrexate; Myositis; Vidarabine | 2000 |
Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 2000 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
Novel treatment strategies in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pentostatin; Randomized Controlled Trials as Topic; Sex Factors; Vidarabine | 2001 |
[Mantle cell lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Rituximab; Vidarabine | 2001 |
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Lymphoproliferative Disorders; Neoplastic Stem Cells; Nucleosides; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Remission Induction; Ribonucleotide Reductases; Vidarabine | 2001 |
Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.
Topics: Antineoplastic Agents; Autoimmunity; Cladribine; Humans; Immunosuppressive Agents; Neoplasms; Neoplasms, Second Primary; Vidarabine | 2001 |
[Chronic lymphocytic leukemia. 2. Therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; Chlorambucil; Dose-Response Relationship, Radiation; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunization, Passive; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Risk Factors; Splenectomy; Steroids; Transplantation, Autologous; Vidarabine | 2001 |
A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Leukemia, B-Cell; Prednisolone; Prognosis; Recurrence; Risk Factors; Salvage Therapy; Vidarabine; Vincristine | 2001 |
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Disease Progression; Dogs; Forecasting; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Methotrexate; Middle Aged; Mycophenolic Acid; Neoplasms; Prednisone; Radiation Chimera; T-Lymphocytes, Cytotoxic; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2001 |
Non-myeloablative hematopoietic stem cell transplantation.
Topics: Animals; Bone Marrow; Chimera; Cyclosporine; Dogs; Drug Administration Schedule; Graft Rejection; Graft Survival; Graft vs Host Reaction; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Models, Animal; Mycophenolic Acid; Safety; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2001 |
Combination chemotherapy and rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Doxorubicin; Flow Cytometry; Humans; Immunotherapy; Lymphoma, Non-Hodgkin; Prednisolone; Proto-Oncogene Proteins c-bcl-2; Rituximab; Time Factors; Translocation, Genetic; Treatment Outcome; Vidarabine; Vincristine | 2001 |
Therapeutic options for acute myelogenous leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Prognosis; Topotecan; Vidarabine | 2001 |
Nucleoside analogues in the treatment of haematological malignancies.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine | 2001 |
Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
Topics: Alkylating Agents; Antimetabolites; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Guidelines as Topic; Humans; Middle Aged; Pentostatin; Plasmapheresis; Purine Nucleosides; Quality of Life; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
[Drug-induced hemolytic anemia].
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Cephalosporins; Cyclosporine; Hemolytic-Uremic Syndrome; Humans; Isoantibodies; Leukemia, Lymphocytic, Chronic, B-Cell; Methyldopa; Procainamide; Purpura, Thrombocytopenic; Quinine; Rho(D) Immune Globulin; Thrombocytopenia; Vidarabine | 2001 |
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2001 |
Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies.
Topics: Angiogenesis Inhibitors; Apoptosis; Cytokines; Fibroblast Growth Factor 2; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2001 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
[Chronic lymphocytic leukemias].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prognosis; Sex Factors; Survival Rate; Vidarabine | 2001 |
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vidarabine; Vincristine | 2002 |
Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2002 |
Cellular and clinical pharmacology of fludarabine.
Topics: Antineoplastic Agents; Biological Availability; Deoxycytidine Kinase; DNA (Cytosine-5-)-Methyltransferases; Drug Evaluation, Preclinical; Humans; Leukemia; Lymphoma; Phosphorylation; Vidarabine; Vidarabine Phosphate | 2002 |
Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer.
Topics: Breast Neoplasms; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2002 |
Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Pentostatin; Transplantation, Homologous; Vidarabine | 2002 |
Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cost of Illness; Cost-Benefit Analysis; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical; Treatment Outcome; United Kingdom; Vidarabine | 2002 |
Fludarabine-induced eosinophilia: case report.
Topics: Antineoplastic Agents; Eosinophilia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Vidarabine | 2002 |
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Nucleosides; Survival Rate; Treatment Failure; Vidarabine | 2002 |
Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vidarabine; Vincristine | 2002 |
Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; beta 2-Microglobulin; Chlorambucil; Cladribine; Clinical Trials as Topic; Combined Modality Therapy; Humans; Interferon-alpha; Neoplasm Recurrence, Local; Plasmapheresis; Rituximab; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
Challenges in treating hematologic malignancies.
Topics: Anemia; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epoetin Alfa; Erythropoietin; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Prognosis; Quality of Life; Recombinant Proteins; Vidarabine | 2002 |
[Nucleoside analogues--new drugs for the treatment of lymphatic cancers].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphoid; Lymphoma; Nucleosides; Pentostatin; Vidarabine | 2001 |
Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.
Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases; Prednisone; Tomography, X-Ray Computed; Vidarabine | 2002 |
[Experience with fludarabine treatment and review of the literature].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Remission Induction; Treatment Outcome; Vidarabine | 2002 |
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chlorambucil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bleomycin; Bone Marrow; Bone Marrow Diseases; Chemotherapy, Adjuvant; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Paraproteins; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Current and developing chemotherapy for CLL.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Survival Rate; Vidarabine | 2002 |
Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2002 |
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Male; Melphalan; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Bone Marrow; Busulfan; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Europe; Female; Genetic Heterogeneity; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Infections; Inflammation; Male; Melphalan; Neutrophils; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Waldenström's macroglobulinemia: a review of therapy.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Plasma Exchange; Rituximab; Splenectomy; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2002 |
[Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies].
Topics: Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Host vs Graft Reaction; Humans; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
[Clinical pharmacology of nucleoside analogues].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Biotransformation; Cytarabine; Cytidine Deaminase; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Half-Life; Humans; Male; Metabolic Clearance Rate; Neoplasm Proteins; Phosphorylation; Prodrugs; Vidarabine | 2002 |
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphoma; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2002 |
Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytokines; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunotherapy, Adoptive; Kidney Neoplasms; Melphalan; Multicenter Studies as Topic; Nephrectomy; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2002 |
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Capecitabine; Cell Membrane; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Tumor Cells, Cultured; Vidarabine | 2002 |
Advances in the treatment of hairy-cell leukaemia.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Cell Adhesion Molecules; Cladribine; Humans; Interferon-alpha; Lectins; Leukemia, Hairy Cell; Neoplasm, Residual; Neoplasms, Second Primary; Pancytopenia; Pentostatin; Receptors, Interleukin-2; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Spleen; Splenectomy; Splenomegaly; Treatment Outcome; Vidarabine | 2003 |
Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Blood Urea Nitrogen; Calcium; Creatinine; Fatal Outcome; Fluid Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Phosphorus; Potassium; Renal Dialysis; Tumor Lysis Syndrome; Uric Acid; Vidarabine | 2003 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Rituximab in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2003 |
Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bowen's Disease; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Fatal Outcome; Female; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lomustine; Male; Middle Aged; Mitoxantrone; Neoplasms, Multiple Primary; Neoplastic Stem Cells; Prednisone; Prognosis; Reed-Sternberg Cells; Remission Induction; Skin Neoplasms; Splenectomy; Tumor Virus Infections; Vidarabine; Vinblastine; Vincristine | 2003 |
Purine nucleoside analogues in the treatment of myleoid leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature.
Topics: Aging; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 15; Chromosomes, Human, Y; Clone Cells; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pancytopenia; Trisomy; Tumor Cells, Cultured; Vidarabine | 2003 |
Fludarabine in Waldenstrom's macroglobulinemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Vidarabine; Waldenstrom Macroglobulinemia | 2003 |
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Mechanism of action of purine analogues in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Division; Cladribine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Phosphorylation; Tumor Suppressor Protein p53; Vidarabine | 2003 |
[Evidence-based therapy for chronic leukemia].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Transplantation, Homologous; Vidarabine | 2003 |
A novel t(15;17) translocation in acute myeloid leukaemia not associated with PML/RARalpha rearrangement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Breakage; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; DNA-Binding Proteins; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Acute; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins; Remission Induction; Salvage Therapy; Thioguanine; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Vidarabine | 2003 |
[Non-myeloablative or reduced intensity stem cell transplantation preparative regimens].
Topics: Alemtuzumab; Alkylating Agents; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Radiotherapy Dosage; T-Lymphocytes; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
[Mini-transplantation from HLA-mismatched donors].
Topics: Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
[Mini-transplantation from cord blood].
Topics: Busulfan; Cyclophosphamide; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
[Reduced-intensity stem cell transplantation (RIST) for lymphoproliferative diseases].
Topics: Busulfan; Cause of Death; Clinical Trials as Topic; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Transplantation Conditioning; Vidarabine | 2003 |
[Non-myeloablative stem cell transplantation for non-malignant hematologic disorders].
Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Hemochromatosis; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
[Nonmyeloablative allogeneic peripheral blood stem cell transplantation of renal cell carcinoma].
Topics: Aged; Carcinoma, Renal Cell; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Kidney Neoplasms; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Oral fludarabine.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Biological Availability; Clinical Trials as Topic; Half-Life; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2003 |
[Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Combined Modality Therapy; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitrogen Mustard Compounds; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Time Factors; Vidarabine | 2003 |
Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy.
Topics: Antineoplastic Agents; Diagnosis, Differential; DNA, Viral; Fatal Outcome; Humans; Immunosuppression Therapy; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Polymerase Chain Reaction; Vidarabine | 2003 |
Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Synergism; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2004 |
Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2004 |
Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Rituximab; Vidarabine | 2004 |
Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2004 |
Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2004 |
Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience.
Topics: Administration, Oral; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2004 |
Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Treatment Outcome; Vidarabine | 2004 |
Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2004 |
Use of fludarabine in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.
Topics: Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Future prospects for fludarabine-containing regimens in the treatment of hematological cancers.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Treatment Outcome; Vidarabine | 2004 |
Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans.
Topics: Aged; Biopsy, Needle; Fluorescent Antibody Technique, Indirect; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycophenolic Acid; Paraneoplastic Syndromes; Pemphigus; Risk Assessment; Severity of Illness Index; Stomatitis; Treatment Outcome; Vidarabine | 2004 |
Treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2004 |
[Waldenstrom macroglobulinemia].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Blood Transfusion; Chlorambucil; Diagnosis, Differential; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Plasmapheresis; Prednisone; Prognosis; Recurrence; Rituximab; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2004 |
Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 2004 |
Reconstructing immunity after allogeneic transplantation.
Topics: Animals; Bone Marrow Transplantation; Dendritic Cells; Gamma Rays; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hyaluronan Receptors; Mice; Mice, Inbred C57BL; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation, Homologous; Vidarabine | 2004 |
The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Vidarabine | 2004 |
Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Safety; Survival Rate; Treatment Outcome; Vidarabine | 2004 |
Blastic natural killer (NK)-cell lymphoma: report of an unusual CD4 negative case and review of the CD4 negative neoplasms with blastic features in the literature.
Topics: Adult; Blast Crisis; Bone Marrow Neoplasms; CD4 Antigens; Diagnosis, Differential; Fatal Outcome; Humans; Immunophenotyping; In Situ Hybridization; Killer Cells, Natural; Lymphoma, Non-Hodgkin; Male; Neoplasm Invasiveness; RNA, Viral; Skin Neoplasms; Vidarabine | 2004 |
Purine analogs in leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Pentostatin; Purines; Stem Cell Transplantation; Vidarabine | 2004 |
[New perspectives in the evolution of prognosis and treatment of chronic lymphocytic leukaemia].
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Mutation; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Recurrence; Remission Induction; Rituximab; Stem Cell Transplantation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis.
Topics: Alkylating Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MEDLINE; Neutrophils; Risk; Time Factors; Treatment Outcome; Vidarabine | 2004 |
The role of mitoxantrone in the treatment of indolent lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Neoplasm Staging; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Survival Analysis; Vidarabine | 2005 |
Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Cladribine; Clinical Trials as Topic; Glycoproteins; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Random Allocation; Rituximab; Time Factors; Vidarabine | 2005 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
[Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nucleoside Transport Proteins; Nucleosides; Phosphorylation; Vidarabine | 2005 |
[News in therapeutic management of chronic lymphoid leukemia].
Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 2005 |
Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Economic assessment on the management of chronic lymphocytic leukaemia.
Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Agents; Chlorambucil; Cost-Benefit Analysis; Health Care Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Vidarabine | 2005 |
Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia (CLL) treated with fludarabine: case report and review of literature.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mycobacterium tuberculosis; Tomography, X-Ray Computed; Tuberculosis; Vidarabine | 2005 |
Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation.
Topics: Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Middle Aged; Time Factors; Transplantation Conditioning; Vidarabine | 2005 |
Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Membrane; Cell Proliferation; Cell Survival; Cladribine; DNA; DNA Damage; DNA Repair; DNA-Directed DNA Polymerase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Models, Biological; Models, Chemical; Nucleosides; RNA; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2005 |
[T-large granular lymphocyte leukaemia. An important differential diagnosis to Felty's syndrome].
Topics: Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Felty Syndrome; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Leukemia, T-Cell; Methotrexate; Vidarabine | 2006 |
Guidelines on the management of Waldenström macroglobulinaemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Plasma Exchange; Prognosis; Rituximab; Stem Cell Transplantation; Thalidomide; Vidarabine; Waldenstrom Macroglobulinemia | 2006 |
[Progress and perspectives in the treatment of systemic lupus erythematosus].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antineoplastic Agents, Alkylating; Azathioprine; Cladribine; Cyclophosphamide; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mycophenolic Acid; Vidarabine | 2005 |
Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Purine Nucleosides; Risk Assessment; Treatment Outcome; Vidarabine | 2006 |
[State of the art in the treatment of chronic leukemias].
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine | 2006 |
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Cladribine; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vidarabine | 2006 |
Purine antagonists for chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Chlorambucil; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Vidarabine | 2006 |
Fludarabine in chronic lymphocytic leukaemia.
Topics: Administration, Oral; Aged; Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Survival Analysis; Vidarabine | 2006 |
[Reduced-intensity cord blood transplantation for adult hematological diseases].
Topics: Adult; Age Factors; Antigens, CD34; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Diseases; Hematologic Neoplasms; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2006 |
Role of fludarabine in hematological malignancies.
Topics: Animals; Antineoplastic Agents; Hematologic Neoplasms; Humans; Prodrugs; Vidarabine | 2006 |
Management of symptomatic, untreated chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Management; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Risk Assessment; Treatment Outcome; Vidarabine | 2007 |
Chronic lymphocytic leukemia: current and emerging treatment approaches.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosomes, Human, Pair 12; Cyclophosphamide; Disease-Free Survival; Drug Screening Assays, Antitumor; Flow Cytometry; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Polymerase Chain Reaction; Risk Factors; Survival Rate; Trisomy; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2006 |
Current treatment options in prolymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Drug Therapy; Humans; Leukemia, Prolymphocytic; Pentostatin; Purine Nucleosides; Rituximab; Splenectomy; Stem Cell Transplantation; Vidarabine | 2007 |
Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Lymphocyte Depletion; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; CD52 Antigen; Cyclophosphamide; Glycoproteins; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2007 |
Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Vidarabine | 2007 |
Fludarabine: a review of its use in non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine | 2007 |
Chemoimmunotherapy of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Rituximab; Vidarabine | 2007 |
Minimal residual disease assessment in chronic lymphocytic leukaemia.
Topics: Alleles; Antibodies, Monoclonal; Antigens, CD19; CD5 Antigens; Combined Modality Therapy; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Polymerase Chain Reaction; Sensitivity and Specificity; Stem Cell Transplantation; Vidarabine | 2007 |
[Chronic lymphoid leukemia and intravenous immunoglobulins].
Topics: Agammaglobulinemia; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multicenter Studies as Topic; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome; Vidarabine | 2007 |
Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Fanconi Anemia; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphocyte Depletion; Male; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2008 |
Antibody therapy for chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drugs, Investigational; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Pentostatin; Rituximab; Vidarabine | 2008 |
Nelarabine: a new purine analog in the treatment of hematologic malignancies.
Topics: Arabinonucleosides; Clinical Trials as Topic; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Leukemia-Lymphoma, Adult T-Cell; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Vidarabine | 2006 |
Non-MALT marginal zone lymphomas.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Italy; L-Lactate Dehydrogenase; Lymph Nodes; Lymphocytosis; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prognosis; Splenectomy; Splenic Neoplasms; Survival Analysis; Vidarabine | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Pentostatin in chronic lymphocytic leukemia.
Topics: Adenosine Deaminase Inhibitors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 2008 |
[Chronic lymphocytic leukemia and the related disorders].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chromosome Aberrations; Gene Rearrangement; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Recombination, Genetic; Rituximab; Time Factors; Vidarabine | 2008 |
Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Child; Child, Preschool; Donor Selection; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Living Donors; Lymphocyte Depletion; Male; Peripheral Blood Stem Cell Transplantation; Risk Adjustment; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Alkylating agents for Waldenstrom's macroglobulinaemia.
Topics: Alkylating Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Prednisone; Randomized Controlled Trials as Topic; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Complement Activation; Complement System Proteins; Cyclophosphamide; Cytokines; Drug Eruptions; Female; Fever; Humans; Leukopenia; Lymphoma, Mantle-Cell; Mitoxantrone; Risk Factors; Rituximab; Splenomegaly; Thrombocytopenia; Vidarabine | 2009 |
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lymphoma; Neutropenia; Opportunistic Infections; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2009 |
Rituximab-based treatments in Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Doxorubicin; Humans; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine | 2009 |
Treatment of fludarabine-refractory chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Salvage Therapy; Stem Cell Transplantation; Vidarabine | 2009 |
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retreatment; Transplantation, Homologous; Vidarabine | 2009 |
Pentostatin treatment combinations in chronic lymphocytic leukemia.
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Forecasting; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Pentostatin; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2009 |
Update in the management of chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Congresses as Topic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Patient Selection; Vidarabine | 2009 |
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Recurrence; Rituximab; Vidarabine | 2009 |
Tumor lysis syndrome following chlorambucil therapy for chronic lymphocytic leukemia: case report and review of the literature.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Risk Factors; Tumor Lysis Syndrome; Vidarabine | 2009 |
Immune hemolytic anemia--selected topics.
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Blood Group Incompatibility; Cladribine; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lymphocyte Subsets; Lymphoproliferative Disorders; Postoperative Complications; Rituximab; Splenectomy; Transfusion Reaction; Transplantation; Transplantation, Homologous; Venous Thromboembolism; Vidarabine | 2009 |
State-of-the-art treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Combined Modality Therapy; Cytostatic Agents; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Rituximab; Salvage Therapy; Thionucleotides; Transplantation, Homologous; Vidarabine | 2009 |
Novel therapeutic approaches in systemic lupus erythematosus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Cyclophosphamide; Cytokines; Humans; Immunotherapy; Interferons; Lupus Erythematosus, Systemic; Rituximab; Signal Transduction; Stem Cell Transplantation; T-Lymphocytes; Vidarabine | 2010 |
Cutaneous Richter's syndrome, prognosis, and clinical, histological and immunohistological patterns: report of four cases and review of the literature.
Topics: Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD5 Antigens; Cell Transformation, Viral; Epstein-Barr Virus Infections; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Ki-1 Antigen; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Skin Neoplasms; Vidarabine | 2010 |
Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Decision Support Techniques; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Markov Chains; Prednisone; Quality-Adjusted Life Years; Rituximab; Vidarabine; Vincristine | 2010 |
Regulatory T cell as a target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; Lenalidomide; Mice; Models, Animal; Myeloablative Agonists; Neoplasms; T-Lymphocytes, Regulatory; Thalidomide; Vidarabine | 2010 |
Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation.
Topics: Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukoencephalopathies; Posterior Leukoencephalopathy Syndrome; Prodrugs; Vidarabine | 2011 |
Advances in the treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drugs, Investigational; Forecasting; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Rituximab; Salvage Therapy; Vidarabine | 2006 |
Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Graft vs Tumor Effect; Humans; Immunologic Factors; Immunotherapy; Lymphocyte Transfusion; Lymphoma, Follicular; Melphalan; Methotrexate; Middle Aged; Multicenter Studies as Topic; Rituximab; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Vidarabine | 2007 |
Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.
Topics: Antineoplastic Agents; Clinical Trials as Topic; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Salvage Therapy; Vidarabine | 2010 |
[Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].
Topics: Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2010 |
Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Clofarabine; Cross-Linking Reagents; Hematologic Neoplasms; Humans; Preoperative Care; Stem Cell Transplantation; Vidarabine | 2010 |
Chemoimmunotherapy of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Disease Progression; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Failure; Vidarabine | 2010 |
Ofatumumab in the treatment of chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cyclophosphamide; Evidence-Based Medicine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Rituximab; Treatment Outcome; Vidarabine | 2010 |
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
[Bone marrow failure due to telomere associated gene mutation].
Topics: Animals; Cell Cycle Proteins; Dyskeratosis Congenita; Genes, Dominant; Genes, Recessive; Genes, X-Linked; Hematopoietic Stem Cell Transplantation; Humans; Mice; Mutation; Nuclear Proteins; Oxymetholone; RNA; Telomerase; Telomere; Telomere-Binding Proteins; Transplantation Conditioning; Vidarabine | 2010 |
Current immunochemotherapy strategies in follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Nitrogen Mustard Compounds; Prednisone; Radioimmunotherapy; Rituximab; Stem Cell Transplantation; Vidarabine; Vincristine | 2010 |
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Mice; Rituximab; Vidarabine | 2010 |
The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; United Kingdom; Vidarabine | 2010 |
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Approval; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Randomized Controlled Trials as Topic; Rituximab; United States; United States Food and Drug Administration; Vidarabine | 2011 |
Refractory chronic lymphocytic leukemia--new therapeutic strategies.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Survival Analysis; Therapies, Investigational; Vidarabine | 2010 |
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Cytotoxicity, Immunologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Vidarabine | 2011 |
[Specific palatal infiltration in B-cell chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Cyclophosphamide; Diagnosis, Differential; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Mitoxantrone; Palate, Soft; Red-Cell Aplasia, Pure; Rituximab; Vidarabine | 2011 |
[A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Vidarabine | 2011 |
How I manage cold agglutinin disease.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Immunosuppressive Agents; Middle Aged; Rituximab; Vidarabine | 2011 |
Purine analog toxicity in patients with hairy cell leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Purines; Vidarabine | 2011 |
Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality-Adjusted Life Years; Vidarabine | 2011 |
[Practical considerations and questions in the treatment of chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Prognosis; Recurrence; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2011 |
Allogeneic stem cell transplantation in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Lymphoma, Follicular; Mice; Myeloablative Agonists; Recurrence; Remission Induction; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2011 |
Rituximab in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2011 |
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Topics: Agammaglobulinemia; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2012 |
Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2011 |
The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Salvage Therapy; Vidarabine | 2012 |
The treatment of relapsed refractory chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Vidarabine | 2011 |
Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Contraindications; Cryoglobulins; Drug Combinations; Erythrocyte Transfusion; Female; Humans; Middle Aged; Precision Medicine; Remission Induction; Rituximab; Vidarabine | 2012 |
Alemtuzumab for patients with chronic lymphocytic leukaemia.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2012 |
A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2012 |
Late graft failure in FA--case report and review of the literature.
Topics: Antigens, CD34; Antineoplastic Agents; Child; Fanconi Anemia; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Neutrophils; Risk Factors; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Renal failure secondary to leukemic infiltration of kidneys in CLL--a case report and review of literature.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Delayed Diagnosis; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Lymph Nodes; Male; Renal Dialysis; Rituximab; Vidarabine | 2013 |
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2012 |
Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Liver; Myeloablative Agonists; Ovarian Neoplasms; Vidarabine; Whole-Body Irradiation | 2013 |
Fludarabine in chronic lymphocytic leukemia with membranous nephropathy.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Follow-Up Studies; Glomerulonephritis, Membranous; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proteinuria; Rare Diseases; Risk Assessment; Treatment Outcome; Vidarabine | 2013 |
Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning.
Topics: Adult; Anemia, Aplastic; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine | 2013 |
Do different conditioning regimens really make a difference?
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunotherapy; Medical Oncology; Middle Aged; Neoplasms; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?
Topics: Adult; Antilymphocyte Serum; Child; Comorbidity; Cyclophosphamide; Cyclosporine; Graft vs Leukemia Effect; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
[Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcosis; Cryptococcus neoformans; Cutaneous Fistula; Cyclophosphamide; Diabetes Mellitus, Type 2; Female; Fungemia; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Neutropenia; Opportunistic Infections; Osteolysis; Osteomyelitis; Rituximab; Vidarabine | 2013 |
The changing paradigm of chronic lymphocytic leukemia management.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Rituximab; Vidarabine | 2013 |
Fludarabine: a review of the clear benefits and potential harms.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Vidarabine | 2013 |
Fulminant hepatitis due to human adenovirus.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Aged; Antibodies, Monoclonal, Murine-Derived; Biopsy; Female; Hepatitis, Viral, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Liver; Rituximab; Vidarabine | 2014 |
Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia: report of a case and review of the literature.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Blood Platelets; Congenital Bone Marrow Failure Syndromes; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Melphalan; Methylprednisolone; Mucositis; Neutrophils; Thrombocytopenia; Transplantation Conditioning; Vidarabine | 2014 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine | 2014 |
[Hemophagocytic lymphohistiocytosis].
Topics: Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease Progression; Doxorubicin; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Methotrexate; Multiple Organ Failure; Prednisolone; Prednisone; Rituximab; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Vincristine | 2014 |
Central nervous system toxicities of chemotherapeutic agents.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cisplatin; Cytarabine; Fluorouracil; Humans; Ifosfamide; Methotrexate; Neurotoxicity Syndromes; Posterior Leukoencephalopathy Syndrome; Vidarabine; Vincristine | 2014 |
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrophenols; Phytochemicals; Piperazines; Protein Kinase Inhibitors; Quercetin; Sulfonamides; Vidarabine | 2014 |
Plasmablastic lymphoma following combination treatment with fludarabine and rituximab for nongastric mucosa-associated lymphoid tissue lymphoma: a case report and review of literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasms, Second Primary; Rituximab; Vidarabine | 2014 |
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoproliferative Disorders; Rituximab; Vidarabine | 2015 |
[Regulatory T cells in cancer immunotherapy].
Topics: Antibodies, Monoclonal; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; Cyclophosphamide; Humans; Immune Tolerance; Immunosuppressive Agents; Immunotherapy; Ipilimumab; Molecular Targeted Therapy; Neoplasms; Programmed Cell Death 1 Receptor; Receptors, CCR4; T-Lymphocytes, Regulatory; Vidarabine | 2014 |
A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Nitrogen Mustard Compounds; Pentostatin; Physical Fitness; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2015 |
Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Richter syndrome: an aggressive transformation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clone Cells; Cyclophosphamide; Disease Progression; Doxorubicin; Hospice and Palliative Care Nursing; Humans; Hypercalcemia; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Male; Neoplastic Stem Cells; Organoplatinum Compounds; Palliative Care; Prednisone; Prognosis; Risk Factors; Rituximab; Salvage Therapy; Syndrome; Vidarabine; Vincristine | 2015 |
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers; CD5 Antigens; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Cyclophosphamide; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2015 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Chlorambucil; Clinical Trials as Topic; Comorbidity; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2015 |
[Acquired pure red cell aplasia in a patient with B cell chronic lymphocytic leukemia after fludarabine therapy].
Topics: Aged; Antineoplastic Agents; Cyclosporine; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Red-Cell Aplasia, Pure; Treatment Outcome; Vidarabine | 2015 |
Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Practice Guidelines as Topic; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2016 |
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Methotrexate; Mouth Mucosa; Myeloablative Agonists; Severity of Illness Index; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis.
Topics: Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Randomized Controlled Trials as Topic; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Prognosis; Rituximab; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2016 |
[Treatment of Gaucher disease with allogeneic hematopoietic stem cell transplantation: report of three cases and review of literatures].
Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; China; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Gaucher Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mycophenolic Acid; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2015 |
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides; Vidarabine | 2016 |
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine | 2016 |
Mycobacterium genavense-induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature.
Topics: Abdomen; Adolescent; Alemtuzumab; Antibiotic Prophylaxis; Antibiotics, Antitubercular; Antibodies, Monoclonal, Humanized; Bone Marrow Transplantation; Bronchoalveolar Lavage Fluid; Cyclosporine; Diabetes Mellitus, Type 1; Diarrhea; Genetic Diseases, X-Linked; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytes; Humans; Immune System Diseases; Immunosuppressive Agents; Lymph Nodes; Male; Melphalan; Mycobacterium Infections, Nontuberculous; Mycophenolic Acid; Nontuberculous Mycobacteria; Photopheresis; Polymerase Chain Reaction; Transplantation Conditioning; Vidarabine | 2017 |
How I treat autoimmune hemolytic anemia.
Topics: Aged; Algorithms; Anemia, Hemolytic, Autoimmune; Coombs Test; Erythrocyte Transfusion; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Serologic Tests; Splenectomy; Vidarabine | 2017 |
Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.
Topics: Administration, Intravenous; Biomarkers; Demyelinating Autoimmune Diseases, CNS; Diagnosis, Differential; Glycoproteins; Humans; Immunoglobulins; Immunologic Factors; Monoclonal Gammopathy of Undetermined Significance; Myeloablative Agonists; Peripheral Nervous System Diseases; Plasmapheresis; Prognosis; Rituximab; Vidarabine | 2017 |
Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Lymphoma, Non-Hodgkin; Odds Ratio; Remission Induction; Vidarabine | 2017 |
FCR achieves long-term durable remissions in patients with
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Remission Induction; Rituximab; Time Factors; Vidarabine | 2017 |
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Vidarabine | 2018 |
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 12; Cyclin D1; Cyclophosphamide; Disease Progression; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Rituximab; Treatment Outcome; Trisomy; Vidarabine | 2018 |
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2018 |
Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis.
Topics: Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine | 2018 |
Pixantrone beyond monotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines; Lymphoma, B-Cell; Mitoxantrone; Prednisone; Rituximab; Salvage Therapy; Vidarabine; Vincristine | 2019 |
Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency.
Topics: Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Primary Immunodeficiency Diseases; Transplantation Conditioning; Vidarabine | 2019 |
Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2020 |
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Vidarabine | 2020 |
The FLAMSA concept-past and future.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies.
Topics: Age Factors; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclosporine; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Methotrexate; Risk Factors; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2021 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
Topics: B-Cell Maturation Antigen; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin D; Immunologic Factors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Receptors, Chimeric Antigen; Recurrence; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2022 |
A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.
Topics: Adult; Child; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine | 2022 |
796 trial(s) available for fludarabine and vidarabine
| Article | Year |
|---|---|
Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Topics: 2-Chloroadenosine; Adult; Antineoplastic Agents; Cladribine; Deoxyadenosines; Drug Resistance; Female; Haptoglobins; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Remission Induction; Vidarabine | 1992 |
Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Evaluation; Female; Glioblastoma; Humans; Isoxazoles; Magnetic Resonance Imaging; Male; Middle Aged; Recurrence; Tomography, X-Ray Computed; Vidarabine | 1991 |
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine; Vidarabine Phosphate | 1991 |
Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vidarabine | 1992 |
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Chromosome Aberrations; Chromosome Disorders; Female; Humans; Immunoglobulin M; Karyotyping; Leukemia, Prolymphocytic; Male; Middle Aged; Prednisone; Remission Induction; Vidarabine | 1991 |
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyt
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Regression Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 1994 |
Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fatal Outcome; Female; Humans; Ifosfamide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pilot Projects; Prednisolone; Prednisone; Remission Induction; Staining and Labeling; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Vidarabine; Vinca Alkaloids; Vincristine | 1995 |
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Vidarabine | 1995 |
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Rate; Vidarabine | 1995 |
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
Topics: Adult; Aged; CD4 Lymphocyte Count; Female; Humans; Immunity, Cellular; Immunoglobulin G; Interferon Type I; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recombinant Proteins; Skin; Survival Analysis; Vidarabine | 1995 |
Fludarabine treatment in resistant Waldenstrom's macroglobulinemia.
Topics: Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Vidarabine; Waldenstrom Macroglobulinemia | 1995 |
[Treatment with fludarabine of chronic refractory lymphoid leukemia].
Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Vidarabine | 1995 |
A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials.
Topics: Antineoplastic Agents; Bayes Theorem; Drug Therapy; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Research Design; Tretinoin; Vidarabine | 1994 |
Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma--the Jerusalem experience.
Topics: Adult; Aged; Bone Marrow Transplantation; Combined Modality Therapy; Female; Humans; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1994 |
Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B-Lymphocytes; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; T-Lymphocytes; Vidarabine | 1994 |
Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Humans; Middle Aged; Remission Induction; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 1993 |
Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mycosis Fungoides; Recombinant Proteins; Remission Induction; Sezary Syndrome; Skin Neoplasms; Vidarabine | 1994 |
Absence of minimal residual disease detectable by FACS, Southern blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine.
Topics: Aged; Antineoplastic Agents; Blotting, Southern; DNA, Neoplasm; Flow Cytometry; Gene Rearrangement; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Remission Induction; Vidarabine | 1994 |
Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
Topics: Antineoplastic Agents; B-Lymphocytes; Camptothecin; Cell Survival; Cells, Cultured; Chlorambucil; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1994 |
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Topics: Antineoplastic Agents; Cladribine; Drug Resistance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1993 |
Chronic lymphocytic leukemia--correlation of response and survival.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Survival Rate; Vidarabine | 1993 |
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Gastrointestinal Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 1993 |
Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Prednisone; Remission Induction; Survival Rate; Vidarabine; Vincristine | 1993 |
Fludarabine in low-grade lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Vidarabine | 1993 |
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Remission Induction; Survival Rate; Vidarabine | 1993 |
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Vidarabine | 1993 |
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
Topics: Adult; Aged; Antineoplastic Agents; Arabinonucleotides; Female; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Vidarabine | 1993 |
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 1993 |
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Conjunctivitis; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pancreatitis; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1993 |
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD4 Antigens; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisone; Prognosis; Regression Analysis; Survival Analysis; Time Factors; Treatment Outcome; Vidarabine | 1993 |
When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)? The French Cooperative Group on C.L.L.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multivariate Analysis; Neoplasm Staging; Peptichemio; Prednisone; Sex Factors; Vidarabine; Vincristine | 1993 |
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vidarabine | 1993 |
Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; CD4 Lymphocyte Count; Female; Humans; Immunosuppression Therapy; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Platelet Count; Survival Analysis; Vidarabine | 1995 |
Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.
Topics: Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cladribine; Combined Modality Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Survival Analysis; Vidarabine | 1995 |
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Drug Resistance, Neoplasm; Female; Hemorrhage; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Remission Induction; Sepsis; Treatment Failure; Vidarabine | 1996 |
Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 1996 |
Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Topics: Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Prospective Studies; Remission Induction; Survival Rate; Time Factors; Vidarabine | 1996 |
A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Sleep Wake Disorders; Thrombocytopenia; Vidarabine | 1996 |
Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Vidarabine | 1996 |
[Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Vidarabine | 1996 |
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Vidarabine | 1996 |
Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Middle Aged; Pentostatin; Vidarabine | 1997 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Treatment Outcome; Vidarabine | 1997 |
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Vidarabine | 1997 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Female; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Vidarabine | 1997 |
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fever; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neutropenia; Vidarabine | 1997 |
Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1998 |
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Retreatment; Risk Factors; Survival Rate; Transplantation, Autologous; Vidarabine | 1998 |
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4 Lymphocyte Count; Disease Progression; Disease-Free Survival; Female; Fever; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisolone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 1998 |
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Vidarabine | 1998 |
High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
Topics: Antigens, CD; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Lymphocyte Count; Male; Middle Aged; Phenotype; Platelet Count; Time Factors; Treatment Outcome; Vidarabine | 1998 |
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Blast Crisis; Cell Cycle; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; In Vitro Techniques; Infusions, Intravenous; Kinetics; Leukemia, Myeloid, Acute; Pilot Projects; Vidarabine | 1995 |
A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
Topics: Adult; Aged; Anti-Inflammatory Agents; Dermatomyositis; Edema; Female; Flow Cytometry; Hematologic Tests; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Pilot Projects; Polymyositis; Prednisone; Treatment Outcome; Vidarabine | 1999 |
Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; CD4 Lymphocyte Count; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 1999 |
Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate; Vidarabine | 1999 |
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Survival Rate; Time Factors; Tretinoin; Vidarabine | 1999 |
Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Vidarabine | 1998 |
Multi-drug resistance in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dexamethasone; Doxorubicin; Drug Resistance, Multiple; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine; Vincristine | 1999 |
Autologous transplantation with peripheral blood stem cells in chronic lymphocytic leukemia. A phase III, randomized, multicenter study. GIMEMA. Gruppo Italiano per le Malattie Ematologiche dell'Adulto. GITMO-Gruppo Italiano Trapianto di Midollo Osseo.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophosphamide; Drug Therapy; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Phenotype; Pilot Projects; Prospective Studies; Statistics as Topic; Survival Rate; Toxicity Tests; Transplantation, Autologous; Vidarabine | 1999 |
A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia. EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chlorambucil; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Pilot Projects; Vidarabine | 1999 |
Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Idarubicin; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Survival Rate; Treatment Outcome; Vidarabine | 1999 |
Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study.
Topics: Adult; Antineoplastic Agents; Base Sequence; Combined Modality Therapy; Disease-Free Survival; DNA Primers; Female; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 1999 |
Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Interferons; Lymphoma, Follicular; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Survival Analysis; Teniposide; Vidarabine | 1999 |
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Treatment Outcome; Vidarabine | 1999 |
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1999 |
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vidarabine | 2000 |
Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases.
Topics: Adolescent; Adult; Ambulatory Care; beta-Thalassemia; Blood Component Transfusion; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Remission Induction; Survival Rate; Thrombocytopenia; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2000 |
Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Rate; Treatment Outcome; Vidarabine | 2000 |
Measures of treatment effectiveness on tumour response and survival: a multi-state model approach.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Vidarabine | 2000 |
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Confidence Intervals; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2000 |
Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Survival Analysis; Vidarabine | 2000 |
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2000 |
Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine | 2000 |
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; DNA, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Treatment Outcome; Vidarabine | 2000 |
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Microsatellite Repeats; Middle Aged; Nuclear Family; Polymerase Chain Reaction; Recurrence; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2000 |
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Melphalan; Pilot Projects; Transplantation Conditioning; Vidarabine | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cross-Over Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Analysis; Vidarabine | 2000 |
Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Disease Progression; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Male; Middle Aged; Prednisone; Treatment Failure; Vidarabine | 2000 |
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Staging; Neutropenia; Rituximab; Vidarabine | 2000 |
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Flow Cytometry; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine | 2001 |
Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Treatment Outcome; Vidarabine | 2001 |
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arabinonucleotides; Biomarkers; Female; Guanosine Triphosphate; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Prolymphocytic; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Treatment Outcome; Vidarabine | 2001 |
Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis.
Topics: Adult; Antineoplastic Agents; Confidence Intervals; Cross-Over Studies; Cyclophosphamide; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lupus Nephritis; Male; Middle Aged; Statistics, Nonparametric; Vidarabine | 2001 |
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Chimera; Combined Modality Therapy; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2001 |
A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Middle Aged; Mycosis Fungoides; Pilot Projects; Sezary Syndrome; Skin Neoplasms; Treatment Outcome; Vidarabine | 2001 |
Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Topics: Age Factors; Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Cohort Studies; Disease-Free Survival; Female; Hemoglobins; Humans; Immunoglobulin M; Male; Models, Biological; Multivariate Analysis; Odds Ratio; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Salvage Therapy; Sex Factors; Vidarabine | 2001 |
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Survival Rate; Vidarabine | 2001 |
Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Vidarabine | 2001 |
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia; Pilot Projects; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine | 2001 |
Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine | 2001 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Humans; Leukemia; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasms; Pneumonia; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2001 |
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Ontario; Respiratory Tract Infections; Skin Diseases, Infectious; Treatment Outcome; United States; Vidarabine | 2001 |
Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Health Status Indicators; Humans; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome; Vidarabine | 2001 |
Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Methylprednisolone; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Rate; Vidarabine | 2001 |
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
Topics: Aged; Anemia; Antineoplastic Agents; Cyclosporine; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Splenectomy; Thrombocytopenia; Vidarabine | 2001 |
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Lineage; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloid Cells; Prospective Studies; Transplantation Chimera; Vidarabine | 2001 |
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2001 |
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Humans; Male; Middle Aged; Mouth Mucosa; Prednisone; Recurrence; Salvage Therapy; Stomatitis; Survival Analysis; Therapeutic Equivalency; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Erythrocyte Transfusion; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Nuclear Family; Platelet Transfusion; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2001 |
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Rituximab; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine | 2001 |
The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Gastric Mucosa; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Absorption; Intestinal Mucosa; Male; Middle Aged; Permeability; Prospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2001 |
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Melphalan; Middle Aged; Survival Analysis; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Topics: Actins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Dexamethasone; DNA; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mitoxantrone; Neoplasm, Residual; Polymerase Chain Reaction; Rituximab; Translocation, Genetic; Vidarabine | 2002 |
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
Topics: Adult; Drug Resistance, Neoplasm; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Middle Aged; Recurrence; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Resistance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2002 |
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Primary Myelofibrosis; Splenomegaly; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Vidarabine | 2002 |
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Tumor Burden; Vidarabine; Vincristine | 2002 |
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Demography; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine | 2002 |
[Fludarabine as primary therapeutic drug in chronic lymphatic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate; Treatment Outcome; Vidarabine | 2002 |
A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Otorhinolaryngologic Neoplasms; Radiation Injuries; Vidarabine | 2002 |
Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2002 |
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Creatinine; Disease-Free Survival; Female; Hematologic Tests; Humans; Kidney Function Tests; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neutrophils; Vidarabine | 2002 |
Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Remission Induction; Vidarabine; Vincristine | 2002 |
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine | 2002 |
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Isogeneic; Vidarabine | 2002 |
Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Lymphoma; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors; Vidarabine | 2002 |
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Vidarabine | 2002 |
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, T-Cell; Male; Neutropenia; Opportunistic Infections; Pilot Projects; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine | 2002 |
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cerebral Hemorrhage; Chills; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Leukemia, B-Cell; Male; Middle Aged; Risk Factors; Rituximab; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vidarabine | 2003 |
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Cyclophosphamide; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Vidarabine | 2002 |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Time Factors; Vidarabine | 2002 |
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Middle Aged; Mycophenolic Acid; Tissue Donors; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Vidarabine | 2002 |
Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Quality of Life; Survival Rate; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Bryostatins; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Vidarabine | 2002 |
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; Esophagitis; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Metabolic Clearance Rate; Middle Aged; Recurrence; Stomatitis; Vidarabine | 2003 |
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Patient Selection; Survival Rate; Time Factors; Vidarabine | 2003 |
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Alanine Transaminase; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival; Treatment Outcome; Vidarabine | 2003 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Mycophenolic Acid; Radiotherapy, Adjuvant; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Vidarabine | 2003 |
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Follow-Up Studies; Graft Survival; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Follow-Up Studies; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2003 |
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Living Donors; Male; Melphalan; Middle Aged; Prognosis; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
Topics: Antineoplastic Agents; Follow-Up Studies; Humans; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Vidarabine; Waldenstrom Macroglobulinemia | 2003 |
Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Middle Aged; Mycophenolic Acid; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine | 2003 |
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Incidence; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2003 |
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Survival Analysis; Treatment Outcome; United States; Vidarabine | 2003 |
Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clone Cells; Cytarabine; Dexamethasone; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplastic Cells, Circulating; Remission Induction; Vidarabine; Vincristine | 2003 |
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Radiation-Protective Agents; Sepsis; Survival Rate; Vidarabine | 2003 |
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Antigens Class I; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Acute; Lymphocyte Transfusion; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Tissue Donors; Vidarabine; Whole-Body Irradiation | 2003 |
Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2003 |
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Graft Survival; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Histocompatibility; Humans; Middle Aged; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.
Topics: Aged; Aged, 80 and over; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Analysis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2003 |
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Platelet Count; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Vidarabine | 2003 |
Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan.
Topics: Adult; Aged; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Animals; Antilymphocyte Serum; Bone Marrow Diseases; Bone Marrow Transplantation; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Radiotherapy Dosage; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Renal Cell; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Male; Melphalan; Middle Aged; Neoplasm Metastasis; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Histocompatibility; Humans; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.
Topics: Adult; Antigens, CD34; Cyclophosphamide; Female; Hematologic Diseases; Hematologic Neoplasms; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutrophils; Peripheral Blood Stem Cell Transplantation; Platelet Count; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Rate; Vidarabine | 2003 |
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Bone Marrow Transplantation; Child; Child, Preschool; Female; Graft Survival; Hematopoiesis; Humans; Immunocompetence; Kinetics; Male; Pilot Projects; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
Topics: Adult; Busulfan; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Patient Selection; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Diphtheria Toxin; Drug Resistance, Neoplasm; Female; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Recombinant Fusion Proteins; Time Factors; Tomography, Emission-Computed; Treatment Outcome; Vidarabine | 2003 |
[Modified FLAG regimen in the management of refractory acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2003 |
The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Transplantation, Isogeneic; Treatment Outcome; Vidarabine | 2003 |
Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Psoriatic; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; DNA-Binding Proteins; E-Selectin; Endothelial Cells; Female; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Lymphocyte Depletion; Male; Middle Aged; P-Selectin; Phosphorylation; Prednisone; STAT1 Transcription Factor; Synovial Membrane; Trans-Activators; Vidarabine | 2003 |
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Incidence; Leukocyte Transfusion; Life Tables; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; STAT1 Transcription Factor; Survival Analysis; Trans-Activators; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Disease Progression; Drug Administration Schedule; Female; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 2003 |
Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vidarabine | 2003 |
[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 2003 |
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
Topics: Adult; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Opportunistic Infections; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Nonmyeloablative stem cell transplantation for lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma; Middle Aged; Recurrence; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine | 2004 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vidarabine | 2004 |
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease Progression; Drug Therapy; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mycophenolic Acid; Opportunistic Infections; Premedication; Prospective Studies; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Risk Factors; Survival Rate; Vidarabine | 2004 |
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Topotecan; Treatment Outcome; Vidarabine | 2004 |
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphocyte Transfusion; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Radiation, Ionizing; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2004 |
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Survival Analysis; Time Factors; Vidarabine | 2004 |
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aging; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine | 2004 |
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
Topics: Adult; Aged; Bendamustine Hydrochloride; Female; Germany; Hematology; Humans; Lymphoma; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Societies, Medical; Time Factors; Vidarabine | 2004 |
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Nervous System Diseases; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Diseases | 2004 |
Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Vidarabine | 2004 |
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
Topics: Adult; Aged; Combined Modality Therapy; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppression Therapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Cytopenia and hematopoietic recovery after low intensity conditioning transplants.
Topics: Adult; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Analysis; Thrombocytopenia; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine | 2004 |
Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Rituximab; Vidarabine | 2004 |
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Nucleoside Transport Proteins; RNA, Messenger; Treatment Outcome; Vidarabine | 2005 |
Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Topotecan; Vidarabine | 2004 |
Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
Topics: Adult; Aged; Antilymphocyte Serum; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2004 |
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Combined Modality Therapy; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinopathies; Humans; Immunosuppressive Agents; Infections; Male; Pancytopenia; Thalassemia; Transfusion Reaction; Transplantation Chimera; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2005 |
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Treatment Outcome; Vidarabine | 2004 |
Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).
Topics: Antigens, CD34; Antilymphocyte Serum; Busulfan; Child, Preschool; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Infant; Lymphocyte Transfusion; Mucopolysaccharidosis I; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Topics: Adenocarcinoma, Clear Cell; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Renal Cell; Cells, Cultured; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Male; Middle Aged; Minor Histocompatibility Antigens; Mycophenolic Acid; Myeloid Cells; T-Lymphocytes, Cytotoxic; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Infections; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Liposomes; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cyclophosphamide; Graft Survival; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppression Therapy; Incidence; Tissue Donors; Treatment Outcome; Vidarabine | 2005 |
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Flow Cytometry; Genes, bcl-2; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; T-Lymphocyte Subsets; Vidarabine | 2005 |
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Risk Factors; Vidarabine; Vindesine | 2005 |
Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 7; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; DNA Damage; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Remission Induction; Rituximab; Time Factors; Vidarabine | 2005 |
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Female; Humans; Lymphoma; Male; Middle Aged; Prospective Studies; Splenic Neoplasms; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Treatment Outcome; Vidarabine | 2005 |
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
Topics: Adult; Aged; Antineoplastic Agents; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Radiation Dosage; Siblings; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
Topics: Adult; Age Distribution; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; CD52 Antigen; Combined Modality Therapy; Female; Glycoproteins; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Leukocyte Common Antigens; Lymphocyte Depletion; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2005 |
Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
Topics: Adult; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2005 |
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
Topics: Adult; Age Factors; Aged; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myelopoiesis; Neoplasms; Neutrophils; Risk Factors; Sex Factors; Syndrome; Transplantation Conditioning; Vidarabine | 2005 |
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Staging; Neutropenia; Patient Selection; Recurrence; Treatment Outcome; Vidarabine | 2005 |
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2005 |
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Topics: Adult; Aged; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vidarabine | 2005 |
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2005 |
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Prospective Studies; Radioimmunotherapy; Treatment Outcome; Vidarabine | 2005 |
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2005 |
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Topics: Acute Disease; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Siblings; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2005 |
Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2005 |
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2005 |
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Gemtuzumab; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunotherapy; Infant; Leukemia, Myeloid, Acute; Male; Pilot Projects; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine | 2005 |
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Remission Induction; Retrospective Studies; Thrombocytopenia; Vidarabine | 2006 |
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Neoplasm Staging; Time Factors; Treatment Outcome; Vidarabine | 2005 |
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Probability; Prognosis; Prospective Studies; Risk Assessment; Rituximab; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2005 |
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosphamide; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Follicular; Male; Middle Aged; Vidarabine | 2005 |
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survival; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Infusions, Intravenous; Living Donors; Male; Myeloablative Agonists; Prospective Studies; Rabbits; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
Topics: Adolescent; Child; Child, Preschool; Combined Modality Therapy; Diarrhea; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Mouth Mucosa; Stomatitis; Survival Rate; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Living Donors; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Siblings; Stem Cell Transplantation; Survival Rate; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
Topics: Adolescent; Adult; Aged; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Remission Induction; Survival Rate; Transplantation Conditioning; Vidarabine | 2006 |
Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sepsis; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD34; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus Infections; Feasibility Studies; Female; Ganciclovir; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Treatment Outcome; Vidarabine | 2006 |
Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Myeloablative Agonists; Podophyllotoxin; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Thalidomide; Treatment Failure; Tumor Necrosis Factor-alpha; Vidarabine | 2007 |
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome; Vidarabine | 2006 |
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Melphalan; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.
Topics: Adult; Anemia, Aplastic; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.
Topics: Adult; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Risk Factors; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Epidemiologic Methods; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2006 |
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Vidarabine | 2006 |
Preclinical assessment of curcumin as a potential therapy for B-CLL.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Curcumin; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; NF-kappa B; NF-kappaB-Inducing Kinase; PPAR gamma; Protein Serine-Threonine Kinases; Rolipram; Signal Transduction; Tumor Cells, Cultured; Vidarabine; Vincristine | 2007 |
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Adducts; DNA Repair; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Vidarabine | 2006 |
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutropenia; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Child; Child, Preschool; Colitis; Endocrine System Diseases; Food Hypersensitivity; Forkhead Transcription Factors; Genes, X-Linked; Graft Survival; Humans; Ichthyosis, X-Linked; Immunologic Deficiency Syndromes; Infant; Leukocyte Count; Melphalan; Postoperative Complications; Reoperation; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Vidarabine | 2006 |
Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Middle Aged; Myeloablative Agonists; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Lymphoid; Leukemia, T-Cell; Male; Middle Aged; Pentostatin; Retrospective Studies; Vidarabine | 2007 |
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vidarabine | 2006 |
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Multivariate Analysis; Remission Induction; Respiratory Tract Infections; Risk Factors; Survival Rate; Vidarabine | 2007 |
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; Cytokines; Disease-Free Survival; Family; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy.
Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Immunoglobulin M; Male; Middle Aged; Paraproteinemias; Polyneuropathies; Prospective Studies; Vidarabine | 2006 |
Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Cyclophosphamide; Cyclosporine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Mycophenolic Acid; Statistics, Nonparametric; Vidarabine; Whole-Body Irradiation | 2007 |
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Drug Interactions; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Topics: Abnormalities, Multiple; Adolescent; Bone Marrow Diseases; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Pilot Projects; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladribine; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood Stem Cell Transplantation; Female; Graft Survival; Graft vs Host Disease; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2007 |
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Male; Middle Aged; Neoplasms, Second Primary; Prognosis; Vidarabine | 2007 |
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotides, Antisense; Proportional Hazards Models; Recurrence; Thionucleotides; Time Factors; Treatment Failure; Treatment Outcome; Vidarabine | 2007 |
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Matched-Pair Analysis; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
Topics: Adult; Aged; CD4 Lymphocyte Count; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lupus Nephritis; Lymphopenia; Male; Middle Aged; Neutropenia; Pilot Projects; Proteinuria; Treatment Outcome; Vidarabine | 2007 |
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survivors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Nausea; Quality of Life; Surveys and Questionnaires; Vidarabine; Vomiting | 2007 |
A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
Topics: Acute Disease; Adult; Chimerism; Cyclophosphamide; Disease-Free Survival; Female; Fertility; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
Topics: Adolescent; Adult; Aged; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; International Cooperation; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biomarkers, Tumor; Chi-Square Distribution; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Statistics, Nonparametric; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2007 |
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gene Rearrangement; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thrombocytopenia; Time Factors; Treatment Outcome; Vidarabine | 2007 |
Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mexico; Middle Aged; Recurrence; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocyte Transfusion; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Vidarabine | 2007 |
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
Topics: Adult; Aged; Antilymphocyte Serum; Feasibility Studies; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Salvage Therapy; Tacrolimus; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2007 |
Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
Topics: Aged; Agranulocytosis; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Reoperation; Siblings; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Recurrence; Thiosemicarbazones; Treatment Outcome; Vidarabine | 2008 |
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Vidarabine | 2007 |
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Platelet Endothelial Cell Adhesion Molecule-1; Vidarabine | 2007 |
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Melphalan; Methotrexate; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate; Vidarabine | 2007 |
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine | 2007 |
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Child, Preschool; Chimerism; Drug Therapy, Combination; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukocyte Reduction Procedures; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Vidarabine | 2007 |
Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Topics: Adult; Bone Marrow Examination; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Primary Myelofibrosis; Remission Induction; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gemtuzumab; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Transplantation, Homologous; Vidarabine | 2008 |
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Humans; Idarubicin; Infant; Infant, Newborn; Interleukin-2; Leukemia, Myeloid, Acute; Male; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Mucopolysaccharidosis I; Pilot Projects; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 2007 |
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Coombs Test; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome; Vidarabine | 2008 |
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Poland; Remission Induction; Vidarabine | 2008 |
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2008 |
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Salvage Therapy; Vidarabine | 2008 |
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Research Design; Rituximab; Statistics, Nonparametric; Survival Analysis; Syndrome; Treatment Outcome; Vidarabine | 2008 |
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2008 |
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Rituximab; Survival Rate; Vidarabine | 2008 |
High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.
Topics: Cord Blood Stem Cell Transplantation; Female; Graft Survival; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Transplantation Conditioning; Treatment Failure; Vidarabine | 2008 |
Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Remission Induction; Treatment Outcome; Vidarabine | 2008 |
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Vidarabine | 2008 |
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Topics: Adult; Age Factors; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Monitoring; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
Topics: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
Topics: Adult; Disease-Free Survival; Female; Follow-Up Studies; Hodgkin Disease; Hospitals, University; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.
Topics: Adult; Aged; Anesthesia Recovery Period; CD8-Positive T-Lymphocytes; Cyclosporine; Female; Flow Cytometry; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms; Peripheral Blood Stem Cell Transplantation; Receptors, Antigen, T-Cell, alpha-beta; Thymus Gland; Time Factors; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2008 |
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Survival Rate; Vidarabine | 2008 |
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Phase I trial of nelarabine in indolent leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Arabinonucleotides; DNA (Cytosine-5-)-Methyltransferases; Drug Therapy, Combination; Female; Guanosine Triphosphate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Tumor Cells, Cultured; Vidarabine | 2008 |
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Infection Control; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Rituximab; Salvage Therapy; Vidarabine | 2008 |
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Probability; Radioimmunotherapy; Risk Assessment; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2008 |
Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.
Topics: Adult; Busulfan; Cell Count; Cord Blood Stem Cell Transplantation; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myeloid; Myeloablative Agonists; Transplantation Conditioning; Treatment Failure; Vidarabine | 2008 |
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2008 |
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Rituximab; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
Topics: Adult; Aged; Blood Component Transfusion; Bone Marrow Transplantation; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Filgrastim; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hemoglobinuria, Paroxysmal; Histocompatibility; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Postoperative Care; Postoperative Complications; Recombinant Proteins; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2008 |
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bayes Theorem; Busulfan; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2008 |
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2008 |
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Topics: Administration, Oral; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neutropenia; Remission Induction; Vidarabine | 2008 |
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Vidarabine; Young Adult | 2008 |
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Comorbidity; Digestive System Diseases; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Reoperation; Risk; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Middle Aged; Myeloablative Agonists; Risk Assessment; Siblings; Survival Analysis; Survival Rate; Vidarabine | 2008 |
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Premedication; Sirolimus; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Immune Tolerance; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Recurrence; Vidarabine | 2008 |
Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease-Free Survival; Flow Cytometry; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2008 |
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Time Factors; Vidarabine | 2009 |
[Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Vidarabine | 2008 |
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Half-Life; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Salvage Therapy; Tissue Distribution; Vidarabine | 2008 |
Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chemotherapy, Adjuvant; Child; Cyclophosphamide; Female; Humans; Interleukin-15; Interleukin-2; Interleukin-7; Kaplan-Meier Estimate; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Myeloablative Agonists; Neoadjuvant Therapy; Neoplasm Metastasis; Pilot Projects; Radiotherapy Dosage; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Vidarabine | 2008 |
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cell Cycle; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Inactivation, Metabolic; Infusions, Intravenous; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Piperidines; Protein Kinase Inhibitors; Recurrence; Salvage Therapy; Treatment Outcome; Tumor Lysis Syndrome; Uridine Diphosphate Glucuronic Acid; Vidarabine | 2009 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2008 |
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an his
Topics: Adult; Aged; Cell Count; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Recombinant Proteins; Stem Cell Factor; Treatment Outcome; Vidarabine | 2009 |
Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Female; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Leukemia, Myeloid, Acute; Lymphocytes; Male; Melphalan; Middle Aged; Neoplastic Cells, Circulating; Transplantation Conditioning; Transplantation, Homologous; Tumor Burden; Vidarabine | 2009 |
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neutropenia; Pneumonia; Prospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Treatment Outcome; Vidarabine | 2009 |
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Genes, Immunoglobulin Heavy Chain; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Receptors, Fc; Rituximab; Survival Analysis; Vidarabine; Young Adult | 2009 |
Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Lymphocyte Depletion; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Family; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Lymphocyte Depletion; Male; Middle Aged; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2009 |
A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.
Topics: Adult; Aged; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Premedication; Reoperation; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
Allogeneic hematopoietic stem cell transplantation of patients with FA and high risk features using fludarabine without radiation.
Topics: Adolescent; Child; Child, Preschool; Fanconi Anemia; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Radiation; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.
Topics: Adolescent; Adult; Aged; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Humans; Immunosuppression Therapy; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycophenolic Acid; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2009 |
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Tretinoin; Vidarabine | 2009 |
Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Vidarabine | 2009 |
Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cyclophosphamide; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Vidarabine | 2009 |
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etanercept; Female; Humans; Immunoglobulin G; Infusions, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Tumor Necrosis Factor; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Tumor Necrosis Factor-alpha; Vidarabine | 2009 |
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Genes, bcl-2; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisone; Remission Induction; Rituximab; Survival Analysis; Vidarabine; Vincristine | 2009 |
Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cytokines; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Humans; Immunotherapy, Adoptive; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome; Vidarabine | 2009 |
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Topics: Acyclovir; Adult; Aged; Antifungal Agents; Antineoplastic Agents, Alkylating; Antiviral Agents; Cyclophosphamide; Cytotoxicity, Immunologic; Female; Fluconazole; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Skin Neoplasms; Vidarabine | 2009 |
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies; Rituximab; Survival Rate; Vidarabine | 2009 |
Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2009 |
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2009 |
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2009 |
[Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 2009 |
Better posttransplant outcome with fludarabine based conditioning in multitransfused fanconi anemia patients who underwent peripheral blood stem cell transplantation.
Topics: Adolescent; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Humans; Male; Peripheral Blood Stem Cell Transplantation; Radiotherapy; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2009 |
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine | 2009 |
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Vidarabine | 2009 |
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents, Alkylating; Chlorambucil; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Survival Rate; Vidarabine | 2009 |
HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer.
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Topics: Administration, Cutaneous; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclin-Dependent Kinase Inhibitor p21; DNA Mutational Analysis; Drug Resistance, Neoplasm; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Signal Transduction; Treatment Failure; Tumor Suppressor Protein p53; Vidarabine | 2009 |
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cell Separation; Cyclophosphamide; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Pilot Projects; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2010 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Rituximab; Vidarabine | 2009 |
Rituximab for polyneuropathy with IgM monoclonal gammopathy.
Topics: Age of Onset; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; B-Lymphocytes; Bone Marrow Cells; Cyclophosphamide; Disability Evaluation; Female; Humans; Immunoglobulin M; Immunologic Factors; Immunosuppressive Agents; Lymphocyte Count; Male; Middle Aged; Muscle Strength; Neural Conduction; Paraproteinemias; Prednisone; Prospective Studies; Rituximab; Sensation; Treatment Outcome; Vidarabine | 2009 |
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunologic Factors; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Leukocyte Common Antigens; Male; Rats; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2009 |
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Vidarabine; Young Adult | 2009 |
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Thionucleotides; Vidarabine | 2009 |
The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Rituximab; Severity of Illness Index; Survival; Treatment Outcome; Vidarabine | 2009 |
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antibodies; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Iodine Radioisotopes; Leukemia, Myeloid; Leukocyte Common Antigens; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Analysis; Survival Rate; Tissue Distribution; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2009 |
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infection Control; Infections; Male; Medical Audit; Methotrexate; Middle Aged; Myeloablative Agonists; Patient Isolation; Postoperative Complications; Rabbits; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
[Effect of FLAG consolidation therapy on mobilization of autologous peripheral blood stem cells in patients with acute myelogenous leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine; Young Adult | 2009 |
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Vidarabine | 2010 |
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
Topics: Adult; Aged; Alemtuzumab; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Bone Marrow Diseases; CD52 Antigen; Cohort Studies; Cytomegalovirus Infections; Feasibility Studies; Female; Glycoproteins; Humans; Hypotension; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Survival Analysis; Vidarabine | 2009 |
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genes, p53; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Somatic Hypermutation, Immunoglobulin; Survival Analysis; Tumor Suppressor Protein p53; Vidarabine; Young Adult; ZAP-70 Protein-Tyrosine Kinase | 2009 |
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD52 Antigen; Cyclophosphamide; Disease Progression; Epidemiologic Methods; Female; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prognosis; Rituximab; Vidarabine | 2010 |
Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Cell Count; Communicable Diseases; Dendritic Cells; Disease-Free Survival; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Histocompatibility Antigens Class I; Humans; Kaplan-Meier Estimate; Lymphocytes; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Recurrence; T-Lymphocytes; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Rituximab; Vidarabine | 2010 |
[FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2010 |
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Quality of Life; Retreatment; Rituximab; Vidarabine | 2010 |
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2010 |
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Cytogenetic Analysis; Female; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Melphalan; Methotrexate; Middle Aged; Mycosis Fungoides; Myeloablative Agonists; Recurrence; Sezary Syndrome; Tacrolimus; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
[Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mitoxantrone; Myeloablative Agonists; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2010 |
High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
Topics: Adult; Aged; Drug Monitoring; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Neutrophil Infiltration; Prodrugs; Renal Insufficiency; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Vidarabine Phosphate; Young Adult | 2011 |
Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Dyskeratosis Congenita; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Peripheral Blood Stem Cell Transplantation; Pulmonary Fibrosis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Apoptosis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Phosphoric Monoester Hydrolases; Purine Nucleosides; Purine-Nucleoside Phosphorylase; Pyrimidinones; Severity of Illness Index; Vidarabine | 2010 |
Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.
Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Feasibility Studies; Female; Graft Survival; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2010 |
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Vidarabine | 2010 |
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Rituximab; Tumor Burden; Vidarabine | 2010 |
Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation.
Topics: Child; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Survival Rate; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2011 |
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Female; Glycoproteins; Graft vs Host Disease; HLA Antigens; Humans; Male; Melphalan; Middle Aged; Siblings; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2010 |
Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
Topics: Adult; Aged; Busulfan; Dose-Response Relationship, Drug; Drug Interactions; Female; Glutathione; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Pharmacokinetics; Precision Medicine; Reproducibility of Results; Vidarabine; Young Adult | 2011 |
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Rituximab; Vidarabine | 2010 |
Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Plasma; Rituximab; Salvage Therapy; Vidarabine | 2011 |
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Topics: Aged; Busulfan; Cancer Vaccines; CD8 Antigens; Cell Proliferation; Cyclophosphamide; Cytokines; Female; Freund's Adjuvant; Humans; Immunotherapy, Adoptive; Lymphocyte Depletion; Male; MART-1 Antigen; Melanoma; Middle Aged; Peptide Fragments; Skin Neoplasms; T-Lymphocytes; Vidarabine | 2010 |
Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
Topics: Adolescent; Adult; Anemia, Aplastic; Antibodies, Monoclonal; Antilymphocyte Serum; Bone Marrow Transplantation; Cell Count; Child; Child, Preschool; Cyclophosphamide; Cytomegalovirus Infections; Erythrocyte Transfusion; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Leukocyte Count; Lymphoproliferative Disorders; Male; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prognosis; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2010 |
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neoplasm, Residual; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2010 |
TP53 mutation and survival in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multivariate Analysis; Mutation; Prognosis; Proportional Hazards Models; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2010 |
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.
Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Rituximab; Thrombocytopenia; Vidarabine | 2010 |
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Italy; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine; Young Adult | 2011 |
Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Rituximab; Severity of Illness Index; Treatment Outcome; Vidarabine | 2010 |
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busulfan; Cell Line, Tumor; Clofarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Rabbits; Remission Induction; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Living Donors; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2011 |
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Rad51 Recombinase; Recombination, Genetic; Treatment Outcome; Vidarabine | 2011 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine | 2010 |
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2010 |
Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
Topics: Adolescent; Adult; Alkylating Agents; Busulfan; Cyclophosphamide; Drug Administration Schedule; Female; Glutathione Transferase; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Isoenzymes; Male; Middle Aged; Polymorphism, Genetic; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2011 |
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Proportional Hazards Models; Recurrence; Rituximab; Time Factors; Treatment Outcome; Vidarabine | 2011 |
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cooperative Behavior; Cyclophosphamide; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoadjuvant Therapy; Rituximab; Spain; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2011 |
A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies.
Topics: Adult; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Disease-Free Survival; Genes, Immunoglobulin Heavy Chain; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; London; Mutation; Proportional Hazards Models; Risk Assessment; Risk Factors; Rituximab; Survival Rate; Time Factors; Treatment Outcome; United States; Vidarabine | 2011 |
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Cutaneous; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Skin Neoplasms; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
Topics: Abnormal Karyotype; Acute Disease; Adolescent; Adult; Amsacrine; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
[Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2011 |
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; DNA Mutational Analysis; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Proportional Hazards Models; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine | 2011 |
⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Humans; Lymphoma, B-Cell; Middle Aged; Radioimmunotherapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Medical Records; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prospective Studies; Radioimmunotherapy; Rituximab; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2012 |
Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Immunotherapy, Active; Lymphoma, Follicular; Middle Aged; Prednisone; Treatment Outcome; Vidarabine; Vincristine; Young Adult | 2011 |
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Salvage Therapy; Smith-Magenis Syndrome; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2011 |
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Vidarabine | 2011 |
The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Double-Blind Method; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucositis; Transplantation Conditioning; Vidarabine; Zinc Sulfate | 2012 |
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Radiopharmaceuticals; Rituximab; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2011 |
Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cytomegalovirus Infections; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Vidarabine | 2011 |
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Immunosuppression Therapy; Male; Middle Aged; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Middle Aged; Prospective Studies; Rituximab; Vidarabine | 2011 |
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Risk Factors; Rituximab; Smith-Magenis Syndrome; Thrombocytopenia; Vidarabine | 2011 |
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Survival Rate; Time Factors; Vidarabine | 2011 |
Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Survival Rate; Thrombocytopenia; Treatment Outcome; Vidarabine; Vomiting | 2012 |
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Topics: Antigens, CD; Cell Separation; Cyclophosphamide; Flow Cytometry; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunophenotyping; Immunosuppressive Agents; Immunotherapy, Adoptive; Interleukin-2; Killer Cells, Natural; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, KIR; Recurrence; Remission Induction; Risk Factors; Transplantation, Homologous; Vidarabine | 2011 |
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Time Factors; United States; Vidarabine | 2011 |
Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Quality-Adjusted Life Years; Rituximab; Survival Rate; Vidarabine | 2012 |
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine | 2011 |
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Nitrogen Mustard Compounds; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2011 |
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Vidarabine | 2011 |
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Salvage Therapy; Vidarabine; Virus Activation | 2012 |
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Rituximab; Treatment Outcome; Vidarabine | 2012 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood Stem Cell Transplantation; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Melphalan; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2012 |
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; North America; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vidarabine | 2011 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Antigens, CD19; Antilymphocyte Serum; Antineoplastic Agents; CD3 Complex; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphocyte Depletion; Male; Myeloablative Agonists; Prospective Studies; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Models, Statistical; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents; Disease-Free Survival; Ethnicity; Graft vs Host Disease; Histocompatibility Testing; HLA-C Antigens; Humans; Killer Cells, Natural; Leukemia, Myeloid; Lymphocyte Depletion; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Receptors, KIR; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2012 |
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; Vidarabine; Vomiting | 2012 |
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2012 |
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Administration Schedule; Drug Dosage Calculations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Computer Simulation; Cyclophosphamide; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Retrospective Studies; Rituximab; Vidarabine | 2012 |
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Follicular; Mitoxantrone; Radioimmunotherapy; Vidarabine | 2012 |
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Myeloablative Agonists; Neoplasm Staging; Recovery of Function; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2012 |
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Prognosis; Prospective Studies; Rituximab; Survival Rate; Vidarabine | 2012 |
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Time Factors; Vidarabine | 2012 |
[The comparison of fludarabine or antithymocyte globulin based non-myeloablative conditioning regimen for haematologic diseases with graft-versus-host disease].
Topics: Adult; Antilymphocyte Serum; Female; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2011 |
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Cell Line, Tumor; Combined Modality Therapy; Complement Activation; Complement C3b; Complement C4b; Complement System Proteins; Cyclophosphamide; Cytotoxicity, Immunologic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Opsonin Proteins; Rituximab; Vidarabine | 2012 |
[Clinical study on efficiency of fludarabine-based regimen for the patients with chronic lymphocytic leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2012 |
Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2012 |
Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Neoplasm Staging; Radiation-Sensitizing Agents; Radiotherapy Dosage; Vidarabine | 2012 |
Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Dose-Response Relationship, Radiation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Radioimmunotherapy; Radiopharmaceuticals; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Yttrium Radioisotopes | 2012 |
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult | 2012 |
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects; Prognosis; Prospective Studies; Remission Induction; Rituximab; Sex Factors; Survival Rate; Tissue Distribution; Vidarabine | 2012 |
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult | 2012 |
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Topics: Adolescent; Adult; Anemia, Aplastic; Antibiotic Prophylaxis; Antilymphocyte Serum; Antiviral Agents; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Postoperative Complications; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult | 2012 |
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cyclophosphamide; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2012 |
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Vidarabine | 2012 |
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Busulfan; Child; Child, Preschool; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Infant; Myeloablative Agonists; Neutrophils; Prospective Studies; Secondary Prevention; Severity of Illness Index; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Treatment of older patients with mantle-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Prospective Studies; Remission Induction; Rituximab; Survival Rate; Vidarabine; Vincristine | 2012 |
Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytarabine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Indicators and Reagents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Vidarabine | 2012 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.
Topics: Adult; Aged; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Lymphopenia; Male; Melanoma; Middle Aged; Pilot Projects; Skin Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Vidarabine | 2012 |
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Recurrence; Risk; Rituximab; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine; Whole-Body Irradiation | 2013 |
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 6; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotype; Male; Middle Aged; Prognosis; Prospective Studies; Trisomy; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Survival Rate; Time Factors; Vidarabine | 2013 |
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Chromosomes, Human, Pair 12; Cyclophosphamide; Education, Medical, Continuing; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Middle Aged; Phosphoproteins; Prognosis; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Trisomy; Tumor Suppressor Protein p53; Vidarabine | 2013 |
Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2013 |
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Cyclophosphamide; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Protein Serine-Threonine Kinases; Survival Analysis; Tumor Suppressor Proteins; United Kingdom; Vidarabine | 2012 |
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Gastroenteritis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.
Topics: Administration, Oral; Aged; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Proportional Hazards Models; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sex Factors; Societies, Medical; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine | 2013 |
Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bendamustine Hydrochloride; Chemotherapy, Adjuvant; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Survival Analysis; Treatment Outcome; Vidarabine | 2013 |
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicen
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.
Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Infant; Male; Myeloablative Agonists; Retrospective Studies; Risk Factors; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Vidarabine | 2013 |
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Mitoxantrone; Proto-Oncogene Proteins; Remission Induction; Treatment Outcome; Vidarabine | 2013 |
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine | 2013 |
Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control.
Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Male; Risk Factors; Thalassemia; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cohort Studies; Female; Humans; Immunotherapy; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Metabolic Clearance Rate; Middle Aged; Rituximab; Time Factors; Treatment Outcome; Vidarabine | 2013 |
In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cladribine; Cyclophosphamide; DNA Fragmentation; Electrophoresis, Agar Gel; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Vidarabine | 2013 |
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunophenotyping; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2013 |
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Diseases; Bone Marrow Failure Disorders; Child; Chronic Disease; Cyclosporine; Female; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Risk Factors; Salvage Therapy; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Phosphoproteins; Prognosis; Prospective Studies; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2013 |
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.
Topics: Aged; Bone Marrow; Female; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Lewis Blood Group Antigens; Male; Middle Aged; Receptors, Antigen, T-Cell; Remission Induction; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2013 |
Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan.
Topics: Adolescent; Allografts; Antilymphocyte Serum; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Infant; Japan; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Myeloablative Agonists; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2013 |
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Prognosis; Vidarabine; Vincristine | 2013 |
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine | 2014 |
Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Alkylating Agents; Busulfan; Cyclophosphamide; Drug Interactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Vidarabine; Young Adult | 2013 |
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Lin
Topics: Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Dexamethasone; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Rituximab; Vidarabine | 2013 |
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2013 |
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cyclophosphamide; Cytochrome P-450 CYP2B6; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pharmacogenetics; Prognosis; Remission Induction; Vidarabine | 2013 |
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Survival Analysis; Vidarabine; Young Adult | 2014 |
Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Graft Survival; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Administration Schedule; Fatigue; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Nausea; NF-kappa B; Pneumonia; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Vidarabine | 2014 |
Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Child; Cyclophosphamide; Drug Substitution; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Pneumonia; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prospective Studies; Rituximab; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2014 |
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vomiting; Young Adult | 2014 |
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Treatment Outcome; Vidarabine | 2014 |
Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; beta-Thalassemia; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Unrelated Donors; Vidarabine | 2014 |
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine | 2014 |
Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Pilot Projects; Radiation Injuries; Recombinant Proteins; Thrombotic Microangiopathies; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Quality of Life; Retreatment; Treatment Outcome; Vidarabine | 2014 |
Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Disease Progression; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Radioimmunotherapy; Radiopharmaceuticals; Transplantation, Autologous; Vidarabine | 2014 |
Oral versus intravenous fludarabine as part of a reduced-intensity conditioning for allogeneic stem cell transplantation.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Allografts; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Male; Mexico; Middle Aged; Myeloablative Agonists; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Time Factors; Vidarabine; Withholding Treatment | 2014 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Child; Child, Preschool; Coculture Techniques; Combined Modality Therapy; Cyclophosphamide; Diphtheria Toxin; Female; Humans; Interleukin-2; K562 Cells; Killer Cells, Natural; Leukemia, Myeloid; Lymphocyte Depletion; Male; Middle Aged; Recombinant Fusion Proteins; Remission Induction; T-Lymphocytes, Regulatory; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2014 |
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Prospective Studies; Siblings; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult | 2014 |
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Female; Graft vs Host Disease; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2015 |
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Focal Adhesion Kinase 1; Gene Expression; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Proportional Hazards Models; Recurrence; Retrospective Studies; Rituximab; RNA, Messenger; RNA, Neoplasm; Vidarabine | 2014 |
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
Topics: Adult; Aged; Analysis of Variance; Antilymphocyte Serum; Blood Donors; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Janus Kinase 2; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prospective Studies; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2014 |
How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prospective Studies; Risk Factors; Rituximab; Treatment Outcome; Vidarabine | 2014 |
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Pilot Projects; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2014 |
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
Topics: Adolescent; Adult; Allografts; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; GATA2 Transcription Factor; Genetic Diseases, Inborn; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2014 |
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Vidarabine | 2014 |
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Combinations; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Immunotherapy, Adoptive; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Receptors, Antigen, T-Cell; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2015 |
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Rituximab; Survival Analysis; Treatment Failure; Vidarabine; Vincristine | 2014 |
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Myeloablative Agonists; Prospective Studies; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.
Topics: Adult; Aged; Bayes Theorem; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2014 |
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Female; Gamma Rays; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Myeloablative Agonists; Myelodysplastic Syndromes; Quality of Life; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Yttrium Radioisotopes | 2015 |
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Topics: Aged; Antineoplastic Agents; Busulfan; Cyclosporine; Female; Frail Elderly; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2015 |
Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.
Topics: Adolescent; Adult; Aged; Allografts; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2015 |
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Rituximab; Sweden; Vidarabine | 2015 |
Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Cells, Cultured; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Treatment Outcome; Vidarabine | 2015 |
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.
Topics: Adolescent; Allografts; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine | 2015 |
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency.
Topics: Adolescent; Adult; Busulfan; Child; Female; Graft Survival; Graft vs Host Disease; Guanine Nucleotide Exchange Factors; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunophenotyping; Immunosuppressive Agents; Male; Methotrexate; Mutation; Myeloablative Agonists; Pilot Projects; Severe Combined Immunodeficiency; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Antineoplastic Agents; Chemoradiotherapy; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Maltose; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2015 |
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2015 |
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Thalidomide; Vidarabine | 2015 |
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Isotretinoin; Leukemia, Myelomonocytic, Juvenile; Male; Middle Aged; Quinolones; Survival Rate; Vidarabine | 2015 |
An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arrhythmias, Cardiac; B-Lymphocytes; Biomarkers; Cardiotoxicity; Complement System Proteins; Cytokines; Drug Resistance, Neoplasm; Electrocardiography; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Retreatment; Treatment Outcome; Vidarabine | 2015 |
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergr
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; CpG Islands; Cyclophosphamide; DNA Methylation; DNA Mutational Analysis; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2015 |
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine | 2015 |
Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Male; Middle Aged; Radiotherapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning.
Topics: Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Middle Aged; Prospective Studies; Rabbits; Survival Rate; Transplantation Conditioning; Vidarabine | 2015 |
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Recurrence; Survival Analysis; Treatment Failure; Vidarabine | 2015 |
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphocyte Count; Lymphocytes; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Monocytes; Prednisone; Prospective Studies; Rituximab; Survival Rate; Vidarabine; Vincristine | 2015 |
Frontline therapy of severe aplastic anaemia with fludarabine, cyclophosphamide and ciclosporin.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Vidarabine | 2015 |
Alternative donor hematopoietic cell transplantation for Fanconi anemia.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Enzyme Inhibitors; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Opportunistic Infections; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2015 |
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Retreatment; Vidarabine | 2015 |
Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Topics: Acute Disease; Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Melphalan; Myeloablative Agonists; Neutropenia; Prospective Studies; Risk; Siblings; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine | 2016 |
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 2016 |
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.
Topics: Adenoviridae; Aged; Aged, 80 and over; Combined Modality Therapy; Dose-Response Relationship, Drug; Escherichia coli; Female; Follow-Up Studies; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Purine-Nucleoside Phosphorylase; Tumor Cells, Cultured; Vidarabine | 2015 |
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Preference; Rituximab; Vidarabine | 2015 |
Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Stu
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Male; Middle Aged; Prospective Studies; Recurrence; Steroids; Transplantation Conditioning; Vidarabine | 2015 |
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult | 2015 |
Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies.
Topics: Adolescent; Adult; Allografts; Busulfan; Child; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphocyte Depletion; Male; Middle Aged; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2015 |
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrroles; Recurrence; Retreatment; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Adhesion Molecules; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Prospective Studies; Radioimmunotherapy; Radioisotopes; Rhenium; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2015 |
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Sirolimus; Stem Cell Transplantation; Survival Rate; Tacrolimus; Vidarabine | 2015 |
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Topics: Adult; Bortezomib; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
Topics: Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2015 |
Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine | 2015 |
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Smith-Magenis Syndrome; Survival Rate; Vidarabine | 2015 |
Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Darbepoetin alfa; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Treatment Outcome; Vidarabine | 2016 |
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Rituximab; Vidarabine | 2015 |
Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Exotoxins; Female; Humans; Immunotoxins; Interleukin-2 Receptor alpha Subunit; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine | 2016 |
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retreatment; Treatment Outcome; Vidarabine | 2015 |
A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2015 |
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Inositol Polyphosphate 5-Phosphatases; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphoric Monoester Hydrolases; Prognosis; Proportional Hazards Models; Transcriptome; Vidarabine | 2015 |
The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2016 |
Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study
Topics: Adolescent; Adult; Allografts; Antilymphocyte Serum; Child; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Male; Melphalan; Prospective Studies; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine | 2016 |
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Opportunistic Infections; Rituximab; Survival Analysis; Vidarabine | 2016 |
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Infections; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2016 |
Successful Outcome With Fludarabine-Based Conditioning Regimen for Hematopoietic Stem Cell Transplantation From Related Donor in Fanconi Anemia: A Single Center Experience From Turkey.
Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Tissue Donors; Transplantation Conditioning; Turkey; Vidarabine | 2016 |
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Risk; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2016 |
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Consolidation Chemotherapy; Drug Administration Schedule; Female; Gemtuzumab; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy; Immunotoxins; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Sialic Acid Binding Ig-like Lectin 3; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine; Young Adult | 2016 |
[Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2016 |
Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mucositis; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Hydroxamic Acids; Infusions, Intravenous; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Quality of Life; Recurrence; Vidarabine; Vorinostat | 2016 |
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Survival Analysis; Thalidomide; Vidarabine | 2016 |
Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Prospective Studies; Republic of Korea; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult | 2016 |
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2016 |
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Case-Control Studies; Cell Transformation, Neoplastic; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Registries; Risk Assessment; Risk Factors; Vidarabine | 2016 |
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; International Agencies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine | 2016 |
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Topics: Bridged Bicyclo Compounds, Heterocyclic; DNA-Activated Protein Kinase; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Proteins; Nuclear Proteins; Purines; Pyrazines; Quinazolinones; Sulfonamides; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured; Vidarabine | 2016 |
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medication Adherence; Middle Aged; Quality of Life; Rituximab; Sex Factors; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2017 |
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Rituximab; Survival Rate; Vidarabine | 2016 |
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Topics: Adult; Aged; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cyclophosphamide; Female; Humans; Immunotherapy; Lymphocyte Depletion; Lymphocyte Subsets; Lymphoma, Non-Hodgkin; Male; Middle Aged; Receptors, Antigen, T-Cell; Syndrome; Transgenes; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Protocols; Cyclophosphamide; Drug Dosage Calculations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Research Design; Time Factors; Treatment Outcome; United Kingdom; Vidarabine | 2016 |
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine | 2017 |
Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Prospective Studies; Proto-Oncogene Proteins c-kit; Translocation, Genetic; Vidarabine; Young Adult | 2017 |
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Recurrence; Retreatment; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2017 |
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Treatment Outcome; Vidarabine | 2017 |
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Trial of novel leukaemia drug is stopped for second time after two more deaths.
Topics: Antineoplastic Agents; Brain Edema; Early Termination of Clinical Trials; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; United States; United States Food and Drug Administration; Vidarabine | 2016 |
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Survival Rate; Time Factors; Treatment Outcome; Vidarabine | 2017 |
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Siblings; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2017 |
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2017 |
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Interferons; Lymphoma, Non-Hodgkin; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Remission Induction; Rituximab; Vidarabine; Young Adult | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
Topics: Adult; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2017 |
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Decitabine; Disease-Free Survival; Epigenesis, Genetic; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Translocation, Genetic; Vidarabine | 2017 |
A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Topics: Adult; Busulfan; Cyclophosphamide; Disease Progression; Factor Analysis, Statistical; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Prognosis; Quality of Life; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine; Young Adult | 2017 |
Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.
Topics: Aged; Allografts; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Middle Aged; Neutrophils; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine | 2017 |
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
Topics: Alemtuzumab; Anemia, Sickle Cell; Calcineurin Inhibitors; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Hydroxyurea; Male; Melphalan; Mycophenolic Acid; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2017 |
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Topics: Abdominal Pain; Adult; Aged; Anemia; Carcinoembryonic Antigen; Cohort Studies; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-6; Lung; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Treatment Outcome; Vidarabine; Vomiting | 2017 |
Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
Topics: Adolescent; Arabinonucleotides; Biomarkers, Pharmacological; Child; Child, Preschool; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Metabolic Clearance Rate; Patient-Specific Modeling; Precision Medicine; Prospective Studies; Transplant Recipients; Transplantation Conditioning; Vidarabine | 2017 |
Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Infant; Leukemia; Male; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Vidarabine | 2017 |
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult | 2017 |
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Implementing the EffTox dose-finding design in the Matchpoint trial.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Blast Crisis; Cytarabine; Humans; Idarubicin; Imidazoles; Models, Statistical; Outcome Assessment, Health Care; Pyridazines; Research Design; Vidarabine | 2017 |
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 17; Cyclophosphamide; DNA Mutational Analysis; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2018 |
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Topics: Adolescent; Adult; Alemtuzumab; Allografts; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Infant; Male; Risk Factors; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine | 2018 |
Augmenting Total Body Irradiation with a Cranial Boost before Stem Cell Transplantation Protects Against Post-Transplant Central Nervous System Relapse in Acute Lymphoblastic Leukemia.
Topics: Adolescent; Adult; Allografts; Central Nervous System Neoplasms; Child; Child, Preschool; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
Topics: Adult; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Siblings; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Vidarabine | 2018 |
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
Topics: Adolescent; Adult; Aged; Antigens, CD20; Cyclophosphamide; Dose-Response Relationship, Drug; Female; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
Topics: Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Juvenile; Male; Myeloablative Agonists; Prognosis; Transplantation Conditioning; Vidarabine | 2018 |
Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Survival Rate; Vidarabine | 2018 |
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.
Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2018 |
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Hematologic Diseases; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Rituximab; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Vidarabine | 2018 |
Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an FBCA conditioning regimen.
Topics: Adult; Allografts; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine | 2018 |
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2018 |
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.
Topics: Adolescent; Adult; Alemtuzumab; Antineoplastic Agents; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.
Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Topics: Adult; Aged; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Incidence; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Prolymphocytic, T-Cell; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Treatment Outcome; Vidarabine | 2019 |
Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Vidarabine; Young Adult | 2019 |
Is pharmacokinetic guidance a must in busulfan regimens?
Topics: Area Under Curve; Busulfan; Cyclophosphamide; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Male; Randomized Controlled Trials as Topic; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2018 |
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Comorbidity; Dose-Response Relationship, Drug; Drug Interactions; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Time Factors; Treatment Outcome; Vidarabine; Young Adult | 2018 |
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modality Therapy; Cyclophosphamide; Drug Approval; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Leukapheresis; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration; Vidarabine; Young Adult | 2019 |
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Registries; Retrospective Studies; Rituximab; Survival Rate; Sweden; Vidarabine | 2019 |
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Prognosis; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2019 |
Renal dysfunction within 90 days of FluBu4 predicts early and late mortality.
Topics: Acute Kidney Injury; Adolescent; Adult; Age Factors; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Models, Biological; Retrospective Studies; Survival Rate; Vidarabine | 2019 |
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Vidarabine | 2019 |
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Survival Rate; Vidarabine | 2019 |
Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oncology Nursing; Risk Factors; Rituximab; Survival Rate; Vidarabine | 2019 |
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Topics: Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; Lymphocyte Depletion; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Survival Rate; Vidarabine | 2019 |
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Mycophenolic Acid; Retrospective Studies; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Risk; Single-Blind Method; Treatment Failure; Vidarabine | 2019 |
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
Topics: Acute Disease; Adult; Allografts; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Infant; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Risk Factors; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2019 |
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.
Topics: Adult; Allografts; Benzylamines; Busulfan; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Proteomics; Signal Transduction; Transplantation Conditioning; Vidarabine | 2019 |
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.
Topics: Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
Topics: Adult; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Enzyme Inhibitors; Female; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neutrophils; Recovery of Function; Retrospective Studies; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2019 |
Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy.
Topics: Acute Disease; Adult; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2019 |
Successful Outcome in Patients with Fanconi Anemia Undergoing T Cell-Replete Mismatched Related Donor Hematopoietic Cell Transplantation Using Reduced-Dose Cyclophosphamide Post-Transplantation.
Topics: Adolescent; Allografts; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Mycophenolic Acid; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Vidarabine | 2019 |
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Progression-Free Survival; Remission Induction; Vidarabine | 2020 |
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Predictive Value of Tests; Rituximab; Vidarabine | 2019 |
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Gene Expression Profiling; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Risk Assessment; Risk Factors; Rituximab; Texas; Time Factors; Transcriptome; Treatment Outcome; Vidarabine | 2019 |
A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease.
Topics: Alemtuzumab; Child; Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infant; Melphalan; Myeloablative Agonists; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2020 |
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Salvage Therapy; Sulfonamides; Vidarabine | 2020 |
Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine.
Topics: Adult; Basiliximab; Cyclophosphamide; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Vidarabine | 2020 |
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
Topics: Acute Disease; Adolescent; Adult; Aged; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Progression-Free Survival; Rituximab; Time; Vidarabine; Vincristine | 2020 |
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
Topics: Antibodies, Monoclonal, Humanized; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Vidarabine | 2020 |
Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.
Topics: Aged; Allografts; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Female; Follow-Up Studies; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Vidarabine; Viral Load; Whole-Body Irradiation | 2020 |
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Baculoviral IAP Repeat-Containing 3 Protein; Biomarkers, Tumor; Cohort Studies; Cyclophosphamide; Extracellular Signal-Regulated MAP Kinases; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Signaling System; Mutation; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2020 |
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prospective Studies; Rituximab; Vidarabine | 2020 |
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large-Cell, Anaplastic; Melphalan; Transplantation Conditioning; Vidarabine | 2020 |
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexamethasone; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Progression-Free Survival; Prospective Studies; Survival Rate; United Kingdom; Vidarabine; Young Adult | 2020 |
Treatment of Testicular Relapse of B-cell Acute Lymphoblastic Leukemia With CD19-specific Chimeric Antigen Receptor T Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Humans; Immunotherapy, Adoptive; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Testicular Neoplasms; Vidarabine | 2020 |
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Agents; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Infusions, Intravenous; Leukapheresis; Lymphoma, Mantle-Cell; Middle Aged; Receptors, Chimeric Antigen; Recurrence; Survival Analysis; T-Lymphocytes; Vidarabine | 2020 |
Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Topics: Aged; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Cell Line, Tumor; Cell Membrane; Cytotoxicity, Immunologic; Female; Humans; Immunoglobulin Fc Fragments; Interleukin-2; Interleukins; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Activation; Male; Mice; Middle Aged; Protein Binding; Protein Engineering; Sialic Acid Binding Ig-like Lectin 3; Vidarabine | 2020 |
Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine | 2020 |
Cold agglutinin disease revisited: a multinational, observational study of 232 patients.
Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Rituximab; Vidarabine | 2020 |
Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study.
Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pharmaceutical Preparations; Prospective Studies; Transplantation Conditioning; Vidarabine | 2021 |
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 Ratio; Confidence Intervals; Cyclophosphamide; Cytokine Release Syndrome; Female; Glycolysis; Humans; Ifosfamide; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Progression-Free Survival; Receptors, Chimeric Antigen; Recurrence; T-Lymphocytes; Thrombocytopenia; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Oxaliplatin; Prednisone; Primary Cell Culture; Rituximab; SAM Domain and HD Domain-Containing Protein 1; Tissue Array Analysis; Vidarabine; Vincristine | 2021 |
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2020 |
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Epitopes; Female; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Ki-1 Antigen; Lymphocyte Depletion; Male; Middle Aged; Stem Cell Transplantation; Vidarabine; Young Adult | 2020 |
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Survival Rate; Vidarabine | 2020 |
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Induction Chemotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Purines; Rituximab; Treatment Outcome; Vidarabine | 2021 |
Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.
Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Prognosis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Topics: Adult; Aged; Antigens, CD19; Cell Proliferation; Cyclophosphamide; Cytokine Release Syndrome; Female; Humans; Immunotherapy, Adoptive; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Progression-Free Survival; T-Lymphocytes; Treatment Outcome; Vidarabine | 2021 |
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Topics: Bone Neoplasms; Child; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Immunity; Immunotherapy, Adoptive; Lymphocyte Activation; Male; Natural Killer T-Cells; Neuroblastoma; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Vidarabine | 2020 |
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EB
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Organ Size; Primary Myelofibrosis; Registries; Retrospective Studies; Spleen; Splenectomy; Survival Rate; Vidarabine | 2021 |
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease Progression; Endpoint Determination; Female; Humans; Immunosuppression Therapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2021 |
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation | 2021 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult | 2021 |
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine | 2021 |
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome; Vidarabine | 2021 |
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2021 |
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2021 |
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult | 2021 |
Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
Topics: Administration, Intravenous; Cell Culture Techniques; Cyclophosphamide; Feasibility Studies; Gene Regulatory Networks; Humans; Immune Checkpoint Inhibitors; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Pilot Projects; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2021 |
Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Female; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Vidarabine | 2021 |
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Rituximab; Treatment Outcome; Vidarabine | 2021 |
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Topics: Adolescent; Adult; Azacitidine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2021 |
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Female; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Myelopoiesis; Myeloproliferative Disorders; Neoplasms, Second Primary; Sulfonamides; Vidarabine | 2022 |
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Biological Products; Biomarkers; Cyclophosphamide; Cytokine Release Syndrome; Drug Therapy, Combination; Female; Humans; Immunotherapy, Adoptive; Leukapheresis; Levetiracetam; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nervous System Diseases; Neutropenia; Propensity Score; Vidarabine; Young Adult | 2021 |
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Transplantation, Homologous; Vidarabine | 2021 |
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Cyclophosphamide; Cytokines; Humans; Inflammation; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Rituximab; T-Lymphocytes; Vidarabine | 2022 |
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Thiotepa; Transplantation Conditioning; Vidarabine | 2022 |
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Bone Marrow; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine | 2022 |
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine | 2022 |
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat | 2022 |
Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2022 |
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2022 |
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2022 |
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Vidarabine | 2022 |
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Transplantation Conditioning; Vidarabine; Young Adult | 2023 |
2193 other study(ies) available for fludarabine and vidarabine
| Article | Year |
|---|---|
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
Topics: Adenosine; Animals; Cell Membrane; CHO Cells; Corpus Striatum; Cricetinae; In Vitro Techniques; Magnetic Resonance Spectroscopy; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Radioligand Assay; Rats; Recombinant Proteins; Ribose; Structure-Activity Relationship | 1995 |
The purine analogs--a therapeutic beauty contest.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |
The purine analogs--a therapeutic beauty contest.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Pentostatin; Vidarabine | 1992 |
Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Listeriosis; Male; Middle Aged; Prednisone; Retrospective Studies; Vidarabine | 1992 |
Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |
New drugs in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1992 |
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.
Topics: Adult; Aged; Antigens, CD; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; CD5 Antigens; Female; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Gene Rearrangement, B-Lymphocyte, Light Chain; Genes, Immunoglobulin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Male; Middle Aged; Prednisone; Survival Analysis; Vidarabine | 1992 |
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.
Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etoposide; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 1992 |
Fludarabine and acute tumor lysis in chronic lymphocytic leukemia.
Topics: Acute Kidney Injury; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Lysis Syndrome; Vidarabine | 1992 |
Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1992 |
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Cycle; Cytarabine; Deoxycytidine Kinase; Drug Synergism; G1 Phase; G2 Phase; Humans; Intracellular Fluid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Metaphase; Nucleotides; S Phase; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1992 |
Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Hindlimb; Leukemia L1210; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Nervous System Diseases; Paralysis; Prodrugs; Thioinosine; Thionucleotides; Vidarabine | 1992 |
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytarabine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Time Factors; Vidarabine | 1992 |
A quantitative assay for fragmented DNA in apoptotic cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; DNA; DNA, Circular; Ethidium; Gemcitabine; Humans; Microchemistry; Phosphorus Radioisotopes; Plasmids; T-Lymphocytes; Time Factors; Vidarabine | 1992 |
Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine.
Topics: Antineoplastic Agents; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Pneumonia, Pneumocystis; Tuberculosis; Vidarabine | 1992 |
Fludarabine-induced cytogenetic remission in prolymphocytic leukemia.
Topics: Aged; Chromosome Aberrations; Chromosome Disorders; Humans; Karyotyping; Leukemia, Prolymphocytic; Male; Vidarabine | 1992 |
Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1992 |
Two views of the immunologic effects of fludarabine.
Topics: Antineoplastic Agents; Burkitt Lymphoma; CD4-Positive T-Lymphocytes; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes, Regulatory; Vidarabine | 1991 |
Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.
Topics: Aphidicolin; Arabinonucleotides; Cell Line; Cell Survival; Clone Cells; Diterpenes; DNA Replication; DNA-Directed DNA Polymerase; Guanosine Monophosphate; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Vidarabine; Vidarabine Phosphate | 1990 |
Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Drug Evaluation; Humans; Injections, Intravenous; Multivariate Analysis; Neoplasms; Vidarabine; Vidarabine Phosphate | 1990 |
Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.
Topics: Antineoplastic Agents; Cell-Free System; Poly A; Protein Biosynthesis; RNA; Temperature; Transcription, Genetic; Vidarabine | 1991 |
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Synergism; Female; Humans; Hydroxyurea; Infusions, Intravenous; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Vidarabine | 1992 |
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Topics: Anti-Infective Agents; Antineoplastic Agents; Drug Compounding; Drug Incompatibility; Infusions, Intravenous; Solutions; Vidarabine | 1991 |
Fludarabine approved for use in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1991 |
Sustained response of refractory prolymphocytic leukemia to fludarabine.
Topics: Aged; Antimetabolites, Antineoplastic; Humans; Leukemia, Prolymphocytic; Leukocyte Count; Male; Remission Induction; Spleen; Vidarabine | 1991 |
Fludarabine.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Vidarabine | 1991 |
Fludarabine therapy in hairy cell leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Leukemia, Hairy Cell; Male; Remission Induction; Vidarabine | 1991 |
Interaction of arabinosyl nucleotides in K562 human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleosides; Arabinonucleotides; Cytarabine; Deoxyribonucleotides; Drug Interactions; Guanosine Triphosphate; Humans; Leukemia; Phosphorylation; Phosphotransferases; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate | 1989 |
Fludarabine shows promise for some leukemia patients.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine; Vidarabine Phosphate | 1989 |
Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay.
Topics: Cell Survival; Cells, Cultured; Cladribine; Colony-Forming Units Assay; Deoxyadenosines; Drug Evaluation, Preclinical; Female; Humans; Kinetics; Neoplasms; Vidarabine | 1986 |
Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides.
Topics: Animals; Blotting, Southern; Cell Line; Chromosome Deletion; Cricetinae; Hypoxanthine Phosphoribosyltransferase; Mutation; RNA, Messenger; Vidarabine | 1989 |
Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production.
Topics: Adenine; Adenosine; Adenosine Triphosphate; Animals; Binding, Competitive; Cell Line; Escherichia coli; Humans; Kidney; Kinetics; Leukemia; Liver; Mice; Phosphates; Purine Nucleosides; Rats; Vidarabine | 1987 |
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Humans; Leukemia; Phosphorylation; Tumor Cells, Cultured; Vidarabine | 1988 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |
Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
Topics: Cells, Cultured; Chromatography, High Pressure Liquid; Cytarabine; Humans; Kinetics; Leukemia; Nucleotides; Vidarabine | 1987 |
Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
Topics: Animals; Biological Transport; Epithelium; Intestine, Small; Kinetics; Leukemia L1210; Mice; Mice, Inbred Strains; Organ Specificity; Phosphorylation; Tritium; Vidarabine | 1987 |
The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cells, Cultured; Deoxyadenosines; Deoxyguanosine; Hydroxyurea; Isoquinolines; Leukemia L1210; Models, Biological; Nucleic Acid Synthesis Inhibitors; Phosphorylases; Pyrazoles; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Thymidine; Vidarabine | 1985 |
Incorporation of 9-beta-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA.
Topics: Carboxylesterase; Carboxylic Ester Hydrolases; Cell Differentiation; Cell Division; Cell Line; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; RNA, Neoplasm; Time Factors; Vidarabine | 1986 |
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Topics: Adenocarcinoma; Arabinonucleotides; Drug Evaluation; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Vidarabine; Vidarabine Phosphate | 1984 |
Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts.
Topics: Cell Survival; Cells, Cultured; Deoxycytidine; DNA, Neoplasm; Humans; Leukemia, Lymphoid; Phosphotransferases; Vidarabine | 1980 |
Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
Topics: Animals; Cell Line; Chromatography, DEAE-Cellulose; Deoxycytidine Kinase; DNA; Electrophoresis, Polyacrylamide Gel; Leukemia L1210; Mice; Mutation; Oxidative Phosphorylation; Phosphotransferases; Vidarabine | 1980 |
Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
Topics: Animals; Cell Survival; Cytidine; Deferoxamine; Deoxyadenosines; Deoxycytidine; Drug Synergism; Hydroxyurea; Kinetics; Leukemia L1210; Mice; Pyrazoles; Vidarabine | 1984 |
Specificity of systems mediating transport of adenosine, 9-beta-d-arabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells.
Topics: Adenosine; Animals; Biological Transport; Kinetics; Leukemia L1210; Mice; Purine Nucleosides; Temperature; Time Factors; Vidarabine | 1983 |
Initial rate kinetics and evidence for duality of mediated transport of adenosine, related purine nucleosides, and nucleoside analogues in L1210 cells.
Topics: Adenosine; Animals; Biological Transport; Cell Membrane; Kinetics; Leukemia L1210; Mice; Purine Nucleosides; Temperature; Time Factors; Vidarabine | 1983 |
2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine.
Topics: Adenine; Adenosine Triphosphate; Animals; Arabinonucleotides; Cell Line; Chromatography, High Pressure Liquid; Leukemia P388; Leukemia, Experimental; Mice; Vidarabine | 1983 |
Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells.
Topics: Adenosine Deaminase Inhibitors; Adenosine Triphosphate; Antineoplastic Agents; Cells, Cultured; Coformycin; DNA; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphoid; T-Lymphocytes; Vidarabine | 1980 |
Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
Topics: Adenosylhomocysteinase; Animals; DNA Polymerase I; DNA Polymerase II; DNA Replication; Hydrolases; Leukemia L1210; Mice; Nucleic Acid Synthesis Inhibitors; Ribonucleotide Reductases; Vidarabine | 1982 |
In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
Topics: Antiviral Agents; Arabinonucleotides; Binding, Competitive; Cell Survival; Deoxycytidine Kinase; HeLa Cells; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Phosphorylation; Ribonucleotide Reductases; Vidarabine | 1982 |
Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.
Topics: Animals; Bone Marrow; Female; Intestinal Mucosa; Kinetics; Leukemia P388; Leukemia, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Vidarabine | 1982 |
Identification of metabolites of 9-beta-D-arabinofuranosyl-2-fluoroadenine, an antitumor and antiviral agent.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Chemical Phenomena; Chemistry; Dogs; Female; Leukemia L1210; Macaca mulatta; Male; Mice; Vidarabine | 1982 |
Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro.
Topics: Antineoplastic Agents; Biological Transport; Bone Marrow; Cell Survival; Cells, Cultured; Chlorambucil; Cladribine; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1995 |
[Fludarabine and fatal hemolytic anemia].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1995 |
Acute leukemia complicating bone marrow hypoplasia in an adult with Shwachman's syndrome.
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Neutropenia; Pancreatic Diseases; Syndrome; Vidarabine | 1993 |
CD23 antigen density is related to serum gamma globulin level, bone marrow reticulin pattern, and treatment in B chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Flow Cytometry; Fluorescent Antibody Technique; gamma-Globulins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Prednisolone; Receptors, IgE; Reticulin; Vidarabine; Vincristine | 1994 |
Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cytarabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Vidarabine | 1994 |
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality Therapy; Cytarabine; Factor VIII; Female; Granulocyte Colony-Stimulating Factor; Hemophilia A; Hemorrhage; Hodgkin Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Plasmapheresis; Prednisone; Procarbazine; Prothrombin; Remission Induction; Thrombocytopenia; Vidarabine; Vincristine | 1995 |
In vitro sensitivity of B-CLL cells to fludarabine and interferons.
Topics: Aged; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cells, Cultured; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Interferon-alpha; Interferon-beta; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1995 |
Remission of leukaemic meningitis after fludarabine.
Topics: Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Meningitis, Aseptic; Remission Induction; Vidarabine | 1995 |
Adaptation of the TdT assay for semi-quantitative flow cytometric detection of DNA strand breaks.
Topics: Antineoplastic Agents; Apoptosis; Cells, Cultured; Cladribine; DNA Damage; DNA Nucleotidylexotransferase; Flow Cytometry; Humans; Lymphocytes; Ultraviolet Rays; Vidarabine | 1995 |
Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Autoimmune Diseases; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Recurrence; Vidarabine | 1995 |
Developments in the treatment of leukaemias and lymphomas.
Topics: Animals; Antineoplastic Agents; Humans; Leukemia; Lymphoma; Vidarabine | 1995 |
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Bacteremia; Drug Administration Schedule; Female; Fever of Unknown Origin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pneumonia; Remission Induction; Survival Rate; Vidarabine | 1995 |
Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Humans; Interferon-alpha; Interleukin-1; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Necrosis Factor-alpha; Vidarabine | 1995 |
Acute renal failure as a consequence of urine stop flow in a patient with chronic lymphocytic leukemia after treatment with fludarabine.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Renal Insufficiency; Urinary Retention; Vidarabine | 1995 |
Renal failure in a patient with chronic lymphocytic leukaemia treated with fludarabine.
Topics: Acute Kidney Injury; Antineoplastic Agents; Glomerulonephritis, Membranoproliferative; Humans; Kidney Glomerulus; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1995 |
Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Topics: Antineoplastic Agents; Cell Survival; Cisplatin; Cross-Linking Reagents; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Drug Synergism; Genome, Human; Humans; Thiourea; Tumor Cells, Cultured; Vidarabine | 1995 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Gentamicin and fludarabine ototoxicity.
Topics: Aged; Antineoplastic Agents; Deafness; Dose-Response Relationship, Drug; Gentamicins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pneumonia; Vidarabine | 1995 |
Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis.
Topics: Antineoplastic Agents; Biopsy; Bronchoscopy; Humans; Lung; Lung Diseases; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Opportunistic Infections; Pneumonia, Pneumocystis; Vidarabine | 1995 |
Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Aphidicolin; Apoptosis; Cell Cycle; Cell Line; Cell Membrane; Deoxycytidine; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; T-Lymphocytes; Time Factors; Tumor Cells, Cultured; Vidarabine | 1995 |
Fludarabine and plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Vidarabine | 1995 |
Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Transfusion Reaction; Vidarabine | 1994 |
First report of fludarabine in gamma-heavy chain disease.
Topics: Aged; Antineoplastic Agents; Follow-Up Studies; Heavy Chain Disease; Humans; Male; Vidarabine | 1994 |
Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Purpura, Thrombocytopenic, Idiopathic; Recurrence; T-Lymphocyte Subsets; Vidarabine | 1994 |
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Separation; Cytarabine; Daunorubicin; Diploidy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 1995 |
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Chromosome Aberrations; Chromosomes, Human, Pair 17; Female; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Sequence Data; Pentostatin; Polymorphism, Single-Stranded Conformational; Survival Rate; Vidarabine | 1995 |
Defective apoptosis due to Bcl-2 overexpression may explain why B-CLL cells accumulate in G0.
Topics: Apoptosis; B-Lymphocytes; Gene Expression Regulation, Leukemic; Humans; Interphase; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 1995 |
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine | 1994 |
2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1994 |
2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1994 |
Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.
Topics: 2-Chloroadenosine; Anemia; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Deoxyadenosines; Fatal Outcome; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Male; Methotrexate; Middle Aged; Neoplastic Stem Cells; Prednisone; Salvage Therapy; Vidarabine; Vincristine; Zidovudine | 1994 |
Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation.
Topics: Animals; Antineoplastic Agents; Male; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage; Vidarabine | 1994 |
Neurological illness following treatment with fludarabine.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nervous System Diseases; Vidarabine | 1994 |
Late listeriosis after fludarabine plus prednisone treatment.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Male; Opportunistic Infections; Prednisone; Time Factors; Vidarabine | 1994 |
The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; DNA; Dose-Response Relationship, Drug; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Radiation Tolerance; S Phase; Vidarabine | 1994 |
Secondary neoplasms in two patients treated with purine analogues.
Topics: Acute Disease; Aged; Cladribine; Female; Humans; Immunocompromised Host; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melanoma; Neoplasms, Second Primary; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.
Topics: Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Tumor Lysis Syndrome; Vidarabine | 1994 |
Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells.
Topics: Aged; Apoptosis; Cladribine; DNA Damage; Female; Humans; In Vitro Techniques; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Tumor Cells, Cultured; Vidarabine | 1994 |
Fludarabine causing tumour lysis syndrome in chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Tumor Lysis Syndrome; Vidarabine | 1994 |
Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance.
Topics: 2-Chloroadenosine; Aged; Chlorambucil; Drug Resistance; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Time Factors; Vidarabine | 1994 |
Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Survival; Cells, Cultured; Cyclophosphamide; Cytotoxicity, Immunologic; Humans; Immunophenotyping; Interferon-alpha; Interleukin-2; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Tumor Cells, Cultured; Vidarabine | 1994 |
Kaposi's sarcoma in an HIV-negative CLL patient as the cause of thrombocytopenia.
Topics: Aged; Antineoplastic Agents; Biopsy; Blood Platelets; HIV Seronegativity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Radionuclide Imaging; Sarcoma, Kaposi; Skin; Technetium Compounds; Thrombocytopenia; Vidarabine | 1994 |
Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Platelet Count; Recurrence; Vidarabine | 1994 |
Effectiveness of fludarabine in end-stage prolymphocytic leukemia.
Topics: Aged; Anemia; Antigens, CD; Antineoplastic Agents; Blood Transfusion; Chlorambucil; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Neoplasm Staging; Splenectomy; Thrombocytopenia; Vidarabine | 1994 |
Prolonged bone marrow aplasia of refractory prolymphocytoid variant of B-cell chronic lymphocytic leukemia related to fludarabine treatment.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukopenia; Male; Middle Aged; Neutropenia; Vidarabine | 1994 |
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
Topics: Adenosine Triphosphate; Apoptosis; Cladribine; Cycloheximide; Dactinomycin; DNA, Neoplasm; Egtazic Acid; Guanosine Triphosphate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Microscopy, Electron; Puromycin; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Uridine Triphosphate; Vidarabine | 1993 |
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Topics: Antineoplastic Agents; Cladribine; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1993 |
Listeriosis after 2-chlorodeoxyadenosine treatment.
Topics: Aged; Antineoplastic Agents; Cladribine; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Vidarabine | 1993 |
Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Red-Cell Aplasia, Pure; Vidarabine | 1993 |
Cytopenia and fludarabine.
Topics: Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neutropenia; Thrombocytopenia; Vidarabine | 1993 |
Cytopenia and fludarabine.
Topics: Adult; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Red-Cell Aplasia, Pure; Vidarabine | 1993 |
Fludarabine and psoriasis.
Topics: Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Psoriasis; Vidarabine | 1994 |
Case report: fatal Staphylococcus aureus sepsis from single-donor platelet transfusion.
Topics: Aged; Antineoplastic Agents; Bacteremia; Blood Donors; Carcinoma, Squamous Cell; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Platelet Transfusion; Skin Neoplasms; Staphylococcal Infections; Staphylococcus aureus; Thrombocytopenia; Vidarabine | 1994 |
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Administration Schedule; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents; Female; Follow-Up Studies; Hemoglobins; Humans; Immunoglobulin M; Middle Aged; Remission Induction; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine.
Topics: Aged; Anemia, Hemolytic, Autoimmune; CD4-CD8 Ratio; Coombs Test; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Vidarabine | 1993 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Synergism; Etoposide; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Pentostatin; Prednisone; Rats; Rats, Inbred Lew; Salvage Therapy; Shock, Cardiogenic; Ventricular Fibrillation; Vidarabine; Vincristine | 1993 |
Listerial brain abscess in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Aged; Antineoplastic Agents; Brain Abscess; Cefotaxime; Drug Therapy, Combination; Gentamicins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Male; Prednisone; Tomography, X-Ray Computed; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 1993 |
Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
Topics: Animals; Antineoplastic Agents; Cell Division; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Sarcoma, Experimental; Vidarabine | 1994 |
Acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Fatal Outcome; Female; Humans; Leukemia, Prolymphocytic; Tumor Lysis Syndrome; Vidarabine | 1993 |
Response criteria with fludarabine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1994 |
A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Methylcellulose; Vidarabine | 1993 |
Fludarabine therapy in Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 1993 |
Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Vidarabine | 1993 |
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia.
Topics: Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Platelet Count; Remission Induction; Vidarabine | 1993 |
Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Brain Diseases; Combined Modality Therapy; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Vidarabine | 1993 |
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 1993 |
Complete remission after fludarabine for chronic lymphocytic leukemia.
Topics: Antigens, CD; Antineoplastic Agents; Blotting, Southern; Bone Marrow; DNA, Neoplasm; Drug Administration Schedule; HLA-DR Antigens; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Time Factors; Vidarabine | 1993 |
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1993 |
Treatment of low grade non-Hodgkin's lymphomas with fludarabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 1993 |
Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation.
Topics: Animals; Antineoplastic Agents; Cobalt Radioisotopes; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Hindlimb; Injections, Intraperitoneal; Paresis; Radiation Dosage; Radiation Injuries, Experimental; Radiation Tolerance; Radioisotope Teletherapy; Rats; Rats, Inbred F344; Spinal Cord; Time Factors; Vidarabine | 1995 |
Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Vidarabine | 1995 |
Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1995 |
Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Polymerase Chain Reaction; Transfusion Reaction; Vidarabine | 1995 |
Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factor 2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Fluorescence; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Tumor Cells, Cultured; Vidarabine | 1996 |
Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenström's macroglobulinemia.
Topics: Aged; Gastroenteritis; Humans; Immunization, Passive; Immunocompromised Host; Immunoglobulins, Intravenous; Male; Mamastrovirus; Opportunistic Infections; Peptic Ulcer; Vidarabine; Virus Diseases; Waldenstrom Macroglobulinemia | 1995 |
Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
Topics: Adult; Antineoplastic Agents; Cytotoxicity, Immunologic; Flow Cytometry; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocyte Subsets; Tumor Cells, Cultured; Vidarabine | 1996 |
Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1996 |
In vivo oxygen consumption rate of DS sarcoma cells on inhibition of DNA synthesis.
Topics: Animals; Antineoplastic Agents; Ascites; Cell Division; Depression, Chemical; DNA, Neoplasm; Lovastatin; Male; Oxygen Consumption; Rats; Rats, Sprague-Dawley; Sarcoma, Experimental; Vidarabine | 1996 |
Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biotransformation; Breast Neoplasms; Carcinoma, Small Cell; Cladribine; Colonic Neoplasms; Cytarabine; Deoxycytidine Kinase; DNA, Complementary; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genetic Vectors; Humans; Lung Neoplasms; Moloney murine leukemia virus; Phosphorylation; Recombinant Fusion Proteins; Tumor Cells, Cultured; Vidarabine | 1996 |
Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Survival; Cytarabine; Deoxycytidine; Drug Interactions; Gemcitabine; HL-60 Cells; Humans; Thymidine; Vidarabine | 1996 |
Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro.
Topics: Antigens, CD19; Apoptosis; B-Lymphocytes; Carrier Proteins; CD5 Antigens; Cladribine; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Neoplasm Proteins; Nucleoside Transport Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; S Phase; Tumor Cells, Cultured; Vidarabine | 1996 |
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
Topics: Antineoplastic Agents; Cell Cycle; Cytarabine; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Mitoxantrone; Protein Binding; Tumor Cells, Cultured; Vidarabine | 1996 |
Transfusion-associated graft-versus-host disease (TA-GVHD) in fludarabine-treated patients: is it time to irradiate blood component?
Topics: Antineoplastic Agents; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Transfusion Reaction; Vidarabine | 1996 |
Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine.
Topics: Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine | 1995 |
2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
Topics: Antineoplastic Agents; Cladribine; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1996 |
Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA.
Topics: Base Sequence; DNA; DNA Polymerase II; Exodeoxyribonuclease V; Exodeoxyribonucleases; Humans; Kinetics; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; Tumor Cells, Cultured; Vidarabine | 1996 |
Fludarabine treatment and transfusion-associated graft-versus-host disease.
Topics: Antineoplastic Agents; Fatal Outcome; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transfusion Reaction; Vidarabine | 1996 |
Fludarabine treatment and transfusion-associated graft-versus-host disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine | 1996 |
Type II mixed cryoglobulinemia treated with fludarabine.
Topics: Antineoplastic Agents; Cryoglobulinemia; Humans; Male; Middle Aged; Remission Induction; Sjogren's Syndrome; Vidarabine | 1996 |
T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; HLA Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Living Donors; Lymphocyte Depletion; Male; Middle Aged; Pancytopenia; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 1996 |
Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role?
Topics: Adult; Antigens, CD; Antineoplastic Agents; Cyclosporine; Flow Cytometry; Follow-Up Studies; Hemoglobins; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Vidarabine | 1995 |
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Central Nervous System Neoplasms; Chromosomes, Human, Pair 8; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Neoplasms; Trisomy; Vidarabine | 1995 |
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; DNA, Neoplasm; Endonucleases; Glucocorticoids; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Mitoxantrone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1996 |
Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Count; Cladribine; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Remission Induction; Retreatment; Survival Rate; Treatment Outcome; Vidarabine | 1996 |
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunoblastic Lymphadenopathy; Male; Middle Aged; Prednisone; Vidarabine; Vincristine | 1996 |
Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies.
Topics: Aged; Antineoplastic Agents; Cladribine; Eosinophilia; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Vidarabine | 1996 |
[Fludarabine and severe autoimmune hemolytic anemia: a new case].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Male; Vidarabine | 1996 |
Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Fatal Outcome; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1996 |
Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine.
Topics: Animals; Antineoplastic Agents; Indomethacin; Male; Mice; Mice, Inbred C3H; Prostaglandin Antagonists; Sarcoma, Experimental; Vidarabine | 1996 |
Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Antimetabolites, Antineoplastic; Drug Carriers; Drug Delivery Systems; Erythrocytes; Humans; Kinetics; Phosphorylation; Vidarabine; Vidarabine Phosphate | 1996 |
Fludarabine in the treatment of essential mixed cryoglobulinaemia.
Topics: Antineoplastic Agents; Cryoglobulinemia; Humans; Vidarabine | 1996 |
Crescentic glomerulonephritis associated with p-ANCA positivity in fludarabine-treated chronic lymphocytic leukaemia.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Antineoplastic Agents; Female; Glomerulonephritis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1996 |
Cold agglutinin hemolysis responding to fludarabine therapy.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antimetabolites; Cyclophosphamide; Drug Resistance; Humans; Male; Vidarabine | 1996 |
Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results.
Topics: Animals; Bone Marrow Transplantation; Cells, Cultured; Cyclophosphamide; Immunosuppressive Agents; Mice; Mice, Inbred C3H; Spleen; T-Lymphocytes; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 1996 |
Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines.
Topics: Antineoplastic Agents; Cisplatin; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Melanoma; Ovarian Neoplasms; Tumor Cells, Cultured; Vidarabine | 1996 |
Seeking the nucleoside transporter.
Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Membrane; Cladribine; Cloning, Molecular; Cytarabine; Deoxycytidine; Erythrocytes; Gemcitabine; Glucose Transporter Type 1; Humans; Leukemia; Lymphoma; Membrane Proteins; Monosaccharide Transport Proteins; Nucleosides; Oocytes; Recombinant Proteins; Uridine; Vidarabine; Xenopus | 1997 |
Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs.
Topics: Adenosine; Amino Acid Sequence; Animals; Antineoplastic Agents; Carrier Proteins; Cladribine; Cloning, Molecular; Cytarabine; Databases, Factual; DNA, Complementary; Equilibrative Nucleoside Transporter 1; Humans; Membrane Proteins; Molecular Sequence Data; Nucleosides; Oocytes; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Tissue Distribution; Uridine; Vidarabine; Xenopus | 1997 |
Purine analogues for treatment of refractory essential mixed cryoglobulinemia.
Topics: 2-Chloroadenosine; Cryoglobulinemia; Deoxyadenosines; Humans; Purines; Vidarabine | 1997 |
Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.
Topics: Apoptosis; B-Lymphocytes; Cell Line, Transformed; Dactinomycin; DNA Fragmentation; Fibroblast Growth Factor 2; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Vidarabine | 1997 |
Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Melphalan; Middle Aged; Tumor Cells, Cultured; Vidarabine | 1997 |
Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
Topics: Administration, Cutaneous; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Recurrence; Vidarabine | 1997 |
Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1997 |
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Antineoplastic Agents; Cisplatin; Cytidine Monophosphate; DNA Adducts; DNA Repair; High Mobility Group Proteins; Humans; Plasmids; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured; Vidarabine | 1997 |
Chronic lymphocytic leukemia in the elderly population.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prednisone; United States; Vidarabine | 1997 |
Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine.
Topics: Affinity Labels; Animals; Anti-HIV Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Cells, Cultured; Drug Interactions; Ducks; Hepadnaviridae Infections; Hepatitis B Virus, Duck; Humans; Thioinosine; Thymidine; Tumor Cells, Cultured; Vidarabine; Zalcitabine | 1997 |
Fludarabine-induced tumour lysis in low-grade non-Hodgkin's lymphoma.
Topics: Acute Disease; Aged; Humans; Lymphoma, Non-Hodgkin; Male; Renal Dialysis; Tumor Lysis Syndrome; Vidarabine | 1997 |
Steroid-responsive interstitial pneumonitis after fludarabine therapy.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Cough; Fatal Outcome; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Interstitial; Male; Neoplasm Recurrence, Local; Prednisolone; Prednisone; Respiratory Distress Syndrome; Respiratory Insufficiency; Vidarabine | 1997 |
[A nidulans bronchial aspergillosis after treatment of low-grade lymphoma with fludarabine].
Topics: Antineoplastic Agents; Aspergillosis; Bronchial Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Vidarabine | 1997 |
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.
Topics: Adult; Antineoplastic Agents; Blood Transfusion, Autologous; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 1997 |
Listeriosis after fludarabine treatment for chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Prednisone; Sulfamethoxazole; Trimethoprim; Vidarabine; Vincristine | 1997 |
Topical treatment of psoriasis with fludarabine.
Topics: Administration, Topical; Antineoplastic Agents; Dermatologic Agents; Humans; Male; Psoriasis; Vidarabine | 1997 |
Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience.
Topics: Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Cause of Death; Drug Evaluation; Fever; Graft vs Host Disease; Hematologic Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Remission Induction; Retrospective Studies; Salvage Therapy; Spain; Survival Analysis; Transfusion Reaction; Treatment Outcome; Vidarabine | 1996 |
Chemotherapeutic purine analogs alter the level of interferon-beta mRNA induced by poly I-poly C in cultured osteosarcoma cells.
Topics: Antineoplastic Agents; Cladribine; Dose-Response Relationship, Drug; eIF-2 Kinase; Gene Expression; Humans; Interferon-beta; Neoplastic Stem Cells; Pentostatin; Poly I-C; Protein Serine-Threonine Kinases; RNA, Messenger; Vidarabine | 1997 |
In vivo 'purging' of residual disease in CLL with Campath-1H.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Pentostatin; Vidarabine | 1997 |
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Topics: Antineoplastic Agents; Binding Sites; Cytarabine; Deoxycytidine; DNA Repair; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Leukemia; Tumor Cells, Cultured; Vidarabine | 1997 |
Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation.
Topics: Animals; Bone Marrow Transplantation; Graft vs Host Disease; Immunosuppressive Agents; Mice; Transplantation, Homologous; Vidarabine | 1997 |
Flare-up of squamous cell carcinoma of the skin following fludarabine therapy for chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; CD4 Lymphocyte Count; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Skin Neoplasms; Vidarabine | 1997 |
Deoxycytidine in human plasma: potential for protecting leukemic cells during chemotherapy.
Topics: Adult; Cladribine; Cytarabine; Deoxycytidine; Deoxycytosine Nucleotides; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 8; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia; Trisomy; Vidarabine | 1997 |
[Nocardia nova pulmonary infection under treatment with fludarabine].
Topics: Aged; Antineoplastic Agents; Humans; Lung Diseases; Male; Nocardia Infections; Vidarabine | 1997 |
Third space sequestration increases toxicity of fludarabine--a case report.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drainage; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pleural Effusion; Sepsis; Vidarabine | 1997 |
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Doxorubicin; Fas Ligand Protein; fas Receptor; Humans; Leukemia-Lymphoma, Adult T-Cell; Ligands; Membrane Glycoproteins; Signal Transduction; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 1997 |
Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis.
Topics: Antineoplastic Agents; Aphidicolin; Apoptosis; Cell Fusion; Cell Line; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Electrophoresis, Gel, Pulsed-Field; Gemcitabine; Humans; In Vitro Techniques; Molecular Weight; Nucleosomes; Vidarabine | 1997 |
Bayesian interim analysis of phase II cancer clinical trials.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Models, Statistical; Research Design; Vidarabine | 1997 |
Role of splenectomy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Case-Control Studies; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Neoplasm Staging; Retrospective Studies; Splenectomy; Survival Analysis; Treatment Outcome; Vidarabine | 1997 |
Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia.
Topics: Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1997 |
Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Drug Interactions; Drug Screening Assays, Antitumor; Female; Guanosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Cells, Cultured; Vidarabine | 1997 |
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Southern; Cell Count; Cisplatin; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Interactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine; Xeroderma Pigmentosum | 1997 |
Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations.
Topics: Aged; Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD5 Antigens; Down-Regulation; Female; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymerase Chain Reaction; Tumor Cells, Cultured; Vidarabine | 1997 |
Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma; Male; Splenic Neoplasms; Vidarabine | 1997 |
Quantification of CMV viraemia in a case of transfusion-related graft-versus-host disease associated with purine analogue treatment.
Topics: Acute Disease; Adult; Antineoplastic Agents; Cytomegalovirus Infections; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Leukemia, Myeloid; Lymphopenia; T-Lymphocytes; Transfusion Reaction; Vidarabine; Viremia | 1997 |
[Successful treatment for advanced and refractory chronic lymphocytic leukemia with fludarabine phosphate].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 1997 |
[Selective aplasia of the red-cell series after fludarabine administration in a patient with chronic B-cell lymphatic leukemia].
Topics: Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Chlorambucil; Cyclophosphamide; Cyclosporine; Doxorubicin; Humans; Hydrocortisone; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methotrexate; Methylprednisolone; Middle Aged; Prednisone; Red-Cell Aplasia, Pure; Vidarabine; Vincristine | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Viral; Antineoplastic Agents; CD4 Lymphocyte Count; Cell Transformation, Neoplastic; DNA Primers; Female; Herpesvirus 4, Human; Humans; In Situ Hybridization; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Vidarabine; Viral Matrix Proteins | 1997 |
P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; bcl-2-Associated X Protein; Chlorambucil; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nuclear Proteins; Polymorphism, Single-Stranded Conformational; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 1997 |
Evans syndrome complicating fludarabine treatment for advanced B-CLL.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Syndrome; Thrombocytopenia; Vidarabine | 1997 |
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Vidarabine | 1997 |
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count; Survival Rate; Treatment Outcome; Vidarabine | 1997 |
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
Topics: Adult; Apoptosis; Blood Platelets; CD40 Ligand; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fas Ligand Protein; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Membrane Glycoproteins; Up-Regulation; Vidarabine | 1998 |
A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia.
Topics: Antineoplastic Agents; Child; Cyclophosphamide; Fanconi Anemia; Female; Humans; Leukemia, Myeloid; Male; Preleukemia; Remission Induction; Risk Factors; Transplantation Conditioning; Vidarabine | 1997 |
Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Autoantibodies; Coombs Test; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Temperature; Vidarabine | 1998 |
Association of myelodysplastic changes with purine analogues.
Topics: 2-Chloroadenosine; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxyadenosines; Female; Humans; Lymphoproliferative Disorders; Male; Myelodysplastic Syndromes; Pentostatin; Vidarabine | 1998 |
Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytomegalovirus Infections; Doxorubicin; Drug Synergism; Female; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Pneumonia, Viral; Prednisolone; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Vidarabine; Vincristine; Viral Load | 1998 |
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Risk Factors; Time Factors; Vidarabine | 1998 |
Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1998 |
Effect of Cladribine, fludarabine, and 5-aza-deoxycytidine on S-adenosylmethionine (SAM) and nucleotides pools in stimulated human lymphocytes.
Topics: Adenine Nucleotides; Adenine Phosphoribosyltransferase; Antineoplastic Agents; Azacitidine; Cells, Cultured; Cladribine; Cytidine Triphosphate; Decitabine; Guanine Nucleotides; Humans; Kinetics; Lymphocyte Activation; Lymphocytes; NAD; Ribonucleotides; S-Adenosylmethionine; Uracil Nucleotides; Vidarabine | 1998 |
Does 2-chlorodeoxyadenosine contribute to alteration of DNA methyltransferase activity?
Topics: Adenosylhomocysteinase; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cladribine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Hydrolases; Kinetics; Leukemia L1210; Mice; Tumor Cells, Cultured; Vidarabine | 1998 |
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine.
Topics: 2-Chloroadenosine; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Deoxyadenosines; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1998 |
Tuberculosis-associated fatal hemophagocytic syndrome in a patient with lymphoma treated with fludarabine.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Tuberculosis; Vidarabine | 1998 |
Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom's macroglobulinemia treated with fludarabine.
Topics: Antineoplastic Agents; Brain Diseases; Female; Humans; Immunosuppressive Agents; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Tuberculoma; Vidarabine; Waldenstrom Macroglobulinemia | 1998 |
Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Drug Resistance; Humans; Immunoglobulin M; Immunosuppressive Agents; Middle Aged; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 1998 |
Simple, fast method of detection apoptosis in lymphoid cells.
Topics: Apoptosis; Blood Cell Count; Cells, Cultured; Chlorambucil; Flow Cytometry; Humans; Immunohistochemistry; Interleukin-4; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Reference Values; Scattering, Radiation; Theophylline; Vidarabine | 1998 |
Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresi
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA Repair; DNA, Neoplasm; Electrophoresis, Gel, Pulsed-Field; Fibrosarcoma; Gemcitabine; Mice; Mice, Inbred C3H; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vidarabine | 1998 |
Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tumor Lysis Syndrome; Vidarabine | 1998 |
Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.
Topics: Administration, Inhalation; Adult; Antineoplastic Agents; Antiviral Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Ribavirin; Vidarabine | 1998 |
New prospects in the treatment of indolent lymphomas with purine analogues.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1998 |
Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.
Topics: Antibodies, Monoclonal; Apoptosis; CD40 Antigens; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Oligonucleotides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-rel; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 1998 |
Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy.
Topics: Aged; Allantoin; Antimetabolites, Antineoplastic; Diuresis; Drug Evaluation; Female; Humans; Kidney Calculi; Kidney Diseases; Kidney Tubules; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oliguria; Treatment Outcome; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Vidarabine | 1998 |
Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Bone Marrow Cells; Cell Count; Cell Differentiation; Cell Division; Clone Cells; Colony-Forming Units Assay; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Vidarabine | 1998 |
In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Lethal Dose 50; Lymphoma, B-Cell; Male; Middle Aged; Vidarabine | 1998 |
Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four cases.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Vidarabine; Vincristine | 1998 |
In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues--correlation with clinical course.
Topics: Antineoplastic Agents; Apoptosis; Cladribine; DNA Nucleotidylexotransferase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Phenotype; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1998 |
Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.
Topics: Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Hemolysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Survival Rate; Time Factors; Vidarabine | 1998 |
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Enhancement, Immunologic; Graft vs Host Disease; Graft vs Host Reaction; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine | 1998 |
When prognosis is poor, does false hope add to leukemia patients' pain?
Topics: Adaptation, Psychological; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 1998 |
Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-arabinofuranosyl-2-fluoroadenine.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Leukemia, Hairy Cell; Mice; Tumor Cells, Cultured; Vidarabine | 1998 |
Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines.
Topics: Adenosine Deaminase Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Division; Cladribine; Deoxyribonucleotides; Enzyme Inhibitors; Humans; Kinetics; Leukemia, T-Cell; Lymphoma, B-Cell; Pentostatin; Ribonucleotides; Tumor Cells, Cultured; Vidarabine | 1998 |
In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Vidarabine | 1998 |
Chronic lymphocytic leukemia in a patient with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Chronic Disease; Fatal Outcome; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1998 |
Fludarabine and hemolytic anemia in chronic lymphocytic leukemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1998 |
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease.
Topics: Adult; Aged; Antineoplastic Agents; Chronic Disease; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasm, Residual; Treatment Outcome; Vidarabine | 1998 |
Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Neoplasm Staging; Opportunistic Infections; Prednisone; Retrospective Studies; Risk Factors; Vidarabine | 1998 |
Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine | 1998 |
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Cycle Proteins; Chromosomes, Human, Pair 17; Cyclin-Dependent Kinase Inhibitor p27; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Precursors; Flavonoids; Gene Deletion; Genes, p53; Growth Inhibitors; Humans; In Situ Hybridization, Fluorescence; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Microtubule-Associated Proteins; Neoplasm Proteins; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 1998 |
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Time Factors; Vidarabine | 1997 |
High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Apoptosis; Chelating Agents; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Egtazic Acid; Enzyme Inhibitors; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Tumor Cells, Cultured; Vidarabine | 1995 |
Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; DNA Fragmentation; DNA Repair; Flow Cytometry; Humans; Lymphocytes; Ultraviolet Rays; Vidarabine | 1996 |
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; K562 Cells; Vidarabine | 1996 |
Fludarabine-related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders.
Topics: Aged; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Humans; Immunosuppressive Agents; Incidence; Infection Control; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Prednisone; Retrospective Studies; Vidarabine | 1998 |
Quantification of apoptosis by the Abbott CD4000 hematology analyzer.
Topics: Apoptosis; Autoanalysis; Cells, Cultured; Female; Flow Cytometry; Hematology; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Theophylline; Vidarabine | 1998 |
Phenotypic changes of leukemic cells in a patient with prolympho-plasmacytic leukaemia after treatment with fludarabine.
Topics: Aged; Antigens, CD; Antineoplastic Agents; Humans; Immunophenotyping; Immunosuppressive Agents; Leukemia, Plasma Cell; Leukemia, Prolymphocytic; Lymphocytes; Male; Phenotype; Vidarabine | 1997 |
Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pancytopenia; Prednisone; Primary Myelofibrosis; Vidarabine; Vincristine | 1998 |
In vitro modulation of bcl-2 protein expression, drug-induced apoptosis and cytotoxicity by interleukin-10 in chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Drug Interactions; Drug Screening Assays, Antitumor; Gene Expression Regulation, Leukemic; Humans; Interleukin-10; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 1998 |
Leukemic pleural effusion in B-cell prolymphocytic leukemia.
Topics: Aged; Antibodies; Antigens, CD20; Antineoplastic Agents; Humans; Immunohistochemistry; Leukemia, B-Cell; Leukemia, Prolymphocytic; Male; Pleural Effusion, Malignant; Remission Induction; Tomography Scanners, X-Ray Computed; Vidarabine | 1998 |
Re: V.I. Avramis et al., Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. Clin. Can
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Leukemia; Terminology as Topic; Vidarabine; Vidarabine Phosphate | 1999 |
Refractory pure red cell aplasia associated with B-CLL: successful treatment with a combination of fludarabine, cyclosporin A and erythropoietin.
Topics: Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Cyclosporine; Erythropoietin; Hemoglobins; Humans; Immunoglobulins, Intravenous; Immunophenotyping; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Red-Cell Aplasia, Pure; Vidarabine | 1999 |
Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cells, Cultured; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1999 |
Chronic lymphocytic leukemia-associated membranous glomerulopathy: remission with fludarabine.
Topics: Antineoplastic Agents; Biopsy; Female; Glomerulonephritis, Membranous; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1999 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine | 1999 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Irreversible renal failure in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Acute Kidney Injury; Antimetabolites, Antineoplastic; Autoantibodies; Erythrocytes; Fatal Outcome; Glomerulonephritis; Humans; Immune Complex Diseases; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Renal Dialysis; Salvage Therapy; Vidarabine | 1999 |
Two cases of toxoplasmic encephalitis in patients with acute T-cell leukaemia and lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; HIV Seronegativity; Humans; Immunocompromised Host; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell; Male; Meningoencephalitis; Methotrexate; Middle Aged; Toxoplasmosis; Vidarabine | 1999 |
Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Analysis; Vidarabine | 1999 |
Chronic lymphocytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome; Vidarabine | 1999 |
Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Guanosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Cells, Cultured; Vidarabine | 1999 |
Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Vidarabine | 1999 |
Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Stem Cells; Vidarabine | 1999 |
Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bryostatins; Cell Division; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured; Vidarabine | 1999 |
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling.
Topics: Alternative Splicing; Antineoplastic Agents; Cyclosporine; Cytokines; DNA-Binding Proteins; Gene Expression Regulation; Humans; Immune Tolerance; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Signal Transduction; STAT1 Transcription Factor; Trans-Activators; Vidarabine | 1999 |
Association between chronic lymphocytic leukemia and sarcoidosis: clinical value of bronchoalveolar lavage.
Topics: Antineoplastic Agents; Bronchoalveolar Lavage Fluid; CD4 Lymphocyte Count; Comorbidity; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Middle Aged; Sarcoidosis; Vidarabine | 1999 |
Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunoglobulin M; Immunosuppressive Agents; Male; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Vidarabine | 1999 |
Fever after cytotoxic therapy of chronic lymphocytic leukemia.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Aztreonam; Candidiasis; Female; Fever; Glycopeptides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Metronidazole; Middle Aged; Monobactams; Vidarabine | 1999 |
Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism.
Topics: Amidohydrolases; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Death; Ceramidases; Enzyme Inhibitors; Gamma Rays; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Myristates; Propanolamines; Protein Biosynthesis; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sphingosine; Vidarabine | 1999 |
Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: successful engraftment with minimal toxicity.
Topics: Adolescent; Child; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 1999 |
Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study.
Topics: Aged; Female; Herpesviridae Infections; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Prospective Studies; Vidarabine | 1999 |
Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Vidarabine | 1999 |
Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Vidarabine | 1999 |
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
Topics: Acute Disease; Antineoplastic Agents; Cladribine; Cytarabine; Fluorescence; Fluorometry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Survival Analysis; Vidarabine | 1999 |
Evan's syndrome precipitated by fludarabine therapy in a case of CLL.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Immune Tolerance; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Thrombocytopenia; Vidarabine | 1999 |
Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1.
Topics: Antineoplastic Agents; Apoptosis; Bryostatins; Cell Differentiation; Cell Division; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Lactones; Leukemia, Myelomonocytic, Acute; Macrolides; U937 Cells; Vidarabine | 1999 |
Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 1999 |
Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
Topics: Ambulatory Care; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cyclophosphamide; Doxorubicin; Humans; Length of Stay; Lymphoma, B-Cell; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Rituximab; Vidarabine; Vincristine | 1999 |
Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay.
Topics: Aged; Antineoplastic Agents; Cause of Death; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Survival Rate; Therapeutics; Vidarabine | 1999 |
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.
Topics: Antineoplastic Agents; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; K562 Cells; Leukemia, Erythroblastic, Acute; Phenotype; Vidarabine | 1999 |
Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia.
Topics: Aged; Antibodies; Chronic Disease; Cyclophosphamide; Factor VIII; Female; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Vidarabine | 1999 |
Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: complete remission of lymphoma with control of autoimmune complications.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Combined Modality Therapy; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transplantation, Autologous; Vidarabine | 1999 |
Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells.
Topics: Antigens, CD34; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins c-bcl-2; Tretinoin; Tumor Cells, Cultured; Vidarabine | 1999 |
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine | 1999 |
[Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Treatment Outcome; Vidarabine | 1999 |
Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Vidarabine | 1999 |
In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Leukemic; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1999 |
A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
Topics: Adult; Alkylating Agents; Anti-Inflammatory Agents; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Glomerular Filtration Rate; Glomerulonephritis, Membranous; Humans; Immunoglobulin G; Immunologic Memory; Immunosuppressive Agents; Lupus Nephritis; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Pilot Projects; Prednisone; Proteinuria; Renal Plasma Flow, Effective; Sinusitis; Vidarabine | 1999 |
Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Middle Aged; Remission Induction; Vidarabine | 1999 |
Resolution of psoriatic skin lesions with fludarabine.
Topics: Antineoplastic Agents; CD4-Positive T-Lymphocytes; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Vidarabine | 1999 |
Inhibition of FAS/FAS-ligand does not block chemotherapy-induced apoptosis in drug sensitive and resistant cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Cycle; Clone Cells; Drug Resistance, Multiple; Etoposide; Fas Ligand Protein; fas Receptor; HL-60 Cells; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Tumor Cells, Cultured; Vidarabine; Vinblastine | 1999 |
Effects of PARP inhibition on drug and Fas-induced apoptosis in leukaemic cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Drug Resistance, Multiple; Enzyme Inhibitors; Etoposide; fas Receptor; Genes, MDR; HL-60 Cells; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Microtubules; Phenanthrenes; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Cells, Cultured; Vidarabine; Vinblastine | 1999 |
In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; bcl-X Protein; CD3 Complex; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine | 1999 |
The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Survival; Cladribine; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine | 1999 |
Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Vidarabine | 1999 |
Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP).
Topics: Antineoplastic Agents; Demyelinating Diseases; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Neurotoxicity Syndromes; Vidarabine | 1999 |
Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.
Topics: Animals; Cell Death; Cladribine; Coformycin; Dexamethasone; Drug Resistance; Etoposide; Genes, p53; Lymphocytes; Mice; Mice, Knockout; Spleen; Vidarabine | 1999 |
Treatment of red cell aplasia in CLL with fludarabine.
Topics: Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Red-Cell Aplasia, Pure; Vidarabine | 1999 |
Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cyclophosphamide; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 1999 |
Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
Topics: Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Pentostatin; Vidarabine | 1999 |
Use of novel plasmid constructs to demonstrate fludarabine triphosphate inhibition of nucleotide excision repair of a site-specific 1,2-d(GpG) intrastrand cisplatin adduct.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Base Sequence; Binding Sites; Cisplatin; DNA; DNA Adducts; DNA Repair; DNA, Recombinant; Dose-Response Relationship, Drug; Humans; Molecular Sequence Data; Oligonucleotides; Plasmids; Substrate Specificity; Tumor Cells, Cultured; Vidarabine | 1999 |
Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Vidarabine | 1999 |
Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chlorambucil; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1999 |
Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus.
Topics: Adult; CD8-Positive T-Lymphocytes; Drug Eruptions; Epidermis; Female; Histocompatibility Antigens Class II; Humans; Immunohistochemistry; Immunophenotyping; Immunosuppressive Agents; In Situ Nick-End Labeling; Intercellular Adhesion Molecule-1; Lymphoma, Non-Hodgkin; Pemphigus; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 1999 |
Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 1999 |
Refractory pure red-cell aplasia associated with B chronic lymphocytic leukemia successfully treated by fludarabine.
Topics: Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Red-Cell Aplasia, Pure; Vidarabine | 1999 |
Successful treatment of lupus with fludarabine.
Topics: Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Male; Middle Aged; Vidarabine | 1999 |
Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
Topics: Antineoplastic Agents; Biological Transport; Biotransformation; Cell Survival; Cladribine; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Phosphorylation; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Vidarabine | 1999 |
The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Viral; Cyclophosphamide; Dexamethasone; Epstein-Barr Virus Infections; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Opportunistic Infections; Vidarabine; Virus Activation | 1999 |
Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.
Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Autoradiography; Brain; Cladribine; Clofarabine; Cytarabine; Lipid Metabolism; Mice; Mice, Inbred C57BL; Thymus Gland; Tissue Distribution; Tritium; Vidarabine | 1999 |
[Chronic lymphatic leukemia and Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasms, Second Primary; Prednisone; Remission Induction; Vidarabine; Vinblastine | 1999 |
Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.
Topics: Acute Disease; Adenosine Deaminase Inhibitors; Antimetabolites, Antineoplastic; Calcitriol; Cell Differentiation; Cladribine; Deoxyadenosines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Monocytes; Neoplasm Proteins; Neoplastic Stem Cells; Pentostatin; Tretinoin; Tumor Cells, Cultured; U937 Cells; Vidarabine | 2000 |
Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclophosphamide; Dexamethasone; DNA Repair; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine | 2000 |
Second treatment with fludarabine in a Waldenström's macroglobulinemia patient.
Topics: Adult; CD4-CD8 Ratio; Humans; Immunosuppressive Agents; Male; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
Splenic lymphoma with villous lymphocytes: dissociated response with fludarabin.
Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Humans; Lymphoma; Splenectomy; Splenic Neoplasms; Treatment Outcome; Vidarabine | 1999 |
Fludarabine containing regimen followed by autologous peripheral blood stem cell transplantation in unselected patients with acute myeloid leukemia: a single center experience.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2000 |
Oochroconis gallopava endophthalmitis in fludarabine treated chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Endophthalmitis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mitosporic Fungi; Opportunistic Infections; Vidarabine | 2000 |
Determination of fludarabine in a pharmaceutical formulation by LC.
Topics: Antineoplastic Agents; Buffers; Calibration; Chromatography, High Pressure Liquid; Methanol; Pharmaceutical Preparations; Phosphates; Reproducibility of Results; Sensitivity and Specificity; Vidarabine | 1999 |
Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Combined Modality Therapy; Escherichia coli; Ganciclovir; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Liver Neoplasms, Experimental; Luminescent Proteins; Mice; Mice, Nude; Orotate Phosphoribosyltransferase; RNA, Messenger; Thymidine Kinase; Tumor Cells, Cultured; Vidarabine | 2000 |
Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
Topics: Aged; Antineoplastic Agents; Biological Transport, Active; Bryostatins; Carrier Proteins; Cladribine; Deoxycytidine Kinase; Dipyridamole; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Male; Membrane Proteins; Nucleoside Transport Proteins; Phosphorylation; Thioinosine; Tumor Cells, Cultured; Vidarabine | 2000 |
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Methotrexate; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate; Vincristine | 2000 |
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Factor Analysis, Statistical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Regression Analysis; Survival Analysis; Vidarabine | 2000 |
Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Vidarabine | 2000 |
New treatment protocol including lympholytic and antiretroviral drugs to inhibit murine AIDS.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Flow Cytometry; Mice; Murine Acquired Immunodeficiency Syndrome; Vidarabine; Viral Load; Zidovudine | 2000 |
Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; DNA Damage; Female; Follicle Stimulating Hormone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Luteinizing Hormone; Male; Middle Aged; Oligospermia; Spermatozoa; Testicular Diseases; Testis; Testosterone; Time Factors; Vidarabine | 2000 |
Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Membrane; DNA Fragmentation; Flow Cytometry; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Phosphatidylserines; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Vidarabine | 2000 |
Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias
Topics: Antineoplastic Agents; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
[The heart in air].
Topics: Aged; Antineoplastic Agents; Cardiac Tamponade; Fatal Outcome; Humans; Lymphoma; Male; Pericardiocentesis; Pneumopericardium; Rupture, Spontaneous; Stomach Ulcer; Tomography, X-Ray Computed; Vidarabine | 2000 |
Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunologic Factors; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Vidarabine | 2000 |
Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Cladribine; Comorbidity; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pentostatin; Prednisolone; Prognosis; Staining and Labeling; Tumor Cells, Cultured; Vidarabine; Vincristine | 2000 |
A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Cells; Bone Marrow Cells; DNA Primers; DNA, Neoplasm; Gene Duplication; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Hodgkin Disease; Humans; Immunization, Passive; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Oligonucleotide Probes; Polymerase Chain Reaction; Reference Standards; Rituximab; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 2000 |
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
Topics: Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Prednisolone; Probability; Prognosis; Retrospective Studies; Risk Factors; Splenectomy; Survival Analysis; Time Factors; Vidarabine | 2000 |
Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines.
Topics: Antineoplastic Agents, Alkylating; DNA Repair; Drug Interactions; Guanine; Humans; Lung Neoplasms; Platinum Compounds; Tumor Cells, Cultured; Vidarabine | 2000 |
Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage.
Topics: Antineoplastic Agents; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deoxycytidine; DNA Damage; Gemcitabine; Thymidine; Tumor Suppressor Protein p53; Vidarabine | 2000 |
An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Lineage; Cyclophosphamide; Disease Models, Animal; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cells; Histocompatibility; Immunosuppressive Agents; Lymphocyte Depletion; Mice; Mice, Inbred C57BL; Transplantation Chimera; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2000 |
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Life Tables; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2000 |
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Administration Schedule; Enzyme Inhibitors; Gemcitabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Ribonucleotide Reductases; Vidarabine | 2000 |
Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Female; Hepatitis B virus; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Vidarabine; Virus Activation; Virus Replication | 2000 |
Cryptococcal infection associated with fludarabine therapy.
Topics: Antineoplastic Agents; CD4-CD8 Ratio; Cryptococcosis; Fatal Outcome; Fungemia; Humans; Immunocompromised Host; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 2000 |
Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Vidarabine | 1999 |
Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Vidarabine | 1999 |
Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Pentostatin; Sezary Syndrome; Survival Rate; Vidarabine | 2000 |
[Efficacy of fludarabine in the treatment of angioimmunoblastic lymphoma (AIL)].
Topics: Humans; Immunoblastic Lymphadenopathy; Immunosuppressive Agents; Male; Middle Aged; Remission Induction; Vidarabine | 2000 |
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Infant, Newborn; Leukemia; Leukemia, Myeloid, Acute; Lung Diseases; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory Distress Syndrome, Newborn; Staphylococcal Infections; Vidarabine | 2000 |
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
Topics: Adult; Antineoplastic Agents; Arthritis, Psoriatic; Autoimmunity; Busulfan; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male; Psoriasis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 2000 |
Fludarabine induced intestinal pseudo-obstruction: case report and literature review.
Topics: Aged; Antineoplastic Agents; Humans; Intestinal Pseudo-Obstruction; Lymphoma, Non-Hodgkin; Male; Radiography; Vidarabine | 2000 |
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Neoplasms; Nuclear Family; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2000 |
A brief history of the brief history of low-dose transplants.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; History, 20th Century; Humans; Immunosuppressive Agents; Neoplasms; United States; Vidarabine | 2000 |
Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Membrane; Cell Size; Cells, Cultured; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2000 |
Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine.
Topics: Antineoplastic Agents; Autoantibodies; Autoimmunity; Contusions; Hemophilia A; Hemorrhage; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 2000 |
Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Male; Purpura, Thrombocytopenic, Idiopathic; Vidarabine | 2000 |
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Topics: Antineoplastic Agents; DNA Fragmentation; DNA Repair; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; RNA, Neoplasm; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 2000 |
Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium; Calcium Channel Blockers; Calcium Signaling; Chlorambucil; Cisplatin; Cladribine; Cyclosporine; DNA Fragmentation; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nifedipine; Prednisolone; Tumor Cells, Cultured; Verapamil; Vidarabine; Vincristine | 2000 |
Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Membrane; Cell Size; Cladribine; DNA Fragmentation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tumor Suppressor Protein p53; Vidarabine | 2000 |
What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Treatment Failure; Vidarabine | 2000 |
Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Mitoxantrone; Panniculitis; Skin Neoplasms; Vidarabine | 2000 |
Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Biopsy; Brain; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Stereotaxic Techniques; Vidarabine | 2000 |
CD8 expression on B cells in chronic lymphocytic leukemia: a case report and review of the literature.
Topics: Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Bone Marrow Cells; CD5 Antigens; CD8 Antigens; Fatal Outcome; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, IgE; Vidarabine | 2000 |
Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Treatment Outcome; Vidarabine | 2000 |
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation.
Topics: Antineoplastic Agents; B-Lymphocytes; Clone Cells; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Transplantation, Autologous; Vidarabine | 2000 |
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Fatal Outcome; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Middle Aged; Nuclear Family; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2000 |
Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antiviral Agents; Carrier Proteins; Cytidine; Deoxycytidine; Electric Conductivity; Gemcitabine; Gene Expression; Humans; Membrane Potentials; Membrane Proteins; Nucleoside Transport Proteins; Nucleosides; Oocytes; Sodium; Substrate Specificity; Uridine; Vidarabine; Xenopus laevis | 2000 |
[Fludarabine treatment of chronic lymphoid leukemia].
Topics: Adult; Antineoplastic Agents; Bone Marrow; Disease Progression; Female; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Retrospective Studies; Vidarabine | 2000 |
Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Acute; Neoplasms, Second Primary; Translocation, Genetic; Vidarabine | 2000 |
Concomitant presentation of Hashimoto's thyroiditis and maltoma of the thyroid in a twenty-year-old man with a rapidly growing mass in the neck.
Topics: Adult; Antineoplastic Agents; Autoantibodies; Humans; Iodide Peroxidase; Lymphoma, B-Cell, Marginal Zone; Male; Thyroglobulin; Thyroid Neoplasms; Thyroidectomy; Thyroiditis, Autoimmune; Thyrotropin; Thyroxine; Triiodothyronine; Vidarabine | 2000 |
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells.
Topics: Arabinonucleotides; Calibration; Chromatography, High Pressure Liquid; Guanosine Triphosphate; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tumor Cells, Cultured; Vidarabine | 2000 |
Sight-threatening varicella zoster virus infection after fludarabine treatment.
Topics: Acyclovir; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Eye Infections, Viral; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Lymphoma, Follicular; Male; Middle Aged; Polymerase Chain Reaction; Retinal Necrosis Syndrome, Acute; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine | 2000 |
Fludarabine therapy in chronic lymphocytic leukemia-associated severe nephrotic syndrome.
Topics: Antineoplastic Agents; Diagnosis, Differential; Female; Glomerulonephritis, Membranous; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nephrotic Syndrome; Proteinuria; Remission Induction; Treatment Outcome; Vidarabine | 2000 |
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Arabinonucleosides; B-Lymphocytes; Cell Survival; Cladribine; Clofarabine; Comet Assay; Deoxyadenosines; DNA Damage; DNA, Mitochondrial; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Potentials; Microinjections; Mitochondria; Time Factors; Tumor Cells, Cultured; Vidarabine | 2000 |
Fludarabine therapy in Waldenström's macroglobulinemia.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Therapeutic Equivalency; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Caspases; DNA; DNA Damage; Enzyme Activation; Humans; Leukemia, Myeloid; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; S Phase; Tumor Cells, Cultured; U937 Cells; Vidarabine; Vidarabine Phosphate | 2000 |
[Cryptococcus neoformans infection in hematologic malignancies].
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Cryptococcosis; Cryptococcus neoformans; Female; France; Hematologic Neoplasms; Humans; Immunity, Cellular; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Vidarabine | 2000 |
Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2000 |
When and how to treat chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Vidarabine | 2000 |
Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Caspase 3; Caspase Inhibitors; Caspases; Ceramides; Chromatography, Thin Layer; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fumonisins; Glutathione; Humans; Image Processing, Computer-Assisted; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphatidylserines; Sphingomyelins; Tumor Cells, Cultured; Vidarabine | 2000 |
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic l
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Clone Cells; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vidarabine | 2000 |
The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.
Topics: Anti-HIV Agents; Cell Survival; Cytidine Triphosphate; Deoxycytosine Nucleotides; Dideoxynucleotides; Drug Interactions; Humans; Hydroxyurea; Lamivudine; Methotrexate; Phosphorylation; Tumor Cells, Cultured; Vidarabine | 2000 |
Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Chromosome Aberrations; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2001 |
[Progressive multifocal leukoencephalopathy in a patient with chronic lymphatic leukemia treated with fludarabine].
Topics: Aged; Antineoplastic Agents; Biopsy; Brain; Diagnosis, Differential; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Vidarabine | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Topotecan; Vidarabine | 2001 |
Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts.
Topics: Child, Preschool; Cyclophosphamide; Fanconi Anemia; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lymphocyte Depletion; Male; Recombinant Proteins; T-Lymphocytes; Tacrolimus; Vidarabine | 2000 |
Red swollen nail folds and nail deformity as presenting findings in chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Fingers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Nails; Nails, Malformed; Skin; Toes; Vidarabine | 2001 |
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment.
Topics: Adult; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Male; Recombinant Proteins; Remission Induction; Time Factors; Vidarabine | 2001 |
Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Immunosuppressive Agents; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
A case of refractory idiopathic pure red cell aplasia responsive to fludarabine treatment.
Topics: Female; Humans; Immunosuppressive Agents; Middle Aged; Red-Cell Aplasia, Pure; Vidarabine | 2001 |
Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Graft Rejection; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2000 |
Reactivation of hepatitis B virus infection during cytotoxic chemotherapy.
Topics: Acute Disease; Aged; Antineoplastic Agents; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 2001 |
Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Arabinonucleotides; Blotting, Western; Drug Interactions; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Lymphoma; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine; U937 Cells; Vidarabine | 2001 |
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
Topics: Adult; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; HL-60 Cells; Humans; Hydroxyurea; Leukemia; Vidarabine | 2001 |
Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD4-Positive T-Lymphocytes; Cells, Cultured; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2001 |
Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Clone Cells; Cyclophosphamide; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Immunoglobulin Heavy Chains; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Lymph Nodes; Neoplasm Proteins; Neoplasm, Residual; Polymerase Chain Reaction; Remission Induction; Sensitivity and Specificity; Treatment Outcome; Vidarabine | 2001 |
New drug combinations for the treatment of murine AIDS and macrophage protection.
Topics: Animals; Anti-HIV Agents; Antiviral Agents; Drug Combinations; Female; Macrophages; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Vidarabine; Zidovudine | 2001 |
Immunoablation followed by autologous hematopoietic stem cell infusion for the treatment of severe autoimmune disease.
Topics: Adolescent; Adult; Antilymphocyte Serum; Autoimmune Diseases; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2000 |
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cell Count; Child; Cohort Studies; Disease-Free Survival; Female; Graft Survival; Histocompatibility; Humans; Leukemia; Life Tables; Lymphoma, Large-Cell, Anaplastic; Male; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Methotrexate; Middle Aged; Neural Tube Defects; Program Evaluation; Recurrence; Survival Analysis; Thalassemia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Fludarabine in the treatment of an active phase of a familial haemophagocytic lymphohistiocytosis.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Histiocytosis, Non-Langerhans-Cell; Humans; Infant; Male; Remission Induction; Vidarabine | 2001 |
A fludarabine-based conditioning regimen for severe aplastic anemia.
Topics: Anemia, Aplastic; Child; Child, Preschool; Combined Modality Therapy; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Transplantation Chimera; Transplantation, Homologous; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Value of Life; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Age Factors; Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Palliative Care; Remission Induction; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2001 |
Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.
Topics: Adult; Arthritis; Aspergillosis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Knee Joint; Male; Middle Aged; Vidarabine | 2001 |
Fatal legionella pneumonia after fludarabine treatment in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Fatal Outcome; Humans; Immunocompromised Host; Legionnaires' Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Vidarabine | 2001 |
[Molecular biology examination in chronic lymphocytic leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Time Factors; Vidarabine | 2001 |
Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.
Topics: Antineoplastic Agents; Cytotoxicity, Immunologic; DNA, Antisense; Down-Regulation; Drug Resistance, Neoplasm; Genes, bcl-2; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine | 2000 |
Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Reversal of fludarabine induced testicular damage in a patient with chronic lymphocytic leukaemia (CLL), by suppression of pituitary-testicular axis using gonadotrophin releasing hormone (GnRH).
Topics: Antineoplastic Agents; Endocrine System; Gonadotropin-Releasing Hormone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pituitary Gland; Sperm Count; Testicular Diseases; Testis; Testosterone; Vidarabine | 2001 |
Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Imbalanced DNA synthesis induced by cytosine arabinoside and fludarabine in human leukemia cells.
Topics: Antineoplastic Agents; Cytarabine; DNA Replication; DNA, Neoplasm; Humans; Leukemia; Tumor Cells, Cultured; Vidarabine | 2001 |
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Chlorambucil; Drug Resistance, Multiple; Genes, bcl-2; Humans; Interleukin-4; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Prednisone; Proto-Oncogene Proteins c-bcl-2; Spleen; Staurosporine; Thymus Gland; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2001 |
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine | 2001 |
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2001 |
Paraneoplastic pemphigus: an association with fludarabine?
Topics: Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Fluorescent Antibody Technique; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine | 2001 |
Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leukemia, Myeloid; Lymphoma; Neoplasms, Multiple Primary; Remission Induction; Vidarabine | 2001 |
Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Prognosis; Retrospective Studies; Survival Analysis; Thymidine Kinase; Treatment Outcome; Vidarabine | 2001 |
Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Synergism; Female; Humans; Killer Cells, Natural; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prognosis; Treatment Outcome; Vidarabine | 2001 |
[Chronic lymphatic leukemia. 3. The concrete case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Prognosis; Vidarabine | 2001 |
Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Drug Resistance, Neoplasm; Flavonoids; Flow Cytometry; Humans; Lethal Dose 50; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine | 2001 |
Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenograstim; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nuclear Family; Psoriasis; Recombinant Proteins; T-Lymphocyte Subsets; Transplantation Chimera; Vidarabine | 2001 |
Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Family Health; Female; Graft Survival; Humans; Immunophenotyping; Infant; Lymphocyte Activation; Metabolism, Inborn Errors; Pregnancy; Purine-Nucleoside Phosphorylase; T-Lymphocytes; Transplantation Conditioning; Transplantation, Isogeneic; Vidarabine | 2001 |
Acute left ventricular failure following melphalan and fludarabine conditioning.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Homologous; Ventricular Dysfunction, Left; Vidarabine | 2001 |
Unrelated cord blood transplantation in a Fanconi anemia patient using fludarabine-based conditioning.
Topics: Antineoplastic Agents; Child, Preschool; Fanconi Anemia; Female; Fetal Blood; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine | 2001 |
Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.
Topics: Adult; Chediak-Higashi Syndrome; Cyclosporine; Fatal Outcome; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; T-Lymphocytes; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Failure; Vidarabine; Whole-Body Irradiation | 2001 |
Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation.
Topics: Adenoviridae Infections; Adenoviruses, Human; Antilymphocyte Serum; Bronchoalveolar Lavage Fluid; Busulfan; Cystitis; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocyte Subsets; Male; Methylprednisolone; Middle Aged; Pneumonia, Viral; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studies; Cell Culture Techniques; Child; Child, Preschool; Cytotoxicity, Immunologic; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immune System; Infections; Killer Cells, Lymphokine-Activated; Lymphocyte Activation; Male; Middle Aged; Phytohemagglutinins; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Autoimmune thrombocytopenia associated with the first cycle of fludarabine therapy in the treatment of relapsed non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Vidarabine | 2001 |
Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis.
Topics: Adult; Antineoplastic Agents; Apoptosis; Biopsy; Cathepsin B; Cathepsin L; Cathepsins; Cell Cycle; Cells, Cultured; Cysteine Endopeptidases; Dermatomyositis; DNA Primers; DNA-Binding Proteins; Gene Expression; Humans; Immunohistochemistry; Interferon-gamma; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Regeneration; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; Trans-Activators; Vidarabine | 2001 |
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Northern; Cisplatin; Complement System Proteins; Cytotoxicity Tests, Immunologic; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Idarubicin; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vidarabine | 2001 |
Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Antineoplastic Agents; Apoptosis; Caspases; Cyclic Nucleotide Phosphodiesterases, Type 4; Down-Regulation; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rolipram; Tumor Cells, Cultured; Vidarabine | 2001 |
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Survival Analysis; Topotecan; Vidarabine | 2001 |
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rituximab; Vidarabine; Virus Activation | 2001 |
Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine.
Topics: Adult; Autoantibodies; Factor VIII; Female; Hemorrhagic Disorders; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Partial Thromboplastin Time; Vidarabine | 2001 |
Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease.
Topics: Antineoplastic Agents; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Salvage Therapy; Transplantation, Homologous; Vidarabine | 2001 |
Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Retrospective Studies; Treatment Outcome; Vidarabine; Vincristine | 2001 |
Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intensity conditioning regimens.
Topics: Adolescent; Adult; Antigens, CD34; Blood Cell Count; Child; Child, Preschool; Female; Graft Survival; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Male; Middle Aged; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cyclophosphamide; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Pancytopenia; Prednisone; Red-Cell Aplasia, Pure; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2001 |
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell Count; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Karyotyping; Methotrexate; Middle Aged; Monosomy; Myelodysplastic Syndromes; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Arabinonucleotides; Clofarabine; Cyclophosphamide; DNA; DNA Repair; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Nucleosides; Time Factors; Vidarabine | 2001 |
Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
Topics: Animals; Cyclophosphamide; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; Immunosuppressive Agents; Mice; Mice, Inbred AKR; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; T-Lymphocytes, Cytotoxic; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2001 |
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.
Topics: Adult; Aged; Antigens, CD34; Busulfan; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2001 |
Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.
Topics: Adolescent; Adult; Aged; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Karyotyping; Lymphoproliferative Disorders; Male; Middle Aged; Prognosis; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitric Oxide; Triazenes; Vidarabine | 2001 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Cyclophosphamide; Cyclosporine; Feasibility Studies; Ganciclovir; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infection Control; Leukemia, Myeloid; Prednisone; Premedication; Recurrence; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine; Viral Load | 2002 |
Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure.
Topics: Adult; Anabolic Agents; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Cyclosporine; Diabetes Complications; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Iron Overload; Methylprednisolone; T-Lymphocytes; Transfusion Reaction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Analysis of recurrent failure times data: should the baseline hazard be stratified?
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rhinitis; Treatment Failure; Vidarabine | 2001 |
Evidence of inhibition of DNA methylation by fludarabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cell Line; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Vidarabine | 2000 |
Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Correlation between chromosome damage and apoptosis induced by fludarabine and idarubicin in normal human lymphocytes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cells, Cultured; Chromosome Aberrations; DNA Fragmentation; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Idarubicin; Lymphocytes; Mutagens; Vidarabine | 2002 |
Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Topics: 2-Chloroadenosine; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium Channel Blockers; Chlorambucil; Deoxyadenosines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Palatine Tonsil; Protein Kinase C; Staurosporine; Tumor Cells, Cultured; Verapamil; Vidarabine | 2002 |
Hematopoietic cell transplantation beyond first remission.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Nuclear Family; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndrome.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cyclophosphamide; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Penicillin V; Transplantation Chimera; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine; Wiskott-Aldrich Syndrome | 2002 |
Toxoplasmic encephalitis in a non-HIV patient with follicular lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Interferon-alpha; Lymphoma, Follicular; Opportunistic Infections; Prednisone; Salvage Therapy; Teniposide; Toxoplasmosis, Cerebral; Vidarabine | 2002 |
Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Bone Marrow Cells; Busulfan; Cell Count; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2001 |
Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; bcl-X Protein; Drug Resistance, Neoplasm; Female; Fibronectins; Humans; Integrin alpha4beta1; Integrins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Peptide Fragments; Proto-Oncogene Proteins c-bcl-2; Receptors, Lymphocyte Homing; Tumor Cells, Cultured; Vidarabine | 2002 |
[Lupus nephritis: treatments for today and tomorrow].
Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal; Bone Marrow Transplantation; CD40 Ligand; Cladribine; Drug Administration Schedule; Drug Therapy, Combination; Forecasting; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenolic Acid; Oligonucleotides; Plasmapheresis; Vidarabine | 2001 |
High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2002 |
CD80 antigen expression as a predictor of ex vivo chemosensitivity in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; B7-1 Antigen; Deoxyadenosines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2002 |
Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Vidarabine | 2000 |
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Risk Factors; Survival Rate; Vidarabine | 2002 |
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine | 2002 |
Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.
Topics: Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Ribosomal Proteins; RNA-Binding Proteins; Vidarabine | 2002 |
Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
Topics: Adult; Cohort Studies; Disease Progression; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Recurrence; Retrospective Studies; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |
Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.
Topics: 2-Chloroadenosine; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nucleosides; Vidarabine | 2002 |
Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.
Topics: Aged; Antineoplastic Agents; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine | 2002 |
Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.
Topics: Aged; Cladribine; Drug Evaluation; Humans; Immunoglobulin M; Immunosuppressive Agents; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2002 |
Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine.
Topics: Aged; Diagnosis, Differential; DNA, Viral; Humans; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Polymerase Chain Reaction; Vidarabine | 2002 |
Membranoproliferative glomerulonephritis in association with chronic lymphocytic leukaemia: a report of three cases.
Topics: Adult; Aged; Antineoplastic Agents; Chlorambucil; Drug Therapy, Combination; Female; Glomerular Mesangium; Glomerulonephritis, Membranoproliferative; Humans; Kidney Glomerulus; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Fluorescence; Middle Aged; Paraproteinemias; Prednisolone; Treatment Outcome; Vidarabine | 2002 |
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Renal Cell; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Pilot Projects; Sarcoma; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Topics: Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Computer Systems; DNA, Neoplasm; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neoplastic Cells, Circulating; Polymerase Chain Reaction; Rituximab; Vidarabine | 2002 |
Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Staining and Labeling; Survival Analysis; Vidarabine | 2002 |
Inhibition of nucleotide excision repair by fludarabine in normal lymphocytes in vitro, measured by the alkaline single cell gel electrophoresis (Comet) assay.
Topics: Antineoplastic Agents; Aphidicolin; Apoptosis; Comet Assay; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Kinetics; Lymphocytes; Time Factors; Ultraviolet Rays; Vidarabine | 2002 |
Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Follow-Up Studies; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplasms, Second Primary; Rituximab; Time Factors; Vidarabine | 2002 |
Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Chlorambucil; Cladribine; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2002 |
Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Carcinoma, Merkel Cell; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Rituximab; Salvage Therapy; Vidarabine | 2002 |
Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide.
Topics: Apoptosis; Cytotoxicity Tests, Immunologic; Drug Interactions; Endothelium, Vascular; Epithelial Cells; Humans; Immunity; Intercellular Adhesion Molecule-1; Leukocytes; Polydeoxyribonucleotides; Protective Agents; Tumor Cells, Cultured; Vidarabine | 2002 |
Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Blotting, Western; Cell Line; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Humans; Polymerase Chain Reaction; Protein Binding; RNA, Messenger; STAT1 Transcription Factor; Trans-Activators; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2002 |
Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine.
Topics: Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Male; Middle Aged; Opportunistic Infections; Time Factors; Vidarabine | 2002 |
Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning.
Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Lymphoma, B-Cell; Middle Aged; Multiple Myeloma; Remission Induction; Reoperation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2002 |
Cast nephropathy in a case of Waldenström's macroglobulinemia.
Topics: Aged; Biopsy; Female; Humans; Immunoglobulin A; Immunohistochemistry; Immunosuppressive Agents; Kidney Diseases; Kidney Glomerulus; Renal Dialysis; Vidarabine; Waldenstrom Macroglobulinemia | 2002 |
[Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Transplantation Conditioning; Transplantation Tolerance; Vidarabine | 2002 |
Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
Topics: Adult; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Cladribine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Vidarabine | 2002 |
Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Count; Cyclophosphamide; Dexamethasone; Enzyme Activation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; Mitoxantrone; Protein Conformation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2002 |
Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.
Topics: Alkaloids; CDC2-CDC28 Kinases; cdc25 Phosphatases; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA Damage; Enzyme Activation; Enzyme Inhibitors; Humans; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Vidarabine | 2002 |
Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation.
Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Case-Control Studies; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Proteins; Ribonucleotide Reductases; Vidarabine | 2002 |
Fludarabine treatment of cryoglobulinemic glomerulonephritis.
Topics: Adult; Cryoglobulinemia; Disease-Free Survival; Fatal Outcome; Female; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; RNA, Viral; Vidarabine; Viral Load | 2002 |
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Agents; Dendritic Cells; Flow Cytometry; Fluorescent Antibody Technique; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Neoplasms; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Vidarabine | 2002 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cause of Death; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Interstitial; Lymphoproliferative Disorders; Male; Middle Aged; Risk Factors; Vidarabine | 2002 |
Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin.
Topics: Adolescent; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoiesis; Histocompatibility; Humans; Immunosuppressive Agents; Male; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antiviral Agents; Cyclophosphamide; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Respiratory Syncytial Virus Infections; Ribavirin; Vidarabine | 2002 |
The triterpenoid CDDO induces apoptosis in refractory CLL B cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Caspases; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitric Oxide; Oleanolic Acid; Vidarabine | 2002 |
CML after treatment for lymphoid malignancy: Therapy-related CML or coincidence?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Neoplasms, Second Primary; Time Factors; Vidarabine | 2002 |
Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Female; Fractures, Bone; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Intellectual Disability; Male; Methylprednisolone; Mycophenolic Acid; Obesity; Peripheral Blood Stem Cell Transplantation; Prednisolone; Remission Induction; Siblings; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2002 |
Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphocytes; Lymphoma; Remission Induction; Splenic Neoplasms; Vidarabine | 2002 |
Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Aortic Valve Stenosis; Female; Heart Failure; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Middle Aged; Pulmonary Eosinophilia; Vidarabine | 2002 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Infections; Life Tables; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Spain; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; United Kingdom; Vidarabine | 2002 |
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce dura
Topics: Adult; Aged; Child; Cyclosporine; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Remission Induction; Survival Rate; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Homologous; Vidarabine | 2003 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Segmental coecal cytomegalovirus colitis during fludarabine, cytarabine and mitoxantrone induction chemotherapy for myelodysplastic syndrome.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cecal Diseases; Colitis; Cytarabine; Cytomegalovirus Infections; Female; Humans; Middle Aged; Mitoxantrone; Vidarabine | 2002 |
Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen.
Topics: Antimetabolites; Child, Preschool; Cord Blood Stem Cell Transplantation; Dyskeratosis Congenita; Humans; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adult; Aged; Aged, 80 and over; Biological Transport; Carrier Proteins; Cell Survival; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes; Male; Melphalan; Membrane Transport Proteins; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured; Vidarabine | 2003 |
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine.
Topics: Female; Guillain-Barre Syndrome; Herpes Zoster; Herpesvirus 3, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Vidarabine; Virus Activation | 2002 |
Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |
Haploidentical stem cell transplantation for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Disease-Free Survival; Haplotypes; Histocompatibility; Humans; Killer Cells, Natural; Leukemia; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |
Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
Topics: Adult; Busulfan; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Severe hypoglycemia in a patient with acute renal failure due to tumor lysis syndrome.
Topics: Acute Kidney Injury; Antineoplastic Agents; Female; Humans; Hypoglycemia; Leukemia, Lymphoid; Middle Aged; Severity of Illness Index; Tumor Lysis Syndrome; Vidarabine | 2002 |
Repeated cycles of alternate administration of fludarabine and Zidovudine plus Didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Didanosine; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Leukemia Virus, Murine; Lymph Nodes; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Proviruses; Reverse Transcriptase Inhibitors; Treatment Outcome; Vidarabine; Zidovudine | 2002 |
[Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia].
Topics: Aged; Antineoplastic Agents; Biopsy; Brain; Chronic Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Polymerase Chain Reaction; Vidarabine | 2002 |
Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Factor VIIa; Fatal Outcome; Female; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Acute; Lung Diseases; Pneumothorax; Pulmonary Alveoli; Recombinant Proteins; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
The effects of cladribine and fludarabine on DNA methylation in K562 cells.
Topics: Adenosine; Antineoplastic Agents; Cell Survival; Cladribine; CpG Islands; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Humans; K562 Cells; Tumor Cells, Cultured; Vidarabine | 2003 |
Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Cell Line; Cladribine; Clofarabine; Cytogenetics; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Leukemia; Phenotype; Phosphorylation; Ribonucleotide Reductases; Vidarabine | 2003 |
[Successful treatment with fludarabine of chronic lymphocytic leukemia associated with nephrotic syndrome].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nephrotic Syndrome; Vidarabine | 2002 |
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Adenoviridae Infections; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2002 |
Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Myeloid; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Siblings; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Stem Cell Transplantation; Vidarabine; Whole-Body Irradiation | 2002 |
Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Graft Survival; Histiocytosis, Non-Langerhans-Cell; Humans; Infant; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cytomegalovirus; Cytomegalovirus Infections; Humans; Incidence; Melphalan; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Activation; Whole-Body Irradiation | 2003 |
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine | 2003 |
Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, T-Cell; Male; Middle Aged; Neutropenia; Vidarabine | 2003 |
The relevance of nonmyeloablative transplants in developing countries: lessons from the UK experience.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cohort Studies; Cross-Cultural Comparison; Developing Countries; Graft vs Host Disease; Histocompatibility Testing; Humans; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; United Kingdom; Vidarabine | 2003 |
[Whipple's disease as a complication of chronic lymphocytic leukemia treated with fludarabine].
Topics: Antineoplastic Agents; Fatal Outcome; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Vidarabine; Whipple Disease | 2002 |
CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
Topics: Aged; Aged, 80 and over; Apoptosis; Autocrine Communication; B-Lymphocytes; CD40 Antigens; CD40 Ligand; Female; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha; Up-Regulation; Vidarabine | 2003 |
Immune thrombocytopenia induced by fludarabine successfully treated with rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2003 |
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; Survival Rate; Transplantation Conditioning; Vidarabine | 2002 |
Facial paresis after fludarabine treatment for advanced chronic lymphocytic leukaemia.
Topics: Aged; Facial Paralysis; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Shock, Septic; Vidarabine | 2002 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia | 2003 |
Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia.
Topics: Animals; Apoptosis; Crosses, Genetic; Cyclophosphamide; Drug Therapy, Combination; Graft vs Host Disease; Leukemia, B-Cell; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Skin; Spleen; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2003 |
Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
Topics: Antineoplastic Agents; Female; Humans; Hypergammaglobulinemia; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Middle Aged; Remission Induction; Vidarabine | 2003 |
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Treatment Outcome; Vidarabine | 2003 |
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubicin; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Vidarabine; Vincristine | 2003 |
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
Topics: Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Intestines; Life Tables; Liver; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Organ Specificity; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Severity of Illness Index; Skin; Survival Analysis; Time Factors; Tissue Donors; Transplantation Conditioning; Vidarabine; Washington; Whole-Body Irradiation | 2003 |
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Pentostatin; Thrombocytopenia; Treatment Outcome; Vidarabine | 2003 |
Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation.
Topics: Child; Fanconi Anemia; Female; Haploidy; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2003 |
Bilateral orbital masses in a patient with B-cell chronic lymph.
Topics: Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Orbital Neoplasms; Treatment Outcome; Vidarabine | 2003 |
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Salvage Therapy; Time Factors; Vidarabine | 2002 |
Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.
Topics: Annexin A5; Apoptosis; Apoptosis Regulatory Proteins; Caenorhabditis elegans Proteins; Cell Cycle; Cell Division; Cell Line, Tumor; Coloring Agents; Cyclin D3; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Cyclins; Down-Regulation; Fluorescein-5-isothiocyanate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Vidarabine | 2002 |
Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Apoptosis; Cisplatin; Cytarabine; Deoxyadenosines; DNA Fragmentation; Doxorubicin; Endodeoxyribonucleases; Etoposide; Humans; In Situ Nick-End Labeling; Leukemia, Mast-Cell; Microscopy, Electron; Neoplasm Proteins; Tumor Cells, Cultured; Vidarabine; Vincristine | 2003 |
Evaluation of thymic output by measurement of T-cell-receptor gene rearrangement excisional circles (TREC) in patients who have received fludarabine.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Gene Rearrangement, T-Lymphocyte; Humans; Immune System; Male; Middle Aged; Polymerase Chain Reaction; T-Lymphocyte Subsets; Thymus Gland; Vidarabine | 2003 |
The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Colony-Forming Units Assay; Cyclosporine; Enzyme Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Vidarabine | 2003 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine.
Topics: Aged; Antineoplastic Agents; Humans; Lymphoma, T-Cell; Male; Necrosis; Panniculitis; Vidarabine | 2003 |
Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Time Factors; Vidarabine | 2003 |
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Chlorambucil; Cyclophosphamide; DNA Damage; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gamma Rays; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Risk Factors; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2003 |
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Transfusion; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Transfusion; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Topics: Adenocarcinoma; Cyclophosphamide; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Living Donors; Middle Aged; Pancreatic Neoplasms; Siblings; Stem Cell Transplantation; Time Factors; Tomography, X-Ray Computed; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2003 |
Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2003 |
Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Vidarabine | 2003 |
Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase Inhibitors; Caspases; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cyclin D2; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Subcellular Fractions; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vidarabine | 2003 |
Non-myeloablative hematopoietic stem cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Hepatitis B; Humans; Liver Cirrhosis; Lymphoma, T-Cell; Male; Middle Aged; Time Factors; Vidarabine | 2003 |
Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Humans; Interleukin-2; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cell Transplantation; Prednisone; Recombinant Fusion Proteins; Remission Induction; Rituximab; Time Factors; Vidarabine; Vincristine | 2003 |
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.
Topics: Adult; Anemia, Sideroblastic; Antilymphocyte Serum; Fatal Outcome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase 3; Caspases; Cytarabine; Daunorubicin; Drug Interactions; Humans; Leukemia, Myeloid; Membrane Glycoproteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine | 2003 |
Fludarabine versus cyclophosphamide, vincristine, and prednisone in recurrent low-grade lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, Non-Hodgkin; Prednisone; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Reproducibility of Results; Social Behavior; Survival; Vidarabine; Vincristine | 2003 |
Bilateral optic disc swelling as the presenting sign of Waldenström's macroglobulinaemia.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Optic Disk; Papilledema; Prednisone; Vidarabine; Waldenstrom Macroglobulinemia | 2003 |
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Topics: Adult; Aged; Busulfan; Child; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Probability; Retrospective Studies; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness.
Topics: Adult; Blood Transfusion; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunosuppressive Agents; Jehovah's Witnesses; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Religion and Medicine; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Refusal; Vidarabine | 2003 |
Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine.
Topics: Aphidicolin; Apoptosis; Caspase 3; Caspase 8; Caspases; Cell Survival; Cells, Cultured; DNA Repair; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fas Ligand Protein; fas Receptor; Humans; Immunoblotting; Lymphocytes; Membrane Glycoproteins; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine; Signal Transduction; Time Factors; Tumor Suppressor Protein p53; Ultraviolet Rays; Vidarabine | 2003 |
Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Vidarabine; Virus Activation | 2003 |
Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Amino Acid Chloromethyl Ketones; Antibodies; Antibodies, Monoclonal; Antigens, CD; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin A; Immunoglobulin D; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Neprilysin; Palatine Tonsil; Vidarabine | 2003 |
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Disease Progression; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2003 |
Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression.
Topics: Acquired Immunodeficiency Syndrome; Acute-Phase Proteins; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Cell Survival; Cells, Cultured; Disease Reservoirs; DNA-Binding Proteins; Erythrocytes; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages; Proviruses; STAT3 Transcription Factor; Trans-Activators; Vidarabine; Viral Load; Virus Replication | 2003 |
Early reappearance of primary solid cancer in patients treated with purine analogs.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Colic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Purines; Remission Induction; Treatment Outcome; Vidarabine | 2003 |
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Platelet Count; Transplantation, Autologous; Vidarabine | 2004 |
Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors.
Topics: Adolescent; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft Survival; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Kinetics; Male; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine | 2003 |
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Case-Control Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Frequency; Genes, bcl-2; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Vidarabine | 2003 |
Fludarabine-related myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Flow Cytometry; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Vidarabine | 2003 |
Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin.
Topics: Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2003 |
[Gastrointestinal cancer].
Topics: Adult; Aged; Cyclophosphamide; Female; Gastrointestinal Neoplasms; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Oral fludarabine: a viewpoint by Dieter Huhn.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Clinical Trials as Topic; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2003 |
Oral fludarabine: a viewpoint by David Oscier.
Topics: Administration, Oral; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2003 |
Oral fludarabine: a viewpoint by Bruce D. Cheson.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2003 |
Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.
Topics: Bone Marrow Transplantation; Busulfan; Chediak-Higashi Syndrome; Child, Preschool; Graft vs Host Disease; Humans; Injections, Intravenous; Male; Siblings; Time Factors; Vidarabine | 2003 |
Effects of etoposide and fludarabine in subtoxic doses on karyotype of human malignant lymphoid Namalwa cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatids; Chromosome Aberrations; Chromosomes; Culture Media; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Humans; Karyotyping; Lymphoma; Mutagens; Vidarabine | 2003 |
Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases.
Topics: Adult; Aged; Cyclosporine; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Myeloid Cells; Prospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2003 |
The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cell Division; Cladribine; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplastic Stem Cells; Piperazines; Pyrimidines; Tumor Stem Cell Assay; Vidarabine | 2003 |
Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Topics: Animals; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; Graft vs Host Disease; Graft vs Leukemia Effect; Histocompatibility; Hyaluronan Receptors; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Mice; Mice, Inbred Strains; T-Lymphocytes; Transplantation, Homologous; Vidarabine | 2003 |
Post-transcriptional regulation of inducible nitric oxide synthase in chronic lymphocytic leukemia B cells in pro- and antiapoptotic culture conditions.
Topics: Aged; Aged, 80 and over; Alternative Splicing; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Base Sequence; Caspase 3; Caspases; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Interleukin-4; Isoenzymes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Sequence Data; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; RNA Processing, Post-Transcriptional; RNA, Messenger; Sequence Deletion; Sequence Homology, Nucleic Acid; Signal Transduction; Transcription, Genetic; Vidarabine | 2004 |
Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs.
Topics: Antibiotics, Antineoplastic; Antigens, CD34; Apoptosis; Benzoquinones; Blotting, Western; Bone Marrow Cells; Cell Separation; Chlorambucil; Down-Regulation; Enzyme Inhibitors; Flow Cytometry; HSP70 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinones; Rifabutin; RNA, Messenger; T-Lymphocytes; Time Factors; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes; Male; Middle Aged; Time Factors; Transplantation, Autologous; Vidarabine | 2004 |
Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carrier State; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B virus; Hepatitis C Antibodies; Humans; Lamivudine; Liver Failure; Lymphoma, Non-Hodgkin; Male; Middle Aged; Sequence Homology; Vidarabine; Virus Activation | 2003 |
In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine.
Topics: Aged; Aged, 80 and over; Apoptosis; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Survival; Cells, Cultured; Chronic Disease; Female; Humans; Immunosuppressive Agents; Leukemia, B-Cell; Male; Middle Aged; Statistics, Nonparametric; Vidarabine | 2003 |
Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Chlorambucil; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Protein Binding; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine | 2003 |
Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.
Topics: Adult; Aged; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Viremia | 2003 |
Successful allogeneic stem cell transplantation with fludarabine-based conditioning regimen in severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Transplantation Conditioning; Vidarabine | 2003 |
Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Adhesion; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Humans; Immunoblotting; Integrin alpha4beta1; Leukemia, B-Cell; Ligands; Lysine; Proto-Oncogene Proteins c-bcl-2; Sequence Analysis, DNA; Signal Transduction; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine | 2003 |
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Erythrocyte Transfusion; Fatal Outcome; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Platelet Transfusion; Risk Factors; Vidarabine | 2003 |
[Seventeen cases of nonmyeloablative stem cell transplantation using a conditioning regimen containing fludarabine].
Topics: Adult; Female; Follow-Up Studies; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
[Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].
Topics: Adolescent; Adult; Female; Follow-Up Studies; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
[Pressure pain in the left epigastrium: blood picture provides diagnosis. Chronic lymphatic leukemia].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytosis; Lymphocyte Count; Male; Middle Aged; Prednisone; Splenomegaly; Time Factors; Ultrasonography; Vidarabine | 2003 |
Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic liquid chromatography.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Leukemia; Reproducibility of Results; Sensitivity and Specificity; Vidarabine | 2004 |
Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Intestinal Polyposis; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Prednisone; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2003 |
[Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Risk Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Albuterol; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Calcium; Cell Line, Tumor; Chlorambucil; Cyclic AMP; Ethanolamines; Female; Formoterol Fumarate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Vidarabine | 2004 |
Fatal fludarabine-induced extensive bone marrow necrosis in a patient with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Diseases; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Vidarabine | 2003 |
Fludarabine induced immune thrombocytopenia in a patient with CD5 positive B cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Vidarabine | 2003 |
B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen.
Topics: Adult; Antigens, CD; Antigens, CD20; Antilymphocyte Serum; B-Lymphocytes; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphoproliferative Disorders; Male; Middle Aged; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
[Hairy cell leukemia: report on one case with survival for 10 years].
Topics: Aged; Humans; Immunophenotyping; Interferon alpha-2; Interferon-alpha; Leukemia, Hairy Cell; Male; Recombinant Proteins; Vidarabine | 2003 |
45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Prednisone; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Vincristine | 2003 |
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine | 2004 |
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Evaluation; Drug Resistance; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Sequence Deletion; Treatment Outcome; Vidarabine | 2004 |
Reversible acute renal failure following single administration of fludarabine.
Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Combined Modality Therapy; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine | 2003 |
Fludarabine-induced hemolytic anemia: successful treatment by rituximab.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Blood Transfusion; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2004 |
Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Female; Graft vs Tumor Effect; Humans; Melphalan; Ovarian Neoplasms; Vidarabine | 2004 |
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Child; Child, Preschool; Cladribine; Female; Fever; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2004 |
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
Topics: Adult; Aged; Antilymphocyte Serum; Bone Marrow Transplantation; Cladribine; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Cyclophosphamide; Disease Progression; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Second Primary; Syndrome; Time Factors; Vidarabine | 2003 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Hypoxia/re-oxygenation-induced, redox-dependent activation of STAT1 (signal transducer and activator of transcription 1) confers resistance to apoptotic cell death via hsp70 induction.
Topics: Acetylcysteine; Animals; Apoptosis; Cell Hypoxia; Cells, Cultured; DNA-Binding Proteins; Enzyme Inhibitors; Fibroblasts; Gene Expression Regulation; Hepatocytes; HSP70 Heat-Shock Proteins; Janus Kinase 2; Male; MAP Kinase Signaling System; Oxidation-Reduction; Oxidative Stress; Oxygen; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred Lew; STAT1 Transcription Factor; Trans-Activators; Tyrphostins; Vidarabine | 2004 |
Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine | 2004 |
[Drug-resistant B cell chronic lymphocytic leukemia safely treated with rituximab to control leukemic cell increment and platelet transfusion dependence].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Hepatomegaly; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytosis; Male; Middle Aged; Platelet Transfusion; Rituximab; Vidarabine | 2004 |
Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Rituximab; Treatment Failure; Vidarabine | 2004 |
Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chlorambucil; Complement System Proteins; Culture Media, Serum-Free; Humans; Immunoglobulin Fab Fragments; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2004 |
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Aspergillus fumigatus: a rare cause of vertebral osteomyelitis.
Topics: Aspergillus fumigatus; Humans; Leukemia, B-Cell; Opportunistic Infections; Osteomyelitis; Purine Nucleosides; Spinal Diseases; Vidarabine | 2004 |
Fludarabine in chronic lymphocytic leukemia and other hematological malignancies: progress in treatment. Fludarabine supplement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine | 2004 |
[Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 2004 |
Transient absence of hepatic uptake on gallium-67 scintigraphy following fludarabine therapy.
Topics: Antineoplastic Agents; Citrates; Gallium; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liver; Male; Metabolic Clearance Rate; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Spleen; Time Factors; Vidarabine | 2004 |
High dose chlorambucil in the treatment of lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vidarabine | 2004 |
The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Division; Cell Line, Transformed; Clone Cells; Drug Synergism; Humans; Immunotoxins; N-Glycosyl Hydrolases; Plant Proteins; Ribosome Inactivating Proteins, Type 1; Rituximab; Saporins; Tumor Cells, Cultured; Vidarabine | 2004 |
Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Apoptosis; B-Lymphocytes; Biomarkers, Tumor; Cell Cycle; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Microfilament Proteins; Muscle Proteins; Rituximab; Sensitivity and Specificity; Tumor Protein, Translationally-Controlled 1; Vidarabine | 2004 |
[Reduced intensity stem cell transplantation for metastatic renal cell carcinoma].
Topics: Adult; Busulfan; Carcinoma, Renal Cell; Cyclosporine; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kidney Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Salvage Therapy; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2004 |
Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection.
Topics: Aged; Antineoplastic Agents; Clone Cells; DNA, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Deletion; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasms, Second Primary; Polymerase Chain Reaction; Reed-Sternberg Cells; Vidarabine | 2004 |
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Treatment Outcome; Vidarabine | 2005 |
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; Female; Gastrointestinal Neoplasms; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Survival Rate; Treatment Outcome; Vidarabine; Vincristine | 2004 |
Fludarabine combination regimen severely affected peripheral blood stem cell mobilization.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Humans; Kinetics; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2004 |
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
Topics: Antineoplastic Agents, Alkylating; Graft Rejection; Granulocyte Precursor Cells; Hematologic Diseases; Humans; Immunosuppressive Agents; Melphalan; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2004 |
Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Ionomycin; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleotides; Pentostatin; Prognosis; Tumor Cells, Cultured; Vidarabine | 2004 |
Fludarabine as the possible cause of acute myelofibrosis.
Topics: Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Primary Myelofibrosis; Vidarabine | 2004 |
Fludarabine- and cyclophosphamide-based nonmyeloablative conditioning regimen for transplantation of chronic granulomatous disease: possible correlation with prolonged pure red cell aplasia.
Topics: ABO Blood-Group System; Adolescent; Blood Group Incompatibility; Cyclophosphamide; Graft Survival; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Male; Neutrophils; Red-Cell Aplasia, Pure; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases.
Topics: Adult; Aged; Blood Platelets; Cyclosporine; Feasibility Studies; Female; Fetal Blood; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neutrophils; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
Severe T-mediated bone marrow aplasia in a patient with splenic lymphoma with villous lymphocytes (SLVL) previously treated with fludarabine regimen.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Humans; Lymphoma, B-Cell; Splenic Neoplasms; T-Lymphocytes; Vidarabine | 2004 |
Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegalovirus Infections; Drug Therapy, Combination; Fanconi Anemia; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Living Donors; Male; Postoperative Complications; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Acute renal failure after nonmyeloablative hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adult; Aged; Behavior Therapy; Cohort Studies; Cyclosporine; Female; Glomerular Filtration Rate; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Stem Cell Transplantation; Tacrolimus; Time Factors; Vidarabine | 2004 |
9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells.
Topics: Antineoplastic Agents; Aryl Hydrocarbon Receptor Nuclear Translocator; DNA-Binding Proteins; Enzyme Activation; Female; Gene Expression; Gene Silencing; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Aryl Hydrocarbon; RNA, Messenger; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured; Vascular Endothelial Growth Factors; Vidarabine | 2004 |
Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells.
Topics: Apoptosis; B-Lymphocytes; Cell Cycle; Cell Division; Cell Line; DNA-Binding Proteins; Down-Regulation; Gene Expression; Genetic Vectors; Green Fluorescent Proteins; Humans; Nuclear Proteins; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; STAT1 Transcription Factor; Trans-Activators; Tumor Suppressor Protein p53; Vidarabine | 2004 |
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Chimera; Disease Progression; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients.
Topics: Aged; Busulfan; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporine; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mycophenolic Acid; Neoplasm Recurrence, Local; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Cycle Proteins; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia; Pyridines; Reactive Oxygen Species; Vidarabine | 2004 |
Fatal peripheral neuropathy following FLA chemotherapy.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Interactions; Fatal Outcome; Humans; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrimidines; Triazoles; Vidarabine; Voriconazole | 2004 |
Successful reduced-intensity allogeneic transplantation utilizing a fludarabine-based preparative regimen in a patient with chronic lymphocytic leukaemia and a history of fludarabine-associated autoimmune haemolytic anaemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2004 |
Reversible paraneoplastic neuropathy associated with T-cell large granular lymphocyte leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclosporine; Dexamethasone; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Male; Middle Aged; Mitoxantrone; Nerve Degeneration; Paraneoplastic Polyneuropathy; Paresthesia; Sural Nerve; T-Lymphocytes; Urinary Retention; Vidarabine | 2004 |
Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antirheumatic Agents; Arthritis, Rheumatoid; CD3 Complex; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Transplantation Chimera; Vidarabine | 2004 |
Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Fever of Unknown Origin; Filgrastim; Granulocyte Colony-Stimulating Factor; Guillain-Barre Syndrome; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Transplantation, Autologous; Vidarabine | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Safety; Survival Rate; Treatment Outcome; Vidarabine | 2004 |
High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cell Survival; Cells, Cultured; Chlorambucil; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasm Staging; Predictive Value of Tests; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2004 |
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged; Neoplasm Staging; Opportunistic Infections; Risk Factors; Vidarabine | 2004 |
The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Topics: Apoptosis; B-Lymphocytes; Benzodiazepines; Benzodiazepinones; Case-Control Studies; Caspase 3; Caspases; Cross-Linking Reagents; DNA Damage; DNA Repair; Enzyme Activation; Humans; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrroles; T-Lymphocytes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2004 |
Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update.
Topics: Adult; Aged; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphocytes; Lymphoma; Middle Aged; Splenectomy; Splenic Neoplasms; Vidarabine | 2004 |
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.
Topics: Adamantane; Apoptosis; B-Lymphocytes; Cells, Cultured; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Hydroquinones; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Vidarabine | 2005 |
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infection Control; Infections; Leukemia, Myeloid; Male; Middle Aged; Mycophenolic Acid; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Inhibition of repair of carboplatin-induced DNA damage by 9-beta-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes.
Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Carboplatin; Cell Proliferation; DNA Damage; DNA Repair; Drug Interactions; Humans; Lymphocytes; Tumor Cells, Cultured; Vidarabine | 2004 |
Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation.
Topics: Antilymphocyte Serum; Busulfan; Epstein-Barr Virus Infections; Guillain-Barre Syndrome; Humans; Male; Middle Aged; Samarium; Stem Cell Transplantation; Vidarabine; Virus Activation | 2004 |
Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Coloring Agents; Cyclophosphamide; DNA Damage; Enzyme Inhibitors; Flow Cytometry; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Membrane Potentials; Mitochondria; Mitoxantrone; Proteins; Reactive Oxygen Species; Staurosporine; Time Factors; Translocation, Genetic; Tumor Suppressor Protein p53; Vidarabine | 2004 |
Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Mitochondrial Proteins; Nitric Oxide; Nuclear Proteins; Nuclear Respiratory Factor 1; Organelle Biogenesis; Transcription Factors; Tumor Cells, Cultured; Vidarabine | 2004 |
Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.
Topics: Adolescent; Anemia, Aplastic; Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Transplantation Conditioning; Vidarabine | 2004 |
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Synergism; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2004 |
[Establishment of nonmyeloablative allogeneic stem cell transplantation model in H-2 haploidentical mice and its related study].
Topics: Animals; Female; Graft vs Host Disease; H-2 Antigens; Haplotypes; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Male; Mice; Mice, Inbred C57BL; Transplantation Chimera; Transplantation, Homologous; Vidarabine | 2004 |
High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Culture Media, Serum-Free; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Oligonucleotide Array Sequence Analysis; Phenotype; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2005 |
Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.
Topics: Antineoplastic Agents; Blotting, Western; Equilibrative-Nucleoside Transporter 2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vidarabine | 2005 |
Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect.
Topics: Aged; Annexin A5; Antigens, CD19; Antineoplastic Agents; Apoptosis; CD5 Antigens; Cell Death; Cell Survival; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Monocytes; Time Factors; Vidarabine | 2004 |
Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Caspase 8; Caspases; Cell Line, Tumor; Cladribine; Fas-Associated Death Domain Protein; Humans; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2004 |
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cladribine; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Idarubicin; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Melphalan; Prednisolone; Survival Analysis; Vidarabine; Vincristine | 2004 |
The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cladribine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Leukemia, Myeloid; Male; Middle Aged; Quinolones; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine | 2004 |
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cell Survival; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Tumor Cells, Cultured; Vidarabine | 2004 |
Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia.
Topics: Acute Kidney Injury; Administration, Oral; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Lysis Syndrome; Vidarabine | 2004 |
Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Coloring Agents; Cytarabine; Deoxycytidine; DNA; Gemcitabine; HL-60 Cells; Humans; Inhibitory Concentration 50; Nucleosides; Tetrazolium Salts; Thiazoles; Vidarabine | 2004 |
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.
Topics: Adult; Aged; Antigens, CD; CD8-Positive T-Lymphocytes; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Histocompatibility Testing; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Burkitt Lymphoma; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunophenotyping; In Situ Hybridization, Fluorescence; Interphase; Life Tables; Male; Middle Aged; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Solubility; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2005 |
Effect of fludarabine on leukocyte functions.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Degranulation; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; HL-60 Cells; Humans; Hypochlorous Acid; Neutrophils; Peroxidase; Vidarabine | 2004 |
Conditioning regimen of melphalan, fludarabine and total body irradiation in unmanipulated HLA haploidentical stem cell transplantation based on feto-maternal tolerance.
Topics: Adult; Antineoplastic Agents, Alkylating; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Genistein induces G2 arrest in malignant B cells by decreasing IL-10 secretion.
Topics: Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Cell Cycle Proteins; Cell Proliferation; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Flow Cytometry; G2 Phase; Genistein; Humans; Interferon-gamma; Interleukin-10; Receptors, Interleukin; Receptors, Interleukin-10; RNA, Messenger; Tumor Cells, Cultured; Vidarabine | 2004 |
Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB.
Topics: Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lysophospholipids; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Lysophosphatidic Acid; Tumor Cells, Cultured; Vidarabine | 2005 |
Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Apoptosis; Cell Survival; DNA-Binding Proteins; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; STAT1 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Tyrphostins; Vidarabine | 2005 |
Effects of fludarabine treatment on murine lupus nephritis.
Topics: Animals; Cyclophosphamide; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Immunosuppressive Agents; Kidney Glomerulus; Lupus Nephritis; Lymphocyte Count; Male; Mice; Spleen; Vidarabine | 2004 |
Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.
Topics: Acute Kidney Injury; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chronic Disease; Disseminated Intravascular Coagulation; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Renal Dialysis; Transplantation Conditioning; Vidarabine | 2005 |
PNP with Waldenström's macroglobulinaemia.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Humans; Male; Paraneoplastic Syndromes; Pemphigus; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia.
Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Salvage Therapy; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Successful bone marrow transplantation in a patient with c-mpl-mutated congenital amegakaryocytic thrombocytopenia from a carrier donor.
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Child; Female; Heterozygote; Humans; Immunosuppressive Agents; Megakaryocytes; Point Mutation; Thrombocytopenia; Thrombopoietin; Vidarabine | 2005 |
Fludarabine: risk factor for aggressive behaviour of squamous cell carcinoma of the skin?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Humans; Immunocompromised Host; Lymphoma, B-Cell; Male; Skin Neoplasms; T-Lymphocytes; Vidarabine | 2005 |
Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prednisolone; Retreatment; Survival Analysis; Turkey; Vidarabine | 2004 |
The influence of chemotherapy on bone marrow in patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Vidarabine | 2004 |
[Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Treatment Outcome; Vidarabine | 2004 |
Fludarabine-based conditioning used in successful bone marrow transplantation from an unrelated donor in a heavily transfused patient with severe aplastic anemia.
Topics: Adolescent; Anemia, Aplastic; Blood Transfusion; Bone Marrow Transplantation; Female; Humans; Immunosuppressive Agents; Severity of Illness Index; Tissue Donors; Transplantation Conditioning; Vidarabine | 2005 |
Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
Topics: Adult; Antilymphocyte Serum; Blood Transfusion, Autologous; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Middle Aged; Pilot Projects; Primary Myelofibrosis; Prospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2005 |
Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Disease Progression; Female; Herpesvirus 4, Human; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Reed-Sternberg Cells; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2005 |
Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia.
Topics: Antigens, CD34; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Cell Fractionation; Cohort Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Opportunistic Infections; Pneumonia, Bacterial; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.
Topics: Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Middle Aged; Multiple Myeloma; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Blood Transfusion; Bone Marrow Transplantation; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Histocompatibility; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; T-Lymphocytes; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3).
Topics: Adenosine; Animals; Antineoplastic Agents; Cation Transport Proteins; Cladribine; Conserved Sequence; DNA; Ethnicity; Genetic Variation; Haplotypes; Humans; Membrane Transport Proteins; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Oocytes; Vidarabine; Xenopus laevis | 2005 |
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine | 2005 |
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Methylprednisolone; Middle Aged; Mycophenolic Acid; Patient Selection; Postoperative Complications; Recurrence; Renal Dialysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2005 |
Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Pharmacokinetics; Transplantation, Homologous; Vidarabine | 2005 |
Analysis of 1H NMR-detectable mobile lipid domains for assessment of apoptosis induced by inhibitors of DNA synthesis and replication.
Topics: Apoptosis; Cell Line, Tumor; Cell Membrane; DNA Replication; Etoposide; Humans; Hydrogen; Magnetic Resonance Spectroscopy; Membrane Lipids; Quercetin; Vidarabine | 2005 |
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Mycophenolic Acid; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2005 |
Changing the way we think about chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Rituximab; Vidarabine | 2005 |
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Comorbidity; Female; Graft Rejection; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Probability; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2005 |
Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity.
Topics: Antineoplastic Agents; Cell Line; Cell Movement; Endothelial Cells; Endothelium, Vascular; Oligodeoxyribonucleotides; Polydeoxyribonucleotides; Transplantation Conditioning; Vascular Diseases; Vidarabine | 2005 |
Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF.
Topics: Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Leukemia, Lymphocytic, Chronic, B-Cell; Peripheral Blood Stem Cell Transplantation; Treatment Failure; Vidarabine | 2005 |
Lymphoma: diagnosis, staging, natural history, and treatment strategies.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Vidarabine | 2005 |
p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Female; Genes, p53; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Treatment Outcome; Vidarabine | 2005 |
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Caspases; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Humans; In Vitro Techniques; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lignans; Magnolia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phytotherapy; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2005 |
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Vidarabine; Whole-Body Irradiation | 2005 |
Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine.
Topics: Antineoplastic Agents; Cell Transformation, Viral; Clone Cells; Drug Resistance, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Hodgkin Disease; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Micromanipulation; Middle Aged; Reed-Sternberg Cells; Vidarabine | 2005 |
Five-month marrow aplasia in a child with refractory acute myeloid leukemia: successful management with continuous granulocyte support and reduced-intensity conditioning followed by matched unrelated bone marrow transplantation.
Topics: Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Female; Graft vs Host Disease; Granulocytes; Humans; Leukemia, Myelomonocytic, Acute; Melphalan; Neoplasm Recurrence, Local; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Chromones; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; MAP Kinase Signaling System; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; U937 Cells; Vidarabine | 2005 |
Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure.
Topics: Acute Kidney Injury; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Renal Dialysis; Vidarabine | 2005 |
A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Jurkat Cells; Leukemia; Mass Spectrometry; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Vidarabine | 2005 |
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Topics: Actins; Apoptosis; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Chemotaxis; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Molecular Weight; Oligopeptides; Peptides; Receptors, CXCR4; Stromal Cells; Structure-Activity Relationship; Time Factors; Vidarabine | 2005 |
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine | 2005 |
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; B-Lymphocytes; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Caspase 9; Caspases; Cell Aggregation; Cell Survival; Cells, Cultured; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2005 |
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation; Case-Control Studies; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; DNA-Binding Proteins; Forkhead Transcription Factors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Interleukin-10; L-Selectin; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Receptors, Interleukin-2; Receptors, Nerve Growth Factor; Receptors, Tumor Necrosis Factor; T-Lymphocyte Subsets; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vidarabine | 2005 |
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Agents; Disease-Free Survival; Graft vs Host Disease; Humans; Immunophenotyping; Melphalan; Multiple Myeloma; Proportional Hazards Models; Receptors, Immunologic; Receptors, KIR; Recurrence; Risk; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microcirculation; Middle Aged; Neoplasm, Residual; Neovascularization, Pathologic; Vidarabine | 2005 |
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Disease Susceptibility; Female; Herpesviridae Infections; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia, Pneumocystis; Risk; Rituximab; Vidarabine | 2005 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine | 2005 |
Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Topics: Administration, Oral; Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
Topics: Female; Graft Survival; Graft vs Host Disease; Histiocytosis, Langerhans-Cell; Humans; Infant; Langerhans Cells; Male; Melphalan; Prognosis; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Disease Progression; Female; Humans; Pleural Effusion; Recurrence; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Treatment Outcome; Vidarabine; Vincristine | 2005 |
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; CD4-CD8 Ratio; Dexamethasone; Female; Humans; Immunosuppression Therapy; Infections; Interferons; Lymphoma; Male; Middle Aged; Mitoxantrone; Neutropenia; Vidarabine | 2005 |
Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Treatment Outcome; Vidarabine | 2005 |
An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Middle Aged; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2005 |
Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome; Vidarabine | 2005 |
Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myasthenia Gravis; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2005 |
Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Disease Progression; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Sirolimus; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Bone Marrow; Chromosomes, Human, Pair 7; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Monosomy; Neoplasms, Second Primary; Vidarabine | 2005 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukocyte Count; Liver; Male; Middle Aged; Mucositis; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Female; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Treatment Outcome; Vidarabine | 2006 |
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Teniposide; Treatment Outcome; Vidarabine | 2005 |
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia.
Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Diagnosis, Differential; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Vidarabine | 2005 |
Richter's syndrome--the downside of fludarabine?
Topics: Antineoplastic Agents; Epstein-Barr Virus Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Syndrome; Vidarabine | 2005 |
Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Agents; Cyclophosphamide; Cyclosporine; Dexamethasone; Drug Resistance, Neoplasm; Humans; Leukemia, T-Cell; Male; Mitoxantrone; Prednisolone; Red-Cell Aplasia, Pure; Remission Induction; Vidarabine | 2005 |
'Specific' cutaneous infiltrate of B-cell chronic lymphocytic leukemia at the site of a florid herpes simplex infection.
Topics: Aged; Antineoplastic Agents; Herpes Zoster; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Neoplasm Staging; Skin Neoplasms; Treatment Outcome; Vidarabine | 2005 |
Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning.
Topics: Adolescent; Adult; Child; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2005 |
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Hemoglobins; Humans; Immunoglobulin M; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; B-Lymphocytes; Brefeldin A; Cells, Cultured; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Golgi Apparatus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Middle Aged; Multiple Myeloma; Protein Transport; Tumor Necrosis Factor Ligand Superfamily Member 13; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vidarabine | 2006 |
Apoptosis of peripheral human blood lymphocytes induced by physical-chemical influences and generation of reactive oxygen species.
Topics: Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Lymphocytes; Microscopy, Fluorescence; Radiation, Ionizing; Reactive Oxygen Species; Temperature; Vidarabine | 2005 |
Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.
Topics: Animals; Binding, Competitive; Biotransformation; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxyadenine Nucleotides; Deoxycytosine Nucleotides; DNA; Drug Interactions; Drug Resistance, Neoplasm; Hydroxyurea; Mice; Nucleosides; Vidarabine | 2005 |
Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Disease Management; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prognosis; Rituximab; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 5; Drug Administration Schedule; Humans; Male; Monosomy; Myelodysplastic Syndromes; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Recurrence; Regression Analysis; Remission Induction; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Nephrotic Syndrome; Proteinuria; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2005 |
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Risk Assessment; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
[Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulins; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myeloablative Agonists; Rituximab; Severity of Illness Index; Thrombocytopenia; Treatment Outcome; Vidarabine | 2005 |
Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2.
Topics: Animals; Equilibrative-Nucleoside Transporter 2; Female; Haplotypes; Humans; Inosine; Mutation; Oocytes; Polymorphism, Genetic; Tritium; Uridine; Vidarabine; Xenopus laevis | 2006 |
Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.
Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Biological Transport; Cell Line; Cladribine; Clofarabine; Humans; Membrane Transport Proteins; Recombinant Proteins; Vidarabine; Xenopus laevis | 2006 |
Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cerebrospinal Fluid; Drug Evaluation; Female; Humans; Injections, Intravenous; Injections, Spinal; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 2005 |
Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carrier Proteins; Cell Survival; Chlorambucil; Flow Cytometry; Gene Expression; Glycoproteins; Humans; Immunoglobulin G; Interleukin-1; Interleukin-8; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Oligonucleotide Array Sequence Analysis; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2006 |
Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cladribine; Cyclophosphamide; Humans; Molecular Structure; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Vidarabine | 2005 |
Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Vidarabine | 2006 |
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Creatinine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Recombinant Proteins; Renal Insufficiency; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Vidarabine | 2005 |
Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen.
Topics: Adrenoleukodystrophy; Busulfan; Child; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance Imaging; Male; Myeloablative Agonists; Transplantation Conditioning; Vidarabine | 2005 |
An irradiation-free nonmyeloablative bone marrow transplantation model: importance of the balance between donor T-cell number and the intensity of conditioning.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Cell Transplantation; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Lymphocyte Count; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Spleen; T-Lymphocytes; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Radioimmunotherapy; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2006 |
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
Topics: Acyclovir; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cohort Studies; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Dexamethasone; Diphtheria Toxin; DNA, Viral; Doxorubicin; Female; Fever; Follow-Up Studies; Ganciclovir; Hematologic Neoplasms; Humans; Interleukin-2; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Transplantation, Autologous; Valacyclovir; Valine; Vidarabine; Vincristine; Viremia; Virus Activation | 2005 |
OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channels; Cell Line, Tumor; Cholestenones; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopy, Electron; Mitochondrial Membranes; Saponins; Vidarabine | 2005 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical Protocols; Combined Modality Therapy; Comorbidity; Deferoxamine; Disease-Free Survival; Erythrocyte Transfusion; Erythropoietin; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Hemosiderosis; Humans; Hydroxyurea; Immunosuppressive Agents; Iron Chelating Agents; Life Tables; Liver Cirrhosis; Male; Phlebotomy; Postoperative Complications; Survival Analysis; Thalassemia; Transfusion Reaction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Female; Gene Deletion; Genes, Immunoglobulin Heavy Chain; Genetic Predisposition to Disease; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2006 |
[Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Dexamethasone; Doxorubicin; Female; Hemoglobins; Humans; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Myeloma Proteins; Neoplasm Recurrence, Local; Remission Induction; Vidarabine; Vincristine | 2005 |
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2006 |
Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Fatal Outcome; Humans; Lymphoma, Follicular; Middle Aged; Remission Induction; Rituximab; Vidarabine; West Nile Fever; West Nile virus | 2005 |
Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Case-Control Studies; Cyclophosphamide; Fas Ligand Protein; fas Receptor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Middle Aged; Mitoxantrone; Solubility; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors; Vidarabine | 2005 |
Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; ATPases Associated with Diverse Cellular Activities; Bone Marrow; Bone Resorption; Cell Differentiation; Cell Line; Electrophoretic Mobility Shift Assay; Gene Expression Regulation; Interferon-gamma; LIM Domain Proteins; Mice; Osteoclasts; Proteasome Endopeptidase Complex; Response Elements; Signal Transduction; STAT1 Transcription Factor; Transcription Factors; Vidarabine | 2006 |
The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Dose-Response Relationship, Radiation; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.
Topics: Adult; Biomarkers, Tumor; Bone Marrow; Bone Marrow Neoplasms; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Female; Gene Expression Regulation, Neoplastic; Graft Survival; Graft vs Tumor Effect; Humans; Mammaglobin A; Middle Aged; Myeloablative Agonists; Neoplasm Proteins; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Uteroglobin; Vidarabine | 2006 |
Significance of VH genes mutation status for prognosis of CLL patients.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Flow Cytometry; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 2005 |
Resistant pure red cell aplasia after allogeneic bone marrow transplantation with major ABO mismatch treated by purified CD34+ cell infusion.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Bone Marrow Transplantation; Erythropoietin; Female; Humans; Leukocyte Transfusion; Medical Errors; Red-Cell Aplasia, Pure; Rituximab; Transplantation, Homologous; Vidarabine | 2006 |
Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Costs and Cost Analysis; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Living Donors; Melphalan; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Health Services; Humans; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Retrospective Studies; United Kingdom; Vidarabine; Vincristine | 2006 |
Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Hemolysis; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Vidarabine | 2006 |
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Topotecan; Vidarabine | 2006 |
Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.
Topics: Adult; Bone Marrow; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Fludarabine induced autoimmune haemolytic anaemia in a patient with chronic lymphocytic leukaemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Vidarabine | 2006 |
[Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].
Topics: Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Barbiturates; bcl-2-Associated X Protein; Benzophenanthridines; Benzopyrans; Caspase 9; Caspases; Cell Line; Cell Line, Tumor; Cell Survival; Chlorambucil; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; HeLa Cells; Humans; Ligands; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; Phenanthridines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Rats, Wistar; RNA, Small Interfering; Staurosporine; Time Factors; Vidarabine | 2006 |
PS exposure increases the susceptibility of cells to fusion with DOTAP liposomes.
Topics: Antineoplastic Agents; Apoptosis; Cell Membrane; Chlorides; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluorescent Dyes; HeLa Cells; Humans; Jurkat Cells; Liposomes; Manganese Compounds; Membrane Fusion; Mitoxantrone; Phosphatidylserines; Phospholipid Transfer Proteins; Quaternary Ammonium Compounds; Staurosporine; Vidarabine | 2006 |
Positron emission tomography--positive distal femur following fludarabine, dexamethasone and mitoxantrone chemotherapy.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Femur; Humans; Injections, Intravenous; Male; Middle Aged; Mitoxantrone; Osteonecrosis; Positron-Emission Tomography; Vidarabine | 2006 |
Exacerbation of chronic epidural abscess following a fludarabine-based preparative regimen.
Topics: Acetamides; Anemia, Aplastic; Anti-Infective Agents; Epidural Abscess; Graft vs Host Disease; Humans; Linezolid; Male; Middle Aged; Myeloablative Agonists; Oxazolidinones; Radiography; Staphylococcal Infections; Stem Cell Transplantation; Vidarabine | 2006 |
Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Humans; Male; Mexico; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Transcription Factors; Tumor Suppressor Protein p53; Vidarabine | 2006 |
Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Annexin A5; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cytotoxicity Tests, Immunologic; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2006 |
[Second nonmyeloablative allogeneic peripheral blood stem cell transplantation with more immunosuppressive conditioning regimen for the late graft failure of the patient with acute myeloid leukemia].
Topics: Antineoplastic Agents; Cyclophosphamide; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Animals; Antigens, CD34; Antilymphocyte Serum; Cyclophosphamide; Female; Graft vs Host Disease; Horses; Humans; Immunosuppressive Agents; Male; Micropore Filters; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; CD40 Antigens; Cell Line, Tumor; Cell Survival; Cyclohexanones; Down-Regulation; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2006 |
The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia.
Topics: Anemia, Hemolytic, Autoimmune; Case-Control Studies; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Vidarabine | 2006 |
[Fever and dyspnea in a patient with chronic lymphatic leukemia under treatment with fludarabine].
Topics: Aged; Antineoplastic Agents; Dyspnea; Female; Fever; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Vidarabine | 2006 |
Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease Progression; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prednisolone; Remission Induction; Risk Factors; Rituximab; Treatment Outcome; Vidarabine | 2006 |
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cells, Cultured; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Transcription, Genetic; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2006 |
Fludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathway.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Extracellular Signal-Regulated MAP Kinases; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Interleukin-8; Monocytes; Transcription Factor AP-1; U937 Cells; Vidarabine | 2006 |
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Crohn Disease; Cytarabine; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Liver; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Male; Methylprednisolone; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Spleen; Transplantation, Homologous; Vidarabine | 2006 |
Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
Topics: Adult; Amyloidosis; Diarrhea; Drug Therapy, Combination; Heart Diseases; Humans; Hypotension; Japan; Kidney Diseases; Male; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
The infectious consequences of rituximab addition to fludarabine-containing regimens.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Drug Interactions; Humans; Lymphoma, AIDS-Related; Rituximab; Vidarabine | 2006 |
[Inhibition effect of fludarabine on the growth of myelodysplastic syndrome cell line MUTZ-1 and its mechanism].
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Survivin; Vidarabine | 2006 |
Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient.
Topics: Aged; Antifungal Agents; Antineoplastic Agents; Cryptococcosis; Fluconazole; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Male; Opportunistic Infections; Radiography, Thoracic; Tomography, X-Ray Computed; Treatment Outcome; Vidarabine | 2007 |
F-ara-AMP is a substrate of cytoplasmic 5'-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation.
Topics: 5'-Nucleotidase; Chromatography, High Pressure Liquid; Cytoplasm; Humans; Kinetics; Magnetic Resonance Spectroscopy; Vidarabine; Vidarabine Phosphate | 2006 |
[Effect of inhibitors of signal transducer and activator of transcription-1/3 on expression of tumor necrosis factor-alpha induced by high mobility group box-1 protein inflammatory response in rat peritoneal macrophages].
Topics: Animals; Cells, Cultured; Drug Interactions; HMGB1 Protein; Macrophages, Peritoneal; Male; Rats; Rats, Wistar; Signal Transduction; Sirolimus; STAT1 Transcription Factor; STAT3 Transcription Factor; Transcription, Genetic; Tumor Necrosis Factor-alpha; Vidarabine | 2006 |
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Bone Marrow Diseases; Child; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2006 |
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2006 |
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
Topics: Animals; Antineoplastic Agents; CD5 Antigens; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Neoplasm Proteins; Proto-Oncogene Proteins; Tumor Cells, Cultured; Vidarabine | 2006 |
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
Another case of myelodysplasia with monosomy 7 following fludarabine-based chemotherapy.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 7; Female; Humans; Lymphoma, Follicular; Middle Aged; Monosomy; Myelodysplastic Syndromes; Vidarabine | 2006 |
An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Stem Cell Transplantation; Vidarabine | 2006 |
Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mucositis; Opportunistic Infections; Pilot Projects; Quality of Life; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2006 |
[Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisolone; Rituximab; Vidarabine; Vincristine | 2005 |
Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: rituximab as the treatment of choice?
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Rituximab; Treatment Outcome; Vidarabine | 2007 |
Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.
Topics: Adult; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Computer Simulation; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; European Union; Fees and Charges; Germany; Health Care Costs; Humans; Lymphoma, Follicular; Male; Models, Economic; Prednisone; Reproducibility of Results; Rituximab; Sensitivity and Specificity; Vidarabine; Vincristine | 2006 |
Hemophagocytosis during fludarabine-based SCT for systemic juvenile idiopathic arthritis.
Topics: Adolescent; Arthritis, Juvenile; Child; Female; Humans; Macrophage Activation; Male; Myeloablative Agonists; Stem Cell Transplantation; Syndrome; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2006 |
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Neoplasms, Second Primary; Prednisone; Recurrence; Remission Induction; Time Factors; Vidarabine; Vincristine | 2006 |
Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine.
Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Female; Hepatitis B; Hepatitis B Surface Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phylogeny; Vidarabine | 2006 |
Diagnosis of a primary testicular lymphoma by echography and magnetic resonance imaging.
Topics: Aged; alpha-Fetoproteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Methotrexate; Neoplasm Proteins; Orchiectomy; Prednisone; Prognosis; Rituximab; Testicular Neoplasms; Ultrasonography; Vidarabine; Vincristine | 2006 |
Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
Topics: Animals; Bone Marrow Transplantation; Flow Cytometry; Graft vs Leukemia Effect; Mice; Mice, Inbred C57BL; Spleen; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Graft failure and severe autoimmune haemolysis following fludarabine-based reduced-intensity matched unrelated donor bone marrow transplantation for severe aplastic anaemia: salvage by second transplant with conventional dose conditioning.
Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Bone Marrow Transplantation; Female; Graft Rejection; Humans; Salvage Therapy; Tissue Donors; Vidarabine | 2006 |
Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia.
Topics: Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Pilot Projects; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematologic Neoplasms; Humans; Leukemia; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Risk Factors; Rituximab; Vidarabine | 2006 |
Central line-related bacteraemia due to Roseomonas mucosa in a neutropenic patient with acute myeloid leukaemia in Piraeus, Greece.
Topics: Acute Disease; Adult; Amikacin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bacteremia; Base Sequence; Catheterization, Central Venous; Cytarabine; Humans; Leukemia, Myeloid; Male; Methylobacteriaceae; Molecular Sequence Data; Neutropenia; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; RNA, Bacterial; RNA, Ribosomal, 16S; Vidarabine | 2006 |
Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Family; Graft vs Host Disease; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2006 |
Concomitant Epstein-Barr virus-negative large B-cell lymphoma (Richter syndrome) and Epstein-Barr virus- positive B-cell lymphoproliferation after treatment with fludarabine and cyclophosphamide in a patient with B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epstein-Barr Virus Infections; Fatal Outcome; Herpesvirus 4, Human; Humans; Immunoglobulin A; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Tumor Lysis Syndrome; Vidarabine | 2006 |
Preparation of a fludarabine intermediate via selective alkylation of 2-fluoroadenine.
Topics: Adenine; Alkylation; Arabinose; Nucleic Acid Conformation; Pentanols; Stereoisomerism; Vidarabine | 2006 |
[Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Cyclosporine; Graft vs Host Disease; Humans; Infant; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tissue Donors; Transplantation Conditioning; Vidarabine | 2006 |
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Signal Transduction; T-Lymphocytes; Time Factors; Vidarabine | 2006 |
[Remission in T-cell prolymphocytic leukemia during the FMC treatment course].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 2006 |
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.
Topics: Adult; Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bacterial Infections; Causality; Female; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Rituximab; Vidarabine | 2006 |
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Middle Aged; Postoperative Complications; Primary Myelofibrosis; Spleen; Time Factors; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; T-Lymphocytes, Regulatory; Thalidomide; Treatment Failure; Tumor Necrosis Factor-alpha; Vidarabine | 2007 |
Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Czech Republic; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hospital Costs; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Philadelphia Chromosome; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cladribine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Kidney Neoplasms; Oxidoreductases; Transfection; Vidarabine | 2007 |
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Ultraviolet Rays; Vidarabine | 2006 |
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Remission Induction; Stem Cells; Treatment Outcome; Vidarabine | 2006 |
Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine.
Topics: Antineoplastic Agents; Bone Neoplasms; Child; Disease Progression; Fatal Outcome; Female; Humans; Immunosuppression Therapy; Magnetic Resonance Imaging; Myeloablative Agonists; Osteosarcoma; Pleural Neoplasms; Radiography, Thoracic; Vidarabine | 2006 |
Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
Topics: Acute Disease; Antifungal Agents; Cause of Death; Chronic Disease; Cyclosporine; Cytomegalovirus Infections; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Mycoses; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine | 2006 |
Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy.
Topics: Adenine; Animals; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cercocebus atys; Drug Carriers; Erythrocytes; Female; Humans; Macrophages; Male; Myeloablative Agonists; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; STAT1 Transcription Factor; T-Lymphocyte Subsets; Tenofovir; Vidarabine; Viremia; Virus Replication | 2006 |
Herpes simplex and Epstein-Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Acyclovir; Aged; Antineoplastic Agents; Antiviral Agents; Female; Gene Expression Profiling; Gene Expression Regulation, Viral; Herpesviridae Infections; Herpesvirus 1, Human; Herpesvirus 2, Human; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphadenitis; Vidarabine | 2006 |
Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Flow Cytometry; Gene Expression; Gene Expression Profiling; Genistein; Humans; Interleukin-10; Leukemia, B-Cell; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2007 |
Flow cytometric evaluation of red blood cell chimerism after bone marrow transplantation in Iranian patients: a preliminary study.
Topics: ABO Blood-Group System; Adolescent; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; Child; Erythrocytes; Female; Flow Cytometry; Fluorescein-5-isothiocyanate; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Iran; Male; Vidarabine | 2006 |
Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
Topics: Aged; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2006 |
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
Topics: Azacitidine; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; Estrogen Receptor alpha; Genes, APC; Genes, BRCA1; Humans; K562 Cells; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Vidarabine | 2006 |
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Reoperation; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cross Reactions; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Radiation; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gamma Rays; Gene Expression Profiling; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Radiation Tolerance; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT1 Transcription Factor; Tumor Cells, Cultured; Vidarabine | 2007 |
Treatment-related myelodysplasia following fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2006 |
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Risk; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esophageal Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Cellular; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lichenoid Eruptions; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mucositis; Paraneoplastic Syndromes; Pemphigus; Prednisone; Recurrence; Rituximab; T-Lymphocytes; Vidarabine; Vincristine | 2007 |
MicroRNAs in leukemia.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Disease Progression; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Leukemia; Mice; MicroRNAs; Piperidines; Prognosis; Vidarabine | 2006 |
Conditioning with fludarabine alone and allogeneic transplantation as a successful rescue therapy for persistent, severe iatrogenic aplasia after relapse of acute myeloid leukemia.
Topics: Anemia, Aplastic; Female; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Leukemia, Myeloid; Middle Aged; Myeloablative Agonists; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug Induced Liver Injury; Cholangitis; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Hematologic Diseases; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Incidence; Infant, Newborn; Liver Diseases; Liver Function Tests; Male; Melphalan; Middle Aged; Postoperative Complications; Risk Factors; Tacrolimus; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Topics: Alemtuzumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cladribine; Etodolac; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Purines; Rituximab; Spectrometry, Fluorescence; Vidarabine | 2006 |
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Immunotherapy; Leukopenia; Lymphoma, Follicular; Middle Aged; Parvoviridae Infections; Parvovirus B19, Human; Prednisolone; Recurrence; Rituximab; Vidarabine; Vincristine; Viremia | 2006 |
Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chimerism; Chronic Disease; Cohort Studies; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Injections, Intravenous; Lymphocyte Transfusion; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Topics: Aged; Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; CD52 Antigen; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Drug Resistance; Glycoproteins; Hemoglobins; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Splenectomy; Treatment Outcome; Vidarabine; Vincristine | 2007 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chi-Square Distribution; Disease-Free Survival; Drug Resistance, Multiple; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Phenotype; Prognosis; Remission Induction; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Vidarabine | 2007 |
Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Deletion; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Toxicity Tests; Treatment Outcome; Vidarabine | 2007 |
Oral fludarabine treatment of cutaneous infiltration in a patient with B-cell chronic lymphocytic leukaemia.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Skin; Treatment Outcome; Vidarabine | 2007 |
Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Injections, Intraperitoneal; Leukemia L1210; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Sulfonamides; Survival Analysis; Time Factors; Tumor Burden; Vidarabine; Weight Loss; Xenograft Model Antitumor Assays | 2007 |
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclosporine; Demyelinating Diseases; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Stem Cell Transplantation; Vidarabine | 2007 |
Improved outcome after relapse in children with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Cytogenetics; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Recurrence; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate; Sweden; Treatment Outcome; Vidarabine | 2007 |
Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.
Topics: Angioplasty, Balloon; Animals; Aorta; Cardiovascular Agents; Carotid Artery Injuries; Carotid Stenosis; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Feasibility Studies; Hyperplasia; Janus Kinase 2; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Prosthesis Design; Rabbits; Rats; Rats, Wistar; RNA, Antisense; STAT1 Transcription Factor; Stents; Time Factors; Transfection; Tunica Intima; Vidarabine | 2007 |
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Agents; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinopathies; Humans; Immunologic Deficiency Syndromes; Infant; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2007 |
Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
Topics: Academies and Institutes; Antineoplastic Agents; Aspergillosis; Cyclophosphamide; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Michigan; Middle Aged; Myeloablative Agonists; Neoplasms; Opportunistic Infections; Retrospective Studies; Review Literature as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Burkitt Lymphoma; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 8; Chromosomes, Human, X; Clone Cells; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Genes, myc; Humans; Karyotyping; Lymph Nodes; Lymphoma, AIDS-Related; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Mutagenesis, Insertional; Pleural Effusion, Malignant; Prednisone; Rituximab; Translocation, Genetic; Trisomy; Vidarabine; Vincristine | 2007 |
Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Blast Crisis; Chimera; Cord Blood Stem Cell Transplantation; Disease Progression; Fatal Outcome; Female; Graft Rejection; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Immunity, Maternally-Acquired; Isoantigens; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine | 2007 |
Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child, Preschool; Cyclophosphamide; Dyskeratosis Congenita; Female; Humans; Vidarabine | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Vidarabine | 2007 |
17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Chromosome Deletion; Chromosomes, Human, Pair 17; DNA (Cytosine-5-)-Methyltransferases; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine | 2007 |
Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: a study of 25 consecutive patients and a literature review.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; DNA (Cytosine-5-)-Methyltransferases; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Renal Cell; Colonic Neoplasms; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Rectal Neoplasms; Sarcoma; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome.
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Anti-Inflammatory Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisolone; Remission Induction; Sweet Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Allogeneic bone marrow transplantation for Pearson's syndrome.
Topics: Antifungal Agents; Antilymphocyte Serum; Antineoplastic Agents; Aspergillosis, Allergic Bronchopulmonary; Base Sequence; Bone Marrow Transplantation; DNA, Mitochondrial; Electron Transport; Female; Genetic Diseases, Inborn; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Leukemia, Myeloid; Melphalan; Mitochondrial Diseases; Myeloablative Agonists; Sequence Deletion; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine | 2007 |
Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Registries; Remission Induction; Retrospective Studies; Sarcoma; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Advances in CLL.
Topics: Antibodies, Monoclonal; Biomarkers; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Therapy, Combination; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 2007 |
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Red-Cell Aplasia, Pure; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2007 |
Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappaB signal pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cells, Cultured; Human T-lymphotropic virus 1; Humans; Lymphocyte Activation; NF-kappa B; Signal Transduction; T-Lymphocytes; Vidarabine | 2007 |
Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Caspases; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; Minor Histocompatibility Antigens; Proto-Oncogene Proteins c-bcl-2; Rituximab; RNA, Small Interfering; Tumor Cells, Cultured; Vidarabine; Vincristine | 2007 |
Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine.
Topics: Cell Transformation, Neoplastic; Female; Genes, Immunoglobulin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Vidarabine | 2007 |
Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.
Topics: Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lung; Male; Melphalan; Myeloablative Agonists; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome; Vidarabine | 2007 |
Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Etoposide; Female; Graft Survival; Histiocytosis, Langerhans-Cell; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Melphalan; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vinblastine | 2007 |
Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
Topics: Agammaglobulinemia; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Humans; Immunocompromised Host; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Opportunistic Infections; Skin Diseases, Bacterial; Vidarabine | 2007 |
Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Cell Activating Factor; B-Lymphocytes; Bone Marrow; Cell Lineage; Cells, Cultured; Cyclophosphamide; Cytokines; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lymphopoiesis; Middle Aged; Myelopoiesis; Neutropenia; Rituximab; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2007 |
Gene expression signatures that predict radiation exposure in mice and humans.
Topics: Animals; Cyclophosphamide; DNA; DNA Damage; Dose-Response Relationship, Radiation; Environmental Exposure; Female; Gene Expression; Gene Expression Profiling; Gene Regulatory Networks; Genes; Humans; Leukocytes, Mononuclear; Mass Screening; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Particle Accelerators; Radiation Dosage; Radiation Injuries, Experimental; Radiation, Ionizing; Sensitivity and Specificity; Single-Blind Method; Species Specificity; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Fluorescent Antibody Technique, Direct; Humans; Immunoglobulin A; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Paraneoplastic Syndromes; Pemphigus; Rituximab; Vidarabine | 2007 |
Dictyostelium discoideum salvages purine deoxyribonucleosides by highly specific bacterial-like deoxyribonucleoside kinases.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Deoxyribonucleosides; Dictyostelium; Gene Expression Regulation; Kinetics; Models, Molecular; Molecular Sequence Data; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Recombinant Proteins; Substrate Specificity; Vidarabine | 2007 |
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasms, Second Primary; Rituximab; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2008 |
Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation.
Topics: Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Enzyme Inhibitors; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; India; Male; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; beta-Thalassemia; Blood Group Incompatibility; Busulfan; Child, Preschool; Cyclosporine; Epstein-Barr Virus Infections; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Plasma Exchange; Red-Cell Aplasia, Pure; Remission, Spontaneous; Retrospective Studies; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2007 |
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Stem Cell Transplantation; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Combined Modality Therapy; Erythema Infectiosum; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Parvovirus B19, Human; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiography, Thoracic; Recurrence; Thiotepa; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Topics: Adolescent; Adult; Busulfan; Child; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia; Male; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
In vitro effect of fludarabine, cyclophosphamide, and cytosine arabinoside on chromosome breakage in Fanconi anemia patients: relevance to stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Cells, Cultured; Chromosome Breakage; Chromosome Fragility; Cyclophosphamide; Cytarabine; Fanconi Anemia; Female; Humans; Male; Myeloablative Agonists; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2007 |
Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Electrochemotherapy; Electroporation; Gene Transfer Techniques; Genes, Bacterial; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Neoplasms, Experimental; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Rats; Rats, Inbred Lew; RNA, Messenger; Vidarabine; Xenograft Model Antitumor Assays | 2007 |
Acquired hemophilia in chronic lymphocytic leukemia.
Topics: Aged; Autoantibodies; Cyclophosphamide; Factor VIII; Female; Hemophilia A; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Time Factors; Treatment Outcome; Vidarabine | 2007 |
Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cause of Death; Chi-Square Distribution; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Hepatitis; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Kaplan-Meier Estimate; Living Donors; Lymphocyte Depletion; Male; Middle Aged; Proportional Hazards Models; Reoperation; Retrospective Studies; Statistics, Nonparametric; Survival Analysis; Survival Rate; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prognosis; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
[Ulcers in a patient with chronic lymphocytic leukemia].
Topics: Antimetabolites, Antineoplastic; Ear Diseases; Ear, External; Hand Dermatoses; Herpes Simplex; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Skin Ulcer; Vidarabine | 2007 |
Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, T-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Medical Oncology; Mitoxantrone; Treatment Outcome; Vidarabine | 2007 |
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Topics: B-Lymphocytes; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Models, Biological; Polymerase Chain Reaction; Protein Tyrosine Phosphatases; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Reverse Transcriptase Polymerase Chain Reaction; Sulfites; Vidarabine | 2007 |
Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.
Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Factor VIII; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Hemophilia A; Humans; Mice; Swine; Transgenes; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cross-Linking Reagents; DNA; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrroles; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 2007 |
Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cytarabine; Directed Molecular Evolution; Drosophila melanogaster; Genes, Transgenic, Suicide; Genetic Therapy; Glioblastoma; Humans; Lethal Dose 50; Mutation; Neoplasms; Osteosarcoma; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Substrate Specificity; Transduction, Genetic; Vidarabine | 2007 |
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation; CD2 Antigens; CTLA-4 Antigen; Forkhead Transcription Factors; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Interferon-gamma; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Transplantation Chimera; Vidarabine | 2007 |
Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Alkylator-free conditioning regimen for patients with acquired aplastic anemia, transplanted from genetically identical twins.
Topics: Alkylating Agents; Anemia, Aplastic; Antineoplastic Agents; Contraindications; Female; Follow-Up Studies; Humans; Male; Myeloablative Agonists; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Twins, Monozygotic; Vidarabine | 2007 |
[Reactivation of familial hemophagocytic lymphohistiocytosis after non-myeloablative cord blood stem cell transplantation resulted in the early graft failure].
Topics: Antilymphocyte Serum; Child, Preschool; Cord Blood Stem Cell Transplantation; DNA; Female; Graft Rejection; Histocompatibility Testing; Humans; Killer Cells, Natural; Lymphocyte Activation; Lymphohistiocytosis, Hemophagocytic; Recurrence; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2007 |
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Busulfan; Cyclophosphamide; Cytomegalovirus Infections; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Combination therapies for previously untreated CLL.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Vidarabine | 2007 |
Regurgitation of esophageal mucosa.
Topics: Adult; Busulfan; Esophagitis; Esophagus; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucositis; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine; Vomiting | 2007 |
Paraneoplastic pemphigus associated with fludarabine use.
Topics: Antineoplastic Agents; Humans; Immunoglobulin G; Keratinocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine | 2007 |
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival.
Topics: Adolescent; Adult; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Fanconi Anemia; Female; Graft Survival; Histocompatibility Testing; Humans; Infant; Male; Middle Aged; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine | 2007 |
Diffuse large B-cell lymphoma developing following treatment of Waldenstrom's macroglobulinaemia: spontaneous resolution upon cessation of fludarabine.
Topics: Aged; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2007 |
Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Living Donors; Lymphocyte Depletion; Male; Melphalan; Multiple Organ Failure; Postoperative Complications; Reoperation; Retrospective Studies; Spain; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Wiskott-Aldrich Syndrome | 2007 |
[Visual cortes--is it a concern?].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Blindness, Cortical; Carmustine; Cathartics; Cholinergic Antagonists; Cisplatin; Cyclosporine; Dopamine Agents; Drug-Related Side Effects and Adverse Reactions; Hallucinations; Humans; Interferons; Serotonin Agents; Tacrolimus; Vidarabine; Vincristine; Visual Cortex | 2007 |
Fludarabine delivery by autologous red blood cells induces macrophage depletion in chronically SIV-infected Sooty Mangabeys.
Topics: Animals; Cercocebus atys; Dialysis; Drug Administration Schedule; Drug Delivery Systems; Erythrocytes; Macrophages; Phosphorylation; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Vidarabine; Viral Load | 2006 |
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemistry, Pharmaceutical; Drug Stability; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Mitoxantrone; Solubility; Vidarabine | 2008 |
Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Child; Dyskeratosis Congenita; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Male; Transplantation Conditioning; Vidarabine | 2007 |
Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Topics: Adult; Aged; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Extramedullary, extranodal lymphoplasmacytic lymphoma with macroglobulinemia: long-term complete remission with fludarabine.
Topics: Aged; Antineoplastic Agents; Humans; Lung Neoplasms; Male; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2007 |
Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Genes, p53; Humans; Isoelectric Point; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Mutation; Neoplasm Proteins; Peptide Fragments; Peptide Hydrolases; Phosphorylation; Protein Processing, Post-Translational; Protein Structure, Tertiary; Tumor Suppressor Protein p53; Vidarabine | 2008 |
CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; CD40 Ligand; Cell Proliferation; Cell Survival; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Mice; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine; Tumor Cells, Cultured; Vidarabine | 2007 |
Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.
Topics: Aged; Epstein-Barr Virus Infections; Everolimus; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Vidarabine | 2007 |
Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Opportunistic Infections; Toxoplasmosis, Cerebral; Vidarabine | 2007 |
[Allogenic transplantation of hemopoietic stem cells in low-intensity regimes in patients with hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Myeloablative Agonists; Risk; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
[Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Treatment Outcome; Vidarabine | 2007 |
Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Graft vs Host Disease; Humans; Male; Middle Aged; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
A novel regimen incorporating the concomitant administration of fludarabine and alemtuzumab for the treatment of refractory adult acute lymphoblastic leukaemia: a report of three cases.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Female; Humans; Male; Middle Aged; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Vidarabine | 2007 |
Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; DNA-Binding Proteins; Female; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Rituximab; Transcriptional Elongation Factors; Translocation, Genetic; Vidarabine | 2007 |
Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Disease-Free Survival; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphatic Irradiation; Middle Aged; Muromonab-CD3; Peripheral Blood Stem Cell Transplantation; Pneumonia; Retreatment; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Middle Aged; Rituximab; Vidarabine | 2008 |
Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prognosis; Purine Nucleotides; Risk Factors; Vidarabine | 2007 |
Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab--double jeopardy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Prognosis; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Male; Middle Aged; Models, Biological; Rituximab; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Aspergillosis; CD52 Antigen; Drug Evaluation; Drug Resistance, Neoplasm; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Records; Netherlands; Opportunistic Infections; Pneumonia, Pneumocystis; Remission Induction; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2007 |
[Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].
Topics: Aged; Amifostine; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Treatment Outcome; Vidarabine | 2007 |
[Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
Topics: Animals; Cyclophosphamide; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Models, Animal; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-bcl-2; Regulatory Elements, Transcriptional; RNA, Messenger; RNA, Neoplasm; Time Factors; Translocation, Genetic; Vidarabine | 2008 |
Fludarabine reduces survivability of HepG2 cells through VEGF under hypoxia.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Oxygen; Vascular Endothelial Growth Factor A; Vidarabine | 2007 |
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Topics: Aged; Alleles; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Cyclophosphamide; DNA Breaks, Double-Stranded; DNA-Binding Proteins; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine | 2007 |
Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis.
Topics: Adult; Aged; Cohort Studies; Colony-Stimulating Factors; Cyclophosphamide; Female; Finland; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Transplantation, Autologous; Treatment Failure; Vidarabine | 2008 |
Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Neoplasms; Vidarabine | 2007 |
Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2007 |
Have we forgotten the purpose of phase III studies?
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD52 Antigen; Chlorambucil; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Research Design; Vidarabine | 2007 |
Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Antilymphocyte Serum; Busulfan; Child; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Sex Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2007 |
Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Brefeldin A; Cell Line, Tumor; Cisplatin; Dactinomycin; Doxorubicin; Humans; Imatinib Mesylate; Interferons; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-mdm2; Pyrimidines; STAT1 Transcription Factor; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Fludarabine induces growth arrest and apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and decreases production of Th1 cytokines via inhibition of nuclear factor kappaB.
Topics: Apoptosis; Humans; Immunosuppressive Agents; Jurkat Cells; Leukocytes, Mononuclear; NF-kappa B; Signal Transduction; T-Lymphocytes; Th1 Cells; Tumor Necrosis Factor-alpha; Vidarabine | 2008 |
CD-34 selected hematopoetic stem cell transplantation from HLA identical family members for fanconi anemia.
Topics: Adolescent; Antigens, CD34; Antineoplastic Agents; Child; DNA (Cytosine-5-)-Methyltransferases; Fanconi Anemia; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Lymphocyte Depletion; Male; Recombinant Proteins; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2008 |
Cannabinoid receptors expression in bone marrow trephine biopsy of chronic lymphocytic leukaemia patients treated with purine analogues.
Topics: Antineoplastic Agents; B-Lymphocytes; Biopsy; Bone Marrow Cells; Cladribine; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Receptors, Cannabinoid; Vidarabine | 2007 |
Imatinib inhibition of fludarabine uptake in T-lymphocytes.
Topics: Antineoplastic Agents; Benzamides; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dose-Response Relationship, Drug; Drug Interactions; Humans; Imatinib Mesylate; In Vitro Techniques; Piperazines; Pyrimidines; Thioinosine; Vidarabine | 2008 |
Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; Chlorocebus aethiops; Drug Therapy; Humans; Lymphoma; Measles virus; Membrane Cofactor Protein; Mice; Mice, Transgenic; Prodrugs; Purine-Nucleoside Phosphorylase; Vero Cells; Vidarabine | 2007 |
Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.
Topics: Adult; Anemia, Sickle Cell; Directed Tissue Donation; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Kidney Failure, Chronic; Male; Myeloablative Agonists; Siblings; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group.
Topics: Adolescent; Adult; Child; Child, Preschool; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Male; Probability; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase Inhibitors; Caspases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Mice; Mitochondria; Mitochondrial Proteins; Protease Inhibitors; Receptors, IgE; Signal Transduction; Survival Rate; Tumor Cells, Cultured; Vidarabine; Xenograft Model Antitumor Assays | 2008 |
[MALT (mucosa-associated lymphoid tissue) lymphoma of the lacrimal gland].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Eye Neoplasms; Humans; Lacrimal Apparatus; Lymphoma, B-Cell, Marginal Zone; Male; Mitoxantrone; Rituximab; Vidarabine | 2007 |
Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients.
Topics: Adolescent; Antigens, CD34; Antineoplastic Agents; CD3 Complex; Child; Child, Preschool; Disease-Free Survival; Female; Graft vs Leukemia Effect; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Prospective Studies; Recurrence; Stem Cells; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Genes, APC; Genes, BRCA1; Genes, Tumor Suppressor; Humans; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Receptors, Retinoic Acid; Vidarabine | 2007 |
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Equilibrative Nucleoside Transporter 1; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Tetradecanoylphorbol Acetate; Vidarabine | 2008 |
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.
Topics: Apoptosis; B-Lymphocytes; Drug Screening Assays, Antitumor; Drug Synergism; Fatty Acids, Nonesterified; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lipid Metabolism; Lipoprotein Lipase; Multigene Family; Neoplasm Proteins; Orlistat; Phospholipases; Proto-Oncogene Proteins c-bcr; Tumor Cells, Cultured; Vidarabine | 2008 |
Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia.
Topics: Adolescent; Anemia, Aplastic; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Transplantation Conditioning; Vidarabine | 2008 |
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Topics: Adult; Aged; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Blast Crisis; Cell Cycle; Cell Line, Tumor; Chlorambucil; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperazines; Proto-Oncogene Proteins c-mdm2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Vidarabine | 2008 |
Invasive fungal sinusitis in patients treated with fludarabine.
Topics: Adolescent; Adult; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus flavus; Aspergillus fumigatus; Child; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucormycosis; Rhizopus; Sinusitis; Vidarabine | 2008 |
Therapeutic experience of Bing-Neel Syndrome associated with Waldenstrom's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Brain; Central Nervous System Diseases; Cranial Irradiation; Female; Humans; Middle Aged; Rituximab; Syndrome; Vidarabine; Waldenstrom Macroglobulinemia | 2007 |
Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.
Topics: Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biomarkers; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Rituximab; Serum Globulins; Vidarabine | 2008 |
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cytotoxicity, Immunologic; Humans; Interleukins; Membrane Proteins; Proto-Oncogene Proteins; Rituximab; STAT1 Transcription Factor; STAT5 Transcription Factor; Up-Regulation; Vidarabine | 2008 |
Switching of donor cells after urgent second cord blood transplantation for suspected graft failure.
Topics: Adult; Anti-Inflammatory Agents; Bone Marrow; Cord Blood Stem Cell Transplantation; Delayed Graft Function; Donor Selection; Female; Ferritins; Graft Survival; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Macrophages; Methylprednisolone; Myeloablative Agonists; Tissue Donors; Transplantation Conditioning; Vascular Diseases; Vidarabine | 2007 |
Graft-versus-myeloma effects in reduced-intensity cord blood transplantation.
Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Remission Induction; Retrospective Studies; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Long-term donor-specific tolerance in rat cardiac allografts by intrabone marrow injection of donor bone marrow cells.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Radiation; Graft Survival; Heart Transplantation; Injections; Rats; Rats, Inbred BN; Rats, Inbred F344; Time Factors; Transplantation Tolerance; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2008 |
Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
Topics: Adolescent; Adult; Aged; Aspergillosis; Bacteremia; Busulfan; Catheterization, Central Venous; Chronic Disease; Communicable Diseases; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pneumonia, Bacterial; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Successful treatment of chronic granulomatous disease with fludarabine-based reduced-intensity conditioning and unrelated bone marrow transplantation.
Topics: Bone Marrow Transplantation; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Chronic; Humans; Male; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2008 |
Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
Topics: Adult; Aged; Denmark; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Hospitalization; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Outpatient Clinics, Hospital; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Caspase 3; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Killer Cells, Natural; Leukemia; Stem Cells; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Vidarabine | 2008 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Thrombocytopenia; Vidarabine | 2007 |
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine | 2008 |
[Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fibroblast Growth Factor 2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vascular Endothelial Growth Factor A; Vidarabine | 2007 |
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Chromosome Deletion; Chromosomes, Human, Pair 17; Drug Resistance, Neoplasm; Enzyme Activation; Female; Free Radical Scavengers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Oxidative Stress; Oxides; Poly(ADP-ribose) Polymerases; Prognosis; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine | 2008 |
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
Topics: Acute Disease; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine | 2008 |
Successful bone marrow transplantation in a girl with Fanconi anemia and preterminal renal failure.
Topics: Bone Marrow Transplantation; Child, Preschool; Directed Tissue Donation; Fanconi Anemia; Female; Graft Survival; Graft vs Host Disease; Hemibody Irradiation; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Function Tests; Mycophenolic Acid; Siblings; Transplantation Chimera; Transplantation Conditioning; Vesico-Ureteral Reflux; Vidarabine | 2008 |
Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 2008 |
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Furans; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Nerve Tissue Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Potential role of a mismatched HLA-specific CTL clone developed pre-transplant in graft rejection following cord blood transplantation.
Topics: Clone Cells; Cord Blood Stem Cell Transplantation; Electroporation; Female; Graft Rejection; Histocompatibility Testing; HLA Antigens; HLA-A Antigens; HLA-B Antigens; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Leukemia, Myelomonocytic, Acute; Male; Melphalan; Middle Aged; Polymerase Chain Reaction; Receptors, Antigen, T-Cell; T-Lymphocytes, Cytotoxic; Transfection; Transplantation Chimera; Vidarabine | 2008 |
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; France; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Registries; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Time; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2008 |
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukocytes; Oligonucleotide Array Sequence Analysis; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; TCF Transcription Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Brain; Female; Gadolinium; Humans; Image Enhancement; Leukoencephalopathy, Progressive Multifocal; Lymphoproliferative Disorders; Magnetic Resonance Imaging; Middle Aged; Rituximab; Time; Vidarabine | 2008 |
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.
Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Immunologic Memory; Interferon-gamma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Vidarabine; Whole-Body Irradiation | 2008 |
Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Granulocytes; Humans; Hypoglycemic Agents; Leukocyte Count; Lymphoma, B-Cell, Marginal Zone; Male; Metformin; Neutropenia; Splenic Neoplasms; Vidarabine | 2008 |
Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.
Topics: Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Lysophospholipids; Multiple Myeloma; Mutagens; NF-kappa B; RNA, Messenger; Vascular Endothelial Growth Factor A; Vidarabine | 2008 |
A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
Topics: Administration, Oral; Busulfan; Child; Child, Preschool; Female; History, Ancient; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Pilot Projects; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.
Topics: Adult; Aged; Antineoplastic Agents; Chromatography, Liquid; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Male; Mass Spectrometry; Middle Aged; Phenotype; T-Lymphocytes; Vidarabine | 2009 |
Use of TAGVHD warnings in patients receiving purine analogue chemotherapy.
Topics: Blood Transfusion; Enzyme Inhibitors; Graft vs Host Disease; Health Policy; Humans; Retrospective Studies; Risk Factors; Transfusion Reaction; Vidarabine | 2008 |
Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future.
Topics: Administration, Oral; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Lysis Syndrome; Vidarabine | 2008 |
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Treatment Outcome; Tumor Lysis Syndrome; Urate Oxidase; Vidarabine | 2008 |
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation, Homologous; Vidarabine | 2008 |
Comparable engraftment and chimerism kinetics using oral and intravenous fludarabine as part of a reduced intensity conditioning regimen.
Topics: Administration, Oral; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Kinetics; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Retreatment with fludarabine and cyclosporine for one case of refractory pure red cell aplasia.
Topics: Adult; Cyclosporine; Female; Humans; Immunosuppressive Agents; Red-Cell Aplasia, Pure; Vidarabine | 2008 |
Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.
Topics: Adult; Agammaglobulinemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; CD4 Lymphocyte Count; Cyclophosphamide; Female; Humans; Immunocompromised Host; Immunoglobulin Class Switching; Immunoglobulins, Intravenous; Immunologic Memory; Immunophenotyping; Lymphoma, Follicular; Rituximab; Sinusitis; Vidarabine | 2008 |
Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Hypertension, Pulmonary; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Saudi Arabia; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Disease-Free Survival; Family; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Retrospective Studies; Time Factors; Transplantation, Homologous; Vidarabine | 2008 |
Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia.
Topics: Databases, Factual; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine | 2008 |
[Treatment of refractory severe autoimmune disease by combined therapy with Chinese drug and autohemopoietic stem cell transplantation].
Topics: Adolescent; Adult; Antilymphocyte Serum; Autoimmune Diseases; Combined Modality Therapy; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hematopoietic Stem Cell Transplantation; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Phytotherapy; Transplantation, Autologous; Treatment Outcome; Vidarabine; Young Adult | 2008 |
Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome.
Topics: Abnormalities, Multiple; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft vs Host Disease; Humans; Male; Melphalan; Pancreatic Diseases; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2008 |
Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Humans; Immunoblotting; Inhibitory Concentration 50; Kidney Tubules, Proximal; Membrane Transport Proteins; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 2009 |
Selective killing of Mycobacterium avium-infected macrophages by inhibition of phosphorylated signal transducer and activator of transcription type 1.
Topics: Antineoplastic Agents; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Macrophages; Mycobacterium avium; Phosphorylation; STAT1 Transcription Factor; Time Factors; Vidarabine | 2008 |
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
Topics: bcl-X Protein; Caspases; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Thiazoles; Tumor Cells, Cultured; Vidarabine | 2008 |
Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.
Topics: Antineoplastic Agents; Cell Division; Cells, Cultured; Coculture Techniques; Cytokines; Cytotoxicity Tests, Immunologic; Dose-Response Relationship, Drug; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Vidarabine | 2008 |
Irreversible visual loss and optic nerve dysfunction associated with central retinal vein occlusion in Waldenstrom Macroglobulinemia.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Male; Optic Nerve; Optic Nerve Diseases; Plasmapheresis; Prognosis; Retinal Vein; Risk Factors; Rituximab; Vidarabine; Vision, Low; Visual Acuity; Waldenstrom Macroglobulinemia | 2007 |
Severe prolonged immunosuppression following fludarabine and rituximab combination therapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Drug Therapy, Combination; Female; Humans; Immune Tolerance; Lymphatic Diseases; Middle Aged; Rituximab; Vidarabine | 2008 |
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
Topics: Antineoplastic Agents; Caspase 3; Cell Death; Cytochromes c; Drug Resistance, Neoplasm; Glutathione; Glutathione Peroxidase; Humans; In Vitro Techniques; Isothiocyanates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Oxidation-Reduction; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Vidarabine | 2008 |
Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403.
Topics: Aged; Antineoplastic Agents; Databases, Factual; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Neoplasms, Second Primary; Research Design; Sex Factors; Time Factors; Treatment Outcome; Vidarabine | 2008 |
Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Research Design; Treatment Outcome; Vidarabine | 2008 |
Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization.
Topics: Antineoplastic Agents; Bone Marrow; Cell Movement; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Endothelium, Vascular; Hematopoietic Stem Cells; Humans; Mesenchymal Stem Cells; Stromal Cells; Vidarabine | 2008 |
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Biomarkers, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulin Heavy Chains; In Vitro Techniques; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Prognosis; Proto-Oncogene Proteins c-bcl-2; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2008 |
Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells.
Topics: Animals; Antibodies; Antigens, CD; Apoptosis; Cattle; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Lymphoma; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Single-Blind Method; Vidarabine | 2008 |
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.
Topics: Adult; Antineoplastic Agents; Bacteremia; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Retrospective Studies; Risk Factors; Survival Rate; Vidarabine | 2008 |
Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cord Blood Stem Cell Transplantation; Cytarabine; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Kinetics; Male; Middle Aged; Risk Assessment; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Epstein-Barr virus reactivation is a potentially severe complication in chronic lymphocytic leukemia patients with poor prognostic biological markers and fludarabine refractory disease.
Topics: Adult; Aged; Biomarkers, Tumor; Drug Resistance, Neoplasm; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Vidarabine; Virus Activation | 2008 |
A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Prolymphocytic, B-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Rituximab; Vidarabine | 2009 |
Fludarabine based treatment caused improvement of anemia in a patient with T-cell LGL leukemia despite evidence of the persistence of the abnormal T-cell clone.
Topics: Aged; Anemia; Clone Cells; Female; Humans; Leukemia, T-Cell; Treatment Outcome; Vidarabine | 2008 |
Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calorimetry, Differential Scanning; Cell Survival; Cells, Cultured; Cladribine; Cyclophosphamide; DNA Damage; Drug Combinations; Drug Monitoring; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myeloid Cell Leukemia Sequence 1 Protein; Phase Transition; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2009 |
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; Benzothiazoles; Chlorambucil; Female; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitochondria; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Toluene; Transcription, Genetic; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Massive swelling of the cervical region: an uncommon manifestation of B cell chronic lymphocytic leukemia.
Topics: Adipose Tissue; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lipectomy; Lipomatosis, Multiple Symmetrical; Lymph Nodes; Middle Aged; Neck; Vidarabine | 2008 |
Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma.
Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Renal Dialysis; Transplantation Conditioning; Vidarabine | 2009 |
Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Female; Hematopoietic Stem Cells; HLA Antigens; Humans; Leukemia; Male; Middle Aged; Recurrence; Siblings; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2008 |
Images in haematology. Cerebral nocardiosis in a patient with lymphoplasmacytic lymphoma treated with fludarabine.
Topics: Aged, 80 and over; Antineoplastic Agents; Central Nervous System Bacterial Infections; Humans; Male; Nocardia Infections; Opportunistic Infections; Tomography, X-Ray Computed; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2008 |
Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Blood Component Removal; Bone Marrow Cells; Cell Culture Techniques; Cell Survival; Colony-Forming Units Assay; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Models, Biological; Nitrogen Mustard Compounds; Reference Values; Stem Cells; Vidarabine | 2009 |
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Myeloablative Agonists; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Leptin inhibits rosiglitazone-induced adipogenesis in murine primary adipocytes.
Topics: Adipocytes; Adipogenesis; Animals; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation; Leptin; Mice; Mice, Inbred C57BL; Phosphorylation; PPAR gamma; Rosiglitazone; Signal Transduction; STAT1 Transcription Factor; Thiazolidinediones; Time Factors; Vidarabine | 2008 |
Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytomegalovirus Infections; Diagnosis, Differential; Disease Progression; Epstein-Barr Virus Infections; Female; Genome, Viral; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Monitoring, Physiologic; Vidarabine | 2008 |
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult | 2009 |
Umbilical cord-blood transplantations from unrelated donors in patients with inherited metabolic diseases: Single-institute experience.
Topics: Administration, Oral; Busulfan; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Lysosomal Storage Diseases; Male; Methotrexate; Peroxisomal Disorders; Vidarabine | 2008 |
Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells.
Topics: Adult; Androstadienes; Animals; Benzaldehydes; Cell Line; Cell Proliferation; Cell Survival; CHO Cells; Chromosome Aberrations; Cricetinae; Cricetulus; DNA; DNA Breaks, Double-Stranded; DNA Ligases; DNA Repair; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fibroblasts; Foreskin; Humans; Lymphocytes; Male; Mitotic Index; S Phase; Vidarabine; Wortmannin | 2008 |
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; B-Lymphocytes; Cell Communication; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gossypol; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Stromal Cells; Tumor Cells, Cultured; Vidarabine | 2009 |
Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Chimerism; Cyclophosphamide; Follow-Up Studies; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Kaplan-Meier Estimate; Male; Melphalan; Postoperative Complications; Pulmonary Aspergillosis; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Caspase 2; Cell Line, Tumor; Cytosol; DNA Damage; DNA Repair; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Leukemia; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine | 2008 |
Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Topics: Animals; Cyclophosphamide; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Injections, Intraperitoneal; Kinetics; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Living Donors; Lymphocyte Transfusion; Male; Metabolic Diseases; Prospective Studies; Retrospective Studies; Severe Combined Immunodeficiency; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2008 |
Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction.
Topics: Adult; Aged; Antineoplastic Agents; Cyclosporine; Disease-Free Survival; Female; Glomerular Filtration Rate; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Middle Aged; Mycophenolic Acid; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2008 |
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Equilibrative-Nucleoside Transporter 2; Female; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphoric Monoester Hydrolases; Tumor Cells, Cultured; Vidarabine | 2008 |
Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mitoxantrone; Panniculitis; Skin Neoplasms; Vidarabine | 2008 |
Thalidomide induces phosphorylation of histone H2AX and increases rate of apoptosis caused by fludarabine in malignant lymphocytes of chronic lymphocytic leukemia in short-term cell cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Culture Techniques; Drug Synergism; Fluorescent Antibody Technique; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Phosphorylation; Thalidomide; Tumor Cells, Cultured; Vidarabine | 2009 |
Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Female; Graft Rejection; Humans; Immunosuppressive Agents; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2009 |
Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT.
Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Fetal Blood; Humans; Male; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Recurrence; Vidarabine | 2009 |
[First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment].
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cyclophosphamide; Drug Costs; Frail Elderly; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloablative Agonists; Opportunistic Infections; Risk Factors; Rituximab; Vidarabine | 2009 |
Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Blotting, Western; Cladribine; Drug Synergism; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Confocal; Middle Aged; Reactive Oxygen Species; Tumor Cells, Cultured; Valproic Acid; Vidarabine | 2009 |
Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Hepatitis B, Chronic; Humans; Liver; Liver Failure, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Rituximab; Vidarabine | 2008 |
Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Gene Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2009 |
Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Survival; Chlorambucil; Cytotoxicity Tests, Immunologic; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Statistics, Nonparametric; Thiazoles; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
Topics: Antineoplastic Agents; Apoptosis; Cell Communication; Cell Division; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Hedgehog Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligodeoxyribonucleotides, Antisense; Signal Transduction; Stromal Cells; Transcription Factors; Vidarabine; Zinc Finger Protein GLI1 | 2008 |
Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine | 2009 |
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Rituximab; Treatment Outcome; Vidarabine | 2009 |
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Flow Cytometry; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymerase Chain Reaction; Remission Induction; Rituximab; Vidarabine | 2009 |
The combined use of Flu/ATG in nonmyeloablative SCT for severe aplastic anemia with multiple earlier transfusions.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine | 2008 |
The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
Topics: Antineoplastic Agents; CD40 Ligand; Cytoprotection; DNA; Drug Synergism; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Prognosis; Sesquiterpenes; Vidarabine | 2008 |
Radiosensitization by inhibiting STAT1 in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Humans; Kidney Neoplasms; Radiation-Sensitizing Agents; STAT1 Transcription Factor; Vidarabine | 2009 |
HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood-brain barrier: modulatory effects of STAT1 signaling.
Topics: AIDS Dementia Complex; Blood-Brain Barrier; Brain; Cell Adhesion; Cell Movement; Cells, Cultured; Chromones; Cytokines; Endothelial Cells; Enzyme Inhibitors; Flavonoids; HIV Envelope Protein gp120; HIV-1; Humans; Interleukin-6; Interleukin-8; Microvessels; Mitogen-Activated Protein Kinase Kinases; Models, Neurological; Monocytes; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; STAT1 Transcription Factor; Vidarabine | 2009 |
Oxidative stress and delta-ALA-D activity in different conditioning regimens in allogeneic bone marrow transplantation patients.
Topics: Adult; Antioxidants; Ascorbic Acid; Bone Marrow Transplantation; Catalase; Cyclophosphamide; Enzyme Activation; Female; Humans; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Porphobilinogen Synthase; Superoxide Dismutase; Vidarabine | 2009 |
Dasatinib induces a response in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Dasatinib; Female; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Jejunal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Rituximab; src-Family Kinases; Thiazoles; Tomography, X-Ray Computed; Vidarabine | 2009 |
Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cyclosporine; Female; Glomerular Filtration Rate; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Premedication; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2009 |
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Myeloablative Agonists; Ovary; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Leukemia; Male; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2009 |
Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Cytarabine; Cytochrome P-450 CYP3A; Drug Delivery Systems; Infusions, Intravenous; Liver; Liver Neoplasms; Male; Mice; Nucleosides; Prodrugs; Thymidine; Tissue Distribution; Vidarabine | 2009 |
Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity.
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Cell Line, Tumor; Chlorambucil; Cytotoxins; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Formazans; Glucosyltransferases; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Chemical; Molecular Structure; Tetrazolium Salts; Vidarabine | 2009 |
Chronic lymphocytic leukaemia: current first-line therapy.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2009 |
Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.
Topics: Adrenal Cortex Hormones; Annexin A5; Apoptosis; Chlorambucil; Down-Regulation; Flow Cytometry; Gene Expression Regulation, Enzymologic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Plasmids; Prognosis; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Syk Kinase; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2009 |
T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Prednisone; Vidarabine; Vincristine | 2010 |
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
Topics: ADAM Proteins; Antineoplastic Agents; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; DNA Mutational Analysis; Gene Expression Regulation, Neoplastic; Genes, Immunoglobulin Heavy Chain; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lipoprotein Lipase; Mutation; Remission Induction; Treatment Outcome; Vidarabine | 2009 |
Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Prospective Studies; Risk Factors; Stomatitis; Transplantation Conditioning; Vidarabine; Young Adult | 2009 |
Assessment of bone marrow response in Waldenström's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Flow Cytometry; Humans; Immunoglobulin M; Immunohistochemistry; Male; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Chlorambucil; Cladribine; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Prognosis; Time Factors; Tumor Cells, Cultured; Vidarabine | 2009 |
Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pancytopenia; Vidarabine | 2009 |
A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Conflict of Interest; Cost-Benefit Analysis; Cross-Over Studies; Cyclophosphamide; Disease-Free Survival; Drug Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Practice Guidelines as Topic; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Vidarabine | 2009 |
Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Receptors, Tumor Necrosis Factor; Risk Factors; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha; Vidarabine | 2009 |
Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antigens, Viral; Bone Marrow Transplantation; Busulfan; Cytomegalovirus Infections; Disease Susceptibility; Female; Humans; Immunosuppressive Agents; Incidence; Intestinal Mucosa; Japan; Male; Middle Aged; Myeloablative Agonists; Postoperative Complications; Radiation Injuries; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2009 |
Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.
Topics: Adult; Aged; Anthracyclines; Arrhythmias, Cardiac; Busulfan; Female; Heart Diseases; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2010 |
FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Autoimmune Diseases; Bone Marrow Transplantation; Forkhead Transcription Factors; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin E; Infant; Interleukin-7 Receptor alpha Subunit; Male; Melphalan; T-Lymphocytes, Regulatory; Transplantation Conditioning; Vidarabine; X-Linked Combined Immunodeficiency Diseases | 2009 |
Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Myeloablative Agonists; Positron-Emission Tomography; Severity of Illness Index; Time Factors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2010 |
Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2009 |
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting.
Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Donors; Busulfan; Catheter Ablation; Cost-Benefit Analysis; Cyclophosphamide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mexico; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bendamustine Hydrochloride; Cyclophosphamide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Mitochondria; Nitrogen Mustard Compounds; Nuclear Proteins; Proto-Oncogene Proteins; Purine Nucleosides; Pyrimidinones; Rituximab; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2009 |
Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Clinical Protocols; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2010 |
Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.
Topics: Adolescent; Adult; Area Under Curve; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2010 |
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2009 |
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Caspase 3; Cell Line, Tumor; Curcumin; Gene Expression Profiling; Humans; Immunoglobulin Variable Region; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Oxazines; Phosphorylation; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Syk Kinase; Vidarabine | 2009 |
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
Topics: Adult; Aged; Alleles; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Early Termination of Clinical Trials; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Haplotypes; Humans; Infections; Lymphoma, Follicular; Lymphopenia; Male; Mannose-Binding Lectin; Middle Aged; Multicenter Studies as Topic; Neutropenia; Prospective Studies; Risk; Rituximab; Spain; Vidarabine; Young Adult | 2009 |
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.
Topics: Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cohort Studies; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Rabbits; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality of Life; Survival Analysis; Technology Assessment, Biomedical; Vidarabine | 2009 |
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
Topics: Animals; CD4-Positive T-Lymphocytes; CD40 Antigens; CD8-Positive T-Lymphocytes; Clone Cells; Cytotoxicity, Immunologic; Female; Flow Cytometry; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Mice; Middle Aged; Minor Histocompatibility Antigens; Myeloablative Agonists; NIH 3T3 Cells; T-Lymphocytes; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
Diagnosis by sheer coincidence.
Topics: Aged; Antineoplastic Agents; Diuretics; Echocardiography, Doppler; Female; Heart Failure; Hodgkin Disease; Humans; Incidental Findings; Pulmonary Subvalvular Stenosis; Tomography, X-Ray Computed; Transposition of Great Vessels; Vidarabine | 2009 |
Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.
Topics: Adolescent; Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Successful allo-SCT in a Fanconi anemia patient with renal impairment using reduced doses of CY and fludarabine.
Topics: Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Humans; Renal Insufficiency; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2010 |
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancytopenia; Prevalence; Retrospective Studies; Thrombocytopenia; Time Factors; Vidarabine | 2010 |
Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bone Marrow Diseases; Cell Lineage; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Rituximab; Vidarabine | 2009 |
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; bcl-X Protein; Biphenyl Compounds; Dexamethasone; Doxorubicin; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Mimicry; Nitrophenols; Piperazines; Prognosis; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Vidarabine | 2009 |
A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Topics: 1-Propanol; Acetonitriles; Antimetabolites, Antineoplastic; Capecitabine; Chemical Precipitation; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Floxuridine; Fluorouracil; Furans; Humans; Linear Models; Pyrimidines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Trichloroacetic Acid; Uracil; Vidarabine | 2010 |
Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Diseases; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Interferon-alpha; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Retrospective Studies; Rituximab; Vidarabine; Vincristine | 2009 |
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Aged; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2009 |
Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Male; Middle Aged; Mycophenolic Acid; Pancreatic Neoplasms; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Tumor Necrosis Factor-alpha; Vidarabine; Whole-Body Irradiation | 2009 |
Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; DNA Mutational Analysis; Frameshift Mutation; Gene Expression Regulation, Leukemic; Genes, p53; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Neoplasm Proteins; Prognosis; Rituximab; Survival Analysis; Tumor Suppressor Protein p53; Vidarabine | 2009 |
Lymphoplasmacytic lymphoma with IgA hypergammaglobulinemia and liver involvement.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antirheumatic Agents; Cyclophosphamide; Female; Humans; Hypergammaglobulinemia; Immunoglobulin A; Immunologic Factors; Liver Diseases; Rituximab; Thailand; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cell Survival; Cells, Cultured; Cladribine; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclophosphamide; Drug Synergism; Female; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Vidarabine | 2009 |
Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.
Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Living Donors; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Examination; Dermatitis, Exfoliative; Diagnostic Errors; Erythema; Fatal Outcome; Humans; Immunophenotyping; Leukemia, Prolymphocytic, T-Cell; Leukemic Infiltration; Male; Prednisone; Skin; T-Lymphocytes; Treatment Failure; Vidarabine | 2009 |
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Child; Chronic Disease; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Feasibility Studies; Humans; Immunotherapy; Infections; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2009 |
Renal dysfunction due to leukemic infiltration of kidneys in a case of chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Middle Aged; Prednisolone; Renal Dialysis; Renal Insufficiency; Ultrasonography; Vidarabine | 2010 |
Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Death; Cladribine; Cohort Studies; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2009 |
[Brucella bacteremia reactivation 70 years after the primary infection].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Brucella melitensis; Brucellosis; Combined Modality Therapy; Cyclophosphamide; Doxycycline; Drug Therapy, Combination; Female; France; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Lymphoma, Non-Hodgkin; Recurrence; Rifampin; Rituximab; Spain; Time Factors; Vidarabine | 2010 |
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Disease-Free Survival; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Caspase 8; DNA (Cytosine-5-)-Methyltransferases; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunoblotting; Immunoglobulin Heavy Chains; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microtubules; Middle Aged; Oxazepines; Prognosis; Pyrroles; Tubulin; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2009 |
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemotherapy, Adjuvant; Dasatinib; Humans; Immunosuppressive Agents; Leukemia; Male; Philadelphia Chromosome; Pyrimidines; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
[Clinical analysis of 14 patients with lymphoma associated hemophagocytic syndrome].
Topics: Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Prognosis; Retrospective Studies; Treatment Outcome; Vidarabine | 2009 |
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.
Topics: Antineoplastic Agents; Blotting, Western; DNA Damage; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gene Silencing; Genes, p53; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 2009 |
Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression.
Topics: Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Cell Survival; Cells, Cultured; Female; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysophospholipids; Male; Middle Aged; Receptors, Lysophosphatidic Acid; Receptors, Purinergic P2; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Vascular Endothelial Growth Factor A; Vidarabine | 2009 |
Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
Topics: Administration, Oral; Adult; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Half-Life; Heart Rate; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Chemical; Vidarabine; Vidarabine Phosphate | 2010 |
Keratotic vascular papules over the feet: a case of Waldenström's macroglobulinaemia-associated cutaneous macroglobulinosis.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Diagnosis, Differential; Fluorescent Antibody Technique, Direct; Foot Diseases; Humans; Immunoglobulin M; Keratosis; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Survival; Cells, Cultured; Cladribine; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Cyclophosphamide; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Purines; Roscovitine; Vidarabine | 2010 |
Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Vidarabine | 2009 |
Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Activation; Young Adult | 2010 |
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Rituximab; Vidarabine | 2010 |
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
[Conditioning regimen containing fludarabine instead of cyclophosphamide for haploidentical hematopoietic stem cell transplantation].
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2010 |
Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Blotting, Western; Caspase 3; Caspase 9; Cell Separation; Drug Synergism; Enzyme Activation; Female; Flow Cytometry; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Vidarabine | 2010 |
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Cyclophosphamide; Drug Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Risk; Rituximab; Thalidomide; Treatment Outcome; Vidarabine | 2010 |
Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.
Topics: Female; Graft vs Host Disease; Humans; Janus Kinase 2; Melphalan; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2009 |
CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Autoimmunity; CD40 Ligand; Cells, Cultured; Cladribine; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Vidarabine | 2010 |
Progressive multifocal leukencephalopathy and cerebral toxoplasmosis in a patient with CLL.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Humans; Immunocompromised Host; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Rituximab; Toxoplasmosis, Cerebral; Vidarabine; Virus Activation | 2010 |
Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Caspase Inhibitors; Cytoskeleton; Dexamethasone; Flow Cytometry; Fluorescent Antibody Technique; HL-60 Cells; Humans; Isoenzymes; Jurkat Cells; Mitoxantrone; Octoxynol; Protein Kinase C; Protein Kinase C-theta; Protein Multimerization; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrin; Vidarabine; Vimentin | 2010 |
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
Topics: Adolescent; Adult; Age Factors; Aged; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Inhibition of STAT1 accelerates bone fracture healing.
Topics: Animals; Bony Callus; Calcification, Physiologic; Chlorocebus aethiops; Core Binding Factor Alpha 1 Subunit; COS Cells; Disease Models, Animal; Enzyme Inhibitors; Fracture Healing; Gene Expression; Mice; Mice, Mutant Strains; Osteoblasts; Osteogenesis; Sp7 Transcription Factor; STAT1 Transcription Factor; Tibial Fractures; Transcription Factors; Vidarabine | 2010 |
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.
Topics: Adult; Aged; Antigens, CD19; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cancer Vaccines; CD40 Ligand; CD5 Antigens; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Female; Humans; Hyaluronan Receptors; Immunization; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; T-Lymphocytes, Cytotoxic; Vidarabine | 2010 |
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
Topics: Age Factors; Aged; Aging; Blood Donors; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine | 2010 |
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Feasibility Studies; Female; Haplotypes; Humans; Immunotherapy; Infant; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prognosis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Remission Induction; Vidarabine; Young Adult | 2010 |
Natural pregnancy and delivery after unrelated bone marrow transplantation using fludarabine-based regimen in a Fanconi anemia patient.
Topics: Bone Marrow Transplantation; Child; Delivery, Obstetric; Fanconi Anemia; Female; Fertility; Humans; Myeloablative Agonists; Pregnancy; Pregnancy Outcome; Vidarabine; Young Adult | 2010 |
[Correlation of deoxycytidine kinase gene expression with fludarabine resistance in patients with chronic lymphocytic leukemia].
Topics: Aged; Aged, 80 and over; Case-Control Studies; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2010 |
Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
Topics: Adult; Aged; Aging; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Severity of Illness Index; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2010 |
Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.
Topics: Adult; Aged; Aging; Antilymphocyte Serum; beta 2-Microglobulin; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2010 |
All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.
Topics: Antineoplastic Agents; Autocrine Communication; Cell Membrane; Cytosol; Enzyme Activation; HeLa Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Promyelocytic, Acute; Membrane Transport Proteins; Mitogen-Activated Protein Kinase 3; Protein Transport; rhoA GTP-Binding Protein; Transcription, Genetic; Transforming Growth Factor beta1; Tretinoin; Vidarabine | 2010 |
Clinical and imaging features of fludarabine neurotoxicity.
Topics: Adult; Antineoplastic Agents; Brain; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurotoxicity Syndromes; Vidarabine | 2010 |
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
Topics: Adolescent; Antigens, CD19; Antineoplastic Agents; CD3 Complex; Child; Child, Preschool; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2010 |
Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; Biomarkers; Bone Marrow Cells; Caspase 3; Chronic Disease; Cladribine; Disease Progression; Enzyme Activation; Humans; Leukemia, Lymphoid; Membrane Glycoproteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
Rapid vision loss associated with fludarabine administration.
Topics: Antineoplastic Agents; Blindness; Brain Diseases; Electroretinography; Evoked Potentials, Visual; Fatal Outcome; Female; Humans; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Myeloablative Agonists; Retina; Retinal Diseases; Retrospective Studies; Vidarabine; Young Adult | 2010 |
In defence of the use of modern chemotherapy regimens for the treatment of patients with chronic lymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2009 |
Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Chimerism; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Myeloablative Agonists; T-Lymphocytes; Transplantation Conditioning; Transplantation, Heterologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
Topics: Aged; Apoptosis; Female; Hemoglobins; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Leukocytes, Mononuclear; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Platelet Count; Vidarabine | 2008 |
Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caspase 3; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mitochondria; Piperazines; Pyrimidines; Vidarabine | 2010 |
Haemophagocytic syndrome and Hodgkin's disease variant of Richter's syndrome after fludarabine for CLL.
Topics: Aged; Antineoplastic Agents; Epstein-Barr Virus Infections; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Male; Vidarabine | 2010 |
Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Cohort Studies; Female; Follow-Up Studies; Genotype; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Minor Histocompatibility Antigens; Polymorphism, Single Nucleotide; Proportional Hazards Models; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Diseases; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Severity of Illness Index; Vidarabine | 2010 |
A rare occurrence of hairy cell leukemia in the Thai population: a case report.
Topics: Adult; Antineoplastic Agents; Asian People; Bone Marrow; Cyclophosphamide; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Hairy Cell; Male; Splenectomy; Treatment Outcome; Vidarabine | 2010 |
Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease.
Topics: Age of Onset; Anti-Bacterial Agents; Antibodies, Monoclonal; Child; Drug Therapy, Combination; Gene Deletion; Granulomatous Disease, Chronic; Humans; Inflammatory Bowel Diseases; Male; NADPH Oxidases; Steroids; Treatment Outcome; Vidarabine | 2010 |
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chronic Disease; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Living Donors; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Drug-induced immune hemolytic anemia.
Topics: Anemia, Hemolytic; Anti-Bacterial Agents; Antineoplastic Agents; Cefotetan; Ceftriaxone; Coombs Test; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperacillin; Vidarabine | 2010 |
Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells.
Topics: Adenosine; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cholecalciferol; Cladribine; DNA Methylation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Receptors, Retinoic Acid; Resveratrol; Stilbenes; Transcriptional Activation; Tretinoin; Vidarabine | 2010 |
Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia.
Topics: Actinomycetales Infections; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; CD4 Lymphocyte Count; Chronic Disease; Female; Humans; Leukemia, Lymphoid; Lymphopenia; Opportunistic Infections; Pneumonia, Bacterial; Rhodococcus equi; Vidarabine | 2010 |
Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunomodulation; Immunotherapy; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Rituximab; Survival Rate; Vidarabine | 2010 |
[Female case of successful engraftment after PBSCT from her HLA-haploidentical son for severe aplastic anemia during maintenance peritoneal dialysis].
Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Cyclophosphamide; Female; Graft Survival; Haploidy; HLA Antigens; Humans; Immunosuppressive Agents; Middle Aged; Nuclear Family; Peripheral Blood Stem Cell Transplantation; Peritoneal Dialysis, Continuous Ambulatory; Rabbits; Severity of Illness Index; Tacrolimus; Transplantation Conditioning; Vidarabine | 2010 |
Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Genes, myc; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Vidarabine | 2010 |
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Europe; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
Topics: Adolescent; Adult; Busulfan; Drug Therapy, Combination; Feasibility Studies; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.
Topics: ADP-ribosyl Cyclase 1; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Proteins; Cladribine; DNA-Binding Proteins; Enzyme Activation; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Simvastatin; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Chromosome Mapping; Chromosomes, Human, X; Cyclophosphamide; Dystrophin; Follow-Up Studies; Gene Deletion; Gene Expression Regulation; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Male; Muscular Dystrophy, Duchenne; Reoperation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2010 |
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
Topics: Adult; Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine; Vindesine | 2010 |
Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Confidence Intervals; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Choice of immunosuppression influences cytomegalovirus DNAemia in cynomolgus monkey (Macaca fascicularis) islet allograft recipients.
Topics: Analgesics, Non-Narcotic; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus; Daclizumab; DNA, Viral; Ganciclovir; Humans; Immunoglobulin G; Immunosuppressive Agents; Islets of Langerhans Transplantation; Leukocytes; Macaca fascicularis; Organometallic Compounds; Organophosphorus Compounds; Retrospective Studies; Sirolimus; T-Lymphocytes; Tacrolimus; Transplantation, Homologous; Valganciclovir; Vidarabine | 2010 |
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Fever; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neutropenia; Pneumonia; Treatment Outcome; United States; United States Food and Drug Administration; Vidarabine | 2010 |
LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.
Topics: Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prognosis; Purines; Tumor Necrosis Factor-alpha; Vidarabine | 2010 |
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Female; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Treatment Outcome; Vidarabine | 2011 |
High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine | 2010 |
Auer rod-like inclusions in a low-grade B-cell leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Separation; Cyclophosphamide; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Inclusion Bodies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Electron, Transmission; Middle Aged; Rituximab; Vidarabine | 2010 |
HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus.
Topics: Antineoplastic Agents; Blood Transfusion; Disease Transmission, Infectious; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine; Virus Activation | 2010 |
Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.
Topics: Adolescent; Cell Separation; Child; Cyclosporine; Flow Cytometry; Forkhead Transcription Factors; Genetic Diseases, X-Linked; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Infant; Male; Mycophenolic Acid; Myeloablative Agonists; Reverse Transcriptase Polymerase Chain Reaction; Syndrome; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2010 |
Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.
Topics: Adult; Aged, 80 and over; Apoptosis; Cells, Cultured; Drug Synergism; fas Receptor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Quercetin; Receptors, Death Domain; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Vidarabine | 2010 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
[Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Humans; Immunophenotyping; Leukemia, Prolymphocytic, B-Cell; Male; Prognosis; Rituximab; Treatment Outcome; Vidarabine | 2010 |
Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
Topics: Adult; Aged; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Prednisone; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2011 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; Cells, Cultured; Chlorocebus aethiops; Cyclophosphamide; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Measles virus; Mice; Mice, SCID; Molecular Targeted Therapy; Oncolytic Viruses; Salvage Therapy; Tumor Burden; Vero Cells; Vidarabine; Xenograft Model Antitumor Assays | 2010 |
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2011 |
Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT.
Topics: Adult; Aged; Cyclosporine; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Male; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2011 |
Effect of FCGR2A and FCGR3A variants on CLL outcome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Genotype; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, IgG; Rituximab; Treatment Outcome; Vidarabine | 2010 |
Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL).
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Czech Republic; Disease Management; Female; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2010 |
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Treatment Outcome; Vidarabine | 2011 |
Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
Topics: ADP-ribosyl Cyclase 1; Adult; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Proteins; Cladribine; DNA-Binding Proteins; Drug Therapy, Combination; Enzyme Activation; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Membrane Glycoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Resveratrol; Stilbenes; Tumor Suppressor Proteins; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2011 |
Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation.
Topics: Administration, Oral; Adult; Animals; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Female; Forced Expiratory Volume; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lung; Male; Middle Aged; Myeloablative Agonists; Pulmonary Diffusing Capacity; Rabbits; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vital Capacity | 2011 |
Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Agents; Blood Platelets; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Neutrophils; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
Topics: Adjuvants, Immunologic; Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; Cell Communication; Coculture Techniques; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Proteins; Receptors, CXCR4; Rituximab; Stromal Cells; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured; Vidarabine | 2010 |
Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Repair; Drug Synergism; Humans; Hydroxylamines; Leukemia, Lymphocytic, Chronic, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Uracil-DNA Glycosidase; Vidarabine | 2010 |
B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Separation; Coloring Agents; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Phenotype; Recombinant Proteins; Rituximab; Vidarabine | 2010 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Thailand; Vidarabine; Young Adult | 2010 |
What's new in Waldenström macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.
Topics: Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Humans; Longitudinal Studies; Lymphocyte Count; Male; Melphalan; Multivariate Analysis; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2011 |
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2010 |
Biclonal follicular lymphoma: histological, clinical and molecular characteristics.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosome Breakpoints; Clone Cells; Dexamethasone; Female; Gene Rearrangement; Genes, bcl-2; Humans; Lymphoma, Follicular; Mitoxantrone; Molecular Sequence Data; Neoplasm Staging; Polymerase Chain Reaction; Vidarabine | 2010 |
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Male; Middle Aged; Myeloablative Agonists; T-Lymphocyte Subsets; T-Lymphocytes; Vidarabine | 2011 |
Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Assessment; Vidarabine | 2010 |
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.
Topics: Adult; Cord Blood Stem Cell Transplantation; Cryopreservation; Disease-Free Survival; Female; Graft Rejection; Graft vs Host Disease; HLA Antigens; Humans; Lymphocyte Count; Male; Middle Aged; Prospective Studies; Recurrence; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2011 |
Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative dis
Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Cell Transformation, Neoplastic; Clone Cells; Epstein-Barr Virus Infections; Fatal Outcome; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Immunoblastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Plasma Cells; Vidarabine | 2010 |
Chronic lymphocytic leukaemia--moving towards cure?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Time Factors; Treatment Outcome; Vidarabine | 2010 |
Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Survival Rate; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
Topics: Area Under Curve; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Disorders; Cyclophosphamide; Humans; Male; Middle Aged; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
Topics: Acute Disease; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lung; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Clofarabine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine | 2011 |
Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Survival Rate; T-Lymphocytes; Thymus Gland; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; CD40 Antigens; Cisplatin; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2011 |
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Drug Combinations; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Prognosis; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vidarabine; Young Adult | 2011 |
Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia.
Topics: Aged; Angiomatosis, Bacillary; Anti-Bacterial Agents; Antineoplastic Agents; Bacteriological Techniques; Bartonella quintana; Drug Therapy; Female; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Microscopy; Osteomyelitis; Treatment Failure; Vidarabine | 2011 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2010 |
High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.
Topics: Antiviral Agents; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Neuralgia, Postherpetic; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Activation | 2011 |
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine Kinase; DNA Mutational Analysis; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphoma, Follicular; Lymphopenia; Neutropenia; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Vidarabine | 2011 |
Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita.
Topics: Antilymphocyte Serum; Cyclosporine; Dyskeratosis Congenita; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Male; Mycophenolic Acid; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine Kinase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Follicular; Lymphopenia; Neutropenia; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Treatment Outcome; Vidarabine | 2011 |
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.
Topics: Age Factors; Aged; Antilymphocyte Serum; Busulfan; Comorbidity; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Stem cell transplantation using non-myeloablative conditioning regimen with fludarabine for hematological malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Vidarabine | 2010 |
Alloreactive natural killer cells promote haploidentical hematopoietic stem cell transplantation by expansion of recipient-derived CD4(+) CD25(+) regulatory T cells.
Topics: Animals; CD4-Positive T-Lymphocytes; Cyclophosphamide; Dendritic Cells; Female; Hematopoietic Stem Cell Transplantation; Immunotherapy, Adoptive; Interleukin-2 Receptor alpha Subunit; Killer Cells, Natural; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred C57BL; T-Lymphocytes, Regulatory; Thymus Gland; Transplantation Conditioning; Transplantation Tolerance; Transplantation, Homologous; Vidarabine | 2011 |
Unrelated donor transplantation for acute myelogenous leukemia in first remission.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Salvage Therapy; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Flow Cytometry; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Receptors, CXCR4; Survival Analysis; Tumor Cells, Cultured; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2011 |
Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Topics: Adult; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Reoperation; Republic of Korea; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vidarabine | 2010 |
Diagnostic and therapeutic challenges.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymph Nodes; Male; Middle Aged; Retinal Neoplasms; Rituximab; Splenomegaly; Tomography, X-Ray Computed; Vidarabine; Vision, Low; Visual Acuity; Vitreoretinopathy, Proliferative; Vitreous Hemorrhage | 2011 |
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Aza Compounds; Base Sequence; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Genes, p53; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mutation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF; Vidarabine | 2011 |
The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Drug Synergism; Female; Graft Survival; Graft vs Host Disease; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Lymphocyte Depletion; Mice; Mice, Inbred BALB C; Pentostatin; Transplantation Chimera; Transplantation, Homologous; Vidarabine | 2011 |
Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes.
Topics: Adult; Aged; Area Under Curve; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2011 |
Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).
Topics: Adolescent; Adult; Busulfan; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring.
Topics: Busulfan; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Maximum Tolerated Dose; Monitoring, Physiologic; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immune System; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 2011 |
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medi
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; European Union; Female; Health Services; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Practice Guidelines as Topic; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Enzyme Activation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proliferating Cell Nuclear Antigen; Proteasome Endopeptidase Complex; Purine Nucleosides; Tumor Suppressor Protein p53; Ubiquitination; Up-Regulation; Vidarabine | 2011 |
Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cladribine; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Humans; Lymphoma, B-Cell; Mitochondria; Molecular Chaperones; Proteome; Purines; Vidarabine | 2011 |
Synthesis and biological properties of the cytotoxic 14-membered macrolides aspergillide A and B.
Topics: Antineoplastic Agents; Aspergillus; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Inhibitory Concentration 50; Macrolides; Marine Biology; Molecular Structure; Stereoisomerism; Vidarabine | 2011 |
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.
Topics: Adult; Aged; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Nod2 Signaling Adaptor Protein; Polymorphism, Single Nucleotide; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Graft Survival; Humans; Infant; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Cord Blood Stem Cell Transplantation; Cyclosporine; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Mycophenolic Acid; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
The RNA activator ds-p21 potentiates the cytotoxicity induced by fludarabine in Dohh2 cells.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation; Humans; Lymphoma, Non-Hodgkin; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-6; RNA, Double-Stranded; RNA, Messenger; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Retrospective Studies; Rituximab; Transplantation Conditioning; Vidarabine | 2011 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID.
Topics: Acute Disease; Antineoplastic Agents; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Female; Fetal Blood; Graft vs Host Disease; Histocompatibility Testing; Humans; Infant; Lung Diseases, Fungal; Male; Pneumonia, Bacterial; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; X-Linked Combined Immunodeficiency Diseases | 2011 |
DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; ATP Binding Cassette Transporter, Subfamily B; Benzaldehydes; Blotting, Western; Caffeine; Cell Cycle Proteins; Cell Line, Tumor; Chromones; Cyclosporine; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine | 2010 |
A transient IgE monoclonal protein in a child.
Topics: Adrenoleukodystrophy; Antibodies, Monoclonal; Busulfan; Child; Cyclosporine; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Immunoglobulin E; Immunosuppressive Agents; Vidarabine; Virus Activation | 2011 |
Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2011 |
Antithymocyte globulin-induced acute lung injury during transplantation for aplastic anemia.
Topics: Acute Lung Injury; Anemia, Aplastic; Animals; Anti-Bacterial Agents; Antilymphocyte Serum; Bacterial Infections; Bone Marrow Transplantation; Child; Cyclophosphamide; Horses; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Transplantation Conditioning; Vancomycin; Vidarabine | 2011 |
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Female; Graft Rejection; Heart Transplantation; Humans; Liver Transplantation; Lymphoproliferative Disorders; Male; Remission Induction; Rituximab; Vidarabine | 2011 |
FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Feasibility Studies; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radioimmunotherapy; Retrospective Studies; Rituximab; Vidarabine; Yttrium Radioisotopes | 2011 |
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Personalizing treatment for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Receptors, CXCR4; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2011 |
Early initial therapy of advanced follicular lymphoma: the need for vigilance.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Follow-Up Studies; Humans; Lymphoma, Follicular; Neoadjuvant Therapy; Population Surveillance; Rituximab; Vidarabine | 2011 |
STAT1-mediated signal integration between IFNγ and LPS leads to increased EC and SMC activation and monocyte adhesion.
Topics: Antineoplastic Agents; Atherosclerosis; Cell Adhesion; Cell Line; Endothelial Cells; Gene Expression; Humans; Interferon-gamma; Lipopolysaccharides; Monocytes; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Signal Transduction; STAT1 Transcription Factor; Toll-Like Receptor 4; Vidarabine | 2011 |
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Topics: Adult; Aged; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Opportunistic Infections; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
[A preliminary study on efficacy of allogeneic hematopoietic stem cell transplantation by myeloablative conditioning regimen with fludarabine for high risk leukemia patients].
Topics: Adolescent; Adult; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2011 |
[Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].
Topics: Adolescent; Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Humans; International Classification of Diseases; Male; Middle Aged; Prognosis; Recurrence; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2011 |
Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chimerism; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic 'sensor/effector' compounds.
Topics: Antineoplastic Agents; Apoptosis; Catalysis; Cell Survival; Drug Synergism; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Organic Chemicals; Oxidation-Reduction; Reactive Oxygen Species; Vidarabine | 2011 |
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning.
Topics: Adult; Animals; Antilymphocyte Serum; Carotid Arteries; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Probability; Rabbits; Retrospective Studies; Salvage Therapy; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2012 |
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Case-Control Studies; Female; Humans; Immunoglobulin M; Immunologic Memory; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Lymphoma, Non-Hodgkin; Male; Middle Aged; Orthomyxoviridae; Rituximab; Tumor Necrosis Factor Receptor Superfamily, Member 7; Vidarabine | 2011 |
Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follicle Stimulating Hormone; Humans; Immunotherapy, Adoptive; Middle Aged; Neoplasms; Ovary; Primary Ovarian Insufficiency; Radiotherapy; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2011 |
New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Flow Cytometry; Gene Rearrangement, T-Lymphocyte; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Myeloid; Leukocytes, Mononuclear; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Thymus Gland; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Prognosis; Recurrence; Remission Induction; Tandem Repeat Sequences; Vidarabine | 2011 |
Immune hemolysis after fludarabine-based reduced intensity conditioning and allogeneic PBSC transplantation for CML with minor ABO incompatibility.
Topics: Antineoplastic Agents; Blood Group Incompatibility; Female; Hemolysis; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Waldenström's macroglobulinemia and nephrotic syndrome with membranous nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Glomerulonephritis, Membranous; Humans; Immunoglobulin lambda-Chains; Immunoglobulin M; Male; Nephrotic Syndrome; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2011 |
Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Drug Monitoring; Female; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Pilot Projects; Recombinant Proteins; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine | 2011 |
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line; Cell Survival; CHO Cells; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Organoplatinum Compounds; Oxaliplatin; Signal Transduction; Vidarabine | 2011 |
Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Glomerulonephritis, Membranoproliferative; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2011 |
Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Chlorocebus aethiops; Combined Modality Therapy; Female; GPI-Linked Proteins; Humans; Male; Measles virus; Mice; Mice, SCID; Neoplasm Proteins; Oncolytic Virotherapy; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Vero Cells; Vidarabine; Xenograft Model Antitumor Assays | 2011 |
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Risk; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2011 |
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Primary Myelofibrosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Infections; Kaplan-Meier Estimate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Glomerulosclerosis, Focal Segmental; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Rituximab; Vidarabine | 2011 |
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Topics: Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prospective Studies; Recurrence; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2011 |
Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Berlin; beta-Lactams; Case-Control Studies; Ciprofloxacin; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lorazepam; Male; Middle Aged; Odds Ratio; Piperacillin; Population Surveillance; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine; Young Adult | 2011 |
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Siblings; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult | 2012 |
Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Clinical Trials as Topic; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2012 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 5; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Translocation, Genetic; Vidarabine | 2011 |
Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT.
Topics: Adult; Aged; Cryotherapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms.
Topics: Animals; Cell Line; Enzyme Inhibitors; Humans; Interleukin-17; Keratin-17; Keratinocytes; Mice; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Stilbenes; Vidarabine | 2011 |
Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Reoperation; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Hemianopsia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Rituximab; Vidarabine | 2012 |
Gastric mucosa-associated lymphoid tissue lymphoma: how to attack the T… for two?
Topics: Antineoplastic Agents; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Tumor Microenvironment; Vidarabine | 2011 |
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Oligonucleotides; Prognosis; Risk Factors; Rituximab; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2012 |
Successful cord blood transplantation with reduced-intensity conditioning for childhood cerebral X-linked adrenoleukodystrophy at advanced and early stages.
Topics: Adrenoleukodystrophy; Brain; Child; Cord Blood Stem Cell Transplantation; Humans; Male; Melphalan; Myeloablative Agonists; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2012 |
Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with fludarabine: effect on tumor microenvironment.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; T-Lymphocyte Subsets; Tumor Microenvironment; Vidarabine | 2011 |
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Genetic Diseases, Inborn; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Melphalan; Myeloablative Agonists; Neoplasms; Neutrophils; Recombinant Proteins; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2011 |
Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cell Survival; Forkhead Transcription Factors; Genetic Diseases, X-Linked; Graft Enhancement, Immunologic; Graft Survival; Humans; Immunologic Deficiency Syndromes; Infant; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Male; Melphalan; Point Mutation; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thiotepa; Thymus Gland; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cystitis; Disease-Free Survival; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Male; Prospective Studies; Saudi Arabia; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Mouth Diseases; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Female; Flow Cytometry; Genes, Immunoglobulin Heavy Chain; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2012 |
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Death; Cell Survival; Cyclophosphamide; Depsipeptides; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Monocytes; Peptides, Cyclic; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Vidarabine | 2012 |
Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Cyclophosphamide; Female; Humans; Immunoglobulin M; Livedo Reticularis; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Rituximab; Vidarabine | 2012 |
Atypical cytogenetics in therapy-related myelodysplastic syndrome secondary to indolent B-cell lymphoma.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 20; Female; Flow Cytometry; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2011 |
The effects of chemotherapeutic agents on differentiated chordoma cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Chordoma; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Imatinib Mesylate; Methotrexate; Piperazines; Pyrimidines; Vidarabine; Vincristine | 2011 |
Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine; Viral Load; Viremia; Virus Activation | 2011 |
Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia; Lymphoma; Salvage Therapy; Vidarabine | 2011 |
Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; B-Lymphocytes; CD5 Antigens; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Neoplasm, Residual; Reference Values; ROC Curve; Sensitivity and Specificity; Vidarabine | 2011 |
Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; CD3 Complex; Child; Down-Regulation; Female; Forkhead Transcription Factors; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hyaluronan Receptors; Immunosuppression Therapy; Interleukin-2 Receptor alpha Subunit; Interleukin-7 Receptor alpha Subunit; Leukocytes, Mononuclear; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Myeloablative Agonists; Protein Binding; Rabbits; Radiation Tolerance; T-Lymphocytes, Regulatory; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients.
Topics: Adolescent; Adult; Cause of Death; Child; Child, Preschool; Fanconi Anemia; Female; Graft Rejection; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.
Topics: Adult; Aged; Aged, 80 and over; CD4-Positive T-Lymphocytes; Cells, Cultured; Coculture Techniques; Flow Cytometry; Forkhead Transcription Factors; Humans; Immunomodulation; Interleukin-2 Receptor alpha Subunit; Interleukin-7 Receptor alpha Subunit; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tumor Necrosis Factor Receptor Superfamily, Member 7; Vidarabine | 2011 |
Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukocyte Count; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Myelodysplastic Syndromes; Platelet Count; Statistics as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2011 |
CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers, Tumor; Cohort Studies; Female; Humans; Lectins, C-Type; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Vidarabine | 2012 |
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 2012 |
Comment on research report by Gruson and colleagues, this issue.
Topics: Antibodies, Monoclonal, Murine-Derived; Female; Humans; Immunologic Factors; Male; Polyradiculoneuropathy; Rituximab; Vidarabine | 2011 |
Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Autoantigens; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin M; Immunologic Factors; Male; Middle Aged; Myelin-Associated Glycoprotein; Paraproteinemias; Polyradiculoneuropathy; Rituximab; Vidarabine | 2011 |
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Treatment Outcome; Vidarabine | 2012 |
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; B-Lymphocytes; Biomarkers, Tumor; Cell Line, Tumor; Female; Humans; Hydrogen Peroxide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphorylation; Proteome; Reactive Oxygen Species; Signal Transduction; Single-Cell Analysis; Vidarabine | 2011 |
Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.
Topics: Antineoplastic Agents; Cell Death; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; Tumor Cells, Cultured; Vidarabine | 2012 |
Fludarabine versus chlorambucil: is the debate over?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Remission Induction; Vidarabine | 2011 |
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Topics: Amino Acid Sequence; Antineoplastic Agents; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Sequence Data; Mutation; Oligonucleotide Array Sequence Analysis; Phosphoproteins; Polymorphism, Single Nucleotide; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Sequence Homology, Amino Acid; Spliceosomes; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjögren syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biopsy; Cyclophosphamide; Drug Therapy, Combination; Eyelids; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Necrobiotic Xanthogranuloma; Paraproteinemias; Rituximab; Sjogren's Syndrome; Treatment Outcome; Vidarabine | 2011 |
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
Topics: Age Factors; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Radiation Dosage; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2011 |
Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go.
Topics: Antineoplastic Agents; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2011 |
Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2012 |
Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Apoptosis; CD40 Ligand; Cell Proliferation; Crotonates; Drug Resistance, Neoplasm; Humans; Hydroxybutyrates; Interleukin-4; Isoxazoles; Janus Kinases; Leflunomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitriles; Signal Transduction; STAT Transcription Factors; Toluidines; Tumor Cells, Cultured; Vidarabine | 2012 |
LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Down-Regulation; Drug Synergism; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxamic Acids; Indoles; Leukemia; MAP Kinase Kinase 4; Mice; Mice, Nude; NF-kappa B; Panobinostat; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine | 2011 |
Anti-CD20: tales of identical twins?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Vidarabine | 2011 |
Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Incidence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Rituximab; Vidarabine | 2012 |
Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purines; Roscovitine; Vidarabine | 2012 |
Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Mucositis; Myeloablative Agonists; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biphenyl Compounds; CD40 Antigens; CD40 Ligand; Coculture Techniques; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Mice; Middle Aged; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; NIH 3T3 Cells; Nitrophenols; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Tumor Cells, Cultured; Vidarabine | 2012 |
Fludarabine nucleoside modulates nuclear "survival and death" proteins in resistant chronic lymphocytic leukemia cells.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nuclear Proteins; Nucleosides; Protein Processing, Post-Translational; Vidarabine | 2011 |
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dasatinib; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Thiazoles; Treatment Outcome; Vidarabine | 2012 |
Chemotherapy: New FluCam combination therapy has familiar limitations.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Cyclophosphamide; Drug Therapy, Combination; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2011 |
The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzamides; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Protein Serine-Threonine Kinases; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2012 |
Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart.
Topics: Animals; Antineoplastic Agents; Butadienes; Cardiomegaly; Cells, Cultured; Collagen; Disease Models, Animal; Down-Regulation; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Humans; Imidazoles; Interleukin-6; Male; MAP Kinase Signaling System; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Rats; Rats, Wistar; STAT1 Transcription Factor; STAT3 Transcription Factor; Vidarabine | 2012 |
Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Annexin A5; Antineoplastic Agents; Apoptosis; Biological Transport; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Primary Cell Culture; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tretinoin; Tritium; Vidarabine | 2012 |
Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.
Topics: Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD18 Antigens; Cell Adhesion; Cell Communication; Coculture Techniques; Culture Media, Conditioned; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Integrin beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Primary Cell Culture; Signal Transduction; Vascular Cell Adhesion Molecule-1; Vidarabine | 2012 |
Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient.
Topics: Antineoplastic Agents; Brain; DNA, Viral; Herpesvirus 7, Human; Humans; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Vidarabine | 2011 |
Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Recurrence; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2012 |
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Remission Induction; Retrospective Studies; Translocation, Genetic; Vidarabine | 2012 |
Fludarabine may overcome resistance to rituximab in IgM-related neuropathy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Drug Resistance; Female; Humans; Immunoglobulin M; Male; Middle Aged; Polyneuropathies; Rituximab; Vidarabine | 2012 |
Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Female; Graft Rejection; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2012 |
A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita.
Topics: Adult; Antilymphocyte Serum; Combined Modality Therapy; Cyclophosphamide; Dyskeratosis Congenita; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2012 |
Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.
Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Binding, Competitive; CHO Cells; Cladribine; Clofarabine; Cricetinae; Cricetulus; Cytotoxins; Humans; Purinergic P1 Receptor Agonists; Radioligand Assay; Receptors, Purinergic P1; Vidarabine | 2012 |
Individualized fludarabine-based regimen in elderly patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2012 |
Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Serologic Tests; Titrimetry; Vidarabine; Vincristine; Virus Activation | 2012 |
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Area Under Curve; Biopsy; Busulfan; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Liver; Male; Middle Aged; Stem Cell Transplantation; Time Factors; Vidarabine | 2012 |
[Modern times: back to past, back to future].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multiple Myeloma; Pyrazines; Rituximab; Vidarabine | 2012 |
Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.
Topics: Animals; Animals, Newborn; Busulfan; Genes, Reporter; Genetic Vectors; Graft Survival; Green Fluorescent Proteins; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Immune Tolerance; Immunosuppressive Agents; Lentivirus; Macaca mulatta; Simian Immunodeficiency Virus; Transduction, Genetic; Transgenes; Transplantation Conditioning; Vidarabine | 2012 |
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Rabbits; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine | 2012 |
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Baculoviral IAP Repeat-Containing 3 Protein; Blotting, Western; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; In Situ Hybridization, Fluorescence; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; NF-kappa B; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Vidarabine | 2012 |
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-15; Interleukin-7; Lymphocyte Depletion; Lymphoma; Male; Middle Aged; Prednisone; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine; Vincristine | 2012 |
[Classic Hodgkin's lymphoma in post-treatment hairy cell leukemia: report of a case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Leukemia, Hairy Cell; Male; Mitoxantrone; Neoplasms, Multiple Primary; Rituximab; Splenectomy; Vidarabine; Vinblastine | 2011 |
Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Bone Marrow Cells; Cell Communication; Cell Line; Cell Survival; Coculture Techniques; Culture Media, Conditioned; Cysteine; Cystine; Drug Resistance, Neoplasm; Flow Cytometry; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Organoplatinum Compounds; Oxaliplatin; Reactive Oxygen Species; Stromal Cells; Tumor Cells, Cultured; Vidarabine | 2012 |
IFN-γ synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Cell Survival; Cells, Cultured; Cytokines; Dexamethasone; Drug Resistance; Female; Humans; Interferon-gamma; Janus Kinases; Lipopolysaccharides; Macrophages, Alveolar; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; Toll-Like Receptor 2; Toll-Like Receptor 4; Vidarabine | 2012 |
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Disease-Free Survival; DNA Mutational Analysis; DNA-Binding Proteins; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Mutation, Missense; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Serine-Threonine Kinases; Rituximab; Tumor Suppressor Proteins; Vidarabine | 2012 |
Risk categories and refractory CLL in the era of chemoimmunotherapy.
Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Forecasting; Genes, p53; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Prognosis; Risk Assessment; Rituximab; Terminology as Topic; Treatment Failure; Vidarabine | 2012 |
FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Salvage Therapy; Survival Rate; Vidarabine | 2012 |
Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.
Topics: Adolescent; Adult; Busulfan; Chi-Square Distribution; Disease-Free Survival; Drug Therapy, Combination; Feasibility Studies; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Matched sibling donor stem cell transplantation for Fanconi anemia patients with T-cell somatic mosaicism.
Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chimerism; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Fanconi Anemia; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Male; Mosaicism; Stem Cell Transplantation; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisolone; Rituximab; Teniposide; Vidarabine | 2012 |
T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.
Topics: Adult; Aged; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Middle Aged; Neoadjuvant Therapy; Rituximab; Survival Analysis; Time Factors; Vidarabine | 2012 |
Stem cell factor-displaying simian immunodeficiency viral vectors together with a low conditioning regimen allow for long-term engraftment of gene-marked autologous hematopoietic stem cells in macaques.
Topics: Animals; Antigens, CD34; Chimerism; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; HEK293 Cells; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hemophilia A; Humans; Lymphocyte Count; Macaca fascicularis; Male; Myeloablative Agonists; Radiation-Sensitizing Agents; Recombinant Proteins; Simian Immunodeficiency Virus; Stem Cell Factor; Transduction, Genetic; Transplantation Conditioning; Transplantation, Autologous; Vidarabine; Whole-Body Irradiation | 2012 |
N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Proliferation; Drug Synergism; Fenretinide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sulfonamides; Vidarabine | 2012 |
Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis.
Topics: Blood Component Transfusion; Blood Donors; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Infant; Infant, Newborn; Japan; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Reoperation; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2012 |
Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Topics: Antineoplastic Agents; Aphidicolin; Biotransformation; Cell Line, Tumor; Cell Survival; Cladribine; Deoxycytidine; Deoxycytidine Kinase; Enzyme Activation; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Kinetics; Mutation; Phosphorylation; Purine Nucleosides; Pyrimidine Nucleosides; Serine; Structure-Activity Relationship; Substrate Specificity; Vidarabine | 2012 |
Splenic re-irradiation for waldenstrőm's macroglobulinemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Radiotherapy, Conformal; Spleen; Thalidomide; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
[Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].
Topics: Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes.
Topics: Atherosclerosis; Cell Line; Cell Separation; gag Gene Products, Human Immunodeficiency Virus; Gene Expression Regulation; GTP-Binding Proteins; HIV Antigens; HIV Infections; HIV-1; Humans; Inflammation; Isoxazoles; Janus Kinases; Lipid Metabolism; Lipopolysaccharide Receptors; Macrophages; Monocytes; Neoplasm Proteins; Neutralization Tests; Phenotype; Phosphorylation; PPAR gamma; Receptors for Activated C Kinase; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; STAT1 Transcription Factor; Thiazolidinediones; Vaccination; Vidarabine | 2012 |
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.
Topics: Abnormal Karyotype; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Fatal Outcome; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Prednisone; Vidarabine; Vincristine | 2013 |
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Enzymes; Female; Gemtuzumab; Genetic Heterogeneity; Genotype; Humans; Idarubicin; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine | 2013 |
Striking the right balance: optimizing conditioning regimens for unrelated donor bone marrow transplant for severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; Male; Transplantation Conditioning; Vidarabine | 2012 |
miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
Topics: Antineoplastic Agents; Apoptosis; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Vidarabine | 2012 |
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; CASP8 and FADD-Like Apoptosis Regulating Protein; Cells, Cultured; Cytoprotection; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Resorcinols; Signal Transduction; Survivin; Tumor Microenvironment; Vidarabine | 2012 |
Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cytosol; DNA-Binding Proteins; Humans; Membrane Proteins; Nuclear Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2012 |
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.
Topics: Animals; Apoptosis; CD40 Antigens; CD40 Ligand; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunophenotyping; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phenotype; Receptor Tyrosine Kinase-like Orphan Receptors; Resorcinols; STAT3 Transcription Factor; Stromal Cells; Vidarabine | 2012 |
Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study.
Topics: Antineoplastic Agents; Apoptosis; Cladribine; DNA, Complementary; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Transcriptome; Tumor Cells, Cultured; Vidarabine | 2012 |
Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.
Topics: Adult; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Cyclin-Dependent Kinase Inhibitor p21; Cyclophosphamide; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Prognosis; Protein Serine-Threonine Kinases; Randomized Controlled Trials as Topic; Signal Transduction; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2012 |
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Sirolimus; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Epstein-Barr virus-negative classical Hodgkin's lymphoma in a patient with T-cell prolymphocytic leukemia treated with fludarabine.
Topics: Antineoplastic Agents; Female; Herpesvirus 4, Human; Hodgkin Disease; Humans; Leukemia, Prolymphocytic, T-Cell; Middle Aged; Neoplasms, Second Primary; Vidarabine | 2012 |
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
Topics: Antineoplastic Agents; Autophagy; Cell Culture Techniques; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Starvation; Tumor Cells, Cultured; Vidarabine | 2012 |
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Dactinomycin; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Mice, Transgenic; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2012 |
HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Blood Proteins; Cell Nucleus; Cyclophosphamide; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, Antigen, B-Cell; RNA, Messenger; src-Family Kinases; Subcellular Fractions; Substrate Specificity; Vidarabine | 2012 |
Cytomegalovirus oesophagitis following treatment with fludarabine for refractory lymphoplasmacytic lymphoma.
Topics: Antineoplastic Agents; Antiviral Agents; Biopsy; Cytomegalovirus Infections; Diagnosis, Differential; Endoscopy, Digestive System; Esophagitis; Ganciclovir; Humans; Immunocompromised Host; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Valganciclovir; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.
Topics: Adenosine Deaminase; Agammaglobulinemia; Bone Marrow Transplantation; Busulfan; Child, Preschool; Humans; Living Donors; Male; Severe Combined Immunodeficiency; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2013 |
The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
Topics: Antineoplastic Agents; Biological Assay; Drug Monitoring; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Patient Selection; Predictive Value of Tests; Prognosis; Random Allocation; Randomized Controlled Trials as Topic; Survival Rate; Vidarabine | 2013 |
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cyclophosphamide; DNA Probes; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Rituximab; Translocation, Genetic; Vidarabine | 2012 |
Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.
Topics: Adolescent; Antineoplastic Agents; Child; Combined Modality Therapy; Fanconi Anemia; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Lymphocyte Depletion; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Fludarabine and cladribine induce changes in surface proteins on human B-lymphoid cell lines involved with apoptosis, cell survival, and antitumor immunity.
Topics: Antigens, CD; Apoptosis; B-Lymphocytes; Burkitt Lymphoma; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Survival; Cladribine; Drug Resistance, Neoplasm; Flow Cytometry; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Reproducibility of Results; Signal Transduction; Up-Regulation; Vidarabine | 2012 |
Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities.
Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Comorbidity; Disease-Free Survival; Humans; Incidence; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2012 |
Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytic Sarcoma; Histocompatibility; Histocompatibility Testing; HLA Antigens; Humans; Male; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Successful treatment of γ-heavy-chain disease with rituximab and fludarabine.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Heavy Chain Disease; Humans; Lymphoma, B-Cell; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
T-cell large granular lymphocytic leukemia: treatment experience with fludarabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Richter syndrome and fludarabine: a controversial relationship.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Vidarabine | 2013 |
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).
Topics: Adult; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Vidarabine | 2013 |
Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.
Topics: Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Immunoprecipitation; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; NF-kappa B; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine | 2012 |
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Brain Edema; Cerebellar Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nervous System Diseases; Neurosurgical Procedures; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2013 |
Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Topics: Aged; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcus neoformans; Cyclophosphamide; Drug Therapy, Combination; Fatal Outcome; Flucytosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meningitis, Cryptococcal; Rituximab; Time Factors; Vidarabine | 2013 |
S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Topics: Aged; Animals; Antineoplastic Agents; Cell Cycle Proteins; Female; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Nuclear Proteins; Piperazines; Prognosis; Protein Splicing; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Suppressor Protein p53; Vidarabine | 2012 |
Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Cytogenetics; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Time Factors; Translocation, Genetic; Vidarabine | 2012 |
Preservation of fertility in women undergoing reduced-intensity conditioning allogeneic transplantation with a fludarabine-based regime.
Topics: Adult; Biomarkers; Estradiol; Female; Fertility Preservation; Follicle Stimulating Hormone, Human; Hematopoietic Stem Cell Transplantation; Humans; Infertility, Female; Luteinizing Hormone; Myeloablative Agonists; Ovary; Pregnancy; Pregnancy Rate; Retrospective Studies; Risk Assessment; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Ultrasonography; Vidarabine; Young Adult | 2012 |
Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cryoglobulinemia; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2013 |
The effect of cyclosporine initiation time on the outcome of matched allogeneic stem-cell transplantation following fludarabine-based conditioning.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
[Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Flow Cytometry; Hospitals, County; Humans; Hungary; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prednisolone; Remission Induction; Treatment Outcome; Vidarabine; Vincristine | 2012 |
Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomal Proteins, Non-Histone; Female; Humans; Imidazoles; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleoproteins; Oncogene Proteins; Piperazines; Poly-ADP-Ribose Binding Proteins; Prognosis; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2012 |
Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors.
Topics: Adolescent; Adult; Child; Child, Preschool; Chimerism; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2013 |
Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Topics: Adult; Cytogenetic Analysis; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prognosis; Prospective Studies; Remission Induction; Translocation, Genetic; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Leukemia specific loss of heterozygosity of MHC in a CLL patient: disease state impacts timing of confirmatory typing.
Topics: Antibodies, Monoclonal, Murine-Derived; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Histocompatibility Testing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Loss of Heterozygosity; Male; Middle Aged; Myeloablative Agonists; Rituximab; Time Factors; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2013 |
Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation.
Topics: Adolescent; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukoencephalopathies; Male; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine | 2013 |
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Drug Administration Schedule; Female; Graft vs Host Reaction; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2013 |
Visceral varicella in a patient with chronic lymphocytic leukemia treated with fludarabine: a case report.
Topics: Antineoplastic Agents; Chickenpox; Herpesvirus 3, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine; Virus Activation | 2013 |
Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocytes; Male; Melphalan; Middle Aged; Monocytes; Prognosis; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2013 |
Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia; Busulfan; Child, Preschool; Humans; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Siblings; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine | 2013 |
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Vidarabine | 2012 |
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Living Donors; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2013 |
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cell Line, Tumor; CpG Islands; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Rituximab; RNA, Small Interfering; Thionucleotides; Toll-Like Receptor 9; Vidarabine; Xenograft Model Antitumor Assays | 2013 |
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Erythema; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2013 |
Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide.
Topics: Cyclophosphamide; Disease Progression; Female; Humans; Immunosuppressive Agents; Middle Aged; Neural Conduction; Peripheral Nerves; Polyneuropathies; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Treatment Outcome; Vidarabine | 2013 |
Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Disease-Free Survival; Female; Gene Dosage; Gene Knockdown Techniques; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Prognosis; Risk Factors; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Transcriptome; Up-Regulation; Vidarabine | 2013 |
A non-fatal case of invasive zygomycete (Lichtheimia corymbifera) infection in an allogeneic haematopoietic cell transplant recipient.
Topics: Antifungal Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Mucorales; Mucormycosis; Peripheral Blood Stem Cell Transplantation; Triazoles; Vidarabine | 2013 |
Exacerbation of lymphomatoid papulosis during rituximab therapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphomatoid Papulosis; Male; Middle Aged; Prednisolone; Rituximab; Vidarabine; Vincristine | 2014 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Mitoxantrone; Radionuclide Imaging; Retrospective Studies; Treatment Outcome; Vidarabine | 2013 |
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, SCID; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Spleen; Syk Kinase; Vidarabine; Xenograft Model Antitumor Assays | 2013 |
In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphotoxin-alpha; MicroRNAs; Prognosis; Toll-Like Receptors; Vidarabine | 2013 |
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Randomized Controlled Trials as Topic; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2013 |
The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Fluorouracil; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotype; Male; Middle Aged; Neoplasms; Telomere; Vidarabine | 2013 |
Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy.
Topics: Aged; Antineoplastic Agents; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Time Factors; Vidarabine | 2012 |
Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Cells, Cultured; Child; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Myeloablative Agonists; Secondary Prevention; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Drug Therapy, Combination; Humans; Hypergammaglobulinemia; Immunoglobulin G; Immunologic Factors; Lacrimal Apparatus; Lymph Nodes; Lymphatic Diseases; Male; Retinal Degeneration; Rituximab; Vasculitis; Vidarabine | 2013 |
[A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2012 |
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Innate; Leukemia; Lymphoma; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recovery of Function; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.
Topics: Adult; Aged; Blood Platelets; Female; Ferritins; Follow-Up Studies; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Medicare; Middle Aged; Risk Factors; Rituximab; SEER Program; Survival Rate; Treatment Outcome; United States; Vidarabine | 2013 |
Fludarabine in paediatric steroid-refractory inflammatory lung injury after stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Child, Preschool; Female; Humans; Immunosuppressive Agents; Infant; Inflammation; Lung Injury; Lymphocyte Count; Male; Stem Cell Transplantation; Steroids; T-Lymphocytes; Vidarabine | 2013 |
Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.
Topics: Adult; Aged; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Time Factors; Transplantation Conditioning; Vidarabine | 2013 |
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.
Topics: Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Graft Rejection; Graft Survival; Humans; Infant; Male; Myeloablative Agonists; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2013 |
Outcomes in critically ill chronic lymphocytic leukemia patients.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Hospital Mortality; Humans; Intensive Care Units; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Rituximab; Treatment Outcome; Vidarabine | 2013 |
In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
Topics: Adult; Aged; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Lymphocyte Count; Lymphocyte Depletion; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
[Subcutaneous panniculitis-like T-cell lymphoma following treatment with rituximab and cyclophosphamide].
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Transformation, Neoplastic; Cyclophosphamide; Diagnosis, Differential; Gene Rearrangement, T-Lymphocyte; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell, Cutaneous; Male; Mitomycin; Neoplasms, Second Primary; Panniculitis; Rituximab; Subcutaneous Tissue; T-Lymphocytes; Vidarabine | 2013 |
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinofuranosylcytosine Triphosphate; Bacterial Proteins; Biosensing Techniques; Cell Line, Tumor; Cytarabine; HL-60 Cells; Humans; K562 Cells; Leukemia; Luminescent Measurements; Luminescent Proteins; Treatment Outcome; Vidarabine | 2013 |
Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Caspase 3; Caspase 9; Cladribine; Cyclophosphamide; Down-Regulation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proteasome Inhibitors; Rituximab; Sirolimus; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vidarabine | 2013 |
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Middle Aged; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Arachidonic Acid; Cell Line, Tumor; Docosahexaenoic Acids; Doxorubicin; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, B-Cell; Lipid Peroxidation; Malondialdehyde; Organ Specificity; Reactive Oxygen Species; Vidarabine; Vincristine; Vitamin E | 2013 |
Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; International Agencies; Male; Neoplasm Grading; Neoplasm Staging; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2013 |
The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; Female; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; Mitochondrial Membrane Transport Proteins; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2013 |
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Efficacy of oral fludarabine in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2013 |
Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia.
Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Blood Platelets; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Neutrophils; Retrospective Studies; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2013 |
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2013 |
Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation.
Topics: Animals; Bone Marrow Transplantation; Central Nervous System; Cyclophosphamide; Gamma Rays; Green Fluorescent Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Monocytes; Myeloablative Agonists; Retina; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2013 |
Release of an ~55kDa fragment containing the actin-binding domain of β-spectrin by caspase-8 during FND-induced apoptosis depends on the presence of protein 4.1.
Topics: Actins; Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Brain; Caspase 8; Caspase Inhibitors; Cytoskeletal Proteins; Dexamethasone; Drug Interactions; Erythrocyte Membrane; Humans; Jurkat Cells; Membrane Proteins; Mitoxantrone; Molecular Sequence Data; Protein Structure, Tertiary; Proteolysis; Spectrin; Swine; Vidarabine | 2013 |
Successful fludarabine-based hematopoietic stem cell transplantation in a pediatric patient with idiopathic CD4+ lymphocytopenia.
Topics: CD4-Positive T-Lymphocytes; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphopenia; Myeloablative Agonists; Opportunistic Infections; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2013 |
Less could be better: the case for reducing the dose of cyclophosphamide for children undergoing allogeneic stem cell transplant for severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Transplantation Conditioning; Vidarabine | 2013 |
Sirolimus as maintenance treatment in an infant with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance; Humans; Infant; Male; Red-Cell Aplasia, Pure; Sirolimus; Splenectomy; Treatment Outcome; Vidarabine | 2014 |
Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bayes Theorem; Biomarkers, Tumor; Blotting, Western; Carboplatin; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Survival Rate; Tumor Cells, Cultured; Vidarabine | 2013 |
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2013 |
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukocyte Transfusion; Male; Methotrexate; Middle Aged; Pilot Projects; Secondary Prevention; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Effect of IFN-α on KC and LIX expression: role of STAT1 and its effect on neutrophil recruitment to the spleen after lipopolysaccharide stimulation.
Topics: Animals; Blotting, Western; Chemokines; Chemokines, CXC; Gene Expression; Imidazoles; Immunohistochemistry; Interferon-alpha; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Oligonucleotide Array Sequence Analysis; p38 Mitogen-Activated Protein Kinases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Spleen; STAT1 Transcription Factor; Vidarabine | 2013 |
Drug repurposing for gastrointestinal stromal tumor.
Topics: Apoptosis; Auranofin; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Drug Repositioning; Gastrointestinal Stromal Tumors; Humans; Vidarabine | 2013 |
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Rituximab; Treatment Outcome; Vidarabine | 2013 |
[Fatal zygomycosis caused by Mucor indicus after haplo-identical stem cell transplantation].
Topics: Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Mucor; Treatment Outcome; Vidarabine; Zygomycosis | 2013 |
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Bcl-2-Like Protein 11; Beclin-1; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysosomal-Associated Membrane Protein 2; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Ubiquitin-Activating Enzymes; Vidarabine | 2013 |
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine | 2013 |
[Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2013 |
Cyclosporine-related posterior reversible encephalopathy syndrome after cord blood stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Posterior Leukoencephalopathy Syndrome; Radiography; Vidarabine; Whole-Body Irradiation | 2013 |
Hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen in pediatric patients with Griscelli syndrome type 2.
Topics: Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immune System; Immunologic Deficiency Syndromes; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Myeloablative Agonists; Piebaldism; Primary Immunodeficiency Diseases; Prospective Studies; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2013 |
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2013 |
Fludarabine treatment favors the retention of miR-485-3p by prostate cancer cells: implications for survival.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Male; MicroRNAs; Prostatic Neoplasms; Vidarabine | 2013 |
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-1 Antigen; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Synergism; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Vidarabine; Xenograft Model Antitumor Assays | 2013 |
Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma.
Topics: Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Neutrophils; Remission Induction; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine; Wiskott-Aldrich Syndrome | 2013 |
Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, Liquid; Cladribine; Drug Stability; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Vidarabine | 2013 |
Fludarabine in Waldenstrom's macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Disease-Free Survival; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia.
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hypophosphatasia; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cell Transplantation; Myeloablative Agonists; Retreatment; Vidarabine | 2013 |
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Treatment Outcome; Vidarabine | 2013 |
The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; DNA Breaks, Double-Stranded; Gene Expression Regulation, Leukemic; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proliferating Cell Nuclear Antigen; Signal Transduction; Transcriptional Activation; Tumor Suppressor Protein p53; Vidarabine | 2013 |
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoprevention; Chronic Disease; Disease Progression; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Recurrence; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Fully automated radiosynthesis of 2-[18F]fludarabine for PET imaging of low-grade lymphoma.
Topics: Automation; Chromatography, High Pressure Liquid; Fluorine Radioisotopes; Humans; Lymphoma; Positron-Emission Tomography; Quality Control; Vidarabine | 2014 |
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine | 2013 |
2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models.
Topics: Adult; Animals; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Lymphoma, Follicular; Mice; Mice, SCID; Positron-Emission Tomography; Radiometry; Tissue Distribution; Vidarabine | 2014 |
Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.
Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation, Homologous; Vidarabine | 2013 |
The quest for the optimal conditioning regimen: some answers, more questions.
Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2013 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine | 2013 |
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catalytic Domain; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA Helicases; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Histones; Humans; Indoles; Ku Autoantigen; Leukemia, Lymphoid; Middle Aged; Niacinamide; Oligonucleotides; Phosphorylation; Protein Binding; Telomerase; Vidarabine | 2013 |
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Female; Humans; Immune Tolerance; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Neoadjuvant Therapy; Pancytopenia; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2013 |
B-cell function after unrelated umbilical cord blood transplantation using a minimal-intensity conditioning regimen in patients with X-SCID.
Topics: Antineoplastic Agents; B-Lymphocytes; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; HLA Antigens; Humans; Immunoglobulins; Infant; Male; Melphalan; Survival Rate; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; X-Linked Combined Immunodeficiency Diseases | 2013 |
Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Line; Cell Proliferation; Cimicifuga; Deoxycytidine; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Humans; Male; Nucleosides; Phytotherapy; Plant Extracts; Prostate; Prostatic Neoplasms; RNA, Small Interfering; Saponins; Thymidine; Vidarabine | 2013 |
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Observational Studies as Topic; Prednisone; Prospective Studies; Rituximab; Treatment Outcome; United States; Vidarabine; Vincristine | 2013 |
Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.
Topics: Chromatography, Liquid; Humans; Intracellular Fluid; Leukocytes, Mononuclear; Mass Spectrometry; Tandem Mass Spectrometry; Vidarabine | 2013 |
Fludarabine, low-dose cyclophosphamide and rabbit antithymocyte globulin allowed stable engraftment after allogeneic peripheral blood stem cell transplantation for poly-transfused dyskeratosis congenita patient: case report.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Graft vs Host Disease; Humans; Male; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2013 |
Successful treatment of both acute leukemia and active Crohn's disease after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and busulfan: a case report.
Topics: Acute Disease; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Crohn Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Transplantation Conditioning; Vidarabine | 2013 |
An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lung Diseases; Lymphocytes; Male; Middle Aged; Mucositis; Outcome Assessment, Health Care; Proportional Hazards Models; Quality of Life; Recovery of Function; Retrospective Studies; Surveys and Questionnaires; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine | 2011 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Topics: Age Factors; Aged; B-Lymphocytes; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2013 |
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Australia; Bone Marrow Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Myeloablative Agonists; New Zealand; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
Topics: Adult; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Drug Synergism; Enzyme Activation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Tumor Cells, Cultured; Up-Regulation; Valproic Acid; Vidarabine | 2014 |
First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Comorbidity; Creatinine; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multivariate Analysis; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Rituximab; Vidarabine | 2013 |
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Topics: Adult; Age Factors; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Middle Aged; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine | 2014 |
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Topics: Adenine Nucleotides; Antineoplastic Agents, Alkylating; Apoptosis; Arabinonucleosides; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Clofarabine; DNA Damage; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia, Myeloid, Acute; Mitochondria; Nuclear Proteins; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2014 |
Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Female; Graft vs Host Disease; Humans; Male; Melphalan; Methotrexate; Middle Aged; Vidarabine; Young Adult | 2014 |
[Ultra high risk chronic lymphocytic leukemia - characteristics and treatment options].
Topics: Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2013 |
[A comparative study of fludarabine-based versus CHOP-like regimens in untreated primary indolent lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Non-Hodgkin; Vidarabine | 2013 |
In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
Topics: Amino Acid Sequence; Binding Sites; Cells, Cultured; Computer Simulation; Cyclic S-Oxides; Endothelial Cells; Humans; Interferon-alpha; Interferon-gamma; Molecular Docking Simulation; Molecular Sequence Data; Phosphorylation; Protein Binding; Sequence Alignment; src Homology Domains; STAT1 Transcription Factor; STAT2 Transcription Factor; STAT3 Transcription Factor; Vidarabine | 2013 |
Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cells, Cultured; Female; Gene Expression; Humans; Immunity, Cellular; Interleukin-17; Kaplan-Meier Estimate; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; T-Lymphocytes, Regulatory; Th17 Cells; Treatment Outcome; Vidarabine | 2013 |
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Public Health Surveillance; Registries; Salvage Therapy; Sweden; Treatment Outcome; Vidarabine | 2014 |
Chronic lymphocytic leukemia in a child: a challenging diagnosis in pediatric oncology practice.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Receptor Nuclear Translocator; Cyclophosphamide; Female; Gene Deletion; Humans; Leukemia, Prolymphocytic, T-Cell; Rituximab; Treatment Outcome; Vidarabine | 2014 |
Richter syndrome: chronic lymphocytic leukemia transformation into Hodgkin's disease.
Topics: Antineoplastic Agents; Antiviral Agents; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Vidarabine | 2013 |
Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Recurrence, Local; Rituximab; Vidarabine | 2013 |
Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Salvage Therapy; Vidarabine | 2014 |
The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Secondary Prevention; Survival Analysis; Vidarabine | 2014 |
Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Treatment Outcome; Vidarabine | 2014 |
Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
Topics: Adenoviridae Infections; Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Lung; Male; Myeloablative Agonists; Roseolovirus Infections; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?
Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2014 |
Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Myeloablative Agonists; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2014 |
STAT1 interaction with E3-14.7K in monocytes affects the efficacy of oncolytic adenovirus.
Topics: Active Transport, Cell Nucleus; Adenoviridae; Adenovirus E3 Proteins; Analysis of Variance; Animals; Blotting, Western; Cell Line; DNA, Complementary; Enzyme-Linked Immunosorbent Assay; Gene Deletion; Humans; Immunoprecipitation; Mice; Microscopy, Confocal; Monocytes; Oncolytic Viruses; Phosphorylation; Real-Time Polymerase Chain Reaction; STAT1 Transcription Factor; Vidarabine | 2014 |
Cyclophosphamide for CLL: to be or not CYP2B activated?
Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cyclophosphamide; Cytochrome P-450 CYP2B6; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 2013 |
Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cross Infection; Female; Graft vs Host Disease; Health Care Costs; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Patient Readmission; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Second malignancies in chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chlorambucil; Combined Modality Therapy; Ear Neoplasms; Early Diagnosis; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Neoplasms, Second Primary; Risk; Rituximab; Skin; Skin Neoplasms; Vidarabine | 2014 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child; Child, Preschool; China; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Middle Aged; Myeloablative Agonists; Prognosis; Retrospective Studies; Risk Factors; Transplantation Conditioning; Vidarabine; Young Adult | 2014 |
Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
Topics: Adolescent; Antineoplastic Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Herpesvirus 3, Human; Humans; Immunity, Cellular; Immunosuppression Therapy; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; T-Lymphocytes; Vidarabine; Virus Activation; Young Adult | 2014 |
HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia.
Topics: Adolescent; Antigens, CD34; Child; Fanconi Anemia; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Lymphocyte Depletion; Male; Myeloablative Agonists; Prospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2014 |
Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Lenalidomide; Male; Purines; Quinazolinones; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thalidomide; Vidarabine | 2014 |
Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Kidney; Multivariate Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2014 |
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boron Compounds; Caspase 3; Caspase 9; Cell Death; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Gossypol; Humans; Intracellular Membranes; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mitochondria; Neoplasm Staging; Permeability; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2014 |
Multifocal central nervous system demyelination and Lhermitte's phenomenon secondary to combination chemotherapy for chronic lymphocytic leukaemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Hamartoma Syndrome, Multiple; Hereditary Central Nervous System Demyelinating Diseases; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Rituximab; Vidarabine | 2014 |
A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia.
Topics: Adolescent; Adult; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Preoperative Care; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2014 |
A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Case-Control Studies; Cyclin-Dependent Kinase 9; Drug Synergism; HEK293 Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Transcription, Genetic; Vidarabine | 2014 |
[The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2013 |
Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.
Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Lung Diseases; Lymphocyte Depletion; Male; Middle Aged; Myeloablative Agonists; Respiratory Function Tests; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2014 |
Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Merkel Cell; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Merkel cell polyomavirus; Neoplasms, Multiple Primary; Polyomavirus Infections; Rituximab; Skin Neoplasms; Tumor Virus Infections; Vidarabine | 2014 |
Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cyclophosphamide; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2014 |
Outcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning.
Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Immunohistochemistry; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Pleural Effusion; Treatment Outcome; Tumor Lysis Syndrome; Vidarabine | 2014 |
Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2014 |
Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Bone Marrow Cells; CD40 Antigens; Cell Cycle; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Female; Gene Deletion; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Naphthoquinones; Nitrogen Mustard Compounds; Stromal Cells; Survivin; Toll-Like Receptor 9; Vidarabine | 2014 |
Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.
Topics: Adult; Aged; Bacteremia; C-Reactive Protein; Citrulline; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mucositis; Myeloablative Agonists; Neutropenia; Prospective Studies; Transplantation Conditioning; Vidarabine | 2014 |
Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Vidarabine | 2014 |
Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Comorbidity; Cyclophosphamide; Databases, Factual; Disease Management; Doxorubicin; Ethnicity; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medicare; Practice Patterns, Physicians'; Prednisone; Rituximab; SEER Program; Socioeconomic Factors; Treatment Outcome; United States; Vidarabine; Vincristine | 2014 |
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multivariate Analysis; Oral Hygiene; Prednisone; Sirolimus; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Cord Blood Stem Cell Transplantation; Drug Interactions; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycoses; Premedication; Prospective Studies; Risk Factors; Transplantation Conditioning; Vidarabine; Voriconazole; Young Adult | 2014 |
[Fludarabine-based increased-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia].
Topics: Adolescent; Adult; Anemia, Aplastic; Child; Child, Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2014 |
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Germany; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Office Visits; Prednisone; Prospective Studies; Registries; Rituximab; Vidarabine | 2015 |
Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Bone Marrow Cells; Cells, Cultured; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Primary Cell Culture; Stromal Cells; Time Factors; Vidarabine | 2014 |
The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
Topics: Aged; Amyloid Precursor Protein Secretases; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Receptor, Notch1; Tetrahydronaphthalenes; Tumor Cells, Cultured; Valine; Vidarabine | 2015 |
Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.
Topics: Adenine Nucleotides; Arabinonucleosides; Chromatography, Liquid; Clofarabine; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Vidarabine | 2014 |
The effects of fludarabine on rat cerebral ischemia.
Topics: Animals; Apoptosis; Brain; Infarction, Middle Cerebral Artery; Male; Phosphorylation; Rats; Rats, Sprague-Dawley; STAT1 Transcription Factor; STAT3 Transcription Factor; Vidarabine | 2015 |
Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.
Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Male; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2014 |
Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.
Topics: Antineoplastic Agents; B7-H1 Antigen; Down-Regulation; Histocompatibility Antigens Class I; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-gamma; Phosphorylation; Proteasome Endopeptidase Complex; Protein Stability; RNA Interference; RNA, Messenger; RNA, Small Interfering; STAT1 Transcription Factor; T-Lymphocytes; Tumor Cells, Cultured; Vidarabine | 2014 |
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Female; Genes, Immunoglobulin; Genes, p53; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Prospective Studies; Receptor, Notch1; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2014 |
Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Intracellular Signaling Peptides and Proteins; Lymphoproliferative Disorders; Male; Melphalan; Mutation; Myeloablative Agonists; Prognosis; Retrospective Studies; Signaling Lymphocytic Activation Molecule Associated Protein; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2014 |
Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Male; Middle Aged; Multivariate Analysis; Peptide Hydrolases; Pilot Projects; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases; Vidarabine | 2015 |
Small lymphocytic lymphoma presenting as bulky renal incidentaloma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Humans; Kidney; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Rituximab; Tomography, X-Ray Computed; Vidarabine | 2014 |
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2014 |
Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Lymphoma; Tumor Suppressor Proteins; Unfolded Protein Response; Vidarabine | 2014 |
Diverse intracellular pathogens activate type III interferon expression from peroxisomes.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Differentiation; Cell Line; Cyclohexanes; DEAD Box Protein 58; DEAD-box RNA Helicases; Enzyme Inhibitors; Humans; Immunity, Innate; Interferons; Intestinal Mucosa; Janus Kinase 2; Mice; p38 Mitogen-Activated Protein Kinases; Peroxisomes; Pyridones; Receptors, Immunologic; Reoviridae; Reoviridae Infections; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Tyrphostins; Vidarabine | 2014 |
Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Membrane; Down-Regulation; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Matrix Metalloproteinase 9; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Transcription, Genetic; Up-Regulation; Vidarabine | 2014 |
Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Outcome Assessment, Health Care; Prednisone; Rituximab; SEER Program; Survival Analysis; United States; Vidarabine; Vincristine | 2015 |
Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia.
Topics: Adolescent; Carcinoma, Squamous Cell; Child; Child, Preschool; Cyclophosphamide; Cystitis; Fanconi Anemia; Female; Gamma Rays; Hematopoietic Stem Cell Transplantation; Hemorrhage; Histocompatibility Testing; Humans; Infant; Male; Myeloablative Agonists; Oropharyngeal Neoplasms; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2014 |
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cladribine; Clone Cells; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mass Spectrometry; Mice; Proteomics; Rituximab; Vidarabine; Xenograft Model Antitumor Assays | 2014 |
Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphopro
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Calcineurin; Child; Combined Modality Therapy; Drug Resistance, Neoplasm; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Mycophenolic Acid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Therapy; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine | 2015 |
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2014 |
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Vidarabine | 2014 |
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation.
Topics: Acute Disease; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Prognosis; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine | 2014 |
Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease.
Topics: Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease Progression; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Living Donors; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins c-ets; Repressor Proteins; Ring Chromosomes; Rituximab; Transplantation Chimera; Vidarabine | 2014 |
A myeloablative conditioning regimen with fludarabine demonstrates good results in UCBT for 30 pediatric patients with hematologic malignancies, especially acute lymphoblastic leukemia.
Topics: Adolescent; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Humans; Male; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Transplantation Conditioning; Vidarabine | 2014 |
Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Rituximab; Vidarabine | 2014 |
Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
Topics: B-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Oxidative Phosphorylation; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Vidarabine | 2014 |
Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.
Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Risk Factors; Survival Rate; Thalassemia; Transplantation Conditioning; Vidarabine | 2014 |
Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen.
Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Female; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2014 |
Successful hematopoietic reconstitution by unrelated donor cord blood transplantation in children with Fanconi anemia: report of 3 cases.
Topics: Animals; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoiesis; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Rabbits; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD.
Topics: Adolescent; Adult; Aged; BK Virus; Busulfan; Cystitis; Cytomegalovirus Infections; Female; Graft vs Host Disease; HLA Antigens; Humans; Male; Middle Aged; Multivariate Analysis; Polyomavirus Infections; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Viremia; Young Adult | 2014 |
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine | 2014 |
Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Time Factors; Vidarabine; Virus Activation | 2015 |
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Depletion; Male; Mucopolysaccharidosis I; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
[Detection of p53 gene deletion in Xinjiang patients with chronic lymphocytic leukemia by fluorescence in situ hybridization and its clinical significance].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2014 |
Successful transplantation of kidney allografts in sensitized rats after syngeneic hematopoietic stem cell transplantation and fludarabine.
Topics: Animals; Base Sequence; DNA Primers; Female; Hematopoietic Stem Cell Transplantation; Kidney Transplantation; Polymerase Chain Reaction; Rats; Rats, Inbred Lew; Vidarabine | 2014 |
[The outcome of thirteen patients with nonmalignant hematologic diseases treated with HLA haploidentical stem cell transplantation].
Topics: Anemia, Aplastic; Busulfan; Graft vs Host Disease; Hematologic Diseases; Histocompatibility; HLA Antigens; Humans; Incidence; Methotrexate; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child, Preschool; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Transplantation Conditioning; Vidarabine | 2015 |
Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Topics: Adolescent; Adult; Aged; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2015 |
Silica network improve the effect of fludarabine and paclitaxel on HCT8 cell line.
Topics: Biocompatible Materials; Cell Shape; Endothelial Cells; Humans; Microscopy, Electron, Scanning; Paclitaxel; Silicon Dioxide; Spectrophotometry, Infrared; Tumor Cells, Cultured; Vidarabine; X-Ray Diffraction | 2014 |
[Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Rituximab; Vidarabine | 2014 |
Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Topics: Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Injections, Intravenous; Male; Myeloablative Agonists; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult | 2015 |
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Thiotepa; Vidarabine | 2015 |
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias].
Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Female; Graft Survival; Graft vs Host Disease; Haplotypes; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Vidarabine | 2015 |
[Retrospective analysis of therapeutic efficacy of haploidentical allogeneic hematopoietic stem cell transplantation for severe aplastic anemia].
Topics: Adolescent; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclosporine; Graft vs Host Disease; Haploidy; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Siblings; Survival Rate; Tissue Donors; Transplantation Conditioning; Vidarabine | 2014 |
[Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML].
Topics: Adolescent; Adult; Allografts; Cytarabine; Disease-Free Survival; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2014 |
Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
The impact of SF3B1 mutations in CLL on the DNA-damage response.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cohort Studies; DNA Damage; DNA Mutational Analysis; Doxorubicin; Flow Cytometry; Gene Deletion; Gene Expression Regulation, Leukemic; Genome, Human; Histones; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phosphoproteins; Piperazines; Prognosis; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Tumor Suppressor Protein p53; Vidarabine | 2015 |
Successful T-cell-depleted haploidentical hematopoietic stem cell transplantation in a child with dyskeratosis congenita after a fludarabine-based conditioning regimen.
Topics: Child; Dyskeratosis Congenita; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; T-Lymphocytes; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2015 |
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; CD40 Ligand; Cell Hypoxia; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrogen Mustard Compounds; Nitrophenols; Oxygen; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides; Vidarabine | 2015 |
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Prolonged remission of marginal zone lymphoma in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Receptors, Tumor Necrosis Factor; Remission Induction; Rituximab; Treatment Outcome; Tumor Necrosis Factor-alpha; Vidarabine | 2014 |
Extensive acute toxic leukoencephalopathy induced by fludarabine: two months follow-up on brain MRI.
Topics: Antineoplastic Agents; Brain; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Follow-Up Studies; Humans; Leukemia; Leukoencephalopathies; Male; Middle Aged; Treatment Outcome; Vidarabine | 2015 |
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Chimerism; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Lymphoproliferative Disorders; Male; Melphalan; Mucopolysaccharidoses; Myeloablative Agonists; Retrospective Studies; Severe Combined Immunodeficiency; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.
Topics: Aged; Allografts; Busulfan; Disease-Free Survival; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2016 |
Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.
Topics: Antilymphocyte Serum; Busulfan; Child, Preschool; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Myeloablative Agonists; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2015 |
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Gene Expression Regulation, Leukemic; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Multivariate Analysis; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Vidarabine; Young Adult | 2014 |
B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lymphoma, B-Cell; Prednisone; Recurrence; Remission Induction; Risk; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Virus Activation | 2014 |
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Retreatment; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Outcome Assessment, Health Care; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Survival Analysis; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2015 |
Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Japan; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2015 |
Treatment-refractory hypereosinophilic syndrome responding to fludarabine in a 12-year-old boy.
Topics: Bone Marrow; Child; Combined Modality Therapy; Humans; Hypereosinophilic Syndrome; Male; Treatment Outcome; Vidarabine | 2015 |
Cytomegalovirus retinitis complicating combination therapy with rituximab and fludarabine.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Cytomegalovirus Retinitis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Rituximab; Vidarabine | 2015 |
[Efficacies of hematopoietic stem cell transplantation for severe aplastic anemia: a report of 43 patients].
Topics: Adolescent; Adult; Anemia, Aplastic; Child; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Siblings; Transplantation Conditioning; Vidarabine; Young Adult | 2014 |
HLA-matched related-donor HSCT in Fanconi anemia patients conditioned with cyclophosphamide and fludarabine.
Topics: Adolescent; Child; Cyclophosphamide; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT.
Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Comorbidity; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Vidarabine | 2015 |
I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Hematologic Diseases; Humans; Male; Melphalan; Middle Aged; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2015 |
Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.
Topics: Adolescent; Allografts; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Databases, Factual; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Quality of Health Care; Quality of Life; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2015 |
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Multivariate Analysis; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Vidarabine; Virus Diseases; Whole-Body Irradiation; Young Adult | 2015 |
The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor.
Topics: 5'-Nucleotidase; Cytosol; Electrophoresis, Capillary; Enzyme Inhibitors; HL-60 Cells; Humans; Molecular Docking Simulation; Mutagenesis, Site-Directed; Vidarabine | 2015 |
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2015 |
Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Predictive Value of Tests; Prospective Studies; Recurrence; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2015 |
Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
Topics: Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
[Elderly chronic lymphocytic leukemia combined with invasive aspergillosis infection in one case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Rituximab; Vidarabine | 2015 |
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Survival Analysis; Treatment Outcome; Vidarabine | 2015 |
Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Line, Tumor; Cladribine; Clofarabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Real-Time Polymerase Chain Reaction; Vidarabine | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Mucopolysaccharidoses; Myeloablative Agonists; Neurodegenerative Diseases; Practice Guidelines as Topic; Prognosis; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Pathological fractures in a patient with chronic lymphatic leucaemia without disease progression.
Topics: Accidental Falls; Allopurinol; Antineoplastic Agents; Bone Marrow; Female; Femur; Fractures, Bone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Osteolysis; Pelvis; Positron-Emission Tomography; Radiography; Rituximab; Sacrum; Sodium Bicarbonate; Treatment Outcome; Vidarabine | 2015 |
[Successful treatment of Bing-Neel syndrome using combination therapy with fludarabine and rituximab].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Bone Marrow; Drug Combinations; Humans; Magnetic Resonance Imaging; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2015 |
Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.
Topics: Adult; Aged; Busulfan; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2015 |
Permanent chemotherapy-induced nonscarring alopecia and premature ovarian failure.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Primary Ovarian Insufficiency; Thiotepa; Vidarabine | 2015 |
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Topics: Acrylonitrile; Aniline Compounds; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Coculture Techniques; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Stromal Cells; Tumor Microenvironment; Vidarabine | 2015 |
[Chronic lymphatic leukemia].
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Rituximab; Vidarabine | 2015 |
[Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2015 |
Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside-Nucleoside Analogue Radiosensitization.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cytarabine; DNA Breaks, Double-Stranded; DNA Repair; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Green Fluorescent Proteins; Homologous Recombination; Humans; Microscopy, Confocal; Rad51 Recombinase; Radiation-Sensitizing Agents; RNA Interference; Vidarabine; X-Rays | 2015 |
Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Child; Child, Preschool; Chimerism; Graft Survival; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2015 |
[Establishment of a graft-versus-host disease mouse model for haplo-identical bone marrow transplantation with busulfan and fludarabine conditioning regimen].
Topics: Animals; Bone Marrow Transplantation; Busulfan; Disease Models, Animal; Drug Combinations; Graft vs Host Disease; Mice; Transplantation Conditioning; Vidarabine | 2015 |
IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Cell Survival; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance; Gemcitabine; Green Fluorescent Proteins; Guanosine Monophosphate; HEK293 Cells; Humans; Immunoblotting; Inosine Monophosphate; Nucleotides; Phosphorylation; Prodrugs; Substrate Specificity; Vidarabine | 2015 |
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chimerism; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2015 |
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.
Topics: Adult; Aged; Benzylamines; Busulfan; Cell Movement; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Enzyme Inhibitors; Female; Growth Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MAP Kinase Signaling System; Middle Aged; Oxides; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Vidarabine | 2015 |
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Cell Death; Cell Line, Tumor; Cytosine Deaminase; Docetaxel; Dose-Response Relationship, Drug; Enzymes; Flucytosine; Fluorouracil; Humans; Methanol; Molecular Targeted Therapy; Organoselenium Compounds; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Recombinant Fusion Proteins; Selenomethionine; Taxoids; Tubulin Modulators; Vidarabine | 2015 |
Diagnosis: Melanoderma after Hematopoietic Stem Cell Transplantation.
Topics: Antilymphocyte Serum; Busulfan; Deferoxamine; Diagnosis, Differential; Ecchymosis; Humans; Infant; Iron Overload; Male; Melanosis; Peripheral Blood Stem Cell Transplantation; Severe Combined Immunodeficiency; Transfusion Reaction; Transplantation Conditioning; Vidarabine | 2015 |
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
Topics: Antineoplastic Agents; Bone Marrow; Cladribine; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Genetic Therapy; Hematopoietic Stem Cell Transplantation; HL-60 Cells; Humans; Vidarabine | 2015 |
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
Topics: Animals; Antigens, CD19; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cyclophosphamide; Disease Models, Animal; Down-Regulation; Flow Cytometry; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Lymphoma; Mice; Mice, SCID; Real-Time Polymerase Chain Reaction; Receptors, Antigen, T-Cell; Recombinant Fusion Proteins; T-Lymphocytes; Vidarabine; Xenograft Model Antitumor Assays | 2015 |
Effective treatment of Bing-Neel Syndrome with oral fludarabine: a case series of four consecutive patients.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2016 |
Phospholipid derivatives of cladribine and fludarabine: synthesis and biological properties.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransformation; Cell Line, Tumor; Cell Survival; Cladribine; Diglycerides; Humans; Male; Mice; Mice, Inbred ICR; Molecular Structure; Organophosphonates; Phospholipids; Prodrugs; Rats; Rats, Wistar; Vidarabine | 2015 |
Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center.
Topics: Adult; Antilymphocyte Serum; Busulfan; Cohort Studies; Cross-Sectional Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
Topics: Adoptive Transfer; Animals; Cisplatin; Cyclophosphamide; Cytotoxins; Deoxycytidine; Drug Resistance; Etoposide; Female; Fibrosarcoma; Gemcitabine; Lymph Nodes; Lymphocyte Depletion; Lymphopenia; Methylcholanthrene; Mice; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Vidarabine; Whole-Body Irradiation | 2015 |
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Remission Induction; Rituximab; Vidarabine | 2015 |
Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
Topics: Adult; Antigens, CD34; Antilymphocyte Serum; B-Lymphocyte Subsets; Blood Component Removal; Busulfan; Cross-Sectional Studies; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Factors; T-Lymphocyte Subsets; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Turkey; Vidarabine | 2015 |
[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
Topics: Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.
Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Count; Cell Lineage; Cyclophosphamide; Female; Flow Cytometry; GPI-Linked Proteins; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Neoplastic Cells, Circulating; Receptors, Cell Surface; Receptors, IgG; Rituximab; Vidarabine | 2015 |
The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia.
Topics: Antigens, CD19; Antineoplastic Agents; Apoptosis; Blood Cells; Bone Marrow Cells; Caspase 3; CD5 Antigens; Cell Line, Tumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine | 2015 |
Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Collagen Type VII; Epidermolysis Bullosa Dystrophica; Epithelial Cells; Fibroblasts; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Mutation; Myeloablative Agonists; RNA, Messenger; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Lymphoproliferative Disorders; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2015 |
ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Survival; Cells, Cultured; Drug Synergism; Female; Flow Cytometry; Heterocyclic Compounds, 1-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Potential, Mitochondrial; Middle Aged; Reactive Oxygen Species; Vidarabine | 2015 |
Successful Treatment With Total Skin Electron Beam Therapy in a Child With Isolated Cutaneous Relapsed AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Electrons; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Skin Diseases; Vidarabine | 2015 |
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution].
Topics: Adult; Aged; Allografts; Busulfan; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2015 |
Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Administration Schedule; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Phosphoproteins; Receptor, Notch1; Recurrence; Remission Induction; Retrospective Studies; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2015 |
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calreticulin; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease Progression; Female; Graft Survival; Humans; Janus Kinase 2; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Polycythemia Vera; Primary Myelofibrosis; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2015 |
Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Quality of Life; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Female; Gene Expression; Genetic Diseases, Inborn; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Myeloablative Agonists; Pilot Projects; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Biological Assay; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gamma Rays; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multiplex Polymerase Chain Reaction; Mutation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Sensitivity and Specificity; Tumor Suppressor Protein p53; Vidarabine | 2015 |
An atypical case of bilateral posterior scleritis in a patient with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Eye Neoplasms; Fluorescein Angiography; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Rituximab; Scleritis; Vidarabine | 2015 |
Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; Humans; Isotope Labeling; Lymphoma, Mantle-Cell; Male; Proteomics; Tandem Mass Spectrometry; Tumor Cells, Cultured; Vidarabine | 2015 |
Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myelin-Associated Glycoprotein; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Retrospective Studies; Severity of Illness Index; Vidarabine | 2015 |
[Efficacy of Nonmyeloablative Allogeneic Hematopoietic Stem Cells for 14 Case of Severe Acquired Aplastic Anemia].
Topics: Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Mycophenolic Acid; Neutrophils; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine | 2015 |
Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 9; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunoglobulin Heavy Chains; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mutation; Tumor Suppressor Protein p53; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2016 |
Leukaemia cutis after starting bendamustine: cause or coincidence?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Erythema Nodosum; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Rituximab; Skin; Vidarabine | 2015 |
Successful Allogeneic Hematopoietic Stem Cell Transplantation in XIAP Deficiency Using Reduced-Intensity Conditioning.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Child, Preschool; Genetic Diseases, X-Linked; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Male; Melphalan; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Europe; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Multivariate Analysis; Retrospective Studies; Societies, Medical; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies.
Topics: Adult; Aged; Bone Marrow Diseases; Busulfan; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Local bacteria affect the efficacy of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Aziridines; Biotransformation; Cladribine; Colonic Neoplasms; Deoxycytidine; Escherichia coli; Female; Gemcitabine; Injections, Intralesional; Injections, Subcutaneous; Listeria; Mice; Neoplasm Transplantation; Skin; Treatment Outcome; Vidarabine | 2015 |
[STAT signaling pathway mediates high glucose induced cardiac fibroblasts proliferation and collagen deposition in vitro].
Topics: Aminosalicylic Acids; Animals; Benzenesulfonates; Cell Proliferation; Cells, Cultured; Collagen Type I; Collagen Type III; Fibroblasts; Glucose; Myocardium; Phosphorylation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Up-Regulation; Vidarabine | 2015 |
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Biphenyl Compounds; Busulfan; Child; Child, Preschool; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Ditiocarb; Epoxy Compounds; Female; Humans; Infant; Male; Methanol; Prodrugs; Reference Standards; Solvents; Vidarabine; Water | 2016 |
Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.
Topics: Aged; Aged, 80 and over; Allografts; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Efficient Fludarabine-Activating PNP From Archaea as a Guidance for Redesign the Active Site of E. Coli PNP.
Topics: Adenosine; Arabinonucleosides; Archaeal Proteins; Binding, Competitive; Biocatalysis; Catalytic Domain; Crystallography, X-Ray; Escherichia coli Proteins; Isoenzymes; Kinetics; Models, Molecular; Molecular Structure; Protein Binding; Protein Domains; Purine-Nucleoside Phosphorylase; Substrate Specificity; Sulfolobus solfataricus; Vidarabine | 2016 |
Improved Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Infantile Malignant Osteopetrosis Using Fludarabine-Based Conditioning.
Topics: Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Hypercalcemia; Infant; Infant, Newborn; Male; Osteopetrosis; Postoperative Complications; Tissue Donors; Tissue Survival; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Alemtuzumab, Fludarabine, Low-Dose TBI, and Double Umbilical Cord Transplant for Primary Graft Failure in a Patient with Recurrent HLH.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Salvage Therapy; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2016 |
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Second Primary; Prognosis; Recurrence; Remission Induction; Retreatment; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Bevacizumab; Cell Adhesion; Cell Line, Tumor; Cell Movement; Disease Progression; Drug Synergism; Female; Focal Adhesion Kinase 1; Gene Expression Regulation, Neoplastic; Humans; Integrin beta1; Neoplasm Invasiveness; Ovarian Neoplasms; Signal Transduction; Vidarabine | 2015 |
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
Topics: Adenine; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Cyclophosphamide; Cytokines; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Vidarabine | 2015 |
Successful Engraftment and Durable Graft-versus-host Disease Control with Haploidentical Peripheral Blood and a Short-term Conditioning Regimen for Primary Graft Failure.
Topics: Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
Topics: Administration, Intravenous; Adult; Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2016 |
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease Susceptibility; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; IgG Deficiency; Immunocompromised Host; Immunotherapy; Incidence; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia; Prednisone; Proportional Hazards Models; Retrospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine; Young Adult | 2015 |
The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; BRCA1 Protein; Cell Line, Tumor; Chromatography, Liquid; Cyclin D1; DNA Damage; DNA Repair; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; NF-kappa B p52 Subunit; Nucleolin; Phosphoproteins; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; Signal Transduction; Tandem Mass Spectrometry; Tumor Suppressor Protein p53; Vidarabine | 2015 |
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Prednisolone; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Rituximab; Survival Rate; Vidarabine | 2016 |
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Female; Follow-Up Studies; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Statistical; Quality-Adjusted Life Years; Rituximab; Treatment Outcome; Vidarabine | 2016 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2016 |
Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocytes; Melphalan; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Separation; Cyclophosphamide; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exome; Humans; Immunoprecipitation; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Neoplasm Recurrence, Local; Ribosomal Proteins; Rituximab; Transfection; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
Synthesis, characterization and bioevaluation of drug-collagen hybrid materials for biomedical applications.
Topics: Collagen Type I; Drug Delivery Systems; Epirubicin; Humans; Materials Testing; Pharmaceutical Preparations; Vidarabine | 2016 |
Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer.
Topics: Adenocarcinoma; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Male; Middle Aged; Myeloablative Agonists; Neoplasm Metastasis; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Role of Tumor Necrosis Factor-Producing Mesenchymal Stem Cells on Apoptosis of Chronic B-lymphocytic Tumor Cells Resistant to Fludarabine-based Chemotherapy.
Topics: Adipose Tissue; Adult; Antineoplastic Agents; Apoptosis; Cells, Cultured; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mesenchymal Stem Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Vidarabine | 2015 |
[Molecular diagnosis and hematopoietic stem cell transplantation in 17 children with inherited bone marrow failure syndrome].
Topics: Anemia, Aplastic; Anemia, Diamond-Blackfan; Bone Marrow Diseases; Bone Marrow Failure Disorders; Child; Dyskeratosis Congenita; Fanconi Anemia; Fetal Blood; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Retrospective Studies; Siblings; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2015 |
Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations.
Topics: Antibodies, Monoclonal, Humanized; CD40 Antigens; Heterografts; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2016 |
[Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Methotrexate; Mycophenolic Acid; Retrospective Studies; Siblings; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Clinical and laboratory outcomes after umbilical cord blood transplantation in a patient with mucolipidosis II alpha/beta.
Topics: Abnormalities, Multiple; Animals; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Immunoglobulins; Mucolipidoses; Psychomotor Disorders; Rabbits; Transferases (Other Substituted Phosphate Groups); Transplantation, Homologous; Vidarabine | 2016 |
Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; C-Reactive Protein; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.
Topics: Alemtuzumab; Bone Marrow; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Dyskeratosis Congenita; Graft Survival; Hematopoietic Stem Cell Transplantation; Heterozygote; Humans; Immunosuppressive Agents; Male; Mutation; Transplantation Conditioning; Vidarabine; Whole Body Imaging | 2016 |
[Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Follicular; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine; Young Adult | 2015 |
Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Topics: Adolescent; Adult; Anthracyclines; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Child; Child, Preschool; China; Consolidation Chemotherapy; Cytarabine; Female; Humans; Incidence; Infant; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Prospective Studies; Survival Rate; Vidarabine; Young Adult | 2016 |
[Chronic alveolar condensations with erythematous cutaneous lesions].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Deoxycytidine; Diagnosis, Differential; Doxorubicin; Erythema; Female; Gemcitabine; Humans; Lung Neoplasms; Mycosis Fungoides; Pulmonary Alveoli; Skin Neoplasms; Vidarabine | 2016 |
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2016 |
Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity.
Topics: Adult; Agammaglobulinemia; Antilymphocyte Serum; Cyclophosphamide; Genetic Diseases, X-Linked; Humans; Immunity, Humoral; Immunoglobulin A; Immunoglobulin M; Male; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Blood Platelets; Cord Blood Stem Cell Transplantation; Feasibility Studies; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neutrophils; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comorbidity; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Topics: Adenine Nucleotides; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Child; Cladribine; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2016 |
Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Siblings; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
An unusual manifestation in a patient with Neurofibromatosis type 1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cyclophosphamide; Diagnosis, Differential; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neurofibromatosis 1; Rituximab; Treatment Outcome; Vidarabine | 2016 |
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Mycophenolic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Agents; DNA Transposable Elements; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutagenesis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins B-raf; Transcription Factors; Tumor Cells, Cultured; Vidarabine | 2016 |
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bayes Theorem; Chlorambucil; Contraindications; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2016 |
[The role and place of high-dose immunosuppressive therapy and autologous transplantation of hematopoietic stem cells for autoimmune diseases].
Topics: Adult; Age Factors; Antilymphocyte Serum; Arthritis, Rheumatoid; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Melphalan; Multiple Sclerosis; Patient Acuity; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2016 |
Dendrimer-based nanoparticles for potential personalized therapy in chronic lymphocytic leukemia: Targeting the BCR-signaling pathway.
Topics: Antineoplastic Agents; B-Lymphocytes; Base Sequence; Cell Line, Tumor; Chromosomes, Human, Pair 17; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Microarray Analysis; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Polypropylenes; Precision Medicine; Proto-Oncogene Proteins c-bcr; Sequence Deletion; Signal Transduction; Trisaccharides; Vidarabine | 2016 |
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Positron-Emission Tomography; Remission Induction; Rituximab; Tomography, X-Ray Computed; Treatment Outcome; Vidarabine | 2016 |
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kaplan-Meier Estimate; Living Donors; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Recurrence; Republic of Korea; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Female; Germany; Health Care Surveys; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
Topics: Adult; Brentuximab Vedotin; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lung Diseases; Male; Melphalan; Middle Aged; Nausea; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Comparative Analysis between [(18)F]Fludarabine-PET and [(18)F]FDG-PET in a Murine Model of Inflammation.
Topics: Animals; Fluorodeoxyglucose F18; Inflammation; Mice; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Distribution; Vidarabine | 2016 |
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Consolidation Chemotherapy; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.
Topics: Adult; Aged; Cohort Studies; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precision Medicine; Recurrence; Regression Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
Topics: Age Factors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cells, Cultured; Drug Synergism; Female; Humans; Immunoblotting; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Mice, Inbred NZB; Neoplasms, Experimental; NF-kappa B; Proto-Oncogene Proteins c-akt; Rotenone; Signal Transduction; Tumor Cells, Cultured; Vidarabine | 2016 |
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Cells; Busulfan; Cyclophosphamide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transpla
Topics: Adolescent; Adult; Aged; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Monocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Female; Humans; Male; Middle Aged; Pancytopenia; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2016 |
[Clinical Summarization of Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: A Report of 100 Cases].
Topics: Antilymphocyte Serum; Disease-Free Survival; Graft vs Host Disease; HLA Antigens; Humans; Incidence; Leukemia; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies].
Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Leukemia; Mycophenolic Acid; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Middle Aged; Myeloablative Agonists; Pneumonia; Prospective Studies; Seizures; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Cladribine and Fludarabine Nucleotides Induce Distinct Hexamers Defining a Common Mode of Reversible RNR Inhibition.
Topics: Biopolymers; Chromatography, Gel; Cladribine; Fluorescence Polarization; Nucleotides; Ribonucleotide Reductases; Vidarabine | 2016 |
Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.
Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Infant; Lymphocyte Depletion; Male; Neoplasms; Receptors, Antigen, T-Cell, alpha-beta; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.
Topics: Adolescent; Adult; Aged; Area Under Curve; Busulfan; Female; Humans; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders.
Topics: Adolescent; Adult; Alemtuzumab; Bone Marrow Transplantation; Child; Child, Preschool; Female; Follow-Up Studies; Graft Survival; Hemoglobinopathies; Humans; Male; Melphalan; Myeloablative Agonists; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.
Topics: Antineoplastic Agents; Aphidicolin; Apoptosis; Cladribine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2016 |
Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen.
Topics: Cell Lineage; Chimerism; Disease-Free Survival; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunologic Deficiency Syndromes; Infant; Infant, Newborn; Melphalan; Stem Cell Transplantation; Stem Cells; Vidarabine | 2016 |
Addition of High-Dose Cytarabine to Fludarabine-Based Conditioning for Hematopoietic Stem Cell Transplantation for Treating Fanconi Anemia Patients with Advanced Myeloid Malignancy: A Single-Center Experience and Literature Review.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Cytarabine; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine | 2016 |
High prevalence of small- and large-fiber neuropathy in a prospective cohort of patients with moderate to severe chronic GvHD.
Topics: Adolescent; Adult; Cohort Studies; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Prevalence; Prospective Studies; Small Fiber Neuropathy; Vidarabine; Young Adult | 2016 |
Targeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog Fludarabine.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Combined Modality Therapy; Deoxycytidine Kinase; Drug Delivery Systems; Female; Humans; Ovarian Neoplasms; Phosphorylation; Receptor, ErbB-2; Tumor Cells, Cultured; Vidarabine | 2016 |
Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Chromatin Assembly and Disassembly; Clofarabine; Depsipeptides; DNA Damage; Drug Synergism; Histone Code; Humans; Metabolic Networks and Pathways; Tumor Cells, Cultured; Vidarabine | 2016 |
Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases; Male; Myeloablative Agonists; Respiratory Function Tests; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cost-Benefit Analysis; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Markov Chains; Meta-Analysis as Topic; Middle Aged; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Treatment Outcome; United Kingdom; Vidarabine | 2016 |
A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies.
Topics: Adult; Aged; Busulfan; Female; Graft Survival; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning.
Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Male; Middle Aged; Myeloablative Agonists; Siblings; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays.
Topics: Aged; Aged, 80 and over; Antimetabolites; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dendrimers; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polypropylenes; Trisaccharides; Vidarabine | 2017 |
Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient.
Topics: Aged; Allografts; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Mycophenolic Acid; Tacrolimus; Transplantation Conditioning; Vidarabine | 2018 |
Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.
Topics: Adult; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calcineurin Inhibitors; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, B-Cell; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
[SYNERGISTIC ACTIVITY OF DEGUELIN AND FLUDARABINE IN PRIMARY CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) AND IN A CLL MURINE MODEL].
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Primary Cell Culture; Rotenone; Tumor Cells, Cultured; Vidarabine | 2014 |
US regulator stops leukemia treatment trial after three patients die.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunotherapy; Leukemia; Treatment Failure; United States; United States Food and Drug Administration; Vidarabine | 2016 |
Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid; Male; Melphalan; Myeloablative Agonists; Myeloproliferative Disorders; Remission Induction; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
The FDA, Juno Therapeutics, and the ethical imperative of transparency.
Topics: Brain Edema; Clinical Trials, Phase II as Topic; Disclosure; Drug Industry; Drugs, Investigational; Humans; Immunotherapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Safety-Based Drug Withdrawals; United States; United States Food and Drug Administration; Vidarabine | 2016 |
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Mitosis; Mutation; Nucleosides; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Increased IL-10/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Female; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Interleukin-10; Interleukin-17; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nuclear Receptor Subfamily 1, Group F, Member 3; Prognosis; Rituximab; T-Lymphocytes, Regulatory; Th17 Cells; Vidarabine | 2016 |
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
Topics: Adult; Aged; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine | 2017 |
TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.
Topics: Adult; Aged; Apoptosis; Apoptosis Regulatory Proteins; Cell Survival; Female; Glycolysis; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphoric Monoester Hydrolases; Prognosis; RNA, Messenger; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine; Young Adult | 2016 |
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
Topics: Adult; Aged; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Radiation Dosage; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
Topics: Animals; Apoptosis; Cell Line, Tumor; Clinical Trials as Topic; Dioxoles; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 2017 |
Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine | 2017 |
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr
Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Recurrence; Vidarabine | 2017 |
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyurea; Models, Biological; Mutation; Neoplasms; NF-kappa B; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2017 |
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cohort Studies; Disease Management; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Neoplasm Invasiveness; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine | 2017 |
Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia.
Topics: Anemia, Diamond-Blackfan; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2017 |
PPI-G4 Glycodendrimers Upregulate TRAIL-Induced Apoptosis in Chronic Lymphocytic Leukemia Cells.
Topics: Adult; Apoptosis; Cell Line, Tumor; Dendrimers; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligonucleotide Array Sequence Analysis; Polypropylenes; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Vidarabine | 2017 |
Spousal hematopoietic stem cell transplantation.
Topics: Adult; Allografts; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fatal Outcome; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Leukemia; Male; Melphalan; Middle Aged; Radiotherapy Dosage; Recurrence; Spouses; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2017 |
[Clinical Efficacy of Haploidentical Allo-HSCT of Reduced Intensity Preconditioning Combined with Induced Immune Tolerance after Transplantation for Severe Aplastic Anemia].
Topics: Anemia, Aplastic; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Fathers; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Immune Tolerance; Male; Methotrexate; T-Lymphocyte Subsets; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
Topics: Aminobenzoates; Apoptosis; Ataxia Telangiectasia Mutated Proteins; B-Lymphocytes; Cell Cycle Checkpoints; Cell Line, Transformed; Cell Survival; Cyclophosphamide; Herpesvirus 4, Human; Histones; Humans; Naphthalenes; S Phase; Signal Transduction; Telomerase; Telomere; Telomere Homeostasis; Vidarabine | 2016 |
Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D3; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Repressor Proteins; Vidarabine | 2017 |
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia.
Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Stem Cell Transplantation; Survival Rate; Vidarabine | 2017 |
Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antineoplastic Agents, Immunological; Child; Child, Preschool; Graft vs Host Disease; Half-Life; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Count; Melphalan; Prospective Studies; Transplantation Conditioning; Vidarabine | 2017 |
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.
Topics: Adult; Aged; Busulfan; Erythrocyte Transfusion; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Leukocyte Reduction Procedures; Lymphocyte Depletion; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Stem Cell Transplantation; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
Topics: Antilymphocyte Serum; BK Virus; Busulfan; Case-Control Studies; Cystitis; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Length of Stay; Male; Middle Aged; Myeloablative Agonists; Polyomavirus Infections; Recurrence; Risk Factors; Sex Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2017 |
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.
Topics: Adult; Aged; Alemtuzumab; Allografts; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2017 |
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Allografts; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Vidarabine | 2017 |
Successful Myeloablative Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in a Young Girl With GATA2 Deficiency and Emberger Syndrome.
Topics: Busulfan; Child, Preschool; Female; GATA2 Transcription Factor; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphedema; Myeloablative Agonists; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine | 2017 |
Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood.
Topics: Acute Disease; Adolescent; Adult; Alopecia; Busulfan; Child; Child, Preschool; Cross-Sectional Studies; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Risk Factors; Transplantation Conditioning; Vidarabine | 2017 |
Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation.
Topics: Animals; Bone Marrow Diseases; CD8-Positive T-Lymphocytes; Cyclophosphamide; Disease Models, Animal; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Major Histocompatibility Complex; Mice, Inbred BALB C; Myeloablative Agonists; Spleen; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2017 |
Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Quality-Adjusted Life Years; Rituximab; Vidarabine | 2017 |
Fludarabine resistance mediated by aminoglycoside-3'-phosphotransferase-IIa and the structurally related eukaryotic cAMP-dependent protein kinase.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Transformed; Cloning, Molecular; Cyclic AMP-Dependent Protein Kinases; Drug Resistance, Neoplasm; Fibroblasts; Gene Expression Regulation, Enzymologic; Humans; Kanamycin Kinase; Molecular Structure; Structure-Activity Relationship; Vidarabine | 2017 |
Fludarabine is effective in treating refractory hemophagocytic lymphohistiocytosis with brucellosis.
Topics: Anti-Bacterial Agents; Brucellosis; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Treatment Outcome; Vidarabine | 2017 |
Influences of FLU/BU and FLU/MEL on incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2017 |
Differential effects of low-dose fludarabine or 5-fluorouracil on the tumor growth and myeloid derived immunosuppression status of tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Growth Processes; Cell Line, Tumor; Female; Fluorouracil; Immune Tolerance; Lymphoma; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Vidarabine | 2017 |
Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cladribine; Clofarabine; Humans; Limit of Detection; Neoplasms; Polyphosphates; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Vidarabine | 2017 |
Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Chromatography, Liquid; Clofarabine; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Isotopes; Limit of Detection; Tandem Mass Spectrometry; Transplantation Conditioning; Vidarabine | 2017 |
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Databases, Factual; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Risk Factors; Rituximab; Vidarabine; Young Adult; Yttrium Radioisotopes | 2017 |
[18F]Fludarabine-PET in a murine model of multiple myeloma.
Topics: Animals; Fluorine Radioisotopes; Heterografts; Mice; Mice, Nude; Multiple Myeloma; Myeloablative Agonists; Positron-Emission Tomography; Vidarabine | 2017 |
Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.
Topics: 5' Untranslated Regions; 5'-Nucleotidase; Adolescent; Adult; Allografts; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; GPI-Linked Proteins; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Polymorphism, Genetic; Vidarabine | 2017 |
Involvement of STAT1 in proliferation and invasiveness of trophoblastic cells.
Topics: Cell Line; Cell Movement; Cell Proliferation; Gene Expression Regulation; Humans; Interleukins; Oncostatin M; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Trophoblasts; Vidarabine | 2017 |
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bayes Theorem; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrazoles; Pyrimidines; Vidarabine | 2017 |
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
Topics: Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Sulfonamides; Vidarabine | 2017 |
Fludarabine inhibits STAT1-mediated up-regulation of caspase-3 expression in dexamethasone-induced osteoblasts apoptosis and slows the progression of steroid-induced avascular necrosis of the femoral head in rats.
Topics: Animals; Apoptosis; Caspase 3; Dexamethasone; Femur Head Necrosis; Gene Expression Regulation; Glucocorticoids; Humans; Osteoblasts; Phosphorylation; Rats; STAT1 Transcription Factor; Vidarabine | 2017 |
Extensive ulcerated lesions in a patient with cutaneous myeloid sarcoma responded to twice-daily fludarabine and cytarabine regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Cytarabine; Drug Administration Schedule; Fatal Outcome; Humans; Male; Positron Emission Tomography Computed Tomography; Sarcoma, Myeloid; Skin Neoplasms; Skin Ulcer; Treatment Outcome; Vidarabine | 2018 |
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; Hematopoietic Stem Cell Transplantation; HLA-C Antigens; Humans; Leukemia, Myeloid, Acute; Ligands; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2017 |
Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hearing Loss, Unilateral; Humans; Idarubicin; Leukemia, Monocytic, Acute; Leukemic Infiltration; Male; Orbit; Tumor Lysis Syndrome; Vidarabine | 2017 |
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Melphalan; Middle Aged; Myelodysplastic Syndromes; Rabbits; Risk Assessment; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.
Topics: Adult; Aged; Cord Blood Stem Cell Transplantation; Female; Humans; Male; Middle Aged; Thiotepa; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Blockage of Wnt/β-Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro-Preliminary Study.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cluster Analysis; Dendrimers; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nanoparticles; Tumor Stem Cell Assay; Vidarabine; Wnt Signaling Pathway | 2017 |
Persistence of the losing cord blood unit following double cord blood transplantation: finding the unseen.
Topics: Adolescent; Adult; Blood Cells; Bone Marrow Cells; Busulfan; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Hematopoiesis; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Topics: Adult; Age Factors; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Patient Selection; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2018 |
IFN-γ aggravates neointimal hyperplasia by inducing endoplasmic reticulum stress and apoptosis in macrophages by promoting ubiquitin-dependent liver X receptor-α degradation.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Apolipoproteins E; Apoptosis; Endoplasmic Reticulum Stress; Hyperplasia; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Interferon-gamma; Liver X Receptors; Macrophages; Male; Mice; Mice, Knockout; Neointima; Protein Inhibitors of Activated STAT; Ubiquitin; Ubiquitination; Vidarabine | 2017 |
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Topics: Adult; Antigens, CD19; B-Lymphocytes; Cyclophosphamide; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Receptors, Antigen, T-Cell; T-Lymphocytes; Vidarabine | 2017 |
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.
Topics: Antineoplastic Agents; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Risk; Vidarabine | 2017 |
Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cystitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infant; Male; Middle Aged; Transplantation Conditioning; Vascular Diseases; Vidarabine | 2017 |
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2017 |
Downregulated SOCS1 expression activates the JAK1/STAT1 pathway and promotes polarization of macrophages into M1 type.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Drugs, Chinese Herbal; Enzyme Inhibitors; Gene Expression Regulation; Interferon-gamma; Interleukin-10; Interleukin-4; Janus Kinase 1; Macrophages, Peritoneal; Mice; Phosphorylation; Primary Cell Culture; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Suppressor of Cytokine Signaling 1 Protein; Tumor Necrosis Factor-alpha; Vidarabine | 2017 |
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cel
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2017 |
HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Cohort Studies; Dexamethasone; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Transplantation, Haploidentical; Transplantation, Homologous; Vidarabine; Young Adult | 2018 |
IL-27 Modulates Chemokine Production in TNF-α -Stimulated Human Oral Epithelial Cells.
Topics: Cell Line; Chemokine CCL20; Chemokines; Humans; Interleukin-27; Interleukin-8; Mouth Mucosa; Phosphorylation; Pyridines; Receptors, Interleukin; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha; Tyrphostins; Vidarabine | 2017 |
Toward Individualizing Conditioning Regimens in Reduced-Intensity Transplantation.
Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Precision Medicine; Survival Analysis; Transplantation Conditioning; Vidarabine | 2017 |
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calcineurin Inhibitors; Cyclophosphamide; Databases, Factual; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2018 |
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine | 2017 |
Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Retrospective Studies; Vidarabine | 2018 |
Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Mycophenolic Acid; Premedication; Tacrolimus; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2018 |
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Rituximab; Vidarabine; Vincristine | 2018 |
Reply to S. Opat et al.
Topics: Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2017 |
Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support.
Topics: Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2017 |
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Staging; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2018 |
Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen.
Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured; Vidarabine | 2018 |
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proportional Hazards Models; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Successful Nonmyeloablative Allogeneic Stem Cell Transplant in a Child With Emberger Syndrome and GATA2 Mutation.
Topics: Allografts; Antilymphocyte Serum; Child; Cyclophosphamide; Female; GATA2 Deficiency; GATA2 Transcription Factor; Graft vs Host Disease; Humans; Mutation; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Skin Diseases; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Vidarabine | 2018 |
Intravenous immunoglobulin as salvage therapy for refractory thrombotic thrombocytopenic purpura.
Topics: Adult; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Recurrence; Registries; Retrospective Studies; Salvage Therapy; Splenectomy; Treatment Outcome; Vidarabine; Vincristine; Young Adult | 2018 |
The struggle to do no harm in clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation.
Topics: Animals; Complement C4b; Composite Tissue Allografts; Desensitization, Immunologic; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Hindlimb; Immunosuppressive Agents; Isoantibodies; Male; Models, Animal; Myeloablative Agonists; Peptide Fragments; Rats, Inbred Lew; Skin Transplantation; Tacrolimus; Time Factors; Transplantation, Isogeneic; Vascularized Composite Allotransplantation; Vidarabine | 2018 |
The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Carrier Proteins; Caspase 7; CRADD Signaling Adaptor Protein; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; NF-kappa B; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Up-Regulation; Vidarabine | 2018 |
[Outcomes of alternative donor allogeneic hematopoietic stem cell transplantation for Fanconi anemia: a five cases report].
Topics: Antilymphocyte Serum; Bone Marrow; Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine | 2018 |
Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Molecular Structure; Purine Nucleosides; Vidarabine | 2018 |
Efficacy of Rituximab for Patients with Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2017 |
Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation; Young Adult | 2018 |
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Vidarabine | 2019 |
Coexistence of t(2;14;11)(p16.1;q32;q23) and t(14;19)(q32;q13.3) chromosome translocations in a patient with chronic lymphocytic leukemia: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 2; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Translocation, Genetic; Vidarabine | 2017 |
Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Infant; Italy; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2018 |
Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.
Topics: Adolescent; Adult; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Humans; Male; Severity of Illness Index; Survival Rate; Tissue Donors; Vidarabine | 2018 |
FDG PET and MRI Findings in a Case of Bing-Neel Syndrome.
Topics: Brain; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron Emission Tomography Computed Tomography; Vidarabine | 2018 |
Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Melphalan; Myeloablative Agonists; Osteopetrosis; Prognosis; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2018 |
Single centre results of targeted busulphan, fludarabine and serotherapy conditioning in haematopoietic stem cell transplantation for haemophagocytic lymphohistiocytosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunization, Passive; Lymphohistiocytosis, Hemophagocytic; Male; Transplantation Conditioning; Vidarabine | 2018 |
Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Busulfan; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Tumor Burden; Vidarabine | 2018 |
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine | 2018 |
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; France; Humans; Immunosuppression Therapy; Incidence; Lymphoma, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Prognosis; Rituximab; Survival Rate; Vidarabine | 2018 |
DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Progression; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mutation; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Vidarabine | 2018 |
A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model.
Topics: Animals; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Cell Survival; Cellular Microenvironment; Disease Models, Animal; Female; Fetal Therapies; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Hepatocytes; Lentivirus; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2018 |
Posttransplant Cyclophosphamide for HLA-haploidentical Transplantation in Patients With Mucopolysaccharidosis.
Topics: Allografts; Antilymphocyte Serum; Busulfan; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Male; Mucopolysaccharidoses; Survival Rate; Transplantation Conditioning; Vidarabine | 2018 |
Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Down Syndrome; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Vidarabine; Vorinostat | 2019 |
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine | 2018 |
An ultrasonic nanobubble-mediated PNP/fludarabine suicide gene system: A new approach for the treatment of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Gene Transfer Techniques; Genes, Transgenic, Suicide; Green Fluorescent Proteins; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms; Nanostructures; Purine-Nucleoside Phosphorylase; Ultrasonics; Vidarabine | 2018 |
Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis.
Topics: Adrenoleukodystrophy; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucopolysaccharidoses; Transplantation Conditioning; Transplantation, Haploidentical; Transplantation, Homologous; Vidarabine | 2018 |
Apoptosis of CD19+ chimeric antigen receptor T cells after treatment with chemotherapeutic agents.
Topics: Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cyclophosphamide; Humans; Membrane Potentials; Receptors, Antigen, T-Cell; Recombinant Fusion Proteins; Vidarabine | 2018 |
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prospective Studies; Rituximab; Vidarabine | 2018 |
Fludarabine and neurotoxicity in engineered T-cell therapy.
Topics: Antigens, CD19; Humans; Immunotherapy, Adoptive; Neurotoxicity Syndromes; Receptors, Antigen, T-Cell; T-Lymphocytes; Vidarabine | 2018 |
Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Busulfan; China; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation.
Topics: Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Busulfan; Cyclosporine; Gastroparesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Methotrexate; Nausea; Unrelated Donors; Vidarabine; Vomiting | 2018 |
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice.
Topics: Animals; Cell Line, Tumor; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Transplantation Conditioning; Vidarabine | 2018 |
TBI: To Be (Irradiated) or Not To Be? That Remains the Question.
Topics: Busulfan; Cyclophosphamide; Vidarabine; Whole-Body Irradiation | 2018 |
Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients.
Topics: Adolescent; Area Under Curve; Body Surface Area; Child; Child, Preschool; Female; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Nonlinear Dynamics; Pediatrics; Republic of Korea; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2019 |
Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2018 |
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Topics: Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Ontario; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retreatment; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpla
Topics: Busulfan; Europe; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Vidarabine | 2018 |
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine | 2019 |
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Drug Evaluation; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Retrospective Studies; Siblings; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2018 |
Successful hematopoietic cell transplantation in Fanconi anemia patients with renal impairment using ultra-reduced doses of cyclophosphamide and fludarabine.
Topics: Cyclophosphamide; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Transplantation Conditioning; Vidarabine | 2018 |
Fludarabine-based reduced toxicity yet myeloablative conditioning is effective and safe particularly in patients with high-risk thalassemia undergoing allogeneic transplantation.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Retrospective Studies; Thalassemia; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2018 |
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes.
Topics: Adolescent; Adult; Busulfan; China; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Vidarabine; Young Adult | 2019 |
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
Topics: Aged; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; DNA Damage; Female; Follow-Up Studies; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Prognosis; Receptors, Antigen, B-Cell; Repressor Proteins; Rituximab; Signal Transduction; Survival Rate; Vidarabine | 2019 |
Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
Topics: Adult; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Transplantation Conditioning; Vidarabine | 2018 |
Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation; Young Adult | 2018 |
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
Topics: Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; THP-1 Cells; Vidarabine | 2018 |
Affecting NF-κB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticles.
Topics: Cell Line, Tumor; Dendrimers; Gene Expression Regulation; Humans; Leukemia, Lymphoid; Nanoparticles; NF-kappa B; Protein Array Analysis; Signal Transduction; Transcriptome; Vidarabine | 2018 |
A 56-year-old woman with blindness and mental status changes.
Topics: Antineoplastic Agents; Blindness; Female; Humans; Leukoencephalopathies; Mental Disorders; Middle Aged; Vidarabine | 2018 |
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2019 |
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Young Adult | 2018 |
Chemotherapy based combinations in AML: Time to take a step back?
Topics: Anthracyclines; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Vidarabine | 2018 |
[
Topics: Animals; Central Nervous System Neoplasms; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glioblastoma; Heterografts; Histocytochemistry; Humans; Image Processing, Computer-Assisted; Lymphoma; Magnetic Resonance Imaging; Neoplasm Transplantation; Positron-Emission Tomography; Radiopharmaceuticals; Rats, Nude; Sensitivity and Specificity; Vidarabine | 2018 |
Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Models, Biological; Myeloablative Agonists; Transplantation Conditioning; Vidarabine; Young Adult | 2019 |
TLR4/NF-κB axis induces fludarabine resistance by suppressing TXNIP expression in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Lipopolysaccharide Receptors; Lipopolysaccharides; NF-kappa B; Signal Transduction; THP-1 Cells; Toll-Like Receptor 4; Vidarabine | 2018 |
Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Purines; Remission Induction; RNA, Long Noncoding; Vidarabine | 2018 |
Waldenström macroglobulinaemia terminating in acute lymphoblastic leukaemia after treatment with fludarabine.
Topics: Aged; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine; Waldenstrom Macroglobulinemia | 2019 |
Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Disease Susceptibility; Female; Flow Cytometry; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation; Sirolimus; Treatment Outcome; Vidarabine | 2019 |
Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Line, Tumor; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Spleen; Survival Rate; Transcription Factor Brn-3A; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Ubiquitination; Vidarabine | 2018 |
Long-Term Follow-Up of
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2018 |
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2018 |
Downregulating STAT1/caspase-3 signaling with fludarabine to alleviate progression in a rat model of steroid-induced avascular necrosis of the femoral head.
Topics: Animals; Caspase 3; Dexamethasone; Disease Models, Animal; Disease Progression; Down-Regulation; Femur Head; Femur Head Necrosis; Male; Rats, Sprague-Dawley; Signal Transduction; STAT1 Transcription Factor; Vidarabine | 2019 |
Impact of low-dose irradiation and in vivo T-cell depletion on hematopoietic stem cell transplantation for non-malignant diseases using fludarabine-based reduced-intensity conditioning.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Lymphocyte Depletion; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2019 |
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2019 |
Immunosuppressive Total Nodal Irradiation-Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Topics: Adolescent; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Follow-Up Studies; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppression Therapy; Kaplan-Meier Estimate; Lymphatic Irradiation; Muromonab-CD3; Myeloablative Agonists; Radiotherapy Dosage; Retreatment; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2019 |
Visual loss secondary to fludarabine toxicity: optical coherence tomography findings in two patients.
Topics: Antineoplastic Agents; Follow-Up Studies; Hematologic Neoplasms; Humans; Prognosis; Retina; Tomography, Optical Coherence; Vidarabine; Vision, Low; Visual Acuity; Visual Field Tests; Visual Fields | 2019 |
Telomere length predicts for outcome to FCR chemotherapy in CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Telomere; Vidarabine | 2019 |
Fludarabine-Specific Molecular Interactions with Maltose-Modified Poly(propyleneimine) Dendrimer Enable Effective Cell Entry of the Active Drug Form: Comparison with Clofarabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clofarabine; Dendrimers; Humans; Maltose; Polypropylenes; Surface Plasmon Resonance; U937 Cells; Vidarabine | 2019 |
Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; DNA Damage; Female; Gene Expression Regulation, Leukemic; Humans; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minichromosome Maintenance Complex Component 7; RNA, Messenger; Up-Regulation; Vidarabine; Virus Replication | 2019 |
Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.
Topics: Adult; Allografts; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytochrome P-450 CYP2B6; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Pharmacogenomic Testing; Pharmacogenomic Variants; Vidarabine | 2020 |
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2019 |
Distinct cellular responses to replication stress leading to apoptosis or senescence.
Topics: Apoptosis; Cell Line, Tumor; Cellular Senescence; DNA Replication; Humans; Lamin Type A; MCF-7 Cells; Mutation; Tumor Suppressor Protein p53; Vidarabine | 2019 |
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2019 |
First Report of a Patient With Natural Killer-Lymphoblastic Leukemia/Lymphoma in Korea.
Topics: Antineoplastic Agents; Bone Marrow Cells; Clopidogrel; Drug Therapy, Combination; Female; Humans; Killer Cells, Natural; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Republic of Korea; Tomography, X-Ray Computed; Vidarabine | 2019 |
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Rituximab; Survival Rate; Vidarabine | 2019 |
Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation.
Topics: Abatacept; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-2 Antigen; CD28 Antigens; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation | 2019 |
FLAI induction regimen in elderly patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Sex Factors; Time Factors; Transplantation, Homologous; Vidarabine | 2019 |
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Patient Selection; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Treatment Outcome; Vidarabine | 2019 |
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs.
Topics: Adenine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Heme Oxygenase-1; Histone Deacetylase 1; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Nude; Middle Aged; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyridines; Random Allocation; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine; Xenograft Model Antitumor Assays | 2019 |
High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fas Ligand Protein; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prognosis; Treatment Outcome; Vidarabine | 2019 |
High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Case-Control Studies; Cladribine; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Vidarabine | 2019 |
Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.
Topics: Aged; Antigens, CD19; B-Lymphocytes; Cell Separation; Cyclophosphamide; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Kinetics; Leukemia, B-Cell; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell; Remission Induction; T-Lymphocytes; Vidarabine | 2019 |
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Mutation; Predictive Value of Tests; Prognosis; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2019 |
Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Variable Region; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mutation; Neoplasm, Residual; Prognosis; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2019 |
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2019 |
Structural Basis for Inhibition of Human Primase by Arabinofuranosyl Nucleoside Analogues Fludarabine and Vidarabine.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antiviral Agents; Catalytic Domain; Crystallography, X-Ray; DNA Primase; Enzyme Assays; Humans; Protein Binding; Vidarabine | 2019 |
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2019 |
Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia.
Topics: Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Retrospective Studies; Rituximab; Vidarabine | 2019 |
Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine | 2020 |
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.
Topics: Adult; Aged; Bone Marrow; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Proportional Hazards Models; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity.
Topics: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine | 2020 |
[Effect of miR-214 on Fludarabine Resistance in Chronic Lymphocytic Leukemia].
Topics: Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Phosphatidylinositol 3-Kinases; Vidarabine | 2019 |
Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Melphalan; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2020 |
Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Busulfan; Case-Control Studies; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Karnofsky Performance Status; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Staging; Risk Factors; Skin; Skin Neoplasms; Tissue Donors; Transplantation Conditioning; Ultraviolet Rays; Vidarabine; Whole-Body Irradiation; Young Adult | 2020 |
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2020 |
FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Child, Preschool; Cytarabine; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Vidarabine | 2021 |
Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Line, Tumor; Dendrimers; Drug Development; Heterografts; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Neoplasms, Experimental; Polypropylenes; Tissue Distribution; Trisaccharides; Vidarabine | 2020 |
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vidarabine | 2019 |
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy.
Topics: Adult; Aged; Cyclophosphamide; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Rituximab; Treatment Outcome; Vidarabine | 2019 |
Elucidation of binding interactions and mechanism of Fludarabine with dsDNA via multispectroscopic and molecular docking studies.
Topics: Binding Sites; DNA; Hydrogen Bonding; Molecular Docking Simulation; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Vidarabine; Viscosity | 2020 |
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
Topics: Age Factors; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2020 |
Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation.
Topics: Busulfan; Child; Child, Preschool; Drug Eruptions; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (t
Topics: Adult; Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Female; Hematologic Neoplasms; HLA Antigens; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Cord blood infusion-accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Blood Transfusion; Child; Child, Preschool; Drug Therapy, Combination; Female; Fetal Blood; Hematopoiesis; Humans; Immunosuppressive Agents; Male; Middle Aged; Recovery of Function; Severity of Illness Index; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2020 |
The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors.
Topics: Animals; Cell Line, Tumor; Escherichia coli; Genetic Therapy; Genetic Vectors; Glioma; Humans; Lentivirus; Mice; Mice, Nude; Purine-Nucleoside Phosphorylase; Squamous Cell Carcinoma of Head and Neck; Trichomonas vaginalis; Vidarabine | 2020 |
Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Randomized Controlled Trials as Topic; Research Design; Vidarabine | 2020 |
Mendelian susceptibility to mycobacterial disease-Challenges in hematopoietic stem cell transplantation.
Topics: Allografts; Child, Preschool; Dexamethasone; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Infant; Male; Mutation; Mycobacterium; Mycobacterium Infections; Receptors, Interleukin-12; Transplantation Conditioning; Vidarabine | 2020 |
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Transplantation Conditioning; Vidarabine | 2020 |
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report.
Topics: Antilymphocyte Serum; Busulfan; Ectodermal Dysplasia; Hematopoietic Stem Cell Transplantation; Humans; I-kappa B Kinase; Immunologic Deficiency Syndromes; Infant; Male; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Calcineurin Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms, Second Primary; Proportional Hazards Models; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2020 |
Systemic Large-Vessel Vasculitis and Retroperitoneal Fibrosis in the Setting of T-Cell Chronic Lymphocytic Leukemia: A Case Report.
Topics: Aged; Antineoplastic Agents; Aorta, Thoracic; Chest Pain; Computed Tomography Angiography; Coronary Vessels; Cyclophosphamide; Humans; Leukemia, Prolymphocytic, T-Cell; Lymphadenopathy; Male; Prednisone; Retroperitoneal Fibrosis; Systemic Vasculitis; Treatment Outcome; Vidarabine | 2020 |
Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2020 |
A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2020 |
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease Management; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2020 |
Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome.
Topics: Antineoplastic Agents, Alkylating; Child; Cytarabine; Female; Fetal Blood; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Shwachman-Diamond Syndrome; Transplantation Conditioning; Vidarabine | 2021 |
The interaction mechanism between fludarabine and human serum albumin researched by comprehensive spectroscopic methods and molecular docking technique.
Topics: Humans; Molecular Docking Simulation; Serum Albumin, Human; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Vidarabine | 2020 |
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2020 |
Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2020 |
Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
Topics: Antigens, CD; Antineoplastic Agents; B-Lymphocytes; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Receptors, Cell Surface; Vidarabine | 2020 |
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cyclophosphamide; Female; Follow-Up Studies; Humans; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Prognosis; Progression-Free Survival; Skin Neoplasms; Vidarabine | 2020 |
Retrospective institutional analysis of fludarabine/8 Gy TBI reduced intensity conditioning in high risk ALL.
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Coculture Techniques; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunotherapy; Interleukin-1beta; Male; Mice, Inbred C57BL; Mice, Transgenic; Myeloid-Derived Suppressor Cells; Sex Characteristics; T-Lymphocytes; Vidarabine | 2020 |
DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy.
Topics: Bendamustine Hydrochloride; DNA Methylation; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Suppressor Protein p53; Vidarabine | 2020 |
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine.
Topics: Adult; Aged; Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Neoplasm Transplantation; Polyethylene Glycols; Treatment Outcome; Tumor Microenvironment; Vidarabine | 2020 |
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Topics: Aged; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2020 |
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Pharmacological; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mass Spectrometry; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Piperidines; Purines; Quinazolinones; Vidarabine | 2020 |
Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide.
Topics: Anemia, Aplastic; Bone Marrow Transplantation; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine | 2020 |
Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Multiple, Fungal; Drug Substitution; Fatal Outcome; Febrile Neutropenia; Female; Filgrastim; Fluconazole; Humans; Immunocompromised Host; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperacillin, Tazobactam Drug Combination; Purines; Quinazolinones; Recurrence; Rituximab; Scedosporium; Triazoles; Valacyclovir; Vidarabine | 2020 |
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Retrospective Studies; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2021 |
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2020 |
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?
Topics: Busulfan; Humans; Leukemia, Myeloid, Acute; Melphalan; Transplantation Conditioning; Vidarabine | 2020 |
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Topics: Allografts; Busulfan; Cohort Studies; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Melphalan; Myeloablative Agonists; Recurrence; Registries; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.
Topics: Busulfan; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine | 2020 |
Donor's graft ex vivo T-cell depletion with fludarabine reduces graft-versus-host disease signs and improves survival after intestinal transplantation - an experimental study.
Topics: Animals; Graft vs Host Disease; Rats; Rats, Inbred Lew; T-Lymphocytes; Transplantation, Homologous; Vidarabine | 2020 |
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.
Topics: Aged; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myeloablative Agonists; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2020 |
Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2021 |
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunological Synapses; Immunophenotyping; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Piperidines; Purines; Quinazolinones; Rituximab; T-Lymphocytes; Vidarabine | 2020 |
Fludarabine, Campath, and Low-Dose Cyclophosphamide (FCC
Topics: Alemtuzumab; Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Sirolimus; Tacrolimus; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Topics: Age Factors; Aged; Busulfan; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Radiation Dosage; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2020 |
Interim Phase 2 ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL.
Topics: Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Immunotherapy, Adoptive; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Salvage Therapy; Vidarabine | 2020 |
Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL.
Topics: Animals; Cell Line, Tumor; Dendrimers; Drug Delivery Systems; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred NOD; Neoplasms, Experimental; Pilot Projects; Polypropylenes; Trisaccharides; Vidarabine | 2020 |
Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning.
Topics: Adolescent; Adult; Anemia, Aplastic; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2020 |
Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in pediatric patient with IL10 receptor deficiency.
Topics: Child; Drug Administration Schedule; Drug Therapy, Combination; Female; Genetic Markers; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Myeloablative Agonists; Primary Immunodeficiency Diseases; Receptors, Interleukin-10; Transplantation Conditioning; Vidarabine | 2021 |
Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
Topics: Adult; Age Factors; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acut
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2021 |
HuR Affects Proliferation and Apoptosis of Chronic Lymphocytic Leukemia Cells via NF-
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Chlorambucil; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Humans; I-kappa B Kinase; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; TNF Receptor-Associated Factor 1; Tumor Necrosis Factor-alpha; Up-Regulation; Vidarabine | 2020 |
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Vidarabine | 2021 |
IFN‑γ induces apoptosis in human melanocytes by activating the JAK1/STAT1 signaling pathway.
Topics: Cell Line; Cell Survival; Gene Expression Regulation; Humans; Interferon-gamma; Janus Kinase 1; MAP Kinase Signaling System; Melanocytes; Phosphorylation; STAT1 Transcription Factor; Vidarabine | 2020 |
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Topics: Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Calreticulin; Cell Line, Tumor; Cytarabine; Daunorubicin; Dendritic Cells; Etoposide; Extracellular Space; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Immunogenic Cell Death; Leukemia, Myeloid, Acute; Lymphocyte Activation; Neoplasm Proteins; Organelles; Protein Transport; T-Lymphocyte Subsets; Vidarabine | 2020 |
Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).
Topics: Adenosine Monophosphate; Amino Acid Sequence; Betacoronavirus; Binding Sites; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; Enzyme Inhibitors; Folic Acid; Genome, Viral; Glucosides; Humans; Methyltransferases; Molecular Docking Simulation; Mutation; Pandemics; Pneumonia, Viral; RNA Helicases; SARS-CoV-2; Stilbenes; Vidarabine; Viral Nonstructural Proteins | 2020 |
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine | 2021 |
Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies.
Topics: Adult; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Prednisone; Prognosis; Retrospective Studies; Rituximab; Vidarabine | 2020 |
Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2020 |
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Primary Myelofibrosis; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine | 2021 |
Improving survival rates for patients with acute myeloid leukemia: Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Humans; Leukemia, Myeloid, Acute; Survival Rate; Transplantation Conditioning; Vidarabine | 2020 |
Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Edema; Cyclophosphamide; Demyelinating Diseases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Steroids; Vidarabine | 2021 |
Haploidentical Stem Cell Transplant With Post-transplant Cyclophosphamide for Chediak-Higashi Syndrome: A Very Rare Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chediak-Higashi Syndrome; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Prognosis; Transplantation Conditioning; Vidarabine | 2021 |
Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.
Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytokine Release Syndrome; Humans; Lymphocyte Depletion; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Remission Induction; T-Lymphocytes; Vidarabine | 2020 |
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine | 2020 |
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
Topics: Adult; Area Under Curve; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2021 |
Haploidentical Stem Cell Transplant With Post Transplant Cyclophosphamide for Chronic Granulomatous Disease With Thiotepa, Busulfan, and Fludarabine as Conditioning.
Topics: Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine | 2021 |
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Vidarabine | 2020 |
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Drug Repositioning; Gene Expression Regulation, Neoplastic; Humans; Mesothelioma; Pleural Neoplasms; Risedronic Acid; STAT1 Transcription Factor; Vidarabine | 2021 |
Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy.
Topics: Aged; Antineoplastic Agents; Fatal Outcome; Humans; Immunotherapy, Adoptive; Leukoencephalopathies; Lymphoma, Large B-Cell, Diffuse; Male; Neurotoxicity Syndromes; Retroperitoneal Neoplasms; Vidarabine | 2021 |
Fludarabine modulates expression of type VII collagen during haematopoietic stem cell transplantation for recessive dystrophic epidermolysis bullosa.
Topics: Collagen Type VII; Epidermolysis Bullosa Dystrophica; Hematopoietic Stem Cell Transplantation; Humans; Phosphatidylinositol 3-Kinases; Vidarabine | 2021 |
Systemic capillary leak syndrome: a rare but potentially life-threatening cause of protein loss and oedema in B cell prolymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Cyclophosphamide; Edema; Humans; Hypoalbuminemia; Leukemia, Prolymphocytic, B-Cell; Male; Middle Aged; Rituximab; Serum Albumin, Human; Treatment Outcome; Vidarabine | 2020 |
Periodontitis aggravates kidney injury by upregulating STAT1 expression in a mouse model of hypertension.
Topics: Animals; Disease Models, Animal; Gene Knockdown Techniques; Humans; Hypertension; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Periodontitis; Porphyromonas gingivalis; Renal Insufficiency, Chronic; STAT1 Transcription Factor; Up-Regulation; Vidarabine | 2021 |
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
Topics: Busulfan; Child, Preschool; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Leukocyte Count; Male; Melphalan; Primary Immunodeficiency Diseases; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2021 |
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Female; Ferritins; Humans; Immunotherapy, Adoptive; Infections; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Retrospective Studies; Thrombocytopenia; Vidarabine; Young Adult | 2021 |
Design, Synthesis and In Vitro Cytotoxic Activity of New 6,9-Disubstituted Purine Analogues.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Drug Design; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Molecular Structure; Purines; Vidarabine | 2020 |
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chlorambucil; Cohort Studies; Denmark; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Risk Assessment; Survival Analysis; Vidarabine | 2021 |
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Topics: Aged; Allografts; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Progression-Free Survival; Retrospective Studies; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2021 |
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Syngeneic leukemia models using lentiviral transgenics.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Viral; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Immunocompetence; Lentivirus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Oncogenes; Transplantation, Isogeneic; Vidarabine | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Topics: Antibodies, Viral; B-Cell Maturation Antigen; Cough; COVID-19; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; Cyclophosphamide; Disease Progression; Fever; Hospitalization; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Middle Aged; Multiple Myeloma; Receptors, Chimeric Antigen; SARS-CoV-2; Vidarabine | 2021 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Propensity Score; Transplantation Conditioning; Vidarabine | 2021 |
Bone marrow transplant using fludarabine-based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia.
Topics: Bone Marrow Transplantation; Child; Drug Therapy, Combination; Fanconi Anemia; Humans; Lymphocyte Depletion; Myeloablative Agonists; Siblings; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2021 |
Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71.
Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Cells, Cultured; Enterovirus A, Human; Humans; Phlebovirus; RNA Viruses; Vidarabine; Virus Replication; Zika Virus | 2021 |
An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Humans; Retrospective Studies; Vidarabine; Young Adult | 2021 |
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
Topics: Adult; Clinical Trials, Phase II as Topic; Cyclophosphamide; Cytokines; Female; Humans; Immunotherapy, Adoptive; Length of Stay; Lymphocyte Depletion; Male; Melanoma; Middle Aged; Myeloablative Agonists; Receptors, Chimeric Antigen; Recovery of Function; Skin Neoplasms; T-Lymphocytes; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2021 |
Conditioning with 10 Gy Total Body Irradiation, Cyclophosphamide, and Fludarabine without ATG Is Associated with Improved Outcome of Cord Blood Transplantation in Children with Acute Leukemia.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Infant; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2021 |
Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies.
Topics: Antilymphocyte Serum; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Radiation-free myeloablative conditioning consisting of fludarabine added to full-dose busulfan and cyclophosphamide in single-unit cord blood transplantation for adults.
Topics: Adult; Blood Platelets; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloablative Agonists; Neutrophils; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine | 2021 |
Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Iran; Male; Middle Aged; Prognosis; Quality of Life; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2021 |
Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Antiviral Agents; Binding Sites; COVID-19; COVID-19 Drug Treatment; Enzyme Induction; HEK293 Cells; HeLa Cells; Humans; Interferon Type I; Phosphorylation; Promoter Regions, Genetic; Receptors, Virus; STAT1 Transcription Factor; Vidarabine | 2021 |
Full Dose Cyclophosphamide with the Addition of Fludarabine for Matched Sibling Transplants in Severe Aplastic Anemia.
Topics: Adult; Anemia, Aplastic; Cyclophosphamide; Humans; Prospective Studies; Retrospective Studies; Siblings; Vidarabine | 2021 |
Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.
Topics: Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Nomograms; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Prognosis; Rituximab; Survival Rate; Telomere Homeostasis; Tumor Suppressor Protein p53; Vidarabine | 2022 |
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2021 |
[Cutaneous complications following hematopoietic stem cell transplantation].
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Disease; Dermatomycoses; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Genitalis; Humans; Induction Chemotherapy; Malassezia; Male; Melphalan; Middle Aged; Morocco; Prospective Studies; Skin Diseases; Skin Diseases, Infectious; Vidarabine; Young Adult | 2021 |
Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Vidarabine | 2021 |
Successful allogeneic stem cell transplantation with fludarabine-based reduced intensity conditioning in bone marrow failure syndrome 4.
Topics: Antineoplastic Agents; Bone Marrow Failure Disorders; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2021 |
MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2021 |
Does fludarabine have a beneficial effect in recessive dystrophic epidermolysis bullosa?
Topics: Collagen Type VII; Epidermolysis Bullosa Dystrophica; Humans; Skin; Vidarabine | 2021 |
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
Topics: Aged; Busulfan; Graft vs Host Disease; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Vidarabine | 2021 |
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
Topics: Administration, Intravenous; Adolescent; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Glutathione Transferase; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Models, Biological; Polymorphism, Genetic; Precision Medicine; Transplantation Conditioning; Vidarabine; Young Adult | 2021 |
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Propensity Score; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2021 |
Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8
Topics: Adenoviridae; Animals; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Immunologic Surveillance; Immunosuppression Therapy; Inflammation; Liver Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Male; Mice, Inbred C57BL; Oncolytic Viruses; Recombinant Fusion Proteins; Treatment Outcome; Vidarabine; Virus Replication | 2021 |
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modality Therapy; Cyclophosphamide; Cytokine Release Syndrome; Female; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Leukapheresis; Lymphocyte Depletion; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Pancytopenia; Progression-Free Survival; Receptors, Antigen, T-Cell; Retrospective Studies; Salvage Therapy; Vidarabine | 2021 |
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; DNA Mutational Analysis; Female; Gene Expression Regulation, Leukemic; Genomics; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Rituximab; RNA Splicing; Vidarabine | 2021 |
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines.
Topics: Antimalarials; Antineoplastic Agents; Apoptosis; Artemisinins; Biomarkers; Cell Proliferation; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1; Vidarabine | 2021 |
Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.
Topics: Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; DNA-Binding Proteins; Etoposide; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; Liver Neoplasms; Lymphoma, T-Cell; PAX5 Transcription Factor; Prognosis; Proto-Oncogene Proteins c-ets; Remission Induction; Repressor Proteins; Splenic Neoplasms; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2022 |
Non-myeloablative umbilical cord blood transplantation for atypical dyskeratosis congenita.
Topics: Alemtuzumab; Antineoplastic Agents; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Dyskeratosis Congenita; Female; Germ-Line Mutation; Humans; Mismatch Repair Endonuclease PMS2; Vidarabine; Whole-Body Irradiation | 2022 |
Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2022 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
Topics: Antilymphocyte Serum; Busulfan; Chimerism; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine | 2022 |
Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning.
Topics: Antineoplastic Agents; Busulfan; Child; Child, Preschool; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Male; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen.
Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2022 |
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Humans; Immunotherapy, Adoptive; Infant; Prospective Studies; Recurrence; Retrospective Studies; Vidarabine; Young Adult | 2022 |
Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.
Topics: Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cyclophosphamide; Humans; Neoplasms; Nucleosides; Tumor Suppressor Protein p53; Vidarabine | 2022 |
Fludarabine-based Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Bone Marrow Failure Syndrome Type 3.
Topics: Bone Marrow Failure Disorders; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Transplantation Conditioning; Vidarabine | 2022 |
Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Topics: Adolescent; Antineoplastic Agents; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2022 |
5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.
Topics: Antiviral Agents; Cell Line; COVID-19 Drug Treatment; Deoxyguanosine; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Microbial Sensitivity Tests; Nucleic Acid Synthesis Inhibitors; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Thionucleosides; Tubercidin; Vidarabine; Vidarabine Phosphate | 2022 |
Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Rituximab; Treatment Outcome; Vidarabine | 2022 |
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Topics: Antigens, CD19; Child; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Retrospective Studies; Vidarabine; Young Adult | 2022 |
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
Topics: Alkylating Agents; AMP-Activated Protein Kinases; Antineoplastic Agents; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Caspase 3; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Nucleosides; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; STAT5 Transcription Factor; Sulfonamides; Transplantation Conditioning; Vidarabine | 2022 |
Proteomic Analysis Reveals a Novel Therapeutic Strategy Using Fludarabine for Steroid-Resistant Asthma Exacerbation.
Topics: Animals; Asthma; Cytokines; Mice; Mice, Inbred BALB C; Ovalbumin; Proteomics; Steroids; Vidarabine | 2022 |
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Propensity Score; Retrospective Studies; Vidarabine | 2022 |
Combined Effects of Fludarabine and Interferon Alpha on Autophagy Regulation Define the Phase of Cell Survival and Promotes Responses in LLC-MK2 and K562 Cells.
Topics: Antiviral Agents; Autophagy; Cell Survival; Humans; Interferon-alpha; K562 Cells; TOR Serine-Threonine Kinases; Vidarabine | 2022 |
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice.
Topics: Animals; CRISPR-Cas Systems; Dependovirus; Endonucleases; Gene Editing; Genetic Vectors; Homologous Recombination; Humans; Mice; Vidarabine | 2022 |
Single-dose (4.5 mg/m
Topics: Adult; Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Vidarabine | 2022 |
First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18 F-Fludarabine and l -[methyl- 11 C]Methionine.
Topics: Adrenal Cortex Hormones; Brain Neoplasms; Diagnosis, Differential; Fluorodeoxyglucose F18; Glioblastoma; Humans; Lymphoma; Methionine; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Vidarabine | 2022 |
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2022 |
Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning.
Topics: Creatinine; Graft vs Host Disease; Humans; Iothalamic Acid; Melphalan; Retrospective Studies; Vidarabine | 2022 |
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
Topics: Aged; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2022 |
Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Humans; Infant; Male; Retrospective Studies; Thiotepa; Vidarabine; Young Adult | 2022 |
Successful desensitization protocol for a patient with fludarabine anaphylaxis during hematopoietic transplantation.
Topics: Anaphylaxis; Desensitization, Immunologic; Drug Hypersensitivity; Hematopoietic Stem Cell Transplantation; Humans; Vidarabine | 2022 |
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2022 |
Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery.
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine | 2022 |
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities.
Topics: Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Beyond fludarabine: pentostatin plus cyclophosphamide are a well-tolerated alternative in reduced intensity conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Pentostatin; Transplantation Conditioning; Vidarabine | 2022 |
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2023 |
Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2022 |
Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results fro
Topics: Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2023 |
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2023 |
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2023 |
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Vidarabine | 2023 |
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine | 2023 |
Haploidentical Transplant Achieves Long-Term Remission in Relapsed Refractory Leukemia With Fludarabine-Induced Neurotoxicity Complication.
Topics: Child; Hematopoietic Stem Cell Transplantation; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Transplants; Vidarabine | 2023 |
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2023 |
Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine and Discussion of Treatment.
Topics: Carcinoma, Squamous Cell; Humans; Skin Neoplasms; Vidarabine | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |
Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
Topics: Immunotherapy, Adoptive; Receptors, Antigen, T-Cell; Vidarabine | 2023 |
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; East Asian People; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prospective Studies; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2023 |
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine | 2023 |
del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.
Topics: Chromosome Aberrations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Prognosis; Receptors, TNF-Related Apoptosis-Inducing Ligand; Vidarabine | 2023 |
Quantification of Clofarabine and Fludarabine in Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Chromatography, High Pressure Liquid; Clofarabine; Humans; Tandem Mass Spectrometry; Vidarabine | 2024 |